
<html lang="en"     class="pb-page"  data-request-id="e6d1af02-56db-48c8-9f2c-50637061d3b5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2010.53.issue-19;website:website:acspubs;article:article:10.1021/jm100189a;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives" /></meta><meta name="dc.Creator" content="Ioannis S.  Vizirianakis" /></meta><meta name="dc.Creator" content="Maria  Chatzopoulou" /></meta><meta name="dc.Creator" content="Ioannis D.  Bonovolias" /></meta><meta name="dc.Creator" content="Ioannis  Nicolaou" /></meta><meta name="dc.Creator" content="Vassilis J.  Demopoulos" /></meta><meta name="dc.Creator" content="Asterios S.  Tsiftsoglou" /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 20, 2010" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm100189a" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm100189a" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm100189a" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm100189a" /></link>
        
    
    

<title>Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm100189a" /></meta><meta property="og:title" content="Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives" /></meta><meta property="og:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta property="og:description" content="" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="" /></meta><meta name="twitter:image" content="https://pubs.acs.org/pb-assets/images/CoverImages_2by1Scaled/jmcmar-1595795902140.png" /></meta><meta name="twitter:title" content="Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm100189a"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm100189a">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm100189a&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm100189a&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm100189a&amp;href=/doi/10.1021/jm100189a" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 6779-6810</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm100509v" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ioannis+S.++Vizirianakis">Ioannis S. Vizirianakis</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Chatzopoulou">Maria Chatzopoulou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ioannis+D.++Bonovolias">Ioannis D. Bonovolias</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ioannis++Nicolaou">Ioannis Nicolaou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vassilis+J.++Demopoulos">Vassilis J. Demopoulos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Asterios+S.++Tsiftsoglou">Asterios S. Tsiftsoglou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Laboratory of Pharmacology</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Laboratory of Pharmaceutical Chemistry</span></div><div class="aff-info" id="aut"><span class="aff-text">Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +30-2310-997658. Fax: +30-2310-997645. E-mail: <a href="/cdn-cgi/l/email-protection#acc5dac5d6c5deecdcc4cddec182cdd9d8c482cbde"><span class="__cf_email__" data-cfemail="bed7c8d7c4d7ccfeced6dfccd390dfcbcad690d9cc">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm100189a&amp;href=/doi/10.1021%2Fjm100189a" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 6779–6810</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 20, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 February 2010</li><li><span class="item_label"><b>Published</b> online</span>20 July 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 October 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm100189a" title="DOI URL">https://doi.org/10.1021/jm100189a</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6779%26pageCount%3D32%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DIoannis%2BS.%2BVizirianakis%252C%2BMaria%2BChatzopoulou%252C%2BIoannis%2BD.%2BBonovolias%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D19%26contentID%3Djm100189a%26title%3DToward%2Bthe%2BDevelopment%2Bof%2BInnovative%2BBifunctional%2BAgents%2BTo%2BInduce%2BDifferentiation%2Band%2BTo%2BPromote%2BApoptosis%2Bin%2BLeukemia%253A%2BClinical%2BCandidates%2Band%2BPerspectives%26numPages%3D32%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6810%26publicationDate%3DOctober%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm100189a"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4039</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm100189a" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ioannis&quot;,&quot;last_name&quot;:&quot;S. Vizirianakis&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Chatzopoulou&quot;},{&quot;first_name&quot;:&quot;Ioannis&quot;,&quot;last_name&quot;:&quot;D. Bonovolias&quot;},{&quot;first_name&quot;:&quot;Ioannis&quot;,&quot;last_name&quot;:&quot;Nicolaou&quot;},{&quot;first_name&quot;:&quot;Vassilis&quot;,&quot;last_name&quot;:&quot;J. Demopoulos&quot;},{&quot;first_name&quot;:&quot;Asterios&quot;,&quot;last_name&quot;:&quot;S. Tsiftsoglou&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;6779-6810&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm100189a&quot;},&quot;abstract&quot;:&quot;&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100189a&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100189a" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100189a&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100189a" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100189a&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100189a" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm100189a&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100189a&amp;href=/doi/10.1021/jm100189a" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm100189a" /></input><a href="/doi/pdf/10.1021/jm100189a" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm100189a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm100189a%26sid%3Dliteratum%253Aachs%26pmid%3D20925433%26genre%3Darticle%26aulast%3DVizirianakis%26date%3D2010%26atitle%3DToward%2Bthe%2BDevelopment%2Bof%2BInnovative%2BBifunctional%2BAgents%2BTo%2BInduce%2BDifferentiation%2Band%2BTo%2BPromote%2BApoptosis%2Bin%2BLeukemia%253A%2BClinical%2BCandidates%2Band%2BPerspectives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D19%26spage%3D6779%26epage%3D6810%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291881" title="Differentiation">Differentiation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/19" title="Go to Volume 53, Issue 19"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jmcmar.2010.53.issue-19/production/jmcmar.2010.53.issue-19.largecover.jpg" alt="Go to Volume 53, Issue 19"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although the outcome of therapy for leukemia has improved over the years, mainly in younger patients, less than a third of adults with acute myeloid leukemia (AML<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>), <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: 5-FU, 5-fluorouracil; 6-MP, 6-mercaptopurine; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; APL, acute promyeloid leukemia; Ara-C, cytarabine (cytosine arabinoside); ATRA, all-trans retinoic acid; Bcl, B-cell lymphoma; CDKs, cyclin-dependent kinases; CENP, centromere protein; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CRABPs, cellular retinoic acid-binding proteins; CSF-1R, colony stimulating factor 1 receptor; DHFR, dihydrofolate reductase; DMSO, dimethyl sulfoxide; DNMTs, DNA methyltransferases; DZNep, 3-deazaneplanocin A; EGCG, (−)-epigallocatechin 3-gallate; ERK, extracellular signal-regulated protein kinase; FKBP12, FK506-binding protein; FLT3, fms-like tyrosine kinase 3; FPP, farnesyl pyrophosphate; FRB, FKBP-rapamycin-binding domain; FTase, farnesyl transferase; FTI, farnesyl transferase inhibitor; G-CSF, granulocyte-colony stimulating factor; GIST, gastrointestinal stromal tumor; HDACs, histone deacetylases; HDACIs, histone deacetylase inhibitors; HES, hypereosinophilic syndrome; HMBA, hexamethylene bisacetamide; hOCT1, human organic cation transporter 1; HSCs, hematopoietic stem cells; HSP90, heat shock protein 90; IFN, interferon; ITD, internal tandem duplication; LICs, leukemia initiating cells; LSCs, leukemic stem cells; MAPK, mitogen activated protein kinase; MDS, myelodysplastic syndrome; MDR, multidrug resistance; MEL, murine erythroleukemia cells; MM, multiple myeloma; MTHFR, 5,10-methylentetrahydrofolate reductase; mTOR, mammalian target of rapamycin; MTX, methotrexate; NF-κB, nuclear factor κB; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small-cell lung cancer; P-gp, P-glycoprotein; PDGFR, platelet derived growth factor receptor; PEG, polyethylene glycol; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PKI, protein kinase inhibitor; PTEN, phosphatase and tensin homologue; RAR, retinoic acid receptor; RBCs, red blood cells; RXR, retinoid X receptor; SAHA, suberoylanilidehydroxamic acid; SAR, structure−activity relation; SBHA, suberic bishydroxamic acid; SMI, small molecule inhibitor; TG, thioguanine; TNF, tumor necrosis factor; TPMT, thiopurine <i>S</i>-methyltransferase; TrkA, tropomyosin receptor kinase A; TSA, trichostatin; TYMS, thymidylate synthase; VEGFR, vascular endothelial growth factor receptor; VPA, valproic acid; XIAP, X-linked inhibitor of apoptosis protein.</p></div> for example, are cured by current treatments, a fact stressing the need for new therapeutic approaches. Since leukemias are considered disorders of self-renewal, differentiation, and apoptosis of hematopoietic stem cells (HSCs) and/or their early progenitors, the treatment of leukemia is rapidly changing from conventional chemotherapy toward a more innovative individualized and targeted therapy.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a></div><div class="NLM_p">The discovery of leukemia stems cells (LSCs) in the late 1990s<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> as a minor fraction within the subpopulation of hematopoietic cells and the compelling research efforts initiated thereafter have clearly shown that many malignancies are maintained via stemlike cells having the capacity for indefinite self-renewal. This LSC hypothesis has established the notion that the emergence of drug resistance and the clinical relapse of leukemias following an initial remission induced by cytotoxic or targeted therapy agents is related to acquired mutations of LSCs. Therefore, eradication of LSCs is considered necessary for the radical treatment of leukemias. As a matter of fact, novel exploitable targets for leukemia therapy emerged including enzymes like tyrosine kinases involved in signal transduction pathways, genes encoding proteins that regulate apoptosis and differentiation of malignant cells, cell-lineage transcriptional factors, angiogenesis factors, and unique proteins driving the cell cycle machinery.<a onclick="showRef(event, 'ref1 ref2 ref5 ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref5 ref6 ref7 ref8 ref9 ref10">(1, 2, 5-10)</a> Interestingly, within the group of antileukemia agents exist small molecule drugs like tyrosine kinase inhibitors, proteasome inhibitors, farnesyl transferase inhibitors, hypomethylating agents, histone deacetylase inhibitors, mTOR targeting agents, bcl-2 inhibitors, and inhibitors of cyclin-dependent kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><div class="NLM_p">This paper is a comprehensive overview of the scientific efforts made to develop novel antileukemia therapeutics by presenting chemical, pharmacological, and pharmacogenomic data obtained during preclinical and clinical assessment of these agents. Furthermore, the designated synthesis of new medicines inducing differentiation, cell cycle arrest, and/or promoting apoptosis along with multitargeted therapeutics will be also discussed. Such novel agents can be used in combination with other agents modulating different signaling pathways and molecular targets within the leukemia cells to overcome the emergence of drug resistance. This information can then be discussed from a pharmacogenomic view of antileukemia therapeutics. Individual genetic variations recorded in antileukemia drug therapy can be critical for personalized medicine and their clinical exploitation can achieve better pharmacotherapy outcomes.</div><figure id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Diagrammatic presentation of molecular targets for known classes of small molecule antileukemia drugs used in clinical practice or under development and the proposed strategy for innovative multifunctional leukemia therapeutics (see text for details). Abbreviations are as follows: HSP, heat shock protein; RAR, retinoid acid receptor; RXR, retinoid X receptor; DNMTs, DNA methyltransferases; HDACs, histone deacetylases; CDKs, cyclin-dependent kinases; mTOR, mammalian target of rapamycin; FT, farnesyl transferase; FLT3, Fms-like tyrosine kinase 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Leukemias as Clonal Disorders of HSCs and Early Multipotent Progenitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15126" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15126" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Studies in the early 1970s by Fialkow et al. have revealed that human leukemias are more or less clonal disorders originating from self-proliferating hematopoietic cells in the bone marrow.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Although myeloblasts, erythroblasts, lymphoblasts, and others of early undifferentiated progenitors were considered responsible for specific types of acute or chronic myeloid, erythroid, and lymphoid leukemias, it was not clear which one of the stem cells and/or early progenitors are involved in leukemogenesis.</div><div class="NLM_p">The study of experimental leukemias (mouse and human) in culture and the unique ability of certain cell fraction in the leukemic cell population to develop colonies with unrestricted ability to grow via self-renewal made quite clear and also confirmed that leukemias are indeed clonal disorders initiating from a small number of undifferentiated cells. In term of properties, such cells were grown and maturated in vitro (cultures) and in vivo (animals) having a specific neoplastic phenotype relatively stable.<a onclick="showRef(event, 'ref2 ref10'); return false;" href="javascript:void(0);" class="ref ref2 ref10">(2, 10)</a> In contrast to normal hematopoietic cells, leukemic cells remain in culture undifferentiated with an acquired ability to proliferate and invade but unable to senesce.</div><div class="NLM_p last">The evidence that normal hematopoietic cells grown in fetal liver or in spleen can be transformed into leukemia cells able to propagate the leukemia in mice, and also samples of primary leukemic cells derived from leukemic subjects are grown and developed the disease in NOD/SCID mice,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> leaves no doubt that leukemogenesis is initiated at the level of either HSCs or early uncommitted progenitors. LSCs exhibit the same cell surface antigens with normal HSCs. Leukemias usually are initiated within the bone marrow environment and affect normal hematopoiesis either via paracrine function or otherwise in the stem cell niche.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Regardless how LSCs and leukemia-initiating cells (LICs) are born, grow, progress via self-renewal, and intersect with normal HSCs in their microenvironment, their existence indicates that leukemic cell growth and/or self-renewal is regulated at the cellular level via signaling pathways induced by external stimuli and operating at different levels: level of HSC niche, erythroblastic islands, and other sites. SCF/c-kit, Notch, Wnt, and Epo are critical signaling pathways that give the ability to LSCs to propagate the disease. Moreover, epigenetic events or production of fused transcription factors and enzymes also appear to contribute to leukemic cell growth and maintenance.<a onclick="showRef(event, 'ref1 ref5 ref12'); return false;" href="javascript:void(0);" class="ref ref1 ref5 ref12">(1, 5, 12)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">3 Conceptual Approaches Exploiting Induction of Differentiation and Apoptosis To Eradicate LSCs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chemotherapy of human leukemias with the use of conventional antineoplastic agents administered under several combination protocols is accompanied by severe adverse reactions, including myelosuppression, loss of hair, and transient damage of rapidly replicating tissues. This less selective pharmacological approach used for years was based on the principle of “just killing” in any way the leukemia cells using all types of antineoplastic agents (antimetabolites, antitumor antibiotics, alkylating agents, blockers of mitosis, and even organometallic compounds and natural products).</div><div class="NLM_p">The knowledge accumulated over the past several years on the nature of leukemic cells indicates that such cells can be converted into nondividing growth arrested cells unable to support malignant growth.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Moreover, it has been established that apoptosis can also be induced in leukemic cells using pharmaceutical agents and metabolic modulators, like kinase inhibitors. All this understanding taken together with the dependency of leukemia cells on microenvironmental factors and external stimuli suggests that multilevel targeting can be a fruitful approach to eradicate leukemia cells under less harmful conditions to adjacent normal tissues.<a onclick="showRef(event, 'ref1 ref5 ref12'); return false;" href="javascript:void(0);" class="ref ref1 ref5 ref12">(1, 5, 12)</a> A future challenge will then be to design agents that can differentiate leukemia cells into nondividing/nonmalignant growth-arrested cells and/or promote cell death concomitantly or thereafter in leukemia cell differentiated progeny.</div><figure id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Conceptual approaches combining induction of differentiation and promotion of apoptosis (cell death) of leukemia cells. Differentiation inducing agents (DIA) can disrupt self-renewal and cause growth arrest in terminal differentiated progeny unable to support malignant growth (A and C<sub>1</sub>). In contrast, apoptosis promoting agents (APA) can stimulate cell death signaling in undifferentiated as well as differentiated progenitors of leukemic cells (B and C<sub>1</sub>). Finally, differentiation and apoptosis hybrid (DAH) agents represent molecules with structural domains as bifunctional agents that can promote differentiation and/or apoptosis leading to eradication of leukemic cells (cell death) (C<sub>2</sub>) (see text for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Therefore, at least three classes of agents can be developed, as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>: (a) agents able to induce terminal cell differentiation and cessation of self-renewal, (b) agents able to exclusively promote apoptosis by acting at intrinsic or extrinsic signaling pathways, and (c) agents having structural domains that can promote both processes concomitantly by regulating gene activation and/or repression processes. Agents belonging to class A can be very potent inducers of leukemia cell differentiation, like retinoids, As<sub>2</sub>O<sub>3</sub>, potent molecules like suberoylanilide hydroxamic acid (SAHA, <b>1b</b>), phenyl acetate, and butyric acid analogues, or other agents like pyridine derivatives, cyclic ureas, and many others reported elsewhere.<a onclick="showRef(event, 'ref2 ref9'); return false;" href="javascript:void(0);" class="ref ref2 ref9">(2, 9)</a> Class B agents that can promote apoptosis can be either targeted antibodies or inhibitors of kinases involved in cell signaling pathways, tumor necrosis factor (TNF) and TRAIL-like agents as well as BH-mimetics, blocking the function of Bcl protein in mitochondria.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Agents of class A and class B can be combined appropriately, used either sequentially or in parallel, as depicted for class C<sub>1</sub>. Although these agents may differ in their optimum inducing concentration in promoting differentiation and/or apoptosis, pharmacokinetics studies may provide useful and effective management protocols for allowing them to carry out both functions. The most challenging approach, however, has been the design and development of agents of class C<sub>2</sub>. Hybrid agents sharing structural domains responsible for promoting differentiation induction and apoptosis in the same leukemia cells can be useful agents to disrupt their functions. The latter class of pharmaceutical agents must regulate critical steps involved in epigenetic regulation of gene activation and silencing. This can be done either via modulation of trans- and cis-elements of superfine structure of chromatin by interacting either directly on the genome at specific promoter sequences or distant elements or via cofactors regulating the active and repressive transcription complexes. Such innovative antileukemic agents can be combined even with relatively lower concentrations of conventional antineoplastic agents.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">4 Human Leukemia Cells Can Be Converted into Differentiated Nondividing Progeny</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery made by Friend et al. (1971)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> that virus-transformed hematopoietic progenitors derived from mouse spleen cells can be differentiated into hemoglobin producing cells in culture created the fertile ground and sparked many differentiation-related studies in oncology with mouse or human experimental leukemias. Differentiation of many leukemia cell lines (MEL, K-562, HEL, HL-60, KJ1, just to mention few) confirmed the working hypothesis proposed by L. Sachs that leukemic cells still retain the ability to differentiate via epigenetic regulation, regardless of the existing genetic abnormalities in such cells. Conversion of highly malignant leukemia cells into growth-arrested and nondividing progenies (myeloid or erythroid) provided the frame for the so-called “differentiation therapy of cancer”, a field that recently began to yield interesting antileukemia therapeutics for the treatment of PML, myelodysplastic syndrome (MDS), and other malignancies.<a onclick="showRef(event, 'ref2 ref14'); return false;" href="javascript:void(0);" class="ref ref2 ref14">(2, 14)</a></div><div class="NLM_p">Over the past 30 years, a lot of innovations were made by using in vitro models of leukemia cell differentiation. Such systems have been reviewed elsewhere.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In all these cases, the induction of leukemic cell differentiation was achieved in parallel with the development of suitable inducing agents and/or metabolic inhibitors also capable of restricting cell growth of these cells (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Among the various agents developed, either from high-throughput screening or selection based on predictive structure−activity relations (SAR) methodology, are agents likely to act at specific cell targets, such as metabolic enzymes, retinoid receptors, epigenetic regulators (transcription factors and cis-regulatory elements), and/or proteins with as yet unknown mechanism(s) of action. It is emphasized that the agents developed so far as potent inducers of leukemic cell differentiation using the MEL, HL-60, or K-562 cell model systems are quite diverse in structure and physicochemical properties because of targeting of various cellular components. The site of action also varies from cell membrane sites, signaling pathways, cell cycle kinases, cytoplasmic proteins, nuclear receptors, and several other components.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The development of these inducers thus far gave several classes of low molecular weight agents, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Some of these agents are cytotoxic on a molecular basis, and others are potent inducers of differentiation that cause cell growth arrest. This depends on their optimum concentration; some of them are nonspecific in causing cell-cycle arrest and cell death, while other agents do the opposite. However, an important issue is the development of bi- or multifunctional agents acting at multiple levels and capable of eradicating the population of LSCs, quiescent or not efficiently. By developing agents that carry two or three functional pharmacophore groups in their molecular structures to modulate different target molecules, one should expect to see better antileukemic agents with improved clinical outcome (Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Chemical Inducers Triggering in Vitro Differentiation of Leukemia Cell Models<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inducer</th><th class="colsep0 rowsep0" align="center">cell model</th><th class="colsep0 rowsep0" align="center">terminal differentiated phenotype</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1-α,25-dihydroxyvitamin D<sub>3</sub></td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">monocytic/macrophage</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3-deazauridine</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-azacytidine (<b>2a</b>)</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-56HL-602</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-FU</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6-TG</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">actinomycin D</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">activin A</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">antifolates</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">anthracyclins</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aphidicolin</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">megakaryocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apicidin</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ara-C</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">monocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">benzodiazepines</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bis-hydroxamic acids</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">butyric acid</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">monocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bryostatin-1</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">monocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">camptothecin</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">chromomycin</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cis-platin</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyclic ureas and thioureas</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dbcAMP</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DMSO</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">herbimycin</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hemin</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HMBA (<b>1a</b>)</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic/megakaryocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hydroxyurea</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hypoxanthine</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mithramycin</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phenyl acetate (PA)</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phorbol esters (PMA, TPA)</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">monocytic/macrophage</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">megakaryocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PMEA</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">purine analogues</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pyridine derivatives</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resveratrol</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">retinoids</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA (<b>1b</b>)</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sodium butyrate</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic/megakaryocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tallimustine</td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tiazofurin</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">granulocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TSA</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tunicamycin</td><td class="colsep0 rowsep0" align="left">HL-60</td><td class="colsep0 rowsep0" align="left">monocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">UDP</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bitamin B<sub>12</sub></td><td class="colsep0 rowsep0" align="left">K-562</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">xylosyladenosine</td><td class="colsep0 rowsep0" align="left">MEL</td><td class="colsep0 rowsep0" align="left">erythrocytic</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">For details see ref <a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">2</a>. Abbreviations: Ara-C, cytarabine (cytosine arabinoside); DMSO, dimethyl sulfoxide; 5-FU, 5-fluorouracil; HMBA, hexamethylene bisacetamide; PMEA, 9-(2-phosphonylmethoxyethyl)adenine; SAHA, suberoylanilide hydroxamic acid; 6-TG, 6-thioguanine; TSA, trichostatin; UDP, ureido derivatives of pyridine.</p></div></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">5 Differentiation Inducing Agents</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03758" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03758" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of Charlotte Friend established the notion that induction of differentiation by chemical agents in leukemic cells could reprogram the cells toward proliferation arrest and/or programmed cell death.<a onclick="showRef(event, 'ref1 ref13 ref15'); return false;" href="javascript:void(0);" class="ref ref1 ref13 ref15">(1, 13, 15)</a> The first experimental attempts, as initial basic research focused on chemical inducers of differentiation, drew attention to “polar/apolar compounds”, later known as hybrid polar compounds. Structure optimization of hexamethylene bisacetamide (HMBA, <b>1a</b>) led to the discovery of <b>1b</b>, a histone deacetylase inhibitor (HDACI). Experimentation with cytotoxic nucleoside analogues implicated in epigenetic regulation of gene expression, along with histone acetylation and methylation, revealed that compounds such as 5-azacytidine<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (<b>2a</b>) and 5-deoxyazacytidine<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (decitabine, <b>2b</b>) induce differentiation of leukemic cells in lower concentrations, with parallel inhibition of DNA methylation via inhibition of the enzyme DNA methyltransferase (DNMT). Finally, induction of differentiation of teratocarcinoma cells by retinoic acid<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and discovery of retinoic acid receptors<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> revealed its regulatory role in key signaling pathways and its successful clinical application to treat acute promyelocytic leukemia (APL). These three classes of agents are the most extensively studied in the search of chemical inducers of differentiation of leukemic cells and are more thoroughly presented below.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">5.1 Hybrid/Polar Compounds and HDAC Inhibitors</h3><div class="NLM_p">Hybrid/polar compounds were named on the basis of their physicochemical properties to have polar groups at their terminals and a highly hydrophobic linker in the middle of the molecule.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><b>1a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> the most promising agent of hybrid/polar compounds, reached phase II clinical trials on MDS and AML.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The discouraging results of this trial (high doses, suboptimal activity, and important toxicities) urged researchers to further optimize the potency of <b>1a</b>. Since tri- and tetraamides proved to be ineffective,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> replacement of the acetamide moiety with the metal chelating <i>N</i>-hydroxyamide emerged as an optimal one, and as a result, the synthesized suberic bishydroxamic acid (SBHA) displayed significantly increased differentiation-induced potency to leukemic cells compared to <b>1a</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Structure variations led to the discovery of <b>1b</b>, later named as vorinostat (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A), that was the most potent compound at that time.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>1b</b> proved to be a HDACI<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and after extensive clinical investigation was launched recently as an FDA approved drug for the treatment of the rare cutaneous T-cell lymphoma.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Also, romidepsin very recently (November 2009) gained FDA approval for the same pathological condition.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p">Since HDACIs have been extensively reviewed recently,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> attention will be given here on HDACIs that are in clinical trials for leukemia. HDACIs are studied either alone or commonly in combination with DNMT inhibitors. JNJ16241199<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> is in preclinical development for leukemias, and pyroxamide and SB939<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> are in phase I clinical trials for hematological malignancies. Further HDACIs in development are belinostat, entinostat, mocetinostat, romidepsin, panobinostat, and <b>1b</b>, which have been advanced to phase III clinical trials as a monotherapy or in combination with other agents (more information about these compounds can be found in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Combination trials of these inhibitors with hypomethylating agents are also commented in the paragraphs below.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Significant HDAC Inhibitors in Clinical Trials for Leukemia<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">category</th><th class="colsep0 rowsep0" align="center">leukemia clinical trials</th><th class="colsep0 rowsep0" align="center">phase (NCT ID)<a class="ref internalNav" href="#t2fn1" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">belinostat (PXD101, NSC 726630), TopoTarget</td><td class="colsep0 rowsep0" align="left">hydroxamic acid</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00357032)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with idarubicin</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00878722)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">entinostat (MS-275, MS275, SNDX-275, NSC 706995), Syndax Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">benzamide</td><td class="colsep0 rowsep0" align="left">MDS, AML, ALL, combination with GM-CSF</td><td class="colsep0 rowsep0" align="left">phase II (NCT00462605)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hematologic cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00015925)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mocetinostat (MGCD0103), MethylGene</td><td class="colsep0 rowsep0" align="left">benzamide</td><td class="colsep0 rowsep0" align="left">CLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00431873)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">untreated AML, high risk MDS</td><td class="colsep0 rowsep0" align="left">phase II (NCT00374296)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">high risk MDS, AML</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00324220)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDS, leukemia</td><td class="colsep0 rowsep0" align="left">phase I (NCT00324194, NCT00324129)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pivanex, Titan Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">short chain fatty acid</td><td class="colsep0 rowsep0" align="left">CLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00083473)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pyroxamide</td><td class="colsep0 rowsep0" align="left">hydroxamic acid</td><td class="colsep0 rowsep0" align="left">advanced cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00042900)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SB939, SBIO</td><td class="colsep0 rowsep0" align="left">hydroxamic acid</td><td class="colsep0 rowsep0" align="left">solid tumors, hematologic malignancies</td><td class="colsep0 rowsep0" align="left">phase I (NCT00741234)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">romidepsin (FR901228, FK228, NSC630176), Gloucester Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">bicyclic depsipeptide</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00062075)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDS, AML, NHL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00042822)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CLL and small lympholytic lymphoma, combination with bortezomib</td><td class="colsep0 rowsep0" align="left">phase I (NCT00963274)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hematologic cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00024180)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">panobinostat (LBH 589, LBH589, NVP-LBH589, LBH489B, LBH489A), Novartis</td><td class="colsep0 rowsep0" align="left">hydroxamic acid (iv and po) flexibility in developing combination regiments</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00880269)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase II/III (NCT00449761, NCT00451035)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ALL, AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00723203)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with idarubicin</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00840346)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML, combination with imatinib</td><td class="colsep0 rowsep0" align="left">phase I (NCT00686218)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">T-cell lymphoma and leukemia</td><td class="colsep0 rowsep0" align="left">phase II (NCT00699296)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat (zolinza, SAHA, <b>1b</b>), Merck</td><td class="colsep0 rowsep0" align="left">hydroxamic acid (FDA approved Oct 2006 for cTCL)</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00305773)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with sorafenib</td><td class="colsep0 rowsep0" align="left">phase I (NCT00875745)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">leukemia, MDS, combination with idarubicin</td><td class="colsep0 rowsep0" align="left">phase I (NCT00331513)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with idarubicin and cytarabine</td><td class="colsep0 rowsep0" align="left">phase II (NCT00656617)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with gemtuzumab and azacytidine</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00895934)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">acute leukemia, MDS, combination with cytarabine and etoposide</td><td class="colsep0 rowsep0" align="left">phase I (NCT00357305)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with gemtuzumab</td><td class="colsep0 rowsep0" align="left">phase II (NCT00673153)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma, CLL, NHL, combination with cladribine and rituximab</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00764517)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">B-cell CLL and small lymphocytic lymphoma, combination with rituximab and fludarabine phosphate</td><td class="colsep0 rowsep0" align="left">phase II (NCT00918723)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">acute leukemia or CML, combination with flavopiridol</td><td class="colsep0 rowsep0" align="left">phase I (NCT00278330)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with bortezomib</td><td class="colsep0 rowsep0" align="left">phase II (NCT00818649)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML, ALL, combination with dasatinib</td><td class="colsep0 rowsep0" align="left">phase I (NCT00816283)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ALL, lymphoblastic lymphoma, with decitabine and combination chemotherapy</td><td class="colsep0 rowsep0" align="left">phase I (NCT00882206)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; cTCL, cutaneous T-cell lymphoma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma.</p></div><div class="footnote" id="t2fn1"><sup>b</sup><p class="last">Represents the National Clinical Trials identifier (NCT ID).</p></div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">5.2 DNMT Inhibitors</h3><div class="NLM_p">DNMTs are the enzymes responsible for DNA methylation in mammals, being part of the epigenetic regulation of gene expression in eukaryotic cells. Epigenetic regulation of gene expression is the “switch” turning genes on and off by DNA methylation of CpG islands and/or histone modifications (acetylation, methylation) in specific lysine and arginine residues.<a onclick="showRef(event, 'ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31">(28-31)</a> Inactivation of tumor suppressor genes is a phenomenon often observed in the initiation and progression of leukemia as well as in malignancy in general. In a recent study,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the genes <i>THBS1</i> and <i>Ril</i> were found to be 100% hypermethylated in leukemia cell lines, and <i>ECAD</i>, <i>P15</i>, <i>ER</i>, <i>TMS1</i>, and <i>THBS4</i> were over 60% hypermethylated in leukemia cell lines. Furthermore, in a study in which bone marrow samples from AML patients were analyzed, it was found that 95% had at least one of the following genes hypermethylated and 75% had two or more. The genes referred to are calcitonin, estrogen receptor, <i>E</i>-cadherin, <i>p15</i>, <i>p16</i>, <i>Rb</i>, <i>GST-Pi</i>, and <i>HIC1</i>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Also, the role of DNA hypermethylation in acute lymphocytic leukemia (ALL) initiation and progression was presented recently.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> On this basis, hypomethylating agents could prove to be useful tools in leukemia therapy and some of them are in clinical trials or in clinical use.</div><div class="NLM_p">Hypomethylating agents, or more specifically DNMT inhibitors, can be divided into two categories<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> with respect to their chemical structure: nucleoside analogues and non-nucleoside inhibitors. The second can be further divided into small molecule inhibitors (SMIs) and natural products.</div><div class="NLM_p">The most studied nucleoside analogues are <b>2a</b>, <b>2b</b>, and zebularine<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (<b>2c</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B1). The first two are highly cytotoxic compounds, but at lower concentrations they can induce differentiation of leukemic cells and have an impact on DNA methylation.<a onclick="showRef(event, 'ref16 ref17 ref35'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref35">(16, 17, 35)</a> So far, they are FDA approved for the treatment of MDS and chronic myelomonocytic leukemia (CMML), but they also are included in a number of clinical trials, alone or in combination, for other malignancies (Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Azacytidine and Decitabine in Clinical Trials for Leukemia<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">conditions</th><th class="colsep0 rowsep0" align="center">phase (NCT ID)<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">azacytidine (<b>2a</b>) (5-azacytidine, NSC-102816, Vidaza), Celgene</td><td class="colsep0 rowsep0" align="left">CLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00413478)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT01016600) phase II (NCT00728520, NCT00387647, NCT00739388)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00813124)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase II (NCT00795548, NCT00915785)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase III (NCT00887068, NCT00422890)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, CMML, MDS</td><td class="colsep0 rowsep0" align="left">phase I (NCT00528983, NCT00761722)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with VPA and ATRA</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00326170)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II (NCT00339196)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with bortezomib</td><td class="colsep0 rowsep0" align="left">phase I (NCT00624936)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with standard chemotherapy</td><td class="colsep0 rowsep0" align="left">phase II (NCT00915252)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with gemtuzumab</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00766116)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II (NCT00658814)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with lenalinomide</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00890929)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with Ara-C</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00569010)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with lenalinomide</td><td class="colsep0 rowsep0" align="left">phase I (NCT00923234)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDS, CMML, combination with AsO<sub>3</sub></td><td class="colsep0 rowsep0" align="left">phase II (NCT00118196)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">decitabine (<b>2b</b>) (2′-deoxy-5-azacytidine, dezocytidine, NSC-127716, Dacogen), Eisai</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase III (NCT00260832)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II/III (NCT00398983)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II, (NCT00358644, NCT00492401)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase I (NCT00538876, NCT00986804, NCT00882206)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ALL</td><td class="colsep0 rowsep0" align="left">phase I (NCT00349596)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with bexarotene</td><td class="colsep0 rowsep0" align="left">phase I, NCT01001143</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00042003, NCT00042016, NCT00041990)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CMML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00113321)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase II (NCT00760084)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase I (NCT00049582)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, ALL</td><td class="colsep0 rowsep0" align="left">phase I (NCT00042796)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with AsO<sub>3</sub> and ascorbic acid</td><td class="colsep0 rowsep0" align="left">phase I (NCT00671697)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with rapamycin</td><td class="colsep0 rowsep0" align="left">phase I (NCT00861874)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with VPA + ATRA</td><td class="colsep0 rowsep0" align="left">phase II (NCT00867672)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, combination with bortezomib</td><td class="colsep0 rowsep0" align="left">phase I (NCT00703300)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML, combination with imatinib</td><td class="colsep0 rowsep0" align="left">phase II (NCT00054431)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with gemtuzumab</td><td class="colsep0 rowsep0" align="left">phase II (NCT00882102)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with clofarabine</td><td class="colsep0 rowsep0" align="left">phase II (NCT00778375)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS, combination with G-CSF and Ara-C</td><td class="colsep0 rowsep0" align="left">phase II (NCT00740181)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">leukemia, MDS, CML</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00002832, NCT00002831)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">leukemia, myelodysplastic syndromes, myeloproliferative disorders, combination with romidepsin</td><td class="colsep0 rowsep0" align="left">phase I (NCT00114257)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; ATRA, all trans retinoic acid; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; VPA, valproic acid.</p></div><div class="footnote" id="t3fn1"><sup>b</sup><p class="last">Represents the National Clinical Trials identifier (NCT ID).</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Clinical Trials Combining HDAC and DNMT Inhibitors<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">HDAC and DNMT inhibitors</th><th class="colsep0 rowsep0" align="center">conditions</th><th class="colsep0 rowsep0" align="center">phase (NCT ID)<a class="ref internalNav" href="#t4fn1" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VPA + azacytidine</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase II (NCT00382590)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sodium phenylbutyrate + azacytidine</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase I (NCT00004871)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, NHL, nSCLC, multiple myeloma, prostate cancer</td><td class="colsep0 rowsep0" align="left">phase II (NCT00006019)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VPA + decitabine</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00075010)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II (NCT00414310)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, CLL, small lymphocytic lymphoma</td><td class="colsep0 rowsep0" align="left">phase I (NCT00079378)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">belinostat + azacytidine</td><td class="colsep0 rowsep0" align="left">advanced hematological malignancies</td><td class="colsep0 rowsep0" align="left">phase I (NCT00351975)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">entinostat + azacytidine</td><td class="colsep0 rowsep0" align="left">CML, AML, MDS</td><td class="colsep0 rowsep0" align="left">phase I (NCT00101179)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II (NCT00313586)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mocetinostat + azacytidine</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00666497)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">panobinostat + azacytidine</td><td class="colsep0 rowsep0" align="left">MDS, CMML, AML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00946647)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">panobinostat + decitabine</td><td class="colsep0 rowsep0" align="left">MDS, AML</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00691938)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">romidepsin + decitabine</td><td class="colsep0 rowsep0" align="left">leukemia, MDS</td><td class="colsep0 rowsep0" align="left">phase I (NCT00114257)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat + azacytidine</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase II (NCT00948064)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00392353)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vorinostat + decitabine</td><td class="colsep0 rowsep0" align="left">NHL, AML, ALL, CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00275080, NCT00479232)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">hematologic cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00357708)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; nSCLC, non-small-cell lung cancer; VPA, valproic acid.</p></div><div class="footnote" id="t4fn1"><sup>b</sup><p class="last">Represents the National Clinical Trials identifier (NCT ID).</p></div></div></div><div class="NLM_p"><b>2b</b> is incorporated in the DNA where it traps DNMTs. DNMTs methylate cytosine residues at the 5′-C. Since the 5′-C is replaced with a nitrogen atom in the molecule of <b>2b</b>, no methylation can take place and a covalent bond is generated between the enzyme and the triazine nucleosides after its incorporation into DNA.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In low doses the result is hypomethylation, but in higher doses steric inhibition of DNA replication and repair due to the bulky adducts is thought to be the cause of <b>2b</b> cytotoxicity.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><b>2a</b> is thought to be converted to <b>2b</b> by ribonucleotide reductase before its incorporation into DNA. Besides, its cell growth inhibitory effect is also caused by its incorporation into RNA molecules and by affecting protein synthesis.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>2c</b>, initially synthesized as a cytidine deaminase inhibitor,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> is a deaminocytosine nucleotide that was developed to overcome <b>2a</b> and <b>2b</b> instability in neutral and acidic aqueous solutions in order to make oral administration of the drug feasible.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> However, low clinical efficiency, mostly due to cytidine deaminase inactivation and antagonism with the increased cytidine and deoxycytidine levels, has hindered its further development.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Finally, a second generation inhibitor currently under preclinical development is the <b>2b</b> dinucleotide SGI-110<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (<b>2d</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B1) that has proved advantageous in the manner of cytidine deaminase inactivation but has no improved stability in comparison to <b>2b</b>.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Differentiation inducing agents (DIA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the field of SMIs, a number of compounds have been found to possess DNMT’s inhibitory activity. At first, the approach to test known drugs for inhibitory activity was used, and hydralazine, procaine, and procainamide were recognized as DNMT inhibitors.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> A series of constraint analogues of procaine were also synthesized but with no inhibitory activity.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Also, a second approach applied was the rational design by using an in silico method that resulted in the identification of RG-108<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (<b>2e</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B2) as a DNMT1 inhibitor. <b>2e</b> was found to inhibit DNMT1 without binding covalently to it and caused DNA hypomethylation and reactivation of tumor suppressor genes,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> a fact of therapeutic significance in cancer to restrict cell proliferation.</div><div class="NLM_p">The most intriguing natural products that exhibit DNMT inhibitory activity are (−)-epigallocatechin 3-gallate (EGCG, <b>2f</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B3)<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and curcumin,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> though the multiple biological effects of these compounds and their antioxidant nature may intervene and deteriorate the evaluation of their beneficial anticancer activity.</div><div class="NLM_p last">So far, the most promising results come from the field of nucleoside analogues, since <b>2a</b> and <b>2b</b> induce strong demethylation as well as reactivation of tumor suppressor genes with the drawback of cytotoxicity and pH-related instability. <b>2c</b> and <b>2e</b> cause mediocre demethylation with mild or no cytotoxicity and can be used as lead compounds for further development.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">5.3 Combining HDAC and DNMT Inhibitors</h3><div class="NLM_p">As mentioned before, gene promoter hypermethylation and core histone hypoacetylation are epigenetic modifications that cause silencing of tumor suppressor genes and contribute to malignancy. A connection between hypermethylated gene promoter regions and histone modifications is emerging in the last couple decades, leading to thorough examination of potential synergistic anticancer activity of these two separate mechanisms of epigenetic regulation.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48-50)</a> The finding that the HDACI trichostatin (TSA) alone cannot up-regulate the expression of hypermethylated genes but that this becomes feasible upon co-treatment with the DNMT inhibitor <b>2b</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> generated the idea of combining the two agents in therapeutics in order to act synergistically for the re-expression of genes. Thus, sequential administration of a DNMT inhibitor followed by a HDACI could potentially increase the response rate and duration to benefit the therapeutic outcome. Alternatively, one also can consider the possibility of combining DNMT inhibitors with agents causing histone lysine demethylation, as recently proposed.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p last">The numerous clinical trials that employed DNMT and HDACI are described in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. The initial studies with HDACI such as valproic acid (VPA) and phenyl butyrate were insufficient to prove a distinct synergism, but this could be attributed to their low HDACI activity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In order to further explore the therapeutic potential of such an approach, more potent small molecule HDACIs should be evaluated in newly designed clinical trials. Some of them are now in progress.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">5.4 Retinoids and Retinoid Mimetics</h3><div class="NLM_p">Targeting the nuclear retinoid receptors has so far been proven as a reliable and effective method in the differentiation therapy of APL. Since the initial FDA approval of all-trans retinoic acid (ATRA, <b>3a</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C),<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> extensive studies have been taking place in order to reduce its severe side effects, improve its stability, and overcome the acquired tumor resistance. Modifications made on <b>3a</b> include the addition of heteroatoms to the candidate molecules and the replacement of the polyene chain with an aromatic ring, which resulted in the synthesis of the retinoid acid receptor α (RAR<sub>α</sub>) selective tamibarotene (AM80, <b>3b</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C) (EC<sub>50</sub> = 45, 235, and 591 nM, for RAR<sub>α</sub>, RAR<sub>β</sub>, and RAR<sub>γ</sub>, respectively).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a><b>3b</b> exhibits greater stability and bioavailability than <b>3a</b> because of the absence of the polyene chain and its less hydrophobic character. Also, it appears to bind poorly to cellular retinoic acid-binding proteins (CRABPs). As a result, <b>3b</b> has the potential to overcome ATRA-acquired resistance, since it is related to CRABPs that enhance <b>3a</b> catabolism and result in inefficiency.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> Furthermore, lack of binding to RAR<sub>γ</sub> receptor seems to diminish adverse effects, a fact that also favors <b>3b</b> compared to <b>3a</b>.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><b>3b</b> has also proved to be effective in patients that relapsed after complete remission with <b>3a</b> (58% against 20% complete remission with second treatment with <b>3a</b>). Further clinical trials enhanced these clinical results to the point of <b>3b</b> commercial availability (2005 in Japan, Toko Pharmaceuticals) and also fast drug designation for relapsed or refractory APL by the FDA (June 2007).</div><div class="NLM_p last">As an alternative route to overcome the above-mentioned <b>3a</b>'s drawbacks in adverse effects and emergence of resistance, targeting of the retinoid X nuclear receptor (RXR) emerged. Ligands that bind selectively to RXR emerged, and the term “rexinoids” arose.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Literature of rexinoids accumulated,<a onclick="showRef(event, 'ref57 ref58 ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59 ref60 ref61 ref62 ref63">(57-63)</a> but the most important compound of this category is considered to be the FDA approved bexarotene (<b>3c</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>C)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> for the treatment of cutaneous T-cell lymphoma. The putative use of <b>3c</b> on leukemia is still in preclinical stages, and for that reason it will not be extensively reviewed in this paper. Regardless of their multifunctionality, none of these retinoid compounds have entered clinical trials for the treatment of leukemia, so an extensive analysis is also out of the scope of this Perspective.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">6 Induction of Apoptosis in Leukemias</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">6.1 Bcl-2 Inhibitors</h3><div class="NLM_p">Extensive therapeutic exploration of apoptotic pathways has established B-cell lymphoma (Bcl) proteins as a new target for cancer therapy over the past years. Antisense RNA technology was the first approach applied to suppress Bcl-2 function, but subsequently the development of SMIs was considered as a more promising therapeutic strategy. The target region of the Bcl-2 protein was identified within a hydrophobic groove, the so-called BH3 binding region. The hunt to “get into the groove”<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> started with the screening of natural product libraries and continued with computer-based screening methodology of small molecules and the application of NMR fragment screening. Up to today, several candidates have been in preclinical development with very promising results, and some of them even reached clinical trials as monotherapy or combination therapy for leukemia. Most clinical trials are directed toward chronic lymphoid leukemia (CLL), since overexpression of Bcl-2 is observed in this type of hematologic malignancy.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">Although focus will be imposed on the development of SMIs regarding the <i>BCL-2</i> gene, two of the most important paradigms of antisense technology with successful introduction into clinical practice must be mentioned: oblimersen sodium<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> (Genta, G3139, <b>4a</b>) and SPC 2996<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> (<b>4b</b>). In particular, <b>4a</b> is a 18-nucleotide antisense molecule targeting the initiation codon region (codons 1−6) of BCL-2 mRNA.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Oblimersen sodium has successfully completed a phase I/II clinical trial on chronic myeloid leukemia (CML) treatment as a monotherapy and is currently under further clinical investigation (up to phase III trials) as combination therapy for CLL, CML, AML, and ALL.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Some of the biodistribution problems that arose because of its polyanionic character and rapid metabolism are hoped to be solved through PEGylation of the molecule.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Furthermore, applying the new technology of locked nucleic acids, <b>4b</b> is a 16-nucleotide antisense molecule that has reached the clinic and is now examined in a phase I/II trial in patients with relapsed or refractory CLL.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Screening of natural products for potential Bcl-2 inhibitors revealed that black tea polyphenols, and especially <b>2f</b>, inhibit Bcl-2 function, although with limited specificity, since these molecules also affect other pathways related to cell survival.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> However, a plethora of natural products has already been studied for <i>BCL-2</i> gene suppression including antimycin A,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> chelerythrine,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> and purpurogallin,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> but the most intensively studied and currently in clinical trials is (−)-gossypol [AT-101 (<b>4c</b>) Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>].</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. BH<sub>3</sub> Mimetics in Clinical Trials for Leukemia<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">trials on leukemia</th><th class="colsep0 rowsep0" align="center">further clinical trials</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">obatoclax mesylate (<b>4e</b>) (GX15-070), Gemin X Biotechnologies</td><td class="colsep0 rowsep0" align="left">Bcl-2, Bcl-XL, Bcl-w, Mcl-1</td><td class="colsep0 rowsep0" align="left">CLL (phase I/II)</td><td class="colsep0 rowsep0" align="left">MDS (phase II), myelofibrosis with myeloid metaplasia (phase II), mantle cell lymphoma (phase I), nSCLC (phase I/II), Hodgkin’s disease (phase II), NHL (phase I/II), SCLC (phase I/II), MM (phase I/II)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML (phase II)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABT-263 (<b>4j</b>) (RG7423), Abbott Laboratories</td><td class="colsep0 rowsep0" align="left">Bcl-XL, Bcl-2, Bcl-w, Bcl-B</td><td class="colsep0 rowsep0" align="left">hematologic malignancies (phase I/IIa)</td><td class="colsep0 rowsep0" align="left">SCLC (phase I), lymphoma, CD20(+) (phase I), solid tumors (and combination) (phase I)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CLL (B-cell) (phase I), phase II</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-gossypol (<b>4a</b>) (AT-101, levo-gossypol), Ascenta Therapeutics</td><td class="colsep0 rowsep0" align="left">Bcl-2, Bcl-XL, Bcl-w, Mcl-1</td><td class="colsep0 rowsep0" align="left">B-cell malignancies (CLL) phase II, combination with lenalidomide (CLL) phase I/II, combination with rituximab (CLL) phase II</td><td class="colsep0 rowsep0" align="left">prostate cancer (phase II), lung cancer (phase I/II), adrenocortical carcinoma (phase II), brain and CNS tumors (phase I/II), lymphoma (phase I), nSCLC (phase I), esophageal or GE junction cancer (phase I/II), SCLC (phase I/II), follicular lymphoma (phase II)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Source: Oncology KnowledgeBase <a href="http://oncologyknowledgebase.com/Login.aspx?ReturnUrl=%2fDefault.aspx" class="extLink">http://oncologyknowledgebase.com/Login.aspx?ReturnUrl=%2fDefault.aspx</a>. Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; CNS, central nervous system; GE, gastroesophageal; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; nSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.</p></div></div></div><div class="NLM_p"><b>4c</b> is currently under phase II clinical trials for CLL. <b>4c</b> binds Bcl-2 (<i>K</i><sub>i</sub> = 320 nM), Bcl-X<sub>L</sub> (<i>K</i><sub>i</sub> = 480 nM), and Mcl-1 (<i>K</i><sub>i</sub> = 180 nM).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> In studies where cell population isolated from patients with CLL was used, <b>4c</b> exhibits an EC<sub>50</sub> of 2 μM.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> But despite its potent binding and good pharmacokinetic profile, this molecule remains a highly reactive aldehyde and thus exhibits important cellular toxicity. On this basis and with the prospect to improve Bcl binding, several analogues have emerged: apogossypol (<b>4d</b>), apogossypolone (<b>4e</b>), and TW37 (<b>4f</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The first two, which are in preclinical development, do not possess the aldehyde group of gossypol and appear to better target Bcl-2 and Mcl-1.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76, 77)</a> The synthetic <b>4f</b> molecule appears to be the most promising with submicromolar IC<sub>50</sub> values for Bcl-2 and Mcl-1 and micromolar values for Bcl-X<sub>L</sub>.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Its binding affinity to Mcl-1 is of extreme importance to avoid the implication of drug resistance,<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> and the fact that <b>4f</b> is a pan-Bcl inhibitor establishes it as a promising compound for further development.</div><figure id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. BH<sub>3</sub> mimetics (BCL binding molecules).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, obatoclax mesylate (<b>4g</b>, Gemin X Biotechnologies, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>) derived from lead optimization of prodigiosin, tripyrrole natural products<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> has reached phase II clinical trials for the treatment of CLL and AML. With an EC<sub>50</sub> of 1.7 μM exhibited in B-cells derived from CLL patients,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a><b>4g</b> binding to Bcl-2, Bcl-w, Bcl-X<sub>L</sub>, and Mcl-1 is in the low micromolar range, although there is certain variability in the values reported, probably due to its poor solubility.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> However, a report from a recent phase I trial has confirmed a very short <i>t</i><sub>1/2</sub> and modest single agent activity of <b>4g</b>, thus suggesting a possible use in combination therapy only.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p last">Finally, in the area of rational design, additional SMIs have been identified by computational screening. These are HA14-1<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> (<b>4k</b>), its soluble analogue sHA14-1<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> (<b>4l</b>), and BH3I-1 (<b>4m</b>) and analogues.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Such molecules are some of the Bcl-2 suppressors identified thus far, but none of them advanced to clinical development. Abbott Laboratories through NMR fragment screening developed a series of compounds including A-385358<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> (<b>4h</b>) and ABT-737<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> (<b>4i</b>). Such experience led researchers recently to identify ABT-263 (<b>4j</b>), which exhibits acceptable oral bioavailability and is now under clinical development.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> As far as these molecules are concerned, the Bcl-X<sub>L</sub> hydrophobic groove was initially divided into two smaller sites that were separately targeted by SMIs, which were linked and slightly optimized to constitute a single precursor molecule bearing the acylsulfonamide moiety (Bcl-X<sub>L</sub><i>K</i><sub>i</sub> = 0.036 μM).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Attempts to minimize binding to human serum albumin yielded the molecule <b>4h</b>.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> At this point, Bcl-X<sub>L</sub> was specifically targeted, so <b>4h</b> bound much less tightly to Bcl-2 (<i>K</i><sub>i</sub> = 67 nM), compared with the binding to Bcl-X<sub>L</sub> (<i>K</i><sub>i</sub> = 0.8 nM). In order to achieve dual inhibition of both Bcl-2 and Bcl-X<sub>L</sub>, binding deeper in the groove was imperative and the piperidine moiety was under the scope at this time. Replacement with a piperazine moiety that is further substituted with a 4′-chlorobiphenyl moiety was the most favorable, and <b>4i</b> was discovered.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a><b>4i</b> had high affinity for both Bcl-2 and Bcl-X<sub>L</sub> (8 and 30 nM, respectively), and CLL cells proved to undergo apoptosis at very low concentrations (EC<sub>50</sub> = 4.5 nM and EC<sub>50</sub> = 7 nM),<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91, 92)</a> but this compound stayed at the preclinical level because of low aqueous solubility (<1 μg/mL) and poor oral bioavailability.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Three sites were then selected as the most prone to further optimization: (1) the dimethylamino group was converted to morpholine in an effort to improve the metabolic properties of the molecule, though with the drawback of reduced potency; (2) the nitro group, a site of potent toxicity, was replaced with a trifluoromethylsulfonyl group (in order to retain the electron-withdrawing properties and as a consequence the low p<i>K</i><sub>a</sub> of the sulfonamide group required for activity); (3) the biphenyl moiety transformed one phenyl ring to an appropriate cycloalkene in order to conserve rigidity but excluded another metabolically active site.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The result was the generation of <b>4j</b> that, despite its poor water solubility, was up to 50% bioavailable in animal models after oral delivery<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> because of its limited metabolism. <b>4j</b> attained high affinity for Bcl-2, Bcl-X<sub>L</sub>, and Bcl-w (<1 nM), but no activity against Mcl-1 was observed. In ALL xenograft models, <b>4j</b> induced complete tumor regression<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> and it advanced to clinical trials for hematologic malignancies.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">6.2 Tyrosine Kinase Inhibitors</h3><div class="NLM_p">Protein kinases are one of the most popular targets in the developmental therapeutics area of oncology. Since kinases mediate signaling pathways related to tumor suppressor genes or oncogenes and are implicated in the regulation of apoptosis, proliferation, invasion, and differentiation, targeting them has been proved to be an efficient pharmacological intervention in malignancy. Since tyrosine kinase targeting in hematological malignancies has been recently reviewed by Chase and Cross,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> attention here will be only to the inhibitors, with emphasis given on their structure−activity relationships and kinase inhibitory profile. Following imatinib’s (<b>5a</b>) breakthrough few years ago, seven kinase inhibitors were developed and entered the market, namely, <b>5a</b> [launched in 2001, Novartis, for CML, gastrointestinal stromal tumors (GIST), and hypereosinophilic syndrome (HES)], erlotinib [2005, OSI Pharmaceuticals/Gentech/Roche, for non-small-cell lung cancer (NSCLC) and pancreas cancer], gefitinib (2005, Astra-Zeneca, for NSCLC), dasatinib (<b>5c</b>) (2006, Bristol-Myers Squibb, for imatinib resistant CML), nilotinib (<b>5b</b>) (2007, Novartis, for imatinib resistant CML), sorafenib (<b>6f</b>) (2007, Bayer/Onyx, for renal cancer), sunitinib (<b>6d</b>) (2007, Pfizer, for renal cancer and imatinib refractory GIST), and lapatinib (2007, GlaxoSmithKline, for breast cancer). Since additional small molecule kinase inhibitors are under clinical and preclinical development for treatment of various malignancies other than leukemia, their coverage is beyond the scope of this paper.</div><div id="sec6_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">6.2.1 Bcr-Abl Kinase Inhibitors</h4><div class="NLM_p">Targeting the chimaeric Bcr-Abl tyrosine kinase found in the majority of Ph<sup>+</sup> (reciprocal translocation between chromosomes 9 and 22) CML patients, <b>5a</b> was developed as an effective inhibitor from a series of protein kinase C (PKC) inhibitors where the phenylaminopyrimidine core proved to have leadlike properties.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Structure optimization led to the phenylaminopyrimidine compound <b>5a</b><a onclick="showRef(event, 'ref8 ref97'); return false;" href="javascript:void(0);" class="ref ref8 ref97">(8, 97)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) that had the appropriate solubility and bioavailability to proceed to the clinic.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a><b>5a</b> proved to be a very selective inhibitor among various kinases (Abl, c-Kit, Lck, PDGFR, and CSF-1R),<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> a property believed to result from its binding to the inactive conformation of Bcr-Abl, the so-called “DGF-out” conformation.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> But while selectivity is generally observed, the vulnerability to mutations of this class of inhibitors is the common cause of therapeutic inefficiency. Specifically, the “gatekeeper” (T315I) and also other mutations of Bcr-Abl turn the balance toward the active conformation,<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> rendering <b>5a</b> and other inhibitors inactive.</div><div class="NLM_p">This is partially attributed to the occurrence of specific mutations in the gene encoding the Bcr-Abl fusion tyrosine kinase that cause conformational changes and alter <b>5a</b>’s affinity and effectiveness. Another Bcr-Abl independent mechanism of imatinib resistance is overexpression of the efflux protein glycoprotein (P-gp) in CML that it is likely to reduce the intracellular concentrations of <b>5a</b> to subtherapeutic levels, since <b>5a</b> is a Pg-p substrate.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> To this end, the accumulated knowledge thus far from structural and mechanistic insights of the polymorphic imatinib-insensitive Bcr-Abl kinase were further exploited to override the emergence of <b>5a</b> clinical resistance in the newer protein kinase inhibitor (PKI) drugs.<a onclick="showRef(event, 'ref7 ref103'); return false;" href="javascript:void(0);" class="ref ref7 ref103">(7, 103)</a> Indeed, such a direction has led to the clinical development of antileukemia multitarget kinase inhibitors <b>5b</b> and <b>5c</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) that are potent inhibitors of multiple kinases, inhibit both wild-type and mutated Bcr-Abl kinase, and are approved for the treatment of imatinib-resistant CML patients.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Unlike <b>5a</b>, <b>5c</b> is not a substrate of P-gp and also human organic cation transporter 1 (hOCT1), properties that are also beneficial in treating imatinib-resistant CML.<a onclick="showRef(event, 'ref102 ref104'); return false;" href="javascript:void(0);" class="ref ref102 ref104">(102, 104)</a></div><figure id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Bcr-Abl tyrosine kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>5b</b>, a phenylaminopyrimidine like <b>5a</b>, was developed as a less stringent <b>5a</b> analogue in order to bind putative mutated Bcr-Abl domains.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a><b>5b</b> is 20-fold more potent than <b>5a</b>, has increased selectivity, and was found to retain activity against 14 of 15 imatinib-resistant Bcr-Abl mutants.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a><b>5c</b>, on the other hand, an aminothiazole Src/Abl kinase inhibitor<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a> with activity on other kinases (Kit, PDGFR, ephrin A receptor kinase,<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> and the Tec kinase Btk<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a>), has even greater affinity (∼325-fold more potent than <b>5a</b>) due, at least partially, to its binding in inactive and active conformations of Bcr-Abl kinase.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> In CML cell models bearing imatinib-resistant mutants, <b>5c</b> was found to be active in 14 of 15 cases.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Recently, <sup>18</sup>F-dasatinib was synthesized to be used as a prognostic tool for kinase inhibitory activity with PET technology.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Also in clinical development are the benzamide Abl/Lyn kinase inhibitor bafetinib<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> (<b>5d</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) and the 3-quinolinecarbonitrile Src/Abl inhibitor bosutinib<a onclick="showRef(event, 'ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref115 ref116">(115, 116)</a> (<b>5e</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). <b>5e</b> is currently in phase III clinical trials for CML, whereas <b>5d</b> is in phase I. All these compounds were proved to be active against the majority of imatinib-resistant CML cells. The exception in all cases is the gatekeeper mutation T315I of Bcr-Abl, and resistance is thought to be caused by the loss of a hydrogen bond within the side chain of this residue.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p">The binding of chemical molecules to kinases has been extensively studied, along with the selectivity factors affecting it and their modes of binding. Crystallographic studies complemented with molecular simulation approaches have provided the positions for inhibitor/enzyme interactions for each inhibitor.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> A common structural characteristic of most of the inhibitors synthesized is the pyrimidine core, also present in ATP. Each inhibitor binds through different sites in the ATP binding cleft of Bcr-Abl, and apart from the structural flexibility of inhibitors, also of great importance in binding to mutant Bcr-Abl forms is the size/volume of the gatekeeper’s side chain because it allows access to the hydrophobic cleft located behind it.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Loss of activity through disruption of hydrogen bond formation with the side chain of the gatekeeper residue is another resistance mechanism, as mentioned above. In order to override this “Achilles' heel” in CML therapy, many compounds are currently in preclinical and clinical development.</div><div class="NLM_p">Multitargeted kinase inhibitors may afford a solution due to “off-target” activities they exhibit.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> XL228<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> and PHA-739358<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> (<b>5f</b>), KW2449<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> (<b>5g</b>), and AT9283<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> (<b>5h</b>) (identified as Aurora kinase inhibitors, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) have potency against the mutant T315I and are in clinical development for CML therapy.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The aforementioned inhibitors are ATP-competitive but share the property of no interaction with the gatekeeper residue, rendering them capable of T315I inhibition, and this could be clinically effective in resistant CML patients.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> Of novel mechanism, but not yet fully characterized, is homoarringtonine<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> (<b>5i</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), a proapoptotic cephalotaxine ester, in phase II clinical trials for patients with T315I mutant CML. Along with <b>5f</b>, DCC-2036<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> (<b>5j</b>, structure not disclosed) is also under clinical development. <b>5j</b> is an inhibitor targeting “switch pockets” distant from the gatekeeper region. However, tozasertib (<b>5k</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), a multitargeted Aurora kinase inhibitor, was recently withdrawn from a phase II clinical trial because of the rise of significant cardiotoxicity (see Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> for information on second generation inhibitors).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Second Generation Bcr-Abl Inhibitors in the Market and in Clinical Development<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">molecular targets other than Bcr-Abl</th><th class="colsep0 rowsep0" align="center">T315I inhibition</th><th class="colsep0 rowsep0" align="center">status</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nilotinib (<b>5b</b>) (AMN-107, Tasigna), Novartis</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">marketed for imatinib resistant CML</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinib (<b>5c</b>) (BMS-354825, Sprycel), Bristol-Myers Squibb</td><td class="colsep0 rowsep0" align="left">Kit, PDGFR, ephrin A receptor kinase, and Tec kinase Btk</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">marketed for imatinib resistant CML</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bafetinib (<b>5d</b>) (NS-187, INNO-406, CNS-9), Nippon Shinyaku</td><td class="colsep0 rowsep0" align="left">Lyn</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bosutinib (<b>5e</b>) (SKI-606), Wyeth</td><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">phase III</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XL228, Exelixis</td><td class="colsep0 rowsep0" align="left">Aurora A, IGF1, Src</td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AT9283 (<b>5h</b>), Astex Therapeutics</td><td class="colsep0 rowsep0" align="left">Aurora A and B, JAK-2, JAK-3</td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KW2449 (<b>5g</b>), Kyowa Hakko Kirin Pharma Inc.</td><td class="colsep0 rowsep0" align="left">FLT3, FGFR, Aurora A</td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PHA-739358 (<b>5f</b>), Nerviano Medical Sciences</td><td class="colsep0 rowsep0" align="left">Aurora</td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DCC-2036 (<b>5j</b>), Deciphera Pharmaceuticals LLC</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase I/II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">homoarringtonine (<b>5i</b>), Chemgenex Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">unknown mechanism of action</td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tozasertib (<b>5k</b>) (MK-0457, VX-680, VE-465), Merck</td><td class="colsep0 rowsep0" align="left">Aurora kinase, FLT3, JAK-2</td><td class="colsep0 rowsep0" align="left">positive</td><td class="colsep0 rowsep0" align="left">phase II (terminated)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: CML, chronic myeloid leukemia; FLT3, fms-like tyrosine kinase 3; IGF1, insulin like growth factor 1; PDGFR, platelet derived growth factor receptor.</p></div></div></div><div class="NLM_p">Another approach to circumvent resistance is the use of “allosteric” inhibitors that are non-ATP-competitive. Of these molecules, attention has been drawn to GNF-2<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> (<b>5l</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), a compound that binds to the myristate binding cleft at the N-terminus, resulting in stabilization of the protein in its inactive state, and ON012380<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> (<b>5m</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>), a potent inhibitor that blocks the substrate-binding site of Bcr-Abl. Unfortunately, these molecules have not been registered for clinical evaluation so far. Finally, other strategies under development to circumvent the emergence of resistance in CML patients are the application of innovative molecules such as small interfering RNAs (siRNAs), transcript-specific ribozymes, antisense oligonucleotide and peptide nucleic acids.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><div class="NLM_p last">Even though selectivity was initially sought in order for an inhibitor to proceed to the clinic, recently focus has been on multitargeted kinase inhibitors. With multitargeted kinase inhibitors, by the use of a single inhibitor, multiple components of the same signaling pathway can be regulated or multiple signaling pathways and cellular processes can be related to cell survival, differentiation, or apoptosis, thus leading to a more efficacious therapy and eradication of resistant cells. In such a case, more than one leukemia type (e.g., AML, ALL) or even solid tumors could be eventually treated. On the other hand, selectivity is sought in order to minimize severe side effects of a broad range kinase inhibitors. Additional studies on novel and current inhibitors may provide a solution to this dilemma to keep in balance the specificity with the multitargeted capacity, in terms of improved therapeutic outcome. Alternative strategies to address this issue discussed above should also provide ground for advancement in drug development in this area, in order for us to lead to safer therapy with diminished resistance and remissions.</div></div><div id="sec6_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">6.2.2 FLT3 Inhibitors</h4><div class="NLM_p">Activating mutations of the fms-like tyrosine kinase 3 (<i>FLT3</i>) gene are the second most common in AML (∼30% of patients) and the most important prognostic factor so far.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The most usual polymorphic form is internal tandem duplication (ITD) in the juxtamembrane domain of FLT3, but to a lesser extent point mutations of the tyrosine kinase are also observed.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Published data have indicated that FLT3 inhibitors suppress growth of leukemia cell lines and primary AML cells, a fact that is dependent upon expression of mutant FLT3 for growth.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Interestingly, one of the most important findings is the existence of a FLT3 mutant form in the LSC population.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> So far, many compounds have been investigated in preclinical studies and eight of them are now registered for clinical trials.</div><div class="NLM_p">Tyrphostins (AG1295, AG1296), originally developed as PDGFR and c-KIT inhibitors, were the first inhibitors reported to directly inhibit FLT3 autophosphorylation<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> but never reached clinical trials because of their lack of specificity.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><div class="NLM_p">Two indolocarbazoles, lestaurtinib (<b>6a</b>, CEP-701, KT-5555, SPM-924, Cephalon)<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> and midostaurin (<b>6b</b>, PKC412, Novartis)<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134, 135)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), both staurosporine analogues, were initially identified as tropomyosin receptor kinase A (TrkA) and PKC inhibitors, respectively, but were later recognized as potent FLT3 inhibitors. Both these compounds appear to have mediocre effects as a monotherapy, but complete remissions were reached (80−100% of patients) when combined with induction chemotherapy.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a></div><figure id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. FLT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Indolinones have been extensively investigated as FLT3 inhibitors, although this activity arose from selectivity studies and the compounds were initially developed as vascular endothelial growth factor receptor (VEGFR) inhibitors. The most studied compounds are SU5416<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> (<b>6c</b>) and <b>6d</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), the last being therapeutically used in renal cell carcinoma and imatinib resistant GIST. Both these compounds have inhibitory activity on c-KIT, PDGFR, and VEGFR. <b>6d</b> (SU11248, SUTENT, Sugen) was developed on the basis of previous SAR that verified that this molecule exhibited the most optimal overall profile in terms of potency for inhibiting receptor tyrosine kinase targets, solubility, protein binding, in vivo pharmacokinetic properties, and antitumor efficacy.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> On the contrary, however, the development of <b>6c</b> was terminated because of the short half-life of this compound in vivo, a result that gave poor pharmacokinetic properties to the molecule and limited clinical usefulness.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a></div><div class="NLM_p"><b>6d</b> as a monotherapy resulted in partial responses of short duration,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> an effect also observed with <b>6f</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). <b>6f</b> (BAY 43-9006, NEXAVAR, Bayer) is marketed for renal cell carcinoma, but the finding that it effectively inhibits FLT3-WT (wild type) and FLT3-ITD (mutated)<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> opened clinical trials for AML patients. Inefficient as a single agent and with activity only for FLT3-ITD AML,<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> it was also studied in phase II trials with induction chemotherapy, and the last registered clinical trial is a combination of G-CSF and Plerixafor plus <b>6f</b> (programmed to start on March 2010<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>).</div><div class="NLM_p">Two more agents were registered for clinical trials but they were discontinued. A phase I clinical trial with dovitinib<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> (<b>6g</b>, CHIR-258, TKI258, Novartis, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) on AML patients was terminated because of time-dependent drug accumulation in the body.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The piperazinylquinazoline tandutinib (<b>6e</b>) (MLN518, CT53518, Millennium, Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) studied in a phase II trial has shown reduction of peripheral AML blast cells in 30% of patients examined in FLT3-ITD AML but with limited efficacy on patients with FLT3 point mutations.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The latter caused discontinuation of the phase II trial.</div><div class="NLM_p">The compounds that were tested until now were “accidentally” found as FLT3 inhibitors and what was lacking from the area of trials was a selective inhibitor, rationally designed for FLT3 inhibition. AC220 (<b>6i</b>) (developed by Ambit Biosciences), a bis-arylurea derivative, is the most recent clinical candidate in the category of FLT3 inhibitors. Discovered from lead optimization of AB-530<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> (<b>6h</b>), <b>6i</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) is lacking the carboxamide group and has the addition of a highly water-soluble morpholine in order to exhibit an improved water solubility and pharmacokinetics.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> When compared to the other FLT3 inhibitors that entered clinical trials, <b>6i</b> was the most potent cellular FLT3-ITD inhibitor tested and also had the most enhanced inhibitory effect on cell proliferation along with highly attained selectivity.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Apart from FLT3, kinases with binding affinities within 10-fold <i>K</i><sub>d</sub> (1.6 nM) were c-KIT, PDGFRα, PDGFRβ, RET, and CSF1R and within 100-fold <i>K</i><sub>d</sub> were FLT1, FLT4, DDR1, and VEGFR2.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> When tested in a phase I clinical trial in AML patients, the toxicology profile was acceptable, rendering this compound tolerable and along with the excellent pharmacokinetic profile exhibited in humans and its beneficial clinical effects. The progression of <b>6i</b> to phase II was justified.<a onclick="showRef(event, 'ref147 ref148'); return false;" href="javascript:void(0);" class="ref ref147 ref148">(147, 148)</a></div><div class="NLM_p">Regarding the structural requirements of SMIs for binding to FLT3 kinase, the limited information is attributed to unsuccessful attempts to cocrystallize a FLT3−inhibitor complex. All the inhibitors discovered so far are ATP competitive based on biochemical assays, indicating the ability of these molecules to bind in the ATP pocket of FLT3.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Thus, general observations on structure are a purine/pyrimidine moiety mimicking the adenine structure in ATP and an aromatic domain that binds in the back pocket of the ATP site.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div><div class="NLM_p last">In summary, the AML patients who harbor FLT3 mutations have the greater possibility to benefit from FLT3 inhibitors therapy. Data obtained thus far have shown that FLT3 inhibitors exhibit optimal therapeutic potential when combined with conventional chemotherapy. The sequence of coadministered agents seems important, so that factor should be taken under consideration in clinical trials.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Also, focus should be given on pharmacokinetic profile as well as toxicity of future inhibitors in order to attain stable therapeutic concentration levels in the plasma over long periods of time, a factor of crucial importance in clinical responses.</div></div><div id="sec6_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">6.2.3 VEGFR Inhibitors</h4><div class="NLM_p last">In acute leukemia, angiogenesis was identified as another potential therapeutic target.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> In the most studied leukemia being AML, VEGF and other proangiogenic proteins are involved in its pathophysiology, since VEGF-promoted angiogenesis in bone marrow was positively correlated to AML progression.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Compounds that have been examined in clinical trials for leukemias are <b>6c</b>, <b>6d</b>, vatalanib,<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> pazopanib,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and <b>6f</b>. Since the main field of investigation for these compounds is solid tumor biology and therapy, only phase I trials have taken place for leukemia with insufficient results.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> However, combination therapy trials of these compounds with other anticancer agents either of novel mechanism or of conventional chemotherapeutics are still in great demand in oncology.</div></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22">6.3 mTOR Inhibitors</h3><div class="NLM_p">Rapamycin (<b>7a</b>, sirolimus, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) and its analogues (also called “rapalogues”) are the most studied of this field. Initially isolated from <i>Streptomyces hygroscopicus</i> in the mid-1970s in a sample collected from the Easter Island Rapa Nui, <b>7a</b> was first characterized as a potent antifungal and immunosuppressive agent. Antitumor activity was detected on a NCI screening program taking place in the 1980s, although its mechanism of action was unknown until the mid-1990s when the mammalian target protein of rapamycin (mTOR) was identified. mTOR exists in two forms, mTOR1 and mTOR2.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Extensive clinical trials on <b>7a</b> delivery for a variety of pathological conditions resulted in its approval by the FDA as an immunosuppressor in kidney transplantation in the late 1990s.<a onclick="showRef(event, 'ref157 ref158'); return false;" href="javascript:void(0);" class="ref ref157 ref158">(157, 158)</a></div><div class="NLM_p">Structurally, <b>7a</b> is a macrocyclic lactone, including two regions that bind to mTOR and the FK506-binding protein (FKBP12). To be biologically active, <b>7a</b> forms a complex with FKBP12, which in turn binds to FKBP-rapamycin-binding domain (FRB) domain adjacent to the catalytic domain of mTOR, thus inhibiting the signaling cascade.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> The “rapalogues” mostly examined all bear these two regions unmodified with derivatization affecting only the substituent on C-42 as has previously been revealed. Interestingly enough, these compounds interact only with mTOR complex 1 (mTORC1), since the FRB domain in mTORC2 seems to be inaccessible to them.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> This effect has been blamed for the modest activity of rapalogues in the clinic, since there is feedback activation of PI3K/AKT signaling.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><div class="NLM_p">The most studied analogues of <b>7a</b> are everolimus (<b>7b</b>), temsirolimus (<b>7c</b>), and deforolimus (<b>7d</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). All these compounds share great similarity to the parent compound being modified only to the C-42 substituent. <b>7c</b>, the 42-[2,2-bis(hydroxymethyl)]propionic ester of <b>7a</b>, has improved water solubility in comparison to the parent compound, and it is the first analogue to be developed. After extensive clinical testing in a number of malignancies, <b>7c</b> acquired FDA approval in 2007 for the treatment of advanced renal cell carcinoma. In hematological malignancies it is currently being studied in CLL, AML, CML either alone or in combination with other anticancer agents (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>), but the most promising results came from a clinical trial on mantle cell lymphoma with a response rate of 38%.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> In mantle cell lymphoma cells, mTOR signaling was shown to be activated and contributing to tumor cell survival and progression. On the other hand, mutations on phosphatase and tensin homologue (<i>PTEN</i>), which acts as a tumor suppressor gene, were found in most cancers and thought to be responsible for rendering the cells resistant to apoptosis. The same cell population, though, has proved to be significantly more sensitive to sirolimus (<b>7a</b>), a fact of clinical importance that needs further investigation in order to explore mTOR and PTEN functions in mutated forms of malignancy.<a onclick="showRef(event, 'ref163 ref164'); return false;" href="javascript:void(0);" class="ref ref163 ref164">(163, 164)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Rapalogues (mTOR Inhibitors) in Currently Ongoing Clinical Trials for Leukemia<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">combination trials</th><th class="colsep0 rowsep0" align="center">leukemia</th><th class="colsep0 rowsep0" align="center">phase (NCT ID)<a class="ref internalNav" href="#tbl7-fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sirolimus (<b>7a</b>) (rapamycin, Rapamune), Wyeth</td><td class="colsep0 rowsep0" align="left">monotherapy</td><td class="colsep0 rowsep0" align="left">acute leukemia, NHL</td><td class="colsep0 rowsep0" align="left">phase I (NCT00068302)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+mitoxantrone</td><td class="colsep0 rowsep0" align="left">AML, CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00780104)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+etoposide</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+cytarabine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+PEG-asparaginase</td><td class="colsep0 rowsep0" align="left">ALL</td><td class="colsep0 rowsep0" align="left">phase I (NCT00957320)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+corticosteroids</td><td class="colsep0 rowsep0" align="left">ALL</td><td class="colsep0 rowsep0" align="left">phase I (NCT00874562)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+etoposide</td><td class="colsep0 rowsep0" align="left">ALL, CML</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00776373)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+cytarabine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+combination chemotherapy</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00634244)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">temsirolimus (<b>7c</b>) (CCI-779, Torisel), Wyeth</td><td class="colsep0 rowsep0" align="left">monotherapy</td><td class="colsep0 rowsep0" align="left">CLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00290472)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NHL, CLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00084474)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+clofarabine</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00775593)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+imatinib</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00101088)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+IMC-A12</td><td class="colsep0 rowsep0" align="left">advanced or metastatic cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00678223)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">everolimus (<b>7b</b>) (RAD001, RAD001C, Afinitor, Certican), Novartis Pharma</td><td class="colsep0 rowsep0" align="left">monotherapy</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00636922)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ALL</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00968253)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+PKC412</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase I (NCT00819546)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+panobinostat</td><td class="colsep0 rowsep0" align="left">lymphoma, MM</td><td class="colsep0 rowsep0" align="left">phase I (NCT00962507)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+bortezomib</td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma, NHL</td><td class="colsep0 rowsep0" align="left">phase I (NCT00671112)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+alemtuzumab</td><td class="colsep0 rowsep0" align="left">CLL</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00935792)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+nilotinib</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00762632)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+cytarabine</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00544999)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+daunorubicin</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma.</p></div><div class="footnote" id="tbl7-fn2"><sup>b</sup><p class="last">Represents the National Clinical Trials Identifier (NCT ID).</p></div></div></div><div class="NLM_p"><b>7b</b>, 42-<i>O</i>-(2-hydroxyethyl)rapamycin, is an analogue developed for per os administration. It is currently approved as an immunosuppressive agent by FDA for kidney and heart transplantation (CERTICAN), as well as for renal cell carcinoma resistant to treatment with <b>6d</b> or <b>6f</b> (AFINITOR). <b>7b</b> is also undergoing clinical trials for AML and ALL as monotherapy, as well as combination therapy with classical chemotherapeutic agents or epigenetic drugs for AML, MDS, CLL, myeloma, and lymphoma (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>). It is of great importance that in AML cells, <b>7c</b> and <b>7b</b> suppress assembly of mTORC2, inhibiting AKT signaling in vitro and in vivo.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> As deregulation of the PI3K/AKT pathway is a common feature of hematological malignancies, inhibition of mTOR may provide a useful novel therapeutic strategy.</div><div class="NLM_p"><b>7d</b> is a dimethylphosphinate rapamycin analogue that retains high affinity to FKBP12 and is also stable in organic solvents, water (regardless of the pH), and plasma. Administration is possible via the intravenous route or per os.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Most clinical trials on <b>7d</b> have focused on sarcoma and endometrial cancer, but as far as leukemia is concerned, a phase II study in patients with refractory hematologic malignancies has been conducted, showing partial benefit for patients.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><div class="NLM_p">There is a plethora of other rapalogues synthesized with precursor-directed biosynthesis, genetic manipulation, and directed mutasynthesis.<a onclick="showRef(event, 'ref167 ref168 ref169 ref170'); return false;" href="javascript:void(0);" class="ref ref167 ref168 ref169 ref170">(167-170)</a> However, since these analogues never reached the clinic, we will not focus on them and examine instead some SMIs of mTOR.</div><div class="NLM_p">Selective SMIs of mTOR have been synthesized but are still at preclinical levels of evaluation.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Thus far, attention has been drawn to mixed mTOR/PI3K inhibitors such as SF1126<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> (<b>7e</b>), NVP-BEZ235<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> (<b>7g</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), and XL-765<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> (<b>7h</b>, structure undisclosed) that are currently in phase I clinical trials. <b>7e</b> is a prodrug of the morpholinochromenone LY294002 (<b>7f</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>) with improved solubility and bioavailability that exhibits pan-PI3K inhibition and is now undergoing phase I evaluation for advanced or metastatic solid tumors.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a><b>7g</b> is an imidazo[4,5-<i>c</i>]quinoline that inhibits PI3K/mTOR by binding to their ATP cleft with low nanomolar affinity.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Finally, <b>7h</b> is also a nanomolar inhibitor of PI3K and mTOR currently in three phase I trials on solid tumors and gliomas.</div><figure id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. mTOR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24">6.4 Proteasome Inhibitors</h3><div class="NLM_p">The potential role of proteasome in leukemia has been extensively reviewed.<a onclick="showRef(event, 'ref175 ref176 ref177'); return false;" href="javascript:void(0);" class="ref ref175 ref176 ref177">(175-177)</a> Following commercialization of bortezomib<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> (<b>8a</b>) for the effective treatment of multiple myeloma and cell lymphoma, a number of proteasome inhibitors have been synthesized and, apart from <b>8a</b>, four of them [MLN9708<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> (<b>8b</b>), salinosporamide A<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> (<b>8i</b>), carfilzomib<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> (<b>8e</b>), and CEP-18770<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> (<b>8c</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>)] are being evaluated in clinical trials on hematological malignancies (mostly in multiple myeloma and lymphoma).</div><figure id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proteasome inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Depending on the structure, the proteasome inhibitors thus far studied can be divided into five classes: peptide aldehydes, peptide boronates, peptide vinyl sulfones, peptide epoxyketones, and β-lactones.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Apart from β-lactones, all the other classes of inhibitors are peptides harboring an electrophilic group at one end that can form covalent bonds with the catalytic threonine residue of the proteasome subunits.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> β-Lactones form adducts. Peptide aldehydes and vinyl sulfones share metabolic instability, lack selectivity,<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> and are not potent candidates for further development and clinical application.</div><div class="NLM_p"><b>8a</b> (MLN341, LDP-341, PS-341, MG-341, VELCADE, developed by Millenium Pharmaceuticals) is an <i>N</i>-acyl-pseudodipeptidylboronic acid and was developed in an effort to replace the aldehyde moiety of proteasome inhibitors. Peptidyl aldehydes are also potent inhibitors of thiol proteases and calpains and display instability due to the acidity of the α-proton. Replacement of the aldehyde with the boronic acid moiety was favorable in terms of potency as well as selectivity, since <b>8a</b> displayed IC<sub>50</sub> = 0.6 nM and a 200 000-fold selectivity for proteasome over cathepsins.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Preclinical studies,<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> followed by extensive clinical trials resulted in commercialization and the continuation of clinical trials for a variety of indications. Currently <b>8a</b> is included in 453 clinical trials, 41 of which refer to leukemia treatment.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A large number of trials that promote combination therapy with <b>8a</b> are also under investigation, and some of the most promising for leukemia include combinations with tipifarnib<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> (<b>9a</b>), <b>2a</b>/<b>2b</b>, <b>1b</b>, and romidepsin and classic chemotherapy.</div><div class="NLM_p"><b>8b</b> is a novel proteasome inhibitor also developed by Millenium Pharmaceuticals. It is an orally bioavailable inhibitor that in plasma rapidly hydrolyzes to its metabolite MLN2238, capable of binding reversibly to the chymotrypsine-like subunit of the 20S proteasome.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> It first entered clinical trials on March 2009 in a phase I trial for advanced nonhematological malignancies. Following that trial, two more phase I trials for lymphoma and multiple myeloma emerged, as well as a phase I/II trial on patients with relapsed or refractory multiple myeloma.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Another boronic acid in clinical development is <b>8c</b>. Bearing the pyridylcarboxamide moiety, this dipeptylboronic acid was developed as an oral proteasome inhibitor. It displays selectivity for the trypsin over chymotrypsin activity (more than 1000-fold), and in a panel of 42 protease assays only modest inhibition of cathepsin G and chymase was observed. Cellular permeability is very high (EC<sub>50</sub> = 13.5 nM in the MOLT-4 cellular assay and IC<sub>50</sub> = 13.7 nM in the enzyme assay), and oral bioavailability in rats and mice was 54% and 39%, respectively.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a><b>8c</b> is currently in a phase II clinical trial on relapsed multiple myeloma refractory to recent therapy.</div><div class="NLM_p">Upon delivery of <b>8a</b> at recommended doses, limiting toxicity arose that was related to peripheral neuropathy and thrombocytopenia, in part due to the inhibition of serine proteases (although much less in potency, there is parallel inhibition of them). In this context, compounds of alternative chemical structure were sought and a very promising candidate proved to be carfilzomib (PR-171, <b>8e</b>). <b>8e</b>, a structural analogue of the natural product epoxomicin (<b>8d</b>), belongs to the epoxyketone class of proteasome inhibitors. <b>8e</b> exhibits potency equal to that of <b>8a</b> but greater selectivity for the chymotrypsin-like activity of the protasome. Furthermore, in preclinical evaluation, <b>8e</b> exhibited promising tolerability and efficacy that resulted in clinical evaluation trials, up to phase II, as a treatment for hematological malignancies.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a></div><div class="NLM_p">As an epoxide, <b>8e</b>, is very reactive and its stability was too problematic to allow oral administration. On the basis of such data, accepted oral bioavailability values were warranted, and afterward through a series of structure optimization, the novel inhibitor PR-047 (<b>8f</b>) was developed (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Though an epoxide, the methoxymethylene chains improved the molecule’s solubility and shortening of the peptide part improved bioavailability.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a><b>8f</b> is still in preclinical evaluation, but with IC<sub>50</sub> = 82 nM and oral bioavailability of 17% (mouse), 21% (rat), and 39% (dog), it has been recommended for clinical development.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></div><div class="NLM_p">From the field of natural products, lactacystin (<b>8g</b>) and <b>8i</b> are two proteasome inhibitors of the β-lactone class. <b>8g</b> is a thioester prodrug, precursor to clasto-lactacystin (or omuralide, <b>8h</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) which is the active β-lactone-γ-lactam.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> This bicyclic ring system is also found in <b>8i</b> but differently substituted and is considered to be the active pharmacophore of this group of compounds after evaluation of hydrolyzed derivatives. <b>8i</b> is a product of the marine actinomycete <i>Salinospora tropica</i> that acts as an irreversibly bound inhibitor of the proteasome. Moreover, apart from the chymotrypsin-like activity (2.6 nM) it also inhibits trypsin-like activity (21 nM) and to a lesser degree caspase-like activity (430 nM).<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a><b>8i</b> is currently investigated in phase I clinical trials for advanced malignancies, relapsed/refractory multiple myeloma, solid tumors, and lymphoma. Also, preclinical studies have shown potential use in CLL,<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> and combination therapy with HDACIs is also conducted in leukemia cells<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> and in a phase I clinical trial (NCT00667082).</div><div class="NLM_p last">The binding kinetics of proteasome inhibitors seems to be of utmost importance in their pharmacological profile. In particular, irreversible inhibitors might be trapped in proteasomes in readily available sights upon their first entrance in the body (e.g., RBCs, liver), a fact that renders lower concentration inhibitors to exhibit therapeutic efficacy in malignant sites (“sink effect”).<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Such disadvantages are considered to be diminished in the cases of <b>8a</b> and <b>8b</b> as well as <b>8c</b> which are slowly and rapidly reversible inhibitors, respectively. However, most studies are needed to verify the pharmacological importance of such an approach.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">6.5 Farnesyl Transferase Inhibitors (FTIs)</h3><div class="NLM_p">The Ras family of genes encodes proteins implicated in key cellular processes such as proliferation, differentiation, and survival. Ras activation is dependent on isoprenylation (farnesylation catalyzed by FTase or geranylation catalyzed by GGTase) signaling its transport from the cytoplasm to the membrane. <i>Ras</i> is frequently deregulated in human cancer. Focusing on hematological malignancies, <i>Ras</i> mutations have been observed in 10−65% of cases studied. More specifically, <i>Ras</i> mutations have been encountered in 5−15% of patients in ALL, 10−40% in MDS, 15% in AML, and up to 65% in CMML.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Moreover, <i>Ras</i> activation can occur through other mechanisms such as through the Bcr-Abl chimaeric kinase in CML.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><div class="NLM_p">FTIs were first synthesized in an effort to prevent activation of RAS by blocking its post-translational modifications.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> These molecules prevent the transfer of a farnesyl moiety to a cystein residue (belonging to the CAAX motif; C stands for cysteine, A for aliphatic amino acid, and X for any amino acid) of numerous substrate proteins, RAS included.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> So far, FTIs are categorized in four classes of inhibitors based on the approach being able to block FTase.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></div><div id="sec6_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">6.5.1 Farnesyl Pyrophosphate (FPP) Analogues</h4><div class="NLM_p last">Examples of these agents, such as α-hydroxyfarnesylphosphonic acid, were among the first FTIs to demonstrate inhibition in cell culture.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> However, the design and synthesis of these analogues were swiftly terminated, since FPP is used in multiple normal cellular processes and these analogues could result in excessive toxicity.</div></div><div id="sec6_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">6.5.2 CAAX Peptidomimetics</h4><div class="NLM_p last">The most promising agent, L-788123, was tested in a phase I clinical trial for advanced solid tumors but was discontinued because of severe toxicity (grade IV thrombocytopenia, fatigue, and cardiac conduction abnormalities).<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> The agents that comprise this category were all extensively ionized at normal pH values and exhibited limited membrane permeability resulting in reduced in vivo activity.</div></div><div id="sec6_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">6.5.3 Bisubstrate Analogues</h4><div class="NLM_p last">These agents were developed in an effort to simultaneously target both FPP and CAAX. Problematic pharmacokinetic profile, however, was once again displayed, since these agents had poor intracellular infusion due to their large size.</div></div><div id="sec6_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">6.5.4 Nonpeptidomimetic Inhibitors</h4><div class="NLM_p">This category includes heterogeneous small molecules belonging to a variety of chemical structures. These non-peptide mimetics share the common feature of competition with the protein−CAAX motif. Since the previous categories of FTIs had unfavorable physicochemical properties resulting in poor pharmacokinetics, the development of such inhibitors was focused on small-molecule non-peptide mimetic agents. The most promising agents evaluated thus far [the orally bioavailable <b>9a</b>, lonafarnib<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> (<b>9b</b>), and the iv administered BMS-214662<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> (<b>9c</b>) (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>)] were further processed in clinical trials and are still under evaluation as a monotherapy or in combination with other anticancer drugs for the treatment of leukemia and other malignancies (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Farnesyl Transferase Inhibitors in Clinical Trials for Leukemia<a class="ref internalNav" href="#tbl8-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">combination trials</th><th class="colsep0 rowsep0" align="center">leukemia</th><th class="colsep0 rowsep0" align="center">phase (NCT ID)<a class="ref internalNav" href="#tbl8-fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tipifarnib (<b>9a</b>) (R115777, Zarnestra), Janssen Pharmacutica</td><td class="colsep0 rowsep0" align="left">monotherapy</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">phase I (NCT00022451)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">advanced hematologic cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00005967)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase III (NCT00093990, NCT00093470)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II (NCT00354146, NCT00093418, NCT00048503, NCT00045396, NCT00027872)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase I (NCT00101296)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDS</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00005846)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase I (NCT00005845)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase II (NCT00045396)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00004009)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">GLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00331591, NCT00360776)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+cytarabine, daunorubicin</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00101153)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+idarubicin, cytarabine</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00096122)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+chemotherapy</td><td class="colsep0 rowsep0" align="left">AML, MDS</td><td class="colsep0 rowsep0" align="left">phase I (NCT00124644)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II/III (NCT00454480)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+etoposide</td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00112853)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">phase II (NCT00602771)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+bortezomib</td><td class="colsep0 rowsep0" align="left">AML, CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00383474)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00510939)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+imatinib</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00040105)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lonafarnib (<b>9b</b>) (SCH 66336, Sarasar), Schering-Plough</td><td class="colsep0 rowsep0" align="left">monotherapy</td><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00034684)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00038597)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MDS, CMML</td><td class="colsep0 rowsep0" align="left">phase III (NCT00109538)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">+imatinib</td><td class="colsep0 rowsep0" align="left">CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00047502)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-214662 (<b>9c</b>), Bristol-Myers Squibb</td><td class="colsep0 rowsep0" align="left">monotherapy</td><td class="colsep0 rowsep0" align="left">acute leukemia, MDS, CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00006213)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl8-fn1"><div class="footnote" id="tbl8-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; GLL, large granular lymphocyte leukemia; MDS, myelodysplastic syndrome.</p></div><div class="footnote" id="tbl8-fn2"><sup>b</sup><p class="last">Represents the National Clinical Trials Identifier (NCT ID).</p></div></div></div><div class="NLM_p"><b>9a</b> was the first FTI to enter the clinic in 1997. It is the most extensively studied FTI, counting over 70 clinical trials on various malignancies. In hematologic malignancies it has reached phase III trials either alone or in combination with other anticancer agents. <b>9a</b> emerged from structure optimization after an initial computer-assisted screening procedure on antifungal libraries of Janssen. The imidazole ring in its structure seems of utmost importance, being also a common feature with <b>9c</b>, targeting the Zn<sup>2+</sup> ion of FTase.</div><div class="NLM_p">Having a stereocenter, the (<i>R</i>)-enantiomer of <b>9a</b> proved to be about 50-fold more potent than the (<i>S</i>)-enantiomer, reaching IC<sub>50</sub> and EC<sub>50</sub> values of 0.6 and 1.8 nM, respectively.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Its good oral bioavailability and linear pharmacokinetic profile contributed to the numerous clinical evaluations conducted thus far. From the very beginning, it was apparent that its use is more beneficial in hematologic malignancies in comparison to solid tumors.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Moreover, <b>9a</b>’s concentration in bone marrow of leukemic patients appears to be 3- to 4-fold higher than serum levels, making myeloid malignancies the most potent to clinical response.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> So far, <b>9a</b> has been clinically evaluated mostly in AML but also in MDS and CML.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> The most recent combination clinical trials including <b>9a</b> with conventional chemotherapy are in phase III evaluation, and other trials with etoposide and <b>8a</b> are in phase II. Combination of <b>8a</b> with <b>9a</b> has been also advantageous, since it overcomes resistance in multiple myeloma and AML cells in a preclinical survey.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a></div><figure id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Farnesyl transferase inhibitors (FTIs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The benzocycloheptapyridyl pharmacophore emerged from studies based on the screening of a library of chemical compounds initially developed as potential antihistaminics by Schering-Plough. Derivatization of the lead compound SCH-37370 resulted in the discovery of <b>9b</b>, a compound that, except for its optimal potency (IC<sub>50</sub> = 1.9 nM and COS IC<sub>50</sub> = 10 nM), also had an advantageous pharmacokinetic profile and could be administered orally (76% oral bioavailability).<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Crystallography studies on the complex of FTase with <b>9b</b> inspired the synthesis of indolocycloheptapyridyl compounds<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> that were further optimized to produce a second generation of inhibitors bearing the known moiety of the imidazole. The most potent inhibitor (SCH-226374) exhibited FTase IC<sub>50</sub> in the subnanomolar range and acceptable pharmacokinetic behavior but did not proceed to clinical testing.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a></div><div class="NLM_p">The clinical evaluation of <b>9b</b> is centered on progeria (HutChinson-Gilford Syndrome) and solid tumors. Although there are some clinical trials for leukemia therapy, especially in CML, additional studies are required for final conclusions on <b>9b</b>’s potency in leukemia to be reached, since the results so far were not extremely promising. To this end, combination trials should also be conducted, since FTIs seem to synergize with other anticancer agents.</div><div class="NLM_p"><b>9c</b>, the less studied FTI, was derived from SAR studies on a series of compounds bearing the imidazolylmethyltetrahydrobenzodiazepine scaffold. This agent demonstrated an IC<sub>50</sub> of 1.35 nM, an EC<sub>50</sub> of 0.025 μM in cells (NIH3T3 SAG assay), and oral bioavailability of up to 56%.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> However, because of gastrointestinal and liver toxicity observed after its oral administration, most recent studies have used the intravenous route.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> In preclinical studies, <b>9c</b> is cytotoxic against several cell lines,<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> but in the phase I clinical trial conducted on AML and MDS patients the responses were characterized as “transient” and of “minimal significance”.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Even though clinical investigations for <b>9c</b> ceased, the more recent observations for potential apoptosis induction in myeloma,<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> B-CLL,<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> and CML cells<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> may draw the attention back to the continuation of its development. The latter is of great importance, since selective induction of apoptosis in leukemia cells as well as in LSCs has emerged as a fruitful approach in treating leukemia.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a></div><div class="NLM_p last">Although designed to block Ras signaling, the finding that <b>9a</b> induced apoptosis in myeloma cells in a Ras-independent manner<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> raised skepticism on the mechanism behind the use of FTIs. So far, the molecular targets identified that seem to be implicated in the mode of action of FTIs include farnesylated proteins such as Rho proteins, the PTP-CAAX phosphatase, lamins A and B, and CENPs (further information can be found in Raponi et al.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a>). Also, signaling pathways like the PI3K-AKT and MAPK/ERK, Fas, NF-κB, and VEGF have been correlated to clinical response to FTIs.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> In conclusion, the results obtained from the clinical trials with FTIs look promising, although the exact underlying mechanism of FTI activity remains uncertain because of the multiple signaling pathways that are dependent on farnesylation. Another field that needs to be further explored is the upcoming resistance to the current developed FTIs,<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> in order to direct the drug design of future inhibitors and define markers to identify patients most likely to respond to this treatment.</div></div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">6.6 CDK Inhibitors</h3><div class="NLM_p">Targeting of proteins that regulate the cell cycle progression has drawn the attention of pharmaceutical companies in the 1990s. Cyclin-dependent kinases (CDKs) are key cell cycle regulating proteins, and their function is causally related to cell proliferation potential. Very quickly they became a promising target and research on inhibitors began, initially on pan-CDK inhibitors and gradually on more selective ones. Deregulation of CDK functionality is very common (expressed as CDK hyperactivation or endogenous CDK inhibitors inactivation),<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> and CDK inhibitors are being evaluated in a number of trials for their clinical efficacy. Since the literature on CDK inhibitors is vast, only those that have undergone clinical evaluation are mentioned (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. CDK Inhibitors in Current Clinical Trials on Leukemia<a class="ref internalNav" href="#tbl9-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">targeted CDK molecule</th><th class="colsep0 rowsep0" align="center">conditions</th><th class="colsep0 rowsep0" align="center">phase (NCT ID)<a class="ref internalNav" href="#tbl9-fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AG-024322 (<b>10h</b>), Pfizer</td><td class="colsep0 rowsep0" align="left">CDK1, CDK2, and CDK4</td><td class="colsep0 rowsep0" align="left">advanced cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00147485)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">flavopiridol (<b>10a</b>) (HL275, L-868275, HMR-1275, NSC-649890, alvocidib), Sanofi-Aventis</td><td class="colsep0 rowsep0" align="left">pan-CDK inhibitor</td><td class="colsep0 rowsep0" align="left">acute leukemia</td><td class="colsep0 rowsep0" align="left">phase I (NCT00470197)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">refractory lymphoma or MM</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00112723)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">acute leukemia or CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00278330)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML</td><td class="colsep0 rowsep0" align="left">phase II (NCT00795002, NCT00634244)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, ALL, or CML</td><td class="colsep0 rowsep0" align="left">phase I (NCT00101231)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CLL or prolymphotic leukemia</td><td class="colsep0 rowsep0" align="left">phase II (NCT00464633, NCT00098371)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CLL or small lymphocytic lymphoma</td><td class="colsep0 rowsep0" align="left">phase I (NCT00058240, NCT00735930, NCT00377104)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P276-00 (<b>10c</b>), Nicholas Piramal</td><td class="colsep0 rowsep0" align="left">pan-CDK inhibitor</td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00882063)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma</td><td class="colsep0 rowsep0" align="left">phase II (NCT00843050)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PD-0332991 (<b>10d</b>), Pfizer</td><td class="colsep0 rowsep0" align="left">CDK4 and CDK6</td><td class="colsep0 rowsep0" align="left">advanced cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00141297)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma</td><td class="colsep0 rowsep0" align="left">phase I (NCT00420056)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MM</td><td class="colsep0 rowsep0" align="left">phase I/II (NCT00555906)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SCH 7727965 (<b>10e</b>), Schering-Plough</td><td class="colsep0 rowsep0" align="left">CDK1, CDK2, CDK5, and CDK9</td><td class="colsep0 rowsep0" align="left">advanced cancer</td><td class="colsep0 rowsep0" align="left">phase I (NCT00871663, NCT00871910)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AML, ALL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00798213)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">mantle cell lymphoma, CLL</td><td class="colsep0 rowsep0" align="left">phase II (NCT00871546)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SNS-032 (<b>10f</b>) (BMS-387032), Synesis</td><td class="colsep0 rowsep0" align="left">CDK2, CDK7, and CDK9</td><td class="colsep0 rowsep0" align="left">B-lymphoid malignancies</td><td class="colsep0 rowsep0" align="left">phase I (NCT00446342)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl9-fn1"><div class="footnote" id="tbl9-fn1"><sup>a</sup><p class="last">Source: <a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a>. Abbreviations: ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphoid leukemia; CML, chronic myeloid leukemia; MM, multiple myeloma.</p></div><div class="footnote" id="tbl9-fn2"><sup>b</sup><p class="last">Represents the National Clinical Trials Identifier (NCT ID).</p></div></div></div><div class="NLM_p">A number of flavonoids have been found to be effective CDK inhibitors. The more extensively studied are flavopiridol<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> (<b>10a</b>) and P276-00<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> (<b>10c</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). <b>10a</b> is a semisynthetic compound derived from the natural compound rohitukine (<i>Dysoxylum binectariferum</i>) and the first CDK inhibitor to enter clinical trials. Of the many clinical trials that have taken place, the most promising results come from recent studies on CLL<a onclick="showRef(event, 'ref216 ref218 ref219 ref220'); return false;" href="javascript:void(0);" class="ref ref216 ref218 ref219 ref220">(216, 218-220)</a> and AML.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> The scientific interest coming from the CLL studies is the fact that effectiveness was correlated and linked to certain cytogenetic abnormalities [del(17p13) and del(11q22)] related to disease pathophysiology. Indeed, the clinical response was much greater among the patients exhibiting cytogenetic abnormalities, with a percentage of success reaching 40% and 70%, respectively, thus leading regulatory authorities to grant an orphan drug status for the treatment of CLL in 2007.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> On the other hand, <b>10a</b> was combined with Ara-C and mitoxantrone as a therapeutic alternative in AML, where the response rate reached up to 75% and the survival rates for patients significantly increased.</div><div class="NLM_p"><b>10c</b> belongs to a group of synthetic flavones studied mostly on solid tumors but recently registered for a phase I/II trial on multiple myeloma (MM) and a phase II trial on mantle cell lymphoma. <b>10c</b> is a more potent CDK inhibitor compared to <b>10a</b> (up to 3-fold antiproliferative activity in human cancer cell lines), with nanomolar affinity to CDK1, CDK4, and CDK9 and micromolar affinity to CDK2, CDK6, and CDK7.<a onclick="showRef(event, 'ref217 ref223'); return false;" href="javascript:void(0);" class="ref ref217 ref223">(217, 223)</a></div><div class="NLM_p">Another important class of CDK inhibitors is purine-based compounds. Olomoucine was one of the first inhibitors identified and the lead compound for the synthesis of roscovitine.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> The (<i>R</i>)-isomer of roscovitine<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> (seliciclib, CYC202, <b>10b</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) was found to be more potent and entered clinical trials on solid tumors, although with no encouraging results due to its pan-CDK inhibitory activity. The analogues purvalanol A<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> and NU6140<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> are in preclinical development as the more recent pyrazolotriazine bioisoster N-&-N1 (GP0210).<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> Because they are more potent but have no particular selectivity, their potential clinical usage is still under question.</div><div class="NLM_p">The pyrimidine scaffold also seems to be of critical importance in developing efficient CDK inhibitors. On the basis of former observations on pyrido[2,3-<i>d</i>]pyrimidin-7-ones, PD-0332991<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> (<b>10d</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) emerged as a selective CDK4 and CDK6 inhibitor (IC<sub>50</sub> of 11 and 16 nM, respectively).<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a><b>10d</b> is currently studied in phase I and phase II clinical trials either as a monotherapy or in combination with <b>8a</b> and dexamethazone. Also of the pyrimidine core and under clinical evaluation is the pyrazolo[1,5-<i>a</i>]pyrimidine SCH 727965<a onclick="showRef(event, 'ref231'); return false;" href="javascript:void(0);" class="ref ref231">(231)</a> (<b>10e</b>) that has been found to effectively inhibit CDK1, CDK2, CDK5, and CDK9. This CDK inhibitor is currently included in four clinical trials regarding hematological malignancies (monotherapy or combination therapy), but results from these trials have yet to be published in order to evaluate its potential clinical use.</div><div class="NLM_p">The aminothiazole SNS-032<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> (BMS-387032, <b>10f</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) is an inhibitor of CDK2, CDK7, and CDK9 and is currently in a phase I clinical trial on B-lymphoid malignancies (CLL, mantle cell lymphoma). Additionally, its mechanism of action in CLL is being elucidated as stated by Chen et al.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> In particular, the poor bioavailability of this compound was attributed to its ability to act as a substrate of P-gp, a fact that allowed scientists to generate new advanced analogues with improved permeability and lower efflux.<a onclick="showRef(event, 'ref234 ref235'); return false;" href="javascript:void(0);" class="ref ref234 ref235">(234, 235)</a></div><figure id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cycline dependent kinase (CDK) inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Identified from fragment-based screening, the pan-CDK inhibitor AT7519<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> (<b>10g</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) is in phase I clinical trials on advanced solid tumors and non-Hodgkin’s lymphoma (NHL). Its affinity is higher for CDK2, CDK4, and CDK5 (47, 67, and 18 nM, respectively).<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(236)</a> In another phase I clinical trial in advanced cancer, the indazole AG-024322<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(237)</a> (<b>10h</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) was found to be inadequate for differentiating from other pharmaceutic interventions and the trial was terminated.</div><div class="NLM_p">CDK inhibitors that are currently in clinical trials for cancer therapy, other than leukemia, are the pan-CDK inhibitor of the diaminopyrimidine scaffold R547<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(238)</a> (<b>10i</b>, Ro-4584820) (phase I trials on solid tumors) and the 4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline PHA-848125<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> (phase II trial on thymic carcinoma) (<b>10j</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). The last is a potent orally bioavailable pan-CDK inhibitor that exhibits slightly higher affinity for CDK2 but is also active against CDK4, CDK5, CDK7, with additional good water solubility.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(239)</a> Also under preclinical evaluation are the 3-aminopyrazole PNU-292137<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(240)</a> (<b>10k</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>) and the selective CDK1 inhibitor RO-3306<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(241)</a> (<b>10l</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>).</div><div class="NLM_p last">Since CDK inhibitors were tested in clinical trials for more than a decade and none advanced to the market yet, mostly because of mediocre response rates and significant toxicities, the effectiveness of this therapeutic intervention was questioned. In order to proceed more efficiently, the more thorough elucidation of the functions that each CDK is responsible for within the cell should be verified, whereas the genetic characterization of various cancer cell phenotypes that could be potential targets for specific CDK inhibition should be further exploited.<a onclick="showRef(event, 'ref242'); return false;" href="javascript:void(0);" class="ref ref242">(242)</a> Another aspect that also needs attention while evaluating CDK inhibitors for their clinical potential is their pharmacokinetics. This is why sufficient exposure throughout the cell cycle should be guaranteed with a reasonable route of administration because of the existing tumor cell heterogeneity.<a onclick="showRef(event, 'ref243'); return false;" href="javascript:void(0);" class="ref ref243">(243)</a></div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33">6.7 Other Apoptosis Promoting Agents</h3><div class="NLM_p">Aurora kinase inhibitors, as well as heat-shock protein 90 (HSP90) inhibitors, are currently in clinical trials for evaluation on leukemia and other malignancies, as reviewed elsewhere.<a onclick="showRef(event, 'ref244 ref245'); return false;" href="javascript:void(0);" class="ref ref244 ref245">(244, 245)</a> Furthermore, compounds targeting signaling pathways that are under clinical evaluation for leukemia are PF-04449913 (Hedgehog inhibitor)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and the γ-secretase inhibitor MK0752 (targeting Notch).<a onclick="showRef(event, 'ref246'); return false;" href="javascript:void(0);" class="ref ref246">(246)</a> Targeting X-linked inhibitor of apoptosis proteins (XIAPs), the small molecule AEG40826 and the antisense oligonucleotide AEG 35156 are currently in clinical trials. The last has advanced to phase II in combination with chemotherapeutics for the treatment of AML.<a onclick="showRef(event, 'ref247'); return false;" href="javascript:void(0);" class="ref ref247">(247)</a> Results seem very encouraging especially in the combination trial, since the complete response rate in patients with AML refractory to single agent chemotherapy reached 91%.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a></div><div class="NLM_p last">The skepticism on specific enzyme targeting and its efficiency on a heterogeneous disease such as cancer has led researchers to seek alternative routes in fighting the disease. Multitarget kinase inhibitors, combination of agents that act through different signaling pathways or combination of conventional with novel therapeutics, are under investigation; such attempts have already been described above. Apart from multitarget kinase inhibitors, the simultaneous inhibition of different signaling pathways with one molecule is a strategy under consideration, though such an approach still has not been evaluated in the clinic. Such an example comes with CU-201 (developed by Curis), a multitargeted inhibitor of HDAC, Abl, and Src.<a onclick="showRef(event, 'ref249'); return false;" href="javascript:void(0);" class="ref ref249">(249)</a> Another novel proposed strategy is targeting of signaling networks instead of specific enzymes. The molecular chaperone HSP90 is such a nodal protein implicated in multiple signaling networks. In addition, its participation in mitochondria homeostasis permitted Kang and Altieri to target HSP90 in that cellular compartment<a onclick="showRef(event, 'ref250'); return false;" href="javascript:void(0);" class="ref ref250">(250)</a> as a means to increase selectivity. In particular, combinatorial chemistry proved to be a useful tool and their compounds (gamitrinibs whose chemical structures consist of a mitochondria targeting part, a linker, and an HSP90 inhibitor) have proven to be successful in xenografted human tumor cell lines in mice. However, this approach is still in its infancy, so more studies are needed to further evaluate the therapeutic potential.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">7 Future Directions for Antileukemic Research</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">7.1 Therapeutic Strategies To Specifically Target LSCs</h3><div class="NLM_p">The discovery of potential molecular targets as well as the development of more effective and less cytotoxic anticancer drugs still remains a highly challenging endeavor almost 35 years after the “war on cancer” was declared.<a onclick="showRef(event, 'ref251'); return false;" href="javascript:void(0);" class="ref ref251">(251)</a> To overcome the main obstacles hampering anticancer drug discovery, it is crucial to elucidate and thoroughly understand the molecular complexity and cellular heterogeneity seen in tumor cell initiation and progression.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Experimental evidence accumulated since 1997 supports the cancer stem cell hypothesis, meaning that a specific cell population within the tumor has the capacity for self-renewal as well as the proliferative potential to maintain and expand the population of malignant cells.<a onclick="showRef(event, 'ref252 ref253 ref254'); return false;" href="javascript:void(0);" class="ref ref252 ref253 ref254">(252-254)</a> Cancer stem cells remain resistant and invulnerable to standard chemotherapy because of their quiescent state, while they express typical markers of stem cells. It is still not clear if cancer stem cells originate from genetically or epigenetically deregulated normal stem cells or by dedifferentiation of somatic tumor cells to the stemlike counterparts. Data published by Blair et al.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and by Bonnet and Dick<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> showed that a subpopulation of purified leukemic cells (Thy1<sup>−</sup>, CD34<sup>+</sup>, CD38<sup>−</sup>) injected into NOD/SCID mice caused leukemia histologically similar to that of the donor. If leukemias can be considered as a HSC disorder or a reacquisition of HSC characteristics, it can then be expected that many signaling pathways classically associated with leukemia initiation and progression also regulate normal HSC development.<a onclick="showRef(event, 'ref253'); return false;" href="javascript:void(0);" class="ref ref253">(253)</a></div><div class="NLM_p">Normal hematopoiesis requires complex and highly orchestrated interactions between the bone marrow microenvironment (or niche) and HSCs, a process that may be deregulated upon leukemia in a way to cause perturbation of self-renewal of HSCs and support of self-renewal of LSCs.<a onclick="showRef(event, 'ref255 ref256'); return false;" href="javascript:void(0);" class="ref ref255 ref256">(255, 256)</a> Therefore, the development of innovative leukemia therapeutics must be based on the molecular pathways and targets regulating survival and self-renewal of both HSCs and LSCs. These include HSC niche components, signaling pathways (SCF/c-kit-R, EPO-R-JAK2/STAT, Wnt, Notch, HOX), inducer−receptor interactions, superfine chromatin-structure modifications, fused transcription factors, microRNAs, and signaling of apoptosis, as presented elsewhere.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Moreover, recent data indicate the importance of PTEN tumor suppressor and the phosphatidylinositol 3-OH-kinase (PI3K) pathway in LSCs formation.<a onclick="showRef(event, 'ref257'); return false;" href="javascript:void(0);" class="ref ref257">(257)</a> Interestingly enough, it has been shown that <i>Pten</i>-gene loss in mouse HSCs through the activation of β-catenin pathway and via multiple genetic and molecular alterations contributes to LSC transformation and expansion.<a onclick="showRef(event, 'ref258'); return false;" href="javascript:void(0);" class="ref ref258">(258)</a> These data were further strengthened by observations showing that β-catenin is essential for survival and self-renewal of LSCs insensitive to <b>5a</b> treatment in mice with Bcr-Abl-induced CML, thus providing a new strategy for targeting these cells.<a onclick="showRef(event, 'ref248'); return false;" href="javascript:void(0);" class="ref ref248">(248)</a> Recent observations also revealed the proliferative effects of the cytokine interferon-α (IFNα) on LSCs and the importance of eliminating resistance to chemotherapy LSCs in leukemia patients. In particular, it has been indicated that although dormant LSCs are resistant to antiproliferative agent 5-fluorouracil (5-FU), LSCs pretreated with IFNα, and thus exit cell dormancy and induced to proliferate, are efficiently eliminated by 5-FU exposure in vivo.<a onclick="showRef(event, 'ref259'); return false;" href="javascript:void(0);" class="ref ref259">(259)</a> The latter support the notion of the potential therapeutic application of IFNs in shifting quiescent LSCs into the cell cycling state to increase their sensitivity to cytotoxic agents.<a onclick="showRef(event, 'ref260'); return false;" href="javascript:void(0);" class="ref ref260">(260)</a></div><div class="NLM_p last">The identification and purification of LSCs along with the establishment of their characteristics are expected to provide future powerful diagnostic, prognostic, and therapeutic tools in the clinical oncology of leukemias. Moving forward, the identification of molecular mechanisms underlying the behavior of HSCs and LSCs will permit better understanding of how leukemia is initiated and allow more efficient treatment options by innovative bifunctional and multitargeted medicines, impinging on crucial molecular networks and targets that regulate execution decisions of LSCs to self-renew, proliferate, differentiate, and/or undergo apoptosis. To this end, by using genomic approaches to identify potential key regulators of HSC quiescence and leukemogenesis, researchers were able to identify a subset of genes that may contribute to leukemic development from LSCs.<a onclick="showRef(event, 'ref261'); return false;" href="javascript:void(0);" class="ref ref261">(261)</a> Alternatively, detailed understanding of the interactions occurring between normal hematopoietic and leukemic cells within the bone marrow microenvironment can uncover unknown mechanisms that reflect the emergence of drug resistance and heterogeneity seen in leukemic cells.<a onclick="showRef(event, 'ref1 ref10 ref262'); return false;" href="javascript:void(0);" class="ref ref1 ref10 ref262">(1, 10, 262)</a></div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">7.2 Pharmacogenomics and the Development of New Antileukemia Drugs</h3><div class="NLM_p">Identification of novel drug-exploitable molecular targets allowed the development of new molecularly designed anticancer medicines. However, the emergence of rapidly acquired drug resistance to limit clinical efficacy of recently developed chemotherapeutics along with tumor genetic variability and microenvironmental factors suggested that pharmacogenomics-related drug response variations may also contribute to the clinical outcome of cancer patients.<a onclick="showRef(event, 'ref7 ref103'); return false;" href="javascript:void(0);" class="ref ref7 ref103">(7, 103)</a> Furthermore, the concept of genetically based antileukemia drug development is further strengthened by the fact that individual patient genetic makeup also affects the clinical outcome and alters the strategy of drug delivery toward the so-called personalized cancer medicine. Therefore, it becomes obvious that the study and exploitation of interindividual genetic variations are crucial to understand why some antineoplastic agents are safe and effective in some patients but not in others. This means that the assessment of germ line polymorphisms and host pharmacogenomics of specific disease-related as well drug pharmacodynamics- and pharmacokinetics-related genes is now considered as an important approach in developing new antileukemia molecularly targeted medicines and in assessing their efficacy and safety in clinical practice.<a onclick="showRef(event, 'ref7 ref263'); return false;" href="javascript:void(0);" class="ref ref7 ref263">(7, 263)</a></div><div class="NLM_p">Clinical translation of drug-related genetic information has allowed the analysis of genetic variations of drug-metabolizing enzymes, transporters, and receptors on a routine basis as well as the correlation of such data with altered drug-related responses.<a onclick="showRef(event, 'ref263 ref264 ref265'); return false;" href="javascript:void(0);" class="ref ref263 ref264 ref265">(263-265)</a> Technological achievements in DNA microarray methodologies allowed the recording of gene expression profile data in clinical samples that predict a patient's clinical outcome to a given or more than one therapeutic agent.<a onclick="showRef(event, 'ref266'); return false;" href="javascript:void(0);" class="ref ref266">(266)</a> Indeed, leukemia was one of the first diseases in which such an approach was applied in order to analyze the effects of <b>3a</b> on genes and pathways involved in the so-called differentiation therapy of APL.<a onclick="showRef(event, 'ref267'); return false;" href="javascript:void(0);" class="ref ref267">(267)</a> Another example of pharmacogenomics in leukemia is one of thiopurine <i>S</i>-methyltransferase (TPMT), an enzyme involved in the deactivation of 6-mercaptopurine (6-MP) and thioguanine (TG) used for the treatment of childhood ALL. Interindividual genetic variations of the <i>TPMT</i> gene were the first to prove the clinical value of individualizing drug dosage to achieve a better clinical outcome (a specific personalized medicine approach).<a onclick="showRef(event, 'ref265 ref268'); return false;" href="javascript:void(0);" class="ref ref265 ref268">(265, 268)</a> Numerous pharmacogenomic studies have indicated that low TPMT enzyme activity is well correlated with the observed hematopoietic toxicity of thiopurine drugs in clinical practice. Three variant alleles of the <i>TPMT</i> gene (<i>TPMT*2</i>, <i>TPMT*3A</i>, <i>TPMT*3C</i>) were found to account for more than 95% of the inherited variability in TPMT enzyme activity. This finding has permitted genetic identification of patients at high risk of toxicity after thiopurine therapy. Indeed, clinical evidence now indicates that some TPMT-deficient patients that are homozygous in one TPMT gene variant require a reduction of more than 90% of the conventional dose of thiopurine drugs in order to respond efficiently without toxicity in this therapy.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a></div><div class="NLM_p">Another example related to pharmacogenomics of leukemia therapeutics refers to methotrexate (MTX) delivery in childhood ALL treatment protocols. As has been shown, the uptake of MTX within ALL cells is primarily mediated by the transporter SLC19A1, whereas its cellular efflux is mediated by the ATP-binding cassette transporters (ABC transporters) like ABCC2.<a onclick="showRef(event, 'ref270'); return false;" href="javascript:void(0);" class="ref ref270">(270)</a> Such processes contribute toward the achievement of therapeutic intracellular MTX concentrations being able to inhibit its target enzyme dihydrofolate reductase (DHFR) and thus to exert its antileukemia effect. Specific mutations in either the <i>ABCC2</i> transporter gene or folate-dependent enzymes 5,10-methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase (TYMS) have been shown to influence MTX treatment response in childhood ALL.<a onclick="showRef(event, 'ref269'); return false;" href="javascript:void(0);" class="ref ref269">(269)</a> Recently, the synergistic effect of specific TPMT and MTHFR genotypes on the observed 6-MP toxicity in patients with childhood ALL has also been clinically evaluated.<a onclick="showRef(event, 'ref271'); return false;" href="javascript:void(0);" class="ref ref271">(271)</a></div><div class="NLM_p last">Although the prospects for basic research in pharmacogenomics and the generation of considerable amounts of data look very promising, their incorporation in new drug development and clinical practice is quite challenging.<a onclick="showRef(event, 'ref263'); return false;" href="javascript:void(0);" class="ref ref263">(263)</a> Furthermore, by assessment of the actions of drugs at the molecular level, it has been clearly shown that medicines exert their effects via specific “molecular networks” involving several genes and proteins.<a onclick="showRef(event, 'ref2 ref27 ref272'); return false;" href="javascript:void(0);" class="ref ref2 ref27 ref272">(2, 27, 272)</a> The genetic background involved in the response of an organism to delivered drugs is complex and is also determined by the interaction of genes with drugs. This interplay between genes and drugs also implies that their interaction can modulate the pharmacotherapy outcome through either genetic variation or drug-regulated gene expression that consequently leads to phenotypic variation, e.g., differential pharmacological response. The complexity underlying the gene expression profile in crucial cellular decisions related to leukemogenesis is recently outlined by shedding light on the transcriptional network that controls growth arrest and differentiation in human myeloid leukemia cells.<a onclick="showRef(event, 'ref273'); return false;" href="javascript:void(0);" class="ref ref273">(273)</a> Also, concerning the clinical use of epigenetic drugs in MDS to modulate gene expression and affect cell growth, differentiation, and apoptosis, such complexity emerged at the molecular level, since it has been recently shown that DNA methylation inhibitors azacitidine, <b>2b</b>, and <b>2c</b> exert differential effects on the cancer gene expression profile in AML cells.<a onclick="showRef(event, 'ref274'); return false;" href="javascript:void(0);" class="ref ref274">(274)</a> Interestingly enough, the methylation inhibitors neplanocin A and 3-deazaneplanocin A (DZNep) block the in vitro differentiation program of murine erythroleukemia (MEL) cells by activating silent DNA regions,<a onclick="showRef(event, 'ref275'); return false;" href="javascript:void(0);" class="ref ref275">(275)</a> whereas DZNep reactivates developmentally regulated genes by inhibiting histone methylation.<a onclick="showRef(event, 'ref276'); return false;" href="javascript:void(0);" class="ref ref276">(276)</a> In addition, it is now well-known that gene expression can also be affected by environmental factors, like epigenetic phenomena including DNA methylation, histone acetylation, and RNA interference (RNAi) mechanisms that represent crucial mechanisms for establishing specific gene expression patterns in cellular physiology.<a onclick="showRef(event, 'ref5 ref39 ref277'); return false;" href="javascript:void(0);" class="ref ref5 ref39 ref277">(5, 39, 277)</a> The latter might also contribute into interindividual variability seen in drug response, since both environmental and genomic factors may finally modulate drug efficacy and cause toxicity in the body. As a matter of fact, the design of pharmacogenomics studies to analyze the molecular mechanisms underlying drug response variability must be taken into consideration upon attempting to develop innovative anticancer drugs.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">8 Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Experimental evidence accumulated over the past several years has indicated that human leukemias represent disorders of self-renewal, growth, differentiation, and/or apoptosis of HSCs or their early multipotent progenitors. The discovery of LSCs as LICs indicates that human leukemias may arise from such immortalized cells that share specific properties with normal HSCs. It has been said that LSCs are quiescent and thus less vulnerable to conventional antiproliferative agents. LSCs represent quite heterogeneous cell populations that exhibit different degrees of sensitivity to leukemia therapeutics. Therefore, other innovative multifunctional and multilevel target antileukemia agents are desperately needed to eradicate LSCs and their transformed progeny.</div><div class="NLM_p">The fact that leukemia cells regardless of their genetic abnormalities and the acquired multidrug resistance (MDR) are able to regulate their renewal capacity, proliferation, differentiation, and apoptosis at different levels (signaling, growth and proliferation response stimuli, cell cycle-dependent kinases, proteasome activation, etc.) suggests that LSCs (or LICs) cannot be affected by treatment with conventional cytotoxic agents but by targeted therapies on specific sites (e.g., an enzyme) acting at different levels. Multilevel targeting can be done either by using classes of agents that complement each other under a combination chemotherapy approach or by developing bi- or multifunctional agents promoting or blocking more than one vital process of leukemic development. Agents able to block self-renewal, halt cell growth, promote differentiation, and provoke apoptosis can be useful for effective leukemia therapy.</div><div class="NLM_p last">This paper reviews the basic principles of leukemia cell differentiation and apoptosis with emphasis on differentiation inducers, hybrid/polar compounds, HDACIs, DNMT inhibitors, retinoids and retinoid mimetics, Bcl-2 inhibitors, regular and chimeric tyrosine kinase inhibitors, FLT3 kinase inhibitors, VEGFR inhibitors, mTOR inhibitors, proteasome inhibitors, FTIs, CDK inhibitors, and classes of agents developed and under clinical evaluation. The potential role of pharmacogenomics in the development of these new antileukemia agents is comprehensively discussed in a way to achieve improved clinical outcomes through the application of personalized medicine concepts in cancer therapy.</div></div><div class="NLM_back"><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64686" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64686" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ioannis S. Vizirianakis</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Pharmacology</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#660f100f1c0f1426160e07140b480713120e480114"><span class="__cf_email__" data-cfemail="99f0eff0e3f0ebd9e9f1f8ebf4b7f8ecedf1b7feeb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Chatzopoulou</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Pharmaceutical Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ioannis D. Bonovolias</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Pharmacology</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ioannis Nicolaou</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Pharmaceutical Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vassilis J. Demopoulos</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Pharmaceutical Chemistry</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asterios S. Tsiftsoglou</span> - <span class="hlFld-Affiliation affiliation">Laboratory of Pharmacology</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="testing" data-doi="10.1021/jm100189a" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="bio"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ioannis S. Vizirianakis</b> is currently an Associate Professor in Molecular Pharmacology and Pharmacogenomics at Aristotle University of Thessaloniki, Greece. After receiving his degree in Pharmacy (1981) from Aristotle University of Thessaloniki, he joined the department as Research Assistant (1985−1990), obtained a Ph.D. (1991) in Biochemical Pharmacology under Prof. Tsiftsoglou, and finally was assigned as Lecturer (1993) and then Assistant Professor (2003) in Pharmacology. He received a research grant award (1998) from Cancer Coordinating Committee upon his sabbatical at the Tumor Biology Laboratory, University of California, San Francisco. His long-term research interests focus on “differentiation therapy of cancer” and include the development of innovative chemical inducers of differentiation of leukemia cells through the understanding of crucial molecular mechanisms that govern leukemia cell initiation, unrestricted growth as well as blockade of differentiation, and apoptosis.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Maria Chatzopoulou</b> received her degree in Pharmaceutical Sciences in 2006 and her M.Sc. in Pharmaceutical Chemistry in 2008 from Aristotle University of Thessaloniki, Greece. Currently she is a Ph.D. candidate in the Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Aristotle University of Thessaloniki, with a scholarship from the Greek State Scholarship Foundation and under the guidance of Prof. V. J. Demopoulos. Her research activities involve drug design and organic synthesis of pharmaceutical compounds. She has published papers in peer reviewed journals and attended several conferences presenting her results.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ioannis D. Bonovolias</b> received his degree in Pharmaceutical Sciences (B.Pharm.) from Aristotle University of Thessaloniki, Greece, in 2005. Then he carried out graduate studies (2005−2007) in Pharmacology and Therapeutics at the same department and received his M.Sc. degree in 2007 on the mechanisms of drug resistance to antileukemia drugs. He is currently a Ph.D. candidate and under the supervision of Prof. A. S. Tsiftsoglou since 2003. He has published papers in peer reviewed journals and attended several international conferences presenting his results.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ioannis Nicolaou</b> received his degree in Pharmaceutical Sciences from Aristotle University of Thessaloniki, Greece, in 1995. He then started his graduate studies at the Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Aristotle University of Thessaloniki under the guidance of Dr. V.J. Demopoulos, leading to a doctorate degree in 2000. He continued his postdoctorate studies from 2000 to 2004 at Aristotle University of Thessaloniki under a variety of grants. Currently, he is a Lecturer at the Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Aristotle University of Thessaloniki, from September 2005. His research activities involve drug design and synthesis of compounds that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosacharides. Recently, the design and synthesis of derivatives with antileukemic activity entered his field of interest.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Vassilis J. Demopoulos</b> received his degree in Pharmacy from the University of Athens, Greece (1977). He then joined the School of Pharmacy, University of Iowa, as Research Assistant and obtained his Ph.D. in Pharmaceutical Chemistry and Natural Products under Prof. J. G. Cannon (1982). He joined the Department of Chemistry, University of Newfoundland, Canada, as Research Associate (October 1981 to August 1982). In 1985, he returned to Greece, joining the Department of Pharmacy, Aristotle University of Thessaloniki, Greece, as Lecturer (1985−1990), Assistant Professor (1990−2003), Associate Professor (2003−2009), and Professor (2009−present). He is a member of The European Federation for Pharmaceutical Sciences, the Division of Medicinal Chemistry of the American Chemical Society, the Panhellenic Association of Pharmacists, and the Hellenic Society of Medicinal Chemistry (executive committee). His research activities involve drug design and synthesis of bioactive compounds.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id="><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Asterios S. Tsiftsoglou</b> received his degree from the Department of Pharmacy of Aristotle University of Thessaloniki (1972), Greece, and earned his M.Sci., M.Phil. (1978) and completed his Ph.D. (1979) at Yale University, Department of Pharmacology, under Prof. A. C. Sartorelli. He did postdoctoral research at Massachusetts Institute of Technology (CCR) (Cambridge, MA) (1978−1981) and then served as Assistant Professor at the Harvard Medical School (Beth Israel Hospital, Hematology-Oncology) (Boston, MA) (up to 1986). He returned to Aristotle University of Thessaloniki where he teaches Molecular Pharmacology and Biotechnology. He is Professor of Pharmacology and has been Chairman several times. His major research is on leukemia cell differentiation. He is member of several scientific societies, reviewer in peer-reviewed journals, and core member of committees (CPWP, BWP, CAT) in EMEA. He has published close to 100 original papers and chapters in peer reviewed journals and books.</p></figure></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55730" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55730" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Greek State Scholarship Foundation.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57586" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57586" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 277 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonovolias, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsiftsoglou, S. A.</span><span> </span><span class="NLM_article-title">Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.pharmthera.2009.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19306896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVSgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=264-280&author=A.+S.+Tsiftsoglouauthor=I.+D.+Bonovoliasauthor=S.+A.+Tsiftsoglou&title=Multilevel+targeting+of+hematopoietic+stem+cell+self-renewal%2C+differentiation+and+apoptosis+for+leukemia+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy</span></div><div class="casAuthors">Tsiftsoglou, Asterios S.; Bonovolias, Ioannis D.; Tsiftsoglou, Stefanos A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-280</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Human leukemias are considered clonal hematol. malignancies initiated by chromosomal aberrations or epigenetic alterations occurring at the level of either pluripotent hematopoietic stem cells (HSCs) or early multipotent progenitors (MPPs).  Leukemic cells are transformed, immortalized, actively proliferating cells that are still able to differentiate into cells resembling mature blood cells.  Future therapies of leukemias require identification of mol. targets involved in hematopoiesis under normal and leukemic conditions and detailed understanding of the interactions between normal hematopoietic and leukemic cells within the bone marrow micro-environment.  This review presents the basic aspects of hematopoiesis and highlights multilevel exploitable targets for leukemia therapy.  These include HSC niche components, signaling pathways (SCF/c-kit-R, EPO-R-JAK2/STAT, Wnt, Notch, HOX), inducer-receptor interactions, superfine chromatin structure modifications, fused transcription factors, microRNAs and signaling of cell death through the Bcl-2 apoptotic switch (BH3-only proteins).  The classes of therapeutics developed or being under development to eradicate human leukemias include novel antimetabolites, DNA hypomethylating agents, histone deacetylation inhibitors (HDACIs), retinoids and other inducers of differentiation, targeted monoclonal antibodies raised against cell surface proteins, pro-apoptotic receptor agonists (PARAs), BH3 peptidomimetics, cell cycle inhibitors, siRNAs, and perhaps microRNAs.  Some of these agents induce terminal differentiation while others promote cell cycle arrest and apoptosis in leukemia cells.  At last but not least, this article describes the mechanisms of removal of damaged/harmful cells from organs since impairment in clearance of such cells can lead to autoimmune disorders by self-antigens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWpgtYc_75L7Vg90H21EOLACvtfcHk0litgF5q38AaWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVSgtb4%253D&md5=feae94833802f3bdf73724ef209e19db</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26aulast%3DBonovolias%26aufirst%3DI.%2BD.%26aulast%3DTsiftsoglou%26aufirst%3DS.%2BA.%26atitle%3DMultilevel%2520targeting%2520of%2520hematopoietic%2520stem%2520cell%2520self-renewal%252C%2520differentiation%2520and%2520apoptosis%2520for%2520leukemia%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D122%26spage%3D264%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappas, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span> </span><span class="NLM_article-title">Mechanisms involved in the induced differentiation of leukemia cells</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.pharmthera.2003.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=14652113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlylsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=257-290&author=A.+S.+Tsiftsoglouauthor=I.+S.+Pappasauthor=I.+S.+Vizirianakis&title=Mechanisms+involved+in+the+induced+differentiation+of+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms involved in the induced differentiation of leukemia cells</span></div><div class="casAuthors">Tsiftsoglou, Asterios S.; Pappas, Ioannis S.; Vizirianakis, Ioannis S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-290</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Despite the remarkable progress achieved in the treatment of leukemias over the last several years, many problems (multidrug resistance [MDR], cellular heterogeneity, heterogeneous mol. abnormalities, karyotypic instability, and lack of selective action of antineoplastic agents) still remain.  The recent progress in tumor mol. biol. has revealed that leukemias are likely to arise from the disruption of differentiation of early hematopoietic progenitors that fail to give birth to cell lineage restricted phenotypes.  Evidence supporting such mechanisms has been derived from studying bone marrow leukemogenesis and analyzing differentiation of leukemic cell lines in culture that serve as models of erythroleukemic (murine erythroleukemia [MEL] and human leukemia [K562] cells) and myeloid (human promyelocytic leukemia [HL-60] cells) cell maturation.  This paper reviews the current concepts of differentiation, the chem./pharmacol. inducing agents developed thus far, and the mechanisms involved in initiation of leukemic cell differentiation.  Emphasis was given on commitment and the cell lineage transcriptional factors as key regulators of terminal differentiation as well as on membrane-mediated events and signaling pathways involved in hematopoietic cell differentiation.  The developmental program of MEL cells was presented in considerable depth.  It is quite remarkable that the erythrocytic maturation of these cells is orchestrated into specific subprograms and gene expression patterns, suggesting that leukemic cell differentiation represents a highly coordinated set of events that lead to irreversible growth arrest and expression of cell lineage restricted phenotypes.  In MEL and other leukemic cells, differentiation appears to be accompanied by differentiation-dependent apoptosis (DDA), an event that can be exploited chemotherapeutically.  The mechanisms by which the chem. inducers promote differentiation of leukemic cells have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-BJnnA_jv77Vg90H21EOLACvtfcHk0lh7cAYTpuIXEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlylsrw%253D&md5=43bd5e78f2ca2fe96007b82692aff55a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26aulast%3DPappas%26aufirst%3DI.%2BS.%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26atitle%3DMechanisms%2520involved%2520in%2520the%2520induced%2520differentiation%2520of%2520leukemia%2520cells%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D100%26spage%3D257%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Blair, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogge, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ailles, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansdorp, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, H. J.</span><span> </span><span class="NLM_article-title">Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">3104</span><span class="NLM_x">–</span> <span class="NLM_lpage">3112</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=3104-3112&author=A.+Blairauthor=D.+E.+Hoggeauthor=L.+E.+Aillesauthor=P.+M.+Lansdorpauthor=H.+J.+Sutherland&title=Lack+of+expression+of+Thy-1+%28CD90%29+on+acute+myeloid+leukemia+cells+with+long-term+proliferative+ability+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DA.%26aulast%3DHogge%26aufirst%3DD.%2BE.%26aulast%3DAilles%26aufirst%3DL.%2BE.%26aulast%3DLansdorp%26aufirst%3DP.%2BM.%26aulast%3DSutherland%26aufirst%3DH.%2BJ.%26atitle%3DLack%2520of%2520expression%2520of%2520Thy-1%2520%2528CD90%2529%2520on%2520acute%2520myeloid%2520leukemia%2520cells%2520with%2520long-term%2520proliferative%2520ability%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D3104%26epage%3D3112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Bonnet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, J. E.</span><span> </span><span class="NLM_article-title">Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnm0797-730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9212098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1GrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=730-737&author=D.+Bonnetauthor=J.+E.+Dick&title=Human+acute+myeloid+leukemia+is+organized+as+a+hierarchy+that+originates+from+a+primitive+hematopoietic+cell"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</span></div><div class="casAuthors">Bonnet, Dominique; Dick, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">730-737</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clin. heterogeneity.  Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) - termed the SCID leukemia-initiating cell, or SL-IC - possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell.  The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34++CD38-, similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation.  The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKHDGBfY3ALVg90H21EOLACvtfcHk0lh7cAYTpuIXEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1GrtLY%253D&md5=b958aada52385850505d42ef08aeee22</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm0797-730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0797-730%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DD.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26atitle%3DHuman%2520acute%2520myeloid%2520leukemia%2520is%2520organized%2520as%2520a%2520hierarchy%2520that%2520originates%2520from%2520a%2520primitive%2520hematopoietic%2520cell%26jtitle%3DNat.%2520Med.%26date%3D1997%26volume%3D3%26spage%3D730%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, J. D.</span><span> </span><span class="NLM_article-title">Leukaemogenesis: more than mutant genes</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=20029422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2hs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=23-36&author=J.+Chenauthor=O.+Odenikeauthor=J.+D.+Rowley&title=Leukaemogenesis%3A+more+than+mutant+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Leukaemogenesis: More than mutant genes</span></div><div class="casAuthors">Chen, Jianjun; Odenike, Olatoyosi; Rowley, Janet D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Acute leukemias are characterized by recurring chromosomal aberrations and gene mutations that are crucial to disease pathogenesis.  It is now evident that epigenetic modifications, including DNA methylation and histone modifications, substantially contribute to the phenotype of leukemia cells.  An addnl. layer of epigenetic complexity is the pathogenetic role of microRNAs in leukemias, and their key role in the transcriptional regulation of tumor suppressor genes and oncogenes.  The genetic heterogeneity of acute leukemias poses therapeutic challenges, but pharmacol. agents that target components of the epigenetic machinery are promising as a component of the therapeutic arsenal for this group of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBc3XC454rZLVg90H21EOLACvtfcHk0li0J3Mdb9INJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2hs7bE&md5=19e56ddec8ee4b74e87977d66abbe9bb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2765%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26atitle%3DLeukaemogenesis%253A%2520more%2520than%2520mutant%2520genes%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D23%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Hockenbery, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giedt, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manion, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, D. E.</span><span> </span><span class="NLM_article-title">Mitochondria and apoptosis: new therapeutic targets</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2002&pages=203-242&author=D.+M.+Hockenberyauthor=C.+D.+Giedtauthor=J.+W.+O%E2%80%99Neillauthor=M.+K.+Manionauthor=D.+E.+Banker&title=Mitochondria+and+apoptosis%3A+new+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHockenbery%26aufirst%3DD.%2BM.%26aulast%3DGiedt%26aufirst%3DC.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%2BW.%26aulast%3DManion%26aufirst%3DM.%2BK.%26aulast%3DBanker%26aufirst%3DD.%2BE.%26atitle%3DMitochondria%2520and%2520apoptosis%253A%2520new%2520therapeutic%2520targets%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2002%26volume%3D85%26spage%3D203%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+Janneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Million, R. P.</span><span> </span><span class="NLM_article-title">Impact of genetic diagnostics on drug development strategy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=459-462&author=R.+P.+Million&title=Impact+of+genetic+diagnostics+on+drug+development+strategy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillion%26aufirst%3DR.%2BP.%26atitle%3DImpact%2520of%2520genetic%2520diagnostics%2520on%2520drug%2520development%2520strategy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D459%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Tenen, D. G.</span><span> </span><span class="NLM_article-title">Disruption of differentiation in human cancer: AML shows the way</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12563308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVarsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=89-101&author=D.+G.+Tenen&title=Disruption+of+differentiation+in+human+cancer%3A+AML+shows+the+way"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of differentiation in human cancer: AML shows the way</span></div><div class="casAuthors">Tenen, Daniel G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-101</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes.  Recent studies of acute myeloid leukemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer.  This model involves lineage-specific transcription factors, which are involved in normal hematopoietic differentiation.  These factors are often targeted in AML - either by direct mutation or by interference from translocation proteins.  Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUl0uz1MDrVg90H21EOLACvtfcHk0li0J3Mdb9INJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVarsL4%253D&md5=c71e926e55a2410a9d4fa6f66a809469</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc989%26sid%3Dliteratum%253Aachs%26aulast%3DTenen%26aufirst%3DD.%2BG.%26atitle%3DDisruption%2520of%2520differentiation%2520in%2520human%2520cancer%253A%2520AML%2520shows%2520the%2520way%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D89%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strouboulis, J.</span><span> </span><span class="NLM_article-title">Erythropoiesis: model systems, molecular regulators, and developmental programs</span> <span class="citation_source-journal">IUBMB Life</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">830</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=800-830&author=A.+S.+Tsiftsoglouauthor=I.+S.+Vizirianakisauthor=J.+Strouboulis&title=Erythropoiesis%3A+model+systems%2C+molecular+regulators%2C+and+developmental+programs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26aulast%3DStrouboulis%26aufirst%3DJ.%26atitle%3DErythropoiesis%253A%2520model%2520systems%252C%2520molecular%2520regulators%252C%2520and%2520developmental%2520programs%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26spage%3D800%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fialkow, P. J.</span><span> </span><span class="NLM_article-title">Clonal origin of human tumors</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1979&pages=135-143&author=P.+J.+Fialkow&title=Clonal+origin+of+human+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFialkow%26aufirst%3DP.%2BJ.%26atitle%3DClonal%2520origin%2520of%2520human%2520tumors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D1979%26volume%3D30%26spage%3D135%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Zhou, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damelin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geles, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grindley, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirks, P. B.</span><span> </span><span class="NLM_article-title">Tumour-initiating cells: challenges and opportunities for anticancer drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">806</span><span class="NLM_x">–</span> <span class="NLM_lpage">823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd2137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19794444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=806-823&author=B.+B.+Zhouauthor=H.+Zhangauthor=M.+Damelinauthor=K.+G.+Gelesauthor=J.+C.+Grindleyauthor=P.+B.+Dirks&title=Tumour-initiating+cells%3A+challenges+and+opportunities+for+anticancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-initiating cells: challenges and opportunities for anticancer drug discovery</span></div><div class="casAuthors">Zhou, Bin-Bing S.; Zhang, Haiying; Damelin, Marc; Geles, Kenneth G.; Grindley, Justin C.; Dirks, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">806-823</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The hypothesis that cancer is driven by tumor-initiating cells (popularly known as cancer stem cells) has recently attracted a great deal of attention, owing to the promise of a novel cellular target for the treatment of haematopoietic and solid malignancies.  Furthermore, it seems that tumor-initiating cells might be resistant to many conventional cancer therapies, which might explain the limitations of these agents in curing human malignancies.  Although much work is still needed to identify and characterize tumor-initiating cells, efforts are now being directed towards identifying therapeutic strategies that could target these cells.  This Review considers recent advances in the cancer stem cell field, focusing on the challenges and opportunities for anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptUe11eAS07rVg90H21EOLACvtfcHk0li0J3Mdb9INJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurbL&md5=3d179a7e717a84381a679b8df44ff407</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd2137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2137%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%2BB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDamelin%26aufirst%3DM.%26aulast%3DGeles%26aufirst%3DK.%2BG.%26aulast%3DGrindley%26aufirst%3DJ.%2BC.%26aulast%3DDirks%26aufirst%3DP.%2BB.%26atitle%3DTumour-initiating%2520cells%253A%2520challenges%2520and%2520opportunities%2520for%2520anticancer%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D806%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Friend, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T.</span><span> </span><span class="NLM_article-title">Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1971&pages=378-382&author=C.+Friendauthor=W.+Scherauthor=J.+G.+Hollandauthor=T.+Sato&title=Hemoglobin+synthesis+in+murine+virus-induced+leukemic+cells+in+vitro%3A+stimulation+of+erythroid+differentiation+by+dimethyl+sulfoxide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriend%26aufirst%3DC.%26aulast%3DScher%26aufirst%3DW.%26aulast%3DHolland%26aufirst%3DJ.%2BG.%26aulast%3DSato%26aufirst%3DT.%26atitle%3DHemoglobin%2520synthesis%2520in%2520murine%2520virus-induced%2520leukemic%2520cells%2520in%2520vitro%253A%2520stimulation%2520of%2520erythroid%2520differentiation%2520by%2520dimethyl%2520sulfoxide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1971%26volume%3D68%26spage%3D378%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Nowak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeffler, H. P.</span><span> </span><span class="NLM_article-title">Differentiation therapy of leukemia: 3 decades of development</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3655</span><span class="NLM_x">–</span> <span class="NLM_lpage">3665</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3655-3665&author=D.+Nowakauthor=D.+Stewartauthor=H.+P.+Koeffler&title=Differentiation+therapy+of+leukemia%3A+3+decades+of+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DD.%26aulast%3DStewart%26aufirst%3DD.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DDifferentiation%2520therapy%2520of%2520leukemia%253A%25203%2520decades%2520of%2520development%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3655%26epage%3D3665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Sartorelli, A. C.</span><span> </span><span class="NLM_article-title">The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fbjc.1985.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=3899154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADyaL28%252FgtVCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1985&pages=293-302&author=A.+C.+Sartorelli&title=The+1985+Walter+Hubert+lecture.+Malignant+cell+differentiation+as+a+potential+therapeutic+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach</span></div><div class="casAuthors">Sartorelli A C</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-302</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">Most drugs available for cancer chemotherapy exert their effects through cytodestruction.  Although significant advances have been attained with these cytotoxic agents in several malignant diseases, response is often accompanied by significant morbidity and many common malignant tumours respond poorly to existing cytotoxic therapy.  Development of chemotherapeutic agents with non-cytodestructive actions appears desirable.  Considerable evidence exists which indicates that (a) the malignant state is not irreversible and represents a disease of altered maturation, and (b) some experimental tumour systems can be induced by chemical agents to differentiate to mature end-stage cells with no proliferative potential.  Thus, it is conceivable that therapeutic agents can be developed which convert cancer cells to benign forms.  To study the phenomenon of blocked maturation, squamous carcinoma SqCC/Y1 cells were employed in culture.  Using this system it was possible to demonstrate that physiological levels of retinoic acid and epidermal growth factor were capable of preventing the differentiation of these malignant keratinocytes into a mature tissue-like structure.  The terminal differentiation caused by certain antineoplastic agents was investigated in HL-60 promyelocytic leukaemia cells to provide information on the mechanism by which chemotherapeutic agents induce cells to by-pass a maturation block.  The anthracyclines aclacinomycin A and marcellomycin were potent inhibitors of N-glycosidically linked glycoprotein biosynthesis and transferrin receptor activity, and active inducers of maturation; temporal studies suggested that the biochemical effects were associated with the differentiation process. 6-Thioguanine produced cytotoxicity in parental cells by forming analog nucleotide.  In hypoxanthine-guanine phosphoribosyltransferase negative HL-60 cells the 6-thiopurine initiated maturation; this action was due to the free base (and possibly the deoxyribonucleoside), a finding which separated termination of proliferation due to cytotoxicity from that caused by maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmfSxuXFZAegHqQV89nF-2fW6udTcc2eZYIcX8cINRBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FgtVCjsg%253D%253D&md5=56a5c9656a5269ba2df3739f6e1a9a70</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1985.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1985.193%26sid%3Dliteratum%253Aachs%26aulast%3DSartorelli%26aufirst%3DA.%2BC.%26atitle%3DThe%25201985%2520Walter%2520Hubert%2520lecture.%2520Malignant%2520cell%2520differentiation%2520as%2520a%2520potential%2520therapeutic%2520approach%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1985%26volume%3D52%26spage%3D293%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Christman, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzog, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneiderman, N.</span><span> </span><span class="NLM_article-title">Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1983&pages=763-769&author=J.+K.+Christmanauthor=N.+Mendelsohnauthor=D.+Herzogauthor=N.+Schneiderman&title=Effect+of+5-azacytidine+on+differentiation+and+DNA+methylation+in+human+promyelocytic+leukemia+cells+%28HL-60%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristman%26aufirst%3DJ.%2BK.%26aulast%3DMendelsohn%26aufirst%3DN.%26aulast%3DHerzog%26aufirst%3DD.%26aulast%3DSchneiderman%26aufirst%3DN.%26atitle%3DEffect%2520of%25205-azacytidine%2520on%2520differentiation%2520and%2520DNA%2520methylation%2520in%2520human%2520promyelocytic%2520leukemia%2520cells%2520%2528HL-60%2529%26jtitle%3DCancer%2520Res.%26date%3D1983%26volume%3D43%26spage%3D763%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Creusot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christman, J. K.</span><span> </span><span class="NLM_article-title">Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2048</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=6173384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaL38XhtlGntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=2041-2048&author=F.+Creusotauthor=G.+Acsauthor=J.+K.+Christman&title=Inhibition+of+DNA+methyltransferase+and+induction+of+Friend+erythroleukemia+cell+differentiation+by+5-azacytidine+and+5-aza-2%E2%80%B2-deoxycytidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine</span></div><div class="casAuthors">Creusot, Francine; Acs, George; Christman, Judith K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2041-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Treatment of Friend erythroleukemia cells with 5-azacytidine (I)  [320-67-2] and 5-aza-2'-deoxycytidine (II)  [2353-33-5] leads to rapid, time-dependent, and dose-dependent decrease of DNA methyltransferase  [9037-42-7] activity and synthesis of markedly undermethylated DNA.  Since this DNA is at least partially methylated in vivo and serves as an excellent substrate for methylation in vitro, hypomethylation of DNA in analog-treated cells appears to result from the loss of DNA methyltransferase, rather than from an inherent inability of 5-azacytosine-substituted DNA to serve as a Me acceptor.  Inhibition of DNA synthesis blocks the loss of DNA methyltransferase activity while inhibitors of RNA synthesis do not, suggesting that the analogs must be incorporated into DNA to mediate their effect on the enzyme, and that minor substitution of 5-azacytosine for cytosine in DNA (∼0.3%) suffices to inactivate more than 95% of the enzyme in the cell.  Several lines of evidence link changes in the pattern of DNA modification with differentiation.  In this regard, it is significant that 5-azacytidine and 5-aza-2'-deoxycytidine act as weak inducers of erythroid differentiation of Friend erythroleukemia cells in the same concn. range where they affect DNA methyltransferase activity.  For differentiation to proceed, the cells must be washed free of the drugs.  Less than 24 h later, normal levels of DNA methyltransferase activity are restored and within 48 h, DNA isolated from the cells is not detectably undermethylated.  This may in part explain why 5-azacytidine and 5-aza-2'-deoxycytidine induce differentiation in less than 15% of the population despite their initial profound effect on DNA methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogsTJVZQ1RALVg90H21EOLACvtfcHk0lgqAI7KpcsVuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhtlGntLw%253D&md5=67fd34d05b1b76349fb0b2586a049ea5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCreusot%26aufirst%3DF.%26aulast%3DAcs%26aufirst%3DG.%26aulast%3DChristman%26aufirst%3DJ.%2BK.%26atitle%3DInhibition%2520of%2520DNA%2520methyltransferase%2520and%2520induction%2520of%2520Friend%2520erythroleukemia%2520cell%2520differentiation%2520by%25205-azacytidine%2520and%25205-aza-2%25E2%2580%25B2-deoxycytidine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D2041%26epage%3D2048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Strickland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahdavi, V.</span><span> </span><span class="NLM_article-title">The induction of differentiation in teratocarcinoma stem cells by retinoic acid</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1978&pages=393-403&author=S.+Stricklandauthor=V.+Mahdavi&title=The+induction+of+differentiation+in+teratocarcinoma+stem+cells+by+retinoic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStrickland%26aufirst%3DS.%26aulast%3DMahdavi%26aufirst%3DV.%26atitle%3DThe%2520induction%2520of%2520differentiation%2520in%2520teratocarcinoma%2520stem%2520cells%2520by%2520retinoic%2520acid%26jtitle%3DCell%26date%3D1978%26volume%3D15%26spage%3D393%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Leid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambon, P.</span><span> </span><span class="NLM_article-title">Multiplicity generates diversity in the retinoic acid signalling pathways</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1992&pages=427-433&author=M.+Leidauthor=P.+Kastnerauthor=P.+Chambon&title=Multiplicity+generates+diversity+in+the+retinoic+acid+signalling+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeid%26aufirst%3DM.%26aulast%3DKastner%26aufirst%3DP.%26aulast%3DChambon%26aufirst%3DP.%26atitle%3DMultiplicity%2520generates%2520diversity%2520in%2520the%2520retinoic%2520acid%2520signalling%2520pathways%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1992%26volume%3D17%26spage%3D427%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lhWUFMNMlPncQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Reuben, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wife, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">A new group of potent inducers of differentiation in murine erythroleukemia cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">862</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=862-866&author=R.+C.+Reubenauthor=R.+I.+Wifeauthor=R.+Breslow&title=A+new+group+of+potent+inducers+of+differentiation+in+murine+erythroleukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReuben%26aufirst%3DR.%2BC.%26aulast%3DWife%26aufirst%3DR.%2BI.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DA%2520new%2520group%2520of%2520potent%2520inducers%2520of%2520differentiation%2520in%2520murine%2520erythroleukemia%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D862%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaeli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogoloff, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">2604</span><span class="NLM_x">–</span> <span class="NLM_lpage">2069</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1992&pages=2604-2069&author=M.+Andreeffauthor=R.+Stoneauthor=J.+Michaeliauthor=C.+W.+Youngauthor=W.+P.+Tongauthor=H.+Sogoloffauthor=T.+Ervinauthor=D.+Kufeauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Hexamethylene+bisacetamide+in+myelodysplastic+syndrome+and+acute+myelogenous+leukemia%3A+a+phase+II+clinical+trial+with+a+differentiation-inducing+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DMichaeli%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DC.%2BW.%26aulast%3DTong%26aufirst%3DW.%2BP.%26aulast%3DSogoloff%26aufirst%3DH.%26aulast%3DErvin%26aufirst%3DT.%26aulast%3DKufe%26aufirst%3DD.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHexamethylene%2520bisacetamide%2520in%2520myelodysplastic%2520syndrome%2520and%2520acute%2520myelogenous%2520leukemia%253A%2520a%2520phase%2520II%2520clinical%2520trial%2520with%2520a%2520differentiation-inducing%2520agent%26jtitle%3DBlood%26date%3D1992%26volume%3D80%26spage%3D2604%26epage%3D2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span> </span><span class="NLM_article-title">Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">6358</span><span class="NLM_x">–</span> <span class="NLM_lpage">6362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=6358-6362&author=P.+A.+Marksauthor=R.+Breslowauthor=R.+A.+Rifkindauthor=L.+Ngoauthor=R.+Singh&title=Polar%2Fapolar+chemical+inducers+of+differentiation+of+transformed+cells%3A+strategies+to+improve+therapeutic+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DPolar%252Fapolar%2520chemical%2520inducers%2520of%2520differentiation%2520of%2520transformed%2520cells%253A%2520strategies%2520to%2520improve%2520therapeutic%2520potential%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D6358%26epage%3D6362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jursic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Potent cytodifferentiating agents related to hexamethylenebisacetamide</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">5542</span><span class="NLM_x">–</span> <span class="NLM_lpage">5546</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=5542-5546&author=R.+Breslowauthor=B.+Jursicauthor=Z.+F.+Yanauthor=E.+Friedmanauthor=L.+Lengauthor=L.+Ngoauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Potent+cytodifferentiating+agents+related+to+hexamethylenebisacetamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DJursic%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DZ.%2BF.%26aulast%3DFriedman%26aufirst%3DE.%26aulast%3DLeng%26aufirst%3DL.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DPotent%2520cytodifferentiating%2520agents%2520related%2520to%2520hexamethylenebisacetamide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1991%26volume%3D88%26spage%3D5542%26epage%3D5546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jursic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civoli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Second generation hybrid polar compounds are potent inducers of transformed cell differentiation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">5705</span><span class="NLM_x">–</span> <span class="NLM_lpage">5708</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=5705-5708&author=V.+M.+Richonauthor=Y.+Webbauthor=R.+Mergerauthor=T.+Sheppardauthor=B.+Jursicauthor=L.+Ngoauthor=F.+Civoliauthor=R.+Breslowauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Second+generation+hybrid+polar+compounds+are+potent+inducers+of+transformed+cell+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DWebb%26aufirst%3DY.%26aulast%3DMerger%26aufirst%3DR.%26aulast%3DSheppard%26aufirst%3DT.%26aulast%3DJursic%26aufirst%3DB.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DCivoli%26aufirst%3DF.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DSecond%2520generation%2520hybrid%2520polar%2520compounds%2520are%2520potent%2520inducers%2520of%2520transformed%2520cell%2520differentiation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D5705%26epage%3D5708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emiliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">3003</span><span class="NLM_x">–</span> <span class="NLM_lpage">3007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=3003-3007&author=V.+M.+Richonauthor=S.+Emilianiauthor=E.+Verdinauthor=Y.+Webbauthor=R.+Breslowauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=A+class+of+hybrid+polar+inducers+of+transformed+cell+differentiation+inhibits+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DEmiliani%26aufirst%3DS.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DWebb%26aufirst%3DY.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DA%2520class%2520of%2520hybrid%2520polar%2520inducers%2520of%2520transformed%2520cell%2520differentiation%2520inhibits%2520histone%2520deacetylases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D3003%26epage%3D3007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Roses, A. D.</span><span> </span><span class="NLM_article-title">Pharmacogenetics and drug development: the path to safer and more effective drugs</span> <span class="citation_source-journal">Nat. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">656</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrg1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15372086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt12ntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=645-656&author=A.+D.+Roses&title=Pharmacogenetics+and+drug+development%3A+the+path+to+safer+and+more+effective+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics and drug development: the path to safer and more effective drugs</span></div><div class="casAuthors">Roses, Allen D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">645-656</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Pharmacogenetics provides opportunities for informed decision-making along the pharmaceutical pipeline.  There is a growing literature of retrospective studies of marketed medicines that describe efficacy or safety on the basis of patient genotypes.  These studies emphasize the potential prospective use of genome information to enhance success in finding new medicines.  An example of a prospective efficacy pharmacogenetic Phase-IIA proof-of-concept study is described.  Inserting a rapidly performed efficacy pharmacogenetic step after initial clin. data are obtained can provide confidence for a commitment to full drug development.  The rapid identification of adverse events during and after drug development using genomic mapping tools is also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQyBqRboXE2LVg90H21EOLACvtfcHk0lhNgzMQXAqsgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt12ntrs%253D&md5=034b4d97ce4a22ed9ded6fb257742dc2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrg1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1432%26sid%3Dliteratum%253Aachs%26aulast%3DRoses%26aufirst%3DA.%2BD.%26atitle%3DPharmacogenetics%2520and%2520drug%2520development%253A%2520the%2520path%2520to%2520safer%2520and%2520more%2520effective%2520drugs%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2004%26volume%3D5%26spage%3D645%26epage%3D656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Paris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelloni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: from bench to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+deacetylase+inhibitors%3A+from+bench+to+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0lhNgzMQXAqsgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Melki, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S. J.</span><span> </span><span class="NLM_article-title">Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3730</span><span class="NLM_x">–</span> <span class="NLM_lpage">3740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=3730-3740&author=J.+R.+Melkiauthor=P.+C.+Vincentauthor=S.+J.+Clark&title=Concurrent+DNA+hypermethylation+of+multiple+genes+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMelki%26aufirst%3DJ.%2BR.%26aulast%3DVincent%26aufirst%3DP.%2BC.%26aulast%3DClark%26aufirst%3DS.%2BJ.%26atitle%3DConcurrent%2520DNA%2520hypermethylation%2520of%2520multiple%2520genes%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D3730%26epage%3D3740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boumber, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilaythong, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, J. P.</span><span> </span><span class="NLM_article-title">Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11335</span><span class="NLM_x">–</span> <span class="NLM_lpage">11343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11335-11343&author=L.+Shenauthor=Y.+Kondoauthor=S.+Ahmedauthor=Y.+Boumberauthor=K.+Konishiauthor=Y.+Guoauthor=X.+Chenauthor=J.+N.+Vilaythongauthor=J.+P.+Issa&title=Drug+sensitivity+prediction+by+CpG+island+methylation+profile+in+the+NCI-60+cancer+cell+line+panel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DKondo%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBoumber%26aufirst%3DY.%26aulast%3DKonishi%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DVilaythong%26aufirst%3DJ.%2BN.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26atitle%3DDrug%2520sensitivity%2520prediction%2520by%2520CpG%2520island%2520methylation%2520profile%2520in%2520the%2520NCI-60%2520cancer%2520cell%2520line%2520panel%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11335%26epage%3D11343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whetstine, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, R. A.</span><span> </span><span class="NLM_article-title">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.cell.2004.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15620353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2004&pages=941-953&author=Y.+Shiauthor=F.+Lanauthor=C.+Matsonauthor=P.+Mulliganauthor=J.+R.+Whetstineauthor=P.+A.+Coleauthor=R.+A.+Casero&title=Histone+demethylation+mediated+by+the+nuclear+amine+oxidase+homolog+LSD1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span></div><div class="casAuthors">Shi, Yujiang; Lan, Fei; Matson, Caitlin; Mulligan, Peter; Whetstine, Johnathan R.; Cole, Philip A.; Casero, Robert A.; Shi, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Posttranslational modifications of histone N-terminal tails impact chromatin structure and gene transcription.  While the extent of histone acetylation is detd. by both acetyltransferases and deacetylases, it has been unclear whether histone methylation is also regulated by enzymes with opposing activities.  Here, we provide evidence that LSD1 (KIAA0601), a nuclear homolog of amine oxidases, functions as a histone demethylase and transcriptional corepressor.  LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription.  Lysine demethylation occurs via an oxidn. reaction that generates formaldehyde.  Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant derepression of target genes, suggesting that LSD1 represses transcription via histone demethylation.  The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXHr-8kwGdXrVg90H21EOLACvtfcHk0lhip89upIbK9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D&md5=3474569204255e90a832667ba654748b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2004.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2004.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DMatson%26aufirst%3DC.%26aulast%3DMulligan%26aufirst%3DP.%26aulast%3DWhetstine%26aufirst%3DJ.%2BR.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DCasero%26aufirst%3DR.%2BA.%26atitle%3DHistone%2520demethylation%2520mediated%2520by%2520the%2520nuclear%2520amine%2520oxidase%2520homolog%2520LSD1%26jtitle%3DCell%26date%3D2004%26volume%3D119%26spage%3D941%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Roman-Gomez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillejo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiniger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, A.</span><span> </span><span class="NLM_article-title">The role of DNA hypermethylation in the pathogenesis and prognosis of acute lymphoblastic leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1864</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F1042819031000116689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=14738136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1GrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=1855-1864&author=J.+Roman-Gomezauthor=J.+A.+Castillejoauthor=A.+Jimenezauthor=M.+Barriosauthor=A.+Heinigerauthor=A.+Torres&title=The+role+of+DNA+hypermethylation+in+the+pathogenesis+and+prognosis+of+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The role of DNA hypermethylation in the pathogenesis and prognosis of acute lymphoblastic leukemia</span></div><div class="casAuthors">Roman-Gomez, Jose; Castillejo, Juan A.; Jimenez, Antonio; Barrios, Manuel; Heiniger, Anabel; Torres, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1855-1864</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The hallmark of acute lymphoblastic leukemia (ALL) is a progressive appearance of malignant cell behavior that is triggered by the evolution of altered gene function.  ALL has traditionally been viewed as a genetic disease, however, epigenetic defects also play an important role.  DNA promoter methylation has gained increasing recognition as an important mechanism for transcriptional silencing of cancer related genes.  The hypermethylation-assocd. inactivation affects virtually all of the pathways in the ALL cellular network, such as the cell cycle, apoptosis and adhesion.  The identification of these methylation abnormalities and elucidation of the mechanistic events surrounding them are of prime importance, as the methylation status of ALL cells can be used as prognostic biomarker and also can be manipulated in vivo with demethylating agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnI-pB5BH95LVg90H21EOLACvtfcHk0lhip89upIbK9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1GrtLo%253D&md5=6cd1310f24319e234be5bdbd44e2f3f1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F1042819031000116689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000116689%26sid%3Dliteratum%253Aachs%26aulast%3DRoman-Gomez%26aufirst%3DJ.%26aulast%3DCastillejo%26aufirst%3DJ.%2BA.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DBarrios%26aufirst%3DM.%26aulast%3DHeiniger%26aufirst%3DA.%26aulast%3DTorres%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520DNA%2520hypermethylation%2520in%2520the%2520pathogenesis%2520and%2520prognosis%2520of%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D1855%26epage%3D1864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Graham, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R.</span><span> </span><span class="NLM_article-title">The promises and pitfalls of epigenetic therapies in solid tumours</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1129</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=1129-1136&author=J.+S.+Grahamauthor=S.+B.+Kayeauthor=R.+Brown&title=The+promises+and+pitfalls+of+epigenetic+therapies+in+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DJ.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DBrown%26aufirst%3DR.%26atitle%3DThe%2520promises%2520and%2520pitfalls%2520of%2520epigenetic%2520therapies%2520in%2520solid%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D1129%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Kim, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, J. J.</span><span> </span><span class="NLM_article-title">Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1374</span><span class="NLM_x">–</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00158a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1374-1380&author=C.+H.+Kimauthor=V.+E.+Marquezauthor=D.+T.+Maoauthor=D.+R.+Hainesauthor=J.+J.+McCormack&title=Synthesis+of+pyrimidin-2-one+nucleosides+as+acid-stable+inhibitors+of+cytidine+deaminase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm00158a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00158a009%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DMao%26aufirst%3DD.%2BT.%26aulast%3DHaines%26aufirst%3DD.%2BR.%26aulast%3DMcCormack%26aufirst%3DJ.%2BJ.%26atitle%3DSynthesis%2520of%2520pyrimidin-2-one%2520nucleosides%2520as%2520acid-stable%2520inhibitors%2520of%2520cytidine%2520deaminase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1374%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Taylor, S. M.</span><span> </span><span class="NLM_article-title">5-Aza-2′-deoxycytidine: cell differentiation and DNA methylation</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=3-8&author=S.+M.+Taylor&title=5-Aza-2%E2%80%B2-deoxycytidine%3A+cell+differentiation+and+DNA+methylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BM.%26atitle%3D5-Aza-2%25E2%2580%25B2-deoxycytidine%253A%2520cell%2520differentiation%2520and%2520DNA%2520methylation%26jtitle%3DLeukemia%26date%3D1993%26volume%3D7%26spage%3D3%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Kihslinger, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godley, L. A.</span><span> </span><span class="NLM_article-title">The use of hypomethylating agents in the treatment of hematologic malignancies</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1676</span><span class="NLM_x">–</span> <span class="NLM_lpage">1695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F10428190701493910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17786703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSkt7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=1676-1695&author=J.+E.+Kihslingerauthor=L.+A.+Godley&title=The+use+of+hypomethylating+agents+in+the+treatment+of+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The use of hypomethylating agents in the treatment of hematologic malignancies</span></div><div class="casAuthors">Kihslinger, Jane E.; Godley, Lucy A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1676-1695</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Epigenetic alterations, such as DNA methylation and histone modifications, are abnormal in cancer cells, and the use of the hypomethylating agents 5-azacitidine and decitabine are important addns. to our arsenal of active cancer drugs, esp. for the treatment of the myelodysplastic syndromes and acute myeloid leukemia.  Most effective are repeated cycles of the drugs given at doses much lower than originally tested.  Typical overall response rates (complete responses + partial responses + hematol. improvement) for both drugs are in the range of 40 - 50%.  These agents are generally very well tolerated, with myelosuppression being the major side effect.  Postulated to work through hypomethylation of DNA causing induction of gene expression, the precise mechanism of action of these agents is not yet clear.  Future studies are likely to combine these agents with other drugs like the histone deacetylase inhibitors that act in related pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNd1L-OQHIrVg90H21EOLACvtfcHk0lhip89upIbK9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSkt7nL&md5=2d6cdca7796a741198fdc4e4358cfef0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1080%2F10428190701493910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701493910%26sid%3Dliteratum%253Aachs%26aulast%3DKihslinger%26aufirst%3DJ.%2BE.%26aulast%3DGodley%26aufirst%3DL.%2BA.%26atitle%3DThe%2520use%2520of%2520hypomethylating%2520agents%2520in%2520the%2520treatment%2520of%2520hematologic%2520malignancies%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D1676%26epage%3D1695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Plimack, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, J. P.</span><span> </span><span class="NLM_article-title">Decitabine and its role in the treatment of hematopoietic malignancies</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1472</span><span class="NLM_x">–</span> <span class="NLM_lpage">1481</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F10428190701471981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17701577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFymurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=1472-1481&author=E.+R.+Plimackauthor=H.+M.+Kantarjianauthor=J.+P.+Issa&title=Decitabine+and+its+role+in+the+treatment+of+hematopoietic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine and its role in the treatment of hematopoietic malignancies</span></div><div class="casAuthors">Plimack, Elizabeth R.; Kantarjian, Hagop M.; Issa, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1472-1481</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  DNA methylation is responsible for abnormal silencing of many genes, including tumor suppressor genes, in cancer.  Decitabine, an S-phase specific inhibitor of DNA methyltransferase, has been shown to decrease levels of abnormal methylation in neoplasia.  Though initially investigated at high doses as a cytotoxic agent, recent studies show that when administered at low doses, the hypomethylating activity of decitabine is increased with a demonstrated increase in activity in hematopoietic malignancies.  Multiple clin. trials, both in the United States and in Europe, have demonstrated the efficacy of decitabine in acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (MDS).  Recently approved by the United States Food and Drug Administration for the treatment of (MDS), decitabine represents an effective and well-tolerated therapeutic option in this disease, for which treatment options were previously scarce.  While the activity in MDS is promising, primary and secondary resistance remain a problem.  Investigations of combinations of decitabine with other agents, including histone deacetylase inhibitors, are currently ongoing in the hope of substantially prolonging survival in patients with hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrByRslQCHBrVg90H21EOLACvtfcHk0ligCbxdVDEmyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFymurg%253D&md5=357cbfb36e4bae16c7c2ab1eaa540d8b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F10428190701471981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701471981%26sid%3Dliteratum%253Aachs%26aulast%3DPlimack%26aufirst%3DE.%2BR.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26atitle%3DDecitabine%2520and%2520its%2520role%2520in%2520the%2520treatment%2520of%2520hematopoietic%2520malignancies%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D1472%26epage%3D1481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Zebularine: a new drug for epigenetic therapy</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">910</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1042%2FBST0320910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15506921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVSltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=910-912&author=C.+B.+Yooauthor=J.+C.+Chengauthor=P.+A.+Jones&title=Zebularine%3A+a+new+drug+for+epigenetic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Zebularine: a new drug for epigenetic therapy</span></div><div class="casAuthors">Yoo, C. B.; Cheng, J. C.; Jones, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">910-912</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Regulatory genes are often hypermethylated at their promoter 5' regions and silenced in cancer.  Epigenetic therapy with DNA methylation inhibitors were shown to result in the demethylation and reactivation of these genes.  Zebularine is a recently discovered mechanism-based inhibitor of DNA methylation, and has received much attention for its potential in clin. use.  Further studies exploring the effectiveness of zebularine in a variety of settings could allow the development of novel therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrodunLKBfmOrVg90H21EOLACvtfcHk0ligCbxdVDEmyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVSltrc%253D&md5=fa37bd140c829a109198c9657b3f9410</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1042%2FBST0320910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0320910%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DZebularine%253A%2520a%2520new%2520drug%2520for%2520epigenetic%2520therapy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2004%26volume%3D32%26spage%3D910%26epage%3D912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Epigenetic therapy of cancer: past, present and future</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd1930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16485345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1yqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=37-50&author=C.+B.+Yooauthor=P.+A.+Jones&title=Epigenetic+therapy+of+cancer%3A+past%2C+present+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic therapy of cancer: past, present and future</span></div><div class="casAuthors">Yoo, Christine B.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-50</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The initiation and progression of cancer is controlled by both genetic and epigenetic events.  Unlike genetic alterations, which are almost impossible to reverse, epigenetic aberrations are potentially reversible, allowing the malignant cell population to revert to a more normal state.  With the advent of numerous drugs that target specific enzymes involved in the epigenetic regulation of gene expression, the utilization of epigenetic targets is emerging as an effective and valuable approach to chemotherapy as well as chemoprevention of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOQv6jMPAK1LVg90H21EOLACvtfcHk0ligCbxdVDEmyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1yqsA%253D%253D&md5=5c552ef929369b8466d2ab2c324cf092</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd1930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1930%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DEpigenetic%2520therapy%2520of%2520cancer%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D37%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phiasivongsa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6400</span><span class="NLM_x">–</span> <span class="NLM_lpage">6408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6400-6408&author=C.+B.+Yooauthor=S.+Jeongauthor=G.+Eggerauthor=G.+Liangauthor=P.+Phiasivongsaauthor=C.+Tangauthor=S.+Redkarauthor=P.+A.+Jones&title=Delivery+of+5-aza-2%E2%80%B2-deoxycytidine+to+cells+using+oligodeoxynucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DPhiasivongsa%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DRedkar%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DDelivery%2520of%25205-aza-2%25E2%2580%25B2-deoxycytidine%2520to%2520cells%2520using%2520oligodeoxynucleotides%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6400%26epage%3D6408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Altucci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minucci, S.</span><span> </span><span class="NLM_article-title">Epigenetic therapies in haematological malignancies: searching for true targets</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=1137-1145&author=L.+Altucciauthor=S.+Minucci&title=Epigenetic+therapies+in+haematological+malignancies%3A+searching+for+true+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DEpigenetic%2520therapies%2520in%2520haematological%2520malignancies%253A%2520searching%2520for%2520true%2520targets%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D1137%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Castellano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbardella, G.</span><span> </span><span class="NLM_article-title">Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2321</span><span class="NLM_x">–</span> <span class="NLM_lpage">2325</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7015705" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2321-2325&author=S.+Castellanoauthor=D.+Kuckauthor=M.+Salaauthor=E.+Novellinoauthor=F.+Lykoauthor=G.+Sbardella&title=Constrained+analogues+of+procaine+as+novel+small+molecule+inhibitors+of+DNA+methyltransferase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm7015705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7015705%26sid%3Dliteratum%253Aachs%26aulast%3DCastellano%26aufirst%3DS.%26aulast%3DKuck%26aufirst%3DD.%26aulast%3DSala%26aufirst%3DM.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DLyko%26aufirst%3DF.%26aulast%3DSbardella%26aufirst%3DG.%26atitle%3DConstrained%2520analogues%2520of%2520procaine%2520as%2520novel%2520small%2520molecule%2520inhibitors%2520of%2520DNA%2520methyltransferase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2321%26epage%3D2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Siedlecki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boy, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueckner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suhai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielenkiewicz, P.</span><span> </span><span class="NLM_article-title">Discovery of two novel, small-molecule inhibitors of DNA methylation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=678-683&author=P.+Siedleckiauthor=R.+G.+Boyauthor=T.+Muschauthor=B.+Bruecknerauthor=S.+Suhaiauthor=F.+Lykoauthor=P.+Zielenkiewicz&title=Discovery+of+two+novel%2C+small-molecule+inhibitors+of+DNA+methylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiedlecki%26aufirst%3DP.%26aulast%3DBoy%26aufirst%3DR.%2BG.%26aulast%3DMusch%26aufirst%3DT.%26aulast%3DBrueckner%26aufirst%3DB.%26aulast%3DSuhai%26aufirst%3DS.%26aulast%3DLyko%26aufirst%3DF.%26aulast%3DZielenkiewicz%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520two%2520novel%252C%2520small-molecule%2520inhibitors%2520of%2520DNA%2520methylation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D49%26spage%3D678%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Brueckner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Boy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siedlecki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliem, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielenkiewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suhai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiessler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span> </span><span class="NLM_article-title">Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6305</span><span class="NLM_x">–</span> <span class="NLM_lpage">6311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=6305-6311&author=B.+Bruecknerauthor=R.+Garcia+Boyauthor=P.+Siedleckiauthor=T.+Muschauthor=H.+C.+Kliemauthor=P.+Zielenkiewiczauthor=S.+Suhaiauthor=M.+Wiesslerauthor=F.+Lyko&title=Epigenetic+reactivation+of+tumor+suppressor+genes+by+a+novel+small-molecule+inhibitor+of+human+DNA+methyltransferases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrueckner%26aufirst%3DB.%26aulast%3DGarcia%2BBoy%26aufirst%3DR.%26aulast%3DSiedlecki%26aufirst%3DP.%26aulast%3DMusch%26aufirst%3DT.%26aulast%3DKliem%26aufirst%3DH.%2BC.%26aulast%3DZielenkiewicz%26aufirst%3DP.%26aulast%3DSuhai%26aufirst%3DS.%26aulast%3DWiessler%26aufirst%3DM.%26aulast%3DLyko%26aufirst%3DF.%26atitle%3DEpigenetic%2520reactivation%2520of%2520tumor%2520suppressor%2520genes%2520by%2520a%2520novel%2520small-molecule%2520inhibitor%2520of%2520human%2520DNA%2520methyltransferases%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D6305%26epage%3D6311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Sánchez-del-Campo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otón, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tárraga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabezas-Herrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chazarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez-López, J. N.</span><span> </span><span class="NLM_article-title">Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2018</span><span class="NLM_x">–</span> <span class="NLM_lpage">2026</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701346h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2018-2026&author=L.+S%C3%A1nchez-del-Campoauthor=F.+Ot%C3%B3nauthor=A.+T%C3%A1rragaauthor=J.+Cabezas-Herreraauthor=S.+Chazarraauthor=J.+N.+Rodr%C3%ADguez-L%C3%B3pez&title=Synthesis+and+biological+activity+of+a+3%2C4%2C5-trimethoxybenzoyl+ester+analogue+of+epicatechin-3-gallate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm701346h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701346h%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-del-Campo%26aufirst%3DL.%26aulast%3DOt%25C3%25B3n%26aufirst%3DF.%26aulast%3DT%25C3%25A1rraga%26aufirst%3DA.%26aulast%3DCabezas-Herrera%26aufirst%3DJ.%26aulast%3DChazarra%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-L%25C3%25B3pez%26aufirst%3DJ.%2BN.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520a%25203%252C4%252C5-trimethoxybenzoyl%2520ester%2520analogue%2520of%2520epicatechin-3-gallate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2018%26epage%3D2026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovicz, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P. k.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcucci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span> </span><span class="NLM_article-title">Curcumin is a potent DNA hypomethylation agent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">706</span><span class="NLM_x">–</span> <span class="NLM_lpage">709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=706-709&author=Z.+Liuauthor=Z.+Xieauthor=W.+Jonesauthor=R.+E.+Pavloviczauthor=S.+Liuauthor=J.+Yuauthor=P.+k.+Liauthor=J.+Linauthor=J.+R.+Fuchsauthor=G.+Marcucciauthor=C.+Liauthor=K.+K.+Chan&title=Curcumin+is+a+potent+DNA+hypomethylation+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DJones%26aufirst%3DW.%26aulast%3DPavlovicz%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%2Bk.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DFuchs%26aufirst%3DJ.%2BR.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DK.%2BK.%26atitle%3DCurcumin%2520is%2520a%2520potent%2520DNA%2520hypomethylation%2520agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D706%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Brueckner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span> </span><span class="NLM_article-title">DNA methyltransferase inhibitors for cancer therapy</span> <span class="citation_source-journal">Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FPPO.0b013e31803c7245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17464242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=17-22&author=B.+Bruecknerauthor=D.+Kuckauthor=F.+Lyko&title=DNA+methyltransferase+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">DNA methyltransferase inhibitors for cancer therapy</span></div><div class="casAuthors">Brueckner, Bodo; Kuck, Dirk; Lyko, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-22</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Aberrant DNA methylation patterns, including hypermethylation of tumor suppressor genes, have been described in many human cancers.  These epigenetic mutations can be reversed by DNA methyltransferase inhibitors, which provide novel opportunities for cancer therapy.  Clin. concepts for epigenetic therapies are currently being developed by using azanucleosides for the treatment of leukemias and other tumors.  These trials will greatly benefit from the inclusion of mol. markers for monitoring epigenetic changes in patients and for maximizing biol. responses.  In addn., novel inhibitors need to be developed that result in a direct and specific inhibition of DNA methyltransferase activity.  Several recent developments indicate that rational design of small mol. DNA methyltransferase inhibitors is feasible and that this approach can result in the establishment of novel drug candidates.  The use of novel DNA methyltransferase inhibitors in clin. trials that allow monitoring of drug-induced DNA methylation changes should provide the foundation for improved epigenetic cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2K-IsaLfb2bVg90H21EOLACvtfcHk0lieR_LjJSa3gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWhtbk%253D&md5=be3c6585ba67148156fbe87f8b593e25</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1097%2FPPO.0b013e31803c7245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0b013e31803c7245%26sid%3Dliteratum%253Aachs%26aulast%3DBrueckner%26aufirst%3DB.%26aulast%3DKuck%26aufirst%3DD.%26aulast%3DLyko%26aufirst%3DF.%26atitle%3DDNA%2520methyltransferase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520J.%26date%3D2007%26volume%3D13%26spage%3D17%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Ballestar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteller, M.</span><span> </span><span class="NLM_article-title">The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications</span> <span class="citation_source-journal">Prog. Mol. Subcell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1007%2F3-540-27310-7_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15881895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFymsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2005&pages=169-181&author=E.+Ballestarauthor=M.+Esteller&title=The+epigenetic+breakdown+of+cancer+cells%3A+from+DNA+methylation+to+histone+modifications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications</span></div><div class="casAuthors">Ballestar, Esteban; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular and Subcellular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">Epigenetics and Chromatin</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">PMSBA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6484</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  The recognition of epigenetic defects in all types of cancer has represented a revolutionary achievement in cancer research in recent years.  DNA methylation aberrant changes (global hypomethylation and CpG island hypermethylation) were among the first events to be recognized.  The overall scenario comprises a network of factors in which deregulation of DNA methyltransferases leads to a cancer-type specific profile of tumor suppressor genes that become epigenetically silenced.  Over recent years, a better understanding of the machinery that connects DNA methylation, chromatin and transcriptional activity, in which histone modifications stand in a key position, has been achieved.  The identification of these connections has contributed not only to understanding how epigenetic deregulation occurs in cancer but also to developing novel therapies that can reverse epigenetic defects in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFwpmRD0eiLVg90H21EOLACvtfcHk0lg7qMn9QuqB6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFymsLo%253D&md5=9f2e6b19b8ca01061cc7761ea0d0af84</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2F3-540-27310-7_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F3-540-27310-7_7%26sid%3Dliteratum%253Aachs%26aulast%3DBallestar%26aufirst%3DE.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520epigenetic%2520breakdown%2520of%2520cancer%2520cells%253A%2520from%2520DNA%2520methylation%2520to%2520histone%2520modifications%26jtitle%3DProg.%2520Mol.%2520Subcell.%2520Biol.%26date%3D2005%26volume%3D38%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Dobosy, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selker, E. U.</span><span> </span><span class="NLM_article-title">Emerging connections between DNA methylation and histone acetylation</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1007%2FPL00000895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=11437233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1ait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2001&pages=721-727&author=J.+R.+Dobosyauthor=E.+U.+Selker&title=Emerging+connections+between+DNA+methylation+and+histone+acetylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging connections between DNA methylation and histone acetylation</span></div><div class="casAuthors">Dobosy, J. R.; Selker, E. U.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">721-727</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review, with 54 refs.  Modifications of both DNA and chromatin can affect gene expression and lead to gene silencing.  Evidence of links between DNA methylation and histone hypoacetylation is accumulating.  Several proteins that specifically bind to methylated DNA are assocd. with complexes that include histone deacetylases (HDACs).  In addn., DNA methyltransferases of mammals appear to interact with HDACs.  Expts. with animal cells have shown that HDACs are responsible for part of the repressive effect of DNA methylation.  Evidence was found in Neurospora that protein acetylation can in some cases affect DNA methylation.  The available data suggest that the roles of DNA methylation and histone hypoacetylation, and their relationship with each other, can vary, even within an organism.  Some open questions in this emerging field that should be answered in the near future are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyuhEAoa6weLVg90H21EOLACvtfcHk0lg7qMn9QuqB6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1ait7o%253D&md5=e417846766aa5ac71865d26929b08717</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2FPL00000895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00000895%26sid%3Dliteratum%253Aachs%26aulast%3DDobosy%26aufirst%3DJ.%2BR.%26aulast%3DSelker%26aufirst%3DE.%2BU.%26atitle%3DEmerging%2520connections%2520between%2520DNA%2520methylation%2520and%2520histone%2520acetylation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2001%26volume%3D58%26spage%3D721%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Fahrner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baylin, S. B.</span><span> </span><span class="NLM_article-title">Dependence of histone modifications and gene expression on DNA hypermethylation in cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7213</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=7213-7218&author=J.+A.+Fahrnerauthor=S.+Eguchiauthor=J.+G.+Hermanauthor=S.+B.+Baylin&title=Dependence+of+histone+modifications+and+gene+expression+on+DNA+hypermethylation+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahrner%26aufirst%3DJ.%2BA.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DDependence%2520of%2520histone%2520modifications%2520and%2520gene%2520expression%2520on%2520DNA%2520hypermethylation%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D7213%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Cameron, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myohanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baylin, S. B.</span><span> </span><span class="NLM_article-title">Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2F5047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9916800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1MXltlWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=103-107&author=E.+E.+Cameronauthor=K.+E.+Bachmanauthor=S.+Myohanenauthor=J.+G.+Hermanauthor=S.+B.+Baylin&title=Synergy+of+demethylation+and+histone+deacetylase+inhibition+in+the+re-expression+of+genes+silenced+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer</span></div><div class="casAuthors">Cameron, Elizabeth E.; Bachman, Kurtis E.; Myohanen, Sanna; Herman, James G.; Baylin, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Densely methylated DNA assocs. with transcriptionally repressive chromatin characterized by the presence of underacetylated histones.  Recently, these 2 epigenetic processes were dynamically linked.  The methyl-CpG-binding protein MeCP2 appears to reside in a complex with histone deacetylase activity.  MeCP2 can mediate formation of transcriptionally repressive chromatin on methylated promoter templates in vitro, and this process can be reversed by trichostatin A (TSA), a specific inhibitor of histone deacetylase.  Little is known about the relative roles of methylation and histone deacetylase activity in the stable inhibition of transcription on densely methylated endogenous promoters, such as those for silenced alleles of imprinted genes, genes on the female inactive X chromosome, and tumor-suppressor genes inactivated in cancer cells.  The authors show that the hypermethylated genes MLH1, TIMP3, CDKN2B (INK4B, p15), and CDKN2A (INK4, p16) cannot be transcriptionally reactivated with TSA alone in tumor cells in which the authors have shown that TSA alone can upregulate the expression of non-methylated genes.  Following minimal demethylation and slight gene reactivation in the presence of low dose 5-aza-2' deoxycytidine (5Aza-dC), however, TSA treatment results in robust re-expression of each gene.  TSA does not contribute to demethylation of the genes, and none of the treatments alter the chromatin structure assocd. with the hypermethylated promoters.  Thus, although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZCmJwXaY4o7Vg90H21EOLACvtfcHk0lg7qMn9QuqB6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltlWjtA%253D%253D&md5=5f0666dac86ee091d5e06ab0b9403502</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2F5047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F5047%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DE.%2BE.%26aulast%3DBachman%26aufirst%3DK.%2BE.%26aulast%3DMyohanen%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DSynergy%2520of%2520demethylation%2520and%2520histone%2520deacetylase%2520inhibition%2520in%2520the%2520re-expression%2520of%2520genes%2520silenced%2520in%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D1999%26volume%3D21%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baylin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woster, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, R. A.,  Jr.</span><span> </span><span class="NLM_article-title">Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7217</span><span class="NLM_x">–</span> <span class="NLM_lpage">7228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1078-0432.CCR-09-1293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19934284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7217-7228&author=Y.+Huangauthor=T.+M.+Stewartauthor=Y.+Wuauthor=S.+B.+Baylinauthor=L.+J.+Martonauthor=B.+Perkinsauthor=R.+J.+Jonesauthor=P.+M.+Wosterauthor=R.+A.+Casero&title=Novel+oligoamine+analogues+inhibit+lysine-specific+demethylase+1+and+induce+reexpression+of+epigenetically+silenced+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes</span></div><div class="casAuthors">Huang, Yi; Stewart, Tracy Murray; Wu, Yu; Baylin, Stephen B.; Marton, Laurence J.; Perkins, Brandy; Jones, Richard J.; Woster, Patrick M.; Casero, Robert A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7217-7228</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Abnormal DNA CpG island hypermethylation and transcriptionally repressive histone modifications are assocd. with the aberrant silencing of tumor suppressor genes.  Lysine methylation is a dynamic, enzymically controlled process.  Lysine-specific demethylase 1 (LSD1) has recently been identified as a histone lysine demethylase.  LSD1 specifically catalyzes demethylation of mono- and dimethyl-lysine 4 of histone 3 (H3K4), key pos. chromatin marks assocd. with transcriptional activation.  We hypothesized that a novel class of oligoamine analogs would effectively inhibit LSD1 and thus cause the reexpression of aberrantly silenced genes.  Exptl. Design: Human colorectal cancer cells were treated with the oligoamines and changes in mono- and dimethyl-H3K4 and other chromatin marks were monitored.  In addn., treated cells were evaluated for the reexpression of the aberrantly silenced secreted frizzled-related proteins (SFRP) Wnt signaling pathway antagonist genes.  Finally, the effects of the LSD1 inhibitors were evaluated in an in vivo xenograft model.  Results: Treatment of HCT116 human colon adenocarcinoma cells in vitro resulted in increased H3K4 methylation and reexpression of silenced SFRP genes.  This reexpression is also accompanied by a decrease in H3K9me2 repressive mark.  Importantly, cotreatment with low doses of oligoamines and a DNA methyltransferase inhibitor highly induces the reexpression of the aberrantly silenced SFRP2 gene and results in significant inhibition of the growth of established tumors in a human colon tumor model in vivo.  Conclusions: The use of LSD1-inhibiting oligoamine analogs in combination with DNA methyltransferase inhibitors represents a highly promising and novel approach for epigenetic therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk1naS7xW5GbVg90H21EOLACvtfcHk0lg7qMn9QuqB6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zE&md5=0f86cd2d3482aa0a36adacc4f10329dd</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1293%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DStewart%26aufirst%3DT.%2BM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DMarton%26aufirst%3DL.%2BJ.%26aulast%3DPerkins%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DWoster%26aufirst%3DP.%2BM.%26aulast%3DCasero%26aufirst%3DR.%2BA.%26atitle%3DNovel%2520oligoamine%2520analogues%2520inhibit%2520lysine-specific%2520demethylase%25201%2520and%2520induce%2520reexpression%2520of%2520epigenetically%2520silenced%2520genes%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D7217%26epage%3D7228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">McCarthy, M.</span><span> </span><span class="NLM_article-title">FDA approves tretinoin for treatment of APL</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=1995&pages=1552-1552&author=M.+McCarthy&title=FDA+approves+tretinoin+for+treatment+of+APL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%26atitle%3DFDA%2520approves%2520tretinoin%2520for%2520treatment%2520of%2520APL%26jtitle%3DLancet%26date%3D1995%26volume%3D346%26spage%3D1552%26epage%3D1552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Hegde, S.; Schmidt, M.; Anthony, W.</span><span> </span><span class="NLM_article-title">To Market, To Market—2005</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">41</span>, pp  <span class="NLM_fpage">439</span>− <span class="NLM_lpage">477</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=439-477&author=S.+Hegde&author=M.+Schmidt&author=W.+Anthony&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942005%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26pub%3DAcademic%2520Press%26date%3D2006%26volume%3D41%26spage%3D439%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Kagechika, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, K.</span><span> </span><span class="NLM_article-title">Synthetic retinoids: recent developments concerning structure and clinical utility</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5875</span><span class="NLM_x">–</span> <span class="NLM_lpage">5883</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0581821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5875-5883&author=H.+Kagechikaauthor=K.+Shudo&title=Synthetic+retinoids%3A+recent+developments+concerning+structure+and+clinical+utility"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm0581821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0581821%26sid%3Dliteratum%253Aachs%26aulast%3DKagechika%26aufirst%3DH.%26aulast%3DShudo%26aufirst%3DK.%26atitle%3DSynthetic%2520retinoids%253A%2520recent%2520developments%2520concerning%2520structure%2520and%2520clinical%2520utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5875%26epage%3D5883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Look, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landwehr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluethmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMotte, P.</span><span> </span><span class="NLM_article-title">Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">E91</span><span class="NLM_x">–</span> <span class="NLM_lpage">E98</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1995&pages=E91-E98&author=J.+Lookauthor=J.+Landwehrauthor=F.+Bauerauthor=A.+S.+Hoffmannauthor=H.+Bluethmannauthor=P.+LeMotte&title=Marked+resistance+of+RAR+gamma-deficient+mice+to+the+toxic+effects+of+retinoic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLook%26aufirst%3DJ.%26aulast%3DLandwehr%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DF.%26aulast%3DHoffmann%26aufirst%3DA.%2BS.%26aulast%3DBluethmann%26aufirst%3DH.%26aulast%3DLeMotte%26aufirst%3DP.%26atitle%3DMarked%2520resistance%2520of%2520RAR%2520gamma-deficient%2520mice%2520to%2520the%2520toxic%2520effects%2520of%2520retinoic%2520acid%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1995%26volume%3D269%26spage%3DE91%26epage%3DE98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClurg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagoner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P. J. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3146</span><span class="NLM_x">–</span> <span class="NLM_lpage">3155</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00016a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3146-3155&author=M.+F.+Boehmauthor=L.+Zhangauthor=L.+Zhiauthor=M.+R.+McClurgauthor=E.+Bergerauthor=M.+Wagonerauthor=D.+E.+Maisauthor=C.+M.+Sutoauthor=P.+J.+A.+Davies&title=Design+and+synthesis+of+potent+retinoid+X+receptor+selective+ligands+that+induce+apoptosis+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm00016a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00016a018%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhi%26aufirst%3DL.%26aulast%3DMcClurg%26aufirst%3DM.%2BR.%26aulast%3DBerger%26aufirst%3DE.%26aulast%3DWagoner%26aufirst%3DM.%26aulast%3DMais%26aufirst%3DD.%2BE.%26aulast%3DSuto%26aufirst%3DC.%2BM.%26aulast%3DDavies%26aufirst%3DP.%2BJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520retinoid%2520X%2520receptor%2520selective%2520ligands%2520that%2520induce%2520apoptosis%2520in%2520leukemia%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3146%26epage%3D3155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Canan Koch, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dardashti, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesario, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadzan, A. M.</span><span> </span><span class="NLM_article-title">Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980621r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=742-750&author=S.+S.+Canan+Kochauthor=L.+J.+Dardashtiauthor=R.+M.+Cesarioauthor=G.+E.+Crostonauthor=M.+F.+Boehmauthor=R.+A.+Heymanauthor=A.+M.+Nadzan&title=Synthesis+of+retinoid+X+receptor-specific+ligands+that+are+potent+inducers+of+adipogenesis+in+3T3-L1+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm980621r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980621r%26sid%3Dliteratum%253Aachs%26aulast%3DCanan%2BKoch%26aufirst%3DS.%2BS.%26aulast%3DDardashti%26aufirst%3DL.%2BJ.%26aulast%3DCesario%26aufirst%3DR.%2BM.%26aulast%3DCroston%26aufirst%3DG.%2BE.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DNadzan%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520of%2520retinoid%2520X%2520receptor-specific%2520ligands%2520that%2520are%2520potent%2520inducers%2520of%2520adipogenesis%2520in%25203T3-L1%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardecky, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crombie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etgen, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulkner, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grese, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klausing, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibowitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mapes, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marschke, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reifel-Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rungta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyhonas, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span> </span><span class="NLM_article-title">Novel (2<i>E</i>,4<i>E</i>,6<i>Z</i>)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2683</span><span class="NLM_x">–</span> <span class="NLM_lpage">2696</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020340q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2683-2696&author=P.+Y.+Michellysauthor=R.+J.+Ardeckyauthor=J.+H.+Chenauthor=D.+L.+Crombieauthor=G.+J.+Etgenauthor=A.+L.+Faulknerauthor=T.+A.+Greseauthor=R.+A.+Heymanauthor=D.+S.+Karanewskyauthor=K.+Klausingauthor=M.+D.+Leibowitzauthor=S.+Liuauthor=D.+A.+Maisauthor=C.+M.+Mapesauthor=K.+B.+Marschkeauthor=A.+Reifel-Millerauthor=K.+M.+Ogilvieauthor=D.+Rungtaauthor=A.+W.+Thompsonauthor=J.+S.+Tyhonasauthor=M.+F.+Boehm&title=Novel+%282E%2C4E%2C6Z%29-7-%282-alkoxy-3%2C5-dialkylbenzene%29-3-methylocta-2%2C4%2C6-trienoic+acid+retinoid+X+receptor+modulators+are+active+in+models+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm020340q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020340q%26sid%3Dliteratum%253Aachs%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DArdecky%26aufirst%3DR.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DCrombie%26aufirst%3DD.%2BL.%26aulast%3DEtgen%26aufirst%3DG.%2BJ.%26aulast%3DFaulkner%26aufirst%3DA.%2BL.%26aulast%3DGrese%26aufirst%3DT.%2BA.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DKlausing%26aufirst%3DK.%26aulast%3DLeibowitz%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMais%26aufirst%3DD.%2BA.%26aulast%3DMapes%26aufirst%3DC.%2BM.%26aulast%3DMarschke%26aufirst%3DK.%2BB.%26aulast%3DReifel-Miller%26aufirst%3DA.%26aulast%3DOgilvie%26aufirst%3DK.%2BM.%26aulast%3DRungta%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DA.%2BW.%26aulast%3DTyhonas%26aufirst%3DJ.%2BS.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DNovel%2520%25282E%252C4E%252C6Z%2529-7-%25282-alkoxy-3%252C5-dialkylbenzene%2529-3-methylocta-2%252C4%252C6-trienoic%2520acid%2520retinoid%2520X%2520receptor%2520modulators%2520are%2520active%2520in%2520models%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2683%26epage%3D2696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardecky, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arrigo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grese, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibowitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mapes, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montrose-Rafizadeh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reifel-Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rungta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyhonas, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4087</span><span class="NLM_x">–</span> <span class="NLM_lpage">4103</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020401k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4087-4103&author=P.-Y.+Michellysauthor=R.+J.+Ardeckyauthor=J.-H.+Chenauthor=J.+D%E2%80%99Arrigoauthor=T.+A.+Greseauthor=D.+S.+Karanewskyauthor=M.+D.+Leibowitzauthor=S.+Liuauthor=D.+A.+Maisauthor=C.+M.+Mapesauthor=C.+Montrose-Rafizadehauthor=K.+M.+Ogilvieauthor=A.+Reifel-Millerauthor=D.+Rungtaauthor=A.+W.+Thompsonauthor=J.+S.+Tyhonasauthor=M.+F.+Boehm&title=Design%2C+synthesis%2C+and+structure+activity+relationship+studies+of+novel+6%2C7-locked-%5B7-%282-alkoxy-3%2C5-dialkylbenzene%29-3-methylocta%5D-2%2C4%2C6-trienoic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm020401k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020401k%26sid%3Dliteratum%253Aachs%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DArdecky%26aufirst%3DR.%2BJ.%26aulast%3DChen%26aufirst%3DJ.-H.%26aulast%3DD%25E2%2580%2599Arrigo%26aufirst%3DJ.%26aulast%3DGrese%26aufirst%3DT.%2BA.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DLeibowitz%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMais%26aufirst%3DD.%2BA.%26aulast%3DMapes%26aufirst%3DC.%2BM.%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DOgilvie%26aufirst%3DK.%2BM.%26aulast%3DReifel-Miller%26aufirst%3DA.%26aulast%3DRungta%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DA.%2BW.%26aulast%3DTyhonas%26aufirst%3DJ.%2BS.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure%2520activity%2520relationship%2520studies%2520of%2520novel%25206%252C7-locked-%255B7-%25282-alkoxy-3%252C5-dialkylbenzene%2529-3-methylocta%255D-2%252C4%252C6-trienoic%2520acids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4087%26epage%3D4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Takahashi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawachi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagechika, H.</span><span> </span><span class="NLM_article-title">Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3327</span><span class="NLM_x">–</span> <span class="NLM_lpage">3330</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0255320" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFGmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3327-3330&author=B.+Takahashiauthor=K.+Ohtaauthor=E.+Kawachiauthor=H.+Fukasawaauthor=Y.+Hashimotoauthor=H.+Kagechika&title=Novel+retinoid+X+receptor+antagonists%3A+specific+inhibition+of+retinoid+synergism+in+RXR-RAR+heterodimer+actions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Retinoid X Receptor Antagonists: Specific Inhibition of Retinoid Synergism in RXR-RAR Heterodimer Actions</span></div><div class="casAuthors">Takahashi, Bitoku; Ohta, Kiminori; Kawachi, Emiko; Fukasawa, Hiroshi; Hashimoto, Yuichi; Kagechika, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3327-3330</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several 2-(arylamino)pyrimidine-5-carboxylic acids were designed as novel retinoid X receptor (RXR) antagonists.  Two of the tested compds. alone did not exhibit differentiation-inducing activity toward HL-60 cells and did not affect the activity of a retinoic acid receptor (RAR) agonist, Am80, but did inhibit the synergistic activity of an RXR agonist, PA024, in the presence of Am80.  The activity of these compds. was ascribed to selective antagonism at the RXR site of RXR-RAR heterodimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSw-5gTVKi_rVg90H21EOLACvtfcHk0li1gFLtE4mn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFGmtrs%253D&md5=31b3a2daf2698874522c4dade7b1dbc2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm0255320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0255320%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DB.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DKawachi%26aufirst%3DE.%26aulast%3DFukasawa%26aufirst%3DH.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DKagechika%26aufirst%3DH.%26atitle%3DNovel%2520retinoid%2520X%2520receptor%2520antagonists%253A%2520specific%2520inhibition%2520of%2520retinoid%2520synergism%2520in%2520RXR-RAR%2520heterodimer%2520actions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3327%26epage%3D3330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Umemiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyrolles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawachi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagechika, H.</span><span> </span><span class="NLM_article-title">Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">4222</span><span class="NLM_x">–</span> <span class="NLM_lpage">4234</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9704309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=4222-4234&author=H.+Umemiyaauthor=H.+Fukasawaauthor=M.+Ebisawaauthor=L.+Eyrollesauthor=E.+Kawachiauthor=G.+Eisenmannauthor=H.+Gronemeyerauthor=Y.+Hashimotoauthor=K.+Shudoauthor=H.+Kagechika&title=Regulation+of+retinoidal+actions+by+diazepinylbenzoic+acids.+Retinoid+synergists+which+activate+the+RXR-RAR+heterodimers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm9704309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9704309%26sid%3Dliteratum%253Aachs%26aulast%3DUmemiya%26aufirst%3DH.%26aulast%3DFukasawa%26aufirst%3DH.%26aulast%3DEbisawa%26aufirst%3DM.%26aulast%3DEyrolles%26aufirst%3DL.%26aulast%3DKawachi%26aufirst%3DE.%26aulast%3DEisenmann%26aufirst%3DG.%26aulast%3DGronemeyer%26aufirst%3DH.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DKagechika%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520retinoidal%2520actions%2520by%2520diazepinylbenzoic%2520acids.%2520Retinoid%2520synergists%2520which%2520activate%2520the%2520RXR-RAR%2520heterodimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4222%26epage%3D4234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Wagner, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurutka, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Vaart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziller, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furmick, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miguel, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedeschi, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moosavi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danishyar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philp, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khamees, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grupe, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badshah, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, J. W.</span><span> </span><span class="NLM_article-title">Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5950</span><span class="NLM_x">–</span> <span class="NLM_lpage">5966</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900496b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5950-5966&author=C.+E.+Wagnerauthor=P.+W.+Jurutkaauthor=P.+A.+Marshallauthor=T.+L.+Groyauthor=A.+van+der+Vaartauthor=J.+W.+Zillerauthor=J.+K.+Furmickauthor=M.+E.+Graeberauthor=E.+Matroauthor=B.+V.+Miguelauthor=I.+T.+Tranauthor=J.+Kwonauthor=J.+N.+Tedeschiauthor=S.+Moosaviauthor=A.+Danishyarauthor=J.+S.+Philpauthor=R.+O.+Khameesauthor=J.+N.+Jacksonauthor=D.+K.+Grupeauthor=S.+L.+Badshahauthor=J.+W.+Hart&title=Modeling%2C+synthesis+and+biological+evaluation+of+potential+retinoid+X+receptor+%28RXR%29+selective+agonists%3A+novel+analogues+of+4-%5B1-%283%2C5%2C5%2C8%2C8-pentamethyl-5%2C6%2C7%2C8-tetrahydro-2-naphthyl%29ethynyl%5Dbenzoic+acid+%28bexarotene%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm900496b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900496b%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DC.%2BE.%26aulast%3DJurutka%26aufirst%3DP.%2BW.%26aulast%3DMarshall%26aufirst%3DP.%2BA.%26aulast%3DGroy%26aufirst%3DT.%2BL.%26aulast%3Dvan%2Bder%2BVaart%26aufirst%3DA.%26aulast%3DZiller%26aufirst%3DJ.%2BW.%26aulast%3DFurmick%26aufirst%3DJ.%2BK.%26aulast%3DGraeber%26aufirst%3DM.%2BE.%26aulast%3DMatro%26aufirst%3DE.%26aulast%3DMiguel%26aufirst%3DB.%2BV.%26aulast%3DTran%26aufirst%3DI.%2BT.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DTedeschi%26aufirst%3DJ.%2BN.%26aulast%3DMoosavi%26aufirst%3DS.%26aulast%3DDanishyar%26aufirst%3DA.%26aulast%3DPhilp%26aufirst%3DJ.%2BS.%26aulast%3DKhamees%26aufirst%3DR.%2BO.%26aulast%3DJackson%26aufirst%3DJ.%2BN.%26aulast%3DGrupe%26aufirst%3DD.%2BK.%26aulast%3DBadshah%26aufirst%3DS.%2BL.%26aulast%3DHart%26aufirst%3DJ.%2BW.%26atitle%3DModeling%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520potential%2520retinoid%2520X%2520receptor%2520%2528RXR%2529%2520selective%2520agonists%253A%2520novel%2520analogues%2520of%25204-%255B1-%25283%252C5%252C5%252C8%252C8-pentamethyl-5%252C6%252C7%252C8-tetrahydro-2-naphthyl%2529ethynyl%255Dbenzoic%2520acid%2520%2528bexarotene%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5950%26epage%3D5966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badea, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of novel retinoid X receptor-selective retinoids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2930</span><span class="NLM_x">–</span> <span class="NLM_lpage">2941</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00044a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2930-2941&author=M.+F.+Boehmauthor=L.+Zhangauthor=B.+A.+Badeaauthor=S.+K.+Whiteauthor=D.+E.+Maisauthor=E.+Bergerauthor=C.+M.+Sutoauthor=M.+E.+Goldmanauthor=R.+A.+Heyman&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+retinoid+X+receptor-selective+retinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm00044a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00044a014%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBadea%26aufirst%3DB.%2BA.%26aulast%3DWhite%26aufirst%3DS.%2BK.%26aulast%3DMais%26aufirst%3DD.%2BE.%26aulast%3DBerger%26aufirst%3DE.%26aulast%3DSuto%26aufirst%3DC.%2BM.%26aulast%3DGoldman%26aufirst%3DM.%2BE.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%2520retinoid%2520X%2520receptor-selective%2520retinoids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2930%26epage%3D2941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Walensky, L. D.</span><span> </span><span class="NLM_article-title">BCL-2 in the crosshairs: tipping the balance of life and death</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1339</span><span class="NLM_x">–</span> <span class="NLM_lpage">1350</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fsj.cdd.4401992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16763614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFaiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1339-1350&author=L.+D.+Walensky&title=BCL-2+in+the+crosshairs%3A+tipping+the+balance+of+life+and+death"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">BCL-2 in the crosshairs: tipping the balance of life and death</span></div><div class="casAuthors">Walensky, L. D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1339-1350</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of B-cell lymphoma-2 (Bcl-2) protein over 20 years ago revealed a new paradigm in cancer biol.: the development and persistence of cancer can be driven by mol. roadblocks along the natural pathway to cell death.  The subsequent identification of an expansive family of Bcl-2 proteins provoked an intensive investigation of the interplay among these crit. regulators of cell death.  What emerged was a compelling tale of guardians and executioners, each participating in a mol. choreog. that dictates cell fate.  Ten years into the Bcl-2 era, structural details have defined how certain Bcl-2 family proteins interact, and mol. targeting of the Bcl-2 family has since become a pharmacol. quest.  Although many facets of Bcl-2 family death signaling remain a mechanistic mystery, small mols. and peptides that effectively target Bcl-2 are eliminating the roadblock to cell death, raising hopes for a medical breakthrough in cancer and other diseases of deregulated apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJYywVOAOBLVg90H21EOLACvtfcHk0lhG9h-wfX8g0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFaiurs%253D&md5=ffa03ae8cfd55db280c2184913e7dea2</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401992%26sid%3Dliteratum%253Aachs%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26atitle%3DBCL-2%2520in%2520the%2520crosshairs%253A%2520tipping%2520the%2520balance%2520of%2520life%2520and%2520death%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2006%26volume%3D13%26spage%3D1339%26epage%3D1350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Calin, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span> </span><span class="NLM_article-title">Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">4761</span><span class="NLM_x">–</span> <span class="NLM_lpage">4770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=4761-4770&author=G.+A.+Calinauthor=C.+M.+Croce&title=Chronic+lymphocytic+leukemia%3A+interplay+between+noncoding+RNAs+and+protein-coding+genes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26atitle%3DChronic%2520lymphocytic%2520leukemia%253A%2520interplay%2520between%2520noncoding%2520RNAs%2520and%2520protein-coding%2520genes%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D4761%26epage%3D4770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Klasa, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillum, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klem, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankel, S. R.</span><span> </span><span class="NLM_article-title">Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment</span> <span class="citation_source-journal">Antisense Nucleic Acid Drug Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1089%2F108729002760220798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12162702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFersrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=193-213&author=R.+J.+Klasaauthor=A.+M.+Gillumauthor=R.+E.+Klemauthor=S.+R.+Frankel&title=Oblimersen+Bcl-2+antisense%3A+facilitating+apoptosis+in+anticancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment</span></div><div class="casAuthors">Klasa, Richard J.; Gillum, Amanda M.; Klem, Robert E.; Frankel, Stanley R.</div><div class="citationInfo"><span class="NLM_cas:title">Antisense & Nucleic Acid Drug Development</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-213</span>CODEN:
                <span class="NLM_cas:coden">ANADF5</span>;
        ISSN:<span class="NLM_cas:issn">1087-2906</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  The components of the apoptotic program are targets for anticancer therapy.  Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (mAb).  Oblimersen sodium (G3139, Genasense, Genta Inc., Berkeley Heights, NJ) is an antisense oligonucleotide (AS-ON) compd. designed to specifically bind to the first 6 codons of the human bcl-2 mRNA sequence, resulting in degrdn. of bcl-2 mRNA and subsequent decrease in Bcl-2 protein translation.  Oblimersen is the first oligonucleotide to demonstrate proof of principle of an antisense effect in human tumors by the documented downregulation of the target Bcl-2 protein.  A growing body of preclin. and clin. evidence suggests that oblimersen synergizes with many cytotoxic and biol./immunotherapeutic agents against a variety of hematol. malignancies and solid tumors.  Randomized clin. trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia, multiple myeloma, malignant melanoma, and non-small cell lung cancer.  In addn., nonrandomized trials are under way to evaluate oblimersen in non-Hodgkin's lymphoma, acute myeloid leukemia, and hormone-refractory prostate cancer.  Preclin. data also support the clin. evaluation of oblimersen in addnl. tumor types, including chronic myelogenous leukemia and breast, small cell lung, gastric, colon, bladder, and Merkel cell cancers.  Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clin. trials will test this therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphEuKQgz3PnLVg90H21EOLACvtfcHk0lhG9h-wfX8g0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFersrw%253D&md5=e88b1922587419dc625d31a4b4e1020b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1089%2F108729002760220798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108729002760220798%26sid%3Dliteratum%253Aachs%26aulast%3DKlasa%26aufirst%3DR.%2BJ.%26aulast%3DGillum%26aufirst%3DA.%2BM.%26aulast%3DKlem%26aufirst%3DR.%2BE.%26aulast%3DFrankel%26aufirst%3DS.%2BR.%26atitle%3DOblimersen%2520Bcl-2%2520antisense%253A%2520facilitating%2520apoptosis%2520in%2520anticancer%2520treatment%26jtitle%3DAntisense%2520Nucleic%2520Acid%2520Drug%2520Dev.%26date%3D2002%26volume%3D12%26spage%3D193%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Frieden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ørum, H.</span><span> </span><span class="NLM_article-title">Locked nucleic acid holds promise in the treatment of cancer</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F138161208784246234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18473860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslKrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1138-1142&author=M.+Friedenauthor=H.+%C3%98rum&title=Locked+nucleic+acid+holds+promise+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Locked nucleic acid holds promise in the treatment of cancer</span></div><div class="casAuthors">Frieden, Miriam; Oerum, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1138-1142</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry.  Today much is known about the mol. and genetic causes of cancers thus facilitating the development of novel targeted cancer drugs with improved risk-benefit ratios compared to contemporary broadly-acting, cytotoxic cancer drugs.  Antisense therapy, e.g. the use of single stranded oligonucleotides as therapeutic modalities, provides the means to develop such targeted drugs, and in recent years this concept has enjoyed a major renaissance.  Locked Nucleic Acid (LNA) is a novel, third generation RNA analog that displays most if not all of the characteristics required to make potent and safe antisense drugs.  Here we review the key properties of LNA oligonucleotides in the context of their use as safe and effective antisense drugs and provide a status on their therapeutic development in the field of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWg3XR5jMli7Vg90H21EOLACvtfcHk0lhG9h-wfX8g0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslKrsro%253D&md5=df6e1ff8e1745469e1e798159ecdbe17</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2174%2F138161208784246234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784246234%26sid%3Dliteratum%253Aachs%26aulast%3DFrieden%26aufirst%3DM.%26aulast%3D%25C3%2598rum%26aufirst%3DH.%26atitle%3DLocked%2520nucleic%2520acid%2520holds%2520promise%2520in%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2008%26volume%3D14%26spage%3D1138%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borowski, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehlig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benimetskaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, C. A.</span><span> </span><span class="NLM_article-title">Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2007&pages=143-152&author=H.+Zhaoauthor=P.+Pengauthor=C.+Longleyauthor=Y.+Zhangauthor=V.+Borowskiauthor=M.+Mehligauthor=P.+Reddyauthor=J.+Xiaauthor=G.+Borchardauthor=J.+Lipmanauthor=L.+Benimetskayaauthor=C.+A.+Stein&title=Delivery+of+G3139+using+releasable+PEG-linkers%3A+impact+on+pharmacokinetic+profile+and+anti-tumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DP.%26aulast%3DLongley%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DMehlig%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DBorchard%26aufirst%3DG.%26aulast%3DLipman%26aufirst%3DJ.%26aulast%3DBenimetskaya%26aufirst%3DL.%26aulast%3DStein%26aufirst%3DC.%2BA.%26atitle%3DDelivery%2520of%2520G3139%2520using%2520releasable%2520PEG-linkers%253A%2520impact%2520on%2520pharmacokinetic%2520profile%2520and%2520anti-tumor%2520efficacy%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2007%26volume%3D119%26spage%3D143%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Leone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sareth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">8118</span><span class="NLM_x">–</span> <span class="NLM_lpage">8121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=8118-8121&author=M.+Leoneauthor=D.+Zhaiauthor=S.+Sarethauthor=S.+Kitadaauthor=J.+C.+Reedauthor=M.+Pellecchia&title=Cancer+prevention+by+tea+polyphenols+is+linked+to+their+direct+inhibition+of+antiapoptotic+Bcl-2-family+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DSareth%26aufirst%3DS.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DCancer%2520prevention%2520by%2520tea%2520polyphenols%2520is%2520linked%2520to%2520their%2520direct%2520inhibition%2520of%2520antiapoptotic%2520Bcl-2-family%2520proteins%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D8118%26epage%3D8121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Tzung, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basanez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giedt, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockenbery, D. M.</span><span> </span><span class="NLM_article-title">Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2F35055095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=11175751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1KmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=183-191&author=S.+P.+Tzungauthor=K.+M.+Kimauthor=G.+Basanezauthor=C.+D.+Giedtauthor=J.+Simonauthor=J.+Zimmerbergauthor=K.+Y.+Zhangauthor=D.+M.+Hockenbery&title=Antimycin+A+mimics+a+cell-death-inducing+Bcl-2+homology+domain+3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3</span></div><div class="casAuthors">Tzung, Shie-Pon; Kim, Kristine M.; Basanez, Gorka; Giedt, Chris D.; Simon, Julian; Zimmerberg, Joshua; Zhang, Kam Y. J.; Hockenbery, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Bcl-2-related survival proteins confer cellular resistance to a wide range of agents.  Bcl-xL-expressing hepatocyte cell lines are resistant to tumor necrosis factor and anti-cancer drugs, but are more sensitive than isogenic control cells to antimycin A, an inhibitor of mitochondrial electron transfer.  Computational mol. docking anal. predicted that antimycin A interacts with the Bcl-2 homol. domain 3 (BH3)-binding hydrophobic groove of Bcl-xL.  We demonstrate that antimycin A and a Bak BH3 peptide bind competitively to recombinant Bcl-2.  Antimycin A and BH3 peptide both induce mitochondrial swelling and loss of Δψm on addn. to mitochondria expressing Bcl-xL.  The 2-methoxy deriv. of antimycin A3 is inactive as an inhibitor of cellular respiration but still retains toxicity for Bcl-xL+ cells and mitochondria.  Finally, antimycin A inhibits the pore-forming activity of Bcl-xL in synthetic liposomes, demonstrating that a small non-peptide ligand can directly inhibit the function of Bcl-2-related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgSbrvTv9NbLVg90H21EOLACvtfcHk0ljeLvSZCiAPcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1KmsLc%253D&md5=f013d14a3bf5ae6dd1ac93cc63f527db</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2F35055095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35055095%26sid%3Dliteratum%253Aachs%26aulast%3DTzung%26aufirst%3DS.%2BP.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DBasanez%26aufirst%3DG.%26aulast%3DGiedt%26aufirst%3DC.%2BD.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3DZimmerberg%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DHockenbery%26aufirst%3DD.%2BM.%26atitle%3DAntimycin%2520A%2520mimics%2520a%2520cell-death-inducing%2520Bcl-2%2520homology%2520domain%25203%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D183%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Chan, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flotow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soejarto, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, V. C.</span><span> </span><span class="NLM_article-title">Identification of chelerythrine as an inhibitor of BclXL function</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">20453</span><span class="NLM_x">–</span> <span class="NLM_lpage">20456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=20453-20456&author=S.+L.+Chanauthor=M.+C.+Leeauthor=K.+O.+Tanauthor=L.+K.+Yangauthor=A.+S.+Leeauthor=H.+Flotowauthor=N.+Y.+Fuauthor=M.+S.+Butlerauthor=D.+D.+Soejartoauthor=A.+D.+Bussauthor=V.+C.+Yu&title=Identification+of+chelerythrine+as+an+inhibitor+of+BclXL+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DTan%26aufirst%3DK.%2BO.%26aulast%3DYang%26aufirst%3DL.%2BK.%26aulast%3DLee%26aufirst%3DA.%2BS.%26aulast%3DFlotow%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DN.%2BY.%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DSoejarto%26aufirst%3DD.%2BD.%26aulast%3DBuss%26aufirst%3DA.%2BD.%26aulast%3DYu%26aufirst%3DV.%2BC.%26atitle%3DIdentification%2520of%2520chelerythrine%2520as%2520an%2520inhibitor%2520of%2520BclXL%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D20453%26epage%3D20456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sareth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Discovery, characterization, and structure−activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4259</span><span class="NLM_x">–</span> <span class="NLM_lpage">4264</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030190z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4259-4264&author=S.+Kitadaauthor=M.+Leoneauthor=S.+Sarethauthor=D.+Y.+Zhaiauthor=J.+C.+Reedauthor=M.+Pellecchia&title=Discovery%2C+characterization%2C+and+structure%E2%88%92activity+relationships+studies+of+proapoptotic+polyphenols+targeting+B-cell+lymphocyte%2Fleukemia-2+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm030190z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030190z%26sid%3Dliteratum%253Aachs%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DSareth%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DD.%2BY.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDiscovery%252C%2520characterization%252C%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520studies%2520of%2520proapoptotic%2520polyphenols%2520targeting%2520B-cell%2520lymphocyte%252Fleukemia-2%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4259%26epage%3D4264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolovska-Coleska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701358v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=717-720&author=G.+Tangauthor=Z.+Nikolovska-Coleskaauthor=S.+Qiuauthor=C.+Y.+Yangauthor=J.+Guoauthor=S.+Wang&title=Acylpyrogallols+as+inhibitors+of+antiapoptotic+Bcl-2+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Acylpyrogallols as Inhibitors of Antiapoptotic Bcl-2 Proteins</span></div><div class="casAuthors">Tang, Guozhi; Nikolovska-Coleska, Zaneta; Qiu, Su; Yang, Chao-Yie; Guo, Jie; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of acylpyrogallols were designed, synthesized, and evaluated as small-mol. inhibitors of antiapoptotic Bcl-2 proteins.  The most potent compd. I (TM-179) binds to Bcl-2 with an IC50 of 170 nM and to Mcl-1 with a Ki of 37 nM.  Compd. I potently inhibits cell growth and induces apoptosis in human breast and prostate cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnBgND94TZrVg90H21EOLACvtfcHk0lh4QgWDBCg7Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisbs%253D&md5=fd9ac15e3622bcd5bf45a0b88be93970</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm701358v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701358v%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DG.%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DAcylpyrogallols%2520as%2520inhibitors%2520of%2520antiapoptotic%2520Bcl-2%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D717%26epage%3D720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">James, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prada, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span> </span><span class="NLM_article-title">AT 101, an inhibitor of Bcl-2 family members is cytotoxic to a heterogeneous group of CLL samples and synergistic with rituximab</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">835a</span><span class="NLM_x">–</span> <span class="NLM_lpage">835a</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=835a-835a&author=D.+F.+Jamesauthor=C.+E.+Pradaauthor=J.+E.+Castroauthor=T.+J.+Kipps&title=AT+101%2C+an+inhibitor+of+Bcl-2+family+members+is+cytotoxic+to+a+heterogeneous+group+of+CLL+samples+and+synergistic+with+rituximab"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DPrada%26aufirst%3DC.%2BE.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DAT%2520101%252C%2520an%2520inhibitor%2520of%2520Bcl-2%2520family%2520members%2520is%2520cytotoxic%2520to%2520a%2520heterogeneous%2520group%2520of%2520CLL%2520samples%2520and%2520synergistic%2520with%2520rituximab%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D835a%26epage%3D835a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Arnold, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboukameel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Katib, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. M.</span><span> </span><span class="NLM_article-title">Preclinical studies of apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1186%2F1476-4598-7-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18275607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1c7msFSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=20&author=A.+A.+Arnoldauthor=A.+Aboukameelauthor=J.+Chenauthor=D.+Yangauthor=S.+Wangauthor=A.+Al-Katibauthor=R.+M.+Mohammad&title=Preclinical+studies+of+apogossypolone%3A+a+new+nonpeptidic+pan+small-molecule+inhibitor+of+Bcl-2%2C+Bcl-XL+and+Mcl-1+proteins+in+follicular+small+cleaved+cell+lymphoma+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model</span></div><div class="casAuthors">Arnold Alan A; Aboukameel Amro; Chen Jianyong; Yang Dajun; Wang Shaomeng; Al-Katib Ayad; Mohammad Ramzi M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular Lymphoma (FL).  This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients.  ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC50) of 109 nM and decreased cell number of fresh lymphoma cells.  ApoG2 activated caspases-9, -3, and -8, and the cleavage of Poly (ADP-ribose) polymerase (PARP) and Apoptosis Inducing Factor (AIF).  In the WSU-FSCCL-SCID xenograft model, ApoG2 showed a significant anti-lymphoma effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice.  These studies suggest that ApoG2 can be an effective therapeutic agent against FL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStte8-BzvWi2LFM_lbR1VmfW6udTcc2eY1C-LnFfegQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7msFSltQ%253D%253D&md5=afbd06a687682de8efe3b640c0026b99</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-7-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-7-20%26sid%3Dliteratum%253Aachs%26aulast%3DArnold%26aufirst%3DA.%2BA.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAl-Katib%26aufirst%3DA.%26aulast%3DMohammad%26aufirst%3DR.%2BM.%26atitle%3DPreclinical%2520studies%2520of%2520apogossypolone%253A%2520a%2520new%2520nonpeptidic%2520pan%2520small-molecule%2520inhibitor%2520of%2520Bcl-2%252C%2520Bcl-XL%2520and%2520Mcl-1%2520proteins%2520in%2520follicular%2520small%2520cleaved%2520cell%2520lymphoma%2520model%26jtitle%3DMol.%2520Cancer%26date%3D2008%26volume%3D7%26spage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Becattini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monosov, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.chembiol.2004.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15123268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Wntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=389-395&author=B.+Becattiniauthor=S.+Kitadaauthor=M.+Leoneauthor=E.+Monosovauthor=S.+Chandlerauthor=D.+Zhaiauthor=T.+J.+Kippsauthor=J.+C.+Reedauthor=M.+Pellecchia&title=Rational+design+and+real+time%2C+in-cell+detection+of+the+proapoptotic+activity+of+a+novel+compound+targeting+Bcl-X%28L%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL</span></div><div class="casAuthors">Becattini, Barbara; Kitada, Shinichi; Leone, Marilisa; Monosov, Edward; Chandler, Sharon; Zhai, Dayong; Kipps, Thomas J.; Reed, John C.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Antiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-XL have been recently validated as drug discovery targets for cancer.  Here, by using a combination of mol. modeling, NMR-based structural anal., fluorescence polarization assays, and cell-based assays, we have designed and characterized a novel proapoptotic compd. targeting these proteins.  Our compd., Apogossypol, is capable of binding and inhibiting Bcl-2 and Bcl-XL with high affinity and induces apoptosis of tumor cell lines.  Mechanistic studies on the action of our compd. were also performed via confocal microscopy that provided real-time detection of the interaction with Bcl-XL in intact cells.  Finally, preliminary data on cells freshly isolated from patients affected by chronic lymphocytic leukemia strongly suggest potential applications of Bcl-2 antagonists as chemosensitizers in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3_FN6fhpyVbVg90H21EOLACvtfcHk0lh4QgWDBCg7Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Wntb4%253D&md5=2438e3b17b5c0c83e79e35f122d107d4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DBecattini%26aufirst%3DB.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DMonosov%26aufirst%3DE.%26aulast%3DChandler%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DRational%2520design%2520and%2520real%2520time%252C%2520in-cell%2520detection%2520of%2520the%2520proapoptotic%2520activity%2520of%2520a%2520novel%2520compound%2520targeting%2520Bcl-X%2528L%2529%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Wang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolovska-Coleska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shangary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meagher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuckey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krajewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abaan, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6139</span><span class="NLM_x">–</span> <span class="NLM_lpage">6142</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060460o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6139-6142&author=G.+Wangauthor=Z.+Nikolovska-Coleskaauthor=C.+Y.+Yangauthor=R.+Wangauthor=G.+Tangauthor=J.+Guoauthor=S.+Shangaryauthor=S.+Qiuauthor=W.+Gaoauthor=D.+Yangauthor=J.+Meagherauthor=J.+Stuckeyauthor=K.+Krajewskiauthor=S.+Jiangauthor=P.+P.+Rollerauthor=H.+O.+Abaanauthor=Y.+Tomitaauthor=S.+Wang&title=Structure-based+design+of+potent+small-molecule+inhibitors+of+anti-apoptotic+Bcl-2+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins</span></div><div class="casAuthors">Wang, Guoping; Nikolovska-Coleska, Zaneta; Yang, Chao-Yie; Wang, Renxiao; Tang, Guozhi; Guo, Jie; Shangary, Sanjeev; Qiu, Su; Gao, Wei; Yang, Dajun; Meagher, Jennifer; Stuckey, Jeanne; Krajewski, Krzysztof; Jiang, Sheng; Roller, Peter P.; Abaan, Hatice Ozel; Tomita, York; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6139-6142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was employed to design a new class of small-mol. inhibitors of Bcl-2.  The most potent compd. TW-37 (I) binds to Bcl-2 with a Ki value of 290 nM and also to Bcl-xL and Mcl-1 with high affinities.  Compd. I potently inhibits cell growth in PC-3 prostate cancer cells with an IC50 value of 200 nM and effectively induces apoptosis in a dose-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjCW9ZydQfH7Vg90H21EOLACvtfcHk0liRosYHkkpkVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlurw%253D&md5=a12aec81f60ebf4afa0be8f0c7794d89</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm060460o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060460o%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DShangary%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DKrajewski%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DRoller%26aufirst%3DP.%2BP.%26aulast%3DAbaan%26aufirst%3DH.%2BO.%26aulast%3DTomita%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-based%2520design%2520of%2520potent%2520small-molecule%2520inhibitors%2520of%2520anti-apoptotic%2520Bcl-2%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6139%26epage%3D6142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Mohammad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goustin, A. S.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=20-30&author=R.+Mohammadauthor=A.+Giriauthor=A.+S.+Goustin&title=Small-molecule+inhibitors+of+Bcl-2+family+proteins+as+therapeutic+agents+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DR.%26aulast%3DGiri%26aufirst%3DA.%26aulast%3DGoustin%26aufirst%3DA.%2BS.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520Bcl-2%2520family%2520proteins%2520as%2520therapeutic%2520agents%2520in%2520cancer%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Williamson, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fineran, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gristwood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chawrai, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeper, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmond, G. P.</span><span> </span><span class="NLM_article-title">Anticancer and immunosuppressive properties of bacterial prodiginines</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2217%2F17460913.2.6.605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18041902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKltL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=605-618&author=N.+R.+Williamsonauthor=P.+C.+Fineranauthor=T.+Gristwoodauthor=S.+R.+Chawraiauthor=F.+J.+Leeperauthor=G.+P.+Salmond&title=Anticancer+and+immunosuppressive+properties+of+bacterial+prodiginines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer and immunosuppressive properties of bacterial prodiginines</span></div><div class="casAuthors">Williamson, Neil R.; Fineran, Peter C.; Gristwood, Tamzin; Chawrai, Suresh R.; Leeper, Finian J.; Salmond, George P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">605-618</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Bacterial prodiginines are a family of red-pigmented, tripyrrolic compds. that display numerous biol. activities, including antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive and anticancer properties.  Recently, significant progress has been made in understanding the biosynthesis and regulation of bacterial prodiginines.  An understanding of the biosynthesis of prodiginines will allow engineering of bacterial strains capable of synthesizing novel prodiginines through rational design and mutasynthesis expts.  Bacterial prodiginines and synthetic derivs. are effective proapoptotic agents with multiple cellular targets, and they are active against numerous cancer cell lines, including multidrug-resistant cells, with little or no toxicity towards normal cell lines.  A synthetic deriv., GX15-070 (Obatoclax), developed through structure-activity relationship studies of the pyrrolic ring A of GX15, is in multiple Phase I and II clin. trials in both single and dual-agent studies to treat different types of cancer.  Therefore, prodiginines have real therapeutic potential in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa8nIYvOy7QbVg90H21EOLACvtfcHk0liRosYHkkpkVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKltL3K&md5=d3866a5ebdfdeb1d11da205f46aa24ac</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.2217%2F17460913.2.6.605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460913.2.6.605%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DN.%2BR.%26aulast%3DFineran%26aufirst%3DP.%2BC.%26aulast%3DGristwood%26aufirst%3DT.%26aulast%3DChawrai%26aufirst%3DS.%2BR.%26aulast%3DLeeper%26aufirst%3DF.%2BJ.%26aulast%3DSalmond%26aufirst%3DG.%2BP.%26atitle%3DAnticancer%2520and%2520immunosuppressive%2520properties%2520of%2520bacterial%2520prodiginines%26jtitle%3DFuture%2520Microbiol.%26date%3D2007%26volume%3D2%26spage%3D605%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Campas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosialls, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barragan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iglesias-Serret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santidrian, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll-Mulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Frias, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domingo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, J.</span><span> </span><span class="NLM_article-title">Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1663</span><span class="NLM_x">–</span> <span class="NLM_lpage">1669</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.exphem.2006.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17157163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12qsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1663-1669&author=C.+Campasauthor=A.+M.+Cosiallsauthor=M.+Barraganauthor=D.+Iglesias-Serretauthor=A.+F.+Santidrianauthor=L.+Coll-Muletauthor=M.+de+Friasauthor=A.+Domingoauthor=G.+Ponsauthor=J.+Gil&title=Bcl-2+inhibitors+induce+apoptosis+in+chronic+lymphocytic+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells</span></div><div class="casAuthors">Campas, Clara; Cosialls, Ana M.; Barragan, Montserrat; Iglesias-Serret, Daniel; Santidrian, Antonio F.; Coll-Mulet, Llorenc; de Frias, Merce; Domingo, Alicia; Pons, Gabriel; Gil, Joan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1663-1669</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: Antiapoptotic Bcl-2 is overexpressed in most cases of chronic lymphocytic leukemia (CLL).  The inhibition of the antiapoptotic Bcl-2 proteins is an attractive strategy for either restoring normal apoptotic process in cancer cells or making these cells more susceptible to conventional chemotherapy.  We studied the effect of Bcl-2 inhibitors on the viability of cells from CLL and other mature B-cell neoplasms.  Materials and Methods: We studied the cytotoxic effects of four nonpeptidic cell-permeable Bcl-2 inhibitors (HA14-1, antimycin A, GX15-003, and GX15-070) on B cells from patients with CLL, mantle cell lymphoma (MCL), and splenic marginal zone lymphoma (SMZL).  Moreover, we analyzed the effect of these inhibitors in combination with fludarabine or chlorambucil.  Results: HA14-1 induced apoptosis with an EC50 lower than 50 μM in 26 of the 36 CLL samples analyzed.  The mean EC50 for these sensitive patients was 23 ± 2 μM.  Antimycin A induced apoptosis in 13 of the 18 CLL samples analyzed.  Both HA14-1 and antimycin A induced cytochrome c release from mitochondria and caspase-3 activation.  Moreover, HA14-1 induced apoptosis in peripheral cells from MCL and SMZL.  HA14-1 also induced apoptosis in CLL samples with alterations in p53 or ATM.  Finally, GX compds. induced apoptosis in B cells from 9 of the 11 CLL samples tested.  The combination of either HA14-1, antimycin A, or GX compds. with fludarabine or chlorambucil had additive cytotoxic effects on CLL cells.  Conclusion: Bcl-2 inhibitors induce apoptosis in CLL cells ex vivo and could be used in CLL as monotherapy or given in combination with current chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeJfWnAXcQe7Vg90H21EOLACvtfcHk0lihbfOx0yxBsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12qsrvJ&md5=9bc05a57514c3f1de3e1b24ba3861961</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2006.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2006.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DCampas%26aufirst%3DC.%26aulast%3DCosialls%26aufirst%3DA.%2BM.%26aulast%3DBarragan%26aufirst%3DM.%26aulast%3DIglesias-Serret%26aufirst%3DD.%26aulast%3DSantidrian%26aufirst%3DA.%2BF.%26aulast%3DColl-Mulet%26aufirst%3DL.%26aulast%3Dde%2BFrias%26aufirst%3DM.%26aulast%3DDomingo%26aufirst%3DA.%26aulast%3DPons%26aufirst%3DG.%26aulast%3DGil%26aufirst%3DJ.%26atitle%3DBcl-2%2520inhibitors%2520induce%2520apoptosis%2520in%2520chronic%2520lymphocytic%2520leukemia%2520cells%26jtitle%3DExp.%2520Hematol.%26date%3D2006%26volume%3D34%26spage%3D1663%26epage%3D1669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Lessene, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czabotar, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colman, P. M.</span><span> </span><span class="NLM_article-title">BCL-2 family antagonists for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">989</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=989-1000&author=G.+Lesseneauthor=P.+E.+Czabotarauthor=P.+M.+Colman&title=BCL-2+family+antagonists+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DCzabotar%26aufirst%3DP.%2BE.%26aulast%3DColman%26aufirst%3DP.%2BM.%26atitle%3DBCL-2%2520family%2520antagonists%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D989%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">O’Brien, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claxton, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crump, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viallet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheson, B. D.</span><span> </span><span class="NLM_article-title">Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=299-305&author=S.+M.+O%E2%80%99Brienauthor=D.+F.+Claxtonauthor=M.+Crumpauthor=S.+Faderlauthor=T.+Kippsauthor=M.+J.+Keatingauthor=J.+Vialletauthor=B.+D.+Cheson&title=Phase+I+study+of+obatoclax+mesylate+%28GX15-070%29%2C+a+small+molecule+pan-Bcl-2+family+antagonist%2C+in+patients+with+advanced+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DKipps%26aufirst%3DT.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DViallet%26aufirst%3DJ.%26aulast%3DCheson%26aufirst%3DB.%2BD.%26atitle%3DPhase%2520I%2520study%2520of%2520obatoclax%2520mesylate%2520%2528GX15-070%2529%252C%2520a%2520small%2520molecule%2520pan-Bcl-2%2520family%2520antagonist%252C%2520in%2520patients%2520with%2520advanced%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D299%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Wang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasula, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alnemri, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z. W.</span><span> </span><span class="NLM_article-title">Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">7124</span><span class="NLM_x">–</span> <span class="NLM_lpage">7129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1073%2Fpnas.97.13.7124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=10860979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=7124-7129&author=J.+L.+Wangauthor=D.+X.+Liuauthor=Z.+J.+Zhangauthor=S.+M.+Shanauthor=X.+B.+Hanauthor=S.+M.+Srinivasulaauthor=C.+M.+Croceauthor=E.+S.+Alnemriauthor=Z.+W.+Huang&title=Structure-based+discovery+of+an+organic+compound+that+binds+Bcl-2+protein+and+induces+apoptosis+of+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells</span></div><div class="casAuthors">Wang, Jia-Lun; Liu, Dongxiang; Zhang, Zhi-Jia; Shan, Simei; Han, Xiaobing; Srinivasula, Srinivasa M.; Croce, Carlo M.; Alnemri, Emad S.; Huang, Ziwei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bcl-2 and related proteins are key regulators of apoptosis or programmed cell death implicated in human disease including cancer.  We recently showed that cell-permeable Bcl-2 binding peptides could induce apoptosis of human myeloid leukemia in vitro and suppress its growth in severe combined immunodeficient mice.  Here we report the discovery of HA14-1, a small mol. (mol. wt. = 409) and nonpeptidic ligand of a Bcl-2 surface pocket, by using a computer screening strategy based on the predicted structure of Bcl-2 protein.  In vitro binding studies demonstrated the interaction of HA14-1 with this Bcl-2 surface pocket that is essential for Bcl-2 biol. function.  HA14-1 effectively induced apoptosis of human acute myeloid leukemia (HL-60) cells overexpressing Bcl-2 protein that was assocd. with the decrease in mitochondrial membrane potential and activation of caspase-9 followed by caspase-3.  Cytokine response modifier A, a potent inhibitor of Fas-mediated apoptosis, did not block apoptosis induced by HA14-1.  Whereas HA14-1 strongly induced the death of NIH 3T3 (Apaf-1+/+) cells, it had little apoptotic effect on Apaf-1-deficient (Apaf-1-/-) mouse embryonic fibroblast cells.  These data are consistent with a mechanism by which HA14-1 induces the activation of Apaf-1 and caspases, possibly by binding to Bcl-2 protein and inhibiting its function.  The discovery of this cell-permeable mol. provides a chem. probe to study Bcl-2-regulated apoptotic pathways in vivo and could lead to the development of new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu20JdRurZgbVg90H21EOLACvtfcHk0lihbfOx0yxBsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKit78%253D&md5=f867bbd9941486c0da981cae17cb9c01</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.13.7124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.13.7124%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DLiu%26aufirst%3DD.%2BX.%26aulast%3DZhang%26aufirst%3DZ.%2BJ.%26aulast%3DShan%26aufirst%3DS.%2BM.%26aulast%3DHan%26aufirst%3DX.%2BB.%26aulast%3DSrinivasula%26aufirst%3DS.%2BM.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26aulast%3DAlnemri%26aufirst%3DE.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%2BW.%26atitle%3DStructure-based%2520discovery%2520of%2520an%2520organic%2520compound%2520that%2520binds%2520Bcl-2%2520protein%2520and%2520induces%2520apoptosis%2520of%2520tumor%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D7124%26epage%3D7129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Tian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doshi, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, C.</span><span> </span><span class="NLM_article-title">sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">259</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.canlet.2007.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18037229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCgtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2008&pages=198-208&author=D.+Tianauthor=S.+G.+Dasauthor=J.+M.+Doshiauthor=J.+Pengauthor=J.+Linauthor=C.+Xing&title=sHA+14-1%2C+a+stable+and+ROS-free+antagonist+against+anti-apoptotic+Bcl-2+proteins%2C+bypasses+drug+resistances+and+synergizes+cancer+therapies+in+human+leukemia+cell"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell</span></div><div class="casAuthors">Tian, Defeng; Das, Sonia G.; Doshi, Jignesh M.; Peng, Jun; Lin, Jialing; Xing, Chengguo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">259</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-208</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HA 14-1, a small-mol. antagonist against anti-apoptotic Bcl-2 proteins, was demonstrated to induce selective cytotoxicity toward malignant cells and to overcome drug resistance.  Due to its poor stability and the reactive oxygen species (ROS) generated by its decompn., chem. modification of HA 14-1 is needed for its future development.  We have synthesized a stabilized analog of HA 14-1 - sHA 14-1, which did not induce the formation of ROS.  As expected from a putative antagonist against anti-apoptotic Bcl-2 proteins like HA 14-1, sHA 14-1 disrupted the binding interaction of a Bak BH3 peptide with Bcl-2 or Bcl-XL protein, inhibited the growth of tumor cells through the induction of apoptosis, and circumvented the drug resistance induced by the over-expression of anti-apoptotic Bcl-2 and Bcl-XL proteins.  Interestingly, the impairment of extrinsic apoptotic pathway induced moderate resistance to sHA 14-1.  The moderate resistance suggested that sHA 14-1 generated part of its apoptotic stress through the intrinsic pathway, possibly through its antagonism against anti-apoptotic Bcl-2 proteins.  The resistance indicated that sHA 14-1 generated apoptotic stress through the extrinsic apoptotic pathway as well.  The ability of sHA 14-1 to induce apoptotic stress through both pathways was further supported by the synergism of sHA 14-1 towards the cytotoxicities of Fas ligand and dexamethasone in Jurkat cells.  Taken together, these findings suggest that sHA 14-1 may represent a promising candidate for the treatment of drug-resistant cancers either as a monotherapy or in combination with current cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7lhltQFx1Y7Vg90H21EOLACvtfcHk0lgPZyQjh7FeVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCgtLrF&md5=69292d62ce2e9c50991cb5db760bab0d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2007.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2007.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DD.%26aulast%3DDas%26aufirst%3DS.%2BG.%26aulast%3DDoshi%26aufirst%3DJ.%2BM.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DC.%26atitle%3DsHA%252014-1%252C%2520a%2520stable%2520and%2520ROS-free%2520antagonist%2520against%2520anti-apoptotic%2520Bcl-2%2520proteins%252C%2520bypasses%2520drug%2520resistances%2520and%2520synergizes%2520cancer%2520therapies%2520in%2520human%2520leukemia%2520cell%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D259%26spage%3D198%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Xing, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, Y. Y.</span><span> </span><span class="NLM_article-title">Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=2167-2176&author=C.+Xingauthor=L.+Wangauthor=X.+Tangauthor=Y.+Y.+Sham&title=Development+of+selective+inhibitors+for+anti-apoptotic+Bcl-2+proteins+from+BHI-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DSham%26aufirst%3DY.%2BY.%26atitle%3DDevelopment%2520of%2520selective%2520inhibitors%2520for%2520anti-apoptotic%2520Bcl-2%2520proteins%2520from%2520BHI-1%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D2167%26epage%3D2176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClellan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oost, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oleksijew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltersdorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">Discovery and structure−activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050754u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1165-1181&author=M.+D.+Wendtauthor=W.+Shenauthor=A.+Kunzerauthor=W.+J.+McClellanauthor=M.+Brunckoauthor=T.+K.+Oostauthor=H.+Dingauthor=M.+K.+Josephauthor=H.+Zhangauthor=P.+M.+Nimmerauthor=S.+C.+Ngauthor=A.+R.+Shoemakerauthor=A.+M.+Petrosauthor=A.+Oleksijewauthor=K.+Marshauthor=J.+Bauchauthor=T.+Oltersdorfauthor=B.+A.+Belliauthor=D.+Martineauauthor=S.+W.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=Discovery+and+structure%E2%88%92activity+relationship+of+antagonists+of+B-cell+lymphoma+2+family+proteins+with+chemopotentiation+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm050754u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050754u%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKunzer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DOost%26aufirst%3DT.%2BK.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DNimmer%26aufirst%3DP.%2BM.%26aulast%3DNg%26aufirst%3DS.%2BC.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DBauch%26aufirst%3DJ.%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DBelli%26aufirst%3DB.%2BA.%26aulast%3DMartineau%26aufirst%3DD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520and%2520structure%25E2%2588%2592activity%2520relationship%2520of%2520antagonists%2520of%2520B-cell%2520lymphoma%25202%2520family%2520proteins%2520with%2520chemopotentiation%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1165%26epage%3D1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oost, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClellan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltersdorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061152t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=641-662&author=M.+Brunckoauthor=T.+K.+Oostauthor=B.+A.+Belliauthor=H.+Dingauthor=M.+K.+Josephauthor=A.+Kunzerauthor=D.+Martineauauthor=W.+J.+McClellanauthor=M.+Mittenauthor=S.+C.+Ngauthor=P.+M.+Nimmerauthor=T.+Oltersdorfauthor=C.+M.+Parkauthor=A.+M.+Petrosauthor=A.+R.+Shoemakerauthor=X.+Songauthor=X.+Wangauthor=M.+D.+Wendtauthor=H.+Zhangauthor=S.+W.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=Studies+leading+to+potent%2C+dual+inhibitors+of+Bcl-2+and+Bcl-xL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL</span></div><div class="casAuthors">Bruncko, Milan; Oost, Thorsten K.; Belli, Barbara A.; Ding, Hong; Joseph, Mary K.; Kunzer, Aaron; Martineau, Darlene; McClellan, William J.; Mitten, Michael; Ng, Shi-Chung; Nimmer, Paul M.; Oltersdorf, Tilman; Park, Cheol-Min; Petros, Andrew M.; Shoemaker, Alexander R.; Song, Xiaohong; Wang, Xilu; Wendt, Michael D.; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.; Elmore, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-662</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of the antiapoptotic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy.  Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy.  We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation.  Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2.  This study culminated in the identification of 2 (I), which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, resp.  Compd. 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF2G6VoJIheLVg90H21EOLACvtfcHk0lgPZyQjh7FeVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmug%253D%253D&md5=e7bf502c69c4247c39ce7e070984b3a6</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm061152t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061152t%26sid%3Dliteratum%253Aachs%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DOost%26aufirst%3DT.%2BK.%26aulast%3DBelli%26aufirst%3DB.%2BA.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DKunzer%26aufirst%3DA.%26aulast%3DMartineau%26aufirst%3DD.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DMitten%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DS.%2BC.%26aulast%3DNimmer%26aufirst%3DP.%2BM.%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DC.%2BM.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DStudies%2520leading%2520to%2520potent%252C%2520dual%2520inhibitors%2520of%2520Bcl-2%2520and%2520Bcl-xL%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D641%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Park, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adickes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahir, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6902</span><span class="NLM_x">–</span> <span class="NLM_lpage">6915</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800669s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1WlsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6902-6915&author=C.+M.+Parkauthor=M.+Brunckoauthor=J.+Adickesauthor=J.+Bauchauthor=H.+Dingauthor=A.+Kunzerauthor=K.+C.+Marshauthor=P.+Nimmerauthor=A.+R.+Shoemakerauthor=X.+Songauthor=S.+K.+Tahirauthor=C.+Tseauthor=X.+Wangauthor=M.+D.+Wendtauthor=X.+Yangauthor=H.+Zhangauthor=S.+W.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=Discovery+of+an+orally+bioavailable+small+molecule+inhibitor+of+prosurvival+B-cell+lymphoma+2+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins</span></div><div class="casAuthors">Park, Cheol-Min; Bruncko, Milan; Adickes, Jessica; Bauch, Joy; Ding, Hong; Kunzer, Aaron; Marsh, Kennan C.; Nimmer, Paul; Shoemaker, Alexander R.; Song, Xiaohong; Tahir, Stephen K.; Tse, Christin; Wang, Xilu; Wendt, Michael D.; Yang, Xiufen; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.; Elmore, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6902-6915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of prosurvival proteins such as Bcl-2 and Bcl-XL has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide a novel means for the treatment of cancer.  We recently described the discovery of 1 (ABT-737), which binds Bcl-2, Bcl-XL, and Bcl-w with high affinity, shows robust antitumor activity in murine tumor xenograft models, but is not orally bioavailable.  Herein, we report that targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC50).  The resulting compd., 2 (ABT-263), is orally efficacious in an established xenograft model of human small cell lung cancer, inducing complete tumor regressions in all animals.  Compd. 2 is currently in multiple phase 1 clin. trials in patients with small cell lung cancer and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1JFNLCqAULVg90H21EOLACvtfcHk0ljQXNkCVJBFgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1WlsbvE&md5=83975ec5e8f642abc3507d35d00c9e14</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm800669s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800669s%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%2BM.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DAdickes%26aufirst%3DJ.%26aulast%3DBauch%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DKunzer%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DNimmer%26aufirst%3DP.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DTse%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520bioavailable%2520small%2520molecule%2520inhibitor%2520of%2520prosurvival%2520B-cell%2520lymphoma%25202%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6902%26epage%3D6915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinges, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augeri, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betebenner, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bures, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettesheim, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanze, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of the antiapoptotic protein Bcl-X L from NMR and parallel synthesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">656</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0507532" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=656-663&author=A.+M.+Petrosauthor=J.+Dingesauthor=D.+J.+Augeriauthor=S.+A.+Baumeisterauthor=D.+A.+Betebennerauthor=M.+G.+Buresauthor=S.+W.+Elmoreauthor=P.+J.+Hajdukauthor=M.+K.+Josephauthor=S.+K.+Landisauthor=D.+G.+Nettesheimauthor=S.+H.+Rosenbergauthor=W.+Shenauthor=S.+Thomasauthor=X.+Wangauthor=I.+Zanzeauthor=H.+Zhangauthor=S.+W.+Fesik&title=Discovery+of+a+potent+inhibitor+of+the+antiapoptotic+protein+Bcl-X+L+from+NMR+and+parallel+synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm0507532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0507532%26sid%3Dliteratum%253Aachs%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DDinges%26aufirst%3DJ.%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DBaumeister%26aufirst%3DS.%2BA.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DBures%26aufirst%3DM.%2BG.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DLandis%26aufirst%3DS.%2BK.%26aulast%3DNettesheim%26aufirst%3DD.%2BG.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZanze%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520the%2520antiapoptotic%2520protein%2520Bcl-X%2520L%2520from%2520NMR%2520and%2520parallel%2520synthesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D656%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Del Gaizo Moore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Certo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novina, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letai, A.</span><span> </span><span class="NLM_article-title">Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=112-121&author=V.+Del+Gaizo+Mooreauthor=J.+R.+Brownauthor=M.+Certoauthor=T.+M.+Loveauthor=C.+D.+Novinaauthor=A.+Letai&title=Chronic+lymphocytic+leukemia+requires+BCL2+to+sequester+prodeath+BIM%2C+explaining+sensitivity+to+BCL2+antagonist+ABT-737"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BGaizo%2BMoore%26aufirst%3DV.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DCerto%26aufirst%3DM.%26aulast%3DLove%26aufirst%3DT.%2BM.%26aulast%3DNovina%26aufirst%3DC.%2BD.%26aulast%3DLetai%26aufirst%3DA.%26atitle%3DChronic%2520lymphocytic%2520leukemia%2520requires%2520BCL2%2520to%2520sequester%2520prodeath%2520BIM%252C%2520explaining%2520sensitivity%2520to%2520BCL2%2520antagonist%2520ABT-737%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D112%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Vogler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsdale, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicotera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, G. M.</span><span> </span><span class="NLM_article-title">A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">820</span><span class="NLM_x">–</span> <span class="NLM_lpage">830</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fcdd.2008.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18309326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFygu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=820-830&author=M.+Voglerauthor=D.+Dinsdaleauthor=X.+M.+Sunauthor=K.+W.+Youngauthor=M.+Butterworthauthor=P.+Nicoteraauthor=M.+J.+Dyerauthor=G.+M.+Cohen&title=A+novel+paradigm+for+rapid+ABT-737-induced+apoptosis+involving+outer+mitochondrial+membrane+rupture+in+primary+leukemia+and+lymphoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells</span></div><div class="casAuthors">Vogler, M.; Dinsdale, D.; Sun, X.-M.; Young, K. W.; Butterworth, M.; Nicotera, P.; Dyer, M. J. S.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">820-830</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Primary chronic lymphocytic leukemia (CLL) cells are exquisitely sensitive to ABT-737, a small mol. BCL2-antagonist, which induces many of the classical biochem. and ultrastructural features of apoptosis, including BAX/BAK oligomerization, cytochrome c release, caspase activation and chromatin condensation.  Surprisingly, ABT-737 also induces mitochondrial inner membrane permeabilization (MIMP) resulting in mitochondrial matrix swelling and rupture of the outer mitochondrial membrane (OMM), so permitting the rapid efflux of cytochrome c from mitochondrial cristae and facilitating rapid caspase activation and apoptosis.  BAX and BAK appear to be involved in the OMM discontinuities as they localize to the OMM break points.  Notably, ABT-737 induced mitochondrial matrix swelling and OMM discontinuities in other primary B-cell malignancies, including mantle cell, follicular and marginal zone lymphoma cells but not in several cell lines studied.  Thus, we describe a new paradigm of apoptosis in primary B-cell malignancies, whereby targeting of BCL2 results in all the classical features of apoptosis together with OMM rupture independent of caspase activation.  This mechanism may be far more prevalent than hitherto recognized due to the failure of most methods, used to measure apoptosis, to recognize such a mechanism.  Cell Death and Differentiation (2008) 15, 820-830; doi:10.1038/cdd.2008.25; published online 29 Feb. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhS8da_Sf0bVg90H21EOLACvtfcHk0ljpHityOclmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFygu7s%253D&md5=65590167fb7e08de121ae9c000c11c51</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2008.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2008.25%26sid%3Dliteratum%253Aachs%26aulast%3DVogler%26aufirst%3DM.%26aulast%3DDinsdale%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DX.%2BM.%26aulast%3DYoung%26aufirst%3DK.%2BW.%26aulast%3DButterworth%26aufirst%3DM.%26aulast%3DNicotera%26aufirst%3DP.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DA%2520novel%2520paradigm%2520for%2520rapid%2520ABT-737-induced%2520apoptosis%2520involving%2520outer%2520mitochondrial%2520membrane%2520rupture%2520in%2520primary%2520leukemia%2520and%2520lymphoma%2520cells%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2008%26volume%3D15%26spage%3D820%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Wendt, M. D.</span><span> </span><span class="NLM_article-title">Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein−protein interaction</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1123-1143&author=M.+D.+Wendt&title=Discovery+of+ABT-263%2C+a+Bcl-family+protein+inhibitor%3A+observations+on+targeting+a+large+protein%E2%88%92protein+interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520ABT-263%252C%2520a%2520Bcl-family%2520protein%2520inhibitor%253A%2520observations%2520on%2520targeting%2520a%2520large%2520protein%25E2%2588%2592protein%2520interaction%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1123%26epage%3D1143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Tse, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adickes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitten, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahir, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3421</span><span class="NLM_x">–</span> <span class="NLM_lpage">3428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F0008-5472.CAN-07-5836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18451170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3421-3428&author=C.+Tseauthor=A.+R.+Shoemakerauthor=J.+Adickesauthor=M.+G.+Andersonauthor=J.+Chenauthor=S.+Jinauthor=E.+F.+Johnsonauthor=K.+C.+Marshauthor=M.+J.+Mittenauthor=P.+Nimmerauthor=L.+Robertsauthor=S.+K.+Tahirauthor=Y.+Xiaoauthor=X.+Yangauthor=H.+Zhangauthor=S.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=ABT-263%3A+a+potent+and+orally+bioavailable+Bcl-2+family+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor</span></div><div class="casAuthors">Tse, Christin; Shoemaker, Alexander R.; Adickes, Jessica; Anderson, Mark G.; Chen, Jun; Jin, Sha; Johnson, Eric F.; Marsh, Kennan C.; Mitten, Michael J.; Nimmer, Paul; Roberts, Lisa; Tahir, Stephen K.; Xiao, Yu; Yang, Xiufen; Zhang, Haichao; Fesik, Stephen; Rosenberg, Saul H.; Elmore, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3421-3428</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly assocd. with tumor maintenance, progression, and chemoresistance.  We previously reported the discovery of ABT-737, a potent, small-mol. Bcl-2 family protein inhibitor.  A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens.  Here we report the biol. properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w).  The oral bioavailability of ABT-263 in preclin. animal models is 20% to 50%, depending on formulation.  ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), leading to the initiation of apoptosis within 2 h posttreatment.  In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis.  Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia.  In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clin. relevant therapeutic regimens.  These data provide the rationale for clin. trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies.  The oral efficacy of ABT-263 should provide dosing flexibility to maximize clin. utility both as a single agent and in combination regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojLK8zIgyDWbVg90H21EOLACvtfcHk0ljpHityOclmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSltrs%253D&md5=a43029cc218d25d4e1fb6dd1186475c4</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5836%26sid%3Dliteratum%253Aachs%26aulast%3DTse%26aufirst%3DC.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DAdickes%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DM.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMitten%26aufirst%3DM.%2BJ.%26aulast%3DNimmer%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DL.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DABT-263%253A%2520a%2520potent%2520and%2520orally%2520bioavailable%2520Bcl-2%2520family%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3421%26epage%3D3428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Chase, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span> </span><span class="NLM_article-title">Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases</span> <span class="citation_source-journal">Clin. Sci. (London)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1042%2FCS20060035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16961463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2006&pages=233-249&author=A.+Chaseauthor=N.+C.+Cross&title=Signal+transduction+therapy+in+haematological+malignancies%3A+identification+and+targeting+of+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction therapy in hematological malignancies: identification and targeting of tyrosine kinases</span></div><div class="casAuthors">Chase, Andrew; Cross, Nicholas C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">233-249</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinases play key roles in cell proliferation, survival and differentiation.  Their aberrant activation, caused either by the formation of fusion genes by chromosome translocation or by intragenic changes, such as point mutations or internal duplications, is of major importance in the development of many haematol. malignancies.  An understanding of the mechanisms by which BCR-ABL contributes to the pathogenesis of chronic myeloid leukemia led to the development of imatinib, the first of several tyrosine kinase inhibitors to enter clin. trials.  Although the development of resistance has been problematic, particularly in aggressive disease, the development of novel inhibitors and combination with other forms of therapy shows promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuVz0FE6vN7Vg90H21EOLACvtfcHk0ljpHityOclmKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOntbg%253D&md5=77e66f558e2ebab120965923ec997b2f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1042%2FCS20060035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20060035%26sid%3Dliteratum%253Aachs%26aulast%3DChase%26aufirst%3DA.%26aulast%3DCross%26aufirst%3DN.%2BC.%26atitle%3DSignal%2520transduction%2520therapy%2520in%2520haematological%2520malignancies%253A%2520identification%2520and%2520targeting%2520of%2520tyrosine%2520kinases%26jtitle%3DClin.%2520Sci.%2520%2528London%2529%26date%3D2006%26volume%3D111%26spage%3D233%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Buchdunger, E.; Capedeville, R.</span><span> </span><span class="NLM_article-title">Glivec (Gleevec, Imatinib, STI571): A Targeted Therapy in Chronic Myelogenous Leukemia</span>. In  <span class="citation_source-book">Tyrosine Kinase Inhibitors: From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbro, D.; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Humana Press, Inc.</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">145</span>− <span class="NLM_lpage">160</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=145-160&author=E.+Buchdunger&author=R.+Capedevilleauthor=D.+Fabbro&author=F.+McCormick&title=Tyrosine+Kinase+Inhibitors%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26atitle%3DGlivec%2520%2528Gleevec%252C%2520Imatinib%252C%2520STI571%2529%253A%2520A%2520Targeted%2520Therapy%2520in%2520Chronic%2520Myelogenous%2520Leukemia%26btitle%3DTyrosine%2520Kinase%2520Inhibitors%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbro%26aufirst%3DD.%26pub%3DHumana%2520Press%252C%2520Inc%26date%3D2006%26spage%3D145%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0ljJSLMsNTz-cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FS0960-894X%2896%2900601-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=187-192&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydon&title=Potent+and+selective+inhibitors+of+the+Abl-kinase%3A+phenylamino-pyrimidine+%28PAP%29+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives</span></div><div class="casAuthors">Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-192</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Due to its relatively clear etiol., chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase.  Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEGaTJgyxfUbVg90H21EOLACvtfcHk0ljJSLMsNTz-cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D&md5=35962f1735e8d3a595fdb49d95cdc305</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2896%2900601-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252896%252900601-4%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520Abl-kinase%253A%2520phenylamino-pyrimidine%2520%2528PAP%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D187%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljJSLMsNTz-cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Birault, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A.</span><span> </span><span class="NLM_article-title">Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F092986706777452452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16787217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVais7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1735-1748&author=V.+Biraultauthor=C.+J.+Harrisauthor=J.+Leauthor=M.+Lipkinauthor=R.+Nerellaauthor=A.+Stevens&title=Bringing+kinases+into+focus%3A+efficient+drug+design+through+the+use+of+chemogenomic+toolkits"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits</span></div><div class="casAuthors">Birault, Veronique; Harris, C. John; Le, Joelle; Lipkin, Mike; Nerella, Ravi; Stevens, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1735-1748</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The study of protein target families, as opposed to single targets, has become a very powerful tool in chemogenomics-led drug discovery.  By integrating comprehensive chemoinformatics and bioinformatics databases with customized anal. tools, a 'Toolkit' approach for the target family is possible, thus allowing predictions of the ligand class, affinity, selectivity and likely off-target issues to be made for the guidance of the medicinal chemist.  In this review, we highlight the development and application of the Toolkit approach to the protein kinase superfamily, drawing on examples from lead optimization studies and the design of focused libraries for lead discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofWNQyWDS5BbVg90H21EOLACvtfcHk0lhwNlYLE9tP_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVais7c%253D&md5=7922956ff1a4002fc1dca7f44ca78b0a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F092986706777452452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706777452452%26sid%3Dliteratum%253Aachs%26aulast%3DBirault%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLipkin%26aufirst%3DM.%26aulast%3DNerella%26aufirst%3DR.%26aulast%3DStevens%26aufirst%3DA.%26atitle%3DBringing%2520kinases%2520into%2520focus%253A%2520efficient%2520drug%2520design%2520through%2520the%2520use%2520of%2520chemogenomic%2520toolkits%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D1735%26epage%3D1748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnsmb.1486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18794843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1109-1118&author=M.+Azamauthor=M.+A.+Seeligerauthor=N.+S.+Grayauthor=J.+Kuriyanauthor=G.+Q.+Daley&title=Activation+of+tyrosine+kinases+by+mutation+of+the+gatekeeper+threonine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span></div><div class="casAuthors">Azam, Mohammad; Seeliger, Markus A.; Gray, Nathanael S.; Kuriyan, John; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1109-1118</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases targeted by small-mol. inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site.  Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-α and -β, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells.  Structural anal. reveals that a network of hydrophobic interactions - the hydrophobic spine - characteristic of the active kinase conformation is stabilized by the gatekeeper substitution.  Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase.  Furthermore, a small-mol. inhibitor (compd. 14) that maximizes complementarity with the dismantled spine inhibits the gatekeeper mutation of BCR-ABL-T315I.  These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEoZTY5SkbALVg90H21EOLACvtfcHk0lhwNlYLE9tP_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM&md5=4afc4e5a0850a4510ced3fa5fbda97fa</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1486%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivation%2520of%2520tyrosine%2520kinases%2520by%2520mutation%2520of%2520the%2520gatekeeper%2520threonine%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D1109%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Huang, F.; Clark, E. A.</span><span> </span><span class="NLM_article-title">Pharmacogenomics of Dasatinib (Sprycel)</span>. In  <span class="citation_source-book">Kinase Inhibitor Drugs</span>; <span class="NLM_contrib-group">Li, R.; Stafford, J. A.</span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=F.+Huang&author=E.+A.+Clarkauthor=R.+Li&author=J.+A.+Stafford&title=Kinase+Inhibitor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%26atitle%3DPharmacogenomics%2520of%2520Dasatinib%2520%2528Sprycel%2529%26btitle%3DKinase%2520Inhibitor%2520Drugs%26aulast%3DLi%26aufirst%3DR.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Strategies to overcome resistance to targeted protein kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd1579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15573099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1001-1010&author=H.+Daubauthor=K.+Spechtauthor=A.+Ullrich&title=Strategies+to+overcome+resistance+to+targeted+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to overcome resistance to targeted protein kinase inhibitors</span></div><div class="casAuthors">Daub, Henrik; Specht, Katja; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1001-1010</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Selective inhibition of protein tyrosine kinases is gaining importance as an effective therapeutic approach for the treatment of a wide range of human cancers.  However, as extensively documented for the BCR-ABL oncogene in imatinib-treated leukemia patients, clin. resistance caused by mutations in the targeted oncogene has been obsd.  Here, we look at how structural and mechanistic insights from imatinib-insensitive Bcr-Abl have been exploited to identify second-generation drugs that override acquired target resistance.  These insights have created a rationale for the development of either multi-targeted protein kinase inhibitors or cocktails of selective antagonists as antitumor drugs that combine increased therapeutic potency with a reduced risk of the emergence of mol. resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_U6mWwYG307Vg90H21EOLACvtfcHk0lhwNlYLE9tP_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL3K&md5=49c2ce8b0150e562e382d5246b3c0a42</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnrd1579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1579%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DSpecht%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DStrategies%2520to%2520overcome%2520resistance%2520to%2520targeted%2520protein%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Giannoudis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirmohamed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. E.</span><span> </span><span class="NLM_article-title">Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">3348</span><span class="NLM_x">–</span> <span class="NLM_lpage">3354</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=3348-3354&author=A.+Giannoudisauthor=A.+Daviesauthor=C.+M.+Lucasauthor=R.+J.+Harrisauthor=M.+Pirmohamedauthor=R.+E.+Clark&title=Effective+dasatinib+uptake+may+occur+without+human+organic+cation+transporter+1+%28hOCT1%29%3A+implications+for+the+treatment+of+imatinib-resistant+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiannoudis%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DLucas%26aufirst%3DC.%2BM.%26aulast%3DHarris%26aufirst%3DR.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DR.%2BE.%26atitle%3DEffective%2520dasatinib%2520uptake%2520may%2520occur%2520without%2520human%2520organic%2520cation%2520transporter%25201%2520%2528hOCT1%2529%253A%2520implications%2520for%2520the%2520treatment%2520of%2520imatinib-resistant%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D3348%26epage%3D3354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel ABL kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+ABL+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0lj4K2_SF5Vkcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520ABL%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=M.+Azamauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lj4K2_SF5Vkcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">2-aminothiazole as a novel kinase inhibitor template. Structure−activity relationship studies toward the discovery of <i>N</i>-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6819</span><span class="NLM_x">–</span> <span class="NLM_lpage">6832</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure%E2%88%92activity+relationship+studies+toward+the+discovery+of+N-%282-chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-+piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure%25E2%2588%2592activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-%2520piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.-L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.-L.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: the new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17853901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+the+new+wave+of+BCR-ABL+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Flying under the radar: the new wave of BCR-ABL inhibitors</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia caused by the mutant BCR-ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs.  Quintas-Cardama and colleagues discuss novel BCR-ABL inhibitors that have the potential to overcome such resistance.  The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukemia (CML).  However, most patients with CML receiving imatinib still harbor mol. residual disease and some develop resistance assocd. with ABL kinase domain mutations.  The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clin. trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.  Various medicinal chem. efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clin. trials, including against T315I mutants.  Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2DBi1E-INLVg90H21EOLACvtfcHk0lgeU_7vy7l_dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ&md5=6a8692cd0405f77256df82ae7de21e18</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520the%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burckstummer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">13283</span><span class="NLM_x">–</span> <span class="NLM_lpage">13288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13283-13288&author=O.+Hantschelauthor=U.+Rixauthor=U.+Schmidtauthor=T.+Burckstummerauthor=M.+Kneidingerauthor=G.+Schutzeauthor=J.+Colingeauthor=K.+L.+Bennettauthor=W.+Ellmeierauthor=P.+Valentauthor=G.+Superti-Furga&title=The+Btk+tyrosine+kinase+is+a+major+target+of+the+Bcr-Abl+inhibitor+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBurckstummer%26aufirst%3DT.%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSchutze%26aufirst%3DG.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520Btk%2520tyrosine%2520kinase%2520is%2520a%2520major%2520target%2520of%2520the%2520Bcr-Abl%2520inhibitor%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D13283%26epage%3D13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">Pavlovsky, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span> </span><span class="NLM_article-title">First-line therapy for chronic myeloid leukemia: past, present, and future</span> <span class="citation_source-journal">Am. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fajh.21380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19306355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFels78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2009&pages=287-293&author=C.+Pavlovskyauthor=H.+Kantarjianauthor=J.+E.+Cortes&title=First-line+therapy+for+chronic+myeloid+leukemia%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">First-line therapy for chronic myeloid leukemia: past, present, and future</span></div><div class="casAuthors">Pavlovsky, Carolina; Kantarjian, Hagop; Cortes, Jorge E.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">287-293</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The development of Bcr-Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML).  Std.-dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, producing considerably higher hematol., cytogenetic, and mol. response rates than seen with previous drug therapies.  However, although many patients respond well to std.-dose imatinib initially, some patients do not achieve adequate levels of response or discontinue therapy because of resistance.  One approach to improving treatment response with first-line imatinib may be to increase the imatinib dose (800 mg/day), although recent trial data indicate that overall increases in response rates may be modest.  Newer Bcr-Abl tyrosine kinase inhibitors can induce responses in patients with all phases of imatinib-resistant CML, even those with imatinib-resistant mutations in the BCR-ABL gene.  Furthermore, in initial studies, first-line dasatinib or nilotinib treatment has produced response rates that compare favorably with historical controls treated with imatinib, although confirmation is required from head-to-head clin. trials.  Future clin. approaches may include drug combinations, which may allow quiescent leukemia stem cells to be eradicated.  Further improvements in drug treatment for first-line CML are expected during the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxtuQ60rRVKrVg90H21EOLACvtfcHk0lgeU_7vy7l_dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFels78%253D&md5=3175d0a24157cb4999ff10fed401f5bd</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1002%2Fajh.21380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.21380%26sid%3Dliteratum%253Aachs%26aulast%3DPavlovsky%26aufirst%3DC.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DFirst-line%2520therapy%2520for%2520chronic%2520myeloid%2520leukemia%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2009%26volume%3D84%26spage%3D287%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namavari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillarsetty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresten-Kochetkov, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punzalan, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antczak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djaballah, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5853</span><span class="NLM_x">–</span> <span class="NLM_lpage">5857</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070342g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5853-5857&author=D.+R.+Veachauthor=M.+Namavariauthor=N.+Pillarsettyauthor=E.+B.+Santosauthor=T.+Beresten-Kochetkovauthor=C.+Lambekauthor=B.+J.+Punzalanauthor=C.+Antczakauthor=P.+M.+Smith-Jonesauthor=H.+Djaballahauthor=B.+Clarksonauthor=S.+M.+Larson&title=Synthesis+and+biological+evaluation+of+a+fluorine-18+derivative+of+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm070342g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070342g%26sid%3Dliteratum%253Aachs%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DNamavari%26aufirst%3DM.%26aulast%3DPillarsetty%26aufirst%3DN.%26aulast%3DSantos%26aufirst%3DE.%2BB.%26aulast%3DBeresten-Kochetkov%26aufirst%3DT.%26aulast%3DLambek%26aufirst%3DC.%26aulast%3DPunzalan%26aufirst%3DB.%2BJ.%26aulast%3DAntczak%26aufirst%3DC.%26aulast%3DSmith-Jones%26aufirst%3DP.%2BM.%26aulast%3DDjaballah%26aufirst%3DH.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520fluorine-18%2520derivative%2520of%2520dasatinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5853%26epage%3D5857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1421-1425&author=T.+Asakiauthor=Y.+Sugiyamaauthor=T.+Hamamotoauthor=M.+Higashiokaauthor=M.+Umeharaauthor=H.+Naitoauthor=T.+Niwa&title=Design+and+synthesis+of+3-substituted+benzamide+derivatives+as+Bcr-Abl+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DHigashioka%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%25203-substituted%2520benzamide%2520derivatives%2520as%2520Bcr-Abl%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1421%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-<i>b</i>]quinolines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2977</span><span class="NLM_x">–</span> <span class="NLM_lpage">2980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2977-2980&author=D.+H.+Boschelliauthor=D.+Powellauthor=J.+M.+Golasauthor=F.+Boschelli&title=Inhibition+of+Src+kinase+activity+by+4-anilino-5%2C10-dihydro-pyrimido%5B4%2C5-b%5Dquinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DGolas%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520Src%2520kinase%2520activity%2520by%25204-anilino-5%252C10-dihydro-pyrimido%255B4%252C5-b%255Dquinolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2977%26epage%3D2980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0liFPi-2mSDC7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group">Schenone, S.; Bruno, O.; Radi, M.; Botta, M.</span><span> </span><span class="NLM_article-title">New insights into small-molecule inhibitors of Bcr-Abl</span>.  <span class="citation_source-journal">Med. Res. Rev.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1002/med.20175</span> . Published online: August 27, 2009.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fmed.20175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schenone%2C+S.%3B+Bruno%2C+O.%3B+Radi%2C+M.%3B+Botta%2C+M.+New+insights+into+small-molecule+inhibitors+of+Bcr-Abl.+Med.+Res.+Rev.+%5BOnline+early+access%5D.+DOI%3A+10.1002%2Fmed.20175.+Published+online%3A+August+27%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fmed.20175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20175%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DNew%2520insights%2520into%2520small-molecule%2520inhibitors%2520of%2520Bcr-Abl%26jtitle%3DMed.%2520Res.%2520Rev.%26doi%3D10.1002%2Fmed.20175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group">Liao, J. J.-L.</span><span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&author=J.+J.-L.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0ljKcg6CNoIJ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D409%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span><span class="NLM_x">–</span> <span class="NLM_lpage">5171</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149-5171&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+rational+inhibitor+design+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Pippin, Douglas A.; Salvino, Joseph M.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5149-5171</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review describing the use of Protein Data Bank (PDB) entries specifically for kinase inhibitor drug discovery.  Topics discussed include: the current state of structure-aided ligand design, kinase structure queries and extn. from the PDB, alignment of protein structures, structural classification of ligands, anal. of ligands and binding modes, and ligand design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDINDYVE15cbVg90H21EOLACvtfcHk0ljKcg6CNoIJ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM&md5=a1afc4d6c7f6fa4dd6aa9da8d78f1ee3</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520rational%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149%26epage%3D5171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group">Alvarado, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, J.</span><span> </span><span class="NLM_article-title">Emerging role of Aurora kinase inhibitors in chronic myeloid leukemia</span> <span class="citation_source-journal">Clin. Leuk.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.3816%2FCLK.2007.n.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitFShu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=325-330&author=Y.+Alvaradoauthor=J.+Cort%C3%A9s&title=Emerging+role+of+Aurora+kinase+inhibitors+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of Aurora kinase inhibitors in chronic myeloid leukemia</span></div><div class="casAuthors">Alvarado, Yesid; Cortes, Jorge E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">325-330</span>CODEN:
                <span class="NLM_cas:coden">CLLEAW</span>;
        ISSN:<span class="NLM_cas:issn">1931-6925</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group</span>)
        </div><div class="casAbstract">A review.  Resistance to imatinib and second-generation tyrosine kinase inhibitors is an ongoing problem most frequently mediated through mutations of the Bcr-Abl kinase domain.  One mutation that affects responsiveness to all current available agents is T315I.  Aurora proteins belong to a small family of serine/threonine kinases that are essential for proliferating cells and have been identified as key regulators of different steps in mitosis and meiosis, ranging from the formation of the mitotic spindle up to cytokinesis.  Unexpectedly, Aurora kinase inhibitors have been found to have activity against the T315I bcr-abl mutation, and some of them might rise as important therapeutic options.  The common mechanism of action for protein kinase inhibition is competition with ATP for the active site-binding pocket, which is very similar among the protein kinases, and this could explain the cross-reactivity.  Herein, we discuss the basics of imatinib resistance development and Aurora kinase biol., and describe a selected group of Aurora kinase inhibitors with potential activity in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw6C8XyOCaKrVg90H21EOLACvtfcHk0ljKcg6CNoIJ_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitFShu7Y%253D&md5=ddd42b2ef6c8bb00fcbe6d8b668373e6</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3816%2FCLK.2007.n.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLK.2007.n.025%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarado%26aufirst%3DY.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26atitle%3DEmerging%2520role%2520of%2520Aurora%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Leuk.%26date%3D2007%26volume%3D1%26spage%3D325%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multikinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multikinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group">Howard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800984v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=379-388&author=S.+Howardauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=J.+Curryauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=L.+Fazalauthor=A.+L.+Gillauthor=M.+Heathcoteauthor=S.+Mamanauthor=J.+E.+Matthewsauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=M.+Reuleauthor=D.+Tisiauthor=G.+Williamsauthor=M.+Vinkovicauthor=P.+G.+Wyatt&title=Fragment-based+discovery+of+the+pyrazol-4-yl+urea+%28AT9283%29%2C+a+multitargeted+kinase+inhibitor+with+potent+aurora+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm800984v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800984v%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DHeathcote%26aufirst%3DM.%26aulast%3DMaman%26aufirst%3DS.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520the%2520pyrazol-4-yl%2520urea%2520%2528AT9283%2529%252C%2520a%2520multitargeted%2520kinase%2520inhibitor%2520with%2520potent%2520aurora%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D379%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0lgb1SsTYTR_jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group">Legros, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magaud, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassuto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michallet, M.</span><span> </span><span class="NLM_article-title">BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2204</span><span class="NLM_x">–</span> <span class="NLM_lpage">2206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2204-2206&author=L.+Legrosauthor=S.+Hayetteauthor=F.+E.+Nicoliniauthor=S.+Raynaudauthor=K.+Chabaneauthor=J.+P.+Magaudauthor=J.+P.+Cassutoauthor=M.+Michallet&title=BCR-ABL%28T315I%29+transcript+disappearance+in+an+imatinib-resistant+CML+patient+treated+with+homoharringtonine%3A+a+new+therapeutic+challenge%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLegros%26aufirst%3DL.%26aulast%3DHayette%26aufirst%3DS.%26aulast%3DNicolini%26aufirst%3DF.%2BE.%26aulast%3DRaynaud%26aufirst%3DS.%26aulast%3DChabane%26aufirst%3DK.%26aulast%3DMagaud%26aufirst%3DJ.%2BP.%26aulast%3DCassuto%26aufirst%3DJ.%2BP.%26aulast%3DMichallet%26aufirst%3DM.%26atitle%3DBCR-ABL%2528T315I%2529%2520transcript%2520disappearance%2520in%2520an%2520imatinib-resistant%2520CML%2520patient%2520treated%2520with%2520homoharringtonine%253A%2520a%2520new%2520therapeutic%2520challenge%253F%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D2204%26epage%3D2206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velentza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnchembio760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16415863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=95-102&author=F.+J.+Adrianauthor=Q.+Dingauthor=T.+Simauthor=A.+Velentzaauthor=C.+Sloanauthor=Y.+Liuauthor=G.+Zhangauthor=W.+Hurauthor=S.+Dingauthor=P.+Manleyauthor=J.+Mestanauthor=D.+Fabbroauthor=N.+S.+Gray&title=Allosteric+inhibitors+of+Bcr-abl-dependent+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span></div><div class="casAuthors">Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Doriano; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-102</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the mol. level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity.  Encouraged by the clin. validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacol. agents that could target this kinase by a distinct mechanism.  We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library.  Compds. in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl.  We propose that this new class of compds. inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjXG0lHqHurVg90H21EOLACvtfcHk0lgb1SsTYTR_jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D&md5=c8617fecb6092d71ae163e7cda1e8f94</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnchembio760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio760%26sid%3Dliteratum%253Aachs%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DSloan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DAllosteric%2520inhibitors%2520of%2520Bcr-abl-dependent%2520cell%2520proliferation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D95%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span> </span><span class="NLM_article-title">Experimental non-ATP-competitive therapies for chronic myelogenous leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=932-940&author=A.+Quintas-Cardama&title=Experimental+non-ATP-competitive+therapies+for+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26atitle%3DExperimental%2520non-ATP-competitive%2520therapies%2520for%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D932%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group">Sanz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo-Coco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowenberg, B.</span><span> </span><span class="NLM_article-title">FLT3 inhibition as a targeted therapy for acute myeloid leukemia</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">594</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FCCO.0b013e32833118fd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19684517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=594-600&author=M.+Sanzauthor=A.+Burnettauthor=F.+Lo-Cocoauthor=B.+Lowenberg&title=FLT3+inhibition+as+a+targeted+therapy+for+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibition as a targeted therapy for acute myeloid leukemia</span></div><div class="casAuthors">Sanz, Miguel; Burnett, Alan; Lo-Coco, Francesco; Loewenberg, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">594-600</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The management of acute myeloid leukemia (AML) presents significant challenges, and there remains a need for new therapies with greater efficacy and better tolerability than existing treatments.  An improved understanding of the genetic and mol. changes underlying AML can help both to guide treatment strategies and to predict clin. outcomes, thereby enabling more precise decision-making regarding the optimal treatment strategy for individual patients.  Recent findings: The tyrosine kinase receptor FLT3 plays an important role in the survival and proliferation of blasts, and approx. 25% of patients with AML have mutations in the FLT3 gene.  This protein is therefore an obvious therapeutic target in AML.  Amongst recently developed tyrosine kinase inhibitors of FLT3, lestaurtinib and midostaurin are two orally bioavailable agents that have shown encouraging activity, both preclinically and in relapsed AML, and are now in phase III clin. trials.  These agents are also being tested in combination with conventional chemotherapy.  Summary: Oral FLT3 inhibitors offer a hope of improved treatment outcomes for patients with relapsed and newly diagnosed AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD1m-wC-8Zk7Vg90H21EOLACvtfcHk0liqTMGcle1Uqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjurvL&md5=223ec76f11ca4fdc147267be5a7fbc25</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e32833118fd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e32833118fd%26sid%3Dliteratum%253Aachs%26aulast%3DSanz%26aufirst%3DM.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DLowenberg%26aufirst%3DB.%26atitle%3DFLT3%2520inhibition%2520as%2520a%2520targeted%2520therapy%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2009%26volume%3D21%26spage%3D594%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group">Scheijen, B.; Griffin, J. D.</span><span> </span><span class="NLM_article-title">Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target in Leukemia</span>. In  <span class="citation_source-book">Protein Tyrosine Kinases: From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbro, D.; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Humana Press, Inc.</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">93</span>− <span class="NLM_lpage">114</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=93-114&author=B.+Scheijen&author=J.+D.+Griffinauthor=D.+Fabbro&author=F.+McCormick&title=Protein+Tyrosine+Kinases%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DScheijen%26aufirst%3DB.%26atitle%3DActivated%2520FLT3%2520Receptor%2520Tyrosine%2520Kinase%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Leukemia%26btitle%3DProtein%2520Tyrosine%2520Kinases%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbro%26aufirst%3DD.%26pub%3DHumana%2520Press%252C%2520Inc%26date%3D2006%26spage%3D93%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group">Stone, R. M.</span><span> </span><span class="NLM_article-title">Induction and postremission therapy: new agents</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">496</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=496-498&author=R.+M.+Stone&title=Induction+and+postremission+therapy%3A+new+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26atitle%3DInduction%2520and%2520postremission%2520therapy%253A%2520new%2520agents%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D496%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group">Adolfsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buza-Vidas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hultquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liuba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryder, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borge, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoren, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitnicka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigvardsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, S. E.</span><span> </span><span class="NLM_article-title">Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2005&pages=295-306&author=J.+Adolfssonauthor=R.+Manssonauthor=N.+Buza-Vidasauthor=A.+Hultquistauthor=K.+Liubaauthor=C.+T.+Jensenauthor=D.+Bryderauthor=L.+Yangauthor=O.+J.+Borgeauthor=L.+A.+Thorenauthor=K.+Andersonauthor=E.+Sitnickaauthor=Y.+Sasakiauthor=M.+Sigvardssonauthor=S.+E.+Jacobsen&title=Identification+of+Flt3%2B+lympho-myeloid+stem+cells+lacking+erythro-megakaryocytic+potential+a+revised+road+map+for+adult+blood+lineage+commitment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdolfsson%26aufirst%3DJ.%26aulast%3DMansson%26aufirst%3DR.%26aulast%3DBuza-Vidas%26aufirst%3DN.%26aulast%3DHultquist%26aufirst%3DA.%26aulast%3DLiuba%26aufirst%3DK.%26aulast%3DJensen%26aufirst%3DC.%2BT.%26aulast%3DBryder%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBorge%26aufirst%3DO.%2BJ.%26aulast%3DThoren%26aufirst%3DL.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DSitnicka%26aufirst%3DE.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DSigvardsson%26aufirst%3DM.%26aulast%3DJacobsen%26aufirst%3DS.%2BE.%26atitle%3DIdentification%2520of%2520Flt3%252B%2520lympho-myeloid%2520stem%2520cells%2520lacking%2520erythro-megakaryocytic%2520potential%2520a%2520revised%2520road%2520map%2520for%2520adult%2520blood%2520lineage%2520commitment%26jtitle%3DCell%26date%3D2005%26volume%3D121%26spage%3D295%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group">Levis, M.; Brown, P.; Small, D.</span><span> </span><span class="NLM_article-title">FLT3: A Receptor Tyrosine Kinase Target in Adult and Pediatric AML</span>. In  <span class="citation_source-book">Innovative Leukemia and Lymphoma Therapy</span>; <span class="NLM_contrib-group">Kaspers, G. J. L.; Coiffier, B.; Heinrich, M. C.; Estey, E.</span>, Eds.; <span class="NLM_publisher-name">Informa Healthcare USA, Inc.</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">379</span>− <span class="NLM_lpage">410</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=379-410&author=M.+Levis&author=P.+Brown&author=D.+Smallauthor=G.+J.+L.+Kaspers&author=B.+Coiffier&author=M.+C.+Heinrich&author=E.+Estey&title=Innovative+Leukemia+and+Lymphoma+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DFLT3%253A%2520A%2520Receptor%2520Tyrosine%2520Kinase%2520Target%2520in%2520Adult%2520and%2520Pediatric%2520AML%26btitle%3DInnovative%2520Leukemia%2520and%2520Lymphoma%2520Therapy%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26pub%3DInforma%2520Healthcare%2520USA%252C%2520Inc%26date%3D2008%26spage%3D379%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1182%2Fblood-2004-03-0891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15345597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=54-60&author=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=V.+Klimekauthor=I.+Galinskyauthor=E.+Esteyauthor=S.+D.+Nimerauthor=W.+Grandinauthor=D.+Lebwohlauthor=Y.+Wangauthor=P.+Cohenauthor=E.+A.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Patients+with+acute+myeloid+leukemia+and+an+activating+mutation+in+FLT3+respond+to+a+small-molecule+FLT3+tyrosine+kinase+inhibitor%2C+PKC412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span></div><div class="casAuthors">Stone, Richard M.; DeAngelo, Daniel J.; Klimek, Virginia; Galinsky, Ilene; Estey, Eli; Nimer, Stephen D.; Grandin, Wilson; Lebwohl, David; Wang, Yanfeng; Cohen, Pamela; Fox, Edward A.; Neuberg, Donna; Clark, Jennifer; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-60</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy.  We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth.  The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiol.  The peripheral blast count decreased by 50% in 14 patients (70%).  Seven patients (35%) experienced a greater than 2-log redn. in peripheral blast count for at least 4 wk (median response duration, 13 wk; range, 9-47 wk); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%).  FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study.  PKC412 is an oral tyrosine kinase inhibitor with clin. activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu297bLj2zDLVg90H21EOLACvtfcHk0lgwJmoSoCsqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D&md5=8683325acf03f9cb523b7b8564c531b8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-03-0891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-03-0891%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPatients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520an%2520activating%2520mutation%2520in%2520FLT3%2520respond%2520to%2520a%2520small-molecule%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%252C%2520PKC412%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D54%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FS1535-6108%2802%2900069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12124173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=433-443&author=E.+Weisbergauthor=C.+Boultonauthor=L.+M.+Kellyauthor=P.+Manleyauthor=D.+Fabbroauthor=T.+Meyerauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Inhibition+of+mutant+FLT3+receptors+in+leukemia+cells+by+the+small+molecule+tyrosine+kinase+inhibitor+PKC412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span></div><div class="casAuthors">Weisberg, Ellen; Boulton, Christina; Kelly, Louise M.; Manley, Paul; Fabbro, Doriano; Meyer, Thomas; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML).  Here we report the identification of a small mol. FLT3 tyrosine kinase inhibitor PKC412, which selectively induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC50 < 10 nM) by directly inhibiting the tyrosine kinase.  Ba/F3-FLT3 cell lines made resistant to PKC412 demonstrated overexpression of mutant FLT3, confirming that FLT3 is the target of this drug.  Finally, progressive leukemia was prevented in PKC412-treated Balb/c mice transplanted with marrow transduced with a FLT3-ITD-expressing retrovirus.  PKC412 is a potent inhibitor of mutant FLT3 and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq5mVxGyiCu7Vg90H21EOLACvtfcHk0lgwJmoSoCsqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D&md5=612331d927bd2ca41319b77aaea6cfd1</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900069-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520mutant%2520FLT3%2520receptors%2520in%2520leukemia%2520cells%2520by%2520the%2520small%2520molecule%2520tyrosine%2520kinase%2520inhibitor%2520PKC412%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D1%26spage%3D433%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2588</span><span class="NLM_x">–</span> <span class="NLM_lpage">2603</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980123i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2588-2603&author=L.+Sunauthor=N.+Tranauthor=F.+Tangauthor=H.+Appauthor=P.+Hirthauthor=G.+McMahonauthor=C.+Tang&title=Synthesis+and+biological+evaluations+of+3-substituted+indolin-2-ones%3A+a+novel+class+of+tyrosine+kinase+inhibitors+that+exhibit+selectivity+toward+particular+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases</span></div><div class="casAuthors">Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2588-2603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs).  These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells.  By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells.  Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.  Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs.  The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoPixq8Am5rVg90H21EOLACvtfcHk0lgwJmoSoCsqRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D&md5=536302b717170a630008dac14832204c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm980123i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980123i%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%25203-substituted%2520indolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520tyrosine%2520kinase%2520inhibitors%2520that%2520exhibit%2520selectivity%2520toward%2520particular%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2588%26epage%3D2603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lj3STChTBl3vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span> </span><span class="NLM_article-title">Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">689</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.leukres.2003.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15158089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Smsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=679-689&author=A.+M.+O%E2%80%99Farrellauthor=H.+A.+Yuenauthor=B.+Smolichauthor=A.+L.+Hannahauthor=S.+G.+Louieauthor=W.+Hongauthor=A.+T.+Stopeckauthor=L.+R.+Silvermanauthor=J.+E.+Lancetauthor=J.+E.+Karpauthor=M.+Albitarauthor=J.+M.+Cherringtonauthor=F.+J.+Giles&title=Effects+of+SU5416%2C+a+small+molecule+tyrosine+kinase+receptor+inhibitor%2C+on+FLT3+expression+and+phosphorylation+in+patients+with+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia</span></div><div class="casAuthors">O'Farrell, Anne-Marie; Yuen, Helene A.; Smolich, Beverly; Hannah, Alison L.; Louie, Sharianne G.; Hong, Weiru; Stopeck, Alison T.; Silverman, Lewis R.; Lancet, Jeffrey E.; Karp, Judith E.; Albitar, Maher; Cherrington, Julie M.; Giles, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-689</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is assocd. with dysregulated hematopoietic cell proliferation and increased bone marrow angiogenesis, each regulated by signaling through receptor tyrosine kinases (RTKs).  SU5416 is a small mol. inhibitor of VEGF receptors, c-kit and FLT3 and therefore provides a novel opportunity to target both angiogenesis and proliferation in AML.  SU5416 was assessed in a phase II hematol. malignancy trial in the US, where partial responses were obsd. in two of 33 patients.  Since AML provides a unique platform to evaluate mechanism of action of small mol. inhibitors, investigation of the effect of SU5416 on FLT3 expression and phosphorylation in blood and bone marrow was an addnl. focus of this trial.  Phosphorylated FLT3 was detected by immunopptn./Western anal. in peripheral blood samples from 17 of 22 patients, and seven exhibited strong inhibition of phosphorylation immediately following a 1 h SU5416 infusion, demonstrating that SU5416 can modulate RTK phosphorylation in humans.  Although no clear correlation with clin. response was obsd., anal. of patient plasma drug levels suggested that a threshold SU5416 concn. of 15 μM was assocd. with FLT3 inhibition.  This observation was supported by data from an ex vivo model where AML cells were spiked into human blood, established to mimic the clin. setting and enable more rigorous anal. of effect of SU5416.  In addn., FLT3 protein levels were downregulated in patient bone marrow samples, analyzed by an RIA assay.  To identify putative predictors of response, patient plasma was analyzed for levels of secreted ligands of SU5416 targets; SCF and FLT3 ligand.  Baseline levels of SCF in patients with stable or progressive disease were significantly higher than those in normal donors, whereas FLT3 ligand levels in patients who exhibited progressive disease were significantly lower than those in normal donors.  The translational and clin. analyses described in this report provide some insights into the mechanism and duration of action of SU5416.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbKgOa_gMmDLVg90H21EOLACvtfcHk0lj3STChTBl3vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Smsb8%253D&md5=343e7e6afadc2dffc09c6304e44b98b0</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2003.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2003.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DSmolich%26aufirst%3DB.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DStopeck%26aufirst%3DA.%2BT.%26aulast%3DSilverman%26aufirst%3DL.%2BR.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26atitle%3DEffects%2520of%2520SU5416%252C%2520a%2520small%2520molecule%2520tyrosine%2520kinase%2520receptor%2520inhibitor%252C%2520on%2520FLT3%2520expression%2520and%2520phosphorylation%2520in%2520patients%2520with%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2004%26volume%3D28%26spage%3D679%26epage%3D689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwittay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massimini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scigalla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossfeld, D. K.</span><span> </span><span class="NLM_article-title">A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">986</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=986-993&author=W.+Fiedlerauthor=H.+Serveauthor=H.+Dohnerauthor=M.+Schwittayauthor=O.+G.+Ottmannauthor=A.+M.+O%E2%80%99Farrellauthor=C.+L.+Belloauthor=R.+Allredauthor=W.+C.+Manningauthor=J.+M.+Cherringtonauthor=S.+G.+Louieauthor=W.+Hongauthor=N.+M.+Bregaauthor=G.+Massiminiauthor=P.+Scigallaauthor=W.+E.+Berdelauthor=D.+K.+Hossfeld&title=A+phase+1+study+of+SU11248+in+the+treatment+of+patients+with+refractory+or+resistant+acute+myeloid+leukemia+%28AML%29+or+not+amenable+to+conventional+therapy+for+the+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DSchwittay%26aufirst%3DM.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DAllred%26aufirst%3DR.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DBrega%26aufirst%3DN.%2BM.%26aulast%3DMassimini%26aufirst%3DG.%26aulast%3DScigalla%26aufirst%3DP.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DHossfeld%26aufirst%3DD.%2BK.%26atitle%3DA%2520phase%25201%2520study%2520of%2520SU11248%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520refractory%2520or%2520resistant%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520or%2520not%2520amenable%2520to%2520conventional%2520therapy%2520for%2520the%2520disease%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D986%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatsula, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burd, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocks, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abriola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasavada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span> </span><span class="NLM_article-title">Antitumor activity of sorafenib in FLT3-driven leukemic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=439-445&author=D.+Auclairauthor=D.+Millerauthor=V.+Yatsulaauthor=W.+Pickettauthor=C.+Carterauthor=Y.+Changauthor=X.+Zhangauthor=D.+Wilkieauthor=A.+Burdauthor=H.+Shiauthor=S.+Rocksauthor=R.+Gedrichauthor=L.+Abriolaauthor=H.+Vasavadaauthor=M.+Lynchauthor=J.+Dumasauthor=P.+A.+Trailauthor=S.+M.+Wilhelm&title=Antitumor+activity+of+sorafenib+in+FLT3-driven+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DYatsula%26aufirst%3DV.%26aulast%3DPickett%26aufirst%3DW.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DBurd%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DRocks%26aufirst%3DS.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DAbriola%26aufirst%3DL.%26aulast%3DVasavada%26aufirst%3DH.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26atitle%3DAntitumor%2520activity%2520of%2520sorafenib%2520in%2520FLT3-driven%2520leukemic%2520cells%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D439%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1093%2Fjnci%2Fdjm328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18230792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=184-198&author=W.+Zhangauthor=M.+Konoplevaauthor=Y.+X.+Shiauthor=T.+McQueenauthor=D.+Harrisauthor=X.+Lingauthor=Z.+Estrovauthor=A.+Quintas-Cardamaauthor=D.+Smallauthor=J.+Cortesauthor=M.+Andreeff&title=Mutant+FLT3%3A+a+direct+target+of+sorafenib+in+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span></div><div class="casAuthors">Zhang, Weiguo; Konopleva, Marina; Shi, Yue-xi; McQueen, Teresa; Harris, David; Ling, Xiaoyang; Estrov, Zeev; Quintas-Cardama, Alfonso; Small, Donald; Cortes, Jorge; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concns. in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3.  The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.  Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot anal., resp., and the in vivo effects were detd. by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice).  In a phase 1 clin. trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules.  We detd. their FLT3 mutation status by a polymerase chain reaction assay and analyzed clin. responses by std. criteria.  All statistical tests were two-sided.  Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein.  In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018).  Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs. 7.5% [P = .016] and 75.5% vs. 34% [P = .05], resp.) but not in patients without this mutation.  Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNBWJSPfrsN7Vg90H21EOLACvtfcHk0lgrJSWS8h--Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D&md5=d747b1107866a0299c972c1bcd58c770</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm328%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BX.%26aulast%3DMcQueen%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMutant%2520FLT3%253A%2520a%2520direct%2520target%2520of%2520sorafenib%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D184%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonios-McCrea, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernette-Hammond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Design, structure activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure+activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure%2520activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D52%26spage%3D278%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curley, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokker, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2867</span><span class="NLM_x">–</span> <span class="NLM_lpage">2872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2867-2872&author=J.+J.+Clarkauthor=J.+Coolsauthor=D.+P.+Curleyauthor=J.+C.+Yuauthor=N.+A.+Lokkerauthor=N.+A.+Gieseauthor=D.+G.+Gilliland&title=Variable+sensitivity+of+FLT3+activation+loop+mutations+to+the+small+molecule+tyrosine+kinase+inhibitor+MLN518"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DCurley%26aufirst%3DD.%2BP.%26aulast%3DYu%26aufirst%3DJ.%2BC.%26aulast%3DLokker%26aufirst%3DN.%2BA.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DVariable%2520sensitivity%2520of%2520FLT3%2520activation%2520loop%2520mutations%2520to%2520the%2520small%2520molecule%2520tyrosine%2520kinase%2520inhibitor%2520MLN518%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D2867%26epage%3D2872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5182</span><span class="NLM_x">–</span> <span class="NLM_lpage">5185</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5182-5185&author=H.+K.+Patelauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=J.+Jamesauthor=D.+K.+Treiberauthor=D.+J.+Lockhartauthor=P.+P.+Zarrinkarauthor=S.+S.+Bhagwat&title=Arylcarboxyamino-substituted+diaryl+ureas+as+potent+and+selective+FLT3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DArylcarboxyamino-substituted%2520diaryl%2520ureas%2520as%2520potent%2520and%2520selective%2520FLT3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5182%26epage%3D5185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(5-<i>tert</i>-butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7808</span><span class="NLM_x">–</span> <span class="NLM_lpage">7816</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-butyl-isoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+dihydrochloride+%28AC220%29%2C+a+uniquely+potent%2C+selective%2C+and+efficacious+FMS-like+tyrosine+kinase-3+%28FLT3%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-butyl-isoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520dihydrochloride%2520%2528AC220%2529%252C%2520a%2520uniquely%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghirdaladze, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVetten, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zodelava, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarringkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padre, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corringham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trikha, M.</span><span> </span><span class="NLM_article-title">AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) ohase 1 AML study</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=636&author=J.+Cortesauthor=J.+Foranauthor=D.+Ghirdaladzeauthor=M.+P.+DeVettenauthor=M.+Zodelavaauthor=P.+Holmanauthor=M.+J.+Levisauthor=H.+M.+Kantarjianauthor=G.+Borthakurauthor=J.+Jamesauthor=P.+P.+Zarringkarauthor=R.+N.+Gunawardaneauthor=R.+C.+Armstrongauthor=N.+M.+Padreauthor=W.+Wierengaauthor=R.+Corringhamauthor=M.+Trikha&title=AC220%2C+a+potent%2C+selective%2C+second+generation+FLT3+receptor+tyrosine+kinase+%28RTK%29+inhibitor%2C+in+a+first-in-human+%28FIH%29+ohase+1+AML+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DForan%26aufirst%3DJ.%26aulast%3DGhirdaladze%26aufirst%3DD.%26aulast%3DDeVetten%26aufirst%3DM.%2BP.%26aulast%3DZodelava%26aufirst%3DM.%26aulast%3DHolman%26aufirst%3DP.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarringkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DPadre%26aufirst%3DN.%2BM.%26aulast%3DWierenga%26aufirst%3DW.%26aulast%3DCorringham%26aufirst%3DR.%26aulast%3DTrikha%26aufirst%3DM.%26atitle%3DAC220%252C%2520a%2520potent%252C%2520selective%252C%2520second%2520generation%2520FLT3%2520receptor%2520tyrosine%2520kinase%2520%2528RTK%2529%2520inhibitor%252C%2520in%2520a%2520first-in-human%2520%2528FIH%2529%2520ohase%25201%2520AML%2520study%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2009%26volume%3D114%26spage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foran, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devetten, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padre, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, W.</span><span> </span><span class="NLM_article-title">Human pharmacokinetics of AC220, a potent and selective class III receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1597</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1597&author=J.+Cortesauthor=J.+M.+Foranauthor=M.+P.+Devettenauthor=F.+J.+Gilesauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=M.+H.+Silvermanauthor=K.+A.+Kellyauthor=N.+M.+Padreauthor=S.+Bhagwatauthor=W.+Wierenga&title=Human+pharmacokinetics+of+AC220%2C+a+potent+and+selective+class+III+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DDevetten%26aufirst%3DM.%2BP.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSilverman%26aufirst%3DM.%2BH.%26aulast%3DKelly%26aufirst%3DK.%2BA.%26aulast%3DPadre%26aufirst%3DN.%2BM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DWierenga%26aufirst%3DW.%26atitle%3DHuman%2520pharmacokinetics%2520of%2520AC220%252C%2520a%2520potent%2520and%2520selective%2520class%2520III%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2007%26volume%3D110%26spage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3113</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F092986708786848613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19075657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=3113-3132&author=S.+Schenoneauthor=C.+Brulloauthor=M.+Botta&title=Small+molecules+ATP-competitive+inhibitors+of+FLT3%3A+a+chemical+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3113-3132</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 is a tyrosine kinase (TK), member of the class III TK receptor family, normally expressed in hematopoietic, immune and neural systems, also playing an important role in the pathogenesis of acute leukemias, particularly acute myeloid leukemia (AML), where it is present in constitutively activated mutated forms, correlated with poor prognosis, in a notable percentage of patients.  For these reasons FLT3 soon appeared as a promising target for the therapeutic intervention for this severe and aggressive malignancy; the recent detn. of the crystal structure of the autoinhibited form of FLT3 gave new trend for the design and the synthesis of potent inhibitors.  Small mols. tyrosine kinase inhibitors represent one of the largest drug family currently targeted by pharmaceutical companies for the treatment of cancer.  Exciting examples of such mols. have reached advanced clin. trials and have been recently approved by FDA for the treatment of different solid or hematol. tumors.  Usually TK inhibitors share common features, namely two hydrophobic/arom. regions bearing one or more hydrogen bonding substituents.  These two regions can be connected by different spacers and almost all the mols. contain a component resembling the ATP purine structure.  This review will deal with FLT3 synthetic inhibitors, reporting not only the most important mols. that are in clin. trials, but also the new compds. that have appeared in literature in the last few years.  Our attention will be focused on chem. structures, mechanisms of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaEJysVaMAbVg90H21EOLACvtfcHk0lh6sJ2NDBGvXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D&md5=f0d577bdb45e35fb063b98f35d9329d1</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.2174%2F092986708786848613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708786848613%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520ATP-competitive%2520inhibitors%2520of%2520FLT3%253A%2520a%2520chemical%2520overview%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D3113%26epage%3D3132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span> </span><span class="NLM_article-title">Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4451</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060368s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4451-4454&author=P.+Furetauthor=G.+Boldauthor=T.+Meyerauthor=J.+Roeselauthor=V.+Guagnano&title=Aromatic+interactions+with+phenylalanine+691+and+cysteine+828%3A+a+concept+for+FMS-like+tyrosine+kinase-3+inhibition.+Application+to+the+discovery+of+a+new+class+of+potential+antileukemia+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm060368s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060368s%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGuagnano%26aufirst%3DV.%26atitle%3DAromatic%2520interactions%2520with%2520phenylalanine%2520691%2520and%2520cysteine%2520828%253A%2520a%2520concept%2520for%2520FMS-like%2520tyrosine%2520kinase-3%2520inhibition.%2520Application%2520to%2520the%2520discovery%2520of%2520a%2520new%2520class%2520of%2520potential%2520antileukemia%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4451%26epage%3D4454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0lh6sJ2NDBGvXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group">Padro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retzlaff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Tidow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesters, R. M.</span><span> </span><span class="NLM_article-title">Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1302-1310&author=T.+Padroauthor=R.+Biekerauthor=S.+Ruizauthor=M.+Steinsauthor=S.+Retzlaffauthor=H.+Burgerauthor=T.+Buchnerauthor=T.+Kesslerauthor=F.+Herreraauthor=J.+Kienastauthor=C.+Muller-Tidowauthor=H.+Serveauthor=W.+E.+Berdelauthor=R.+M.+Mesters&title=Overexpression+of+vascular+endothelial+growth+factor+%28VEGF%29+and+its+cellular+receptor+KDR+%28VEGFR-2%29+in+the+bone+marrow+of+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPadro%26aufirst%3DT.%26aulast%3DBieker%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DRetzlaff%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DBuchner%26aufirst%3DT.%26aulast%3DKessler%26aufirst%3DT.%26aulast%3DHerrera%26aufirst%3DF.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMesters%26aufirst%3DR.%2BM.%26atitle%3DOverexpression%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520and%2520its%2520cellular%2520receptor%2520KDR%2520%2528VEGFR-2%2529%2520in%2520the%2520bone%2520marrow%2520of%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26spage%3D1302%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group">Weidenaar, A. C.; de Jonge, H. J. M.; ter Elst, J.; de Bont, E. S. J. M.</span><span> </span><span class="NLM_article-title">Angiogenesis in Hematological Malignancies</span>. In  <span class="citation_source-book">Innovative Leukemia and Lymphoma Therapy</span>; <span class="NLM_contrib-group">Kaspers, G. J. L.; Coiffier, B.; Heinrich, M. C.; Estey, E.</span>, Eds.; <span class="NLM_publisher-name">Informa Healthcare USA, Inc.</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">283</span>− <span class="NLM_lpage">310</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=283-310&author=A.+C.+Weidenaar&author=H.+J.+M.+de+Jonge&author=J.+ter+Elst&author=E.+S.+J.+M.+de+Bontauthor=G.+J.+L.+Kaspers&author=B.+Coiffier&author=M.+C.+Heinrich&author=E.+Estey&title=Innovative+Leukemia+and+Lymphoma+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWeidenaar%26aufirst%3DA.%2BC.%26atitle%3DAngiogenesis%2520in%2520Hematological%2520Malignancies%26btitle%3DInnovative%2520Leukemia%2520and%2520Lymphoma%2520Therapy%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26pub%3DInforma%2520Healthcare%2520USA%252C%2520Inc%26date%3D2008%26spage%3D283%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Targeting the leukemia microenvironment</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F138945007780830827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17584025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFagurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=685-701&author=M.+Konoplevaauthor=M.+Andreeff&title=Targeting+the+leukemia+microenvironment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the leukemia microenvironment</span></div><div class="casAuthors">Konopleva, Marina; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-701</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment.  In hematol. malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium.  In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype.  We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapy-induced death and allow acquisition of a drug-resistant phenotype.  We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction.  Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIexfQEUYTtbVg90H21EOLACvtfcHk0lh6sJ2NDBGvXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFagurg%253D&md5=b8eb2e77c4b83f628b0d2857d7993cab</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.2174%2F138945007780830827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780830827%26sid%3Dliteratum%253Aachs%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520leukemia%2520microenvironment%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D685%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group">Limvorasak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadas, E. M.</span><span> </span><span class="NLM_article-title">Pazopanib: therapeutic developments</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">3091</span><span class="NLM_x">–</span> <span class="NLM_lpage">3102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1517%2F14656560903436493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19954277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=3091-3102&author=S.+Limvorasakauthor=E.+M.+Posadas&title=Pazopanib%3A+therapeutic+developments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib: therapeutic developments</span></div><div class="casAuthors">Limvorasak, Suwicha; Posadas, Edwin M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3091-3102</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clin. development.  Like other orally available VEGFR inhibitors, pazopanib is clin. efficacious and well tolerated.  The recently reported Phase III clin. trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval.  Given the growing no. of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYSKDLcCNZq7Vg90H21EOLACvtfcHk0ligHekbBKx0sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSqt7nO&md5=c05b4fdd434c65a702ec8d49d0d37236</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1517%2F14656560903436493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560903436493%26sid%3Dliteratum%253Aachs%26aulast%3DLimvorasak%26aufirst%3DS.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26atitle%3DPazopanib%253A%2520therapeutic%2520developments%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26spage%3D3091%26epage%3D3102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group">Laplante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">mTOR signaling at a glance</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3589</span><span class="NLM_x">–</span> <span class="NLM_lpage">3594</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1242%2Fjcs.051011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19812304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3589-3594&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+at+a+glance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling at a glance</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3589-3594</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The authors highlight and summarize the current understanding of how mTOR nucleates distinct multiprotein complexes, how intra- and extracellular signals are processed by the mTOR complexes, and how such signals affect cell metab., growth, proliferation, and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5es3QIlHS6bVg90H21EOLACvtfcHk0ligHekbBKx0sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP&md5=7be03ca7a8a3f52e0e974c784a0b9e73</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1242%2Fjcs.051011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.051011%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3589%26epage%3D3594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group">Abdel-Karim, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span> </span><span class="NLM_article-title">Mammalian target of rapamycin as a target in hematological malignancies</span> <span class="citation_source-journal">Curr. Probl. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.currproblcancer.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18655914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1cvnvV2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=161-177&author=I.+A.+Abdel-Karimauthor=F.+J.+Giles&title=Mammalian+target+of+rapamycin+as+a+target+in+hematological+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian target of rapamycin as a target in hematological malignancies</span></div><div class="casAuthors">Abdel-Karim Isam A; Giles Francis J</div><div class="citationInfo"><span class="NLM_cas:title">Current problems in cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">161-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHqulnkyE5ObjnyZkbE8yXfW6udTcc2eZegr3y0HIj1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvnvV2qsg%253D%253D&md5=684db1ce616abf1a8964e571018cb7bf</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.currproblcancer.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.currproblcancer.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Karim%26aufirst%3DI.%2BA.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520as%2520a%2520target%2520in%2520hematological%2520malignancies%26jtitle%3DCurr.%2520Probl.%2520Cancer%26date%3D2008%26volume%3D32%26spage%3D161%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group">Yuan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span> </span><span class="NLM_article-title">Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1186%2F1756-8722-2-45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjlt1Cjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=45&author=R.+Yuanauthor=A.+Kayauthor=W.+J.+Bergauthor=D.+Lebwohl&title=Targeting+tumorigenesis%3A+development+and+use+of+mTOR+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy</span></div><div class="casAuthors">Yuan Ruirong; Kay Andrea; Berg William J; Lebwohl David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase positioned at a central point in a variety of cellular signaling cascades.  The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer has identified mTOR as a major link in tumorigenesis.  Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer.  Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC).  Everolimus is an oral agent that has recently obtained US FDA and EMEA approval for the treatment of advanced RCC after failure of treatment with sunitinib or sorafenib.  Ridaforolimus is not yet approved for any indication.  The use of mTOR inhibitors, either alone or in combination with other anticancer agents, has the potential to provide anticancer activity in numerous tumor types.  Cancer types in which these agents are under evaluation include neuroendocrine tumors, breast cancer, leukemia, lymphoma, hepatocellular carcinoma, gastric cancer, pancreatic cancer, sarcoma, endometrial cancer, and non-small-cell lung cancer.  The results of ongoing clinical trials with mTOR inhibitors, as single agents and in combination regimens, will better define their activity in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzXyuv_r_zDskU0YCbOU3EfW6udTcc2eZegr3y0HIj1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjlt1Cjtw%253D%253D&md5=1d6d43cedd3187c881f7d29f21feb88b</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-2-45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-2-45%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DBerg%26aufirst%3DW.%2BJ.%26aulast%3DLebwohl%26aufirst%3DD.%26atitle%3DTargeting%2520tumorigenesis%253A%2520development%2520and%2520use%2520of%2520mTOR%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2009%26volume%3D2%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group">Tsang, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X. F.</span><span> </span><span class="NLM_article-title">Targeting mammalian target of rapamycin (mTOR) for health and diseases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=112-124&author=C.+K.+Tsangauthor=H.+Qiauthor=L.+F.+Liuauthor=X.+F.+Zheng&title=Targeting+mammalian+target+of+rapamycin+%28mTOR%29+for+health+and+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsang%26aufirst%3DC.%2BK.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DZheng%26aufirst%3DX.%2BF.%26atitle%3DTargeting%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520for%2520health%2520and%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D112%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group">Abraham, R. T.</span><span> </span><span class="NLM_article-title">Identification of TOR signaling complexes: more TORC for the cell growth engine</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=9-12&author=R.+T.+Abraham&title=Identification+of+TOR+signaling+complexes%3A+more+TORC+for+the+cell+growth+engine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DIdentification%2520of%2520TOR%2520signaling%2520complexes%253A%2520more%2520TORC%2520for%2520the%2520cell%2520growth%2520engine%26jtitle%3DCell%26date%3D2002%26volume%3D111%26spage%3D9%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group">Corradetti, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, K. L.</span><span> </span><span class="NLM_article-title">Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6347</span><span class="NLM_x">–</span> <span class="NLM_lpage">6360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6347-6360&author=M.+N.+Corradettiauthor=K.+L.+Guan&title=Upstream+of+the+mammalian+target+of+rapamycin%3A+do+all+roads+pass+through+mTOR%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorradetti%26aufirst%3DM.%2BN.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DUpstream%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520do%2520all%2520roads%2520pass%2520through%2520mTOR%253F%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6347%26epage%3D6360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group">Witzig, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inwards, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luyun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakhil, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5347</span><span class="NLM_x">–</span> <span class="NLM_lpage">5356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2005.13.466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15983389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5347-5356&author=T.+E.+Witzigauthor=S.+M.+Geyerauthor=I.+Ghobrialauthor=D.+J.+Inwardsauthor=R.+Fonsecaauthor=P.+Kurtinauthor=S.+M.+Ansellauthor=R.+Luyunauthor=P.+J.+Flynnauthor=R.+F.+Mortonauthor=S.+R.+Dakhilauthor=H.+Grossauthor=S.+H.+Kaufmann&title=Phase+II+trial+of+single-agent+temsirolimus+%28CCI-779%29+for+relapsed+mantle+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma</span></div><div class="casAuthors">Witzig, Thomas E.; Geyer, Susan M.; Ghobrial, Irene; Inwards, David J.; Fonseca, Rafael; Kurtin, Paul; Ansell, Stephen M.; Luyun, Ronnie; Flynn, Patrick J.; Morton, Roscoe F.; Dakhil, Shaker R.; Gross, Howard; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5347-5356</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 mRNA.  This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.  Patients with relapsed or refractory MCL were eligible to receive temsirolimus 250 mg i.v. every week as a single agent.  Patients with a tumor response after six cycles were eligible to continue drug for a total of 12 cycles or two cycles after complete remission, and were then obsd. without maintenance.  Thirty-five patients were enrolled and were assessable for toxicity; one patient had MCL by histol. but was cyclin D1 neg. and was ineligible for efficacy.  The median age was 70 years (range, 38 to 89 years), 91% were stage 4, and 69% had two or more extranodal sites.  Patients had received a median of three prior therapies (range, one to 11), and 54% were refractory to the last treatment.  The overall response rate was 38% (13 of 34 patients; 90% Cl, 24% to 54%) with one complete response (3%) and 12 partial responses (35%).  The median time-to-progression in all patients was 6.5 mo (95% Cl, 2.9 to 8.3 mo), and the duration of response for the 13 responders was 6.9 mo (95% Cl, 5.2 to 12.4 mo).  Hematol. toxicities were the most common, with 71% (25% of 35 patients) having grade 3 and 11% (four of 35 patients) having grade 4 toxicities obsd.  Thrombocytopenia was the most frequent cause of dose redns. but was of short duration, typically resolving within 1 wk.  Single-agent temsirolimus has substantial antitumor activity in relapsed MCL.  This study demonstrates that agents that selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit.  Further studies of this agent in MCL and other lymphoid malignancies are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLDxT9yqiLVrVg90H21EOLACvtfcHk0liqcEr8rpOXaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLk%253D&md5=98d5b88a5f8468e922fb8bb8ff0e4cd0</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.13.466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.13.466%26sid%3Dliteratum%253Aachs%26aulast%3DWitzig%26aufirst%3DT.%2BE.%26aulast%3DGeyer%26aufirst%3DS.%2BM.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DInwards%26aufirst%3DD.%2BJ.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DKurtin%26aufirst%3DP.%26aulast%3DAnsell%26aufirst%3DS.%2BM.%26aulast%3DLuyun%26aufirst%3DR.%26aulast%3DFlynn%26aufirst%3DP.%2BJ.%26aulast%3DMorton%26aufirst%3DR.%2BF.%26aulast%3DDakhil%26aufirst%3DS.%2BR.%26aulast%3DGross%26aufirst%3DH.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DPhase%2520II%2520trial%2520of%2520single-agent%2520temsirolimus%2520%2528CCI-779%2529%2520for%2520relapsed%2520mantle%2520cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5347%26epage%3D5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group">Peponi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventaki, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassidakis, G. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, L. J.</span><span> </span><span class="NLM_article-title">Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">2171</span><span class="NLM_x">–</span> <span class="NLM_lpage">2180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2353%2Fajpath.2006.051078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17148679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvV2nsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2006&pages=2171-2180&author=E.+Peponiauthor=E.+Drakosauthor=G.+Reyesauthor=V.+Leventakiauthor=G.+Z.+Rassidakisauthor=L.+J.+Medeiros&title=Activation+of+mammalian+target+of+rapamycin+signaling+promotes+cell+cycle+progression+and+protects+cells+from+apoptosis+in+mantle+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma</span></div><div class="casAuthors">Peponi, Evangelia; Drakos, Elias; Reyes, Guadalupe; Leventaki, Vasiliki; Rassidakis, George Z.; Medeiros, L. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2171-2180</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Mantle cell lymphoma (MCL) is characterized by the t(11;14) and cyclin D1 overexpression.  However, addnl. mol. events are most likely required for oncogenesis, possibly through cell cycle and apoptosis deregulation.  We hypothesized that mammalian target of rapamycin (mTOR) is activated in MCL and contributes to tumor proliferation and survival.  In MCL cell lines, pharmacol. inhibition of the phosphoinositide 3-kinase/AKT pathway was assocd. with decreased phosphorylation (activation) of mTOR and its downstream targets phosphorylated (p)-4E-BP1, p-p70S6 kinase, and p-ribosomal protein S6, resulting in apoptosis and cell cycle arrest.  These changes were assocd. with down-regulation of cyclin D1 and the anti-apoptotic proteins cFLIP, BCL-XL, and MCL-1.  Furthermore, silencing of mTOR expression using mTOR-specific short interfering RNA decreased phosphorylation of mTOR signaling proteins and induced cell cycle arrest and apoptosis.  Silencing of eukaryotic initiation factor (eIF4E), a downstream effector of mTOR, recapitulated these results.  We also assessed mTOR signaling in MCL tumors using immunohistochem. methods and a tissue microarray: 10 of 30 (33%) expressed Ser473p-AKT, 13 of 21 (62%) Ser2448p-mTOR, 22 of 22 (100%) p-p70S6K, and 5 of 20 (25%) p-ribosomal protein S6.  Total eIF4E binding protein 1 and eukaryotic initiation factor 4E were expressed in 13 of 14 (93%) and 16 of 29 (55%) MCL tumors, resp.  These findings suggest that the mTOR signaling pathway is activated and may contribute to cell cycle progression and tumor cell survival in MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz8nXkoZHe97Vg90H21EOLACvtfcHk0liqcEr8rpOXaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvV2nsw%253D%253D&md5=97b2c4a9fa1003de6aaec34d2704db55</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2006.051078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2006.051078%26sid%3Dliteratum%253Aachs%26aulast%3DPeponi%26aufirst%3DE.%26aulast%3DDrakos%26aufirst%3DE.%26aulast%3DReyes%26aufirst%3DG.%26aulast%3DLeventaki%26aufirst%3DV.%26aulast%3DRassidakis%26aufirst%3DG.%2BZ.%26aulast%3DMedeiros%26aufirst%3DL.%2BJ.%26atitle%3DActivation%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520signaling%2520promotes%2520cell%2520cycle%2520progression%2520and%2520protects%2520cells%2520from%2520apoptosis%2520in%2520mantle%2520cell%2520lymphoma%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2006%26volume%3D169%26spage%3D2171%26epage%3D2180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bookstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenstein, A.</span><span> </span><span class="NLM_article-title">Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5027</span><span class="NLM_x">–</span> <span class="NLM_lpage">5034</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5027-5034&author=Y.+Shiauthor=J.+Geraauthor=L.+Huauthor=J.+H.+Hsuauthor=R.+Booksteinauthor=W.+Liauthor=A.+Lichtenstein&title=Enhanced+sensitivity+of+multiple+myeloma+cells+containing+PTEN+mutations+to+CCI-779"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGera%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHsu%26aufirst%3DJ.%2BH.%26aulast%3DBookstein%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLichtenstein%26aufirst%3DA.%26atitle%3DEnhanced%2520sensitivity%2520of%2520multiple%2520myeloma%2520cells%2520containing%2520PTEN%2520mutations%2520to%2520CCI-779%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5027%26epage%3D5034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group">Zeng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarbassov dos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samudio, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munsell, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellen Jackson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span> </span><span class="NLM_article-title">Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3509</span><span class="NLM_x">–</span> <span class="NLM_lpage">3512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=3509-3512&author=Z.+Zengauthor=D.+Sarbassov+dosauthor=I.+J.+Samudioauthor=K.+W.+Yeeauthor=M.+F.+Munsellauthor=C.+Ellen+Jacksonauthor=F.+J.+Gilesauthor=D.+M.+Sabatiniauthor=M.+Andreeffauthor=M.+Konopleva&title=Rapamycin+derivatives+reduce+mTORC2+signaling+and+inhibit+AKT+activation+in+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DSarbassov%2Bdos%26aufirst%3DD.%26aulast%3DSamudio%26aufirst%3DI.%2BJ.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DMunsell%26aufirst%3DM.%2BF.%26aulast%3DEllen%2BJackson%26aufirst%3DC.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKonopleva%26aufirst%3DM.%26atitle%3DRapamycin%2520derivatives%2520reduce%2520mTORC2%2520signaling%2520and%2520inhibit%2520AKT%2520activation%2520in%2520AML%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D3509%26epage%3D3512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group">Feldman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curcio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedrosian, C. L.</span><span> </span><span class="NLM_article-title">A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6631</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2005.09.133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16170170" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=6631&author=E.+Feldmanauthor=F.+Gilesauthor=G.+Robozauthor=K.+Yeeauthor=T.+Curcioauthor=V.+M.+Riveraauthor=M.+Albitarauthor=R.+Laliberteauthor=C.+L.+Bedrosian&title=A+phase+2+clinical+trial+of+AP23573%2C+an+mTOR+inhibitor%2C+in+patients+with+relapsed+or+refractory+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.133%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DRoboz%26aufirst%3DG.%26aulast%3DYee%26aufirst%3DK.%26aulast%3DCurcio%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DBedrosian%26aufirst%3DC.%2BL.%26atitle%3DA%2520phase%25202%2520clinical%2520trial%2520of%2520AP23573%252C%2520an%2520mTOR%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520hematologic%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D6631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group">Goss, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanceron, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, S. J.</span><span> </span><span class="NLM_article-title">Generating rapamycin analogues by directed biosynthesis: starter acid substrate specificity of mono-substituted cyclohexane carboxylic acids</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">4071</span><span class="NLM_x">–</span> <span class="NLM_lpage">4073</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=4071-4073&author=R.+J.+Gossauthor=S.+E.+Lanceronauthor=N.+J.+Wiseauthor=S.+J.+Moss&title=Generating+rapamycin+analogues+by+directed+biosynthesis%3A+starter+acid+substrate+specificity+of+mono-substituted+cyclohexane+carboxylic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DR.%2BJ.%26aulast%3DLanceron%26aufirst%3DS.%2BE.%26aulast%3DWise%26aufirst%3DN.%2BJ.%26aulast%3DMoss%26aufirst%3DS.%2BJ.%26atitle%3DGenerating%2520rapamycin%2520analogues%2520by%2520directed%2520biosynthesis%253A%2520starter%2520acid%2520substrate%2520specificity%2520of%2520mono-substituted%2520cyclohexane%2520carboxylic%2520acids%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2006%26volume%3D4%26spage%3D4071%26epage%3D4073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group">Graziani, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritacco, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summers, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabriskie, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernan, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, G. T.</span><span> </span><span class="NLM_article-title">Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol034591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=2385-2388&author=E.+I.+Grazianiauthor=F.+V.+Ritaccoauthor=M.+Y.+Summersauthor=T.+M.+Zabriskieauthor=K.+Yuauthor=V.+S.+Bernanauthor=M.+Greensteinauthor=G.+T.+Carter&title=Novel+sulfur-containing+rapamycin+analogs+prepared+by+precursor-directed+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fol034591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol034591k%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26aulast%3DRitacco%26aufirst%3DF.%2BV.%26aulast%3DSummers%26aufirst%3DM.%2BY.%26aulast%3DZabriskie%26aufirst%3DT.%2BM.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DBernan%26aufirst%3DV.%2BS.%26aulast%3DGreenstein%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DNovel%2520sulfur-containing%2520rapamycin%2520analogs%2520prepared%2520by%2520precursor-directed%2520biosynthesis%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D2385%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group">Gregory, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petkovic, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lill, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaisser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leadlay, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheridan, R. M.</span><span> </span><span class="NLM_article-title">Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4757</span><span class="NLM_x">–</span> <span class="NLM_lpage">4760</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=4757-4760&author=M.+A.+Gregoryauthor=H.+Petkovicauthor=R.+E.+Lillauthor=S.+J.+Mossauthor=B.+Wilkinsonauthor=S.+Gaisserauthor=P.+F.+Leadlayauthor=R.+M.+Sheridan&title=Mutasynthesis+of+rapamycin+analogues+through+the+manipulation+of+a+gene+governing+starter+unit+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DM.%2BA.%26aulast%3DPetkovic%26aufirst%3DH.%26aulast%3DLill%26aufirst%3DR.%2BE.%26aulast%3DMoss%26aufirst%3DS.%2BJ.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DGaisser%26aufirst%3DS.%26aulast%3DLeadlay%26aufirst%3DP.%2BF.%26aulast%3DSheridan%26aufirst%3DR.%2BM.%26atitle%3DMutasynthesis%2520of%2520rapamycin%2520analogues%2520through%2520the%2520manipulation%2520of%2520a%2520gene%2520governing%2520starter%2520unit%2520biosynthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2005%26volume%3D44%26spage%3D4757%26epage%3D4760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group">Khaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leadlay, P. F.</span><span> </span><span class="NLM_article-title">Mutational biosynthesis of novel rapamycins by a strain of <i>Streptomyces hygroscopicus</i> NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase</span> <span class="citation_source-journal">J. Bacteriol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">814</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9473033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVGls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=1998&pages=809-814&author=L.+E.+Khawauthor=G.+A.+Bohmauthor=S.+Metcalfeauthor=J.+Stauntonauthor=P.+F.+Leadlay&title=Mutational+biosynthesis+of+novel+rapamycins+by+a+strain+of+Streptomyces+hygroscopicus+NRRL+5491+disrupted+in+rapL%2C+encoding+a+putative+lysine+cyclodeaminase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase</span></div><div class="casAuthors">Khaw, Lake Ee; Bohm, Gunter A.; Metcalfe, Su; Staunton, James; Leadlay, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809-814</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Gene rapL lies within the region of the Streptomyces hygroscopicus chromosome which contains the biosynthetic gene cluster for the immunosuppressant rapamycin.  Introduction of a frameshift mutation into rapL by ΦC31 phage-mediated gene replacement gave rise to a mutant which did not produce significant amts. of rapamycin.  Growth of this rapL mutant on media contg. added L-pipecolate restored wild-type levels of rapamycin prodn., consistent with a proposal that rapL encodes a specific L-lysine cyclodeaminase important for the prodn. of the L-pipecolate precursor.  In the presence of added proline derivs., rapL mutants synthesized novel rapamycin analogs, indicating a relaxed substrate specificity for the enzyme catalyzing pipecolate incorporation into the macrocycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXMq_O_SW6i7Vg90H21EOLACvtfcHk0lifeM7xTRrn3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVGls7k%253D&md5=d7ed92c4fbc5ba34d1411f7af95a5b5d</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhaw%26aufirst%3DL.%2BE.%26aulast%3DBohm%26aufirst%3DG.%2BA.%26aulast%3DMetcalfe%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DLeadlay%26aufirst%3DP.%2BF.%26atitle%3DMutational%2520biosynthesis%2520of%2520novel%2520rapamycins%2520by%2520a%2520strain%2520of%2520Streptomyces%2520hygroscopicus%2520NRRL%25205491%2520disrupted%2520in%2520rapL%252C%2520encoding%2520a%2520putative%2520lysine%2520cyclodeaminase%26jtitle%3DJ.%2520Bacteriol.%26date%3D1998%26volume%3D180%26spage%3D809%26epage%3D814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group">Verheijen, J.; Yu, K.; Zask, A.; John, E. M.</span><span> </span><span class="NLM_article-title">mTOR Inhibitors in Oncology</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_publisher-name">Academic Press</span>: San Diego, CA,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">43</span>, Chapter 12, pp  <span class="NLM_fpage">189</span>− <span class="NLM_lpage">202</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=189-202&author=J.+Verheijen&author=K.+Yu&author=A.+Zask&author=E.+M.+John&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVerheijen%26aufirst%3DJ.%26atitle%3DmTOR%2520Inhibitors%2520in%2520Oncology%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26pub%3DAcademic%2520Press%26date%3D2008%26volume%3D43%26spage%3D189%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group">Garlich, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kundra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durden, D. L.</span><span> </span><span class="NLM_article-title">A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=206-215&author=J.+R.+Garlichauthor=P.+Deauthor=N.+Deyauthor=J.+D.+Suauthor=X.+Pengauthor=A.+Millerauthor=R.+Muraliauthor=Y.+Luauthor=G.+B.+Millsauthor=V.+Kundraauthor=H.+K.+Shuauthor=Q.+Pengauthor=D.+L.+Durden&title=A+vascular+targeted+pan+phosphoinositide+3-kinase+inhibitor+prodrug%2C+SF1126%2C+with+antitumor+and+antiangiogenic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DDe%26aufirst%3DP.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DSu%26aufirst%3DJ.%2BD.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DKundra%26aufirst%3DV.%26aulast%3DShu%26aufirst%3DH.%2BK.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DA%2520vascular%2520targeted%2520pan%2520phosphoinositide%25203-kinase%2520inhibitor%2520prodrug%252C%2520SF1126%252C%2520with%2520antitumor%2520and%2520antiangiogenic%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D206%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brachmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoemaker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1851</span><span class="NLM_x">–</span> <span class="NLM_lpage">1863</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-08-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18606717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1851-1863&author=S.+M.+Mairaauthor=F.+Staufferauthor=J.+Brueggenauthor=P.+Furetauthor=C.+Schnellauthor=C.+Fritschauthor=S.+Brachmannauthor=P.+Cheneauthor=A.+De+Poverauthor=K.+Schoemakerauthor=D.+Fabbroauthor=D.+Gabrielauthor=M.+Simonenauthor=L.+Murphyauthor=P.+Finanauthor=W.+Sellersauthor=C.+Garcia-Echeverria&title=Identification+and+characterization+of+NVP-BEZ235%2C+a+new+orally+available+dual+phosphatidylinositol+3-kinase%2Fmammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span></div><div class="casAuthors">Maira, Sauveur-Michel; Stauffer, Frederic; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; Brachmann, Saskia; Chene, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; Murphy, Leon; Finan, Peter; Sellers, William; Garcia-Echeverria, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention.  NVP-BEZ235 is an imidazo[4,5-c]quinoline deriv. that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.  In cellular settings using human tumor cell lines, this mol. is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest.  The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer.  Thus, the compd. was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.  Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compd. concn. and PI3K/Akt pathway inhibition.  Collectively, the preclin. data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties.  NVP-BEZ235 is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyO784qv52vrVg90H21EOLACvtfcHk0ljY2_TGiS3BOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D&md5=5b1979e134dd12065198d86dbc11ce15</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0017%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DSchoemaker%26aufirst%3DK.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DD.%26aulast%3DSimonen%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BEZ235%252C%2520a%2520new%2520orally%2520available%2520dual%2520phosphatidylinositol%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520with%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1851%26epage%3D1863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group">Tomillero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moral, M. A.</span><span> </span><span class="NLM_article-title">Gateways to clinical trials</span> <span class="citation_source-journal">Methods Find. Exp. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18985183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhvV2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=543-588&author=A.+Tomilleroauthor=M.+A.+Moral&title=Gateways+to+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Gateways to clinical trials</span></div><div class="casAuthors">Tomillero A; Moral M A</div><div class="citationInfo"><span class="NLM_cas:title">Methods and findings in experimental and clinical pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">543-88</span>
        ISSN:<span class="NLM_cas:issn">0379-0355</span>.
    </div><div class="casAbstract">Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses.  The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Perillyl alcohol, Perphenazine 4-aminobutyrate, PeviPRO/breast cancer, PF-03814735, PHA-739358, Pimecrolimus, Plitidepsin, Posaconazole, Prasterone, Prasugrel, Pregabalin, Prucalopride, PRX-08066; rAAV2-TNFR:Fc, Ranelic acid distrontium salt, Ranibizumab, rCD154-CLL, Retapamulin, RTS,S/SBAS2, rV-PSA-TRICOM/rF-PSA-TRICOM; SG-2000, Sinecatechins, Sirolimus-eluting stent, Sorafenib, SP-1640, Strontium malonate, Succinobucol, Sunitinib malate; Taxus, Teduglutide, Telavancin hydrochloride, Telbivudine, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ustekinumab; V-5 Immunitor, Voriconazole, Vorinostat; Xience V, XL-184, XL-647, XL-765; Y-39983, Zibotentan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkoCAaeXJeddts4TFFB11gfW6udTcc2ea_dff-uY65qLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhvV2kug%253D%253D&md5=66e9a6225768b0c9891162278400e8d7</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTomillero%26aufirst%3DA.%26aulast%3DMoral%26aufirst%3DM.%2BA.%26atitle%3DGateways%2520to%2520clinical%2520trials%26jtitle%3DMethods%2520Find.%2520Exp.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D30%26spage%3D543%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group">McCloskey, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMullin, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, A. E.</span><span> </span><span class="NLM_article-title">The therapeutic potential of the proteasome in leukaemia</span> <span class="citation_source-journal">Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fhon.848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18324639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1ygs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=73-81&author=S.+M.+McCloskeyauthor=M.+F.+McMullinauthor=B.+Walkerauthor=A.+E.+Irvine&title=The+therapeutic+potential+of+the+proteasome+in+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of the proteasome in leukemia</span></div><div class="casAuthors">McCloskey, Scott Marshall; McMullin, Mary Frances; Walker, Brian; Irvine, Alexandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Hematological Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-81</span>CODEN:
                <span class="NLM_cas:coden">HAONDL</span>;
        ISSN:<span class="NLM_cas:issn">0278-0232</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized.  Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms.  The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients.  Malignant cells are more sensitive to proteasome inhibition than normal hematopoietic cells.  Proteasome inhibition enhances many conventional therapies and its role in leukemia is promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS02KkqqnMqrVg90H21EOLACvtfcHk0lg24i2e4gS95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1ygs74%253D&md5=ac7a2b5fe7c0b91cfc7043ec8c20e08e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fhon.848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhon.848%26sid%3Dliteratum%253Aachs%26aulast%3DMcCloskey%26aufirst%3DS.%2BM.%26aulast%3DMcMullin%26aufirst%3DM.%2BF.%26aulast%3DWalker%26aufirst%3DB.%26aulast%3DIrvine%26aufirst%3DA.%2BE.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520the%2520proteasome%2520in%2520leukaemia%26jtitle%3DHematol.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D73%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K.</span><span> </span><span class="NLM_article-title">Proteasome inhibition in hematologic malignancies</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F07853890410030877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15224657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=304-314&author=P.+G.+Richardsonauthor=T.+Hideshimaauthor=C.+Mitsiadesauthor=K.+Anderson&title=Proteasome+inhibition+in+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition in hematologic malignancies</span></div><div class="casAuthors">Richardson, Paul; Hideshima, Teru; Mitsiades, Constantine; Anderson, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (Basingstoke, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Hematol. malignancies, including multiple myeloma (MM), will account for more than 100,000 new cases of cancer and over 57,000 deaths in the United States in 2003.  Treatment of MM is a serious challenge, because despite a variety of available therapies, median survival is short.  A new therapeutic area focuses on inhibiting the activity of the proteasome, a 26S protease complex involved in cell cycle regulation, cell adhesion, inflammation, and protein turnover.  The novel proteasome inhibitor, bortezomib (Velcade), was recently approved for use in patients with refractory and relapsed MM and to date is the only proteasome inhibitor to have entered clin. trials.  Bortezomib has demonstrated activity with manageable toxicity in a variety of hematol. malignancies in addn. to MM, including leukemia and non-Hodgkin's lymphoma.  This article reviews clin. information on bortezomib in hematol. malignancies both as monotherapy and in combination with dexamethasone.  Preliminary reports of bortezomib in combination with Doxil (pegylated liposomal doxorubicin), melphalan, and thalidomide are discussed, and current trials are described.  Available data suggest that bortezomib will be useful in the treatment of a variety of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoASaZlt6m5CLVg90H21EOLACvtfcHk0lg24i2e4gS95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKmtbg%253D&md5=40c9d98b19cf9c829278388481c3b46a</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1080%2F07853890410030877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890410030877%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DProteasome%2520inhibition%2520in%2520hematologic%2520malignancies%26jtitle%3DAnn.%2520Med.%26date%3D2004%26volume%3D36%26spage%3D304%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group">Vink, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. J.</span><span> </span><span class="NLM_article-title">Proteasome inhibition as novel treatment strategy in leukaemia</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1111%2Fj.1365-2141.2006.06170.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16787504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XosFCju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2006&pages=253-262&author=J.+Vinkauthor=J.+Cloosauthor=G.+J.+Kaspers&title=Proteasome+inhibition+as+novel+treatment+strategy+in+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition as novel treatment strategy in leukemia</span></div><div class="casAuthors">Vink, J.; Cloos, J.; Kaspers, G. J. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Following its success in multiple myeloma (MM), proteasome inhibition has become a topic of interest as novel treatment strategy of cancer.  By simultaneously affecting multiple pathways in the cancer cell, such as deregulation of the programmed degrdn. of many cellular proteins, proteasome inhibition causes rapid apoptosis of these cells.  Both in rapidly proliferating leukemic cell lines and in primary leukemic cells isolated from patients, proteasome inhibition results in antileukemic activity.  The normal counterparts of these cells are much more resistant to proteasome inhibitors (PI), thereby resulting in a favorable therapeutic index.  Importantly, while leukemic stem cells are sensitive to proteasome inhibition, normal hematopoietic stem cells are still viable after drug exposure.  Nowadays, many PIs are being identified; bortezomib is the most well known since obtaining Food and Drug Administration approval for clin. use in MM.  This review summarizes the biol. and clin. aspects of proteasome inhibition and discusses the potential role of these inhibitors in the treatment of leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobY9NbVguu5rVg90H21EOLACvtfcHk0lg24i2e4gS95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosFCju7g%253D&md5=91044b824ce9ce6fba2d6874dcd2437c</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2006.06170.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2006.06170.x%26sid%3Dliteratum%253Aachs%26aulast%3DVink%26aufirst%3DJ.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26atitle%3DProteasome%2520inhibition%2520as%2520novel%2520treatment%2520strategy%2520in%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2006%26volume%3D134%26spage%3D253%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruickshank, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klunder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plamondon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. L.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FS0960-894X%2898%2900029-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9871680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1cXhsFKjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=333-338&author=J.+Adamsauthor=M.+Behnkeauthor=S.+Chenauthor=A.+A.+Cruickshankauthor=L.+R.+Dickauthor=L.+Grenierauthor=J.+M.+Klunderauthor=Y.+T.+Maauthor=L.+Plamondonauthor=R.+L.+Stein&title=Potent+and+selective+inhibitors+of+the+proteasome%3A+dipeptidyl+boronic+acids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids</span></div><div class="casAuthors">Adams, Julian; Behnke, Mark; Chen, Shaowu; Cruickshank, Amy A.; Dick, Lawrence R.; Grenier, Louis; Klunder, Jancie M.; Ma, Yu-Ting; Plamondon, Louis; Stein, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-338</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Potent and selective dipeptidyl boronic acid proteasome inhibitors are described.  As compared to peptidyl aldehyde compds., boronic acids in this series display dramatically enhanced potency.  Compds. (I; R = Ph, 1-naphthyl), in particular I (R = Ph), are promising new therapeutics for treatment of cancer and inflammatory diseases.  I (R = Ph) and I (R = 1-naphthyl) in vitro inhibited 20S proteasome with Ki of 0.62 and 0.18, resp., whereas I (R = Ph) showed Ki of 2,300, 630, 320, and 13,000 against common serine proteases such as human leukocyte elastase, human cathepsin G, human chymotrypsin, and thrombin, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLVVXMKjfPbVg90H21EOLACvtfcHk0lg24i2e4gS95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsFKjsr8%253D&md5=e9287f4977f5ab655fedd1fd702aa456</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900029-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900029-8%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DBehnke%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCruickshank%26aufirst%3DA.%2BA.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DKlunder%26aufirst%3DJ.%2BM.%26aulast%3DMa%26aufirst%3DY.%2BT.%26aulast%3DPlamondon%26aufirst%3DL.%26aulast%3DStein%26aufirst%3DR.%2BL.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520proteasome%253A%2520dipeptidyl%2520boronic%2520acids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D333%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernareggi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassara, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arasmo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferretti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Munari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allievi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strepponi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1068</span><span class="NLM_x">–</span> <span class="NLM_lpage">1072</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7010589" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1068-1072&author=B.+D.+Dorseyauthor=M.+Iqbalauthor=S.+Chatterjeeauthor=E.+Mentaauthor=R.+Bernardiniauthor=A.+Bernareggiauthor=P.+G.+Cassaraauthor=G.+D%E2%80%99Arasmoauthor=E.+Ferrettiauthor=S.+De+Munariauthor=A.+Olivaauthor=G.+Pezzoniauthor=C.+Allieviauthor=I.+Strepponiauthor=B.+Ruggeriauthor=M.+A.+Atorauthor=M.+Williamsauthor=J.+P.+Mallamo&title=Discovery+of+a+potent%2C+selective%2C+and+orally+active+proteasome+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Dorsey, Bruce D.; Iqbal, Mohamed; Chatterjee, Sankar; Menta, Ernesto; Bernardini, Raffaella; Bernareggi, Alberto; Cassara, Paolo G.; D'Arasmo, Germano; Ferretti, Edmondo; De Munari, Sergio; Oliva, Ambrogio; Pezzoni, Gabriella; Allievi, Cecilia; Strepponi, Ivan; Ruggeri, Bruce; Ator, Mark A.; Williams, Michael; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1068-1072</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome pathway plays a central role in regulation of the prodn. and destruction of cellular proteins.  These pathways mediate proliferation and cell survival, particularly in malignant cells.  The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy.  Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclin. development, [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid 20 (CEP-18770), is disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkNeu3d81vbVg90H21EOLACvtfcHk0lhie2kElhUKTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D&md5=cfc22ee09c2a4f4d9c695010187c4693</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fjm7010589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010589%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DMenta%26aufirst%3DE.%26aulast%3DBernardini%26aufirst%3DR.%26aulast%3DBernareggi%26aufirst%3DA.%26aulast%3DCassara%26aufirst%3DP.%2BG.%26aulast%3DD%25E2%2580%2599Arasmo%26aufirst%3DG.%26aulast%3DFerretti%26aufirst%3DE.%26aulast%3DDe%2BMunari%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DA.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DAllievi%26aufirst%3DC.%26aulast%3DStrepponi%26aufirst%3DI.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520proteasome%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1068%26epage%3D1072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group">Macherla, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manam, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deyanat-Yazdi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenical, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, B. C. M.</span><span> </span><span class="NLM_article-title">Structure activity relationship studies of Salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">3684</span><span class="NLM_x">–</span> <span class="NLM_lpage">3687</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm048995%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=3684-3687&author=V.+R.+Macherlaauthor=S.+S.+Mitchellauthor=R.+R.+Manamauthor=K.+A.+Reedauthor=T.-H.+Chaoauthor=B.+Nicholsonauthor=G.+Deyanat-Yazdiauthor=B.+Maiauthor=P.+R.+Jensenauthor=W.+F.+Fenicalauthor=S.+T.+C.+Neuteboomauthor=K.+S.+Lamauthor=M.+A.+Palladinoauthor=B.+C.+M.+Potts&title=Structure+activity+relationship+studies+of+Salinosporamide+A+%28NPI-0052%29%2C+a+novel+marine+derived+proteasome+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fjm048995%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm048995%252B%26sid%3Dliteratum%253Aachs%26aulast%3DMacherla%26aufirst%3DV.%2BR.%26aulast%3DMitchell%26aufirst%3DS.%2BS.%26aulast%3DManam%26aufirst%3DR.%2BR.%26aulast%3DReed%26aufirst%3DK.%2BA.%26aulast%3DChao%26aufirst%3DT.-H.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DDeyanat-Yazdi%26aufirst%3DG.%26aulast%3DMai%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DP.%2BR.%26aulast%3DFenical%26aufirst%3DW.%2BF.%26aulast%3DNeuteboom%26aufirst%3DS.%2BT.%2BC.%26aulast%3DLam%26aufirst%3DK.%2BS.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DPotts%26aufirst%3DB.%2BC.%2BM.%26atitle%3DStructure%2520activity%2520relationship%2520studies%2520of%2520Salinosporamide%2520A%2520%2528NPI-0052%2529%252C%2520a%2520novel%2520marine%2520derived%2520proteasome%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D3684%26epage%3D3687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallone, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineaux, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span> </span><span class="NLM_article-title">Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6383</span><span class="NLM_x">–</span> <span class="NLM_lpage">6391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F0008-5472.CAN-06-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17616698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6383-6391&author=S.+D.+Demoauthor=C.+J.+Kirkauthor=M.+A.+Aujayauthor=T.+J.+Buchholzauthor=M.+Dajeeauthor=M.+N.+Hoauthor=J.+Jiangauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=F.+Parlatiauthor=K.+D.+Shenkauthor=M.+S.+Smythauthor=C.+M.+Sunauthor=M.+K.+Valloneauthor=T.+M.+Wooauthor=C.+J.+Molineauxauthor=M.+K.+Bennett&title=Antitumor+activity+of+PR-171%2C+a+novel+irreversible+inhibitor+of+the+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span></div><div class="casAuthors">Demo, Susan D.; Kirk, Christopher J.; Aujay, Monette A.; Buchholz, Tonia J.; Dajee, Maya; Ho, Mark N.; Jiang, Jing; Laidig, Guy J.; Lewis, Evan R.; Parlati, Francesco; Shenk, Kevin D.; Smyth, Mark S.; Sun, Congcong M.; Vallone, Marcy K.; Woo, Tina M.; Molineaux, Christopher J.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6383-6391</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma.  However, significant toxicities have restricted the intensity of bortezomib dosing.  Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clin. development.  In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome.  In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both mols.  Hematol. tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments.  Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.  Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examd. with the exception of the brain.  PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues.  In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent.  The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clin. dosing schedule.  These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clin. testing of PR-171 in the treatment of hematol. malignancies using dose-intensive schedules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzP-VJ4DNRbVg90H21EOLACvtfcHk0lhie2kElhUKTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D&md5=301bcab3e60cbfd518b2f88fb479fa79</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4086%26sid%3Dliteratum%253Aachs%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DVallone%26aufirst%3DM.%2BK.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DMolineaux%26aufirst%3DC.%2BJ.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520activity%2520of%2520PR-171%252C%2520a%2520novel%2520irreversible%2520inhibitor%2520of%2520the%2520proteasome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6383%26epage%3D6391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group">Adams, J.</span><span> </span><span class="NLM_article-title">The proteasome: a suitable antineoplastic target</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15122206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=349-360&author=J.+Adams&title=The+proteasome%3A+a+suitable+antineoplastic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: a suitable antineoplastic target</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-360</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The proteasome is an abundant multi-enzyme complex that provides the main pathway for degrdn. of intracellular proteins in eukaryotic cells.  As such, it controls the levels of proteins that are important for cell-cycle progression and apoptosis in normal and malignant cells; for example, cyclins, caspases, BCL2, and nuclear factor of κB.  A proteasome inhibitor - bortezomib - was developed that has shown efficacy as an anticancer agent in the clinic.  How can targeting such a universal, broadly active cellular component provide the selectivity and specificity that are required for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdI0j9dL6efrVg90H21EOLACvtfcHk0lhgbl-NnVD7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D&md5=eeb2566e017e4aa1223b7bc8adb3b419</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fnrc1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1361%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520proteasome%253A%2520a%2520suitable%2520antineoplastic%2520target%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D349%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and structure−activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of α-amino acid boronates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4192</span><span class="NLM_x">–</span> <span class="NLM_lpage">4199</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9005093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4192-4199&author=Y.+Zhuauthor=X.+Zhaoauthor=X.+Zhuauthor=G.+Wuauthor=Y.+Liauthor=Y.+Maauthor=Y.+Yuanauthor=J.+Yangauthor=Y.+Huauthor=L.+Aiauthor=Q.+Gao&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+structure%E2%88%92activity+relationship+%28SAR%29+discussion+of+dipeptidyl+boronate+proteasome+inhibitors%2C+part+I%3A+comprehensive+understanding+of+the+SAR+of+%CE%B1-amino+acid+boronates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fjm9005093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9005093%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520structure%25E2%2588%2592activity%2520relationship%2520%2528SAR%2529%2520discussion%2520of%2520dipeptidyl%2520boronate%2520proteasome%2520inhibitors%252C%2520part%2520I%253A%2520comprehensive%2520understanding%2520of%2520the%2520SAR%2520of%2520%25CE%25B1-amino%2520acid%2520boronates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4192%26epage%3D4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group">Adams, J.</span><span> </span><span class="NLM_article-title">Development of the proteasome inhibitor PS-341</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=9-16&author=J.+Adams&title=Development+of+the+proteasome+inhibitor+PS-341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520the%2520proteasome%2520inhibitor%2520PS-341%26jtitle%3DOncologist%26date%3D2002%26volume%3D7%26spage%3D9%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, E.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18496498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1czjt1elsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=303-310&author=G.+Martinelliauthor=I.+Iacobucciauthor=S.+Paoliniauthor=E.+Ottaviani&title=Farnesyltransferase+inhibition+in+hematologic+malignancies%3A+the+clinical+experience+with+tipifarnib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib</span></div><div class="casAuthors">Martinelli Giovanni; Iacobucci Ilaria; Paolini Stefania; Ottaviani Emanuela</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-10</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">Increased understanding of the cellular mechanisms associated with various malignancies has allowed researchers to develop agents that selectively target the cellular proteins and pathways implicated in the pathogenesis of malignancy.  Tipifarnib is a specific and potent farnesyltransferase inhibitor that demonstrates in vivo and in vitro activity against a variety of human cancers.  Although tipifarnib was initially thought to target the Ras protein, recent evidence suggests that the presence of ras mutations is not necessary for the antitumor effects of tipifarnib, and that tipifarnib may exert its effects downstream of Ras.  The oral administration and favorable toxicity profile of tipifarnib, combined with its activity in a variety of intracellular pathways that have been implicated in the pathogenesis of hematologic malignancies, make it an especially attractive agent for use in patients with acute myeloid leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia (CML), and multiple myeloma.  Because hematologic malignancies are likely driven by multiple genetic aberrations, the most effective treatment strategy will likely combine multiple agents with complementary mechanisms of action.  Thus, additional studies of combination regimens that incorporate tipifarnib with other antineoplastic agents are crucial.  Early results from studies combining tipifarnib with imatinib or etoposide in CML and AML have been promising and warrant further evaluation in larger clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeRshcOAsdIvtos8R3JUhXfW6udTcc2ebNCAcDMzGaarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjt1elsw%253D%253D&md5=c4450d3586652e9a2e94a5cad462d54d</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DPaolini%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DE.%26atitle%3DFarnesyltransferase%2520inhibition%2520in%2520hematologic%2520malignancies%253A%2520the%2520clinical%2520experience%2520with%2520tipifarnib%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2008%26volume%3D6%26spage%3D303%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group">Kupperman, E.; Berger, A.; Yu, L.; Tsu, C.; Frank, B.; Liu, J.; Blank, J.; Larry, D.; Paul, F.; Yueying, C.; Bannerman, B.; Fitzgerald, M.; Zhang, J.; Yu, J.; Hales, P.; Manfredi, M.; Bolen, J.; Rolfe, M.</span><span> </span><span class="NLM_article-title">Preclinical Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span>. In  <span class="citation_source-book">Proceedings of the Annual Meeting of the American Association of Cancer Research</span>; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Supplement, Abstract 5636.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+Kupperman&author=A.+Berger&author=L.+Yu&author=C.+Tsu&author=B.+Frank&author=J.+Liu&author=J.+Blank&author=D.+Larry&author=F.+Paul&author=C.+Yueying&author=B.+Bannerman&author=M.+Fitzgerald&author=J.+Zhang&author=J.+Yu&author=P.+Hales&author=M.+Manfredi&author=J.+Bolen&author=M.+Rolfe&title=Proceedings+of+the+Annual+Meeting+of+the+American+Association+of+Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26atitle%3DPreclinical%2520Evaluation%2520of%2520the%2520Orally%2520Active%2520Proteasome%2520Inhibitor%2520MLN9708%2520in%2520Preclinical%2520Models%2520of%2520Human%2520Cancer%26btitle%3DProceedings%2520of%2520the%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520of%2520Cancer%2520Research%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group">Zhou, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muchamuel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shwonek, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span> </span><span class="NLM_article-title">Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801329v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3028-3038&author=H.-J.+Zhouauthor=M.+A.+Aujayauthor=M.+K.+Bennettauthor=M.+Dajeeauthor=S.+D.+Demoauthor=Y.+Fangauthor=M.+N.+Hoauthor=J.+Jiangauthor=C.+J.+Kirkauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=Y.+Luauthor=T.+Muchamuelauthor=F.+Parlatiauthor=E.+Ringauthor=K.+D.+Shenkauthor=J.+Shieldsauthor=P.+J.+Shwonekauthor=T.+Stantonauthor=C.+M.+Sunauthor=C.+Sylvainauthor=T.+M.+Wooauthor=J.+Yang&title=Design+and+synthesis+of+an+orally+bioavailable+and+selective+peptide+epoxyketone+proteasome+inhibitor+%28PR-047%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)</span></div><div class="casAuthors">Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; Lewis, Evan R.; Lu, Yan; Muchamuel, Tony; Parlati, Francesco; Ring, Eileen; Shenk, Kevin D.; Shields, Jamie; Shwonek, Peter J.; Stanton, Timothy; Sun, Congcong M.; Sylvain, Catherine; Woo, Tina M.; Yang, Jinfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epoxypeptides such as I are prepd. as carfilzomib analogs and proteasome inhibitors for use as antitumor agents; the inhibition of human 20S proteasomes and of the growth of multidrug-resistant and nonresistant cancer cells by selected compds. and their stabilities in simulated gastric and intestinal fluids and in liver microsomes are detd.  I selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrated an abs. bioavailability of up to 39% in rodents and dogs.  I is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equiv. to i.v. administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models.  I is prepd. in eight steps (longest linear sequence) from Cbz-L-phenylalanine, Boc-O-methyl-L-serine, 2-methyl-5-thiazolecarboxylic acid, and isopropenylmagnesium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNBIBwb8w47Vg90H21EOLACvtfcHk0lgldzH5qQKPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D&md5=688c8d0942539bab2e50617d083bf89a</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm801329v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801329v%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.-J.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRing%26aufirst%3DE.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%2BJ.%26aulast%3DStanton%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520and%2520selective%2520peptide%2520epoxyketone%2520proteasome%2520inhibitor%2520%2528PR-047%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3028%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group">Peese, K.</span><span> </span><span class="NLM_article-title">Orally bioavailable proteasome inhibitors: preclinical development of PR-047</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">906</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=905-906&author=K.+Peese&title=Orally+bioavailable+proteasome+inhibitors%3A+preclinical+development+of+PR-047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeese%26aufirst%3DK.%26atitle%3DOrally%2520bioavailable%2520proteasome%2520inhibitors%253A%2520preclinical%2520development%2520of%2520PR-047%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D905%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, C. M.</span><span> </span><span class="NLM_article-title">Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2600</span><span class="NLM_x">–</span> <span class="NLM_lpage">2605</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070421s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2600-2605&author=K.+B.+Kimauthor=C.+M.+Crews&title=Chemical+genetics%3A+exploring+the+role+of+the+proteasome+in+cell+biology+using+natural+products+and+other+small+molecule+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fjm070421s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070421s%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DChemical%2520genetics%253A%2520exploring%2520the%2520role%2520of%2520the%2520proteasome%2520in%2520cell%2520biology%2520using%2520natural%2520products%2520and%2520other%2520small%2520molecule%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2600%26epage%3D2605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupnik, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConkey, D.</span><span> </span><span class="NLM_article-title">The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1836</span><span class="NLM_x">–</span> <span class="NLM_lpage">1843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-06-0066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16891470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1836-1843&author=S.+Ruizauthor=Y.+Krupnikauthor=M.+Keatingauthor=J.+Chandraauthor=M.+Palladinoauthor=D.+McConkey&title=The+proteasome+inhibitor+NPI-0052+is+a+more+effective+inducer+of+apoptosis+than+bortezomib+in+lymphocytes+from+patients+with+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia</span></div><div class="casAuthors">Ruiz, Stacey; Krupnik, Yelena; Keating, Michael; Chandra, Joya; Palladino, Michael; McConkey, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1836-1843</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Proteasome inhibitors are potent inducers of apoptosis in isolated lymphocytes from patients with chronic lymphocytic leukemia (CLL).  However, the reversible proteasome inhibitor bortezomib (PS-341; Velcade) did not display substantial antitumor activity in CLL patients.  Here, we compared the effects of bortezomib and a new irreversible proteasome inhibitor (NPI-0052) on 20S chymotryptic proteasome activity and apoptosis in isolated CLL cells in vitro.  Although their steady-state (3 h) IC50s as proteasome inhibitors were similar, NPI-0052 exerted its effects more rapidly than bortezomib, and drug washout expts. showed that short exposures to NPI-0052 resulted in sustained (≥24 h) 20S proteasome inhibition, whereas 20S activity recovered in cells exposed to even 10-fold higher concns. of bortezomib.  Thus, brief (15 min) pulses of NPI-0052 were sufficient to induce substantial apoptosis in CLL cells, whereas longer exposure times (≥8 h) were required for commitment to apoptosis in cells exposed to equiv. concns. of bortezomib.  Commitment to apoptosis seemed to be related to caspase-4 activation, in that cells exposed to bortezomib or NPI-0052 could be saved from death by addn. of a selective caspase-4 inhibitor up to 8 h after drug exposure.  Our results show that NPI-0052 is a more effective proapoptotic agent than bortezomib in isolated CLL cells and suggest that the chem. properties of NPI-0052 might also make it an effective therapeutic agent in CLL patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsejYcANSNgrVg90H21EOLACvtfcHk0lgldzH5qQKPJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksbk%253D&md5=c4522479c523151d6c6d44c197c67fd7</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0066%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DKrupnik%26aufirst%3DY.%26aulast%3DKeating%26aufirst%3DM.%26aulast%3DChandra%26aufirst%3DJ.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DMcConkey%26aufirst%3DD.%26atitle%3DThe%2520proteasome%2520inhibitor%2520NPI-0052%2520is%2520a%2520more%2520effective%2520inducer%2520of%2520apoptosis%2520than%2520bortezomib%2520in%2520lymphocytes%2520from%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1836%26epage%3D1843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group">Miller, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, J.</span><span> </span><span class="NLM_article-title">Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">4289</span><span class="NLM_x">–</span> <span class="NLM_lpage">4299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4289-4299&author=C.+P.+Millerauthor=S.+Rudraauthor=M.+J.+Keatingauthor=W.+G.+Wierdaauthor=M.+Palladinoauthor=J.+Chandra&title=Caspase-8+dependent+histone+acetylation+by+a+novel+proteasome+inhibitor%2C+NPI-0052%3A+a+mechanism+for+synergy+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DC.%2BP.%26aulast%3DRudra%26aufirst%3DS.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DChandra%26aufirst%3DJ.%26atitle%3DCaspase-8%2520dependent%2520histone%2520acetylation%2520by%2520a%2520novel%2520proteasome%2520inhibitor%252C%2520NPI-0052%253A%2520a%2520mechanism%2520for%2520synergy%2520in%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4289%26epage%3D4299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group">Dick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P. E.</span><span> </span><span class="NLM_article-title">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.drudis.2010.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=20116451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=243-249&author=L.+R.+Dickauthor=P.+E.+Fleming&title=Building+on+bortezomib%3A+second-generation+proteasome+inhibitors+as+anti-cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span></div><div class="casAuthors">Dick, Lawrence R.; Fleming, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inhibition of the proteasome (a highly abundant enzymic complex responsible for intracellular protein turnover) is an effective anti-cancer therapeutic approach, as demonstrated by the first-in-class agent bortezomib.  Various new proteasome inhibitors are now in development, including peptide boronic acid analogs MLN9708 and CEP-18770, peptide epoxyketones carfilzomib and PR-047, and NPI-0052, a β-lactone compd.  All are potent inhibitors of proteasome activity in vitro but show differences in enzyme binding kinetics, which might affect their pharmacol. and result in different efficacy and safety profiles.  Here, we review the second-generation proteasome inhibitors and assess the potential pharmacol. impact of their different chem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuklkNi02WRbVg90H21EOLACvtfcHk0lhVIfaRJxGTxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D&md5=6a6ceeb81601f467ea56debc9f607738</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DFleming%26aufirst%3DP.%2BE.%26atitle%3DBuilding%2520on%2520bortezomib%253A%2520second-generation%2520proteasome%2520inhibitors%2520as%2520anti-cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D243%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Clinical activity of tipifarnib in hematologic malignancies</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=381-392&author=E.+Jabbourauthor=H.+Kantarjianauthor=J.+Cortes&title=Clinical+activity+of+tipifarnib+in+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DClinical%2520activity%2520of%2520tipifarnib%2520in%2520hematologic%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D381%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=1995&pages=307-313&author=C.+L.+Sawyersauthor=J.+McLaughlinauthor=O.+N.+Witte&title=Genetic+requirement+for+Ras+in+the+transformation+of+fibroblasts+and+hematopoietic+cells+by+the+Bcr-Abl+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DMcLaughlin%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DGenetic%2520requirement%2520for%2520Ras%2520in%2520the%2520transformation%2520of%2520fibroblasts%2520and%2520hematopoietic%2520cells%2520by%2520the%2520Bcr-Abl%2520oncogene%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1995%26volume%3D181%26spage%3D307%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2187</span><span class="NLM_x">–</span> <span class="NLM_lpage">2195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F10428190412331272677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15512806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFGgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=2187-2195&author=E.+Jabbourauthor=H.+Kantarjianauthor=J.+Cortes&title=Clinical+activity+of+farnesyl+transferase+inhibitors+in+hematologic+malignancies%3A+possible+mechanisms+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action</span></div><div class="casAuthors">Jabbour, Elias; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2187-2195</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Farnesyl transferase inhibitors (FTIs) are a novel class of anti-cancer agents that competitively inhibit farnesyl protein transferase (FTase).  Initially developed to inhibit the prenylation necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras.  FTIs have been developed and tested across a wide range of human cancers.  At least 3 agents within this family have been investigated in hematol. malignancies.  These are tipifarnib (R115777, Zarnestra), lonafarnib (SCH66336, SarasarTM), both of which are orally administered, and BMS-214662, which is given i.v.  Preliminary results from clin. trials demonstrate enzyme target inhibition, a favorable toxicity profile and promising efficacy.  Ongoing studies will better det. their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6YPfzcgcuRrVg90H21EOLACvtfcHk0lhVIfaRJxGTxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFGgt7s%253D&md5=a88cf71dee56244c04321f42671221d5</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1080%2F10428190412331272677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190412331272677%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DClinical%2520activity%2520of%2520farnesyl%2520transferase%2520inhibitors%2520in%2520hematologic%2520malignancies%253A%2520possible%2520mechanisms%2520of%2520action%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2004%26volume%3D45%26spage%3D2187%26epage%3D2195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soignet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazina, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzuli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spriggs, D.</span><span> </span><span class="NLM_article-title">A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3894</span><span class="NLM_x">–</span> <span class="NLM_lpage">3903</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=11751480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XltV2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3894-3903&author=C.+D.+Brittenauthor=E.+K.+Rowinskyauthor=S.+Soignetauthor=A.+Patnaikauthor=S.+L.+Yaoauthor=P.+Deutschauthor=Y.+Leeauthor=R.+B.+Lobellauthor=K.+E.+Mazinaauthor=H.+McCreeryauthor=S.+Pezzuliauthor=D.+Spriggs&title=A+phase+I+and+pharmacological+study+of+the+farnesyl+protein+transferase+inhibitor+L-778%2C123+in+patients+with+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies</span></div><div class="casAuthors">Britten, Carolyn D.; Rowinsky, Eric K.; Soignet, Steven; Patnaik, Amita; Yao, Siu-Long; Deutsch, Paul; Lee, Yih; Lobell, Robert B.; Mazina, Kathryn E.; McCreery, Heather; Pezzuli, Sandy; Spriggs, David</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3894-3903</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This Phase I study was performed to assess the feasibility of administering L-778,123, a peptidomimetic farnesyl protein transferase (FPTase) inhibitor, as a continuous i.v. infusion for 7 days every 3 wk and to det. the recommended dose for subsequent disease-directed trials.  This study also sought to characterize the pharmacol. behavior of L-778,123 and to det. whether the desired biol. effect, inhibition of protein farnesylation, could be detected and assessed during treatment.  Patients with advanced solid malignancies were treated with L-778,123 as a continuous i.v. infusion for 7 days every 3 wk at doses ranging from 35 to 1120 mg/m2/day.  On the basis of preclin. studies, toxicity assessments included cardiac telemetry, electrocardiograms, and electroretinograms in addn. to more routine safety monitoring lab. tests.  Plasma sampling was performed to characterize the pharmacokinetics of L-778,123, and peripheral blood mononuclear cells (PBMCs) were sampled to detect and monitor the inhibitory effects of L-778,123 on the prenylation of HDJ2, a chaperone protein that undergoes farnesylation.  Twenty-five patients received 51 complete courses of L-778,123.  An unacceptably high incidence of dose-limiting toxicities, consisting of grade 4 thrombocytopenia, significant prolongation of the QTc interval, and profound fatigue, was obsd. at the 1120 mg/m2/day dose level.  At the next lower L-778,123 dose level, 560 mg/m2/day, seven new patients had no unacceptable toxicity.  Instead, myelosuppression was mild to moderate and QTc prolongation was negligible.  Pharmacokinetics were linear, and L-778,123 plasma concns. at steady-state (mean, 8.09 ± 3.11 μM at 560 mg/m2/day) exceeded IC50 values (range, 0.07-5.35 μM) required for growth inhibition and cytotoxicity in preclin. studies.  The systemic clearance of L-778,123 averaged 106.4 ± 45.6 mL/min/m2, and the terminal half-life of elimination was 2.8 ± 1.0 h.  L-778,123 inhibited HDJ2 prenylation for the duration of the drug infusion in a dose-dependent manner, but seemed to plateau above 560 mg/m2/day.  At the 560 mg/m2/day dose level, the mean percentage of HDJ2 protein in its unprenylated form increased from 1.41% ± 1.71% (pretreatment) to 28.76% ± 6.10% (day 4) and 30.86 ± 4.96 (day 8) and declined to 2.28% ± 2.11% one week after drug discontinuation (day 16).  L-778,123 administered as a continuous 7-day i.v. infusion for 7 days every 21 days is well tolerated at doses of 560 mg/m2/day and results in biol. relevant concns. and consistent inhibition of HDJ2 prenylation in PBMCs.  Although the relationship between drug-related inhibition of HDJ2 prenylation in PBMCs and both prenylation of relevant proteins and growth inhibition in tumor cells is unknown, serial analyses of HDJ2 prenylation provide a pharmacodynamic marker of protein prenylation that may be useful in optimizing the development of drugs targeting FPTase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvNQ9MDGkiAbVg90H21EOLACvtfcHk0lhVIfaRJxGTxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltV2qtA%253D%253D&md5=e598b14bc9b6b808e66a9caa42beb683</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DSoignet%26aufirst%3DS.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DDeutsch%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DMazina%26aufirst%3DK.%2BE.%26aulast%3DMcCreery%26aufirst%3DH.%26aulast%3DPezzuli%26aufirst%3DS.%26aulast%3DSpriggs%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacological%2520study%2520of%2520the%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520L-778%252C123%2520in%2520patients%2520with%2520solid%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3894%26epage%3D3903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penhallow, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusarchyk, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-7-cyano-2,3,4, 5-tetrahydro-1-(1<i>H</i>-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1<i>H</i>-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3587</span><span class="NLM_x">–</span> <span class="NLM_lpage">3595</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000248z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3587-3595&author=J.+T.+Huntauthor=C.+Z.+Dingauthor=R.+Batorskyauthor=M.+Bednarzauthor=R.+Bhideauthor=Y.+Choauthor=S.+Chongauthor=S.+Chaoauthor=J.+Gullo-Brownauthor=P.+Guoauthor=S.+H.+Kimauthor=F.+Y.+Leeauthor=K.+Leftherisauthor=A.+Millerauthor=T.+Mittauthor=M.+Patelauthor=B.+A.+Penhallowauthor=C.+Riccaauthor=W.+C.+Roseauthor=R.+Schmidtauthor=W.+A.+Slusarchykauthor=G.+Viteauthor=V.+Manne&title=Discovery+of+%28R%29-7-cyano-2%2C3%2C4%2C+5-tetrahydro-1-%281H-imidazol-4-ylmethyl%29-3-+%28phenylmethyl%29-4-%282-thienylsulfonyl%29-1H-1%2C4-benzodiazepine+%28BMS-214662%29%2C+a+farnesyltransferase+inhibitor+with+potent+preclinical+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fjm000248z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000248z%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%26aulast%3DBhide%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DChong%26aufirst%3DS.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMitt%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPenhallow%26aufirst%3DB.%2BA.%26aulast%3DRicca%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DSlusarchyk%26aufirst%3DW.%2BA.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DManne%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520%2528R%2529-7-cyano-2%252C3%252C4%252C%25205-tetrahydro-1-%25281H-imidazol-4-ylmethyl%2529-3-%2520%2528phenylmethyl%2529-4-%25282-thienylsulfonyl%2529-1H-1%252C4-benzodiazepine%2520%2528BMS-214662%2529%252C%2520a%2520farnesyltransferase%2520inhibitor%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3587%26epage%3D3595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group">Venet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span> </span><span class="NLM_article-title">Farnesyl protein transferase inhibitor ZARNESTRA R115777—history of a discovery</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1095</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F1568026033452050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12769710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=1095-1102&author=M.+Venetauthor=D.+Endauthor=P.+Angibaud&title=Farnesyl+protein+transferase+inhibitor+ZARNESTRA+R115777%E2%80%94history+of+a+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery</span></div><div class="casAuthors">Venet, Marc; End, David; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1095-1102</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  R115777 (R)-6-amino[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice.  Taking its roots into Janssen's ketoconazole and retinoic acid catabolism programs, our interest into Ras prenylation process led us stepwise to identify the key structural features of R115777.  Methodol., structure activity relationships, and pharmacol. will be presented.  R115777 is currently in phase III clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtyeCXKOTqLVg90H21EOLACvtfcHk0lig29fFQ1T0lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLo%253D&md5=c96fe763cddde79d030cec6a51c04fc7</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.2174%2F1568026033452050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026033452050%26sid%3Dliteratum%253Aachs%26aulast%3DVenet%26aufirst%3DM.%26aulast%3DEnd%26aufirst%3DD.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DFarnesyl%2520protein%2520transferase%2520inhibitor%2520ZARNESTRA%2520R115777%25E2%2580%2594history%2520of%2520a%2520discovery%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26spage%3D1095%26epage%3D1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group">Zujewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woestenborghs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrovsky, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakim, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gress, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussenblatt, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, K. H.</span><span> </span><span class="NLM_article-title">Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">941</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=10673536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1aku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=927-941&author=J.+Zujewskiauthor=I.+D.+Horakauthor=C.+J.+Bolauthor=R.+Woestenborghsauthor=C.+Bowdenauthor=D.+W.+Endauthor=V.+K.+Piotrovskyauthor=J.+Chiaoauthor=R.+T.+Bellyauthor=A.+Toddauthor=W.+C.+Koppauthor=D.+R.+Kohlerauthor=C.+Chowauthor=M.+Nooneauthor=F.+T.+Hakimauthor=G.+Larkinauthor=R.+E.+Gressauthor=R.+B.+Nussenblattauthor=A.+B.+Kremerauthor=K.+H.+Cowan&title=Phase+I+and+pharmacokinetic+study+of+farnesyl+protein+transferase+inhibitor+R115777+in+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer</span></div><div class="casAuthors">Zujewski, J.; Horak, I. D.; Bol, C. J.; Woestenborghs, R.; Bowden, C.; End, D. W.; Piotrovsky, V. K.; Chiao, J.; Belly, R. T.; Todd, A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F. T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.; Cowan, K. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">927-941</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To det. the max.-tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally bid for 5 days every 2 wk.  Patients and Methods: Twenty-seven patients with a median age of 58 yr received 85 cycles of R115777 using an intrapatient and interpatient dose escalation schema.  Drug was administered orally at escalating doses as a soln. (25 to 850 mg bid) or as pellet capsules (500 to 1300 mg bid).  Pharmacokinetics were assessed after the first dose and the last dose administered during cycle 1.  Results: Dose-limiting toxicity of grade 3 neuropathy was obsd. in one patient and grade 2 fatigue (decrease in two performance status levels) was seen in four of six patients treated with 1,300 mg bid.  The most frequent clin. grade 2 or 3 adverse events in any cycle included nausea, vomiting, headache, fatigue, anemia, and hypotension.  Myelosuppression was mild and infrequent.  Peak plasma concns. of R115777 were achieved within 0.5 to 4 h after oral drug administration.  The elimination of R115777 from plasma was biphasic, with sequential half-lives of about 5 h and 16 h.  There was little drug accumulation after bid dosing, and steady-state concns. were achieved within 2 to 3 days.  The pharmacokinetics were dose proportional in the 25 to 325 mg/dose range for the oral soln.  Urinary excretion of unchanged R115777 was less than 0.1% of the oral dose.  One patient with metastatic colon cancer treated at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, and radiog. stable disease for 5 mo.  Conclusion: R115777 is bioavailable after oral administration and has an acceptable toxicity profile.  Based upon pharmacokinetic data, the recommended dose for phase II trials is 500 mg orally bid (total daily dose, 1,000 mg) for 5 consecutive days followed by 9 days of rest.  Studies of continuous dosing and studies of R115777 in combination with chemotherapy are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj_0aFhrLXFLVg90H21EOLACvtfcHk0lig29fFQ1T0lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1aku7s%253D&md5=8cb117c4efd19580a0c99468e5d4d2e1</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZujewski%26aufirst%3DJ.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26aulast%3DBol%26aufirst%3DC.%2BJ.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DBowden%26aufirst%3DC.%26aulast%3DEnd%26aufirst%3DD.%2BW.%26aulast%3DPiotrovsky%26aufirst%3DV.%2BK.%26aulast%3DChiao%26aufirst%3DJ.%26aulast%3DBelly%26aufirst%3DR.%2BT.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DKopp%26aufirst%3DW.%2BC.%26aulast%3DKohler%26aufirst%3DD.%2BR.%26aulast%3DChow%26aufirst%3DC.%26aulast%3DNoone%26aufirst%3DM.%26aulast%3DHakim%26aufirst%3DF.%2BT.%26aulast%3DLarkin%26aufirst%3DG.%26aulast%3DGress%26aufirst%3DR.%2BE.%26aulast%3DNussenblatt%26aufirst%3DR.%2BB.%26aulast%3DKremer%26aufirst%3DA.%2BB.%26aulast%3DCowan%26aufirst%3DK.%2BH.%26atitle%3DPhase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520R115777%2520in%2520advanced%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2000%26volume%3D18%26spage%3D927%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">849</span><span class="NLM_x">–</span> <span class="NLM_lpage">855</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=849-855&author=R.+A.+Mesaauthor=A.+Tefferiauthor=L.+A.+Grayauthor=T.+Reederauthor=G.+Schroederauthor=S.+H.+Kaufmann&title=In+vitro+antiproliferative+activity+of+the+farnesyltransferase+inhibitor+R115777+in+hematopoietic+progenitors+from+patients+with+myelofibrosis+with+myeloid+metaplasia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DL.%2BA.%26aulast%3DReeder%26aufirst%3DT.%26aulast%3DSchroeder%26aufirst%3DG.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vitro%2520antiproliferative%2520activity%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520R115777%2520in%2520hematopoietic%2520progenitors%2520from%2520patients%2520with%2520myelofibrosis%2520with%2520myeloid%2520metaplasia%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D849%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group">Yanamandra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colaco, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parquet, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzzeo, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulware, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaupre, D. M.</span><span> </span><span class="NLM_article-title">Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1078-0432.CCR-05-1792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16428505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=591-599&author=N.+Yanamandraauthor=N.+M.+Colacoauthor=N.+A.+Parquetauthor=R.+W.+Buzzeoauthor=D.+Boulwareauthor=G.+Wrightauthor=L.+E.+Perezauthor=W.+S.+Daltonauthor=D.+M.+Beaupre&title=Tipifarnib+and+bortezomib+are+synergistic+and+overcome+cell+adhesion-mediated+drug+resistance+in+multiple+myeloma+and+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Tipifarnib and Bortezomib are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia</span></div><div class="casAuthors">Yanamandra, Niranjan; Colaco, Nandita M.; Parquet, Nancy A.; Buzzeo, Robert W.; Boulware, David; Wright, Gabriela; Perez, Lia E.; Dalton, William S.; Beaupre, Darrin M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">591-599</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">It has been established in preclin. models of multiple myeloma and acute myeloid leukemia (AML) that the bone marrow microenvironment provides protection from chemotherapy- and death receptor-mediated apoptosis.  This form of resistance, termed de novo drug resistance, occurs independent of chronic exposure to cancer-related therapies and likely promotes the development of multidrug resistance.  Consequently, it is of major interest to identify compds. or drug combinations that can overcome environment-mediated resistance.  In this study, we investigated the activity of tipifarnib (Zarnestra, formerly R115777) combined with bortezomib (Velcade, formerly PS-341) in microenvironment models of multiple myeloma and AML.  The combination proved to be synergistic in multiple myeloma and AML cell lines treated in suspension culture.  Even in tumor cells relatively resistant to tipifarnib, combined activity was maintained.  Tipifarnib and bortezomib were also effective when multiple myeloma and AML cells were adhered to fibronectin, providing evidence that the combination overcomes cell adhesion-mediated drug resistance (CAM-DR).  Of importance, activation of the endoplasmic reticulum stress response was enhanced and correlated with apoptosis and reversal of CAM-DR.  Multiple myeloma and AML cells cocultured with bone marrow stromal cells also remained sensitive, although stromal-adhered tumor cells were partially protected (relative to cells in suspension or fibronectin adhered).  Evaluation of the combination using a transwell app. revealed that stromal cells produce a protective sol. factor.  Investigations are under way to identify the cytokines and/or growth factors involved.  In summary, our study provides the preclin. rationale for trials testing the tipifarnib and bortezomib combination in patients with multiple myeloma and AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa3pLLNQpARLVg90H21EOLACvtfcHk0lij6wI1VqBr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlKgsw%253D%253D&md5=69fb7360fcc8b0ca5f5fed7844383b99</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1792%26sid%3Dliteratum%253Aachs%26aulast%3DYanamandra%26aufirst%3DN.%26aulast%3DColaco%26aufirst%3DN.%2BM.%26aulast%3DParquet%26aufirst%3DN.%2BA.%26aulast%3DBuzzeo%26aufirst%3DR.%2BW.%26aulast%3DBoulware%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DPerez%26aufirst%3DL.%2BE.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26atitle%3DTipifarnib%2520and%2520bortezomib%2520are%2520synergistic%2520and%2520overcome%2520cell%2520adhesion-mediated%2520drug%2520resistance%2520in%2520multiple%2520myeloma%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D591%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group">Njoroge, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remiszewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallams, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deskus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Rosario, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A. K.</span><span> </span><span class="NLM_article-title">(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11(<i>R</i>)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">4890</span><span class="NLM_x">–</span> <span class="NLM_lpage">4902</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4890-4902&author=F.+G.+Njorogeauthor=A.+G.+Taverasauthor=J.+Kellyauthor=S.+Remiszewskiauthor=A.+K.+Mallamsauthor=R.+Wolinauthor=A.+Afonsoauthor=A.+B.+Cooperauthor=D.+F.+Raneauthor=Y.+T.+Liuauthor=J.+Wongauthor=B.+Vibulbhanauthor=P.+Pintoauthor=J.+Deskusauthor=C.+S.+Alvarezauthor=J.+del+Rosarioauthor=M.+Connollyauthor=J.+Wangauthor=J.+Desaiauthor=R.+R.+Rossmanauthor=W.+R.+Bishopauthor=R.+Pattonauthor=L.+Wangauthor=P.+Kirschmeierauthor=A.+K.+Ganguly&title=%28%2B%29-4-%5B2-%5B4-%288-Chloro-3%2C10-dibromo-6%2C11-dihydro-5H-benzo%5B5%2C6%5Dcyclohepta%5B1%2C2-b%5Dpyridin-11%28R%29-yl%29-1-piperidinyl%5D-2-oxo-ethyl%5D-1-piperidinecarboxamide+%28SCH-66336%29%3A+a+very+potent+farnesyl+protein+transferase+inhibitor+as+a+novel+antitumor+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm980462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980462b%26sid%3Dliteratum%253Aachs%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DRemiszewski%26aufirst%3DS.%26aulast%3DMallams%26aufirst%3DA.%2BK.%26aulast%3DWolin%26aufirst%3DR.%26aulast%3DAfonso%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DA.%2BB.%26aulast%3DRane%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DDeskus%26aufirst%3DJ.%26aulast%3DAlvarez%26aufirst%3DC.%2BS.%26aulast%3Ddel%2BRosario%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DR.%2BR.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DPatton%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DGanguly%26aufirst%3DA.%2BK.%26atitle%3D%2528%252B%2529-4-%255B2-%255B4-%25288-Chloro-3%252C10-dibromo-6%252C11-dihydro-5H-benzo%255B5%252C6%255Dcyclohepta%255B1%252C2-b%255Dpyridin-11%2528R%2529-yl%2529-1-piperidinyl%255D-2-oxo-ethyl%255D-1-piperidinecarboxamide%2520%2528SCH-66336%2529%253A%2520a%2520very%2520potent%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520as%2520a%2520novel%2520antitumor%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4890%26epage%3D4902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doll, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalwani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollinger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span> </span><span class="NLM_article-title">Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11(<i>R</i>)-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3854</span><span class="NLM_x">–</span> <span class="NLM_lpage">3864</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010463v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3854-3864&author=A.+G.+Taverasauthor=C.+Akiauthor=J.+Chaoauthor=R.+J.+Dollauthor=T.+Lalwaniauthor=V.+Girijavallabhanauthor=C.+L.+Stricklandauthor=W.+T.+Windsorauthor=P.+Weberauthor=F.+Hollingerauthor=M.+Snowauthor=R.+Pattonauthor=P.+Kirschmeierauthor=L.+Jamesauthor=M.+Liuauthor=A.+Nomeir&title=Exploring+the+role+of+bromine+at+C%2810%29+of+%28%2B%29-4-%5B2-%5B4-%288-chloro-3%2C10-dibromo-+6%2C11-dihydro-5H-benzo%5B5%2C6%5Dcyclohepta%5B1%2C2-b%5Dpyridin-11%28R%29-yl%29-1-piperidinyl%5D-2-oxoethyl%5D-1-piperidinecarboxamide+%28Sch-66336%29%3A+the+discovery+of+indolocycloheptapyridine+inhibitors+of+farnesyl+protein+transferase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm010463v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010463v%26sid%3Dliteratum%253Aachs%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DAki%26aufirst%3DC.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DLalwani%26aufirst%3DT.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DStrickland%26aufirst%3DC.%2BL.%26aulast%3DWindsor%26aufirst%3DW.%2BT.%26aulast%3DWeber%26aufirst%3DP.%26aulast%3DHollinger%26aufirst%3DF.%26aulast%3DSnow%26aufirst%3DM.%26aulast%3DPatton%26aufirst%3DR.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNomeir%26aufirst%3DA.%26atitle%3DExploring%2520the%2520role%2520of%2520bromine%2520at%2520C%252810%2529%2520of%2520%2528%252B%2529-4-%255B2-%255B4-%25288-chloro-3%252C10-dibromo-%25206%252C11-dihydro-5H-benzo%255B5%252C6%255Dcyclohepta%255B1%252C2-b%255Dpyridin-11%2528R%2529-yl%2529-1-piperidinyl%255D-2-oxoethyl%255D-1-piperidinecarboxamide%2520%2528Sch-66336%2529%253A%2520the%2520discovery%2520of%2520indolocycloheptapyridine%2520inhibitors%2520of%2520farnesyl%2520protein%2520transferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3854%26epage%3D3864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span> </span><span class="NLM_article-title">Sch-66336 (Sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F1568026033452104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12769711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=1103-1114&author=A.+G.+Taverasauthor=P.+Kirschmeierauthor=C.+M.+Baum&title=Sch-66336+%28Sarasar%29+and+other+benzocycloheptapyridyl+farnesyl+protein+transferase+inhibitors%3A+discovery%2C+biology+and+clinical+observations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Sch-66336 (Sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: Discovery, biology and clinical observations</span></div><div class="casAuthors">Taveras, Arthur G.; Kirschmeier, Paul; Baum, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1103-1114</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clin. trials.  Sch-66336 (Sarasar), a benzocycloheptapyridyl Farnesyl Transferase Inhibitor (FTI), has been effective in cellular proliferation assays and in in vivo oncol. models both as a single agent and in combination with other anti-cancer agents.  Clin., early evidence is being generated that suggests efficacy in humans, particularly in patients with leukemia.  Herein, we review the biol. of FPT, the discovery of Sch-66336 and other benzocycloheptapyridyl FTIs, and the clin. evaluation of Sch-66336 for the treatment of leukemia and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHkVTUw3LvDLVg90H21EOLACvtfcHk0ljTgMm6YccBAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLs%253D&md5=5fd2662afbbe26c76ed68098c5739081</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.2174%2F1568026033452104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026033452104%26sid%3Dliteratum%253Aachs%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26atitle%3DSch-66336%2520%2528Sarasar%2529%2520and%2520other%2520benzocycloheptapyridyl%2520farnesyl%2520protein%2520transferase%2520inhibitors%253A%2520discovery%252C%2520biology%2520and%2520clinical%2520observations%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26spage%3D1103%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group">Rose, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monticello, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">7507</span><span class="NLM_x">–</span> <span class="NLM_lpage">7517</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7507-7517&author=W.+C.+Roseauthor=F.+Y.+Leeauthor=C.+R.+Fairchildauthor=M.+Lynchauthor=T.+Monticelloauthor=R.+A.+Kramerauthor=V.+Manne&title=Preclinical+antitumor+activity+of+BMS-214662%2C+a+highly+apoptotic+and+novel+farnesyltransferase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DMonticello%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DR.%2BA.%26aulast%3DManne%26aufirst%3DV.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-214662%252C%2520a%2520highly%2520apoptotic%2520and%2520novel%2520farnesyltransferase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7507%26epage%3D7517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2805</span><span class="NLM_x">–</span> <span class="NLM_lpage">2812</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2005.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15728224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktleqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=2805-2812&author=J.+Cortesauthor=S.+Faderlauthor=E.+Esteyauthor=R.+Kurzrockauthor=D.+Thomasauthor=M.+Beranauthor=G.+Garcia-Maneroauthor=A.+Ferrajoliauthor=F.+Gilesauthor=C.+Kollerauthor=S.+O%E2%80%99Brienauthor=J.+Wrightauthor=S.+A.+Baiauthor=H.+Kantarjian&title=Phase+I+study+of+BMS-214662%2C+a+farnesyl+transferase+inhibitor+in+patients+with+acute+leukemias+and+high-risk+myelodysplastic+syndromes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes</span></div><div class="casAuthors">Cortes, Jorge; Faderl, Stefan; Estey, Elihu; Kurzrock, Razelle; Thomas, Deborah; Beran, Miloslav; Garcia-Manero, Guillermo; Ferrajoli, Alessandra; Giles, Francis; Koller, Charles; O'Brien, Susan; Wright, John; Bai, Stephen A.; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2805-2812</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the dose-limiting toxicity (DLT) and max.-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS).  Patients with relapsed or refractory acute leukemias or MDS, or previously untreated but poor candidates for chemotherapy, were included in this phase I study with a 3+3 dose escalation design.  BMS-214662 was administered as a 1-h bolus once weekly at doses of 42 to 157 mg/m2.  Once the MTD was identified, the schedule was changed to a 24-h continuous infusion once weekly (starting dose, 300 mg/m2).  Thirty patients were treated at a dose of 42 (n = 1), 56 (n = 3), 84 (n = 3), 118 (n = 13), 157 (n = 6) or 300 mg/m2 (n = 4).  DLT occurred in 3 patients at 157 mg/m2, including nausea, vomiting, diarrhea, hypokalemia and cardiovascular problems.  No DLT occurred with 24-h continuous infusion.  MTD with a 1-h infusion was 118 mg/m2, with no MTD identified with the 24-h infusion.  Plasma concns. of BMS-214662 correlated with the dose.  Inhibition of FTase activity of approx. 60% occurred after the infusion with recovery to near baseline after 24 h.  Five patients had evidence of antileukemia activity, including two with complete remission with incomplete platelet recovery, one with hematol. improvement, and two with morphol. leukemia-free state.  BMS-214662 is well tolerated at doses of up to 118 mg/m2 as a 1-h infusion.  The toxicity profile and efficacy may be improved with prolonged exposure.  Further investigation of this agent in leukemia is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokuHmnmuGYe7Vg90H21EOLACvtfcHk0liFmFKt8yjnFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktleqtrc%253D&md5=459b44185b0d32b2d4859b33367b90aa</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DS.%2BA.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DPhase%2520I%2520study%2520of%2520BMS-214662%252C%2520a%2520farnesyl%2520transferase%2520inhibitor%2520in%2520patients%2520with%2520acute%2520leukemias%2520and%2520high-risk%2520myelodysplastic%2520syndromes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D2805%26epage%3D2812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group">Gomez-Benito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naval, J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1991</span><span class="NLM_x">–</span> <span class="NLM_lpage">1998</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=1991-1998&author=M.+Gomez-Benitoauthor=I.+Marzoauthor=A.+Anelauthor=J.+Naval&title=Farnesyltransferase+inhibitor+BMS-214662+induces+apoptosis+in+myeloma+cells+through+PUMA+up-regulation%2C+Bax+and+Bak+activation%2C+and+Mcl-1+elimination"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Benito%26aufirst%3DM.%26aulast%3DMarzo%26aufirst%3DI.%26aulast%3DAnel%26aufirst%3DA.%26aulast%3DNaval%26aufirst%3DJ.%26atitle%3DFarnesyltransferase%2520inhibitor%2520BMS-214662%2520induces%2520apoptosis%2520in%2520myeloma%2520cells%2520through%2520PUMA%2520up-regulation%252C%2520Bax%2520and%2520Bak%2520activation%252C%2520and%2520Mcl-1%2520elimination%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D1991%26epage%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group">Marzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Galan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giraldo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Royuela, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Benito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasierra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio-Felix, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naval, J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1599-1604&author=I.+Marzoauthor=P.+Perez-Galanauthor=P.+Giraldoauthor=N.+Lopez-Royuelaauthor=M.+Gomez-Benitoauthor=L.+Larradauthor=P.+Lasierraauthor=D.+Rubio-Felixauthor=A.+Anelauthor=J.+Naval&title=Farnesyltransferase+inhibitor+BMS-214662+induces+apoptosis+in+B-cell+chronic+lymphocytic+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarzo%26aufirst%3DI.%26aulast%3DPerez-Galan%26aufirst%3DP.%26aulast%3DGiraldo%26aufirst%3DP.%26aulast%3DLopez-Royuela%26aufirst%3DN.%26aulast%3DGomez-Benito%26aufirst%3DM.%26aulast%3DLarrad%26aufirst%3DL.%26aulast%3DLasierra%26aufirst%3DP.%26aulast%3DRubio-Felix%26aufirst%3DD.%26aulast%3DAnel%26aufirst%3DA.%26aulast%3DNaval%26aufirst%3DJ.%26atitle%3DFarnesyltransferase%2520inhibitor%2520BMS-214662%2520induces%2520apoptosis%2520in%2520B-cell%2520chronic%2520lymphocytic%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2004%26volume%3D18%26spage%3D1599%26epage%3D1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group">Copland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allan, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holyoake, T. L.</span><span> </span><span class="NLM_article-title">BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2843</span><span class="NLM_x">–</span> <span class="NLM_lpage">2853</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2843-2853&author=M.+Coplandauthor=F.+Pellicanoauthor=L.+Richmondauthor=E.+K.+Allanauthor=A.+Hamiltonauthor=F.+Y.+Leeauthor=R.+Weinmannauthor=T.+L.+Holyoake&title=BMS-214662+potently+induces+apoptosis+of+chronic+myeloid+leukemia+stem+and+progenitor+cells+and+synergizes+with+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopland%26aufirst%3DM.%26aulast%3DPellicano%26aufirst%3DF.%26aulast%3DRichmond%26aufirst%3DL.%26aulast%3DAllan%26aufirst%3DE.%2BK.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWeinmann%26aufirst%3DR.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26atitle%3DBMS-214662%2520potently%2520induces%2520apoptosis%2520of%2520chronic%2520myeloid%2520leukemia%2520stem%2520and%2520progenitor%2520cells%2520and%2520synergizes%2520with%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2843%26epage%3D2853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group">Pellicano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mountford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holyoake, T. L.</span><span> </span><span class="NLM_article-title">BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38− cells, through activation of protein kinase Cbeta</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">4186</span><span class="NLM_x">–</span> <span class="NLM_lpage">4196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=4186-4196&author=F.+Pellicanoauthor=M.+Coplandauthor=H.+G.+Jorgensenauthor=J.+Mountfordauthor=B.+Leberauthor=T.+L.+Holyoake&title=BMS-214662+induces+mitochondrial+apoptosis+in+chronic+myeloid+leukemia+%28CML%29+stem%2Fprogenitor+cells%2C+including+CD34%2B38%E2%88%92+cells%2C+through+activation+of+protein+kinase+Cbeta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPellicano%26aufirst%3DF.%26aulast%3DCopland%26aufirst%3DM.%26aulast%3DJorgensen%26aufirst%3DH.%2BG.%26aulast%3DMountford%26aufirst%3DJ.%26aulast%3DLeber%26aufirst%3DB.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26atitle%3DBMS-214662%2520induces%2520mitochondrial%2520apoptosis%2520in%2520chronic%2520myeloid%2520leukemia%2520%2528CML%2529%2520stem%252Fprogenitor%2520cells%252C%2520including%2520CD34%252B38%25E2%2588%2592%2520cells%252C%2520through%2520activation%2520of%2520protein%2520kinase%2520Cbeta%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D4186%26epage%3D4196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cepero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeng, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boise, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenheld, M. G.</span><span> </span><span class="NLM_article-title">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=14985458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=179-186&author=D.+M.+Beaupreauthor=E.+Ceperoauthor=E.+A.+Obengauthor=L.+H.+Boiseauthor=M.+G.+Lichtenheld&title=R115777+induces+Ras-independent+apoptosis+of+myeloma+cells+via+multiple+intrinsic+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span></div><div class="casAuthors">Beaupre, Darrin M.; Cepero, Enrique; Obeng, Esther A.; Boise, Lawrence H.; Lichtenheld, Mathias G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ras activation is frequently obsd. in multiple myeloma either by mutation or through interleukin-6 receptor signaling.  Recently, drugs designed to inhibit Ras have shown promise in preclin. myeloma models and in clin. trials.  In this report, we characterize the pathways by which the clin. tested farnesyl transferase inhibitor (FTI) R115777 induces apoptosis in multiple myeloma cells.  Contrary to the proposed mechanistic action of FTIs, we found that R115777 induces cell death despite Ras prenylation implying participation of Ras-independent mechanism(s).  Apoptosis proceeded via an intrinsic cascade and was assocd. with an increase in the expression and activity of Bax.  Bax activation correlated with a loss of mitochondrial membrane integrity and activation of the endoplasmic reticulum (ER) stress response.  These pathways activate caspase-9 and consistent with this, cell death was prevented by caspase-9 blockade.  Interestingly, cells over-expressing Bcl-XL remained partially sensitive to R115777 despite suppression of mitochondrial membrane dysfunction and ER-related stress.  Taken together, these results indicate that R115777 induces apoptosis in a Ras-independent fashion via multiple intrinsic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosdUKBKAfDIbVg90H21EOLACvtfcHk0lghB1653L3kOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D&md5=0f36fe2c3351caf511152fcecf89fd9f</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DCepero%26aufirst%3DE.%26aulast%3DObeng%26aufirst%3DE.%2BA.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DLichtenheld%26aufirst%3DM.%2BG.%26atitle%3DR115777%2520induces%2520Ras-independent%2520apoptosis%2520of%2520myeloma%2520cells%2520via%2520multiple%2520intrinsic%2520pathways%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D179%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span> </span><span class="NLM_article-title">Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=56&author=M.+Raponiauthor=R.+T.+Bellyauthor=J.+E.+Karpauthor=J.+E.+Lancetauthor=D.+Atkinsauthor=Y.+Wang&title=Microarray+analysis+reveals+genetic+pathways+modulated+by+tipifarnib+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DBelly%26aufirst%3DR.%2BT.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DAtkins%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DMicroarray%2520analysis%2520reveals%2520genetic%2520pathways%2520modulated%2520by%2520tipifarnib%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBMC%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group">Braun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenaux, P.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1111%2Fj.1365-2141.2008.07099.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18410457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVaqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2008&pages=576-586&author=T.+Braunauthor=P.+Fenaux&title=Farnesyltransferase+inhibitors+and+their+potential+role+in+therapy+for+myelodysplastic+syndromes+and+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia</span></div><div class="casAuthors">Braun, Thorsten; Fenaux, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">576-586</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Novel strategies are required for treatment of acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) patients who are not eligible for intensive chemotherapy and/or allogenic stem cell transplantation.  As activating RAS mutations are frequent in these diseases, one novel approach, consisting of interfering with isoprenylation of RAS proteins by farnesyltransferase inhibitors (FTIs), has been proposed.  Clin. phase II studies with the oral FTIs tipifarnib and lonafarnib in previously untreated AML, MDS and chronic myelomonocytic leukemia yielded rather encouraging results while results in relapsed and/or refractory AML were disappointing.  Results of a phase III trial in untreated AML in the elderly with tipifarnib were also disappointing.  Clin. responses were not related to RAS mutations, suggesting addnl. actions of FTIs on other mol. targets.  The combination of existing FTIs with other treatments, such as chemotherapy (in AML) and hypomethylating agents (in MDS and AML), is under investigation.  Ongoing studies will also det. if gene profiling anal. may help to identify patients that will respond to FTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobd4NZVItqWLVg90H21EOLACvtfcHk0lghB1653L3kOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVaqs7o%253D&md5=7e36330cac4bb7ae30322a67003ce56b</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2008.07099.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2008.07099.x%26sid%3Dliteratum%253Aachs%26aulast%3DBraun%26aufirst%3DT.%26aulast%3DFenaux%26aufirst%3DP.%26atitle%3DFarnesyltransferase%2520inhibitors%2520and%2520their%2520potential%2520role%2520in%2520therapy%2520for%2520myelodysplastic%2520syndromes%2520and%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2008%26volume%3D141%26spage%3D576%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group">Raz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Farnesyl transferase inhibitor resistance probed by target mutagenesis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2102</span><span class="NLM_x">–</span> <span class="NLM_lpage">2109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2102-2109&author=T.+Razauthor=V.+Nardiauthor=M.+Azamauthor=J.+Cortesauthor=G.+Q.+Daley&title=Farnesyl+transferase+inhibitor+resistance+probed+by+target+mutagenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaz%26aufirst%3DT.%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DFarnesyl%2520transferase%2520inhibitor%2520resistance%2520probed%2520by%2520target%2520mutagenesis%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2102%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group">Senderowicz, A. M.</span><span> </span><span class="NLM_article-title">Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=1-9&author=A.+M.+Senderowicz&title=Development+of+cyclin-dependent+kinase+modulators+as+novel+therapeutic+approaches+for+hematological+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26atitle%3DDevelopment%2520of%2520cyclin-dependent%2520kinase%2520modulators%2520as%2520novel%2520therapeutic%2520approaches%2520for%2520hematological%2520malignancies%26jtitle%3DLeukemia%26date%3D2001%26volume%3D15%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooker-McEldowney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broering, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozanski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colevas, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span> </span><span class="NLM_article-title">Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=399-404&author=J.+C.+Byrdauthor=T.+S.+Linauthor=J.+T.+Daltonauthor=D.+Wuauthor=M.+A.+Phelpsauthor=B.+Fischerauthor=M.+Moranauthor=K.+A.+Blumauthor=B.+Rovinauthor=M.+Brooker-McEldowneyauthor=S.+Broeringauthor=L.+J.+Schaafauthor=A.+J.+Johnsonauthor=D.+M.+Lucasauthor=N.+A.+Heeremaauthor=G.+Lozanskiauthor=D.+C.+Youngauthor=J.+R.+Suarezauthor=A.+D.+Colevasauthor=M.+R.+Grever&title=Flavopiridol+administered+using+a+pharmacologically+derived+schedule+is+associated+with+marked+clinical+efficacy+in+refractory%2C+genetically+high-risk+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMoran%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DRovin%26aufirst%3DB.%26aulast%3DBrooker-McEldowney%26aufirst%3DM.%26aulast%3DBroering%26aufirst%3DS.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DD.%2BC.%26aulast%3DSuarez%26aufirst%3DJ.%2BR.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DFlavopiridol%2520administered%2520using%2520a%2520pharmacologically%2520derived%2520schedule%2520is%2520associated%2520with%2520marked%2520clinical%2520efficacy%2520in%2520refractory%252C%2520genetically%2520high-risk%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D399%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-06-0614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17363487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=926-934&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=P.+Mahajanauthor=V.+Waghauthor=S.+Shenoyauthor=D.+Bhatiaauthor=S.+Chileauthor=M.+Sivakumarauthor=A.+Maierauthor=H.+H.+Fiebigauthor=S.+Sharma&title=P276-00%2C+a+novel+cyclin-dependent+inhibitor+induces+G1-G2+arrest%2C+shows+antitumor+activity+on+cisplatin-resistant+cells+and+significant+in+vivo+efficacy+in+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Mahajan, Pravin; Wagh, Vilas; Shenoy, Satyendra; Bhatia, Dimple; Chile, Shailaja; Sivakumar, Meenakshi; Maier, Armin; Fiebig, Heinz-Herbert; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent.  In this study, we have selected a panel of human tumor cell lines and xenografts to allow detn. of selectivity and efficacy of P276-00.  When tested against a panel of 16 cisplatin-sensitive and cisplatin-resistant cell lines, the antiproliferative potential of P276-00 was found to be ∼30-fold higher than cisplatin.  Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was ∼26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers.  Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells.  Asynchronous population of human prostate carcinoma (PC-3) and human promyelocytic leukemia (HL-60) cells when exposed to P276-00 showed arrest of slow-growing PC-3 cells in G2-M with no significant apoptosis obsd. up to 72 h.  Unlike PC-3, significant apoptosis was seen in fast-growing HL-60 cells at 6 h.  However, synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells showed arrest of cells in G1.  H-460 cells undergo apoptosis, which increases with longer exposure to the compd. and also after exposure to P276-00 for 48 h followed by recovery.  In contrast, the normal cells (WI-38) remain arrested in G1 with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells.  After promising in vitro results, P276-00 was checked for in vivo efficacy in murine tumor and human xenograft models.  Growth inhibition of murine colon cancer (CA-51) was significant when P276-00 was administered i.p. at 50 mg/kg daily for 20 treatments.  However, in murine lung carcinoma model (Lewis lung), an increased dose of 60 mg/kg (30 mg/kg twice daily) administered every alternate day i.p. for seven treatments showed significant inhibition in the growth.  Further studies were undertaken to establish the efficacy profile of P276-00 in human tumor xenograft models.  In the two xenograft models studied, P276-00 showed potent in vivo antitumor potential.  Compd. P276-00 at a dose of 35 mg/kg administered daily via the i.p. route for 10 days showed significant (P < 0.05) inhibition in the growth of human colon carcinoma HCT-116 xenograft.  Furthermore, P276-00 at a dose of 50 mg/kg once daily and 30 mg/kg twice daily administered via i.p. route for 20 treatments significantly (P < 0.05) inhibited growth of human non-small cell lung carcinoma H-460 xenograft.  Thus, the in vitro cellular potency, together with in vivo antitumor activity, confirms the potential of P276-00, a cyclin-dependent kinase inhibitor as an anticancer mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogJ_J7_PmrDrVg90H21EOLACvtfcHk0li50A-OLx2ZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D&md5=04e65ada85eb38521909544a4e16a739</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0614%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DWagh%26aufirst%3DV.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DD.%26aulast%3DChile%26aufirst%3DS.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DA.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DP276-00%252C%2520a%2520novel%2520cyclin-dependent%2520inhibitor%2520induces%2520G1-G2%2520arrest%252C%2520shows%2520antitumor%2520activity%2520on%2520cisplatin-resistant%2520cells%2520and%2520significant%2520in%2520vivo%2520efficacy%2520in%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D926%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group">Christian, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span> </span><span class="NLM_article-title">Flavopiridol in the treatment of chronic lymphocytic leukemia</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FCCO.0b013e3282efb9da" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17906454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=573-578&author=B.+A.+Christianauthor=M.+R.+Greverauthor=J.+C.+Byrdauthor=T.+S.+Lin&title=Flavopiridol+in+the+treatment+of+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol in the treatment of chronic lymphocytic leukemia</span></div><div class="casAuthors">Christian, Beth A.; Grever, Michael R.; Byrd, John C.; Lin, Thomas S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">573-578</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The synthetic flavone flavopiridol induces apoptosis of chronic lymphocytic leukemia cells in vitro; however, initial studies administering flavopiridol by a 24- to 72-h continuous i.v. infusion demonstrated no clin. activity.  This review focuses on a novel dosing regimen that has achieved significant clin. activity in relapsed, poor-risk chronic lymphocytic leukemia.  Recent findings: Binding to human plasma proteins reduces free flavopiridol concn. and makes continuous i.v. infusion dosing ineffective.  Pharmacokinetic modeling indicated that administering flavopiridol by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion would achieve serum concns. necessary to induce in-vivo apoptosis.  Our institution conducted a phase I study in relapsed chronic lymphocytic leukemia.  Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia.  Careful monitoring and aggressive intervention for hyperkalemia, including hemodialysis if necessary, allowed flavopiridol to be given safely.  Nineteen of 42 patients responded (45%), including five of 12 patients (42%) with del(17p13) and 13 of 18 patients (72%) with del(11q22).  Summary: Flavopiridol, when administered by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion, is active in high-risk, refractory chronic lymphocytic leukemia.  Careful monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for safe drug administration.  Further studies to optimize the dose and schedule of administration, and to study this drug in other hematol. malignancies, are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6YGpEb0iAxLVg90H21EOLACvtfcHk0li50A-OLx2ZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL&md5=9682028742de790c116d8e99a9aa60c5</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e3282efb9da&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e3282efb9da%26sid%3Dliteratum%253Aachs%26aulast%3DChristian%26aufirst%3DB.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BS.%26atitle%3DFlavopiridol%2520in%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D573%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruninger, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes-Pesquera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugg, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolliffe, L. K.</span><span> </span><span class="NLM_article-title">1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4208</span><span class="NLM_x">–</span> <span class="NLM_lpage">4211</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050267e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4208-4211&author=R.+Linauthor=P.+J.+Connollyauthor=S.+Huangauthor=S.+K.+Wetterauthor=Y.+Luauthor=W.+V.+Murrayauthor=S.+L.+Emanuelauthor=R.+H.+Gruningerauthor=A.+R.+Fuentes-Pesqueraauthor=C.+A.+Ruggauthor=S.+A.+Middletonauthor=L.+K.+Jolliffe&title=1-Acyl-1H-%5B1%2C2%2C4%5Dtriazole-3%2C5-diamine+analogues+as+novel+and+potent+anticancer+cyclin-dependent+kinase+inhibitors%3A+synthesis+and+evaluation+of+biological+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fjm050267e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050267e%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DR.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DWetter%26aufirst%3DS.%2BK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DW.%2BV.%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DGruninger%26aufirst%3DR.%2BH.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DRugg%26aufirst%3DC.%2BA.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DJolliffe%26aufirst%3DL.%2BK.%26atitle%3D1-Acyl-1H-%255B1%252C2%252C4%255Dtriazole-3%252C5-diamine%2520analogues%2520as%2520novel%2520and%2520potent%2520anticancer%2520cyclin-dependent%2520kinase%2520inhibitors%253A%2520synthesis%2520and%2520evaluation%2520of%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4208%26epage%3D4211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozewski, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooker-McEldowney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarjoura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span> </span><span class="NLM_article-title">Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">2637</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=2637-2645&author=M.+A.+Phelpsauthor=T.+S.+Linauthor=A.+J.+Johnsonauthor=E.+Hurhauthor=D.+M.+Rozewskiauthor=K.+L.+Farleyauthor=D.+Wuauthor=K.+A.+Blumauthor=B.+Fischerauthor=S.+M.+Mitchellauthor=M.+E.+Moranauthor=M.+Brooker-McEldowneyauthor=N.+A.+Heeremaauthor=D.+Jarjouraauthor=L.+J.+Schaafauthor=J.+C.+Byrdauthor=M.+R.+Greverauthor=J.+T.+Dalton&title=Clinical+response+and+pharmacokinetics+from+a+phase+1+study+of+an+active+dosing+schedule+of+flavopiridol+in+relapsed+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHurh%26aufirst%3DE.%26aulast%3DRozewski%26aufirst%3DD.%2BM.%26aulast%3DFarley%26aufirst%3DK.%2BL.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BM.%26aulast%3DMoran%26aufirst%3DM.%2BE.%26aulast%3DBrooker-McEldowney%26aufirst%3DM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DClinical%2520response%2520and%2520pharmacokinetics%2520from%2520a%2520phase%25201%2520study%2520of%2520an%2520active%2520dosing%2520schedule%2520of%2520flavopiridol%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D2637%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattenburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colevas, A. D.</span><span> </span><span class="NLM_article-title">Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4467</span><span class="NLM_x">–</span> <span class="NLM_lpage">4473</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1078-0432.CCR-07-0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17671131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlGqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4467-4473&author=J.+E.+Karpauthor=B.+D.+Smithauthor=M.+J.+Levisauthor=S.+D.+Goreauthor=J.+Greerauthor=C.+Hattenburgauthor=J.+Brielauthor=R.+J.+Jonesauthor=J.+J.+Wrightauthor=A.+D.+Colevas&title=Sequential+flavopiridol%2C+cytosine+arabinoside%2C+and+mitoxantrone%3A+a+phase+II+trial+in+adults+with+poor-risk+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia</span></div><div class="casAuthors">Karp, Judith E.; Smith, B. Douglas; Levis, Mark J.; Gore, Steven D.; Greer, Jacqueline; Hattenburg, Catherine; Briel, Janet; Jones, Richard J.; Wright, John J.; Colevas, A. Dimitri</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15, Pt. 1</span>),
    <span class="NLM_cas:pages">4467-4473</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor that is cytotoxic to leukemic blasts.  In a phase I study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%.  We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML.  Exptl. Design: Flavopiridol (50 mg/m2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 gm/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone on day 9.  RESULTS: Flavopiridol caused a ≥50% decrease in peripheral blood blasts in 44% by median day 2 and ≥80% decrease in 26% by day 3.  Self-limited tumor lysis occurred in 53%.  Three (5%) died during therapy (2 multiorgan failure and 1 fungal pneumonia).  Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary AML, 18 of 24 (75%) first relapse after short CR (median CR, 9 mo, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory AML.  Disease-free survival for all CR patients is 40% at 2 years, with newly diagnosed patients having a 2-yr disease-free survival of 50%.  CONCLUSIONS: Flavopiridol has anti-AML activity directly and in combination with ara-C and mitoxantrone.  This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcTLT6Fcz5sbVg90H21EOLACvtfcHk0lgRnS7zljtWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlGqtLs%253D&md5=50904a84f2442f965c30b8e054699661</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0381%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DHattenburg%26aufirst%3DC.%26aulast%3DBriel%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26atitle%3DSequential%2520flavopiridol%252C%2520cytosine%2520arabinoside%252C%2520and%2520mitoxantrone%253A%2520a%2520phase%2520II%2520trial%2520in%2520adults%2520with%2520poor-risk%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4467%26epage%3D4473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span> </span><span class="NLM_article-title">Alvocidib: Orphan Drug Status</span>. Presented at the Committee for Orphan Medicinal Products 84th Plenary Meeting, U.S. Food and Drug Administration,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alvocidib%3A+Orphan+Drug+Status.+Presented+at+the+Committee+for+Orphan+Medicinal+Products+84th+Plenary+Meeting%2C+U.S.+Food+and+Drug+Administration%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DAlvocidib%253A%2520Orphan%2520Drug%2520Status%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascarenhas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamble, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-06-0613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17363486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=918-925&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=R.+D.+Joshiauthor=M.+Sivakumarauthor=M.+Mascarenhasauthor=S.+Kambleauthor=B.+Lalauthor=S.+Sharma&title=In+vitro+antitumor+properties+of+a+novel+cyclin-dependent+kinase+inhibitor%2C+P276-00"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Joshi, Rajendra D.; Sivakumar, Meenakshi; Mascarenhas, Malcolm; Kamble, Shrikant; Lal, Bansi; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (Cdk) and their assocd. pathways represent some of the most attractive targets for the development of anticancer therapeutics.  Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clin. evaluation either as a single agent or in combination with other approved drugs.  In our anticancer drug discovery program, a novel series of flavones were synthesized for evaluation against the activity of Cdk4-D1.  This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function.  We have identified a series of potent Cdk4-D1 inhibitors with IC50 below 250 nmol/L.  In this report, we have described the properties of one of the best compd., P276-00 of the flavone's series.  P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E.  The specificity toward 14 other related and unrelated kinases was also detd.  P276-00 was found to be more selective with IC50s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk kinases.  It showed potent antiproliferative effects against various human cancer cell lines, with an IC50 ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against cancer and normal fibroblast cell lines.  P276-00 was found to be highly selective for cancer cells as compared with normal fibroblast cells.  To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460).  A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser780 phosphorylation was obsd.  P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with ATP and not with retinoblastoma protein.  The compd. also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies.  These data suggest that P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IzehRnQJk7Vg90H21EOLACvtfcHk0lgRnS7zljtWYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D&md5=7cc9256a1cd7a960e5e5497ad409a18b</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0613%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DR.%2BD.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMascarenhas%26aufirst%3DM.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520antitumor%2520properties%2520of%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276-00%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D918%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group">Havlicek, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclerc, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, M.</span><span> </span><span class="NLM_article-title">Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960666x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=408-412&author=L.+Havlicekauthor=J.+Hanusauthor=J.+Veselyauthor=S.+Leclercauthor=L.+Meijerauthor=G.+Shawauthor=M.+Strnad&title=Cytokinin-derived+cyclin-dependent+kinase+inhibitors%3A+synthesis+and+cdc2+inhibitory+activity+of+olomoucine+and+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Fjm960666x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960666x%26sid%3Dliteratum%253Aachs%26aulast%3DHavlicek%26aufirst%3DL.%26aulast%3DHanus%26aufirst%3DJ.%26aulast%3DVesely%26aufirst%3DJ.%26aulast%3DLeclerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DG.%26aulast%3DStrnad%26aufirst%3DM.%26atitle%3DCytokinin-derived%2520cyclin-dependent%2520kinase%2520inhibitors%253A%2520synthesis%2520and%2520cdc2%2520inhibitory%2520activity%2520of%2520olomoucine%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D408%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar0201198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=417-425&author=L.+Meijerauthor=E.+Raymond&title=Roscovitine+and+other+purines+as+kinase+inhibitors.+From+starfish+oocytes+to+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Far0201198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far0201198%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DRoscovitine%2520and%2520other%2520purines%2520as%2520kinase%2520inhibitors.%2520From%2520starfish%2520oocytes%2520to%2520clinical%2520trials%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D417%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group">Legraverend, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunnah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducrot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grierson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leost, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1282</span><span class="NLM_x">–</span> <span class="NLM_lpage">1292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9911130" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1282-1292&author=M.+Legraverendauthor=P.+Tunnahauthor=M.+Nobleauthor=P.+Ducrotauthor=O.+Ludwigauthor=D.+S.+Griersonauthor=M.+Leostauthor=L.+Meijerauthor=J.+Endicott&title=Cyclin-dependent+kinase+inhibition+by+new+C-2+alkynylated+purine+derivatives+and+molecular+structure+of+a+CDK2-inhibitor+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Fjm9911130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9911130%26sid%3Dliteratum%253Aachs%26aulast%3DLegraverend%26aufirst%3DM.%26aulast%3DTunnah%26aufirst%3DP.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DDucrot%26aufirst%3DP.%26aulast%3DLudwig%26aufirst%3DO.%26aulast%3DGrierson%26aufirst%3DD.%2BS.%26aulast%3DLeost%26aufirst%3DM.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DEndicott%26aufirst%3DJ.%26atitle%3DCyclin-dependent%2520kinase%2520inhibition%2520by%2520new%2520C-2%2520alkynylated%2520purine%2520derivatives%2520and%2520molecular%2520structure%2520of%2520a%2520CDK2-inhibitor%2520complex%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1282%26epage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group">Arris, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewsbury, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span> </span><span class="NLM_article-title">Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2797</span><span class="NLM_x">–</span> <span class="NLM_lpage">2804</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990628o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2797-2804&author=C.+E.+Arrisauthor=F.+T.+Boyleauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=E.+F.+Garmanauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=S.+Grantauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=A.+M.+Lawrieauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=E.+A.+Sausvilleauthor=R.+Schultzauthor=W.+Yu&title=Identification+of+novel+purine+and+pyrimidine+cyclin-dependent+kinase+inhibitors+with+distinct+molecular+interactions+and+tumor+cell+growth+inhibition+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Fjm990628o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990628o%26sid%3Dliteratum%253Aachs%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGarman%26aufirst%3DE.%2BF.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSchultz%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DW.%26atitle%3DIdentification%2520of%2520novel%2520purine%2520and%2520pyrimidine%2520cyclin-dependent%2520kinase%2520inhibitors%2520with%2520distinct%2520molecular%2520interactions%2520and%2520tumor%2520cell%2520growth%2520inhibition%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2797%26epage%3D2804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group">Popowycz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettayeb, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferandin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamigeon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mateo-Lozano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notario, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, B.</span><span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (<i>R</i>)-roscovitine analogue</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801340z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=655-663&author=F.+Popowyczauthor=G.+Fournetauthor=C.+Schneiderauthor=K.+Bettayebauthor=Y.+Ferandinauthor=C.+Lamigeonauthor=O.+M.+Tiradoauthor=S.+Mateo-Lozanoauthor=V.+Notarioauthor=P.+Colasauthor=P.+Bernardauthor=L.+Meijerauthor=B.+Joseph&title=Pyrazolo%5B1%2C5-a%5D-1%2C3%2C5-triazine+as+a+purine+bioisostere%3A+access+to+potent+cyclin-dependent+kinase+inhibitor+%28R%29-roscovitine+analogue"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Fjm801340z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801340z%26sid%3Dliteratum%253Aachs%26aulast%3DPopowycz%26aufirst%3DF.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLamigeon%26aufirst%3DC.%26aulast%3DTirado%26aufirst%3DO.%2BM.%26aulast%3DMateo-Lozano%26aufirst%3DS.%26aulast%3DNotario%26aufirst%3DV.%26aulast%3DColas%26aufirst%3DP.%26aulast%3DBernard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DPyrazolo%255B1%252C5-a%255D-1%252C3%252C5-triazine%2520as%2520a%2520purine%2520bioisostere%253A%2520access%2520to%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%2520%2528R%2529-roscovitine%2520analogue%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D655%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quin, J.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toogood, P. L.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2371</span><span class="NLM_x">–</span> <span class="NLM_lpage">2387</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2371-2387&author=S.+N.+VanderWelauthor=P.+J.+Harveyauthor=D.+J.+McNamaraauthor=J.+T.+Repineauthor=P.+R.+Kellerauthor=J.+Quinauthor=R.+J.+Boothauthor=W.+L.+Elliottauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=P.+L.+Toogood&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+specific+inhibitors+of+cyclin-dependent+kinase+4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1021%2Fjm049355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DQuin%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520specific%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2371%26epage%3D2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Gahmen, U.</span><span> </span><span class="NLM_article-title">Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3826</span><span class="NLM_x">–</span> <span class="NLM_lpage">3831</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0600388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3826-3831&author=H.+Luauthor=U.+Schulze-Gahmen&title=Toward+understanding+the+structural+basis+of+cyclin-dependent+kinase+6+specific+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition</span></div><div class="casAuthors">Lu, Heshu; Schulze-Gahmen, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3826-3831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are key players in cell cycle control, and genetic alterations of CDKs and their regulators have been linked to a variety of cancers.  Hence, CDKs are obvious targets for therapeutic intervention in various proliferative diseases, including cancer.  To date, drug design efforts have mostly focused on CDK2 because methods for crystn. of its inhibitor complexes have been well established.  CDK4 and CDK6, however, may be at least as important as enzymes for cell cycle regulation and could provide alternative treatment options.  We describe here two complex structures of human CDK6 with a very specific kinase inhibitor, PD0332991, which is based on a pyrido[2,3-d]pyrimidin-7-one scaffold, and with the less specific aminopurvalanol inhibitor.  Anal. of the structures suggests that relatively small conformational differences between CDK2 and CDK6 in the hinge region are contributing to the inhibitor specificity by inducing changes in the inhibitor orientation that lead to sterical clashes in CDK2 but not CDK6.  These complex structures provide valuable insights for the future development of CDK-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt5qOCDA_blLVg90H21EOLACvtfcHk0liPwCxTvyn4ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D&md5=218bcdfeac3e7371e3ae16ab0a5799db</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fjm0600388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600388%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520cyclin-dependent%2520kinase%25206%2520specific%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3826%26epage%3D3831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group">Dickson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">Development of cell-cycle inhibitors for cancer therapy</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19370178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1M3otVaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=36-43&author=M.+A.+Dicksonauthor=G.+K.+Schwartz&title=Development+of+cell-cycle+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Development of cell-cycle inhibitors for cancer therapy</span></div><div class="casAuthors">Dickson M A; Schwartz G K</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology (Toronto, Ont.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">36-43</span>
        ISSN:<span class="NLM_cas:issn">1198-0052</span>.
    </div><div class="casAbstract">The cell cycle governs the transition from quiescence through cell growth to proliferation.  The key parts of the cell cycle machinery are the cyclin-dependent kinases (CDKS) and the regulatory proteins called cyclins.  The CDKS are rational targets for cancer therapy because their expression in cancer cells is often aberrant and their inhibition can induce cell death.  Inhibitors of CDKS can also block transcription.Several drugs targeting the cell cycle have entered clinical trials.  These agents include flavopiridol, indisulam, AZD5438, SNS-032, bryostatin-1, seliciclib, PD 0332991, and SCH 727965.  Phase i studies have demonstrated that these drugs can generally be administered safely.  Phase ii studies have shown little single-agent activity in solid tumors, but combination studies with cytotoxic chemotherapy have been more promising.  In hematologic malignancies, reports have shown encouraging single-agent and combination activity.  Pharmacodynamic studies show that the dose and schedule of these drugs are crucial to permit maximum therapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgaRuY_68sqszK395ZObgVfW6udTcc2eYgIk78PMTw37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3otVaqsg%253D%253D&md5=450695393901bd4eee8c4183717b1e42</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DDevelopment%2520of%2520cell-cycle%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Oncol.%26date%3D2009%26volume%3D16%26spage%3D36%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span> </span><span class="NLM_article-title"><i>N</i>-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Y.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.+C.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.+C.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylamino%29acyl-2-aminothiazole+inhibitors+of+cyclin-dependent+kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-Dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-+piperidinecarboxamide+%28BMS-387032%29%2C+a+highly+efficacious+and+selective+antitumor+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%2BC.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylamino%2529acyl-2-aminothiazole%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-Dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-%2520piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520a%2520highly%2520efficacious%2520and%2520selective%2520antitumor%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chubb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawtin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunkett, W.</span><span> </span><span class="NLM_article-title">Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">4637</span><span class="NLM_x">–</span> <span class="NLM_lpage">4645</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4637-4645&author=R.+Chenauthor=W.+G.+Wierdaauthor=S.+Chubbauthor=R.+E.+Hawtinauthor=J.+A.+Foxauthor=M.+J.+Keatingauthor=V.+Gandhiauthor=W.+Plunkett&title=Mechanism+of+action+of+SNS-032%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+in+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DChubb%26aufirst%3DS.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DMechanism%2520of%2520action%2520of%2520SNS-032%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4637%26epage%3D4645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group">Choong, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafimova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkin, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoch, U.</span><span> </span><span class="NLM_article-title">A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5763</span><span class="NLM_x">–</span> <span class="NLM_lpage">5765</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.bmcl.2008.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18842409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12rs77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5763-5765&author=I.+C.+Choongauthor=I.+Serafimovaauthor=J.+Fanauthor=D.+Stockettauthor=E.+Chanauthor=S.+Cheetiauthor=Y.+Luauthor=B.+Fahrauthor=P.+Phamauthor=M.+R.+Arkinauthor=D.+H.+Walkerauthor=U.+Hoch&title=A+diaminocyclohexyl+analog+of+SNS-032+with+improved+permeability+and+bioavailability+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties</span></div><div class="casAuthors">Choong, Ingrid C.; Serafimova, Iana; Fan, Junfa; Stockett, David; Chan, Erica; Cheeti, Sravanthi; Lu, Yafan; Fahr, Bruce; Pham, Phuongly; Arkin, Michelle R.; Walker, Duncan H.; Hoch, Ute</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5763-5765</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The identification of a selective CDK2, 7, and 9 inhibitor (compd. 4) with improved permeability is described.  Compd. 4 exhibits comparable CDK selectivity profile to SNS-032, but shows improved permeability and higher bioavailability in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEqkByuQcxcbVg90H21EOLACvtfcHk0lg0h5dKvRSk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12rs77M&md5=d956b4c2e3b15b3d52ddd76f2cef997e</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DChoong%26aufirst%3DI.%2BC.%26aulast%3DSerafimova%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DStockett%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DFahr%26aufirst%3DB.%26aulast%3DPham%26aufirst%3DP.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DHoch%26aufirst%3DU.%26atitle%3DA%2520diaminocyclohexyl%2520analog%2520of%2520SNS-032%2520with%2520improved%2520permeability%2520and%2520bioavailability%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5763%26epage%3D5765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafimova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, I. C.</span><span> </span><span class="NLM_article-title">Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6236</span><span class="NLM_x">–</span> <span class="NLM_lpage">6239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6236-6239&author=J.+Fanauthor=B.+Fahrauthor=D.+Stockettauthor=E.+Chanauthor=S.+Cheetiauthor=I.+Serafimovaauthor=Y.+Luauthor=P.+Phamauthor=D.+H.+Walkerauthor=U.+Hochauthor=I.+C.+Choong&title=Modifications+of+the+isonipecotic+acid+fragment+of+SNS-032%3A+analogs+with+improved+permeability+and+lower+efflux+ratio"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DFahr%26aufirst%3DB.%26aulast%3DStockett%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DSerafimova%26aufirst%3DI.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPham%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DChoong%26aufirst%3DI.%2BC.%26atitle%3DModifications%2520of%2520the%2520isonipecotic%2520acid%2520fragment%2520of%2520SNS-032%253A%2520analogs%2520with%2520improved%2520permeability%2520and%2520lower%2520efflux%2520ratio%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6236%26epage%3D6239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.+Woolford&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group">Lapenna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Cell cycle kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+cycle+kinases+as+therapeutic+targets+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0lgZiMd3R71wrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group">Chu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkovitz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goelzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moliterni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span> </span><span class="NLM_article-title">Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6549</span><span class="NLM_x">–</span> <span class="NLM_lpage">6560</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0606138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6549-6560&author=X.+J.+Chuauthor=W.+DePintoauthor=D.+Bartkovitzauthor=S.+S.+Soauthor=B.+T.+Vuauthor=K.+Packmanauthor=C.+Lukacsauthor=Q.+Dingauthor=N.+Jiangauthor=K.+Wangauthor=P.+Goelzerauthor=X.+Yinauthor=M.+A.+Smithauthor=B.+X.+Higginsauthor=Y.+Chenauthor=Q.+Xiangauthor=J.+Moliterniauthor=G.+Kaplanauthor=B.+Gravesauthor=A.+Loveyauthor=N.+Fotouhi&title=Discovery+of+%5B4-amino-2-%281-methanesulfonylpiperidin-4-ylamino%29pyrimidin-5-yl%5D%282%2C3-difluoro-6-methoxyphenyl%29methanone+%28R547%29%2C+a+potent+and+selective+cyclin-dependent+kinase+inhibitor+with+significant+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1021%2Fjm0606138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0606138%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DX.%2BJ.%26aulast%3DDePinto%26aufirst%3DW.%26aulast%3DBartkovitz%26aufirst%3DD.%26aulast%3DSo%26aufirst%3DS.%2BS.%26aulast%3DVu%26aufirst%3DB.%2BT.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGoelzer%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DHiggins%26aufirst%3DB.%2BX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DMoliterni%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DLovey%26aufirst%3DA.%26aulast%3DFotouhi%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%255B4-amino-2-%25281-methanesulfonylpiperidin-4-ylamino%2529pyrimidin-5-yl%255D%25282%252C3-difluoro-6-methoxyphenyl%2529methanone%2520%2528R547%2529%252C%2520a%2520potent%2520and%2520selective%2520cyclin-dependent%2520kinase%2520inhibitor%2520with%2520significant%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6549%26epage%3D6560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’ Alessio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quartieri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5163</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99+Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N%2C1%2C4%2C4-tetramethyl-8-%7B%5B4-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+a+potent%2C+orally+available+cyclin+dependent+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599%2BAlessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N%252C1%252C4%252C4-tetramethyl-8-%257B%255B4-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520a%2520potent%252C%2520orally%2520available%2520cyclin%2520dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansonna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nugent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warpehoski, M. A.</span><span> </span><span class="NLM_article-title">3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3367</span><span class="NLM_x">–</span> <span class="NLM_lpage">3380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm031145u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3367-3380&author=P.+Pevarelloauthor=M.+G.+Brascaauthor=R.+Amiciauthor=P.+Orsiniauthor=G.+Traquandiauthor=L.+Cortiauthor=C.+Piuttiauthor=P.+Sansonnaauthor=M.+Villaauthor=B.+S.+Pierceauthor=M.+Puliciauthor=P.+Giordanoauthor=K.+Martinaauthor=E.+L.+Fritzenauthor=R.+A.+Nugentauthor=E.+Casaleauthor=A.+Cameronauthor=M.+Ciomeiauthor=F.+Rolettoauthor=A.+Isacchiauthor=G.+Fogliattoauthor=E.+Pesentiauthor=W.+Pastoriauthor=A.+Marsiglioauthor=K.+L.+Leachauthor=P.+M.+Clareauthor=F.+Fiorentiniauthor=M.+Varasiauthor=A.+Vulpettiauthor=M.+A.+Warpehoski&title=3-Aminopyrazole+inhibitors+of+CDK2%2Fcyclin+A+as+antitumor+agents.+1.+Lead+finding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1021%2Fjm031145u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031145u%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DPiutti%26aufirst%3DC.%26aulast%3DSansonna%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DFritzen%26aufirst%3DE.%2BL.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DClare%26aufirst%3DP.%2BM.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWarpehoski%26aufirst%3DM.%2BA.%26atitle%3D3-Aminopyrazole%2520inhibitors%2520of%2520CDK2%252Fcyclin%2520A%2520as%2520antitumor%2520agents.%25201.%2520Lead%2520finding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3367%26epage%3D3380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group">Vassilev, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tovar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knezevic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">10660</span><span class="NLM_x">–</span> <span class="NLM_lpage">10665</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=10660-10665&author=L.+T.+Vassilevauthor=C.+Tovarauthor=S.+Chenauthor=D.+Knezevicauthor=X.+Zhaoauthor=H.+Sunauthor=D.+C.+Heimbrookauthor=L.+Chen&title=Selective+small-molecule+inhibitor+reveals+critical+mitotic+functions+of+human+CDK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26aulast%3DTovar%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKnezevic%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSelective%2520small-molecule%2520inhibitor%2520reveals%2520critical%2520mitotic%2520functions%2520of%2520human%2520CDK1%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D10660%26epage%3D10665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref242"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref242'); return false;" data-citation="" class="refNumLink">242</a></strong><div class="NLM_citation" id="cit242"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lh6Pq7Au9fzpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref243"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref243'); return false;" data-citation="" class="refNumLink">243</a></strong><div class="NLM_citation" id="cit243"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, J. R.</span><span> </span><span class="NLM_article-title">CDK inhibitors in cancer therapy: what is next?</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=16-21&author=M.+Malumbresauthor=P.+Pevarelloauthor=M.+Barbacidauthor=J.+R.+Bischoff&title=CDK+inhibitors+in+cancer+therapy%3A+what+is+next%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26atitle%3DCDK%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520what%2520is%2520next%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D16%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref244"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref244'); return false;" data-citation="" class="refNumLink">244</a></strong><div class="NLM_citation" id="cit244"><span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. C.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: inhibitors in clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+de+Waterauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=D.+Perretauthor=W.+C.+Lee&title=Heat+shock+protein+90%3A+inhibitors+in+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0lh6Pq7Au9fzpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%2BC.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520inhibitors%2520in%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref245"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref245'); return false;" data-citation="" class="refNumLink">245</a></strong><div class="NLM_citation" id="cit245"><span><span class="NLM_contrib-group">Pollard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimore, M.</span><span> </span><span class="NLM_article-title">Discovery and development of Aurora kinase inhibitors as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2629</span><span class="NLM_x">–</span> <span class="NLM_lpage">2651</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2629-2651&author=J.+R.+Pollardauthor=M.+Mortimore&title=Discovery+and+development+of+Aurora+kinase+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Pollard, John R.; Mortimore, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2629-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article summarizes the roles that each of the Aurora kinases plays in mitosis and cancer biol. and discusses how different Aurora inhibition selectivity profiles impact the cellular and in vivo behavior of the drug candidates.  In addn., the wealth of structural biol. information for the Aurora kinases is reviewed.  This will be used to provide a rationale for the cross-reactivity profiles of some the Aurora kinase drug candidates and will review current theories for how selectivity within the Aurora kinase family has been achieved.  Finally the discovery and development of the clin. candidates targeting Aurora kinases will be summarized together with a brief discussion of notable structure-activity relationships (SAR).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojisjXqX2odrVg90H21EOLACvtfcHk0ljvyeKwB4h_SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D&md5=bb59ec8929dd81ae89e606cfb84f18df</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1021%2Fjm8012129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012129%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMortimore%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Aurora%2520kinase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2629%26epage%3D2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref246"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref246'); return false;" data-citation="" class="refNumLink">246</a></strong><div class="NLM_citation" id="cit246"><span><span class="NLM_contrib-group">Deangelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fearen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallob, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aster, J.</span><span> </span><span class="NLM_article-title">A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">6585</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=6585&author=D.+J.+Deangeloauthor=R.+M.+Stoneauthor=L.+B.+Silvermanauthor=W.+Stockauthor=E.+C.+Attarauthor=I.+Fearenauthor=A.+Dallobauthor=C.+Matthewsauthor=J.+Stoneauthor=S.+J.+Freedmanauthor=J.+Aster&title=A+phase+I+clinical+trial+of+the+notch+inhibitor+MK-0752+in+patients+with+T-cell+acute+lymphoblastic+leukemia%2Flymphoma+%28T-ALL%29+and+other+leukemias"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeangelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSilverman%26aufirst%3DL.%2BB.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DAttar%26aufirst%3DE.%2BC.%26aulast%3DFearen%26aufirst%3DI.%26aulast%3DDallob%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DC.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26aulast%3DAster%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520of%2520the%2520notch%2520inhibitor%2520MK-0752%2520in%2520patients%2520with%2520T-cell%2520acute%2520lymphoblastic%2520leukemia%252Flymphoma%2520%2528T-ALL%2529%2520and%2520other%2520leukemias%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D6585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref247"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref247'); return false;" data-citation="" class="refNumLink">247</a></strong><div class="NLM_citation" id="cit247"><span><span class="NLM_contrib-group">Tamm, I.</span><span> </span><span class="NLM_article-title">AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">646</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=638-646&author=I.+Tamm&title=AEG-35156%2C+an+antisense+oligonucleotide+against+X-linked+inhibitor+of+apoptosis+for+the+potential+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamm%26aufirst%3DI.%26atitle%3DAEG-35156%252C%2520an%2520antisense%2520oligonucleotide%2520against%2520X-linked%2520inhibitor%2520of%2520apoptosis%2520for%2520the%2520potential%2520treatment%2520of%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D638%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref248"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref248'); return false;" data-citation="" class="refNumLink">248</a></strong><div class="NLM_citation" id="cit248"><span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallman, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandwein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCasse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolivet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4741</span><span class="NLM_x">–</span> <span class="NLM_lpage">4746</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2009.21.8172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19652057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4741-4746&author=A.+D.+Schimmerauthor=E.+H.+Esteyauthor=G.+Borthakurauthor=B.+Z.+Carterauthor=G.+J.+Schillerauthor=M.+S.+Tallmanauthor=J.+K.+Altmanauthor=J.+E.+Karpauthor=J.+Kassisauthor=D.+W.+Hedleyauthor=J.+Brandweinauthor=W.+Xuauthor=D.+H.+Makauthor=E.+LaCasseauthor=C.+Jacobauthor=S.+J.+Morrisauthor=J.+Jolivetauthor=M.+Andreeff&title=Phase+I%2FII+trial+of+AEG35156+X-linked+inhibitor+of+apoptosis+protein+antisense+oligonucleotide+combined+with+idarubicin+and+cytarabine+in+patients+with+relapsed+or+primary+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia</span></div><div class="casAuthors">Schimmer, Aaron D.; Estey, Elihu H.; Borthakur, Gautam; Carter, Bing Z.; Schiller, Gary J.; Tallman, Martin S.; Altman, Jessica K.; Karp, Judith E.; Kassis, Jeannine; Hedley, David W.; Brandwein, Joseph; Xu, Wei; Mak, Duncan H.; La Casse, Eric; Jacob, Christine; Morris, Stephen J.; Jolivet, Jacques; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">4741-4746</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: X-linked inhibitor of apoptosis protein (XIAP) is an inhibitor of caspases 3 and 9 which are overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance.  We report on a phase I/II trial of the XIAP antisense oligonucleotide AEG35156 in combination with reinduction chemotherapy.  Patients and Methods: Twenty-four patients with rapidly relapsed or refractory AML were treated with escalating doses of AEG35156 (12 to 250 mg/m2) as an i.v. soln. over 2 h and 32 patients were treated with the highest planned dose of 350 mg/m2 in combination with idarubicin and high-dose cytarabine reinduction chemotherapy.  Correlative studies were conducted to det. the effects of AEG35156 on levels of XIAP mRNA.  Results: Knockdown of XIAP mRNA during treatment increased with the dose of the antisense.  All patients who received 350 mg/m2 of AEG35156 had higher than 30% target knockdown with a median maximal knockdown of 90% (range, 48% to 100%).  The overall response rate was higher among the patients receiving the highest dose of AEG35156.  In this group, 15 (47%) of 32 patients achieved complete response (CR)/CR with incomplete platelet count recovery (CRp) compared with only one (4%) of 24 receiving 12 to 250 mg/m2 AEG35156.  Among the patients receiving 350 mg/m2 of AEG35156 in combination with chemotherapy, 10 (91%) of 11 who were refractory to a single induction chemotherapy regimen achieved CR/CRp after reinduction with AEG35156 and chemotherapy.  AEG35156 was well:tolerated save for two cases of peripheral neuropathy in patients receiving multiple doses of AEG35156.  Conclusion: At the highest dose tested, AEG35156 knocks down its target and appears very effective when combined with chemotherapy in patients with AML refractory to a single induction regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPRjZ4-Ji1c7Vg90H21EOLACvtfcHk0ljvyeKwB4h_SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbN&md5=5accdec3d8e3e12e23f327f4a24b0ad4</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.21.8172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.21.8172%26sid%3Dliteratum%253Aachs%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DEstey%26aufirst%3DE.%2BH.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCarter%26aufirst%3DB.%2BZ.%26aulast%3DSchiller%26aufirst%3DG.%2BJ.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DKassis%26aufirst%3DJ.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26aulast%3DBrandwein%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DMak%26aufirst%3DD.%2BH.%26aulast%3DLaCasse%26aufirst%3DE.%26aulast%3DJacob%26aufirst%3DC.%26aulast%3DMorris%26aufirst%3DS.%2BJ.%26aulast%3DJolivet%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DPhase%2520I%252FII%2520trial%2520of%2520AEG35156%2520X-linked%2520inhibitor%2520of%2520apoptosis%2520protein%2520antisense%2520oligonucleotide%2520combined%2520with%2520idarubicin%2520and%2520cytarabine%2520in%2520patients%2520with%2520relapsed%2520or%2520primary%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4741%26epage%3D4746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref249"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref249'); return false;" data-citation="" class="refNumLink">249</a></strong><div class="NLM_citation" id="cit249"><span><span class="NLM_contrib-group">Lai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CU-0201, a potent, small molecule, multi-targeted inhibitor of HDAC, Abl and Src, effectively inhibits proliferation of both hematological and solid-tumor derived cancer cell lines</span> <span class="citation_source-journal">AACR Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2008</span><span class="NLM_x">, </span> <span class="NLM_fpage">5717</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2008&publication_year=2008&pages=5717&author=C.+Laiauthor=X.+Taoauthor=S.+Liuauthor=Y.+Liuauthor=L.+Zhangauthor=R.+Baoauthor=X.+Caiauthor=H.-X.+Zhaiauthor=C.+Qian&title=CU-0201%2C+a+potent%2C+small+molecule%2C+multi-targeted+inhibitor+of+HDAC%2C+Abl+and+Src%2C+effectively+inhibits+proliferation+of+both+hematological+and+solid-tumor+derived+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCU-0201%252C%2520a%2520potent%252C%2520small%2520molecule%252C%2520multi-targeted%2520inhibitor%2520of%2520HDAC%252C%2520Abl%2520and%2520Src%252C%2520effectively%2520inhibits%2520proliferation%2520of%2520both%2520hematological%2520and%2520solid-tumor%2520derived%2520cancer%2520cell%2520lines%26jtitle%3DAACR%2520Meet.%2520Abstr.%26date%3D2008%26volume%3D2008%26spage%3D5717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref250"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref250'); return false;" data-citation="" class="refNumLink">250</a></strong><div class="NLM_citation" id="cit250"><span><span class="NLM_contrib-group">Kang, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plescia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scroggins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altieri, D. C.</span><span> </span><span class="NLM_article-title">Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">454</span><span class="NLM_x">–</span> <span class="NLM_lpage">464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1172%2FJCI37613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19229106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=454-464&author=B.+H.+Kangauthor=J.+Plesciaauthor=H.+Y.+Songauthor=M.+Meliauthor=G.+Colomboauthor=K.+Beebeauthor=B.+Scrogginsauthor=L.+Neckersauthor=D.+C.+Altieri&title=Combinatorial+drug+design+targeting+multiple+cancer+signaling+networks+controlled+by+mitochondrial+Hsp90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90</span></div><div class="casAuthors">Kang, Byoung Heon; Plescia, Janet; Song, Ho Young; Meli, Massimiliano; Colombo, Giorgio; Beebe, Kristin; Scroggins, Bradley; Neckers, Len; Altieri, Dario C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">454-464</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Although therapeutically targeting a single signaling pathway that drives tumor development and/or progression has been effective for a no. of cancers, in many cases this approach has not been successful.  Targeting networks of signaling pathways, instead of isolated pathways, may overcome this problem, which is probably due to the extreme heterogeneity of human tumors.  However, the possibility that such networks may be spatially arranged in specialized subcellular compartments is not often considered in pathway-oriented drug discovery and may influence the design of new agents.  Hsp90 is a chaperone protein that controls the folding of proteins in multiple signaling networks that drive tumor development and progression.  Here, we report the synthesis and properties of Gamitrinibs, a class of small mols. designed to selectively target Hsp90 in human tumor mitochondria.  Gamitrinibs were shown to accumulate in the mitochondria of human tumor cell lines and to inhibit Hsp90 activity by acting as ATPase antagonists.  Unlike Hsp90 antagonists not targeted to mitochondria, Gamitrinibs exhibited a "mitochondriotoxic" mechanism of action, causing rapid tumor cell death and inhibiting the growth of xenografted human tumor cell lines in mice.  Importantly, Gamitrinibs were not toxic to normal cells or tissues and did not affect Hsp90 homeostasis in cellular compartments other than mitochondria.  Therefore, combinatorial drug design, whereby inhibitors of signaling networks are targeted to specific subcellular compartments, may generate effective anticancer drugs with novel mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwkmCaJwfFbrVg90H21EOLACvtfcHk0ljap6ejBKf55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2kt78%253D&md5=fe90af9059cb26c6f906c7cea2a17432</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1172%2FJCI37613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI37613%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DB.%2BH.%26aulast%3DPlescia%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DH.%2BY.%26aulast%3DMeli%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DScroggins%26aufirst%3DB.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DAltieri%26aufirst%3DD.%2BC.%26atitle%3DCombinatorial%2520drug%2520design%2520targeting%2520multiple%2520cancer%2520signaling%2520networks%2520controlled%2520by%2520mitochondrial%2520Hsp90%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D454%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref251"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref251'); return false;" data-citation="" class="refNumLink">251</a></strong><div class="NLM_citation" id="cit251"><span><span class="NLM_contrib-group">Kamb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span> </span><span class="NLM_article-title">Why is cancer drug discovery so difficult?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=115-120&author=A.+Kambauthor=S.+Weeauthor=C.+Lengauer&title=Why+is+cancer+drug+discovery+so+difficult%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DWhy%2520is%2520cancer%2520drug%2520discovery%2520so%2520difficult%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D115%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref252"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref252'); return false;" data-citation="" class="refNumLink">252</a></strong><div class="NLM_citation" id="cit252"><span><span class="NLM_contrib-group">Bonnet, D.</span><span> </span><span class="NLM_article-title">Normal and leukaemic stem cells</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1111%2Fj.1365-2141.2005.05596.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16098060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVentb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2005&pages=469-479&author=D.+Bonnet&title=Normal+and+leukaemic+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Normal and leukaemic stem cells</span></div><div class="casAuthors">Bonnet, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-479</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The blood-related cancer leukemias were the first diseases where human cancer stem cells, or leukemic stem cells (LSC), were isolated.  The hematopoietic system is one of the best tissues for investigating cancer stem cells, because the developmental hierarchy of normal blood formation is well defined.  Leukemias can now be viewed as aberrant hematopoietic processes initiated by rare LSC that have maintained or reacquired the capacity for indefinite proliferation through accumulated mutations and/or epigenetic changes.  Yet, despite their crit. importance, much remains to be learned about the developmental origin of LSC and the mechanisms responsible for their emergence in the course of the disease.  This report will review our current knowledge on normal and LSC development and examine the impact of these discoveries may have clin. and in our understanding of the leukemogenic process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeycxtJ9l9x7Vg90H21EOLACvtfcHk0ljap6ejBKf55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVentb%252FO&md5=15be1b20cc64ae92c080b2e923e15df5</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2005.05596.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2005.05596.x%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DNormal%2520and%2520leukaemic%2520stem%2520cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2005%26volume%3D130%26spage%3D469%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref253"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref253'); return false;" data-citation="" class="refNumLink">253</a></strong><div class="NLM_citation" id="cit253"><span><span class="NLM_contrib-group">Passegue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ailles, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, I. L.</span><span> </span><span class="NLM_article-title">Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11842</span><span class="NLM_x">–</span> <span class="NLM_lpage">11849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11842-11849&issue=Suppl.+1&author=E.+Passegueauthor=C.+H.+Jamiesonauthor=L.+E.+Aillesauthor=I.+L.+Weissman&title=Normal+and+leukemic+hematopoiesis%3A+are+leukemias+a+stem+cell+disorder+or+a+reacquisition+of+stem+cell+characteristics%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPassegue%26aufirst%3DE.%26aulast%3DJamieson%26aufirst%3DC.%2BH.%26aulast%3DAilles%26aufirst%3DL.%2BE.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26atitle%3DNormal%2520and%2520leukemic%2520hematopoiesis%253A%2520are%2520leukemias%2520a%2520stem%2520cell%2520disorder%2520or%2520a%2520reacquisition%2520of%2520stem%2520cell%2520characteristics%253F%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26issue%3DSuppl.%25201%26spage%3D11842%26epage%3D11849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref254"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref254'); return false;" data-citation="" class="refNumLink">254</a></strong><div class="NLM_citation" id="cit254"><span><span class="NLM_contrib-group">Zou, G. M.</span><span> </span><span class="NLM_article-title">Cancer stem cells in leukemia, recent advances</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fjcp.21140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17541982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=440-444&author=G.+M.+Zou&title=Cancer+stem+cells+in+leukemia%2C+recent+advances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in leukemia, recent advances</span></div><div class="casAuthors">Zou, Gang-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">440-444</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The history of stem cell research was started in the early 1900s in Europe where the researcher realized that various types of blood cells came from a particular "stem cells.".  However, it was not until 1963 that the first quant. description of the self-renewal activities of transplanted mouse bone marrow cells were documented by Canadian scientist Ernest A McCulloch and James E Till in Toronto.  The concept of cancer stem cells was used over 50 years ago; whereas the strong evidence for the existence of a Cancer Stem Cells was obtained recently.  Consequently, there is increasing attention in recent year about cancer stem cells.  The findings from recent studies support the concept that stem cells are integral to the development of several forms of human cancer.  Changes in stem cell behavior can contribute to tumor formation.  Leukemia is a cancer of blood-forming tissue, including the bone marrow and lymphatic system.  Leukemic stem cells represent the cancer stem cells in the leukemia.  In this review, we summarize the recent advance in the study of leukemic stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1E0vG_tSOLVg90H21EOLACvtfcHk0ljap6ejBKf55g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7vL&md5=53b983f72e13d6bef49ca2d300101d3e</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21140%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DG.%2BM.%26atitle%3DCancer%2520stem%2520cells%2520in%2520leukemia%252C%2520recent%2520advances%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D440%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref255"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref255'); return false;" data-citation="" class="refNumLink">255</a></strong><div class="NLM_citation" id="cit255"><span><span class="NLM_contrib-group">Kavalerchik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, C. H.</span><span> </span><span class="NLM_article-title">Chronic myeloid leukemia stem cells</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2911</span><span class="NLM_x">–</span> <span class="NLM_lpage">2915</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2008.17.5745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18539972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1czntFOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2911-2915&author=E.+Kavalerchikauthor=D.+Goffauthor=C.+H.+Jamieson&title=Chronic+myeloid+leukemia+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myeloid leukemia stem cells</span></div><div class="casAuthors">Kavalerchik Edward; Goff Daniel; Jamieson Catriona H M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2911-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although rare, chronic myeloid leukemia (CML) represents an important paradigm for understanding the molecular events leading to malignant transformation of primitive hematopoietic progenitors.  CML was the first cancer to be associated with a defined genetic abnormality, BCR-ABL, that is necessary and sufficient for initiating chronic phase disease as well as the first cancer to be treated with molecular targeted therapy.  Malignant progenitors or leukemia stem cells (LSCs) evolve as a result of both epigenetic and genetic events that alter hematopoietic progenitor differentiation, proliferation, survival, and self-renewal.  LSCs are rare and divide less frequently, and thus, represent a reservoir for relapse and resistance to a molecularly targeted single agent.  On subverting developmental processes normally responsible for maintaining robust life-long hematopoiesis, the LSCs are able to evade the majority of current cancer treatments that target rapidly dividing cells.  Enthusiasm for the enormous success of tyrosine kinase inhibitors at controlling the chronic phase disease is tempered somewhat by the persistence of the LSC pool in the majority of the patients.  Combined therapies targeting aberrant properties of LSC may obviate therapeutic resistance and relapse in advanced phase and therapeutically recalcitrant CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEj901OUiIPENoizSOkG_FfW6udTcc2ebJUQMw5DeI5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czntFOhtg%253D%253D&md5=b331eb46b7f19258a52a32d40e1d0ec6</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.5745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.5745%26sid%3Dliteratum%253Aachs%26aulast%3DKavalerchik%26aufirst%3DE.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DJamieson%26aufirst%3DC.%2BH.%26atitle%3DChronic%2520myeloid%2520leukemia%2520stem%2520cells%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2911%26epage%3D2915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref256"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref256'); return false;" data-citation="" class="refNumLink">256</a></strong><div class="NLM_citation" id="cit256"><span><span class="NLM_contrib-group">Lane, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scadden, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">The leukemic stem cell niche: current concepts and therapeutic opportunities</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1150</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1150-1157&author=S.+W.+Laneauthor=D.+T.+Scaddenauthor=D.+G.+Gilliland&title=The+leukemic+stem+cell+niche%3A+current+concepts+and+therapeutic+opportunities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DS.%2BW.%26aulast%3DScadden%26aufirst%3DD.%2BT.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DThe%2520leukemic%2520stem%2520cell%2520niche%253A%2520current%2520concepts%2520and%2520therapeutic%2520opportunities%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1150%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref257"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref257'); return false;" data-citation="" class="refNumLink">257</a></strong><div class="NLM_citation" id="cit257"><span><span class="NLM_contrib-group">Hill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span> </span><span class="NLM_article-title">PTEN, stem cells, and cancer stem cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">11755</span><span class="NLM_x">–</span> <span class="NLM_lpage">11759</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=11755-11759&author=R.+Hillauthor=H.+Wu&title=PTEN%2C+stem+cells%2C+and+cancer+stem+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DPTEN%252C%2520stem%2520cells%252C%2520and%2520cancer%2520stem%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D11755%26epage%3D11759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref258"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref258'); return false;" data-citation="" class="refNumLink">258</a></strong><div class="NLM_citation" id="cit258"><span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosessian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iruela-Arispe, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span> </span><span class="NLM_article-title">Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">453</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2008&pages=529-533&author=W.+Guoauthor=J.+L.+Laskyauthor=C.+J.+Changauthor=S.+Mosessianauthor=X.+Lewisauthor=Y.+Xiaoauthor=J.+E.+Yehauthor=J.+Y.+Chenauthor=M.+L.+Iruela-Arispeauthor=M.+Varella-Garciaauthor=H.+Wu&title=Multi-genetic+events+collaboratively+contribute+to+Pten-null+leukaemia+stem-cell+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DLasky%26aufirst%3DJ.%2BL.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DMosessian%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DJ.%2BE.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DIruela-Arispe%26aufirst%3DM.%2BL.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DMulti-genetic%2520events%2520collaboratively%2520contribute%2520to%2520Pten-null%2520leukaemia%2520stem-cell%2520formation%26jtitle%3DNature%26date%3D2008%26volume%3D453%26spage%3D529%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref259"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref259'); return false;" data-citation="" class="refNumLink">259</a></strong><div class="NLM_citation" id="cit259"><span><span class="NLM_contrib-group">Essers, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco-Bose, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waibler, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinke, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchosal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp, A.</span><span> </span><span class="NLM_article-title">IFNalpha activates dormant haematopoietic stem cells in vivo</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">458</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=904-908&author=M.+A.+Essersauthor=S.+Offnerauthor=W.+E.+Blanco-Boseauthor=Z.+Waiblerauthor=U.+Kalinkeauthor=M.+A.+Duchosalauthor=A.+Trumpp&title=IFNalpha+activates+dormant+haematopoietic+stem+cells+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEssers%26aufirst%3DM.%2BA.%26aulast%3DOffner%26aufirst%3DS.%26aulast%3DBlanco-Bose%26aufirst%3DW.%2BE.%26aulast%3DWaibler%26aufirst%3DZ.%26aulast%3DKalinke%26aufirst%3DU.%26aulast%3DDuchosal%26aufirst%3DM.%2BA.%26aulast%3DTrumpp%26aufirst%3DA.%26atitle%3DIFNalpha%2520activates%2520dormant%2520haematopoietic%2520stem%2520cells%2520in%2520vivo%26jtitle%3DNature%26date%3D2009%26volume%3D458%26spage%3D904%26epage%3D908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref260"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref260'); return false;" data-citation="" class="refNumLink">260</a></strong><div class="NLM_citation" id="cit260"><span><span class="NLM_contrib-group">Sipkins, D. A.</span><span> </span><span class="NLM_article-title">Rendering the leukemia cell susceptible to attack</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1307</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1056%2FNEJMcibr0904291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19776414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wjur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1307-1309&author=D.+A.+Sipkins&title=Rendering+the+leukemia+cell+susceptible+to+attack"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Rendering the leukemia cell susceptible to attack</span></div><div class="casAuthors">Sipkins, Dorothy A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1307-1309</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyHjj_mV-1IbVg90H21EOLACvtfcHk0ljzDNahjWfDQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wjur%252FF&md5=fc08183619b47c1a579b49aa354c3220</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1056%2FNEJMcibr0904291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcibr0904291%26sid%3Dliteratum%253Aachs%26aulast%3DSipkins%26aufirst%3DD.%2BA.%26atitle%3DRendering%2520the%2520leukemia%2520cell%2520susceptible%2520to%2520attack%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1307%26epage%3D1309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref261"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref261'); return false;" data-citation="" class="refNumLink">261</a></strong><div class="NLM_citation" id="cit261"><span><span class="NLM_contrib-group">Forsberg, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passegue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prohaska, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagers, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, I. L.</span><span> </span><span class="NLM_article-title">Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e8785</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e8785&author=E.+C.+Forsbergauthor=E.+Passegueauthor=S.+S.+Prohaskaauthor=A.+J.+Wagersauthor=M.+Koevaauthor=J.+M.+Stuartauthor=I.+L.+Weissman&title=Molecular+signatures+of+quiescent%2C+mobilized+and+leukemia-initiating+hematopoietic+stem+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForsberg%26aufirst%3DE.%2BC.%26aulast%3DPassegue%26aufirst%3DE.%26aulast%3DProhaska%26aufirst%3DS.%2BS.%26aulast%3DWagers%26aufirst%3DA.%2BJ.%26aulast%3DKoeva%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DJ.%2BM.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26atitle%3DMolecular%2520signatures%2520of%2520quiescent%252C%2520mobilized%2520and%2520leukemia-initiating%2520hematopoietic%2520stem%2520cells%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De8785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref262"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref262'); return false;" data-citation="" class="refNumLink">262</a></strong><div class="NLM_citation" id="cit262"><span><span class="NLM_contrib-group">Buzzai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licht, J. D.</span><span> </span><span class="NLM_article-title">New molecular concepts and targets in acute myeloid leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FMOH.0b013e3282f3ded0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18300752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjslWisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=82-87&author=M.+Buzzaiauthor=J.+D.+Licht&title=New+molecular+concepts+and+targets+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">New molecular concepts and targets in acute myeloid leukemia</span></div><div class="casAuthors">Buzzai, Monica; Licht, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">82-87</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Most patients with acute myeloid leukemia treated with chemotherapy relapse.  It is increasingly recognized that the cause of chemoresistance and relapse resides within the leukemia stem cell population.  Successful eradication of leukemia stem cells would require a comprehensive profile of both the acquired mol. lesions and intrinsic features of leukemia stem cells.  This review describes recent work identifying mol. markers that may lead to development of novel therapeutics, ultimately aiming to eradicate leukemia stem cells in acute myeloid leukemia.  Recent findings: In recent years, novel specific cell surface antigens have allowed identification of leukemia stem cells and permitted their distinction from normal hematopoietic stem cells.  Novel concepts of leukemia stem cells and niche interaction have elucidated the mechanisms that control leukemia stem cell survival and chemoresistance.  Recent detection of genetic aberrations affecting regulators of HOX gene expression and chromatin modifying enzymes, such as CDX2 and hDOT1L, resp., elucidates new key players in stem cell self-renewal and leukemic transformation.  Summary: The discovery of novel markers and survival pathways for leukemia stem cells has increased our potential to specifically target and eliminate the leukemic stem cell compartment, which is likely to improve clin. outcomes in acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkaiagIzCJkbVg90H21EOLACvtfcHk0ljX8Z8s8-vlbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjslWisLo%253D&md5=53848253a2201d2d77b2ed567b986d00</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e3282f3ded0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e3282f3ded0%26sid%3Dliteratum%253Aachs%26aulast%3DBuzzai%26aufirst%3DM.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26atitle%3DNew%2520molecular%2520concepts%2520and%2520targets%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2008%26volume%3D15%26spage%3D82%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref263"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref263'); return false;" data-citation="" class="refNumLink">263</a></strong><div class="NLM_citation" id="cit263"><span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span> </span><span class="NLM_article-title">Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2165%2F00003088-200746100-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17854232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yktr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=807-824&author=I.+S.+Vizirianakis&title=Clinical+translation+of+genotyping+and+haplotyping+data%3A+implementation+of+in+vivo+pharmacology+experience+leading+drug+prescription+to+pharmacotyping"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping</span></div><div class="casAuthors">Vizirianakis, Ioannis S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">807-824</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  The completion of the Human Genome Project has raised expectations for the translation of genomic knowledge into clin. forms that would lead to improved diagnosis of diseases and identification of new drug targets.  Such an opportunity is quite challenging within science and society, although there is still uncertainty regarding its outcomes in new drug development and healthcare.  Undoubtedly, however, the recent approval by the US FDA of the first two pharmacogenomic tests for genotyping drug-metabolizing enzymes is expected to empower and eventually lead to general applicability of various genetic diagnostic tools to improve pharmacotherapy outcomes in the post-genomic era.  To this end, the application of genomic knowledge and technologies in everyday clin. practice leads personalized medicine concepts towards the achievement of individualized drug selection and dosage profiling (i.e. pharmacotyping) for ensuring max. drug effectiveness and safety.  Within this framework, pharmacogenomic information can implement the existing clin. pharmacol. experience in clin. diagnosis and drug delivery.  The latter can be further advanced through the development of workflow information-based operating systems in healthcare to support the utilization, assessment and outcome of engaged clin. and genomic information.  Such a direction may help to suitably revise and adjust clin. regulatory guidelines as well as clin. pharmacol. guidelines.  This will further facilitate better designing of clin. trials for new drug development as well as pharmacovigilance registries and evaluation of these data.  To critically describe the existing environment, this article comprehensively discusses scientific efforts aimed at making clin. translation of genotyping and haplotyping data more efficient and productive in forms that are readily applicable in everyday healthcare.  In addn., specific and systematic pharmacogenomic and clin. attempts related to the development of new molecularly targeted drugs, as well as improvement of the efficacy and safety of commonly prescribed drugs, are presented.  To this end, the clin. pharmacogenomic experience gained thus far in the use of tyrosine kinase inhibitors in oncol., as well as the process of empowerment through the use of genomic knowledge of the cardiac safety of drugs modulating the function of the human ether-a-go-go-related gene (HERG) potassium channel, represent examples of how the implementation of clin. experience with genomic information guides the development of new drugs and the improvement of pharmacotherapy outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOsrPLCpNNyLVg90H21EOLACvtfcHk0ljX8Z8s8-vlbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yktr%252FN&md5=c30091c9bd805d5fd8ad183d7958419f</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.2165%2F00003088-200746100-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200746100-00001%26sid%3Dliteratum%253Aachs%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26atitle%3DClinical%2520translation%2520of%2520genotyping%2520and%2520haplotyping%2520data%253A%2520implementation%2520of%2520in%2520vivo%2520pharmacology%2520experience%2520leading%2520drug%2520prescription%2520to%2520pharmacotyping%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2007%26volume%3D46%26spage%3D807%26epage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref264"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref264'); return false;" data-citation="" class="refNumLink">264</a></strong><div class="NLM_citation" id="cit264"><span><span class="NLM_contrib-group">Evans, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Relling, M. V.</span><span> </span><span class="NLM_article-title">Pharmacogenomics: translating functional genomics into rational therapeutics</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=487-491&author=W.+E.+Evansauthor=M.+V.+Relling&title=Pharmacogenomics%3A+translating+functional+genomics+into+rational+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DW.%2BE.%26aulast%3DRelling%26aufirst%3DM.%2BV.%26atitle%3DPharmacogenomics%253A%2520translating%2520functional%2520genomics%2520into%2520rational%2520therapeutics%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D487%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref265"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref265'); return false;" data-citation="" class="refNumLink">265</a></strong><div class="NLM_citation" id="cit265"><span><span class="NLM_contrib-group">Weinshilboum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span> </span><span class="NLM_article-title">Pharmacogenomics: bench to bedside</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=739-748&author=R.+Weinshilboumauthor=L.+Wang&title=Pharmacogenomics%3A+bench+to+bedside"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeinshilboum%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DPharmacogenomics%253A%2520bench%2520to%2520bedside%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D739%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref266"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref266'); return false;" data-citation="" class="refNumLink">266</a></strong><div class="NLM_citation" id="cit266"><span><span class="NLM_contrib-group">Bullinger, L.; Dohner, H.; Pollack, J. R.</span><span> </span><span class="NLM_article-title">Genomics in Leukemias</span>. In  <span class="citation_source-book">Genomics and Personalized Medicine</span>; <span class="NLM_contrib-group">Willard, H. F.; Ginsbeing, G. S.</span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Burlington, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">844</span>− <span class="NLM_lpage">855</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FB978-0-12-369420-1.00070-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=844-855&author=L.+Bullinger&author=H.+Dohner&author=J.+R.+Pollackauthor=H.+F.+Willard&author=G.+S.+Ginsbeing&title=Genomics+and+Personalized+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-369420-1.00070-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-369420-1.00070-6%26sid%3Dliteratum%253Aachs%26aulast%3DBullinger%26aufirst%3DL.%26atitle%3DGenomics%2520in%2520Leukemias%26btitle%3DGenomics%2520and%2520Personalized%2520Medicine%26aulast%3DWillard%26aufirst%3DH.%2BF.%26pub%3DElsevier%26date%3D2009%26spage%3D844%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref267"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref267'); return false;" data-citation="" class="refNumLink">267</a></strong><div class="NLM_citation" id="cit267"><span><span class="NLM_contrib-group">Tamayo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slonim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesirov, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitareewan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dmitrovsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lander, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">2907</span><span class="NLM_x">–</span> <span class="NLM_lpage">2912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=2907-2912&author=P.+Tamayoauthor=D.+Slonimauthor=J.+Mesirovauthor=Q.+Zhuauthor=S.+Kitareewanauthor=E.+Dmitrovskyauthor=E.+S.+Landerauthor=T.+R.+Golub&title=Interpreting+patterns+of+gene+expression+with+self-organizing+maps%3A+methods+and+application+to+hematopoietic+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DSlonim%26aufirst%3DD.%26aulast%3DMesirov%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DKitareewan%26aufirst%3DS.%26aulast%3DDmitrovsky%26aufirst%3DE.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DInterpreting%2520patterns%2520of%2520gene%2520expression%2520with%2520self-organizing%2520maps%253A%2520methods%2520and%2520application%2520to%2520hematopoietic%2520differentiation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D2907%26epage%3D2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref268"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref268'); return false;" data-citation="" class="refNumLink">268</a></strong><div class="NLM_citation" id="cit268"><span><span class="NLM_contrib-group">Karas-Kuzelicki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mlinaric-Rascan, I.</span><span> </span><span class="NLM_article-title">Individualization of thiopurine therapy: thiopurine <i>S</i>-methyltransferase and beyond</span> <span class="citation_source-journal">Pharmacogenomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1309-1322&author=N.+Karas-Kuzelickiauthor=I.+Mlinaric-Rascan&title=Individualization+of+thiopurine+therapy%3A+thiopurine+S-methyltransferase+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaras-Kuzelicki%26aufirst%3DN.%26aulast%3DMlinaric-Rascan%26aufirst%3DI.%26atitle%3DIndividualization%2520of%2520thiopurine%2520therapy%253A%2520thiopurine%2520S-methyltransferase%2520and%2520beyond%26jtitle%3DPharmacogenomics%26date%3D2009%26volume%3D10%26spage%3D1309%26epage%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref269"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref269'); return false;" data-citation="" class="refNumLink">269</a></strong><div class="NLM_citation" id="cit269"><span><span class="NLM_contrib-group">Cheok, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pottier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kager, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, W. E.</span><span> </span><span class="NLM_article-title">Pharmacogenetics in acute lymphoblastic leukemia</span> <span class="citation_source-journal">Semin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1053%2Fj.seminhematol.2008.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19100367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=39-51&author=M.+H.+Cheokauthor=N.+Pottierauthor=L.+Kagerauthor=W.+E.+Evans&title=Pharmacogenetics+in+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmocogenetics in acute lymphoblastic leukemia</span></div><div class="casAuthors">Cheok, Meyling H.; Pottier, Nicolas; Kager, Leo; Evans, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">SEHEA3</span>;
        ISSN:<span class="NLM_cas:issn">0037-1963</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.  This exemplary progress is largely due to the optimization of existing treatment modalities rather than the discovery of new antileukemic agents.  However, despite these high cure rates, the annual no. of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers.  The aim of pharmacogenetics is to develop strategies to personalize treatment and tailor therapy to individual patients, with the goal of optimizing efficacy and safety through better understanding of human genome variability and its influence on drug response.  In this review, we summarize recent pharmacogenomic studies related to the treatment of pediatric ALL.  These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp77ZaumGqwLrVg90H21EOLACvtfcHk0ljPVTlkG8yXvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVWitL0%253D&md5=f29bfc618f12bb73cf934034160faae1</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1053%2Fj.seminhematol.2008.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminhematol.2008.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DCheok%26aufirst%3DM.%2BH.%26aulast%3DPottier%26aufirst%3DN.%26aulast%3DKager%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26atitle%3DPharmacogenetics%2520in%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DSemin.%2520Hematol.%26date%3D2009%26volume%3D46%26spage%3D39%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref270"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref270'); return false;" data-citation="" class="refNumLink">270</a></strong><div class="NLM_citation" id="cit270"><span><span class="NLM_contrib-group">Kager, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, W. E.</span><span> </span><span class="NLM_article-title">Pharmacogenomics of acute lymphoblastic leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2F01.moh.0000231424.46148.f9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16755223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFGrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=260-265&author=L.+Kagerauthor=W.+E.+Evans&title=Pharmacogenomics+of+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenomics of acute lymphoblastic leukemia</span></div><div class="casAuthors">Kager, Leo; Evans, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-265</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries.  This has mainly been achieved empirically through carefully controlled, randomized clin. trials.  Due to relative nonspecific action and narrow therapeutic indexes of antileukemic medications, however, current therapy can be assocd. with significant short and long-term adverse effects, and around 20% of patients will not be cured despite intensified treatment.  Pharmacogenomics, which studies the role of inheritance in individual variation in drug disposition and response, could be a useful tool to further improve outcome in this heterogeneous disease by individualization of therapy based on information gained from the genetic 'make-up' of normal host cells and lymphoblastic leukemia cells.  Recent findings: The focus of this review is on recent progress in the field by discussing the results of selected studies in which information from functional genomics, high-throughput mol. analyses, and pharmacodynamics has been integrated to establish pharmacogenomic models.  These models may be used to both maximize efficacy and minimize toxicity of existing antileukemic medications, or to identify novel therapeutic targets in lymphoblasts that are resistant to conventional antileukemic drugs.  Summary: The findings from recent pharmacogenomic studies can be integrated into decision-making in future clin. trials.  Thus there is great promise for advancing event-free survival in childhood leukemia in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_znYJ0KGY6bVg90H21EOLACvtfcHk0ljPVTlkG8yXvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFGrsbc%253D&md5=8d5b5640dc778b4bc16dc47157e9f96c</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1097%2F01.moh.0000231424.46148.f9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.moh.0000231424.46148.f9%26sid%3Dliteratum%253Aachs%26aulast%3DKager%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26atitle%3DPharmacogenomics%2520of%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2006%26volume%3D13%26spage%3D260%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref271"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref271'); return false;" data-citation="" class="refNumLink">271</a></strong><div class="NLM_citation" id="cit271"><span><span class="NLM_contrib-group">Karas-Kuzelicki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazbec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mlinaric-Rascan, I.</span><span> </span><span class="NLM_article-title">Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=971-974&author=N.+Karas-Kuzelickiauthor=J.+Jazbecauthor=M.+Milekauthor=I.+Mlinaric-Rascan&title=Heterozygosity+at+the+TPMT+gene+locus%2C+augmented+by+mutated+MTHFR+gene%2C+predisposes+to+6-MP+related+toxicities+in+childhood+ALL+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaras-Kuzelicki%26aufirst%3DN.%26aulast%3DJazbec%26aufirst%3DJ.%26aulast%3DMilek%26aufirst%3DM.%26aulast%3DMlinaric-Rascan%26aufirst%3DI.%26atitle%3DHeterozygosity%2520at%2520the%2520TPMT%2520gene%2520locus%252C%2520augmented%2520by%2520mutated%2520MTHFR%2520gene%252C%2520predisposes%2520to%25206-MP%2520related%2520toxicities%2520in%2520childhood%2520ALL%2520patients%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref272"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref272'); return false;" data-citation="" class="refNumLink">272</a></strong><div class="NLM_citation" id="cit272"><span><span class="NLM_contrib-group">Lindpaintner, K.</span><span> </span><span class="NLM_article-title">The impact of pharmacogenetics and pharmacogenomics on drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=463-469&author=K.+Lindpaintner&title=The+impact+of+pharmacogenetics+and+pharmacogenomics+on+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindpaintner%26aufirst%3DK.%26atitle%3DThe%2520impact%2520of%2520pharmacogenetics%2520and%2520pharmacogenomics%2520on%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref273"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref273'); return false;" data-citation="" class="refNumLink">273</a></strong><div class="NLM_citation" id="cit273"><span><span class="NLM_contrib-group">Suzuki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Nimwegen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balwierz, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravasi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Hoon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carninci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaru, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanamori-Katayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubosaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akalin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajic, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckhouse, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkegren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brombacher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalk, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloonan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulkner, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojobori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimmond, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatakeyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinzel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hide, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornquist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huminiecki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishihara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwayanagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenhard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennartsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maqungo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matigian, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto-Sato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakabayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakachi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygaard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda-Yabukami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlando, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otomo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachkov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrovsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plessy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovanovic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandelin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmeier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schonbach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahige, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Laurent, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweet, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taft, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teasdale, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teichmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlestedt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterhouse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winther, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavolan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hume, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawazu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitazume, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninomiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiyori, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashizaki, Y.</span><span> </span><span class="NLM_article-title">The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fng.375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19377474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12ktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=553-562&author=H.+Suzukiauthor=A.+R.+Forrestauthor=E.+van+Nimwegenauthor=C.+O.+Daubauthor=P.+J.+Balwierzauthor=K.+M.+Irvineauthor=T.+Lassmannauthor=T.+Ravasiauthor=Y.+Hasegawaauthor=M.+J.+de+Hoonauthor=S.+Katayamaauthor=K.+Schroderauthor=P.+Carninciauthor=Y.+Tomaruauthor=M.+Kanamori-Katayamaauthor=A.+Kubosakiauthor=A.+Akalinauthor=Y.+Andoauthor=E.+Arnerauthor=M.+Asadaauthor=H.+Asaharaauthor=T.+Baileyauthor=V.+B.+Bajicauthor=D.+Bauerauthor=A.+G.+Beckhouseauthor=N.+Bertinauthor=J.+Bjorkegrenauthor=F.+Brombacherauthor=E.+Bulgerauthor=A.+M.+Chalkauthor=J.+Chibaauthor=N.+Cloonanauthor=A.+Daweauthor=J.+Dostieauthor=P.+G.+Engstromauthor=M.+Essackauthor=G.+J.+Faulknerauthor=J.+L.+Finkauthor=D.+Fredmanauthor=K.+Fujimoriauthor=M.+Furunoauthor=T.+Gojoboriauthor=J.+Goughauthor=S.+M.+Grimmondauthor=M.+Gustafssonauthor=M.+Hashimotoauthor=T.+Hashimotoauthor=M.+Hatakeyamaauthor=S.+Heinzelauthor=W.+Hideauthor=O.+Hofmannauthor=M.+Hornquistauthor=L.+Huminieckiauthor=K.+Ikeoauthor=N.+Imamotoauthor=S.+Inoueauthor=Y.+Inoueauthor=R.+Ishiharaauthor=T.+Iwayanagiauthor=A.+Jacobsenauthor=M.+Kaurauthor=H.+Kawajiauthor=M.+C.+Kerrauthor=R.+Kimuraauthor=S.+Kimuraauthor=Y.+Kimuraauthor=H.+Kitanoauthor=H.+Kogaauthor=T.+Kojimaauthor=S.+Kondoauthor=T.+Konnoauthor=A.+Kroghauthor=A.+Krugerauthor=A.+Kumarauthor=B.+Lenhardauthor=A.+Lennartssonauthor=M.+Lindowauthor=M.+Lizioauthor=C.+Macphersonauthor=N.+Maedaauthor=C.+A.+Maherauthor=M.+Maqungoauthor=J.+Marauthor=N.+A.+Matigianauthor=H.+Matsudaauthor=J.+S.+Mattickauthor=S.+Meierauthor=S.+Miyamotoauthor=E.+Miyamoto-Satoauthor=K.+Nakabayashiauthor=Y.+Nakachiauthor=M.+Nakanoauthor=S.+Nygaardauthor=T.+Okayamaauthor=Y.+Okazakiauthor=H.+Okuda-Yabukamiauthor=V.+Orlandoauthor=J.+Otomoauthor=M.+Pachkovauthor=N.+Petrovskyauthor=C.+Plessyauthor=J.+Quackenbushauthor=A.+Radovanovicauthor=M.+Rehliauthor=R.+Saitoauthor=A.+Sandelinauthor=S.+Schmeierauthor=C.+Schonbachauthor=A.+S.+Schwartzauthor=C.+A.+Sempleauthor=M.+Seraauthor=J.+Severinauthor=K.+Shirahigeauthor=C.+Simonsauthor=G.+St+Laurentauthor=M.+Suzukiauthor=T.+Suzukiauthor=M.+J.+Sweetauthor=R.+J.+Taftauthor=S.+Takedaauthor=Y.+Takenakaauthor=K.+Tanauthor=M.+S.+Taylorauthor=R.+D.+Teasdaleauthor=J.+Tegnerauthor=S.+Teichmannauthor=E.+Valenauthor=C.+Wahlestedtauthor=K.+Wakiauthor=A.+Waterhouseauthor=C.+A.+Wellsauthor=O.+Wintherauthor=L.+Wuauthor=K.+Yamaguchiauthor=H.+Yanagawaauthor=J.+Yasudaauthor=M.+Zavolanauthor=D.+A.+Humeauthor=T.+Arakawaauthor=S.+Fukudaauthor=K.+Imamuraauthor=C.+Kaiauthor=A.+Kaihoauthor=T.+Kawashimaauthor=C.+Kawazuauthor=Y.+Kitazumeauthor=M.+Kojimaauthor=H.+Miuraauthor=K.+Murakamiauthor=M.+Murataauthor=N.+Ninomiyaauthor=H.+Nishiyoriauthor=S.+Nomaauthor=C.+Ogawaauthor=T.+Sanoauthor=C.+Simonauthor=M.+Tagamiauthor=Y.+Takahashiauthor=J.+Kawaiauthor=Y.+Hayashizaki&title=The+transcriptional+network+that+controls+growth+arrest+and+differentiation+in+a+human+myeloid+leukemia+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line</span></div><div class="casAuthors">Suzuki, Harukazu; Forrest, Alistair R. R.; van Nimwegen, Erik; Daub, Carsten O.; Balwierz, Piotr J.; Irvine, Katharine M.; Lassmann, Timo; Ravasi, Timothy; Hasegawa, Yuki; de Hoon, Michiel J. L.; Katayama, Shintaro; Schroder, Kate; Carninci, Piero; Tomaru, Yasuhiro; Kanamori-Katayama, Mutsumi; Kubosaki, Atsutaka; Akalin, Altuna; Ando, Yoshinari; Arner, Erik; Asada, Maki; Asahara, Hiroshi; Bailey, Timothy; Bajic, Vladimir B.; Bauer, Denis; Beckhouse, Anthony G.; Bertin, Nicolas; Bjoerkegren, Johan; Brombacher, Frank; Bulger, Erika; Chalk, Alistair M.; Chiba, Joe; Cloonan, Nicole; Dawe, Adam; Dostie, Josee; Engstroem, Paer G.; Essack, Magbubah; Faulkner, Geoffrey J.; Fink, J. Lynn; Fredman, David; Fujimori, Ko; Furuno, Masaaki; Gojobori, Takashi; Gough, Julian; Grimmond, Sean M.; Gustafsson, Mika; Hashimoto, Megumi; Hashimoto, Takehiro; Hatakeyama, Mariko; Heinzel, Susanne; Hide, Winston; Hofmann, Oliver; Hoernquist, Michael; Huminiecki, Lukasz; Ikeo, Kazuho; Imamoto, Naoko; Inoue, Satoshi; Inoue, Yusuke; Ishihara, Ryoko; Iwayanagi, Takao; Jacobsen, Anders; Kaur, Mandeep; Kawaji, Hideya; Kerr, Markus C.; Kimura, Ryuichiro; Kimura, Syuhei; Kimura, Yasumasa; Kitano, Hiroaki; Koga, Hisashi; Kojima, Toshio; Kondo, Shinji; Konno, Takeshi; Krogh, Anders; Kruger, Adele; Kumar, Ajit; Lenhard, Boris; Lennartsson, Andreas; Lindow, Morten; Lizio, Marina; MacPherson, Cameron; Maeda, Norihiro; Maher, Christopher A.; Maqungo, Monique; Mar, Jessica; Matigian, Nicholas A.; Matsuda, Hideo; Mattick, John S.; Meier, Stuart; Miyamoto, Sei; Miyamoto-Sato, Etsuko; Nakabayashi, Kazuhiko; Nakachi, Yutaka; Nakano, Mika; Nygaard, Sanne; Okayama, Toshitsugu; Okazaki, Yasushi; Okuda-Yabukami, Haruka; Orlando, Valerio; Otomo, Jun; Pachkov, Mikhail; Petrovsky, Nikolai; Plessy, Charles; Quackenbush, John; Radovanovic, Aleksandar; Rehli, Michael; Saito, Rintaro; Sandelin, Albin; Schmeier, Sebastian; Schoenbach, Christian; Schwartz, Ariel S.; Semple, Colin A.; Sera, Miho; Severin, Jessica; Shirahige, Katsuhiko; Simons, Cas; St. Laurent, George; Suzuki, Masanori; Suzuki, Takahiro; Sweet, Matthew J.; Taft, Ryan J.; Takeda, Shizu; Takenaka, Yoichi; Tan, Kai; Taylor, Martin S.; Teasdale, Rohan D.; Tegner, Jesper; Teichmann, Sarah; Valen, Eivind; Wahlestedt, Claes; Waki, Kazunori; Waterhouse, Andrew; Wells, Christine A.; Winther, Ole; Wu, Linda; Yamaguchi, Kazumi; Yanagawa, Hiroshi; Yasuda, Jun; Zavolan, Mihaela; Hume, David A.; Arakawa, Takahiro; Fukuda, Shiro; Imamura, Kengo; Kai, Chikatoshi; Kaiho, Ai; Kawashima, Tsugumi; Kawazu, Chika; Kitazume, Yayoi; Kojima, Miki; Miura, Hisashi; Murakami, Kayoko; Murata, Mitsuyoshi; Ninomiya, Noriko; Nishiyori, Hiromi; Noma, Shohei; Ogawa, Chihiro; Sano, Takuma; Simon, Christophe; Tagami, Michihira; Takahashi, Yukari; Kawai, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Using deep sequencing (deepCAGE), the FANTOM4 study measured the genome-wide dynamics of transcription-start-site usage in the human monocytic cell line THP-1 throughout a time course of growth arrest and differentiation.  Modeling the expression dynamics in terms of predicted cis-regulatory sites, we identified the key transcription regulators, their time-dependent activities and target genes.  Systematic siRNA knockdown of 52 transcription factors confirmed the roles of individual factors in the regulatory network.  These results indicate that cellular states are constrained by complex networks involving both pos. and neg. regulatory interactions among substantial nos. of transcription factors and that no single transcription factor is both necessary and sufficient to drive the differentiation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoHvH8iKtmmLVg90H21EOLACvtfcHk0ljT-hafoOhoNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12ktrc%253D&md5=34bcab613d6036655b35ce8d82047534</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1038%2Fng.375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.375%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DForrest%26aufirst%3DA.%2BR.%26aulast%3Dvan%2BNimwegen%26aufirst%3DE.%26aulast%3DDaub%26aufirst%3DC.%2BO.%26aulast%3DBalwierz%26aufirst%3DP.%2BJ.%26aulast%3DIrvine%26aufirst%3DK.%2BM.%26aulast%3DLassmann%26aufirst%3DT.%26aulast%3DRavasi%26aufirst%3DT.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3Dde%2BHoon%26aufirst%3DM.%2BJ.%26aulast%3DKatayama%26aufirst%3DS.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCarninci%26aufirst%3DP.%26aulast%3DTomaru%26aufirst%3DY.%26aulast%3DKanamori-Katayama%26aufirst%3DM.%26aulast%3DKubosaki%26aufirst%3DA.%26aulast%3DAkalin%26aufirst%3DA.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DArner%26aufirst%3DE.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DAsahara%26aufirst%3DH.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DBajic%26aufirst%3DV.%2BB.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBeckhouse%26aufirst%3DA.%2BG.%26aulast%3DBertin%26aufirst%3DN.%26aulast%3DBjorkegren%26aufirst%3DJ.%26aulast%3DBrombacher%26aufirst%3DF.%26aulast%3DBulger%26aufirst%3DE.%26aulast%3DChalk%26aufirst%3DA.%2BM.%26aulast%3DChiba%26aufirst%3DJ.%26aulast%3DCloonan%26aufirst%3DN.%26aulast%3DDawe%26aufirst%3DA.%26aulast%3DDostie%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DP.%2BG.%26aulast%3DEssack%26aufirst%3DM.%26aulast%3DFaulkner%26aufirst%3DG.%2BJ.%26aulast%3DFink%26aufirst%3DJ.%2BL.%26aulast%3DFredman%26aufirst%3DD.%26aulast%3DFujimori%26aufirst%3DK.%26aulast%3DFuruno%26aufirst%3DM.%26aulast%3DGojobori%26aufirst%3DT.%26aulast%3DGough%26aufirst%3DJ.%26aulast%3DGrimmond%26aufirst%3DS.%2BM.%26aulast%3DGustafsson%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DHatakeyama%26aufirst%3DM.%26aulast%3DHeinzel%26aufirst%3DS.%26aulast%3DHide%26aufirst%3DW.%26aulast%3DHofmann%26aufirst%3DO.%26aulast%3DHornquist%26aufirst%3DM.%26aulast%3DHuminiecki%26aufirst%3DL.%26aulast%3DIkeo%26aufirst%3DK.%26aulast%3DImamoto%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DIshihara%26aufirst%3DR.%26aulast%3DIwayanagi%26aufirst%3DT.%26aulast%3DJacobsen%26aufirst%3DA.%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DKawaji%26aufirst%3DH.%26aulast%3DKerr%26aufirst%3DM.%2BC.%26aulast%3DKimura%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKitano%26aufirst%3DH.%26aulast%3DKoga%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DKonno%26aufirst%3DT.%26aulast%3DKrogh%26aufirst%3DA.%26aulast%3DKruger%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DLenhard%26aufirst%3DB.%26aulast%3DLennartsson%26aufirst%3DA.%26aulast%3DLindow%26aufirst%3DM.%26aulast%3DLizio%26aufirst%3DM.%26aulast%3DMacpherson%26aufirst%3DC.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DMaher%26aufirst%3DC.%2BA.%26aulast%3DMaqungo%26aufirst%3DM.%26aulast%3DMar%26aufirst%3DJ.%26aulast%3DMatigian%26aufirst%3DN.%2BA.%26aulast%3DMatsuda%26aufirst%3DH.%26aulast%3DMattick%26aufirst%3DJ.%2BS.%26aulast%3DMeier%26aufirst%3DS.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DMiyamoto-Sato%26aufirst%3DE.%26aulast%3DNakabayashi%26aufirst%3DK.%26aulast%3DNakachi%26aufirst%3DY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DNygaard%26aufirst%3DS.%26aulast%3DOkayama%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DY.%26aulast%3DOkuda-Yabukami%26aufirst%3DH.%26aulast%3DOrlando%26aufirst%3DV.%26aulast%3DOtomo%26aufirst%3DJ.%26aulast%3DPachkov%26aufirst%3DM.%26aulast%3DPetrovsky%26aufirst%3DN.%26aulast%3DPlessy%26aufirst%3DC.%26aulast%3DQuackenbush%26aufirst%3DJ.%26aulast%3DRadovanovic%26aufirst%3DA.%26aulast%3DRehli%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DSandelin%26aufirst%3DA.%26aulast%3DSchmeier%26aufirst%3DS.%26aulast%3DSchonbach%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%2BS.%26aulast%3DSemple%26aufirst%3DC.%2BA.%26aulast%3DSera%26aufirst%3DM.%26aulast%3DSeverin%26aufirst%3DJ.%26aulast%3DShirahige%26aufirst%3DK.%26aulast%3DSimons%26aufirst%3DC.%26aulast%3DSt%2BLaurent%26aufirst%3DG.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DTaft%26aufirst%3DR.%2BJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DTakenaka%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DM.%2BS.%26aulast%3DTeasdale%26aufirst%3DR.%2BD.%26aulast%3DTegner%26aufirst%3DJ.%26aulast%3DTeichmann%26aufirst%3DS.%26aulast%3DValen%26aufirst%3DE.%26aulast%3DWahlestedt%26aufirst%3DC.%26aulast%3DWaki%26aufirst%3DK.%26aulast%3DWaterhouse%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DC.%2BA.%26aulast%3DWinther%26aufirst%3DO.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYanagawa%26aufirst%3DH.%26aulast%3DYasuda%26aufirst%3DJ.%26aulast%3DZavolan%26aufirst%3DM.%26aulast%3DHume%26aufirst%3DD.%2BA.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DK.%26aulast%3DKai%26aufirst%3DC.%26aulast%3DKaiho%26aufirst%3DA.%26aulast%3DKawashima%26aufirst%3DT.%26aulast%3DKawazu%26aufirst%3DC.%26aulast%3DKitazume%26aufirst%3DY.%26aulast%3DKojima%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DH.%26aulast%3DMurakami%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DNinomiya%26aufirst%3DN.%26aulast%3DNishiyori%26aufirst%3DH.%26aulast%3DNoma%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DC.%26aulast%3DSano%26aufirst%3DT.%26aulast%3DSimon%26aufirst%3DC.%26aulast%3DTagami%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DKawai%26aufirst%3DJ.%26aulast%3DHayashizaki%26aufirst%3DY.%26atitle%3DThe%2520transcriptional%2520network%2520that%2520controls%2520growth%2520arrest%2520and%2520differentiation%2520in%2520a%2520human%2520myeloid%2520leukemia%2520cell%2520line%26jtitle%3DNat.%2520Genet.%26date%3D2009%26volume%3D41%26spage%3D553%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref274"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref274'); return false;" data-citation="" class="refNumLink">274</a></strong><div class="NLM_citation" id="cit274"><span><span class="NLM_contrib-group">Flotho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandrock, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plass, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemeyer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbert, M.</span><span> </span><span class="NLM_article-title">The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1019</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1019-1028&author=C.+Flothoauthor=R.+Clausauthor=C.+Batzauthor=M.+Schneiderauthor=I.+Sandrockauthor=S.+Ihdeauthor=C.+Plassauthor=C.+M.+Niemeyerauthor=M.+Lubbert&title=The+DNA+methyltransferase+inhibitors+azacitidine%2C+decitabine+and+zebularine+exert+differential+effects+on+cancer+gene+expression+in+acute+myeloid+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlotho%26aufirst%3DC.%26aulast%3DClaus%26aufirst%3DR.%26aulast%3DBatz%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSandrock%26aufirst%3DI.%26aulast%3DIhde%26aufirst%3DS.%26aulast%3DPlass%26aufirst%3DC.%26aulast%3DNiemeyer%26aufirst%3DC.%2BM.%26aulast%3DLubbert%26aufirst%3DM.%26atitle%3DThe%2520DNA%2520methyltransferase%2520inhibitors%2520azacitidine%252C%2520decitabine%2520and%2520zebularine%2520exert%2520differential%2520effects%2520on%2520cancer%2520gene%2520expression%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1019%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref275"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref275'); return false;" data-citation="" class="refNumLink">275</a></strong><div class="NLM_citation" id="cit275"><span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span> </span><span class="NLM_article-title">Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)-RNAs hybridized to 3′-end flanking sequences of beta(major) globin gene</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1743</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1743&publication_year=2005&pages=101-114&author=I.+S.+Vizirianakisauthor=A.+S.+Tsiftsoglou&title=Blockade+of+murine+erythroleukemia+cell+differentiation+by+hypomethylating+agents+causes+accumulation+of+discrete+small+poly%28A%29-RNAs+hybridized+to+3%E2%80%B2-end+flanking+sequences+of+beta%28major%29+globin+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26atitle%3DBlockade%2520of%2520murine%2520erythroleukemia%2520cell%2520differentiation%2520by%2520hypomethylating%2520agents%2520causes%2520accumulation%2520of%2520discrete%2520small%2520poly%2528A%2529-RNAs%2520hybridized%2520to%25203%25E2%2580%25B2-end%2520flanking%2520sequences%2520of%2520beta%2528major%2529%2520globin%2520gene%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1743%26spage%3D101%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref276"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref276'); return false;" data-citation="" class="refNumLink">276</a></strong><div class="NLM_citation" id="cit276"><span><span class="NLM_contrib-group">Miranda, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortez, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-09-0013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19509260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1579-1588&author=T.+B.+Mirandaauthor=C.+C.+Cortezauthor=C.+B.+Yooauthor=G.+Liangauthor=M.+Abeauthor=T.+K.+Kellyauthor=V.+E.+Marquezauthor=P.+A.+Jones&title=DZNep+is+a+global+histone+methylation+inhibitor+that+reactivates+developmental+genes+not+silenced+by+DNA+methylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation</span></div><div class="casAuthors">Miranda, Tina Branscombe; Cortez, Connie C.; Yoo, Christine B.; Liang, Gangning; Abe, Masanobu; Kelly, Theresa K.; Marquez, Victor E.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1579-1588</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA methylation, histone modifications, and nucleosomal occupancy collaborate to cause silencing of tumor-related genes in cancer.  The development of drugs that target these processes is therefore important for cancer therapy.  Inhibitors of DNA methylation and histone deacetylation have been approved by the Food and Drug Administration for treatment of hematol. malignancies.  However, drugs that target other mechanisms still need to be developed.  Recently, 3-deazaneplanocin A (DZNep) was reported to selectively inhibit trimethylation of lysine 27 on histone H3 (H3K27me3) and lysine 20 on histone H4 (H4K20me3) as well as reactivate silenced genes in cancer cells.  This finding opens the door to the pharmacol. inhibition of histone methylation.  We therefore wanted to further study the mechanism of action of DZNep in cancer cells.  Western blot anal. shows that DZNep globally inhibits histone methylation and is not selective.  Two other drugs, sinefungin and adenosine dialdehyde, have similar effects as DZNep on H3K27me3.  Intriguingly, chromatin immunopptn. of various histone modifications and microarray anal. show that DZNep acts through a different pathway than 5-aza-2'-deoxycytidine (5-aza-CdR), a DNA methyltransferase inhibitor.  These observations give us interesting insight into how chromatin structure affects gene expression.  We also detd. the kinetics of gene activation to understand if the induced changes were somatically heritable.  We found that upon removal of DZNep, gene expression is reduced to its original state.  This suggests that there is a homeostatic mechanism that returns the histone modifications to their "ground state" after DZNep treatment.  Our data show the strong need for further development of histone methylation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGploR0o6_2Q67Vg90H21EOLACvtfcHk0ljZg8dUUV3L1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKgtr8%253D&md5=3de46039cddbeb72ae9b5b11764422c0</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0013%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DT.%2BB.%26aulast%3DCortez%26aufirst%3DC.%2BC.%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DT.%2BK.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DDZNep%2520is%2520a%2520global%2520histone%2520methylation%2520inhibitor%2520that%2520reactivates%2520developmental%2520genes%2520not%2520silenced%2520by%2520DNA%2520methylation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1579%26epage%3D1588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref277"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref277'); return false;" data-citation="" class="refNumLink">277</a></strong><div class="NLM_citation" id="cit277"><span><span class="NLM_contrib-group">Sioud, M.</span><span> </span><span class="NLM_article-title">Therapeutic siRNAs</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=22-28&author=M.+Sioud&title=Therapeutic+siRNAs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSioud%26aufirst%3DM.%26atitle%3DTherapeutic%2520siRNAs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D22%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref238':['cit238'],'ref239':['cit239'],'ref240':['cit240'],'ref241':['cit241'],'ref242':['cit242'],'ref243':['cit243'],'ref244':['cit244'],'ref245':['cit245'],'ref246':['cit246'],'ref247':['cit247'],'ref248':['cit248'],'ref249':['cit249'],'ref250':['cit250'],'ref251':['cit251'],'ref252':['cit252'],'ref253':['cit253'],'ref254':['cit254'],'ref255':['cit255'],'ref256':['cit256'],'ref257':['cit257'],'ref258':['cit258'],'ref259':['cit259'],'ref260':['cit260'],'ref261':['cit261'],'ref262':['cit262'],'ref263':['cit263'],'ref264':['cit264'],'ref265':['cit265'],'ref266':['cit266'],'ref267':['cit267'],'ref268':['cit268'],'ref269':['cit269'],'ref270':['cit270'],'ref271':['cit271'],'ref272':['cit272'],'ref273':['cit273'],'ref274':['cit274'],'ref275':['cit275'],'ref276':['cit276'],'ref277':['cit277']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Chan  Zou</span>, <span class="hlFld-ContribAuthor ">Shu  Zhou</span>, <span class="hlFld-ContribAuthor ">Qi-Zheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Shan  Feng</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (4)
                                     , 1641-1655. <a href="https://doi.org/10.1021/jm301537p" title="DOI URL">https://doi.org/10.1021/jm301537p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm301537p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm301537p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationship%252BStudies%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252BDerivatives%252BLeading%252Bto%252Bthe%252BDiscovery%252Bof%252Ba%252BNovel%252BMultikinase%252BInhibitor%252BThat%252BPotently%252BInhibits%252BFLT3%252Band%252BVEGFR2%252Band%252BEvaluation%252Bof%252BIts%252BActivity%252Bagainst%252BAcute%252BMyeloid%252BLeukemia%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DYang%26aufirst%3DLing-Ling%26date%3D2013%26date%3D2013%26date%3D2012%26date%3D20102012%26date%3D19022013%26date%3D28022013%26date%3D30012013%26volume%3D56%26issue%3D4%26spage%3D1641%26epage%3D1655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  He</span>, <span class="hlFld-ContribAuthor ">Chengqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Gen  Liu</span>, <span class="hlFld-ContribAuthor ">Haoyue  Ma</span>, <span class="hlFld-ContribAuthor ">Mingdong  Jiang</span>, <span class="hlFld-ContribAuthor ">Pan  Li</span>, <span class="hlFld-ContribAuthor ">Qianwei  Lu</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Hongyi  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">Isobavachalcone inhibits acute myeloid leukemia: Potential role for
              ROS
              ‐dependent mitochondrial apoptosis and differentiation. </span><span class="cited-content_cbyCitation_journal-name">Phytotherapy Research</span><span> <strong>2021,</strong> <em>35 </em>
                                    (6)
                                     , 3337-3350. <a href="https://doi.org/10.1002/ptr.7054" title="DOI URL">https://doi.org/10.1002/ptr.7054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ptr.7054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fptr.7054%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytotherapy%2520Research%26atitle%3DIsobavachalcone%252Binhibits%252Bacute%252Bmyeloid%252Bleukemia%25253A%252BPotential%252Brole%252Bfor%252BROS%252B%2525E2%252580%252590dependent%252Bmitochondrial%252Bapoptosis%252Band%252Bdifferentiation%26aulast%3DHe%26aufirst%3DHui%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D6%26spage%3D3337%26epage%3D3350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengqiang  Wang</span>, <span class="hlFld-ContribAuthor ">Gen  Liu</span>, <span class="hlFld-ContribAuthor ">Guojun  Dou</span>, <span class="hlFld-ContribAuthor ">Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Lu  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Ma</span>, <span class="hlFld-ContribAuthor ">Zhuyun  Jiang</span>, <span class="hlFld-ContribAuthor ">Haoyue  Ma</span>, <span class="hlFld-ContribAuthor ">Chenglong  Li</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Mingdong  Jiang</span>, <span class="hlFld-ContribAuthor ">Qianwei  Lu</span>, <span class="hlFld-ContribAuthor ">Pan  Li</span>, <span class="hlFld-ContribAuthor ">Hongyi  Qi</span>. </span><span class="cited-content_cbyCitation_article-title">Z-Ligustilide Selectively Targets AML by Restoring Nuclear Receptors Nur77 and NOR-1-mediated Apoptosis and Differentiation. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2021,</strong> <em>82 </em>, 153448. <a href="https://doi.org/10.1016/j.phymed.2020.153448" title="DOI URL">https://doi.org/10.1016/j.phymed.2020.153448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2020.153448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2020.153448%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DZ-Ligustilide%252BSelectively%252BTargets%252BAML%252Bby%252BRestoring%252BNuclear%252BReceptors%252BNur77%252Band%252BNOR-1-mediated%252BApoptosis%252Band%252BDifferentiation%26aulast%3DWang%26aufirst%3DChengqiang%26date%3D2021%26volume%3D82%26spage%3D153448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dmitrii  Semenok</span>, <span class="hlFld-ContribAuthor ">Jury  Medvedev</span>, <span class="hlFld-ContribAuthor ">Lefki-P.  Giassafaki</span>, <span class="hlFld-ContribAuthor ">Iason  Lavdas</span>, <span class="hlFld-ContribAuthor ">Ioannis  Vizirianakis</span>, <span class="hlFld-ContribAuthor ">Phaedra  Eleftheriou</span>, <span class="hlFld-ContribAuthor ">Antonis  Gavalas</span>, <span class="hlFld-ContribAuthor ">Anthi  Petrou</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>. </span><span class="cited-content_cbyCitation_article-title">4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (9)
                                     , 1751. <a href="https://doi.org/10.3390/molecules24091751" title="DOI URL">https://doi.org/10.3390/molecules24091751</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24091751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24091751%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3D4%25252C5-Diaryl%252B3%2525282H%252529Furanones%25253A%252BAnti-Inflammatory%252BActivity%252Band%252BInfluence%252Bon%252BCancer%252BGrowth%26aulast%3DSemenok%26aufirst%3DDmitrii%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D9%26spage%3D1751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melpomeni  Akrivou</span>, <span class="hlFld-ContribAuthor ">Vera  Demertzidou</span>, <span class="hlFld-ContribAuthor ">Nikoleta  Theodoroula</span>, <span class="hlFld-ContribAuthor ">Fani  Chatzopoulou</span>, <span class="hlFld-ContribAuthor ">Konstantinos  Kyritsis</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Grigoriadis</span>, <span class="hlFld-ContribAuthor ">Alexandros  Zografos</span>, <span class="hlFld-ContribAuthor ">Ioannis  Vizirianakis</span>. </span><span class="cited-content_cbyCitation_article-title">Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Oncology</span><span> <strong>2018,</strong> <em> </em><a href="https://doi.org/10.3892/ijo.2018.4550" title="DOI URL">https://doi.org/10.3892/ijo.2018.4550</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijo.2018.4550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijo.2018.4550%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Oncology%26atitle%3DUncovering%252Bthe%252Bpharmacological%252Bresponse%252Bof%252Bnovel%252Bsesquiterpene%252Bderivatives%252Bthat%252Bdifferentially%252Balter%252Bgene%252Bexpression%252Band%252Bmodulate%252Bthe%252Bcell%252Bcycle%252Bin%252Bcancer%252Bcells%26aulast%3DAkrivou%26aufirst%3DMelpomeni%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ling</span>, <span class="hlFld-ContribAuthor ">Jiao  Feng</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Yanfu  Peng</span>, <span class="hlFld-ContribAuthor ">Tingting  Wang</span>, <span class="hlFld-ContribAuthor ">Xiang  Ge</span>, <span class="hlFld-ContribAuthor ">Qibing  Xu</span>, <span class="hlFld-ContribAuthor ">Xinyang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Dai</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (9)
                                     , 646-651. <a href="https://doi.org/10.1002/cmdc.201700133" title="DOI URL">https://doi.org/10.1002/cmdc.201700133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700133%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BC3-Substituted%252B%2525CE%2525B2-Carboline-Based%252BHistone%252BDeacetylase%252BInhibitors%252Bwith%252BPotent%252BAntitumor%252BActivities%26aulast%3DLing%26aufirst%3DYong%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D9%26spage%3D646%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heron F.  Vieira Torquato</span>, <span class="hlFld-ContribAuthor ">Antonio C.  Ribeiro-Filho</span>, <span class="hlFld-ContribAuthor ">Marcus V.  Buri</span>, <span class="hlFld-ContribAuthor ">Roberto T.  Araújo Júnior</span>, <span class="hlFld-ContribAuthor ">Renata  Pimenta</span>, <span class="hlFld-ContribAuthor ">José Salvador R.  de Oliveira</span>, <span class="hlFld-ContribAuthor ">Valdir C.  Filho</span>, <span class="hlFld-ContribAuthor ">Antonio  Macho</span>, <span class="hlFld-ContribAuthor ">Edgar J.  Paredes-Gamero</span>, <span class="hlFld-ContribAuthor ">Domingos T.  de Oliveira Martins</span>. </span><span class="cited-content_cbyCitation_article-title">Canthin-6-one induces cell death, cell cycle arrest and differentiation in human myeloid leukemia cells. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2017,</strong> <em>1861 </em>
                                    (4)
                                     , 958-967. <a href="https://doi.org/10.1016/j.bbagen.2017.01.033" title="DOI URL">https://doi.org/10.1016/j.bbagen.2017.01.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2017.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2017.01.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DCanthin-6-one%252Binduces%252Bcell%252Bdeath%25252C%252Bcell%252Bcycle%252Barrest%252Band%252Bdifferentiation%252Bin%252Bhuman%252Bmyeloid%252Bleukemia%252Bcells%26aulast%3DVieira%2BTorquato%26aufirst%3DHeron%2BF.%26date%3D2017%26volume%3D1861%26issue%3D4%26spage%3D958%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongshuang  Li</span>, <span class="hlFld-ContribAuthor ">Xinran  Wang</span>, <span class="hlFld-ContribAuthor ">Guiyun  Duan</span>, <span class="hlFld-ContribAuthor ">Chengcai  Xia</span>, <span class="hlFld-ContribAuthor ">Yuliang  Xiao</span>, <span class="hlFld-ContribAuthor ">Furong  Li</span>, <span class="hlFld-ContribAuthor ">Yanqing  Ge</span>, <span class="hlFld-ContribAuthor ">Guirong  You</span>, <span class="hlFld-ContribAuthor ">Junfen  Han</span>, <span class="hlFld-ContribAuthor ">Xiaopan  Fu</span>, <span class="hlFld-ContribAuthor ">Shanhui  Tan</span>, <span class="hlFld-ContribAuthor ">Rongwei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, antitumor activity and preliminary structure-activity relationship of 2-aminothiazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Chinese Universities</span><span> <strong>2016,</strong> <em>32 </em>
                                    (6)
                                     , 929-937. <a href="https://doi.org/10.1007/s40242-016-6304-2" title="DOI URL">https://doi.org/10.1007/s40242-016-6304-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40242-016-6304-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40242-016-6304-2%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Chinese%2520Universities%26atitle%3DSynthesis%25252C%252Bantitumor%252Bactivity%252Band%252Bpreliminary%252Bstructure-activity%252Brelationship%252Bof%252B2-aminothiazole%252Bderivatives%26aulast%3DLi%26aufirst%3DHongshuang%26date%3D2016%26date%3D2016%26volume%3D32%26issue%3D6%26spage%3D929%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">IOANNIS S.  VIZIRIANAKIS</span>, <span class="hlFld-ContribAuthor ">GEORGE A.  MYSTRIDIS</span>, <span class="hlFld-ContribAuthor ">KONSTANTINOS  AVGOUSTAKIS</span>, <span class="hlFld-ContribAuthor ">DIMITRIOS G.  FATOUROS</span>, <span class="hlFld-ContribAuthor ">MARIOS  SPANAKIS</span>. </span><span class="cited-content_cbyCitation_article-title">Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review). </span><span class="cited-content_cbyCitation_journal-name">Oncology Reports</span><span> <strong>2016,</strong> <em>35 </em>
                                    (4)
                                     , 1891-1904. <a href="https://doi.org/10.3892/or.2016.4575" title="DOI URL">https://doi.org/10.3892/or.2016.4575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/or.2016.4575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2For.2016.4575%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Reports%26atitle%3DEnabling%252Bpersonalized%252Bcancer%252Bmedicine%252Bdecisions%25253A%252BThe%252Bchallenging%252Bpharmacological%252Bapproach%252Bof%252BPBPK%252Bmodels%252Bfor%252Bnanomedicine%252Band%252Bpharmacogenomics%252B%252528Review%252529%26aulast%3DVIZIRIANAKIS%26aufirst%3DIOANNIS%2BS.%26date%3D2016%26date%3D2016%26volume%3D35%26issue%3D4%26spage%3D1891%26epage%3D1904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ioannis S  Vizirianakis</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Pharmacology</span><span> <strong>2014,</strong> <em>3 </em>
                                    (4)
                                     , 110. <a href="https://doi.org/10.5497/wjp.v3.i4.110" title="DOI URL">https://doi.org/10.5497/wjp.v3.i4.110</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5497/wjp.v3.i4.110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5497%2Fwjp.v3.i4.110%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Pharmacology%26atitle%3DHarnessing%252Bpharmacological%252Bknowledge%252Bfor%252Bpersonalized%252Bmedicine%252Band%252Bpharmacotyping%25253A%252BChallenges%252Band%252Blessons%252Blearned%26aulast%3DVizirianakis%26aufirst%3DIoannis%2BS%26date%3D2014%26volume%3D3%26issue%3D4%26spage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marialucia  Gallorini</span>, <span class="hlFld-ContribAuthor ">Amelia  Cataldi</span>, <span class="hlFld-ContribAuthor ">Viviana  di Giacomo</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase Modulators and Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">BioDrugs</span><span> <strong>2012,</strong> <em>26 </em>
                                    (6)
                                     , 377-391. <a href="https://doi.org/10.1007/BF03261895" title="DOI URL">https://doi.org/10.1007/BF03261895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/BF03261895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2FBF03261895%26sid%3Dliteratum%253Aachs%26jtitle%3DBioDrugs%26atitle%3DCyclin-Dependent%252BKinase%252BModulators%252Band%252BCancer%252BTherapy%26aulast%3DGallorini%26aufirst%3DMarialucia%26date%3D2012%26date%3D2012%26volume%3D26%26issue%3D6%26spage%3D377%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ioannis S.  Vizirianakis</span>, <span class="hlFld-ContribAuthor ">Dimitrios G.  Fatouros</span>. </span><span class="cited-content_cbyCitation_article-title">Personalized nanomedicine: paving the way to the practical clinical utility of genomics and nanotechnology advancements. </span><span class="cited-content_cbyCitation_journal-name">Advanced Drug Delivery Reviews</span><span> <strong>2012,</strong> <em>64 </em>
                                    (13)
                                     , 1359-1362. <a href="https://doi.org/10.1016/j.addr.2012.09.034" title="DOI URL">https://doi.org/10.1016/j.addr.2012.09.034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.addr.2012.09.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.addr.2012.09.034%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Drug%2520Delivery%2520Reviews%26atitle%3DPersonalized%252Bnanomedicine%25253A%252Bpaving%252Bthe%252Bway%252Bto%252Bthe%252Bpractical%252Bclinical%252Butility%252Bof%252Bgenomics%252Band%252Bnanotechnology%252Badvancements%26aulast%3DVizirianakis%26aufirst%3DIoannis%2BS.%26date%3D2012%26volume%3D64%26issue%3D13%26spage%3D1359%26epage%3D1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramiro  Vázquez</span>, <span class="hlFld-ContribAuthor ">María E.  Riveiro</span>, <span class="hlFld-ContribAuthor ">Mónica  Vermeulen</span>, <span class="hlFld-ContribAuthor ">Eliana  Alonso</span>, <span class="hlFld-ContribAuthor ">Carolina  Mondillo</span>, <span class="hlFld-ContribAuthor ">Graciela  Facorro</span>, <span class="hlFld-ContribAuthor ">Lidia  Piehl</span>, <span class="hlFld-ContribAuthor ">Natalia  Gómez</span>, <span class="hlFld-ContribAuthor ">Albertina  Moglioni</span>, <span class="hlFld-ContribAuthor ">Natalia  Fernández</span>, <span class="hlFld-ContribAuthor ">Alberto  Baldi</span>, <span class="hlFld-ContribAuthor ">Carina  Shayo</span>, <span class="hlFld-ContribAuthor ">Carlos  Davio</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-anti-leukemic activity relationship study of ortho-dihydroxycoumarins in U-937 cells: Key role of the δ-lactone ring in determining differentiation-inducing potency and selective pro-apoptotic action. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (18)
                                     , 5537-5549. <a href="https://doi.org/10.1016/j.bmc.2012.07.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.07.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.07.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructure-anti-leukemic%252Bactivity%252Brelationship%252Bstudy%252Bof%252Bortho-dihydroxycoumarins%252Bin%252BU-937%252Bcells%25253A%252BKey%252Brole%252Bof%252Bthe%252B%2525CE%2525B4-lactone%252Bring%252Bin%252Bdetermining%252Bdifferentiation-inducing%252Bpotency%252Band%252Bselective%252Bpro-apoptotic%252Baction%26aulast%3DV%25C3%25A1zquez%26aufirst%3DRamiro%26date%3D2012%26volume%3D20%26issue%3D18%26spage%3D5537%26epage%3D5549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramiro  Vázquez</span>, <span class="hlFld-ContribAuthor ">María E.  Riveiro</span>, <span class="hlFld-ContribAuthor ">Mónica  Vermeulen</span>, <span class="hlFld-ContribAuthor ">Carolina  Mondillo</span>, <span class="hlFld-ContribAuthor ">Philip H.  Coombes</span>, <span class="hlFld-ContribAuthor ">Neil R.  Crouch</span>, <span class="hlFld-ContribAuthor ">Fathima  Ismail</span>, <span class="hlFld-ContribAuthor ">Dulcie A.  Mulholland</span>, <span class="hlFld-ContribAuthor ">Alberto  Baldi</span>, <span class="hlFld-ContribAuthor ">Carina  Shayo</span>, <span class="hlFld-ContribAuthor ">Carlos  Davio</span>. </span><span class="cited-content_cbyCitation_article-title">Toddaculin, a natural coumarin from Toddalia asiatica, induces differentiation and apoptosis in U-937 leukemic cells. </span><span class="cited-content_cbyCitation_journal-name">Phytomedicine</span><span> <strong>2012,</strong> <em>19 </em>
                                    (8-9)
                                     , 737-746. <a href="https://doi.org/10.1016/j.phymed.2012.03.008" title="DOI URL">https://doi.org/10.1016/j.phymed.2012.03.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phymed.2012.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phymed.2012.03.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytomedicine%26atitle%3DToddaculin%25252C%252Ba%252Bnatural%252Bcoumarin%252Bfrom%252BToddalia%252Basiatica%25252C%252Binduces%252Bdifferentiation%252Band%252Bapoptosis%252Bin%252BU-937%252Bleukemic%252Bcells%26aulast%3DV%25C3%25A1zquez%26aufirst%3DRamiro%26date%3D2012%26volume%3D19%26issue%3D8-9%26spage%3D737%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Chatzopoulou</span>, <span class="hlFld-ContribAuthor ">Ioannis D.  Bonovolias</span>, <span class="hlFld-ContribAuthor ">Ioannis  Nicolaou</span>, <span class="hlFld-ContribAuthor ">Vassilis J.  Demopoulos</span>, <span class="hlFld-ContribAuthor ">Ioannis S.  Vizirianakis</span>, <span class="hlFld-ContribAuthor ">Asterios S.  Tsiftsoglou</span>. </span><span class="cited-content_cbyCitation_article-title">Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>50 </em>, 75-80. <a href="https://doi.org/10.1016/j.ejmech.2012.01.041" title="DOI URL">https://doi.org/10.1016/j.ejmech.2012.01.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2012.01.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2012.01.041%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBis-pyrrolyl-tetrazolyl%252Bderivatives%252Bas%252Bhybrid%252Bpolar%252Bcompounds%25253A%252BA%252Bcase%252Bof%252Blipophilic%252Bfunctional%252Bbioisosterism%252Bwith%252Bbis-acetamides%26aulast%3DChatzopoulou%26aufirst%3DMaria%26date%3D2012%26volume%3D50%26spage%3D75%26epage%3D80" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung-Yong  Seo</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2012,</strong> <em>35 </em>
                                    (2)
                                     , 197-200. <a href="https://doi.org/10.1007/s12272-012-0221-9" title="DOI URL">https://doi.org/10.1007/s12272-012-0221-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-012-0221-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-012-0221-9%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DMulti-targeted%252Bhybrids%252Bbased%252Bon%252BHDAC%252Binhibitors%252Bfor%252Banti-cancer%252Bdrug%252Bdiscovery%26aulast%3DSeo%26aufirst%3DSeung-Yong%26date%3D2012%26date%3D2012%26volume%3D35%26issue%3D2%26spage%3D197%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guogang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Shuobing  Wang</span>, <span class="hlFld-ContribAuthor ">Chuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Qingchang  Huang</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Cytotoxicity Studies of Novel 2-Hydrazonylpyrido[2,3-b]pyrazin-3(4H)-ones. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2012,</strong> <em>345 </em>
                                    (1)
                                     , 49-56. <a href="https://doi.org/10.1002/ardp.201100103" title="DOI URL">https://doi.org/10.1002/ardp.201100103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201100103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201100103%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%252Band%252BCytotoxicity%252BStudies%252Bof%252BNovel%252B2-Hydrazonylpyrido%25255B2%25252C3-b%25255Dpyrazin-3%2525284H%252529-ones%26aulast%3DZhang%26aufirst%3DGuogang%26date%3D2012%26date%3D2011%26volume%3D345%26issue%3D1%26spage%3D49%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ioannis S.  Vizirianakis</span>, <span class="hlFld-ContribAuthor ">Elsa P.  Amanatiadou</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacogenomics and Nanotechnology Toward Advancing Personalized Medicine. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2012,</strong>,, 115-134. <a href="https://doi.org/10.1007/978-3-642-24181-9_7" title="DOI URL">https://doi.org/10.1007/978-3-642-24181-9_7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-642-24181-9_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-642-24181-9_7%26sid%3Dliteratum%253Aachs%26atitle%3DPharmacogenomics%252Band%252BNanotechnology%252BToward%252BAdvancing%252BPersonalized%252BMedicine%26aulast%3DVizirianakis%26aufirst%3DIoannis%2BS.%26date%3D2012%26date%3D2011%26spage%3D115%26epage%3D134%26pub%3DSpringer%2520Berlin%2520Heidelberg%26atitle%3DNanomedicine%252Band%252BNanobiotechnology%26aulast%3DLogothetidis%26aufirst%3DStergios%26date%3D2012%26volume%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T.  Theodosiou</span>, <span class="hlFld-ContribAuthor ">I.S.  Vizirianakis</span>, <span class="hlFld-ContribAuthor ">L.  Angelis</span>, <span class="hlFld-ContribAuthor ">A.  Tsaftaris</span>, <span class="hlFld-ContribAuthor ">N.  Darzentas</span>. </span><span class="cited-content_cbyCitation_article-title">MeSHy: Mining unanticipated PubMed information using frequencies of occurrences and concurrences of MeSH terms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomedical Informatics</span><span> <strong>2011,</strong> <em>44 </em>
                                    (6)
                                     , 919-926. <a href="https://doi.org/10.1016/j.jbi.2011.05.009" title="DOI URL">https://doi.org/10.1016/j.jbi.2011.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jbi.2011.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jbi.2011.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomedical%2520Informatics%26atitle%3DMeSHy%25253A%252BMining%252Bunanticipated%252BPubMed%252Binformation%252Busing%252Bfrequencies%252Bof%252Boccurrences%252Band%252Bconcurrences%252Bof%252BMeSH%252Bterms%26aulast%3DTheodosiou%26aufirst%3DT.%26date%3D2011%26volume%3D44%26issue%3D6%26spage%3D919%26epage%3D926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ioannis S.  Vizirianakis</span>. </span><span class="cited-content_cbyCitation_article-title">Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine: Nanotechnology, Biology and Medicine</span><span> <strong>2011,</strong> <em>7 </em>
                                    (1)
                                     , 11-17. <a href="https://doi.org/10.1016/j.nano.2010.11.002" title="DOI URL">https://doi.org/10.1016/j.nano.2010.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nano.2010.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nano.2010.11.002%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%253A%2520Nanotechnology%252C%2520Biology%2520and%2520Medicine%26atitle%3DNanomedicine%252Band%252Bpersonalized%252Bmedicine%252Btoward%252Bthe%252Bapplication%252Bof%252Bpharmacotyping%252Bin%252Bclinical%252Bpractice%252Bto%252Bimprove%252Bdrug-delivery%252Boutcomes%26aulast%3DVizirianakis%26aufirst%3DIoannis%2BS.%26date%3D2011%26volume%3D7%26issue%3D1%26spage%3D11%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="fig1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Diagrammatic presentation of molecular targets for known classes of small molecule antileukemia drugs used in clinical practice or under development and the proposed strategy for innovative multifunctional leukemia therapeutics (see text for details). Abbreviations are as follows: HSP, heat shock protein; RAR, retinoid acid receptor; RXR, retinoid X receptor; DNMTs, DNA methyltransferases; HDACs, histone deacetylases; CDKs, cyclin-dependent kinases; mTOR, mammalian target of rapamycin; FT, farnesyl transferase; FLT3, Fms-like tyrosine kinase 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Conceptual approaches combining induction of differentiation and promotion of apoptosis (cell death) of leukemia cells. Differentiation inducing agents (DIA) can disrupt self-renewal and cause growth arrest in terminal differentiated progeny unable to support malignant growth (A and C<sub>1</sub>). In contrast, apoptosis promoting agents (APA) can stimulate cell death signaling in undifferentiated as well as differentiated progenitors of leukemic cells (B and C<sub>1</sub>). Finally, differentiation and apoptosis hybrid (DAH) agents represent molecules with structural domains as bifunctional agents that can promote differentiation and/or apoptosis leading to eradication of leukemic cells (cell death) (C<sub>2</sub>) (see text for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Differentiation inducing agents (DIA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. BH<sub>3</sub> mimetics (BCL binding molecules).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Bcr-Abl tyrosine kinase inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. FLT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. mTOR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Proteasome inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Farnesyl transferase inhibitors (FTIs).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/medium/jm-2010-00189a_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Cycline dependent kinase (CDK) inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-19/jm100189a/production/images/large/jm-2010-00189a_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100189a&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 277 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonovolias, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsiftsoglou, S. A.</span><span> </span><span class="NLM_article-title">Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.pharmthera.2009.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19306896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsVSgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=264-280&author=A.+S.+Tsiftsoglouauthor=I.+D.+Bonovoliasauthor=S.+A.+Tsiftsoglou&title=Multilevel+targeting+of+hematopoietic+stem+cell+self-renewal%2C+differentiation+and+apoptosis+for+leukemia+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy</span></div><div class="casAuthors">Tsiftsoglou, Asterios S.; Bonovolias, Ioannis D.; Tsiftsoglou, Stefanos A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">264-280</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Human leukemias are considered clonal hematol. malignancies initiated by chromosomal aberrations or epigenetic alterations occurring at the level of either pluripotent hematopoietic stem cells (HSCs) or early multipotent progenitors (MPPs).  Leukemic cells are transformed, immortalized, actively proliferating cells that are still able to differentiate into cells resembling mature blood cells.  Future therapies of leukemias require identification of mol. targets involved in hematopoiesis under normal and leukemic conditions and detailed understanding of the interactions between normal hematopoietic and leukemic cells within the bone marrow micro-environment.  This review presents the basic aspects of hematopoiesis and highlights multilevel exploitable targets for leukemia therapy.  These include HSC niche components, signaling pathways (SCF/c-kit-R, EPO-R-JAK2/STAT, Wnt, Notch, HOX), inducer-receptor interactions, superfine chromatin structure modifications, fused transcription factors, microRNAs and signaling of cell death through the Bcl-2 apoptotic switch (BH3-only proteins).  The classes of therapeutics developed or being under development to eradicate human leukemias include novel antimetabolites, DNA hypomethylating agents, histone deacetylation inhibitors (HDACIs), retinoids and other inducers of differentiation, targeted monoclonal antibodies raised against cell surface proteins, pro-apoptotic receptor agonists (PARAs), BH3 peptidomimetics, cell cycle inhibitors, siRNAs, and perhaps microRNAs.  Some of these agents induce terminal differentiation while others promote cell cycle arrest and apoptosis in leukemia cells.  At last but not least, this article describes the mechanisms of removal of damaged/harmful cells from organs since impairment in clearance of such cells can lead to autoimmune disorders by self-antigens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWpgtYc_75L7Vg90H21EOLACvtfcHk0lgPbKKEwGnmFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsVSgtb4%253D&md5=feae94833802f3bdf73724ef209e19db</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26aulast%3DBonovolias%26aufirst%3DI.%2BD.%26aulast%3DTsiftsoglou%26aufirst%3DS.%2BA.%26atitle%3DMultilevel%2520targeting%2520of%2520hematopoietic%2520stem%2520cell%2520self-renewal%252C%2520differentiation%2520and%2520apoptosis%2520for%2520leukemia%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D122%26spage%3D264%26epage%3D280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pappas, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span> </span><span class="NLM_article-title">Mechanisms involved in the induced differentiation of leukemia cells</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.pharmthera.2003.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=14652113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlylsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=257-290&author=A.+S.+Tsiftsoglouauthor=I.+S.+Pappasauthor=I.+S.+Vizirianakis&title=Mechanisms+involved+in+the+induced+differentiation+of+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms involved in the induced differentiation of leukemia cells</span></div><div class="casAuthors">Tsiftsoglou, Asterios S.; Pappas, Ioannis S.; Vizirianakis, Ioannis S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-290</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Despite the remarkable progress achieved in the treatment of leukemias over the last several years, many problems (multidrug resistance [MDR], cellular heterogeneity, heterogeneous mol. abnormalities, karyotypic instability, and lack of selective action of antineoplastic agents) still remain.  The recent progress in tumor mol. biol. has revealed that leukemias are likely to arise from the disruption of differentiation of early hematopoietic progenitors that fail to give birth to cell lineage restricted phenotypes.  Evidence supporting such mechanisms has been derived from studying bone marrow leukemogenesis and analyzing differentiation of leukemic cell lines in culture that serve as models of erythroleukemic (murine erythroleukemia [MEL] and human leukemia [K562] cells) and myeloid (human promyelocytic leukemia [HL-60] cells) cell maturation.  This paper reviews the current concepts of differentiation, the chem./pharmacol. inducing agents developed thus far, and the mechanisms involved in initiation of leukemic cell differentiation.  Emphasis was given on commitment and the cell lineage transcriptional factors as key regulators of terminal differentiation as well as on membrane-mediated events and signaling pathways involved in hematopoietic cell differentiation.  The developmental program of MEL cells was presented in considerable depth.  It is quite remarkable that the erythrocytic maturation of these cells is orchestrated into specific subprograms and gene expression patterns, suggesting that leukemic cell differentiation represents a highly coordinated set of events that lead to irreversible growth arrest and expression of cell lineage restricted phenotypes.  In MEL and other leukemic cells, differentiation appears to be accompanied by differentiation-dependent apoptosis (DDA), an event that can be exploited chemotherapeutically.  The mechanisms by which the chem. inducers promote differentiation of leukemic cells have been discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-BJnnA_jv77Vg90H21EOLACvtfcHk0liHXufklqpdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlylsrw%253D&md5=43bd5e78f2ca2fe96007b82692aff55a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2003.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2003.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26aulast%3DPappas%26aufirst%3DI.%2BS.%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26atitle%3DMechanisms%2520involved%2520in%2520the%2520induced%2520differentiation%2520of%2520leukemia%2520cells%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D100%26spage%3D257%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Blair, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogge, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ailles, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansdorp, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, H. J.</span><span> </span><span class="NLM_article-title">Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">3104</span><span class="NLM_x">–</span> <span class="NLM_lpage">3112</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=3104-3112&author=A.+Blairauthor=D.+E.+Hoggeauthor=L.+E.+Aillesauthor=P.+M.+Lansdorpauthor=H.+J.+Sutherland&title=Lack+of+expression+of+Thy-1+%28CD90%29+on+acute+myeloid+leukemia+cells+with+long-term+proliferative+ability+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DA.%26aulast%3DHogge%26aufirst%3DD.%2BE.%26aulast%3DAilles%26aufirst%3DL.%2BE.%26aulast%3DLansdorp%26aufirst%3DP.%2BM.%26aulast%3DSutherland%26aufirst%3DH.%2BJ.%26atitle%3DLack%2520of%2520expression%2520of%2520Thy-1%2520%2528CD90%2529%2520on%2520acute%2520myeloid%2520leukemia%2520cells%2520with%2520long-term%2520proliferative%2520ability%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D3104%26epage%3D3112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Bonnet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, J. E.</span><span> </span><span class="NLM_article-title">Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnm0797-730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9212098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1GrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1997&pages=730-737&author=D.+Bonnetauthor=J.+E.+Dick&title=Human+acute+myeloid+leukemia+is+organized+as+a+hierarchy+that+originates+from+a+primitive+hematopoietic+cell"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell</span></div><div class="casAuthors">Bonnet, Dominique; Dick, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">730-737</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">On the subject of acute myeloid leukemia (AML), there is little consensus about the target cell within the hematopoietic stem cell hierarchy that is susceptible to leukemic transformation, or about the mechanism that underlies the phenotypic, genotypic and clin. heterogeneity.  Here we demonstrate that the cell capable of initiating human AML in non-obese diabetic mice with severe combined immunodeficiency disease (NOD/SCID mice) - termed the SCID leukemia-initiating cell, or SL-IC - possesses the differentiative and proliferative capacities and the potential for self-renewal expected of a leukemic stem cell.  The SL-ICs from all subtypes of AML analyzed, regardless of the heterogeneity in maturation characteristics of the leukemic blasts, were exclusively CD34++CD38-, similar to the cell-surface phenotype of normal SCID-repopulating cells, suggesting that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation.  The SL-ICs were able to differentiate in vivo into leukemic blasts, indicating that the leukemic clone is organized as a hierarchy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKHDGBfY3ALVg90H21EOLACvtfcHk0liHXufklqpdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1GrtLY%253D&md5=b958aada52385850505d42ef08aeee22</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnm0797-730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0797-730%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DD.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26atitle%3DHuman%2520acute%2520myeloid%2520leukemia%2520is%2520organized%2520as%2520a%2520hierarchy%2520that%2520originates%2520from%2520a%2520primitive%2520hematopoietic%2520cell%26jtitle%3DNat.%2520Med.%26date%3D1997%26volume%3D3%26spage%3D730%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odenike, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, J. D.</span><span> </span><span class="NLM_article-title">Leukaemogenesis: more than mutant genes</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">23</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc2765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=20029422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2hs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=23-36&author=J.+Chenauthor=O.+Odenikeauthor=J.+D.+Rowley&title=Leukaemogenesis%3A+more+than+mutant+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Leukaemogenesis: More than mutant genes</span></div><div class="casAuthors">Chen, Jianjun; Odenike, Olatoyosi; Rowley, Janet D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-36</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Acute leukemias are characterized by recurring chromosomal aberrations and gene mutations that are crucial to disease pathogenesis.  It is now evident that epigenetic modifications, including DNA methylation and histone modifications, substantially contribute to the phenotype of leukemia cells.  An addnl. layer of epigenetic complexity is the pathogenetic role of microRNAs in leukemias, and their key role in the transcriptional regulation of tumor suppressor genes and oncogenes.  The genetic heterogeneity of acute leukemias poses therapeutic challenges, but pharmacol. agents that target components of the epigenetic machinery are promising as a component of the therapeutic arsenal for this group of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBc3XC454rZLVg90H21EOLACvtfcHk0liHXufklqpdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2hs7bE&md5=19e56ddec8ee4b74e87977d66abbe9bb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2765%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DOdenike%26aufirst%3DO.%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26atitle%3DLeukaemogenesis%253A%2520more%2520than%2520mutant%2520genes%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D23%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Hockenbery, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giedt, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Neill, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manion, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banker, D. E.</span><span> </span><span class="NLM_article-title">Mitochondria and apoptosis: new therapeutic targets</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2002&pages=203-242&author=D.+M.+Hockenberyauthor=C.+D.+Giedtauthor=J.+W.+O%E2%80%99Neillauthor=M.+K.+Manionauthor=D.+E.+Banker&title=Mitochondria+and+apoptosis%3A+new+therapeutic+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHockenbery%26aufirst%3DD.%2BM.%26aulast%3DGiedt%26aufirst%3DC.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DJ.%2BW.%26aulast%3DManion%26aufirst%3DM.%2BK.%26aulast%3DBanker%26aufirst%3DD.%2BE.%26atitle%3DMitochondria%2520and%2520apoptosis%253A%2520new%2520therapeutic%2520targets%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2002%26volume%3D85%26spage%3D203%26epage%3D242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+Janneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Million, R. P.</span><span> </span><span class="NLM_article-title">Impact of genetic diagnostics on drug development strategy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">459</span><span class="NLM_x">–</span> <span class="NLM_lpage">462</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=459-462&author=R.+P.+Million&title=Impact+of+genetic+diagnostics+on+drug+development+strategy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMillion%26aufirst%3DR.%2BP.%26atitle%3DImpact%2520of%2520genetic%2520diagnostics%2520on%2520drug%2520development%2520strategy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D459%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Tenen, D. G.</span><span> </span><span class="NLM_article-title">Disruption of differentiation in human cancer: AML shows the way</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12563308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXisVarsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=89-101&author=D.+G.+Tenen&title=Disruption+of+differentiation+in+human+cancer%3A+AML+shows+the+way"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of differentiation in human cancer: AML shows the way</span></div><div class="casAuthors">Tenen, Daniel G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-101</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes.  Recent studies of acute myeloid leukemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer.  This model involves lineage-specific transcription factors, which are involved in normal hematopoietic differentiation.  These factors are often targeted in AML - either by direct mutation or by interference from translocation proteins.  Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxQUl0uz1MDrVg90H21EOLACvtfcHk0ljjZDBrqjbvgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXisVarsL4%253D&md5=c71e926e55a2410a9d4fa6f66a809469</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc989%26sid%3Dliteratum%253Aachs%26aulast%3DTenen%26aufirst%3DD.%2BG.%26atitle%3DDisruption%2520of%2520differentiation%2520in%2520human%2520cancer%253A%2520AML%2520shows%2520the%2520way%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D89%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strouboulis, J.</span><span> </span><span class="NLM_article-title">Erythropoiesis: model systems, molecular regulators, and developmental programs</span> <span class="citation_source-journal">IUBMB Life</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">800</span><span class="NLM_x">–</span> <span class="NLM_lpage">830</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=800-830&author=A.+S.+Tsiftsoglouauthor=I.+S.+Vizirianakisauthor=J.+Strouboulis&title=Erythropoiesis%3A+model+systems%2C+molecular+regulators%2C+and+developmental+programs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26aulast%3DStrouboulis%26aufirst%3DJ.%26atitle%3DErythropoiesis%253A%2520model%2520systems%252C%2520molecular%2520regulators%252C%2520and%2520developmental%2520programs%26jtitle%3DIUBMB%2520Life%26date%3D2009%26volume%3D61%26spage%3D800%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fialkow, P. J.</span><span> </span><span class="NLM_article-title">Clonal origin of human tumors</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1979&pages=135-143&author=P.+J.+Fialkow&title=Clonal+origin+of+human+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFialkow%26aufirst%3DP.%2BJ.%26atitle%3DClonal%2520origin%2520of%2520human%2520tumors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D1979%26volume%3D30%26spage%3D135%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Zhou, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damelin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geles, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grindley, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dirks, P. B.</span><span> </span><span class="NLM_article-title">Tumour-initiating cells: challenges and opportunities for anticancer drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">806</span><span class="NLM_x">–</span> <span class="NLM_lpage">823</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd2137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19794444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=806-823&author=B.+B.+Zhouauthor=H.+Zhangauthor=M.+Damelinauthor=K.+G.+Gelesauthor=J.+C.+Grindleyauthor=P.+B.+Dirks&title=Tumour-initiating+cells%3A+challenges+and+opportunities+for+anticancer+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Tumour-initiating cells: challenges and opportunities for anticancer drug discovery</span></div><div class="casAuthors">Zhou, Bin-Bing S.; Zhang, Haiying; Damelin, Marc; Geles, Kenneth G.; Grindley, Justin C.; Dirks, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">806-823</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The hypothesis that cancer is driven by tumor-initiating cells (popularly known as cancer stem cells) has recently attracted a great deal of attention, owing to the promise of a novel cellular target for the treatment of haematopoietic and solid malignancies.  Furthermore, it seems that tumor-initiating cells might be resistant to many conventional cancer therapies, which might explain the limitations of these agents in curing human malignancies.  Although much work is still needed to identify and characterize tumor-initiating cells, efforts are now being directed towards identifying therapeutic strategies that could target these cells.  This Review considers recent advances in the cancer stem cell field, focusing on the challenges and opportunities for anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptUe11eAS07rVg90H21EOLACvtfcHk0ljjZDBrqjbvgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2kurbL&md5=3d179a7e717a84381a679b8df44ff407</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd2137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2137%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DB.%2BB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDamelin%26aufirst%3DM.%26aulast%3DGeles%26aufirst%3DK.%2BG.%26aulast%3DGrindley%26aufirst%3DJ.%2BC.%26aulast%3DDirks%26aufirst%3DP.%2BB.%26atitle%3DTumour-initiating%2520cells%253A%2520challenges%2520and%2520opportunities%2520for%2520anticancer%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D806%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Friend, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, T.</span><span> </span><span class="NLM_article-title">Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">382</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1971&pages=378-382&author=C.+Friendauthor=W.+Scherauthor=J.+G.+Hollandauthor=T.+Sato&title=Hemoglobin+synthesis+in+murine+virus-induced+leukemic+cells+in+vitro%3A+stimulation+of+erythroid+differentiation+by+dimethyl+sulfoxide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFriend%26aufirst%3DC.%26aulast%3DScher%26aufirst%3DW.%26aulast%3DHolland%26aufirst%3DJ.%2BG.%26aulast%3DSato%26aufirst%3DT.%26atitle%3DHemoglobin%2520synthesis%2520in%2520murine%2520virus-induced%2520leukemic%2520cells%2520in%2520vitro%253A%2520stimulation%2520of%2520erythroid%2520differentiation%2520by%2520dimethyl%2520sulfoxide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1971%26volume%3D68%26spage%3D378%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Nowak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeffler, H. P.</span><span> </span><span class="NLM_article-title">Differentiation therapy of leukemia: 3 decades of development</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">3655</span><span class="NLM_x">–</span> <span class="NLM_lpage">3665</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=3655-3665&author=D.+Nowakauthor=D.+Stewartauthor=H.+P.+Koeffler&title=Differentiation+therapy+of+leukemia%3A+3+decades+of+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNowak%26aufirst%3DD.%26aulast%3DStewart%26aufirst%3DD.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26atitle%3DDifferentiation%2520therapy%2520of%2520leukemia%253A%25203%2520decades%2520of%2520development%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D3655%26epage%3D3665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Sartorelli, A. C.</span><span> </span><span class="NLM_article-title">The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">–</span> <span class="NLM_lpage">302</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fbjc.1985.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=3899154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADyaL28%252FgtVCjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1985&pages=293-302&author=A.+C.+Sartorelli&title=The+1985+Walter+Hubert+lecture.+Malignant+cell+differentiation+as+a+potential+therapeutic+approach"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach</span></div><div class="casAuthors">Sartorelli A C</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-302</span>
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    </div><div class="casAbstract">Most drugs available for cancer chemotherapy exert their effects through cytodestruction.  Although significant advances have been attained with these cytotoxic agents in several malignant diseases, response is often accompanied by significant morbidity and many common malignant tumours respond poorly to existing cytotoxic therapy.  Development of chemotherapeutic agents with non-cytodestructive actions appears desirable.  Considerable evidence exists which indicates that (a) the malignant state is not irreversible and represents a disease of altered maturation, and (b) some experimental tumour systems can be induced by chemical agents to differentiate to mature end-stage cells with no proliferative potential.  Thus, it is conceivable that therapeutic agents can be developed which convert cancer cells to benign forms.  To study the phenomenon of blocked maturation, squamous carcinoma SqCC/Y1 cells were employed in culture.  Using this system it was possible to demonstrate that physiological levels of retinoic acid and epidermal growth factor were capable of preventing the differentiation of these malignant keratinocytes into a mature tissue-like structure.  The terminal differentiation caused by certain antineoplastic agents was investigated in HL-60 promyelocytic leukaemia cells to provide information on the mechanism by which chemotherapeutic agents induce cells to by-pass a maturation block.  The anthracyclines aclacinomycin A and marcellomycin were potent inhibitors of N-glycosidically linked glycoprotein biosynthesis and transferrin receptor activity, and active inducers of maturation; temporal studies suggested that the biochemical effects were associated with the differentiation process. 6-Thioguanine produced cytotoxicity in parental cells by forming analog nucleotide.  In hypoxanthine-guanine phosphoribosyltransferase negative HL-60 cells the 6-thiopurine initiated maturation; this action was due to the free base (and possibly the deoxyribonucleoside), a finding which separated termination of proliferation due to cytotoxicity from that caused by maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmfSxuXFZAegHqQV89nF-2fW6udTcc2ea5JxffpnwyjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FgtVCjsg%253D%253D&md5=56a5c9656a5269ba2df3739f6e1a9a70</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1985.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1985.193%26sid%3Dliteratum%253Aachs%26aulast%3DSartorelli%26aufirst%3DA.%2BC.%26atitle%3DThe%25201985%2520Walter%2520Hubert%2520lecture.%2520Malignant%2520cell%2520differentiation%2520as%2520a%2520potential%2520therapeutic%2520approach%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1985%26volume%3D52%26spage%3D293%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Christman, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herzog, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneiderman, N.</span><span> </span><span class="NLM_article-title">Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">763</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1983&pages=763-769&author=J.+K.+Christmanauthor=N.+Mendelsohnauthor=D.+Herzogauthor=N.+Schneiderman&title=Effect+of+5-azacytidine+on+differentiation+and+DNA+methylation+in+human+promyelocytic+leukemia+cells+%28HL-60%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChristman%26aufirst%3DJ.%2BK.%26aulast%3DMendelsohn%26aufirst%3DN.%26aulast%3DHerzog%26aufirst%3DD.%26aulast%3DSchneiderman%26aufirst%3DN.%26atitle%3DEffect%2520of%25205-azacytidine%2520on%2520differentiation%2520and%2520DNA%2520methylation%2520in%2520human%2520promyelocytic%2520leukemia%2520cells%2520%2528HL-60%2529%26jtitle%3DCancer%2520Res.%26date%3D1983%26volume%3D43%26spage%3D763%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Creusot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christman, J. K.</span><span> </span><span class="NLM_article-title">Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1982</span><span class="NLM_x">, </span> <span class="NLM_volume">257</span><span class="NLM_x">, </span> <span class="NLM_fpage">2041</span><span class="NLM_x">–</span> <span class="NLM_lpage">2048</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=6173384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaL38XhtlGntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1982&pages=2041-2048&author=F.+Creusotauthor=G.+Acsauthor=J.+K.+Christman&title=Inhibition+of+DNA+methyltransferase+and+induction+of+Friend+erythroleukemia+cell+differentiation+by+5-azacytidine+and+5-aza-2%E2%80%B2-deoxycytidine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine</span></div><div class="casAuthors">Creusot, Francine; Acs, George; Christman, Judith K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2041-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Treatment of Friend erythroleukemia cells with 5-azacytidine (I)  [320-67-2] and 5-aza-2'-deoxycytidine (II)  [2353-33-5] leads to rapid, time-dependent, and dose-dependent decrease of DNA methyltransferase  [9037-42-7] activity and synthesis of markedly undermethylated DNA.  Since this DNA is at least partially methylated in vivo and serves as an excellent substrate for methylation in vitro, hypomethylation of DNA in analog-treated cells appears to result from the loss of DNA methyltransferase, rather than from an inherent inability of 5-azacytosine-substituted DNA to serve as a Me acceptor.  Inhibition of DNA synthesis blocks the loss of DNA methyltransferase activity while inhibitors of RNA synthesis do not, suggesting that the analogs must be incorporated into DNA to mediate their effect on the enzyme, and that minor substitution of 5-azacytosine for cytosine in DNA (∼0.3%) suffices to inactivate more than 95% of the enzyme in the cell.  Several lines of evidence link changes in the pattern of DNA modification with differentiation.  In this regard, it is significant that 5-azacytidine and 5-aza-2'-deoxycytidine act as weak inducers of erythroid differentiation of Friend erythroleukemia cells in the same concn. range where they affect DNA methyltransferase activity.  For differentiation to proceed, the cells must be washed free of the drugs.  Less than 24 h later, normal levels of DNA methyltransferase activity are restored and within 48 h, DNA isolated from the cells is not detectably undermethylated.  This may in part explain why 5-azacytidine and 5-aza-2'-deoxycytidine induce differentiation in less than 15% of the population despite their initial profound effect on DNA methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogsTJVZQ1RALVg90H21EOLACvtfcHk0ljvcHwu9uFhkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhtlGntLw%253D&md5=67fd34d05b1b76349fb0b2586a049ea5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCreusot%26aufirst%3DF.%26aulast%3DAcs%26aufirst%3DG.%26aulast%3DChristman%26aufirst%3DJ.%2BK.%26atitle%3DInhibition%2520of%2520DNA%2520methyltransferase%2520and%2520induction%2520of%2520Friend%2520erythroleukemia%2520cell%2520differentiation%2520by%25205-azacytidine%2520and%25205-aza-2%25E2%2580%25B2-deoxycytidine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1982%26volume%3D257%26spage%3D2041%26epage%3D2048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Strickland, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahdavi, V.</span><span> </span><span class="NLM_article-title">The induction of differentiation in teratocarcinoma stem cells by retinoic acid</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1978</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">393</span><span class="NLM_x">–</span> <span class="NLM_lpage">403</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1978&pages=393-403&author=S.+Stricklandauthor=V.+Mahdavi&title=The+induction+of+differentiation+in+teratocarcinoma+stem+cells+by+retinoic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStrickland%26aufirst%3DS.%26aulast%3DMahdavi%26aufirst%3DV.%26atitle%3DThe%2520induction%2520of%2520differentiation%2520in%2520teratocarcinoma%2520stem%2520cells%2520by%2520retinoic%2520acid%26jtitle%3DCell%26date%3D1978%26volume%3D15%26spage%3D393%26epage%3D403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Leid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kastner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambon, P.</span><span> </span><span class="NLM_article-title">Multiplicity generates diversity in the retinoic acid signalling pathways</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1992&pages=427-433&author=M.+Leidauthor=P.+Kastnerauthor=P.+Chambon&title=Multiplicity+generates+diversity+in+the+retinoic+acid+signalling+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeid%26aufirst%3DM.%26aulast%3DKastner%26aufirst%3DP.%26aulast%3DChambon%26aufirst%3DP.%26atitle%3DMultiplicity%2520generates%2520diversity%2520in%2520the%2520retinoic%2520acid%2520signalling%2520pathways%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1992%26volume%3D17%26spage%3D427%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">84</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnbt1272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17211407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=84-90&author=P.+A.+Marksauthor=R.+Breslow&title=Dimethyl+sulfoxide+to+vorinostat%3A+development+of+this+histone+deacetylase+inhibitor+as+an+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug</span></div><div class="casAuthors">Marks, Paul A.; Breslow, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-90</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In our quest to understand why DMSO (DMSO) can cause growth arrest and terminal differentiation of transformed cells, we followed a path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a histone deacetylase inhibitor.  SAHA reacts with and blocks the catalytic site of these enzymes.  Extensive structure-activity studies were done along the path from DMSO to SAHA.  SAHA can cause growth arrest and death of a broad variety of transformed cells both in vitro and in tumor-bearing animals at concns. not toxic to normal cells.  SAHA has many protein targets whose structure and function are altered by acetylation, including chromatin-assocd. histones, nonhistone gene transcription factors and proteins involved in regulation of cell proliferation, migration and death.  In clin. trials, SAHA has shown significant anticancer activity against both hematol. and solid tumors at doses well tolerated by patients.  A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma.  More potent analogs of SAHA have shown unacceptable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3endE54rQ7Vg90H21EOLACvtfcHk0lhzirSHXDdp9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1GrsQ%253D%253D&md5=cc2a39d80d5d5bea0a1377bdf48a957d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt1272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1272%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DDimethyl%2520sulfoxide%2520to%2520vorinostat%253A%2520development%2520of%2520this%2520histone%2520deacetylase%2520inhibitor%2520as%2520an%2520anticancer%2520drug%26jtitle%3DNat.%2520Biotechnol.%26date%3D2007%26volume%3D25%26spage%3D84%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Reuben, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wife, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span> </span><span class="NLM_article-title">A new group of potent inducers of differentiation in murine erythroleukemia cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">862</span><span class="NLM_x">–</span> <span class="NLM_lpage">866</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=862-866&author=R.+C.+Reubenauthor=R.+I.+Wifeauthor=R.+Breslow&title=A+new+group+of+potent+inducers+of+differentiation+in+murine+erythroleukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReuben%26aufirst%3DR.%2BC.%26aulast%3DWife%26aufirst%3DR.%2BI.%26aulast%3DBreslow%26aufirst%3DR.%26atitle%3DA%2520new%2520group%2520of%2520potent%2520inducers%2520of%2520differentiation%2520in%2520murine%2520erythroleukemia%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D862%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaeli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sogoloff, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kufe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">2604</span><span class="NLM_x">–</span> <span class="NLM_lpage">2069</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1992&pages=2604-2069&author=M.+Andreeffauthor=R.+Stoneauthor=J.+Michaeliauthor=C.+W.+Youngauthor=W.+P.+Tongauthor=H.+Sogoloffauthor=T.+Ervinauthor=D.+Kufeauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Hexamethylene+bisacetamide+in+myelodysplastic+syndrome+and+acute+myelogenous+leukemia%3A+a+phase+II+clinical+trial+with+a+differentiation-inducing+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DMichaeli%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DC.%2BW.%26aulast%3DTong%26aufirst%3DW.%2BP.%26aulast%3DSogoloff%26aufirst%3DH.%26aulast%3DErvin%26aufirst%3DT.%26aulast%3DKufe%26aufirst%3DD.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHexamethylene%2520bisacetamide%2520in%2520myelodysplastic%2520syndrome%2520and%2520acute%2520myelogenous%2520leukemia%253A%2520a%2520phase%2520II%2520clinical%2520trial%2520with%2520a%2520differentiation-inducing%2520agent%26jtitle%3DBlood%26date%3D1992%26volume%3D80%26spage%3D2604%26epage%3D2069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Marks, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span> </span><span class="NLM_article-title">Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">6358</span><span class="NLM_x">–</span> <span class="NLM_lpage">6362</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1989&pages=6358-6362&author=P.+A.+Marksauthor=R.+Breslowauthor=R.+A.+Rifkindauthor=L.+Ngoauthor=R.+Singh&title=Polar%2Fapolar+chemical+inducers+of+differentiation+of+transformed+cells%3A+strategies+to+improve+therapeutic+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DPolar%252Fapolar%2520chemical%2520inducers%2520of%2520differentiation%2520of%2520transformed%2520cells%253A%2520strategies%2520to%2520improve%2520therapeutic%2520potential%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1989%26volume%3D86%26spage%3D6358%26epage%3D6362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jursic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Potent cytodifferentiating agents related to hexamethylenebisacetamide</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">5542</span><span class="NLM_x">–</span> <span class="NLM_lpage">5546</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=5542-5546&author=R.+Breslowauthor=B.+Jursicauthor=Z.+F.+Yanauthor=E.+Friedmanauthor=L.+Lengauthor=L.+Ngoauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Potent+cytodifferentiating+agents+related+to+hexamethylenebisacetamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DJursic%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DZ.%2BF.%26aulast%3DFriedman%26aufirst%3DE.%26aulast%3DLeng%26aufirst%3DL.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DPotent%2520cytodifferentiating%2520agents%2520related%2520to%2520hexamethylenebisacetamide%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1991%26volume%3D88%26spage%3D5542%26epage%3D5546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jursic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civoli, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">Second generation hybrid polar compounds are potent inducers of transformed cell differentiation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">5705</span><span class="NLM_x">–</span> <span class="NLM_lpage">5708</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=5705-5708&author=V.+M.+Richonauthor=Y.+Webbauthor=R.+Mergerauthor=T.+Sheppardauthor=B.+Jursicauthor=L.+Ngoauthor=F.+Civoliauthor=R.+Breslowauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=Second+generation+hybrid+polar+compounds+are+potent+inducers+of+transformed+cell+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DWebb%26aufirst%3DY.%26aulast%3DMerger%26aufirst%3DR.%26aulast%3DSheppard%26aufirst%3DT.%26aulast%3DJursic%26aufirst%3DB.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DCivoli%26aufirst%3DF.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DSecond%2520generation%2520hybrid%2520polar%2520compounds%2520are%2520potent%2520inducers%2520of%2520transformed%2520cell%2520differentiation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1996%26volume%3D93%26spage%3D5705%26epage%3D5708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emiliani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breslow, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rifkind, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marks, P. A.</span><span> </span><span class="NLM_article-title">A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">3003</span><span class="NLM_x">–</span> <span class="NLM_lpage">3007</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=3003-3007&author=V.+M.+Richonauthor=S.+Emilianiauthor=E.+Verdinauthor=Y.+Webbauthor=R.+Breslowauthor=R.+A.+Rifkindauthor=P.+A.+Marks&title=A+class+of+hybrid+polar+inducers+of+transformed+cell+differentiation+inhibits+histone+deacetylases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DEmiliani%26aufirst%3DS.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DWebb%26aufirst%3DY.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DA%2520class%2520of%2520hybrid%2520polar%2520inducers%2520of%2520transformed%2520cell%2520differentiation%2520inhibits%2520histone%2520deacetylases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D3003%26epage%3D3007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Roses, A. D.</span><span> </span><span class="NLM_article-title">Pharmacogenetics and drug development: the path to safer and more effective drugs</span> <span class="citation_source-journal">Nat. Rev. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">645</span><span class="NLM_x">–</span> <span class="NLM_lpage">656</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrg1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15372086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt12ntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=645-656&author=A.+D.+Roses&title=Pharmacogenetics+and+drug+development%3A+the+path+to+safer+and+more+effective+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenetics and drug development: the path to safer and more effective drugs</span></div><div class="casAuthors">Roses, Allen D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">645-656</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  Pharmacogenetics provides opportunities for informed decision-making along the pharmaceutical pipeline.  There is a growing literature of retrospective studies of marketed medicines that describe efficacy or safety on the basis of patient genotypes.  These studies emphasize the potential prospective use of genome information to enhance success in finding new medicines.  An example of a prospective efficacy pharmacogenetic Phase-IIA proof-of-concept study is described.  Inserting a rapidly performed efficacy pharmacogenetic step after initial clin. data are obtained can provide confidence for a commitment to full drug development.  The rapid identification of adverse events during and after drug development using genomic mapping tools is also reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQyBqRboXE2LVg90H21EOLACvtfcHk0lgr6RFnb_1fmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt12ntrs%253D&md5=034b4d97ce4a22ed9ded6fb257742dc2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrg1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1432%26sid%3Dliteratum%253Aachs%26aulast%3DRoses%26aufirst%3DA.%2BD.%26atitle%3DPharmacogenetics%2520and%2520drug%2520development%253A%2520the%2520path%2520to%2520safer%2520and%2520more%2520effective%2520drugs%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2004%26volume%3D5%26spage%3D645%26epage%3D656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Paris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelloni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors: from bench to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+deacetylase+inhibitors%3A+from+bench+to+clinic"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0lgr6RFnb_1fmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520deacetylase%2520inhibitors%253A%2520from%2520bench%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Melki, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S. J.</span><span> </span><span class="NLM_article-title">Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3730</span><span class="NLM_x">–</span> <span class="NLM_lpage">3740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=3730-3740&author=J.+R.+Melkiauthor=P.+C.+Vincentauthor=S.+J.+Clark&title=Concurrent+DNA+hypermethylation+of+multiple+genes+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMelki%26aufirst%3DJ.%2BR.%26aulast%3DVincent%26aufirst%3DP.%2BC.%26aulast%3DClark%26aufirst%3DS.%2BJ.%26atitle%3DConcurrent%2520DNA%2520hypermethylation%2520of%2520multiple%2520genes%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D3730%26epage%3D3740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boumber, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vilaythong, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, J. P.</span><span> </span><span class="NLM_article-title">Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11335</span><span class="NLM_x">–</span> <span class="NLM_lpage">11343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11335-11343&author=L.+Shenauthor=Y.+Kondoauthor=S.+Ahmedauthor=Y.+Boumberauthor=K.+Konishiauthor=Y.+Guoauthor=X.+Chenauthor=J.+N.+Vilaythongauthor=J.+P.+Issa&title=Drug+sensitivity+prediction+by+CpG+island+methylation+profile+in+the+NCI-60+cancer+cell+line+panel"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DL.%26aulast%3DKondo%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DBoumber%26aufirst%3DY.%26aulast%3DKonishi%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DVilaythong%26aufirst%3DJ.%2BN.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26atitle%3DDrug%2520sensitivity%2520prediction%2520by%2520CpG%2520island%2520methylation%2520profile%2520in%2520the%2520NCI-60%2520cancer%2520cell%2520line%2520panel%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11335%26epage%3D11343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whetstine, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, R. A.</span><span> </span><span class="NLM_article-title">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">941</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.cell.2004.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15620353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2004&pages=941-953&author=Y.+Shiauthor=F.+Lanauthor=C.+Matsonauthor=P.+Mulliganauthor=J.+R.+Whetstineauthor=P.+A.+Coleauthor=R.+A.+Casero&title=Histone+demethylation+mediated+by+the+nuclear+amine+oxidase+homolog+LSD1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span></div><div class="casAuthors">Shi, Yujiang; Lan, Fei; Matson, Caitlin; Mulligan, Peter; Whetstine, Johnathan R.; Cole, Philip A.; Casero, Robert A.; Shi, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Posttranslational modifications of histone N-terminal tails impact chromatin structure and gene transcription.  While the extent of histone acetylation is detd. by both acetyltransferases and deacetylases, it has been unclear whether histone methylation is also regulated by enzymes with opposing activities.  Here, we provide evidence that LSD1 (KIAA0601), a nuclear homolog of amine oxidases, functions as a histone demethylase and transcriptional corepressor.  LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription.  Lysine demethylation occurs via an oxidn. reaction that generates formaldehyde.  Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant derepression of target genes, suggesting that LSD1 represses transcription via histone demethylation.  The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXHr-8kwGdXrVg90H21EOLACvtfcHk0lg6cN0OyQ_FKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D&md5=3474569204255e90a832667ba654748b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2004.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2004.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DMatson%26aufirst%3DC.%26aulast%3DMulligan%26aufirst%3DP.%26aulast%3DWhetstine%26aufirst%3DJ.%2BR.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DCasero%26aufirst%3DR.%2BA.%26atitle%3DHistone%2520demethylation%2520mediated%2520by%2520the%2520nuclear%2520amine%2520oxidase%2520homolog%2520LSD1%26jtitle%3DCell%26date%3D2004%26volume%3D119%26spage%3D941%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Roman-Gomez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castillejo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiniger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres, A.</span><span> </span><span class="NLM_article-title">The role of DNA hypermethylation in the pathogenesis and prognosis of acute lymphoblastic leukemia</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1855</span><span class="NLM_x">–</span> <span class="NLM_lpage">1864</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F1042819031000116689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=14738136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1GrtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=1855-1864&author=J.+Roman-Gomezauthor=J.+A.+Castillejoauthor=A.+Jimenezauthor=M.+Barriosauthor=A.+Heinigerauthor=A.+Torres&title=The+role+of+DNA+hypermethylation+in+the+pathogenesis+and+prognosis+of+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The role of DNA hypermethylation in the pathogenesis and prognosis of acute lymphoblastic leukemia</span></div><div class="casAuthors">Roman-Gomez, Jose; Castillejo, Juan A.; Jimenez, Antonio; Barrios, Manuel; Heiniger, Anabel; Torres, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1855-1864</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The hallmark of acute lymphoblastic leukemia (ALL) is a progressive appearance of malignant cell behavior that is triggered by the evolution of altered gene function.  ALL has traditionally been viewed as a genetic disease, however, epigenetic defects also play an important role.  DNA promoter methylation has gained increasing recognition as an important mechanism for transcriptional silencing of cancer related genes.  The hypermethylation-assocd. inactivation affects virtually all of the pathways in the ALL cellular network, such as the cell cycle, apoptosis and adhesion.  The identification of these methylation abnormalities and elucidation of the mechanistic events surrounding them are of prime importance, as the methylation status of ALL cells can be used as prognostic biomarker and also can be manipulated in vivo with demethylating agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnI-pB5BH95LVg90H21EOLACvtfcHk0lg6cN0OyQ_FKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1GrtLo%253D&md5=6cd1310f24319e234be5bdbd44e2f3f1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F1042819031000116689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1042819031000116689%26sid%3Dliteratum%253Aachs%26aulast%3DRoman-Gomez%26aufirst%3DJ.%26aulast%3DCastillejo%26aufirst%3DJ.%2BA.%26aulast%3DJimenez%26aufirst%3DA.%26aulast%3DBarrios%26aufirst%3DM.%26aulast%3DHeiniger%26aufirst%3DA.%26aulast%3DTorres%26aufirst%3DA.%26atitle%3DThe%2520role%2520of%2520DNA%2520hypermethylation%2520in%2520the%2520pathogenesis%2520and%2520prognosis%2520of%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2003%26volume%3D44%26spage%3D1855%26epage%3D1864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Graham, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, R.</span><span> </span><span class="NLM_article-title">The promises and pitfalls of epigenetic therapies in solid tumours</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1129</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=1129-1136&author=J.+S.+Grahamauthor=S.+B.+Kayeauthor=R.+Brown&title=The+promises+and+pitfalls+of+epigenetic+therapies+in+solid+tumours"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DJ.%2BS.%26aulast%3DKaye%26aufirst%3DS.%2BB.%26aulast%3DBrown%26aufirst%3DR.%26atitle%3DThe%2520promises%2520and%2520pitfalls%2520of%2520epigenetic%2520therapies%2520in%2520solid%2520tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D1129%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Kim, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haines, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, J. J.</span><span> </span><span class="NLM_article-title">Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1986</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1374</span><span class="NLM_x">–</span> <span class="NLM_lpage">1380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00158a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1986&pages=1374-1380&author=C.+H.+Kimauthor=V.+E.+Marquezauthor=D.+T.+Maoauthor=D.+R.+Hainesauthor=J.+J.+McCormack&title=Synthesis+of+pyrimidin-2-one+nucleosides+as+acid-stable+inhibitors+of+cytidine+deaminase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm00158a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00158a009%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DMao%26aufirst%3DD.%2BT.%26aulast%3DHaines%26aufirst%3DD.%2BR.%26aulast%3DMcCormack%26aufirst%3DJ.%2BJ.%26atitle%3DSynthesis%2520of%2520pyrimidin-2-one%2520nucleosides%2520as%2520acid-stable%2520inhibitors%2520of%2520cytidine%2520deaminase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1986%26volume%3D29%26spage%3D1374%26epage%3D1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Taylor, S. M.</span><span> </span><span class="NLM_article-title">5-Aza-2′-deoxycytidine: cell differentiation and DNA methylation</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=3-8&author=S.+M.+Taylor&title=5-Aza-2%E2%80%B2-deoxycytidine%3A+cell+differentiation+and+DNA+methylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BM.%26atitle%3D5-Aza-2%25E2%2580%25B2-deoxycytidine%253A%2520cell%2520differentiation%2520and%2520DNA%2520methylation%26jtitle%3DLeukemia%26date%3D1993%26volume%3D7%26spage%3D3%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Kihslinger, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godley, L. A.</span><span> </span><span class="NLM_article-title">The use of hypomethylating agents in the treatment of hematologic malignancies</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1676</span><span class="NLM_x">–</span> <span class="NLM_lpage">1695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F10428190701493910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17786703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSkt7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=1676-1695&author=J.+E.+Kihslingerauthor=L.+A.+Godley&title=The+use+of+hypomethylating+agents+in+the+treatment+of+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The use of hypomethylating agents in the treatment of hematologic malignancies</span></div><div class="casAuthors">Kihslinger, Jane E.; Godley, Lucy A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1676-1695</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Epigenetic alterations, such as DNA methylation and histone modifications, are abnormal in cancer cells, and the use of the hypomethylating agents 5-azacitidine and decitabine are important addns. to our arsenal of active cancer drugs, esp. for the treatment of the myelodysplastic syndromes and acute myeloid leukemia.  Most effective are repeated cycles of the drugs given at doses much lower than originally tested.  Typical overall response rates (complete responses + partial responses + hematol. improvement) for both drugs are in the range of 40 - 50%.  These agents are generally very well tolerated, with myelosuppression being the major side effect.  Postulated to work through hypomethylation of DNA causing induction of gene expression, the precise mechanism of action of these agents is not yet clear.  Future studies are likely to combine these agents with other drugs like the histone deacetylase inhibitors that act in related pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNd1L-OQHIrVg90H21EOLACvtfcHk0ljCgXGsWOJFDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSkt7nL&md5=2d6cdca7796a741198fdc4e4358cfef0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1080%2F10428190701493910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701493910%26sid%3Dliteratum%253Aachs%26aulast%3DKihslinger%26aufirst%3DJ.%2BE.%26aulast%3DGodley%26aufirst%3DL.%2BA.%26atitle%3DThe%2520use%2520of%2520hypomethylating%2520agents%2520in%2520the%2520treatment%2520of%2520hematologic%2520malignancies%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D1676%26epage%3D1695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Plimack, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Issa, J. P.</span><span> </span><span class="NLM_article-title">Decitabine and its role in the treatment of hematopoietic malignancies</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1472</span><span class="NLM_x">–</span> <span class="NLM_lpage">1481</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F10428190701471981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17701577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFymurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=1472-1481&author=E.+R.+Plimackauthor=H.+M.+Kantarjianauthor=J.+P.+Issa&title=Decitabine+and+its+role+in+the+treatment+of+hematopoietic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Decitabine and its role in the treatment of hematopoietic malignancies</span></div><div class="casAuthors">Plimack, Elizabeth R.; Kantarjian, Hagop M.; Issa, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1472-1481</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  DNA methylation is responsible for abnormal silencing of many genes, including tumor suppressor genes, in cancer.  Decitabine, an S-phase specific inhibitor of DNA methyltransferase, has been shown to decrease levels of abnormal methylation in neoplasia.  Though initially investigated at high doses as a cytotoxic agent, recent studies show that when administered at low doses, the hypomethylating activity of decitabine is increased with a demonstrated increase in activity in hematopoietic malignancies.  Multiple clin. trials, both in the United States and in Europe, have demonstrated the efficacy of decitabine in acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (MDS).  Recently approved by the United States Food and Drug Administration for the treatment of (MDS), decitabine represents an effective and well-tolerated therapeutic option in this disease, for which treatment options were previously scarce.  While the activity in MDS is promising, primary and secondary resistance remain a problem.  Investigations of combinations of decitabine with other agents, including histone deacetylase inhibitors, are currently ongoing in the hope of substantially prolonging survival in patients with hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrByRslQCHBrVg90H21EOLACvtfcHk0ljCgXGsWOJFDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFymurg%253D&md5=357cbfb36e4bae16c7c2ab1eaa540d8b</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F10428190701471981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190701471981%26sid%3Dliteratum%253Aachs%26aulast%3DPlimack%26aufirst%3DE.%2BR.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DIssa%26aufirst%3DJ.%2BP.%26atitle%3DDecitabine%2520and%2520its%2520role%2520in%2520the%2520treatment%2520of%2520hematopoietic%2520malignancies%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2007%26volume%3D48%26spage%3D1472%26epage%3D1481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Zebularine: a new drug for epigenetic therapy</span> <span class="citation_source-journal">Biochem. Soc. Trans.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">910</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1042%2FBST0320910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15506921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptVSltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=910-912&author=C.+B.+Yooauthor=J.+C.+Chengauthor=P.+A.+Jones&title=Zebularine%3A+a+new+drug+for+epigenetic+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Zebularine: a new drug for epigenetic therapy</span></div><div class="casAuthors">Yoo, C. B.; Cheng, J. C.; Jones, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">910-912</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Regulatory genes are often hypermethylated at their promoter 5' regions and silenced in cancer.  Epigenetic therapy with DNA methylation inhibitors were shown to result in the demethylation and reactivation of these genes.  Zebularine is a recently discovered mechanism-based inhibitor of DNA methylation, and has received much attention for its potential in clin. use.  Further studies exploring the effectiveness of zebularine in a variety of settings could allow the development of novel therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrodunLKBfmOrVg90H21EOLACvtfcHk0ljCgXGsWOJFDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptVSltrc%253D&md5=fa37bd140c829a109198c9657b3f9410</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1042%2FBST0320910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST0320910%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DCheng%26aufirst%3DJ.%2BC.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DZebularine%253A%2520a%2520new%2520drug%2520for%2520epigenetic%2520therapy%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2004%26volume%3D32%26spage%3D910%26epage%3D912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Epigenetic therapy of cancer: past, present and future</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">37</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd1930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16485345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1yqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=37-50&author=C.+B.+Yooauthor=P.+A.+Jones&title=Epigenetic+therapy+of+cancer%3A+past%2C+present+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic therapy of cancer: past, present and future</span></div><div class="casAuthors">Yoo, Christine B.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-50</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The initiation and progression of cancer is controlled by both genetic and epigenetic events.  Unlike genetic alterations, which are almost impossible to reverse, epigenetic aberrations are potentially reversible, allowing the malignant cell population to revert to a more normal state.  With the advent of numerous drugs that target specific enzymes involved in the epigenetic regulation of gene expression, the utilization of epigenetic targets is emerging as an effective and valuable approach to chemotherapy as well as chemoprevention of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOQv6jMPAK1LVg90H21EOLACvtfcHk0ljCgXGsWOJFDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1yqsA%253D%253D&md5=5c552ef929369b8466d2ab2c324cf092</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnrd1930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1930%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DEpigenetic%2520therapy%2520of%2520cancer%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D37%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phiasivongsa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6400</span><span class="NLM_x">–</span> <span class="NLM_lpage">6408</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6400-6408&author=C.+B.+Yooauthor=S.+Jeongauthor=G.+Eggerauthor=G.+Liangauthor=P.+Phiasivongsaauthor=C.+Tangauthor=S.+Redkarauthor=P.+A.+Jones&title=Delivery+of+5-aza-2%E2%80%B2-deoxycytidine+to+cells+using+oligodeoxynucleotides"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DJeong%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DPhiasivongsa%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DRedkar%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DDelivery%2520of%25205-aza-2%25E2%2580%25B2-deoxycytidine%2520to%2520cells%2520using%2520oligodeoxynucleotides%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6400%26epage%3D6408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Altucci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minucci, S.</span><span> </span><span class="NLM_article-title">Epigenetic therapies in haematological malignancies: searching for true targets</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1145</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=1137-1145&author=L.+Altucciauthor=S.+Minucci&title=Epigenetic+therapies+in+haematological+malignancies%3A+searching+for+true+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DMinucci%26aufirst%3DS.%26atitle%3DEpigenetic%2520therapies%2520in%2520haematological%2520malignancies%253A%2520searching%2520for%2520true%2520targets%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D1137%26epage%3D1145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Castellano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novellino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbardella, G.</span><span> </span><span class="NLM_article-title">Constrained analogues of procaine as novel small molecule inhibitors of DNA methyltransferase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2321</span><span class="NLM_x">–</span> <span class="NLM_lpage">2325</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7015705" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2321-2325&author=S.+Castellanoauthor=D.+Kuckauthor=M.+Salaauthor=E.+Novellinoauthor=F.+Lykoauthor=G.+Sbardella&title=Constrained+analogues+of+procaine+as+novel+small+molecule+inhibitors+of+DNA+methyltransferase-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm7015705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7015705%26sid%3Dliteratum%253Aachs%26aulast%3DCastellano%26aufirst%3DS.%26aulast%3DKuck%26aufirst%3DD.%26aulast%3DSala%26aufirst%3DM.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DLyko%26aufirst%3DF.%26aulast%3DSbardella%26aufirst%3DG.%26atitle%3DConstrained%2520analogues%2520of%2520procaine%2520as%2520novel%2520small%2520molecule%2520inhibitors%2520of%2520DNA%2520methyltransferase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2321%26epage%3D2325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Siedlecki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boy, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueckner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suhai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielenkiewicz, P.</span><span> </span><span class="NLM_article-title">Discovery of two novel, small-molecule inhibitors of DNA methylation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">678</span><span class="NLM_x">–</span> <span class="NLM_lpage">683</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=678-683&author=P.+Siedleckiauthor=R.+G.+Boyauthor=T.+Muschauthor=B.+Bruecknerauthor=S.+Suhaiauthor=F.+Lykoauthor=P.+Zielenkiewicz&title=Discovery+of+two+novel%2C+small-molecule+inhibitors+of+DNA+methylation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiedlecki%26aufirst%3DP.%26aulast%3DBoy%26aufirst%3DR.%2BG.%26aulast%3DMusch%26aufirst%3DT.%26aulast%3DBrueckner%26aufirst%3DB.%26aulast%3DSuhai%26aufirst%3DS.%26aulast%3DLyko%26aufirst%3DF.%26aulast%3DZielenkiewicz%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520two%2520novel%252C%2520small-molecule%2520inhibitors%2520of%2520DNA%2520methylation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D49%26spage%3D678%26epage%3D683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Brueckner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia Boy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siedlecki, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Musch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliem, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zielenkiewicz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suhai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiessler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span> </span><span class="NLM_article-title">Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6305</span><span class="NLM_x">–</span> <span class="NLM_lpage">6311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=6305-6311&author=B.+Bruecknerauthor=R.+Garcia+Boyauthor=P.+Siedleckiauthor=T.+Muschauthor=H.+C.+Kliemauthor=P.+Zielenkiewiczauthor=S.+Suhaiauthor=M.+Wiesslerauthor=F.+Lyko&title=Epigenetic+reactivation+of+tumor+suppressor+genes+by+a+novel+small-molecule+inhibitor+of+human+DNA+methyltransferases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBrueckner%26aufirst%3DB.%26aulast%3DGarcia%2BBoy%26aufirst%3DR.%26aulast%3DSiedlecki%26aufirst%3DP.%26aulast%3DMusch%26aufirst%3DT.%26aulast%3DKliem%26aufirst%3DH.%2BC.%26aulast%3DZielenkiewicz%26aufirst%3DP.%26aulast%3DSuhai%26aufirst%3DS.%26aulast%3DWiessler%26aufirst%3DM.%26aulast%3DLyko%26aufirst%3DF.%26atitle%3DEpigenetic%2520reactivation%2520of%2520tumor%2520suppressor%2520genes%2520by%2520a%2520novel%2520small-molecule%2520inhibitor%2520of%2520human%2520DNA%2520methyltransferases%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D6305%26epage%3D6311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Sánchez-del-Campo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otón, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tárraga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabezas-Herrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chazarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez-López, J. N.</span><span> </span><span class="NLM_article-title">Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2018</span><span class="NLM_x">–</span> <span class="NLM_lpage">2026</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701346h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2018-2026&author=L.+S%C3%A1nchez-del-Campoauthor=F.+Ot%C3%B3nauthor=A.+T%C3%A1rragaauthor=J.+Cabezas-Herreraauthor=S.+Chazarraauthor=J.+N.+Rodr%C3%ADguez-L%C3%B3pez&title=Synthesis+and+biological+activity+of+a+3%2C4%2C5-trimethoxybenzoyl+ester+analogue+of+epicatechin-3-gallate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm701346h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701346h%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-del-Campo%26aufirst%3DL.%26aulast%3DOt%25C3%25B3n%26aufirst%3DF.%26aulast%3DT%25C3%25A1rraga%26aufirst%3DA.%26aulast%3DCabezas-Herrera%26aufirst%3DJ.%26aulast%3DChazarra%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-L%25C3%25B3pez%26aufirst%3DJ.%2BN.%26atitle%3DSynthesis%2520and%2520biological%2520activity%2520of%2520a%25203%252C4%252C5-trimethoxybenzoyl%2520ester%2520analogue%2520of%2520epicatechin-3-gallate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2018%26epage%3D2026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovicz, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P. k.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcucci, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span> </span><span class="NLM_article-title">Curcumin is a potent DNA hypomethylation agent</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">706</span><span class="NLM_x">–</span> <span class="NLM_lpage">709</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=706-709&author=Z.+Liuauthor=Z.+Xieauthor=W.+Jonesauthor=R.+E.+Pavloviczauthor=S.+Liuauthor=J.+Yuauthor=P.+k.+Liauthor=J.+Linauthor=J.+R.+Fuchsauthor=G.+Marcucciauthor=C.+Liauthor=K.+K.+Chan&title=Curcumin+is+a+potent+DNA+hypomethylation+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DJones%26aufirst%3DW.%26aulast%3DPavlovicz%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DP.%2Bk.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DFuchs%26aufirst%3DJ.%2BR.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DK.%2BK.%26atitle%3DCurcumin%2520is%2520a%2520potent%2520DNA%2520hypomethylation%2520agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D706%26epage%3D709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Brueckner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyko, F.</span><span> </span><span class="NLM_article-title">DNA methyltransferase inhibitors for cancer therapy</span> <span class="citation_source-journal">Cancer J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FPPO.0b013e31803c7245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17464242" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsVWhtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=17-22&author=B.+Bruecknerauthor=D.+Kuckauthor=F.+Lyko&title=DNA+methyltransferase+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">DNA methyltransferase inhibitors for cancer therapy</span></div><div class="casAuthors">Brueckner, Bodo; Kuck, Dirk; Lyko, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Journal (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-22</span>CODEN:
                <span class="NLM_cas:coden">CAJOCB</span>;
        ISSN:<span class="NLM_cas:issn">1528-9117</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Aberrant DNA methylation patterns, including hypermethylation of tumor suppressor genes, have been described in many human cancers.  These epigenetic mutations can be reversed by DNA methyltransferase inhibitors, which provide novel opportunities for cancer therapy.  Clin. concepts for epigenetic therapies are currently being developed by using azanucleosides for the treatment of leukemias and other tumors.  These trials will greatly benefit from the inclusion of mol. markers for monitoring epigenetic changes in patients and for maximizing biol. responses.  In addn., novel inhibitors need to be developed that result in a direct and specific inhibition of DNA methyltransferase activity.  Several recent developments indicate that rational design of small mol. DNA methyltransferase inhibitors is feasible and that this approach can result in the establishment of novel drug candidates.  The use of novel DNA methyltransferase inhibitors in clin. trials that allow monitoring of drug-induced DNA methylation changes should provide the foundation for improved epigenetic cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2K-IsaLfb2bVg90H21EOLACvtfcHk0liFc5zEV4M_eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsVWhtbk%253D&md5=be3c6585ba67148156fbe87f8b593e25</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1097%2FPPO.0b013e31803c7245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPPO.0b013e31803c7245%26sid%3Dliteratum%253Aachs%26aulast%3DBrueckner%26aufirst%3DB.%26aulast%3DKuck%26aufirst%3DD.%26aulast%3DLyko%26aufirst%3DF.%26atitle%3DDNA%2520methyltransferase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520J.%26date%3D2007%26volume%3D13%26spage%3D17%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Ballestar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esteller, M.</span><span> </span><span class="NLM_article-title">The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications</span> <span class="citation_source-journal">Prog. Mol. Subcell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1007%2F3-540-27310-7_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15881895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFymsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2005&pages=169-181&author=E.+Ballestarauthor=M.+Esteller&title=The+epigenetic+breakdown+of+cancer+cells%3A+from+DNA+methylation+to+histone+modifications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The epigenetic breakdown of cancer cells: from DNA methylation to histone modifications</span></div><div class="casAuthors">Ballestar, Esteban; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Molecular and Subcellular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">Epigenetics and Chromatin</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">PMSBA4</span>;
        ISSN:<span class="NLM_cas:issn">0079-6484</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  The recognition of epigenetic defects in all types of cancer has represented a revolutionary achievement in cancer research in recent years.  DNA methylation aberrant changes (global hypomethylation and CpG island hypermethylation) were among the first events to be recognized.  The overall scenario comprises a network of factors in which deregulation of DNA methyltransferases leads to a cancer-type specific profile of tumor suppressor genes that become epigenetically silenced.  Over recent years, a better understanding of the machinery that connects DNA methylation, chromatin and transcriptional activity, in which histone modifications stand in a key position, has been achieved.  The identification of these connections has contributed not only to understanding how epigenetic deregulation occurs in cancer but also to developing novel therapies that can reverse epigenetic defects in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmFwpmRD0eiLVg90H21EOLACvtfcHk0liFc5zEV4M_eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFymsLo%253D&md5=9f2e6b19b8ca01061cc7761ea0d0af84</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2F3-540-27310-7_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F3-540-27310-7_7%26sid%3Dliteratum%253Aachs%26aulast%3DBallestar%26aufirst%3DE.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520epigenetic%2520breakdown%2520of%2520cancer%2520cells%253A%2520from%2520DNA%2520methylation%2520to%2520histone%2520modifications%26jtitle%3DProg.%2520Mol.%2520Subcell.%2520Biol.%26date%3D2005%26volume%3D38%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Dobosy, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selker, E. U.</span><span> </span><span class="NLM_article-title">Emerging connections between DNA methylation and histone acetylation</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">721</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1007%2FPL00000895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=11437233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1ait7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2001&pages=721-727&author=J.+R.+Dobosyauthor=E.+U.+Selker&title=Emerging+connections+between+DNA+methylation+and+histone+acetylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging connections between DNA methylation and histone acetylation</span></div><div class="casAuthors">Dobosy, J. R.; Selker, E. U.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">721-727</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review, with 54 refs.  Modifications of both DNA and chromatin can affect gene expression and lead to gene silencing.  Evidence of links between DNA methylation and histone hypoacetylation is accumulating.  Several proteins that specifically bind to methylated DNA are assocd. with complexes that include histone deacetylases (HDACs).  In addn., DNA methyltransferases of mammals appear to interact with HDACs.  Expts. with animal cells have shown that HDACs are responsible for part of the repressive effect of DNA methylation.  Evidence was found in Neurospora that protein acetylation can in some cases affect DNA methylation.  The available data suggest that the roles of DNA methylation and histone hypoacetylation, and their relationship with each other, can vary, even within an organism.  Some open questions in this emerging field that should be answered in the near future are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyuhEAoa6weLVg90H21EOLACvtfcHk0liFc5zEV4M_eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1ait7o%253D&md5=e417846766aa5ac71865d26929b08717</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2FPL00000895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00000895%26sid%3Dliteratum%253Aachs%26aulast%3DDobosy%26aufirst%3DJ.%2BR.%26aulast%3DSelker%26aufirst%3DE.%2BU.%26atitle%3DEmerging%2520connections%2520between%2520DNA%2520methylation%2520and%2520histone%2520acetylation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2001%26volume%3D58%26spage%3D721%26epage%3D727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Fahrner, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eguchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baylin, S. B.</span><span> </span><span class="NLM_article-title">Dependence of histone modifications and gene expression on DNA hypermethylation in cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7213</span><span class="NLM_x">–</span> <span class="NLM_lpage">7218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=7213-7218&author=J.+A.+Fahrnerauthor=S.+Eguchiauthor=J.+G.+Hermanauthor=S.+B.+Baylin&title=Dependence+of+histone+modifications+and+gene+expression+on+DNA+hypermethylation+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFahrner%26aufirst%3DJ.%2BA.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DDependence%2520of%2520histone%2520modifications%2520and%2520gene%2520expression%2520on%2520DNA%2520hypermethylation%2520in%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D7213%26epage%3D7218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Cameron, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachman, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myohanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baylin, S. B.</span><span> </span><span class="NLM_article-title">Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2F5047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9916800" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1MXltlWjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1999&pages=103-107&author=E.+E.+Cameronauthor=K.+E.+Bachmanauthor=S.+Myohanenauthor=J.+G.+Hermanauthor=S.+B.+Baylin&title=Synergy+of+demethylation+and+histone+deacetylase+inhibition+in+the+re-expression+of+genes+silenced+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer</span></div><div class="casAuthors">Cameron, Elizabeth E.; Bachman, Kurtis E.; Myohanen, Sanna; Herman, James G.; Baylin, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-107</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature America</span>)
        </div><div class="casAbstract">Densely methylated DNA assocs. with transcriptionally repressive chromatin characterized by the presence of underacetylated histones.  Recently, these 2 epigenetic processes were dynamically linked.  The methyl-CpG-binding protein MeCP2 appears to reside in a complex with histone deacetylase activity.  MeCP2 can mediate formation of transcriptionally repressive chromatin on methylated promoter templates in vitro, and this process can be reversed by trichostatin A (TSA), a specific inhibitor of histone deacetylase.  Little is known about the relative roles of methylation and histone deacetylase activity in the stable inhibition of transcription on densely methylated endogenous promoters, such as those for silenced alleles of imprinted genes, genes on the female inactive X chromosome, and tumor-suppressor genes inactivated in cancer cells.  The authors show that the hypermethylated genes MLH1, TIMP3, CDKN2B (INK4B, p15), and CDKN2A (INK4, p16) cannot be transcriptionally reactivated with TSA alone in tumor cells in which the authors have shown that TSA alone can upregulate the expression of non-methylated genes.  Following minimal demethylation and slight gene reactivation in the presence of low dose 5-aza-2' deoxycytidine (5Aza-dC), however, TSA treatment results in robust re-expression of each gene.  TSA does not contribute to demethylation of the genes, and none of the treatments alter the chromatin structure assocd. with the hypermethylated promoters.  Thus, although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZCmJwXaY4o7Vg90H21EOLACvtfcHk0lh2ZDWBPi3VkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltlWjtA%253D%253D&md5=5f0666dac86ee091d5e06ab0b9403502</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2F5047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F5047%26sid%3Dliteratum%253Aachs%26aulast%3DCameron%26aufirst%3DE.%2BE.%26aulast%3DBachman%26aufirst%3DK.%2BE.%26aulast%3DMyohanen%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DJ.%2BG.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26atitle%3DSynergy%2520of%2520demethylation%2520and%2520histone%2520deacetylase%2520inhibition%2520in%2520the%2520re-expression%2520of%2520genes%2520silenced%2520in%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D1999%26volume%3D21%26spage%3D103%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baylin, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woster, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casero, R. A.,  Jr.</span><span> </span><span class="NLM_article-title">Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">7217</span><span class="NLM_x">–</span> <span class="NLM_lpage">7228</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1078-0432.CCR-09-1293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19934284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=7217-7228&author=Y.+Huangauthor=T.+M.+Stewartauthor=Y.+Wuauthor=S.+B.+Baylinauthor=L.+J.+Martonauthor=B.+Perkinsauthor=R.+J.+Jonesauthor=P.+M.+Wosterauthor=R.+A.+Casero&title=Novel+oligoamine+analogues+inhibit+lysine-specific+demethylase+1+and+induce+reexpression+of+epigenetically+silenced+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes</span></div><div class="casAuthors">Huang, Yi; Stewart, Tracy Murray; Wu, Yu; Baylin, Stephen B.; Marton, Laurence J.; Perkins, Brandy; Jones, Richard J.; Woster, Patrick M.; Casero, Robert A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7217-7228</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Abnormal DNA CpG island hypermethylation and transcriptionally repressive histone modifications are assocd. with the aberrant silencing of tumor suppressor genes.  Lysine methylation is a dynamic, enzymically controlled process.  Lysine-specific demethylase 1 (LSD1) has recently been identified as a histone lysine demethylase.  LSD1 specifically catalyzes demethylation of mono- and dimethyl-lysine 4 of histone 3 (H3K4), key pos. chromatin marks assocd. with transcriptional activation.  We hypothesized that a novel class of oligoamine analogs would effectively inhibit LSD1 and thus cause the reexpression of aberrantly silenced genes.  Exptl. Design: Human colorectal cancer cells were treated with the oligoamines and changes in mono- and dimethyl-H3K4 and other chromatin marks were monitored.  In addn., treated cells were evaluated for the reexpression of the aberrantly silenced secreted frizzled-related proteins (SFRP) Wnt signaling pathway antagonist genes.  Finally, the effects of the LSD1 inhibitors were evaluated in an in vivo xenograft model.  Results: Treatment of HCT116 human colon adenocarcinoma cells in vitro resulted in increased H3K4 methylation and reexpression of silenced SFRP genes.  This reexpression is also accompanied by a decrease in H3K9me2 repressive mark.  Importantly, cotreatment with low doses of oligoamines and a DNA methyltransferase inhibitor highly induces the reexpression of the aberrantly silenced SFRP2 gene and results in significant inhibition of the growth of established tumors in a human colon tumor model in vivo.  Conclusions: The use of LSD1-inhibiting oligoamine analogs in combination with DNA methyltransferase inhibitors represents a highly promising and novel approach for epigenetic therapy of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk1naS7xW5GbVg90H21EOLACvtfcHk0lh2ZDWBPi3VkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSnu7zE&md5=0f86cd2d3482aa0a36adacc4f10329dd</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1293%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DStewart%26aufirst%3DT.%2BM.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DMarton%26aufirst%3DL.%2BJ.%26aulast%3DPerkins%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DWoster%26aufirst%3DP.%2BM.%26aulast%3DCasero%26aufirst%3DR.%2BA.%26atitle%3DNovel%2520oligoamine%2520analogues%2520inhibit%2520lysine-specific%2520demethylase%25201%2520and%2520induce%2520reexpression%2520of%2520epigenetically%2520silenced%2520genes%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D7217%26epage%3D7228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">McCarthy, M.</span><span> </span><span class="NLM_article-title">FDA approves tretinoin for treatment of APL</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">346</span><span class="NLM_x">, </span> <span class="NLM_fpage">1552</span><span class="NLM_x">–</span> <span class="NLM_lpage">1552</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=1995&pages=1552-1552&author=M.+McCarthy&title=FDA+approves+tretinoin+for+treatment+of+APL"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%26atitle%3DFDA%2520approves%2520tretinoin%2520for%2520treatment%2520of%2520APL%26jtitle%3DLancet%26date%3D1995%26volume%3D346%26spage%3D1552%26epage%3D1552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Hegde, S.; Schmidt, M.; Anthony, W.</span><span> </span><span class="NLM_article-title">To Market, To Market—2005</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">41</span>, pp  <span class="NLM_fpage">439</span>− <span class="NLM_lpage">477</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=439-477&author=S.+Hegde&author=M.+Schmidt&author=W.+Anthony&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHegde%26aufirst%3DS.%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942005%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26pub%3DAcademic%2520Press%26date%3D2006%26volume%3D41%26spage%3D439%26epage%3D477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Kagechika, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, K.</span><span> </span><span class="NLM_article-title">Synthetic retinoids: recent developments concerning structure and clinical utility</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5875</span><span class="NLM_x">–</span> <span class="NLM_lpage">5883</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0581821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5875-5883&author=H.+Kagechikaauthor=K.+Shudo&title=Synthetic+retinoids%3A+recent+developments+concerning+structure+and+clinical+utility"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm0581821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0581821%26sid%3Dliteratum%253Aachs%26aulast%3DKagechika%26aufirst%3DH.%26aulast%3DShudo%26aufirst%3DK.%26atitle%3DSynthetic%2520retinoids%253A%2520recent%2520developments%2520concerning%2520structure%2520and%2520clinical%2520utility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5875%26epage%3D5883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Look, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landwehr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluethmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeMotte, P.</span><span> </span><span class="NLM_article-title">Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid</span> <span class="citation_source-journal">Am. J. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">E91</span><span class="NLM_x">–</span> <span class="NLM_lpage">E98</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1995&pages=E91-E98&author=J.+Lookauthor=J.+Landwehrauthor=F.+Bauerauthor=A.+S.+Hoffmannauthor=H.+Bluethmannauthor=P.+LeMotte&title=Marked+resistance+of+RAR+gamma-deficient+mice+to+the+toxic+effects+of+retinoic+acid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLook%26aufirst%3DJ.%26aulast%3DLandwehr%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DF.%26aulast%3DHoffmann%26aufirst%3DA.%2BS.%26aulast%3DBluethmann%26aufirst%3DH.%26aulast%3DLeMotte%26aufirst%3DP.%26atitle%3DMarked%2520resistance%2520of%2520RAR%2520gamma-deficient%2520mice%2520to%2520the%2520toxic%2520effects%2520of%2520retinoic%2520acid%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1995%26volume%3D269%26spage%3DE91%26epage%3DE98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClurg, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagoner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, P. J. A.</span><span> </span><span class="NLM_article-title">Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">3146</span><span class="NLM_x">–</span> <span class="NLM_lpage">3155</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00016a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=3146-3155&author=M.+F.+Boehmauthor=L.+Zhangauthor=L.+Zhiauthor=M.+R.+McClurgauthor=E.+Bergerauthor=M.+Wagonerauthor=D.+E.+Maisauthor=C.+M.+Sutoauthor=P.+J.+A.+Davies&title=Design+and+synthesis+of+potent+retinoid+X+receptor+selective+ligands+that+induce+apoptosis+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fjm00016a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00016a018%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhi%26aufirst%3DL.%26aulast%3DMcClurg%26aufirst%3DM.%2BR.%26aulast%3DBerger%26aufirst%3DE.%26aulast%3DWagoner%26aufirst%3DM.%26aulast%3DMais%26aufirst%3DD.%2BE.%26aulast%3DSuto%26aufirst%3DC.%2BM.%26aulast%3DDavies%26aufirst%3DP.%2BJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520retinoid%2520X%2520receptor%2520selective%2520ligands%2520that%2520induce%2520apoptosis%2520in%2520leukemia%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D3146%26epage%3D3155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Canan Koch, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dardashti, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cesario, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croston, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nadzan, A. M.</span><span> </span><span class="NLM_article-title">Synthesis of retinoid X receptor-specific ligands that are potent inducers of adipogenesis in 3T3-L1 cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980621r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=742-750&author=S.+S.+Canan+Kochauthor=L.+J.+Dardashtiauthor=R.+M.+Cesarioauthor=G.+E.+Crostonauthor=M.+F.+Boehmauthor=R.+A.+Heymanauthor=A.+M.+Nadzan&title=Synthesis+of+retinoid+X+receptor-specific+ligands+that+are+potent+inducers+of+adipogenesis+in+3T3-L1+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm980621r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980621r%26sid%3Dliteratum%253Aachs%26aulast%3DCanan%2BKoch%26aufirst%3DS.%2BS.%26aulast%3DDardashti%26aufirst%3DL.%2BJ.%26aulast%3DCesario%26aufirst%3DR.%2BM.%26aulast%3DCroston%26aufirst%3DG.%2BE.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DNadzan%26aufirst%3DA.%2BM.%26atitle%3DSynthesis%2520of%2520retinoid%2520X%2520receptor-specific%2520ligands%2520that%2520are%2520potent%2520inducers%2520of%2520adipogenesis%2520in%25203T3-L1%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardecky, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crombie, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etgen, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulkner, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grese, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klausing, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibowitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mapes, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marschke, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reifel-Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rungta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyhonas, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span> </span><span class="NLM_article-title">Novel (2<i>E</i>,4<i>E</i>,6<i>Z</i>)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">2683</span><span class="NLM_x">–</span> <span class="NLM_lpage">2696</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020340q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2683-2696&author=P.+Y.+Michellysauthor=R.+J.+Ardeckyauthor=J.+H.+Chenauthor=D.+L.+Crombieauthor=G.+J.+Etgenauthor=A.+L.+Faulknerauthor=T.+A.+Greseauthor=R.+A.+Heymanauthor=D.+S.+Karanewskyauthor=K.+Klausingauthor=M.+D.+Leibowitzauthor=S.+Liuauthor=D.+A.+Maisauthor=C.+M.+Mapesauthor=K.+B.+Marschkeauthor=A.+Reifel-Millerauthor=K.+M.+Ogilvieauthor=D.+Rungtaauthor=A.+W.+Thompsonauthor=J.+S.+Tyhonasauthor=M.+F.+Boehm&title=Novel+%282E%2C4E%2C6Z%29-7-%282-alkoxy-3%2C5-dialkylbenzene%29-3-methylocta-2%2C4%2C6-trienoic+acid+retinoid+X+receptor+modulators+are+active+in+models+of+type+2+diabetes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm020340q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020340q%26sid%3Dliteratum%253Aachs%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DArdecky%26aufirst%3DR.%2BJ.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DCrombie%26aufirst%3DD.%2BL.%26aulast%3DEtgen%26aufirst%3DG.%2BJ.%26aulast%3DFaulkner%26aufirst%3DA.%2BL.%26aulast%3DGrese%26aufirst%3DT.%2BA.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DKlausing%26aufirst%3DK.%26aulast%3DLeibowitz%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMais%26aufirst%3DD.%2BA.%26aulast%3DMapes%26aufirst%3DC.%2BM.%26aulast%3DMarschke%26aufirst%3DK.%2BB.%26aulast%3DReifel-Miller%26aufirst%3DA.%26aulast%3DOgilvie%26aufirst%3DK.%2BM.%26aulast%3DRungta%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DA.%2BW.%26aulast%3DTyhonas%26aufirst%3DJ.%2BS.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DNovel%2520%25282E%252C4E%252C6Z%2529-7-%25282-alkoxy-3%252C5-dialkylbenzene%2529-3-methylocta-2%252C4%252C6-trienoic%2520acid%2520retinoid%2520X%2520receptor%2520modulators%2520are%2520active%2520in%2520models%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D2683%26epage%3D2696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Michellys, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardecky, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arrigo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grese, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karanewsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leibowitz, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mapes, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montrose-Rafizadeh, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reifel-Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rungta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyhonas, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, M. F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and structure activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4087</span><span class="NLM_x">–</span> <span class="NLM_lpage">4103</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020401k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4087-4103&author=P.-Y.+Michellysauthor=R.+J.+Ardeckyauthor=J.-H.+Chenauthor=J.+D%E2%80%99Arrigoauthor=T.+A.+Greseauthor=D.+S.+Karanewskyauthor=M.+D.+Leibowitzauthor=S.+Liuauthor=D.+A.+Maisauthor=C.+M.+Mapesauthor=C.+Montrose-Rafizadehauthor=K.+M.+Ogilvieauthor=A.+Reifel-Millerauthor=D.+Rungtaauthor=A.+W.+Thompsonauthor=J.+S.+Tyhonasauthor=M.+F.+Boehm&title=Design%2C+synthesis%2C+and+structure+activity+relationship+studies+of+novel+6%2C7-locked-%5B7-%282-alkoxy-3%2C5-dialkylbenzene%29-3-methylocta%5D-2%2C4%2C6-trienoic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm020401k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020401k%26sid%3Dliteratum%253Aachs%26aulast%3DMichellys%26aufirst%3DP.-Y.%26aulast%3DArdecky%26aufirst%3DR.%2BJ.%26aulast%3DChen%26aufirst%3DJ.-H.%26aulast%3DD%25E2%2580%2599Arrigo%26aufirst%3DJ.%26aulast%3DGrese%26aufirst%3DT.%2BA.%26aulast%3DKaranewsky%26aufirst%3DD.%2BS.%26aulast%3DLeibowitz%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMais%26aufirst%3DD.%2BA.%26aulast%3DMapes%26aufirst%3DC.%2BM.%26aulast%3DMontrose-Rafizadeh%26aufirst%3DC.%26aulast%3DOgilvie%26aufirst%3DK.%2BM.%26aulast%3DReifel-Miller%26aufirst%3DA.%26aulast%3DRungta%26aufirst%3DD.%26aulast%3DThompson%26aufirst%3DA.%2BW.%26aulast%3DTyhonas%26aufirst%3DJ.%2BS.%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure%2520activity%2520relationship%2520studies%2520of%2520novel%25206%252C7-locked-%255B7-%25282-alkoxy-3%252C5-dialkylbenzene%2529-3-methylocta%255D-2%252C4%252C6-trienoic%2520acids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4087%26epage%3D4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Takahashi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawachi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagechika, H.</span><span> </span><span class="NLM_article-title">Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3327</span><span class="NLM_x">–</span> <span class="NLM_lpage">3330</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0255320" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFGmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3327-3330&author=B.+Takahashiauthor=K.+Ohtaauthor=E.+Kawachiauthor=H.+Fukasawaauthor=Y.+Hashimotoauthor=H.+Kagechika&title=Novel+retinoid+X+receptor+antagonists%3A+specific+inhibition+of+retinoid+synergism+in+RXR-RAR+heterodimer+actions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Retinoid X Receptor Antagonists: Specific Inhibition of Retinoid Synergism in RXR-RAR Heterodimer Actions</span></div><div class="casAuthors">Takahashi, Bitoku; Ohta, Kiminori; Kawachi, Emiko; Fukasawa, Hiroshi; Hashimoto, Yuichi; Kagechika, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3327-3330</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several 2-(arylamino)pyrimidine-5-carboxylic acids were designed as novel retinoid X receptor (RXR) antagonists.  Two of the tested compds. alone did not exhibit differentiation-inducing activity toward HL-60 cells and did not affect the activity of a retinoic acid receptor (RAR) agonist, Am80, but did inhibit the synergistic activity of an RXR agonist, PA024, in the presence of Am80.  The activity of these compds. was ascribed to selective antagonism at the RXR site of RXR-RAR heterodimers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSw-5gTVKi_rVg90H21EOLACvtfcHk0lgjuRv_-YIWCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFGmtrs%253D&md5=31b3a2daf2698874522c4dade7b1dbc2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjm0255320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0255320%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DB.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DKawachi%26aufirst%3DE.%26aulast%3DFukasawa%26aufirst%3DH.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DKagechika%26aufirst%3DH.%26atitle%3DNovel%2520retinoid%2520X%2520receptor%2520antagonists%253A%2520specific%2520inhibition%2520of%2520retinoid%2520synergism%2520in%2520RXR-RAR%2520heterodimer%2520actions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3327%26epage%3D3330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Umemiya, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukasawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebisawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eyrolles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawachi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gronemeyer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shudo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagechika, H.</span><span> </span><span class="NLM_article-title">Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">4222</span><span class="NLM_x">–</span> <span class="NLM_lpage">4234</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9704309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=4222-4234&author=H.+Umemiyaauthor=H.+Fukasawaauthor=M.+Ebisawaauthor=L.+Eyrollesauthor=E.+Kawachiauthor=G.+Eisenmannauthor=H.+Gronemeyerauthor=Y.+Hashimotoauthor=K.+Shudoauthor=H.+Kagechika&title=Regulation+of+retinoidal+actions+by+diazepinylbenzoic+acids.+Retinoid+synergists+which+activate+the+RXR-RAR+heterodimers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm9704309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9704309%26sid%3Dliteratum%253Aachs%26aulast%3DUmemiya%26aufirst%3DH.%26aulast%3DFukasawa%26aufirst%3DH.%26aulast%3DEbisawa%26aufirst%3DM.%26aulast%3DEyrolles%26aufirst%3DL.%26aulast%3DKawachi%26aufirst%3DE.%26aulast%3DEisenmann%26aufirst%3DG.%26aulast%3DGronemeyer%26aufirst%3DH.%26aulast%3DHashimoto%26aufirst%3DY.%26aulast%3DShudo%26aufirst%3DK.%26aulast%3DKagechika%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520retinoidal%2520actions%2520by%2520diazepinylbenzoic%2520acids.%2520Retinoid%2520synergists%2520which%2520activate%2520the%2520RXR-RAR%2520heterodimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D4222%26epage%3D4234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Wagner, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jurutka, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groy, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Vaart, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziller, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furmick, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeber, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matro, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miguel, B. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedeschi, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moosavi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Danishyar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philp, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khamees, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grupe, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badshah, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, J. W.</span><span> </span><span class="NLM_article-title">Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5950</span><span class="NLM_x">–</span> <span class="NLM_lpage">5966</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900496b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5950-5966&author=C.+E.+Wagnerauthor=P.+W.+Jurutkaauthor=P.+A.+Marshallauthor=T.+L.+Groyauthor=A.+van+der+Vaartauthor=J.+W.+Zillerauthor=J.+K.+Furmickauthor=M.+E.+Graeberauthor=E.+Matroauthor=B.+V.+Miguelauthor=I.+T.+Tranauthor=J.+Kwonauthor=J.+N.+Tedeschiauthor=S.+Moosaviauthor=A.+Danishyarauthor=J.+S.+Philpauthor=R.+O.+Khameesauthor=J.+N.+Jacksonauthor=D.+K.+Grupeauthor=S.+L.+Badshahauthor=J.+W.+Hart&title=Modeling%2C+synthesis+and+biological+evaluation+of+potential+retinoid+X+receptor+%28RXR%29+selective+agonists%3A+novel+analogues+of+4-%5B1-%283%2C5%2C5%2C8%2C8-pentamethyl-5%2C6%2C7%2C8-tetrahydro-2-naphthyl%29ethynyl%5Dbenzoic+acid+%28bexarotene%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm900496b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900496b%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DC.%2BE.%26aulast%3DJurutka%26aufirst%3DP.%2BW.%26aulast%3DMarshall%26aufirst%3DP.%2BA.%26aulast%3DGroy%26aufirst%3DT.%2BL.%26aulast%3Dvan%2Bder%2BVaart%26aufirst%3DA.%26aulast%3DZiller%26aufirst%3DJ.%2BW.%26aulast%3DFurmick%26aufirst%3DJ.%2BK.%26aulast%3DGraeber%26aufirst%3DM.%2BE.%26aulast%3DMatro%26aufirst%3DE.%26aulast%3DMiguel%26aufirst%3DB.%2BV.%26aulast%3DTran%26aufirst%3DI.%2BT.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DTedeschi%26aufirst%3DJ.%2BN.%26aulast%3DMoosavi%26aufirst%3DS.%26aulast%3DDanishyar%26aufirst%3DA.%26aulast%3DPhilp%26aufirst%3DJ.%2BS.%26aulast%3DKhamees%26aufirst%3DR.%2BO.%26aulast%3DJackson%26aufirst%3DJ.%2BN.%26aulast%3DGrupe%26aufirst%3DD.%2BK.%26aulast%3DBadshah%26aufirst%3DS.%2BL.%26aulast%3DHart%26aufirst%3DJ.%2BW.%26atitle%3DModeling%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520potential%2520retinoid%2520X%2520receptor%2520%2528RXR%2529%2520selective%2520agonists%253A%2520novel%2520analogues%2520of%25204-%255B1-%25283%252C5%252C5%252C8%252C8-pentamethyl-5%252C6%252C7%252C8-tetrahydro-2-naphthyl%2529ethynyl%255Dbenzoic%2520acid%2520%2528bexarotene%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5950%26epage%3D5966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Boehm, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badea, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mais, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyman, R. A.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of novel retinoid X receptor-selective retinoids</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">2930</span><span class="NLM_x">–</span> <span class="NLM_lpage">2941</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00044a014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=2930-2941&author=M.+F.+Boehmauthor=L.+Zhangauthor=B.+A.+Badeaauthor=S.+K.+Whiteauthor=D.+E.+Maisauthor=E.+Bergerauthor=C.+M.+Sutoauthor=M.+E.+Goldmanauthor=R.+A.+Heyman&title=Synthesis+and+structure%E2%88%92activity+relationships+of+novel+retinoid+X+receptor-selective+retinoids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm00044a014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00044a014%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBadea%26aufirst%3DB.%2BA.%26aulast%3DWhite%26aufirst%3DS.%2BK.%26aulast%3DMais%26aufirst%3DD.%2BE.%26aulast%3DBerger%26aufirst%3DE.%26aulast%3DSuto%26aufirst%3DC.%2BM.%26aulast%3DGoldman%26aufirst%3DM.%2BE.%26aulast%3DHeyman%26aufirst%3DR.%2BA.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%2520novel%2520retinoid%2520X%2520receptor-selective%2520retinoids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D2930%26epage%3D2941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Walensky, L. D.</span><span> </span><span class="NLM_article-title">BCL-2 in the crosshairs: tipping the balance of life and death</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1339</span><span class="NLM_x">–</span> <span class="NLM_lpage">1350</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fsj.cdd.4401992" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16763614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFaiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1339-1350&author=L.+D.+Walensky&title=BCL-2+in+the+crosshairs%3A+tipping+the+balance+of+life+and+death"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">BCL-2 in the crosshairs: tipping the balance of life and death</span></div><div class="casAuthors">Walensky, L. D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1339-1350</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery of B-cell lymphoma-2 (Bcl-2) protein over 20 years ago revealed a new paradigm in cancer biol.: the development and persistence of cancer can be driven by mol. roadblocks along the natural pathway to cell death.  The subsequent identification of an expansive family of Bcl-2 proteins provoked an intensive investigation of the interplay among these crit. regulators of cell death.  What emerged was a compelling tale of guardians and executioners, each participating in a mol. choreog. that dictates cell fate.  Ten years into the Bcl-2 era, structural details have defined how certain Bcl-2 family proteins interact, and mol. targeting of the Bcl-2 family has since become a pharmacol. quest.  Although many facets of Bcl-2 family death signaling remain a mechanistic mystery, small mols. and peptides that effectively target Bcl-2 are eliminating the roadblock to cell death, raising hopes for a medical breakthrough in cancer and other diseases of deregulated apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJYywVOAOBLVg90H21EOLACvtfcHk0ljuq2WQ7SUpGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFaiurs%253D&md5=ffa03ae8cfd55db280c2184913e7dea2</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401992&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401992%26sid%3Dliteratum%253Aachs%26aulast%3DWalensky%26aufirst%3DL.%2BD.%26atitle%3DBCL-2%2520in%2520the%2520crosshairs%253A%2520tipping%2520the%2520balance%2520of%2520life%2520and%2520death%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2006%26volume%3D13%26spage%3D1339%26epage%3D1350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Calin, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span> </span><span class="NLM_article-title">Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">4761</span><span class="NLM_x">–</span> <span class="NLM_lpage">4770</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=4761-4770&author=G.+A.+Calinauthor=C.+M.+Croce&title=Chronic+lymphocytic+leukemia%3A+interplay+between+noncoding+RNAs+and+protein-coding+genes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCalin%26aufirst%3DG.%2BA.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26atitle%3DChronic%2520lymphocytic%2520leukemia%253A%2520interplay%2520between%2520noncoding%2520RNAs%2520and%2520protein-coding%2520genes%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D4761%26epage%3D4770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Klasa, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillum, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klem, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankel, S. R.</span><span> </span><span class="NLM_article-title">Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment</span> <span class="citation_source-journal">Antisense Nucleic Acid Drug Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">193</span><span class="NLM_x">–</span> <span class="NLM_lpage">213</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1089%2F108729002760220798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12162702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvFersrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=193-213&author=R.+J.+Klasaauthor=A.+M.+Gillumauthor=R.+E.+Klemauthor=S.+R.+Frankel&title=Oblimersen+Bcl-2+antisense%3A+facilitating+apoptosis+in+anticancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment</span></div><div class="casAuthors">Klasa, Richard J.; Gillum, Amanda M.; Klem, Robert E.; Frankel, Stanley R.</div><div class="citationInfo"><span class="NLM_cas:title">Antisense & Nucleic Acid Drug Development</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-213</span>CODEN:
                <span class="NLM_cas:coden">ANADF5</span>;
        ISSN:<span class="NLM_cas:issn">1087-2906</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  The components of the apoptotic program are targets for anticancer therapy.  Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (mAb).  Oblimersen sodium (G3139, Genasense, Genta Inc., Berkeley Heights, NJ) is an antisense oligonucleotide (AS-ON) compd. designed to specifically bind to the first 6 codons of the human bcl-2 mRNA sequence, resulting in degrdn. of bcl-2 mRNA and subsequent decrease in Bcl-2 protein translation.  Oblimersen is the first oligonucleotide to demonstrate proof of principle of an antisense effect in human tumors by the documented downregulation of the target Bcl-2 protein.  A growing body of preclin. and clin. evidence suggests that oblimersen synergizes with many cytotoxic and biol./immunotherapeutic agents against a variety of hematol. malignancies and solid tumors.  Randomized clin. trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia, multiple myeloma, malignant melanoma, and non-small cell lung cancer.  In addn., nonrandomized trials are under way to evaluate oblimersen in non-Hodgkin's lymphoma, acute myeloid leukemia, and hormone-refractory prostate cancer.  Preclin. data also support the clin. evaluation of oblimersen in addnl. tumor types, including chronic myelogenous leukemia and breast, small cell lung, gastric, colon, bladder, and Merkel cell cancers.  Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clin. trials will test this therapeutic approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphEuKQgz3PnLVg90H21EOLACvtfcHk0lhILBAPADezJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvFersrw%253D&md5=e88b1922587419dc625d31a4b4e1020b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1089%2F108729002760220798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252F108729002760220798%26sid%3Dliteratum%253Aachs%26aulast%3DKlasa%26aufirst%3DR.%2BJ.%26aulast%3DGillum%26aufirst%3DA.%2BM.%26aulast%3DKlem%26aufirst%3DR.%2BE.%26aulast%3DFrankel%26aufirst%3DS.%2BR.%26atitle%3DOblimersen%2520Bcl-2%2520antisense%253A%2520facilitating%2520apoptosis%2520in%2520anticancer%2520treatment%26jtitle%3DAntisense%2520Nucleic%2520Acid%2520Drug%2520Dev.%26date%3D2002%26volume%3D12%26spage%3D193%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Frieden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ørum, H.</span><span> </span><span class="NLM_article-title">Locked nucleic acid holds promise in the treatment of cancer</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1138</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F138161208784246234" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18473860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslKrsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=1138-1142&author=M.+Friedenauthor=H.+%C3%98rum&title=Locked+nucleic+acid+holds+promise+in+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Locked nucleic acid holds promise in the treatment of cancer</span></div><div class="casAuthors">Frieden, Miriam; Oerum, Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1138-1142</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry.  Today much is known about the mol. and genetic causes of cancers thus facilitating the development of novel targeted cancer drugs with improved risk-benefit ratios compared to contemporary broadly-acting, cytotoxic cancer drugs.  Antisense therapy, e.g. the use of single stranded oligonucleotides as therapeutic modalities, provides the means to develop such targeted drugs, and in recent years this concept has enjoyed a major renaissance.  Locked Nucleic Acid (LNA) is a novel, third generation RNA analog that displays most if not all of the characteristics required to make potent and safe antisense drugs.  Here we review the key properties of LNA oligonucleotides in the context of their use as safe and effective antisense drugs and provide a status on their therapeutic development in the field of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWg3XR5jMli7Vg90H21EOLACvtfcHk0lhILBAPADezJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslKrsro%253D&md5=df6e1ff8e1745469e1e798159ecdbe17</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2174%2F138161208784246234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161208784246234%26sid%3Dliteratum%253Aachs%26aulast%3DFrieden%26aufirst%3DM.%26aulast%3D%25C3%2598rum%26aufirst%3DH.%26atitle%3DLocked%2520nucleic%2520acid%2520holds%2520promise%2520in%2520the%2520treatment%2520of%2520cancer%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2008%26volume%3D14%26spage%3D1138%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borowski, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehlig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borchard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benimetskaya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, C. A.</span><span> </span><span class="NLM_article-title">Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy</span> <span class="citation_source-journal">J. Controlled Release</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2007&pages=143-152&author=H.+Zhaoauthor=P.+Pengauthor=C.+Longleyauthor=Y.+Zhangauthor=V.+Borowskiauthor=M.+Mehligauthor=P.+Reddyauthor=J.+Xiaauthor=G.+Borchardauthor=J.+Lipmanauthor=L.+Benimetskayaauthor=C.+A.+Stein&title=Delivery+of+G3139+using+releasable+PEG-linkers%3A+impact+on+pharmacokinetic+profile+and+anti-tumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DP.%26aulast%3DLongley%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DMehlig%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DP.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DBorchard%26aufirst%3DG.%26aulast%3DLipman%26aufirst%3DJ.%26aulast%3DBenimetskaya%26aufirst%3DL.%26aulast%3DStein%26aufirst%3DC.%2BA.%26atitle%3DDelivery%2520of%2520G3139%2520using%2520releasable%2520PEG-linkers%253A%2520impact%2520on%2520pharmacokinetic%2520profile%2520and%2520anti-tumor%2520efficacy%26jtitle%3DJ.%2520Controlled%2520Release%26date%3D2007%26volume%3D119%26spage%3D143%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Leone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sareth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">8118</span><span class="NLM_x">–</span> <span class="NLM_lpage">8121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=8118-8121&author=M.+Leoneauthor=D.+Zhaiauthor=S.+Sarethauthor=S.+Kitadaauthor=J.+C.+Reedauthor=M.+Pellecchia&title=Cancer+prevention+by+tea+polyphenols+is+linked+to+their+direct+inhibition+of+antiapoptotic+Bcl-2-family+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DSareth%26aufirst%3DS.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DCancer%2520prevention%2520by%2520tea%2520polyphenols%2520is%2520linked%2520to%2520their%2520direct%2520inhibition%2520of%2520antiapoptotic%2520Bcl-2-family%2520proteins%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D8118%26epage%3D8121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Tzung, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basanez, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giedt, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockenbery, D. M.</span><span> </span><span class="NLM_article-title">Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2F35055095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=11175751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1KmsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=183-191&author=S.+P.+Tzungauthor=K.+M.+Kimauthor=G.+Basanezauthor=C.+D.+Giedtauthor=J.+Simonauthor=J.+Zimmerbergauthor=K.+Y.+Zhangauthor=D.+M.+Hockenbery&title=Antimycin+A+mimics+a+cell-death-inducing+Bcl-2+homology+domain+3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3</span></div><div class="casAuthors">Tzung, Shie-Pon; Kim, Kristine M.; Basanez, Gorka; Giedt, Chris D.; Simon, Julian; Zimmerberg, Joshua; Zhang, Kam Y. J.; Hockenbery, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Bcl-2-related survival proteins confer cellular resistance to a wide range of agents.  Bcl-xL-expressing hepatocyte cell lines are resistant to tumor necrosis factor and anti-cancer drugs, but are more sensitive than isogenic control cells to antimycin A, an inhibitor of mitochondrial electron transfer.  Computational mol. docking anal. predicted that antimycin A interacts with the Bcl-2 homol. domain 3 (BH3)-binding hydrophobic groove of Bcl-xL.  We demonstrate that antimycin A and a Bak BH3 peptide bind competitively to recombinant Bcl-2.  Antimycin A and BH3 peptide both induce mitochondrial swelling and loss of Δψm on addn. to mitochondria expressing Bcl-xL.  The 2-methoxy deriv. of antimycin A3 is inactive as an inhibitor of cellular respiration but still retains toxicity for Bcl-xL+ cells and mitochondria.  Finally, antimycin A inhibits the pore-forming activity of Bcl-xL in synthetic liposomes, demonstrating that a small non-peptide ligand can directly inhibit the function of Bcl-2-related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgSbrvTv9NbLVg90H21EOLACvtfcHk0lhILBAPADezJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1KmsLc%253D&md5=f013d14a3bf5ae6dd1ac93cc63f527db</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2F35055095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35055095%26sid%3Dliteratum%253Aachs%26aulast%3DTzung%26aufirst%3DS.%2BP.%26aulast%3DKim%26aufirst%3DK.%2BM.%26aulast%3DBasanez%26aufirst%3DG.%26aulast%3DGiedt%26aufirst%3DC.%2BD.%26aulast%3DSimon%26aufirst%3DJ.%26aulast%3DZimmerberg%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DHockenbery%26aufirst%3DD.%2BM.%26atitle%3DAntimycin%2520A%2520mimics%2520a%2520cell-death-inducing%2520Bcl-2%2520homology%2520domain%25203%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D183%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Chan, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flotow, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soejarto, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buss, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, V. C.</span><span> </span><span class="NLM_article-title">Identification of chelerythrine as an inhibitor of BclXL function</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">20453</span><span class="NLM_x">–</span> <span class="NLM_lpage">20456</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=20453-20456&author=S.+L.+Chanauthor=M.+C.+Leeauthor=K.+O.+Tanauthor=L.+K.+Yangauthor=A.+S.+Leeauthor=H.+Flotowauthor=N.+Y.+Fuauthor=M.+S.+Butlerauthor=D.+D.+Soejartoauthor=A.+D.+Bussauthor=V.+C.+Yu&title=Identification+of+chelerythrine+as+an+inhibitor+of+BclXL+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BL.%26aulast%3DLee%26aufirst%3DM.%2BC.%26aulast%3DTan%26aufirst%3DK.%2BO.%26aulast%3DYang%26aufirst%3DL.%2BK.%26aulast%3DLee%26aufirst%3DA.%2BS.%26aulast%3DFlotow%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DN.%2BY.%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DSoejarto%26aufirst%3DD.%2BD.%26aulast%3DBuss%26aufirst%3DA.%2BD.%26aulast%3DYu%26aufirst%3DV.%2BC.%26atitle%3DIdentification%2520of%2520chelerythrine%2520as%2520an%2520inhibitor%2520of%2520BclXL%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D20453%26epage%3D20456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sareth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Discovery, characterization, and structure−activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4259</span><span class="NLM_x">–</span> <span class="NLM_lpage">4264</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030190z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4259-4264&author=S.+Kitadaauthor=M.+Leoneauthor=S.+Sarethauthor=D.+Y.+Zhaiauthor=J.+C.+Reedauthor=M.+Pellecchia&title=Discovery%2C+characterization%2C+and+structure%E2%88%92activity+relationships+studies+of+proapoptotic+polyphenols+targeting+B-cell+lymphocyte%2Fleukemia-2+proteins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fjm030190z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030190z%26sid%3Dliteratum%253Aachs%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DSareth%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DD.%2BY.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDiscovery%252C%2520characterization%252C%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520studies%2520of%2520proapoptotic%2520polyphenols%2520targeting%2520B-cell%2520lymphocyte%252Fleukemia-2%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4259%26epage%3D4264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolovska-Coleska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">720</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm701358v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=717-720&author=G.+Tangauthor=Z.+Nikolovska-Coleskaauthor=S.+Qiuauthor=C.+Y.+Yangauthor=J.+Guoauthor=S.+Wang&title=Acylpyrogallols+as+inhibitors+of+antiapoptotic+Bcl-2+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Acylpyrogallols as Inhibitors of Antiapoptotic Bcl-2 Proteins</span></div><div class="casAuthors">Tang, Guozhi; Nikolovska-Coleska, Zaneta; Qiu, Su; Yang, Chao-Yie; Guo, Jie; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-720</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of acylpyrogallols were designed, synthesized, and evaluated as small-mol. inhibitors of antiapoptotic Bcl-2 proteins.  The most potent compd. I (TM-179) binds to Bcl-2 with an IC50 of 170 nM and to Mcl-1 with a Ki of 37 nM.  Compd. I potently inhibits cell growth and induces apoptosis in human breast and prostate cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXnBgND94TZrVg90H21EOLACvtfcHk0lgldjPODgpjbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWisbs%253D&md5=fd9ac15e3622bcd5bf45a0b88be93970</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fjm701358v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701358v%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DG.%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DAcylpyrogallols%2520as%2520inhibitors%2520of%2520antiapoptotic%2520Bcl-2%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D717%26epage%3D720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">James, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prada, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span> </span><span class="NLM_article-title">AT 101, an inhibitor of Bcl-2 family members is cytotoxic to a heterogeneous group of CLL samples and synergistic with rituximab</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">835a</span><span class="NLM_x">–</span> <span class="NLM_lpage">835a</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2005&pages=835a-835a&author=D.+F.+Jamesauthor=C.+E.+Pradaauthor=J.+E.+Castroauthor=T.+J.+Kipps&title=AT+101%2C+an+inhibitor+of+Bcl-2+family+members+is+cytotoxic+to+a+heterogeneous+group+of+CLL+samples+and+synergistic+with+rituximab"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DPrada%26aufirst%3DC.%2BE.%26aulast%3DCastro%26aufirst%3DJ.%2BE.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DAT%2520101%252C%2520an%2520inhibitor%2520of%2520Bcl-2%2520family%2520members%2520is%2520cytotoxic%2520to%2520a%2520heterogeneous%2520group%2520of%2520CLL%2520samples%2520and%2520synergistic%2520with%2520rituximab%26jtitle%3DBlood%26date%3D2005%26volume%3D106%26spage%3D835a%26epage%3D835a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Arnold, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboukameel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Katib, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammad, R. M.</span><span> </span><span class="NLM_article-title">Preclinical studies of apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1186%2F1476-4598-7-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18275607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1c7msFSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=20&author=A.+A.+Arnoldauthor=A.+Aboukameelauthor=J.+Chenauthor=D.+Yangauthor=S.+Wangauthor=A.+Al-Katibauthor=R.+M.+Mohammad&title=Preclinical+studies+of+apogossypolone%3A+a+new+nonpeptidic+pan+small-molecule+inhibitor+of+Bcl-2%2C+Bcl-XL+and+Mcl-1+proteins+in+follicular+small+cleaved+cell+lymphoma+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model</span></div><div class="casAuthors">Arnold Alan A; Aboukameel Amro; Chen Jianyong; Yang Dajun; Wang Shaomeng; Al-Katib Ayad; Mohammad Ramzi M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Elevated expression of anti-apoptotic Bcl-2 family proteins have been linked to a poor survival rate of patients with Follicular Lymphoma (FL).  This prompted us to evaluate a very potent non-peptidic Small-Molecule Inhibitor (SMI) targeting Bcl-2 family proteins, Apogossypolone (ApoG2) using follicular small cleaved cell lymphoma cell line (WSU-FSCCL) and cell isolated from lymphoma patients.  ApoG2 inhibited the growth of WSU-FSCCL significantly with a 50% growth inhibition of cells (IC50) of 109 nM and decreased cell number of fresh lymphoma cells.  ApoG2 activated caspases-9, -3, and -8, and the cleavage of Poly (ADP-ribose) polymerase (PARP) and Apoptosis Inducing Factor (AIF).  In the WSU-FSCCL-SCID xenograft model, ApoG2 showed a significant anti-lymphoma effect, with %ILS of 84% in the intravenous and 63% in intraperitoneal treated mice.  These studies suggest that ApoG2 can be an effective therapeutic agent against FL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStte8-BzvWi2LFM_lbR1VmfW6udTcc2eZNXvxo6LEtILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c7msFSltQ%253D%253D&md5=afbd06a687682de8efe3b640c0026b99</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-7-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-7-20%26sid%3Dliteratum%253Aachs%26aulast%3DArnold%26aufirst%3DA.%2BA.%26aulast%3DAboukameel%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAl-Katib%26aufirst%3DA.%26aulast%3DMohammad%26aufirst%3DR.%2BM.%26atitle%3DPreclinical%2520studies%2520of%2520apogossypolone%253A%2520a%2520new%2520nonpeptidic%2520pan%2520small-molecule%2520inhibitor%2520of%2520Bcl-2%252C%2520Bcl-XL%2520and%2520Mcl-1%2520proteins%2520in%2520follicular%2520small%2520cleaved%2520cell%2520lymphoma%2520model%26jtitle%3DMol.%2520Cancer%26date%3D2008%26volume%3D7%26spage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Becattini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monosov, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellecchia, M.</span><span> </span><span class="NLM_article-title">Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L)</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">389</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.chembiol.2004.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15123268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Wntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=389-395&author=B.+Becattiniauthor=S.+Kitadaauthor=M.+Leoneauthor=E.+Monosovauthor=S.+Chandlerauthor=D.+Zhaiauthor=T.+J.+Kippsauthor=J.+C.+Reedauthor=M.+Pellecchia&title=Rational+design+and+real+time%2C+in-cell+detection+of+the+proapoptotic+activity+of+a+novel+compound+targeting+Bcl-X%28L%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL</span></div><div class="casAuthors">Becattini, Barbara; Kitada, Shinichi; Leone, Marilisa; Monosov, Edward; Chandler, Sharon; Zhai, Dayong; Kipps, Thomas J.; Reed, John C.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-395</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Antiapoptotic Bcl-2-family proteins Bcl-2 and Bcl-XL have been recently validated as drug discovery targets for cancer.  Here, by using a combination of mol. modeling, NMR-based structural anal., fluorescence polarization assays, and cell-based assays, we have designed and characterized a novel proapoptotic compd. targeting these proteins.  Our compd., Apogossypol, is capable of binding and inhibiting Bcl-2 and Bcl-XL with high affinity and induces apoptosis of tumor cell lines.  Mechanistic studies on the action of our compd. were also performed via confocal microscopy that provided real-time detection of the interaction with Bcl-XL in intact cells.  Finally, preliminary data on cells freshly isolated from patients affected by chronic lymphocytic leukemia strongly suggest potential applications of Bcl-2 antagonists as chemosensitizers in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3_FN6fhpyVbVg90H21EOLACvtfcHk0lj2P0rwuWs9xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Wntb4%253D&md5=2438e3b17b5c0c83e79e35f122d107d4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DBecattini%26aufirst%3DB.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DLeone%26aufirst%3DM.%26aulast%3DMonosov%26aufirst%3DE.%26aulast%3DChandler%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DD.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DRational%2520design%2520and%2520real%2520time%252C%2520in-cell%2520detection%2520of%2520the%2520proapoptotic%2520activity%2520of%2520a%2520novel%2520compound%2520targeting%2520Bcl-X%2528L%2529%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D389%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Wang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolovska-Coleska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shangary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meagher, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuckey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krajewski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roller, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abaan, H. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6139</span><span class="NLM_x">–</span> <span class="NLM_lpage">6142</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060460o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6139-6142&author=G.+Wangauthor=Z.+Nikolovska-Coleskaauthor=C.+Y.+Yangauthor=R.+Wangauthor=G.+Tangauthor=J.+Guoauthor=S.+Shangaryauthor=S.+Qiuauthor=W.+Gaoauthor=D.+Yangauthor=J.+Meagherauthor=J.+Stuckeyauthor=K.+Krajewskiauthor=S.+Jiangauthor=P.+P.+Rollerauthor=H.+O.+Abaanauthor=Y.+Tomitaauthor=S.+Wang&title=Structure-based+design+of+potent+small-molecule+inhibitors+of+anti-apoptotic+Bcl-2+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Potent Small-Molecule Inhibitors of Anti-Apoptotic Bcl-2 Proteins</span></div><div class="casAuthors">Wang, Guoping; Nikolovska-Coleska, Zaneta; Yang, Chao-Yie; Wang, Renxiao; Tang, Guozhi; Guo, Jie; Shangary, Sanjeev; Qiu, Su; Gao, Wei; Yang, Dajun; Meagher, Jennifer; Stuckey, Jeanne; Krajewski, Krzysztof; Jiang, Sheng; Roller, Peter P.; Abaan, Hatice Ozel; Tomita, York; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6139-6142</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was employed to design a new class of small-mol. inhibitors of Bcl-2.  The most potent compd. TW-37 (I) binds to Bcl-2 with a Ki value of 290 nM and also to Bcl-xL and Mcl-1 with high affinities.  Compd. I potently inhibits cell growth in PC-3 prostate cancer cells with an IC50 value of 200 nM and effectively induces apoptosis in a dose-dependent manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjCW9ZydQfH7Vg90H21EOLACvtfcHk0lj2P0rwuWs9xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlurw%253D&md5=a12aec81f60ebf4afa0be8f0c7794d89</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm060460o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060460o%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DNikolovska-Coleska%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DShangary%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DKrajewski%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DRoller%26aufirst%3DP.%2BP.%26aulast%3DAbaan%26aufirst%3DH.%2BO.%26aulast%3DTomita%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DStructure-based%2520design%2520of%2520potent%2520small-molecule%2520inhibitors%2520of%2520anti-apoptotic%2520Bcl-2%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6139%26epage%3D6142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Mohammad, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goustin, A. S.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=20-30&author=R.+Mohammadauthor=A.+Giriauthor=A.+S.+Goustin&title=Small-molecule+inhibitors+of+Bcl-2+family+proteins+as+therapeutic+agents+in+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMohammad%26aufirst%3DR.%26aulast%3DGiri%26aufirst%3DA.%26aulast%3DGoustin%26aufirst%3DA.%2BS.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520Bcl-2%2520family%2520proteins%2520as%2520therapeutic%2520agents%2520in%2520cancer%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Williamson, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fineran, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gristwood, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chawrai, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeper, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmond, G. P.</span><span> </span><span class="NLM_article-title">Anticancer and immunosuppressive properties of bacterial prodiginines</span> <span class="citation_source-journal">Future Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">605</span><span class="NLM_x">–</span> <span class="NLM_lpage">618</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2217%2F17460913.2.6.605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18041902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKltL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=605-618&author=N.+R.+Williamsonauthor=P.+C.+Fineranauthor=T.+Gristwoodauthor=S.+R.+Chawraiauthor=F.+J.+Leeperauthor=G.+P.+Salmond&title=Anticancer+and+immunosuppressive+properties+of+bacterial+prodiginines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer and immunosuppressive properties of bacterial prodiginines</span></div><div class="casAuthors">Williamson, Neil R.; Fineran, Peter C.; Gristwood, Tamzin; Chawrai, Suresh R.; Leeper, Finian J.; Salmond, George P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Future Microbiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">605-618</span>CODEN:
                <span class="NLM_cas:coden">FMUIAR</span>;
        ISSN:<span class="NLM_cas:issn">1746-0913</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Bacterial prodiginines are a family of red-pigmented, tripyrrolic compds. that display numerous biol. activities, including antibacterial, antifungal, antiprotozoal, antimalarial, immunosuppressive and anticancer properties.  Recently, significant progress has been made in understanding the biosynthesis and regulation of bacterial prodiginines.  An understanding of the biosynthesis of prodiginines will allow engineering of bacterial strains capable of synthesizing novel prodiginines through rational design and mutasynthesis expts.  Bacterial prodiginines and synthetic derivs. are effective proapoptotic agents with multiple cellular targets, and they are active against numerous cancer cell lines, including multidrug-resistant cells, with little or no toxicity towards normal cell lines.  A synthetic deriv., GX15-070 (Obatoclax), developed through structure-activity relationship studies of the pyrrolic ring A of GX15, is in multiple Phase I and II clin. trials in both single and dual-agent studies to treat different types of cancer.  Therefore, prodiginines have real therapeutic potential in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa8nIYvOy7QbVg90H21EOLACvtfcHk0ljh5jR3gVDmzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKltL3K&md5=d3866a5ebdfdeb1d11da205f46aa24ac</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.2217%2F17460913.2.6.605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460913.2.6.605%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DN.%2BR.%26aulast%3DFineran%26aufirst%3DP.%2BC.%26aulast%3DGristwood%26aufirst%3DT.%26aulast%3DChawrai%26aufirst%3DS.%2BR.%26aulast%3DLeeper%26aufirst%3DF.%2BJ.%26aulast%3DSalmond%26aufirst%3DG.%2BP.%26atitle%3DAnticancer%2520and%2520immunosuppressive%2520properties%2520of%2520bacterial%2520prodiginines%26jtitle%3DFuture%2520Microbiol.%26date%3D2007%26volume%3D2%26spage%3D605%26epage%3D618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Campas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosialls, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barragan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iglesias-Serret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santidrian, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coll-Mulet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Frias, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domingo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, J.</span><span> </span><span class="NLM_article-title">Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells</span> <span class="citation_source-journal">Exp. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1663</span><span class="NLM_x">–</span> <span class="NLM_lpage">1669</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.exphem.2006.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17157163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12qsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1663-1669&author=C.+Campasauthor=A.+M.+Cosiallsauthor=M.+Barraganauthor=D.+Iglesias-Serretauthor=A.+F.+Santidrianauthor=L.+Coll-Muletauthor=M.+de+Friasauthor=A.+Domingoauthor=G.+Ponsauthor=J.+Gil&title=Bcl-2+inhibitors+induce+apoptosis+in+chronic+lymphocytic+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells</span></div><div class="casAuthors">Campas, Clara; Cosialls, Ana M.; Barragan, Montserrat; Iglesias-Serret, Daniel; Santidrian, Antonio F.; Coll-Mulet, Llorenc; de Frias, Merce; Domingo, Alicia; Pons, Gabriel; Gil, Joan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1663-1669</span>CODEN:
                <span class="NLM_cas:coden">EXHMA6</span>;
        ISSN:<span class="NLM_cas:issn">0301-472X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Objective: Antiapoptotic Bcl-2 is overexpressed in most cases of chronic lymphocytic leukemia (CLL).  The inhibition of the antiapoptotic Bcl-2 proteins is an attractive strategy for either restoring normal apoptotic process in cancer cells or making these cells more susceptible to conventional chemotherapy.  We studied the effect of Bcl-2 inhibitors on the viability of cells from CLL and other mature B-cell neoplasms.  Materials and Methods: We studied the cytotoxic effects of four nonpeptidic cell-permeable Bcl-2 inhibitors (HA14-1, antimycin A, GX15-003, and GX15-070) on B cells from patients with CLL, mantle cell lymphoma (MCL), and splenic marginal zone lymphoma (SMZL).  Moreover, we analyzed the effect of these inhibitors in combination with fludarabine or chlorambucil.  Results: HA14-1 induced apoptosis with an EC50 lower than 50 μM in 26 of the 36 CLL samples analyzed.  The mean EC50 for these sensitive patients was 23 ± 2 μM.  Antimycin A induced apoptosis in 13 of the 18 CLL samples analyzed.  Both HA14-1 and antimycin A induced cytochrome c release from mitochondria and caspase-3 activation.  Moreover, HA14-1 induced apoptosis in peripheral cells from MCL and SMZL.  HA14-1 also induced apoptosis in CLL samples with alterations in p53 or ATM.  Finally, GX compds. induced apoptosis in B cells from 9 of the 11 CLL samples tested.  The combination of either HA14-1, antimycin A, or GX compds. with fludarabine or chlorambucil had additive cytotoxic effects on CLL cells.  Conclusion: Bcl-2 inhibitors induce apoptosis in CLL cells ex vivo and could be used in CLL as monotherapy or given in combination with current chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeJfWnAXcQe7Vg90H21EOLACvtfcHk0ljh5jR3gVDmzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12qsrvJ&md5=9bc05a57514c3f1de3e1b24ba3861961</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.exphem.2006.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.exphem.2006.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DCampas%26aufirst%3DC.%26aulast%3DCosialls%26aufirst%3DA.%2BM.%26aulast%3DBarragan%26aufirst%3DM.%26aulast%3DIglesias-Serret%26aufirst%3DD.%26aulast%3DSantidrian%26aufirst%3DA.%2BF.%26aulast%3DColl-Mulet%26aufirst%3DL.%26aulast%3Dde%2BFrias%26aufirst%3DM.%26aulast%3DDomingo%26aufirst%3DA.%26aulast%3DPons%26aufirst%3DG.%26aulast%3DGil%26aufirst%3DJ.%26atitle%3DBcl-2%2520inhibitors%2520induce%2520apoptosis%2520in%2520chronic%2520lymphocytic%2520leukemia%2520cells%26jtitle%3DExp.%2520Hematol.%26date%3D2006%26volume%3D34%26spage%3D1663%26epage%3D1669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Lessene, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czabotar, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colman, P. M.</span><span> </span><span class="NLM_article-title">BCL-2 family antagonists for cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">989</span><span class="NLM_x">–</span> <span class="NLM_lpage">1000</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=989-1000&author=G.+Lesseneauthor=P.+E.+Czabotarauthor=P.+M.+Colman&title=BCL-2+family+antagonists+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DCzabotar%26aufirst%3DP.%2BE.%26aulast%3DColman%26aufirst%3DP.%2BM.%26atitle%3DBCL-2%2520family%2520antagonists%2520for%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D989%26epage%3D1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">O’Brien, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claxton, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crump, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipps, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viallet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheson, B. D.</span><span> </span><span class="NLM_article-title">Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">299</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=299-305&author=S.+M.+O%E2%80%99Brienauthor=D.+F.+Claxtonauthor=M.+Crumpauthor=S.+Faderlauthor=T.+Kippsauthor=M.+J.+Keatingauthor=J.+Vialletauthor=B.+D.+Cheson&title=Phase+I+study+of+obatoclax+mesylate+%28GX15-070%29%2C+a+small+molecule+pan-Bcl-2+family+antagonist%2C+in+patients+with+advanced+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DClaxton%26aufirst%3DD.%2BF.%26aulast%3DCrump%26aufirst%3DM.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DKipps%26aufirst%3DT.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DViallet%26aufirst%3DJ.%26aulast%3DCheson%26aufirst%3DB.%2BD.%26atitle%3DPhase%2520I%2520study%2520of%2520obatoclax%2520mesylate%2520%2528GX15-070%2529%252C%2520a%2520small%2520molecule%2520pan-Bcl-2%2520family%2520antagonist%252C%2520in%2520patients%2520with%2520advanced%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D299%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Wang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, X. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasula, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croce, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alnemri, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z. W.</span><span> </span><span class="NLM_article-title">Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">7124</span><span class="NLM_x">–</span> <span class="NLM_lpage">7129</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1073%2Fpnas.97.13.7124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=10860979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=7124-7129&author=J.+L.+Wangauthor=D.+X.+Liuauthor=Z.+J.+Zhangauthor=S.+M.+Shanauthor=X.+B.+Hanauthor=S.+M.+Srinivasulaauthor=C.+M.+Croceauthor=E.+S.+Alnemriauthor=Z.+W.+Huang&title=Structure-based+discovery+of+an+organic+compound+that+binds+Bcl-2+protein+and+induces+apoptosis+of+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells</span></div><div class="casAuthors">Wang, Jia-Lun; Liu, Dongxiang; Zhang, Zhi-Jia; Shan, Simei; Han, Xiaobing; Srinivasula, Srinivasa M.; Croce, Carlo M.; Alnemri, Emad S.; Huang, Ziwei</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7124-7129</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bcl-2 and related proteins are key regulators of apoptosis or programmed cell death implicated in human disease including cancer.  We recently showed that cell-permeable Bcl-2 binding peptides could induce apoptosis of human myeloid leukemia in vitro and suppress its growth in severe combined immunodeficient mice.  Here we report the discovery of HA14-1, a small mol. (mol. wt. = 409) and nonpeptidic ligand of a Bcl-2 surface pocket, by using a computer screening strategy based on the predicted structure of Bcl-2 protein.  In vitro binding studies demonstrated the interaction of HA14-1 with this Bcl-2 surface pocket that is essential for Bcl-2 biol. function.  HA14-1 effectively induced apoptosis of human acute myeloid leukemia (HL-60) cells overexpressing Bcl-2 protein that was assocd. with the decrease in mitochondrial membrane potential and activation of caspase-9 followed by caspase-3.  Cytokine response modifier A, a potent inhibitor of Fas-mediated apoptosis, did not block apoptosis induced by HA14-1.  Whereas HA14-1 strongly induced the death of NIH 3T3 (Apaf-1+/+) cells, it had little apoptotic effect on Apaf-1-deficient (Apaf-1-/-) mouse embryonic fibroblast cells.  These data are consistent with a mechanism by which HA14-1 induces the activation of Apaf-1 and caspases, possibly by binding to Bcl-2 protein and inhibiting its function.  The discovery of this cell-permeable mol. provides a chem. probe to study Bcl-2-regulated apoptotic pathways in vivo and could lead to the development of new therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu20JdRurZgbVg90H21EOLACvtfcHk0lj-QljnMt1eug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKit78%253D&md5=f867bbd9941486c0da981cae17cb9c01</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1073%2Fpnas.97.13.7124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.97.13.7124%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%2BL.%26aulast%3DLiu%26aufirst%3DD.%2BX.%26aulast%3DZhang%26aufirst%3DZ.%2BJ.%26aulast%3DShan%26aufirst%3DS.%2BM.%26aulast%3DHan%26aufirst%3DX.%2BB.%26aulast%3DSrinivasula%26aufirst%3DS.%2BM.%26aulast%3DCroce%26aufirst%3DC.%2BM.%26aulast%3DAlnemri%26aufirst%3DE.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%2BW.%26atitle%3DStructure-based%2520discovery%2520of%2520an%2520organic%2520compound%2520that%2520binds%2520Bcl-2%2520protein%2520and%2520induces%2520apoptosis%2520of%2520tumor%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D7124%26epage%3D7129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Tian, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doshi, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, C.</span><span> </span><span class="NLM_article-title">sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">259</span><span class="NLM_x">, </span> <span class="NLM_fpage">198</span><span class="NLM_x">–</span> <span class="NLM_lpage">208</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.canlet.2007.10.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18037229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCgtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2008&pages=198-208&author=D.+Tianauthor=S.+G.+Dasauthor=J.+M.+Doshiauthor=J.+Pengauthor=J.+Linauthor=C.+Xing&title=sHA+14-1%2C+a+stable+and+ROS-free+antagonist+against+anti-apoptotic+Bcl-2+proteins%2C+bypasses+drug+resistances+and+synergizes+cancer+therapies+in+human+leukemia+cell"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell</span></div><div class="casAuthors">Tian, Defeng; Das, Sonia G.; Doshi, Jignesh M.; Peng, Jun; Lin, Jialing; Xing, Chengguo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">259</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-208</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HA 14-1, a small-mol. antagonist against anti-apoptotic Bcl-2 proteins, was demonstrated to induce selective cytotoxicity toward malignant cells and to overcome drug resistance.  Due to its poor stability and the reactive oxygen species (ROS) generated by its decompn., chem. modification of HA 14-1 is needed for its future development.  We have synthesized a stabilized analog of HA 14-1 - sHA 14-1, which did not induce the formation of ROS.  As expected from a putative antagonist against anti-apoptotic Bcl-2 proteins like HA 14-1, sHA 14-1 disrupted the binding interaction of a Bak BH3 peptide with Bcl-2 or Bcl-XL protein, inhibited the growth of tumor cells through the induction of apoptosis, and circumvented the drug resistance induced by the over-expression of anti-apoptotic Bcl-2 and Bcl-XL proteins.  Interestingly, the impairment of extrinsic apoptotic pathway induced moderate resistance to sHA 14-1.  The moderate resistance suggested that sHA 14-1 generated part of its apoptotic stress through the intrinsic pathway, possibly through its antagonism against anti-apoptotic Bcl-2 proteins.  The resistance indicated that sHA 14-1 generated apoptotic stress through the extrinsic apoptotic pathway as well.  The ability of sHA 14-1 to induce apoptotic stress through both pathways was further supported by the synergism of sHA 14-1 towards the cytotoxicities of Fas ligand and dexamethasone in Jurkat cells.  Taken together, these findings suggest that sHA 14-1 may represent a promising candidate for the treatment of drug-resistant cancers either as a monotherapy or in combination with current cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7lhltQFx1Y7Vg90H21EOLACvtfcHk0lj-QljnMt1eug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCgtLrF&md5=69292d62ce2e9c50991cb5db760bab0d</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2007.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2007.10.012%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DD.%26aulast%3DDas%26aufirst%3DS.%2BG.%26aulast%3DDoshi%26aufirst%3DJ.%2BM.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DXing%26aufirst%3DC.%26atitle%3DsHA%252014-1%252C%2520a%2520stable%2520and%2520ROS-free%2520antagonist%2520against%2520anti-apoptotic%2520Bcl-2%2520proteins%252C%2520bypasses%2520drug%2520resistances%2520and%2520synergizes%2520cancer%2520therapies%2520in%2520human%2520leukemia%2520cell%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D259%26spage%3D198%26epage%3D208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Xing, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sham, Y. Y.</span><span> </span><span class="NLM_article-title">Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2167</span><span class="NLM_x">–</span> <span class="NLM_lpage">2176</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=2167-2176&author=C.+Xingauthor=L.+Wangauthor=X.+Tangauthor=Y.+Y.+Sham&title=Development+of+selective+inhibitors+for+anti-apoptotic+Bcl-2+proteins+from+BHI-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DSham%26aufirst%3DY.%2BY.%26atitle%3DDevelopment%2520of%2520selective%2520inhibitors%2520for%2520anti-apoptotic%2520Bcl-2%2520proteins%2520from%2520BHI-1%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D2167%26epage%3D2176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClellan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oost, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oleksijew, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltersdorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">Discovery and structure−activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1165</span><span class="NLM_x">–</span> <span class="NLM_lpage">1181</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050754u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1165-1181&author=M.+D.+Wendtauthor=W.+Shenauthor=A.+Kunzerauthor=W.+J.+McClellanauthor=M.+Brunckoauthor=T.+K.+Oostauthor=H.+Dingauthor=M.+K.+Josephauthor=H.+Zhangauthor=P.+M.+Nimmerauthor=S.+C.+Ngauthor=A.+R.+Shoemakerauthor=A.+M.+Petrosauthor=A.+Oleksijewauthor=K.+Marshauthor=J.+Bauchauthor=T.+Oltersdorfauthor=B.+A.+Belliauthor=D.+Martineauauthor=S.+W.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=Discovery+and+structure%E2%88%92activity+relationship+of+antagonists+of+B-cell+lymphoma+2+family+proteins+with+chemopotentiation+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm050754u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050754u%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKunzer%26aufirst%3DA.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DOost%26aufirst%3DT.%2BK.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DNimmer%26aufirst%3DP.%2BM.%26aulast%3DNg%26aufirst%3DS.%2BC.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DOleksijew%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%26aulast%3DBauch%26aufirst%3DJ.%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DBelli%26aufirst%3DB.%2BA.%26aulast%3DMartineau%26aufirst%3DD.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520and%2520structure%25E2%2588%2592activity%2520relationship%2520of%2520antagonists%2520of%2520B-cell%2520lymphoma%25202%2520family%2520proteins%2520with%2520chemopotentiation%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1165%26epage%3D1181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oost, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martineau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClellan, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oltersdorf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">641</span><span class="NLM_x">–</span> <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm061152t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXptVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=641-662&author=M.+Brunckoauthor=T.+K.+Oostauthor=B.+A.+Belliauthor=H.+Dingauthor=M.+K.+Josephauthor=A.+Kunzerauthor=D.+Martineauauthor=W.+J.+McClellanauthor=M.+Mittenauthor=S.+C.+Ngauthor=P.+M.+Nimmerauthor=T.+Oltersdorfauthor=C.+M.+Parkauthor=A.+M.+Petrosauthor=A.+R.+Shoemakerauthor=X.+Songauthor=X.+Wangauthor=M.+D.+Wendtauthor=H.+Zhangauthor=S.+W.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=Studies+leading+to+potent%2C+dual+inhibitors+of+Bcl-2+and+Bcl-xL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL</span></div><div class="casAuthors">Bruncko, Milan; Oost, Thorsten K.; Belli, Barbara A.; Ding, Hong; Joseph, Mary K.; Kunzer, Aaron; Martineau, Darlene; McClellan, William J.; Mitten, Michael; Ng, Shi-Chung; Nimmer, Paul M.; Oltersdorf, Tilman; Park, Cheol-Min; Petros, Andrew M.; Shoemaker, Alexander R.; Song, Xiaohong; Wang, Xilu; Wendt, Michael D.; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.; Elmore, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">641-662</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of the antiapoptotic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy.  Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy.  We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation.  Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2.  This study culminated in the identification of 2 (I), which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, resp.  Compd. 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF2G6VoJIheLVg90H21EOLACvtfcHk0ljMgZ3HdbPKHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXptVGmug%253D%253D&md5=e7bf502c69c4247c39ce7e070984b3a6</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm061152t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061152t%26sid%3Dliteratum%253Aachs%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DOost%26aufirst%3DT.%2BK.%26aulast%3DBelli%26aufirst%3DB.%2BA.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DKunzer%26aufirst%3DA.%26aulast%3DMartineau%26aufirst%3DD.%26aulast%3DMcClellan%26aufirst%3DW.%2BJ.%26aulast%3DMitten%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DS.%2BC.%26aulast%3DNimmer%26aufirst%3DP.%2BM.%26aulast%3DOltersdorf%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DC.%2BM.%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DStudies%2520leading%2520to%2520potent%252C%2520dual%2520inhibitors%2520of%2520Bcl-2%2520and%2520Bcl-xL%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D641%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Park, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruncko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adickes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahir, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6902</span><span class="NLM_x">–</span> <span class="NLM_lpage">6915</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800669s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1WlsbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6902-6915&author=C.+M.+Parkauthor=M.+Brunckoauthor=J.+Adickesauthor=J.+Bauchauthor=H.+Dingauthor=A.+Kunzerauthor=K.+C.+Marshauthor=P.+Nimmerauthor=A.+R.+Shoemakerauthor=X.+Songauthor=S.+K.+Tahirauthor=C.+Tseauthor=X.+Wangauthor=M.+D.+Wendtauthor=X.+Yangauthor=H.+Zhangauthor=S.+W.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=Discovery+of+an+orally+bioavailable+small+molecule+inhibitor+of+prosurvival+B-cell+lymphoma+2+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins</span></div><div class="casAuthors">Park, Cheol-Min; Bruncko, Milan; Adickes, Jessica; Bauch, Joy; Ding, Hong; Kunzer, Aaron; Marsh, Kennan C.; Nimmer, Paul; Shoemaker, Alexander R.; Song, Xiaohong; Tahir, Stephen K.; Tse, Christin; Wang, Xilu; Wendt, Michael D.; Yang, Xiufen; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H.; Elmore, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6902-6915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of prosurvival proteins such as Bcl-2 and Bcl-XL has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide a novel means for the treatment of cancer.  We recently described the discovery of 1 (ABT-737), which binds Bcl-2, Bcl-XL, and Bcl-w with high affinity, shows robust antitumor activity in murine tumor xenograft models, but is not orally bioavailable.  Herein, we report that targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC50).  The resulting compd., 2 (ABT-263), is orally efficacious in an established xenograft model of human small cell lung cancer, inducing complete tumor regressions in all animals.  Compd. 2 is currently in multiple phase 1 clin. trials in patients with small cell lung cancer and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF1JFNLCqAULVg90H21EOLACvtfcHk0ljMgZ3HdbPKHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1WlsbvE&md5=83975ec5e8f642abc3507d35d00c9e14</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm800669s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800669s%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DC.%2BM.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DAdickes%26aufirst%3DJ.%26aulast%3DBauch%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DKunzer%26aufirst%3DA.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DNimmer%26aufirst%3DP.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DTse%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520bioavailable%2520small%2520molecule%2520inhibitor%2520of%2520prosurvival%2520B-cell%2520lymphoma%25202%2520proteins%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6902%26epage%3D6915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Petros, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinges, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augeri, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumeister, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betebenner, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bures, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajduk, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettesheim, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanze, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of the antiapoptotic protein Bcl-X L from NMR and parallel synthesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">656</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0507532" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=656-663&author=A.+M.+Petrosauthor=J.+Dingesauthor=D.+J.+Augeriauthor=S.+A.+Baumeisterauthor=D.+A.+Betebennerauthor=M.+G.+Buresauthor=S.+W.+Elmoreauthor=P.+J.+Hajdukauthor=M.+K.+Josephauthor=S.+K.+Landisauthor=D.+G.+Nettesheimauthor=S.+H.+Rosenbergauthor=W.+Shenauthor=S.+Thomasauthor=X.+Wangauthor=I.+Zanzeauthor=H.+Zhangauthor=S.+W.+Fesik&title=Discovery+of+a+potent+inhibitor+of+the+antiapoptotic+protein+Bcl-X+L+from+NMR+and+parallel+synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Fjm0507532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0507532%26sid%3Dliteratum%253Aachs%26aulast%3DPetros%26aufirst%3DA.%2BM.%26aulast%3DDinges%26aufirst%3DJ.%26aulast%3DAugeri%26aufirst%3DD.%2BJ.%26aulast%3DBaumeister%26aufirst%3DS.%2BA.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DBures%26aufirst%3DM.%2BG.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26aulast%3DHajduk%26aufirst%3DP.%2BJ.%26aulast%3DJoseph%26aufirst%3DM.%2BK.%26aulast%3DLandis%26aufirst%3DS.%2BK.%26aulast%3DNettesheim%26aufirst%3DD.%2BG.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZanze%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520the%2520antiapoptotic%2520protein%2520Bcl-X%2520L%2520from%2520NMR%2520and%2520parallel%2520synthesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D656%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Del Gaizo Moore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Certo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novina, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letai, A.</span><span> </span><span class="NLM_article-title">Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=112-121&author=V.+Del+Gaizo+Mooreauthor=J.+R.+Brownauthor=M.+Certoauthor=T.+M.+Loveauthor=C.+D.+Novinaauthor=A.+Letai&title=Chronic+lymphocytic+leukemia+requires+BCL2+to+sequester+prodeath+BIM%2C+explaining+sensitivity+to+BCL2+antagonist+ABT-737"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BGaizo%2BMoore%26aufirst%3DV.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DCerto%26aufirst%3DM.%26aulast%3DLove%26aufirst%3DT.%2BM.%26aulast%3DNovina%26aufirst%3DC.%2BD.%26aulast%3DLetai%26aufirst%3DA.%26atitle%3DChronic%2520lymphocytic%2520leukemia%2520requires%2520BCL2%2520to%2520sequester%2520prodeath%2520BIM%252C%2520explaining%2520sensitivity%2520to%2520BCL2%2520antagonist%2520ABT-737%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D112%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Vogler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsdale, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicotera, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, G. M.</span><span> </span><span class="NLM_article-title">A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">820</span><span class="NLM_x">–</span> <span class="NLM_lpage">830</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fcdd.2008.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18309326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFygu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=820-830&author=M.+Voglerauthor=D.+Dinsdaleauthor=X.+M.+Sunauthor=K.+W.+Youngauthor=M.+Butterworthauthor=P.+Nicoteraauthor=M.+J.+Dyerauthor=G.+M.+Cohen&title=A+novel+paradigm+for+rapid+ABT-737-induced+apoptosis+involving+outer+mitochondrial+membrane+rupture+in+primary+leukemia+and+lymphoma+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells</span></div><div class="casAuthors">Vogler, M.; Dinsdale, D.; Sun, X.-M.; Young, K. W.; Butterworth, M.; Nicotera, P.; Dyer, M. J. S.; Cohen, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">820-830</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Primary chronic lymphocytic leukemia (CLL) cells are exquisitely sensitive to ABT-737, a small mol. BCL2-antagonist, which induces many of the classical biochem. and ultrastructural features of apoptosis, including BAX/BAK oligomerization, cytochrome c release, caspase activation and chromatin condensation.  Surprisingly, ABT-737 also induces mitochondrial inner membrane permeabilization (MIMP) resulting in mitochondrial matrix swelling and rupture of the outer mitochondrial membrane (OMM), so permitting the rapid efflux of cytochrome c from mitochondrial cristae and facilitating rapid caspase activation and apoptosis.  BAX and BAK appear to be involved in the OMM discontinuities as they localize to the OMM break points.  Notably, ABT-737 induced mitochondrial matrix swelling and OMM discontinuities in other primary B-cell malignancies, including mantle cell, follicular and marginal zone lymphoma cells but not in several cell lines studied.  Thus, we describe a new paradigm of apoptosis in primary B-cell malignancies, whereby targeting of BCL2 results in all the classical features of apoptosis together with OMM rupture independent of caspase activation.  This mechanism may be far more prevalent than hitherto recognized due to the failure of most methods, used to measure apoptosis, to recognize such a mechanism.  Cell Death and Differentiation (2008) 15, 820-830; doi:10.1038/cdd.2008.25; published online 29 Feb. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFhS8da_Sf0bVg90H21EOLACvtfcHk0ljsJuLYFW571A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFygu7s%253D&md5=65590167fb7e08de121ae9c000c11c51</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2008.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2008.25%26sid%3Dliteratum%253Aachs%26aulast%3DVogler%26aufirst%3DM.%26aulast%3DDinsdale%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DX.%2BM.%26aulast%3DYoung%26aufirst%3DK.%2BW.%26aulast%3DButterworth%26aufirst%3DM.%26aulast%3DNicotera%26aufirst%3DP.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%26aulast%3DCohen%26aufirst%3DG.%2BM.%26atitle%3DA%2520novel%2520paradigm%2520for%2520rapid%2520ABT-737-induced%2520apoptosis%2520involving%2520outer%2520mitochondrial%2520membrane%2520rupture%2520in%2520primary%2520leukemia%2520and%2520lymphoma%2520cells%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2008%26volume%3D15%26spage%3D820%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Wendt, M. D.</span><span> </span><span class="NLM_article-title">Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein−protein interaction</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1143</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1123-1143&author=M.+D.+Wendt&title=Discovery+of+ABT-263%2C+a+Bcl-family+protein+inhibitor%3A+observations+on+targeting+a+large+protein%E2%88%92protein+interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520ABT-263%252C%2520a%2520Bcl-family%2520protein%2520inhibitor%253A%2520observations%2520on%2520targeting%2520a%2520large%2520protein%25E2%2588%2592protein%2520interaction%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1123%26epage%3D1143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Tse, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shoemaker, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adickes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitten, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimmer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tahir, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elmore, S. W.</span><span> </span><span class="NLM_article-title">ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3421</span><span class="NLM_x">–</span> <span class="NLM_lpage">3428</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F0008-5472.CAN-07-5836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18451170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3421-3428&author=C.+Tseauthor=A.+R.+Shoemakerauthor=J.+Adickesauthor=M.+G.+Andersonauthor=J.+Chenauthor=S.+Jinauthor=E.+F.+Johnsonauthor=K.+C.+Marshauthor=M.+J.+Mittenauthor=P.+Nimmerauthor=L.+Robertsauthor=S.+K.+Tahirauthor=Y.+Xiaoauthor=X.+Yangauthor=H.+Zhangauthor=S.+Fesikauthor=S.+H.+Rosenbergauthor=S.+W.+Elmore&title=ABT-263%3A+a+potent+and+orally+bioavailable+Bcl-2+family+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor</span></div><div class="casAuthors">Tse, Christin; Shoemaker, Alexander R.; Adickes, Jessica; Anderson, Mark G.; Chen, Jun; Jin, Sha; Johnson, Eric F.; Marsh, Kennan C.; Mitten, Michael J.; Nimmer, Paul; Roberts, Lisa; Tahir, Stephen K.; Xiao, Yu; Yang, Xiufen; Zhang, Haichao; Fesik, Stephen; Rosenberg, Saul H.; Elmore, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3421-3428</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly assocd. with tumor maintenance, progression, and chemoresistance.  We previously reported the discovery of ABT-737, a potent, small-mol. Bcl-2 family protein inhibitor.  A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens.  Here we report the biol. properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (Ki's of <1 nmol/L for Bcl-2, Bcl-xL, and Bcl-w).  The oral bioavailability of ABT-263 in preclin. animal models is 20% to 50%, depending on formulation.  ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim), leading to the initiation of apoptosis within 2 h posttreatment.  In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis.  Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia.  In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clin. relevant therapeutic regimens.  These data provide the rationale for clin. trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies.  The oral efficacy of ABT-263 should provide dosing flexibility to maximize clin. utility both as a single agent and in combination regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojLK8zIgyDWbVg90H21EOLACvtfcHk0ljsJuLYFW571A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSltrs%253D&md5=a43029cc218d25d4e1fb6dd1186475c4</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5836%26sid%3Dliteratum%253Aachs%26aulast%3DTse%26aufirst%3DC.%26aulast%3DShoemaker%26aufirst%3DA.%2BR.%26aulast%3DAdickes%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DM.%2BG.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMitten%26aufirst%3DM.%2BJ.%26aulast%3DNimmer%26aufirst%3DP.%26aulast%3DRoberts%26aufirst%3DL.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFesik%26aufirst%3DS.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26atitle%3DABT-263%253A%2520a%2520potent%2520and%2520orally%2520bioavailable%2520Bcl-2%2520family%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3421%26epage%3D3428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Chase, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, N. C.</span><span> </span><span class="NLM_article-title">Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases</span> <span class="citation_source-journal">Clin. Sci. (London)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1042%2FCS20060035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16961463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2006&pages=233-249&author=A.+Chaseauthor=N.+C.+Cross&title=Signal+transduction+therapy+in+haematological+malignancies%3A+identification+and+targeting+of+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction therapy in hematological malignancies: identification and targeting of tyrosine kinases</span></div><div class="casAuthors">Chase, Andrew; Cross, Nicholas C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">233-249</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">0143-5221</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Tyrosine kinases play key roles in cell proliferation, survival and differentiation.  Their aberrant activation, caused either by the formation of fusion genes by chromosome translocation or by intragenic changes, such as point mutations or internal duplications, is of major importance in the development of many haematol. malignancies.  An understanding of the mechanisms by which BCR-ABL contributes to the pathogenesis of chronic myeloid leukemia led to the development of imatinib, the first of several tyrosine kinase inhibitors to enter clin. trials.  Although the development of resistance has been problematic, particularly in aggressive disease, the development of novel inhibitors and combination with other forms of therapy shows promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnuVz0FE6vN7Vg90H21EOLACvtfcHk0lg5YXO63s7SdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOntbg%253D&md5=77e66f558e2ebab120965923ec997b2f</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1042%2FCS20060035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20060035%26sid%3Dliteratum%253Aachs%26aulast%3DChase%26aufirst%3DA.%26aulast%3DCross%26aufirst%3DN.%2BC.%26atitle%3DSignal%2520transduction%2520therapy%2520in%2520haematological%2520malignancies%253A%2520identification%2520and%2520targeting%2520of%2520tyrosine%2520kinases%26jtitle%3DClin.%2520Sci.%2520%2528London%2529%26date%3D2006%26volume%3D111%26spage%3D233%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Buchdunger, E.; Capedeville, R.</span><span> </span><span class="NLM_article-title">Glivec (Gleevec, Imatinib, STI571): A Targeted Therapy in Chronic Myelogenous Leukemia</span>. In  <span class="citation_source-book">Tyrosine Kinase Inhibitors: From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbro, D.; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Humana Press, Inc.</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">145</span>− <span class="NLM_lpage">160</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=145-160&author=E.+Buchdunger&author=R.+Capedevilleauthor=D.+Fabbro&author=F.+McCormick&title=Tyrosine+Kinase+Inhibitors%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBuchdunger%26aufirst%3DE.%26atitle%3DGlivec%2520%2528Gleevec%252C%2520Imatinib%252C%2520STI571%2529%253A%2520A%2520Targeted%2520Therapy%2520in%2520Chronic%2520Myelogenous%2520Leukemia%26btitle%3DTyrosine%2520Kinase%2520Inhibitors%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbro%26aufirst%3DD.%26pub%3DHumana%2520Press%252C%2520Inc%26date%3D2006%26spage%3D145%26epage%3D160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lg5YXO63s7SdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FS0960-894X%2896%2900601-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=187-192&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydon&title=Potent+and+selective+inhibitors+of+the+Abl-kinase%3A+phenylamino-pyrimidine+%28PAP%29+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives</span></div><div class="casAuthors">Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-192</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Due to its relatively clear etiol., chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase.  Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEGaTJgyxfUbVg90H21EOLACvtfcHk0lg5YXO63s7SdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D&md5=35962f1735e8d3a595fdb49d95cdc305</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2896%2900601-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252896%252900601-4%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520Abl-kinase%253A%2520phenylamino-pyrimidine%2520%2528PAP%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D187%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhLLTAgO91i6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Birault, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nerella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, A.</span><span> </span><span class="NLM_article-title">Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1735</span><span class="NLM_x">–</span> <span class="NLM_lpage">1748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F092986706777452452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16787217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVais7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1735-1748&author=V.+Biraultauthor=C.+J.+Harrisauthor=J.+Leauthor=M.+Lipkinauthor=R.+Nerellaauthor=A.+Stevens&title=Bringing+kinases+into+focus%3A+efficient+drug+design+through+the+use+of+chemogenomic+toolkits"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Bringing kinases into focus: efficient drug design through the use of chemogenomic toolkits</span></div><div class="casAuthors">Birault, Veronique; Harris, C. John; Le, Joelle; Lipkin, Mike; Nerella, Ravi; Stevens, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1735-1748</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The study of protein target families, as opposed to single targets, has become a very powerful tool in chemogenomics-led drug discovery.  By integrating comprehensive chemoinformatics and bioinformatics databases with customized anal. tools, a 'Toolkit' approach for the target family is possible, thus allowing predictions of the ligand class, affinity, selectivity and likely off-target issues to be made for the guidance of the medicinal chemist.  In this review, we highlight the development and application of the Toolkit approach to the protein kinase superfamily, drawing on examples from lead optimization studies and the design of focused libraries for lead discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofWNQyWDS5BbVg90H21EOLACvtfcHk0lhLLTAgO91i6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVais7c%253D&md5=7922956ff1a4002fc1dca7f44ca78b0a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.2174%2F092986706777452452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706777452452%26sid%3Dliteratum%253Aachs%26aulast%3DBirault%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DC.%2BJ.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLipkin%26aufirst%3DM.%26aulast%3DNerella%26aufirst%3DR.%26aulast%3DStevens%26aufirst%3DA.%26atitle%3DBringing%2520kinases%2520into%2520focus%253A%2520efficient%2520drug%2520design%2520through%2520the%2520use%2520of%2520chemogenomic%2520toolkits%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D1735%26epage%3D1748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1109</span><span class="NLM_x">–</span> <span class="NLM_lpage">1118</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnsmb.1486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18794843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=1109-1118&author=M.+Azamauthor=M.+A.+Seeligerauthor=N.+S.+Grayauthor=J.+Kuriyanauthor=G.+Q.+Daley&title=Activation+of+tyrosine+kinases+by+mutation+of+the+gatekeeper+threonine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of tyrosine kinases by mutation of the gatekeeper threonine</span></div><div class="casAuthors">Azam, Mohammad; Seeliger, Markus A.; Gray, Nathanael S.; Kuriyan, John; Daley, George Q.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1109-1118</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein kinases targeted by small-mol. inhibitors develop resistance through mutation of the 'gatekeeper' threonine residue of the active site.  Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth factor receptor-α and -β, and epidermal growth factor receptor activates the kinase and promotes malignant transformation of BaF3 cells.  Structural anal. reveals that a network of hydrophobic interactions - the hydrophobic spine - characteristic of the active kinase conformation is stabilized by the gatekeeper substitution.  Substitution of glycine for the residues constituting the spine disrupts the hydrophobic connectivity and inactivates the kinase.  Furthermore, a small-mol. inhibitor (compd. 14) that maximizes complementarity with the dismantled spine inhibits the gatekeeper mutation of BCR-ABL-T315I.  These results demonstrate that mutation of the gatekeeper threonine is a common mechanism of activation for tyrosine kinases and provide structural insights to guide the development of next-generation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEoZTY5SkbALVg90H21EOLACvtfcHk0lhLLTAgO91i6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sisb%252FM&md5=4afc4e5a0850a4510ced3fa5fbda97fa</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1486%26sid%3Dliteratum%253Aachs%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DSeeliger%26aufirst%3DM.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DActivation%2520of%2520tyrosine%2520kinases%2520by%2520mutation%2520of%2520the%2520gatekeeper%2520threonine%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D1109%26epage%3D1118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Huang, F.; Clark, E. A.</span><span> </span><span class="NLM_article-title">Pharmacogenomics of Dasatinib (Sprycel)</span>. In  <span class="citation_source-book">Kinase Inhibitor Drugs</span>; <span class="NLM_contrib-group">Li, R.; Stafford, J. A.</span>, Eds.; <span class="NLM_publisher-name">John Wiley & Sons Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=F.+Huang&author=E.+A.+Clarkauthor=R.+Li&author=J.+A.+Stafford&title=Kinase+Inhibitor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DF.%26atitle%3DPharmacogenomics%2520of%2520Dasatinib%2520%2528Sprycel%2529%26btitle%3DKinase%2520Inhibitor%2520Drugs%26aulast%3DLi%26aufirst%3DR.%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%2520Inc%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Specht, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Strategies to overcome resistance to targeted protein kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1001</span><span class="NLM_x">–</span> <span class="NLM_lpage">1010</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd1579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15573099" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1001-1010&author=H.+Daubauthor=K.+Spechtauthor=A.+Ullrich&title=Strategies+to+overcome+resistance+to+targeted+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to overcome resistance to targeted protein kinase inhibitors</span></div><div class="casAuthors">Daub, Henrik; Specht, Katja; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1001-1010</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Selective inhibition of protein tyrosine kinases is gaining importance as an effective therapeutic approach for the treatment of a wide range of human cancers.  However, as extensively documented for the BCR-ABL oncogene in imatinib-treated leukemia patients, clin. resistance caused by mutations in the targeted oncogene has been obsd.  Here, we look at how structural and mechanistic insights from imatinib-insensitive Bcr-Abl have been exploited to identify second-generation drugs that override acquired target resistance.  These insights have created a rationale for the development of either multi-targeted protein kinase inhibitors or cocktails of selective antagonists as antitumor drugs that combine increased therapeutic potency with a reduced risk of the emergence of mol. resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_U6mWwYG307Vg90H21EOLACvtfcHk0ljK0wC-uY3M_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVarsL3K&md5=49c2ce8b0150e562e382d5246b3c0a42</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fnrd1579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1579%26sid%3Dliteratum%253Aachs%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DSpecht%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DStrategies%2520to%2520overcome%2520resistance%2520to%2520targeted%2520protein%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Giannoudis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirmohamed, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, R. E.</span><span> </span><span class="NLM_article-title">Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">3348</span><span class="NLM_x">–</span> <span class="NLM_lpage">3354</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=3348-3354&author=A.+Giannoudisauthor=A.+Daviesauthor=C.+M.+Lucasauthor=R.+J.+Harrisauthor=M.+Pirmohamedauthor=R.+E.+Clark&title=Effective+dasatinib+uptake+may+occur+without+human+organic+cation+transporter+1+%28hOCT1%29%3A+implications+for+the+treatment+of+imatinib-resistant+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiannoudis%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DLucas%26aufirst%3DC.%2BM.%26aulast%3DHarris%26aufirst%3DR.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DClark%26aufirst%3DR.%2BE.%26atitle%3DEffective%2520dasatinib%2520uptake%2520may%2520occur%2520without%2520human%2520organic%2520cation%2520transporter%25201%2520%2528hOCT1%2529%253A%2520implications%2520for%2520the%2520treatment%2520of%2520imatinib-resistant%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D3348%26epage%3D3354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Overriding imatinib resistance with a novel ABL kinase inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">305</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">401</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1126%2Fscience.1099480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15256671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=399-401&author=N.+P.+Shahauthor=C.+Tranauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=C.+L.+Sawyers&title=Overriding+imatinib+resistance+with+a+novel+ABL+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor</span></div><div class="casAuthors">Shah, Neil P.; Tran, Chris; Lee, Francis Y.; Chen, Ping; Norris, Derek; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5682</span>),
    <span class="NLM_cas:pages">399-402</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding.  Crystallog. studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements.  BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants.  BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-pos. bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.  These data illustrate how mol. insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0O0Lhe8nKCrVg90H21EOLACvtfcHk0ljK0wC-uY3M_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1egtrY%253D&md5=b3827c3419b4c6b57893b11fd68f1f96</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099480%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DOverriding%2520imatinib%2520resistance%2520with%2520a%2520novel%2520ABL%2520kinase%2520inhibitor%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D399%26epage%3D401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Bruggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=M.+Azamauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0ljK0wC-uY3M_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBruggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabha, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moquin, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Fex, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span> </span><span class="NLM_article-title">2-aminothiazole as a novel kinase inhibitor template. Structure−activity relationship studies toward the discovery of <i>N</i>-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6819</span><span class="NLM_x">–</span> <span class="NLM_lpage">6832</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6819-6832&author=J.+Dasauthor=P.+Chenauthor=D.+Norrisauthor=R.+Padmanabhaauthor=J.+Linauthor=R.+V.+Moquinauthor=Z.+Shenauthor=L.+S.+Cookauthor=A.+M.+Doweykoauthor=S.+Pittauthor=S.+Pangauthor=D.+R.+Shenauthor=Q.+Fangauthor=H.+F.+de+Fexauthor=K.+W.+McIntyreauthor=D.+J.+Shusterauthor=K.+M.+Gilloolyauthor=K.+Behniaauthor=G.+L.+Schievenauthor=J.+Wityakauthor=J.+C.+Barrish&title=2-aminothiazole+as+a+novel+kinase+inhibitor+template.+Structure%E2%88%92activity+relationship+studies+toward+the+discovery+of+N-%282-chloro-6-methylphenyl%29-2-%5B%5B6-%5B4-%282-hydroxyethyl%29-1-+piperazinyl%29%5D-2-methyl-4-pyrimidinyl%5Damino%29%5D-1%2C3-thiazole-5-carboxamide+%28dasatinib%2C+BMS-354825%29+as+a+potent+pan-Src+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm060727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060727j%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DPadmanabha%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMoquin%26aufirst%3DR.%2BV.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DCook%26aufirst%3DL.%2BS.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3Dde%2BFex%26aufirst%3DH.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26atitle%3D2-aminothiazole%2520as%2520a%2520novel%2520kinase%2520inhibitor%2520template.%2520Structure%25E2%2588%2592activity%2520relationship%2520studies%2520toward%2520the%2520discovery%2520of%2520N-%25282-chloro-6-methylphenyl%2529-2-%255B%255B6-%255B4-%25282-hydroxyethyl%2529-1-%2520piperazinyl%2529%255D-2-methyl-4-pyrimidinyl%255Damino%2529%255D-1%252C3-thiazole-5-carboxamide%2520%2528dasatinib%252C%2520BMS-354825%2529%2520as%2520a%2520potent%2520pan-Src%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6819%26epage%3D6832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.-L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.-L.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Flying under the radar: the new wave of BCR-ABL inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">834</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd2324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17853901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=834-848&author=A.+Quintas-Cardamaauthor=H.+Kantarjianauthor=J.+Cortes&title=Flying+under+the+radar%3A+the+new+wave+of+BCR-ABL+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Flying under the radar: the new wave of BCR-ABL inhibitors</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">834-848</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia caused by the mutant BCR-ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs.  Quintas-Cardama and colleagues discuss novel BCR-ABL inhibitors that have the potential to overcome such resistance.  The introduction of the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec; Novartis) revolutionized the treatment of chronic myeloid leukemia (CML).  However, most patients with CML receiving imatinib still harbor mol. residual disease and some develop resistance assocd. with ABL kinase domain mutations.  The second-generation BCR-ABL inhibitors nilotinib (Tasigna; Novartis) and dasatinib (Sprycel; Bristol-Myers Squibb) have shown significant activity after imatinib failure in clin. trials, but still face similar obstacles to imatinib, including negligible activity against the frequent BCR-ABL T315I mutation and modest effects in advanced phases of CML.  Various medicinal chem. efforts, in part aided by structural studies of the ABL kinase-imatinib complex have resulted in the synthesis of a new generation of BCR-ABL inhibitors, some of which have shown encouraging preliminary activity in clin. trials, including against T315I mutants.  Here, we discuss these emerging therapies, which have the potential to improve the outcome of patients with CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog2DBi1E-INLVg90H21EOLACvtfcHk0lif6QMhb_UEnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSgsLzJ&md5=6a8692cd0405f77256df82ae7de21e18</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnrd2324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2324%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DFlying%2520under%2520the%2520radar%253A%2520the%2520new%2520wave%2520of%2520BCR-ABL%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D834%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burckstummer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schutze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">13283</span><span class="NLM_x">–</span> <span class="NLM_lpage">13288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13283-13288&author=O.+Hantschelauthor=U.+Rixauthor=U.+Schmidtauthor=T.+Burckstummerauthor=M.+Kneidingerauthor=G.+Schutzeauthor=J.+Colingeauthor=K.+L.+Bennettauthor=W.+Ellmeierauthor=P.+Valentauthor=G.+Superti-Furga&title=The+Btk+tyrosine+kinase+is+a+major+target+of+the+Bcr-Abl+inhibitor+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBurckstummer%26aufirst%3DT.%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSchutze%26aufirst%3DG.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520Btk%2520tyrosine%2520kinase%2520is%2520a%2520major%2520target%2520of%2520the%2520Bcr-Abl%2520inhibitor%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D13283%26epage%3D13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">4500</span><span class="NLM_x">–</span> <span class="NLM_lpage">4505</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=4500-4505&author=T.+O%E2%80%99Hareauthor=D.+K.+Waltersauthor=E.+P.+Stoffregenauthor=T.+Jiaauthor=P.+W.+Manleyauthor=J.+Mestanauthor=S.+W.+Cowan-Jacobauthor=F.+Y.+Leeauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=In+vitro+activity+of+Bcr-Abl+inhibitors+AMN107+and+BMS-354825+against+clinically+relevant+imatinib-resistant+Abl+kinase+domain+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DJia%26aufirst%3DT.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DIn%2520vitro%2520activity%2520of%2520Bcr-Abl%2520inhibitors%2520AMN107%2520and%2520BMS-354825%2520against%2520clinically%2520relevant%2520imatinib-resistant%2520Abl%2520kinase%2520domain%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D4500%26epage%3D4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">Pavlovsky, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. E.</span><span> </span><span class="NLM_article-title">First-line therapy for chronic myeloid leukemia: past, present, and future</span> <span class="citation_source-journal">Am. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fajh.21380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19306355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFels78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2009&pages=287-293&author=C.+Pavlovskyauthor=H.+Kantarjianauthor=J.+E.+Cortes&title=First-line+therapy+for+chronic+myeloid+leukemia%3A+past%2C+present%2C+and+future"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">First-line therapy for chronic myeloid leukemia: past, present, and future</span></div><div class="casAuthors">Pavlovsky, Carolina; Kantarjian, Hagop; Cortes, Jorge E.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">287-293</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The development of Bcr-Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML).  Std.-dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, producing considerably higher hematol., cytogenetic, and mol. response rates than seen with previous drug therapies.  However, although many patients respond well to std.-dose imatinib initially, some patients do not achieve adequate levels of response or discontinue therapy because of resistance.  One approach to improving treatment response with first-line imatinib may be to increase the imatinib dose (800 mg/day), although recent trial data indicate that overall increases in response rates may be modest.  Newer Bcr-Abl tyrosine kinase inhibitors can induce responses in patients with all phases of imatinib-resistant CML, even those with imatinib-resistant mutations in the BCR-ABL gene.  Furthermore, in initial studies, first-line dasatinib or nilotinib treatment has produced response rates that compare favorably with historical controls treated with imatinib, although confirmation is required from head-to-head clin. trials.  Future clin. approaches may include drug combinations, which may allow quiescent leukemia stem cells to be eradicated.  Further improvements in drug treatment for first-line CML are expected during the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxtuQ60rRVKrVg90H21EOLACvtfcHk0lgLiL2gjuRK-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFels78%253D&md5=3175d0a24157cb4999ff10fed401f5bd</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1002%2Fajh.21380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.21380%26sid%3Dliteratum%253Aachs%26aulast%3DPavlovsky%26aufirst%3DC.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%2BE.%26atitle%3DFirst-line%2520therapy%2520for%2520chronic%2520myeloid%2520leukemia%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2009%26volume%3D84%26spage%3D287%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Veach, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namavari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillarsetty, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santos, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beresten-Kochetkov, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambek, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Punzalan, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antczak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Jones, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Djaballah, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, S. M.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">5853</span><span class="NLM_x">–</span> <span class="NLM_lpage">5857</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070342g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5853-5857&author=D.+R.+Veachauthor=M.+Namavariauthor=N.+Pillarsettyauthor=E.+B.+Santosauthor=T.+Beresten-Kochetkovauthor=C.+Lambekauthor=B.+J.+Punzalanauthor=C.+Antczakauthor=P.+M.+Smith-Jonesauthor=H.+Djaballahauthor=B.+Clarksonauthor=S.+M.+Larson&title=Synthesis+and+biological+evaluation+of+a+fluorine-18+derivative+of+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm070342g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070342g%26sid%3Dliteratum%253Aachs%26aulast%3DVeach%26aufirst%3DD.%2BR.%26aulast%3DNamavari%26aufirst%3DM.%26aulast%3DPillarsetty%26aufirst%3DN.%26aulast%3DSantos%26aufirst%3DE.%2BB.%26aulast%3DBeresten-Kochetkov%26aufirst%3DT.%26aulast%3DLambek%26aufirst%3DC.%26aulast%3DPunzalan%26aufirst%3DB.%2BJ.%26aulast%3DAntczak%26aufirst%3DC.%26aulast%3DSmith-Jones%26aufirst%3DP.%2BM.%26aulast%3DDjaballah%26aufirst%3DH.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DLarson%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520fluorine-18%2520derivative%2520of%2520dasatinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5853%26epage%3D5857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Asaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashioka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1421</span><span class="NLM_x">–</span> <span class="NLM_lpage">1425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=1421-1425&author=T.+Asakiauthor=Y.+Sugiyamaauthor=T.+Hamamotoauthor=M.+Higashiokaauthor=M.+Umeharaauthor=H.+Naitoauthor=T.+Niwa&title=Design+and+synthesis+of+3-substituted+benzamide+derivatives+as+Bcr-Abl+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DHigashioka%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DM.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%25203-substituted%2520benzamide%2520derivatives%2520as%2520Bcr-Abl%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D1421%26epage%3D1425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-<i>b</i>]quinolines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2977</span><span class="NLM_x">–</span> <span class="NLM_lpage">2980</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2977-2980&author=D.+H.+Boschelliauthor=D.+Powellauthor=J.+M.+Golasauthor=F.+Boschelli&title=Inhibition+of+Src+kinase+activity+by+4-anilino-5%2C10-dihydro-pyrimido%5B4%2C5-b%5Dquinolines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DGolas%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520Src%2520kinase%2520activity%2520by%25204-anilino-5%252C10-dihydro-pyrimido%255B4%252C5-b%255Dquinolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2977%26epage%3D2980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0lgNiYe-4_nnYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group">Schenone, S.; Bruno, O.; Radi, M.; Botta, M.</span><span> </span><span class="NLM_article-title">New insights into small-molecule inhibitors of Bcr-Abl</span>.  <span class="citation_source-journal">Med. Res. Rev.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1002/med.20175</span> . Published online: August 27, 2009.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fmed.20175" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schenone%2C+S.%3B+Bruno%2C+O.%3B+Radi%2C+M.%3B+Botta%2C+M.+New+insights+into+small-molecule+inhibitors+of+Bcr-Abl.+Med.+Res.+Rev.+%5BOnline+early+access%5D.+DOI%3A+10.1002%2Fmed.20175.+Published+online%3A+August+27%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1002%2Fmed.20175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20175%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DNew%2520insights%2520into%2520small-molecule%2520inhibitors%2520of%2520Bcr-Abl%26jtitle%3DMed.%2520Res.%2520Rev.%26doi%3D10.1002%2Fmed.20175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group">Liao, J. J.-L.</span><span> </span><span class="NLM_article-title">Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0608107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=409-424&author=J.+J.-L.+Liao&title=Molecular+recognition+of+protein+kinase+binding+pockets+for+design+of+potent+and+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors</span></div><div class="casAuthors">Liao, Jeffrey Jie-Lou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Many kinase inhibitors have failed in preclin. or clin. development because of the lack of such selectivity that induces intolerable side effects, mostly because the catalytic cleft is highly conserved in sequence and conformation.  Systematic anal. of the crystal structures of protein kinases can offer insight into the design of highly selective kinase inhibitors to overcome these effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroDTl2SBUfbbVg90H21EOLACvtfcHk0lgNiYe-4_nnYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Cmsg%253D%253D&md5=77542d3ba589bd834a0d2b97a24eea05</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm0608107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0608107%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DJ.%2BJ.-L.%26atitle%3DMolecular%2520recognition%2520of%2520protein%2520kinase%2520binding%2520pockets%2520for%2520design%2520of%2520potent%2520and%2520selective%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D409%26epage%3D424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span><span class="NLM_x">–</span> <span class="NLM_lpage">5171</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149-5171&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+rational+inhibitor+design+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Pippin, Douglas A.; Salvino, Joseph M.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5149-5171</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review describing the use of Protein Data Bank (PDB) entries specifically for kinase inhibitor drug discovery.  Topics discussed include: the current state of structure-aided ligand design, kinase structure queries and extn. from the PDB, alignment of protein structures, structural classification of ligands, anal. of ligands and binding modes, and ligand design strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDINDYVE15cbVg90H21EOLACvtfcHk0lgNiYe-4_nnYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWmurnM&md5=a1afc4d6c7f6fa4dd6aa9da8d78f1ee3</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520rational%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149%26epage%3D5171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group">Alvarado, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, J.</span><span> </span><span class="NLM_article-title">Emerging role of Aurora kinase inhibitors in chronic myeloid leukemia</span> <span class="citation_source-journal">Clin. Leuk.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.3816%2FCLK.2007.n.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitFShu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=325-330&author=Y.+Alvaradoauthor=J.+Cort%C3%A9s&title=Emerging+role+of+Aurora+kinase+inhibitors+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging role of Aurora kinase inhibitors in chronic myeloid leukemia</span></div><div class="casAuthors">Alvarado, Yesid; Cortes, Jorge E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">325-330</span>CODEN:
                <span class="NLM_cas:coden">CLLEAW</span>;
        ISSN:<span class="NLM_cas:issn">1931-6925</span>.
    
            (<span class="NLM_cas:orgname">CIG Media Group</span>)
        </div><div class="casAbstract">A review.  Resistance to imatinib and second-generation tyrosine kinase inhibitors is an ongoing problem most frequently mediated through mutations of the Bcr-Abl kinase domain.  One mutation that affects responsiveness to all current available agents is T315I.  Aurora proteins belong to a small family of serine/threonine kinases that are essential for proliferating cells and have been identified as key regulators of different steps in mitosis and meiosis, ranging from the formation of the mitotic spindle up to cytokinesis.  Unexpectedly, Aurora kinase inhibitors have been found to have activity against the T315I bcr-abl mutation, and some of them might rise as important therapeutic options.  The common mechanism of action for protein kinase inhibition is competition with ATP for the active site-binding pocket, which is very similar among the protein kinases, and this could explain the cross-reactivity.  Herein, we discuss the basics of imatinib resistance development and Aurora kinase biol., and describe a selected group of Aurora kinase inhibitors with potential activity in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw6C8XyOCaKrVg90H21EOLACvtfcHk0liB2UhPIJdB0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitFShu7Y%253D&md5=ddd42b2ef6c8bb00fcbe6d8b668373e6</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.3816%2FCLK.2007.n.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLK.2007.n.025%26sid%3Dliteratum%253Aachs%26aulast%3DAlvarado%26aufirst%3DY.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26atitle%3DEmerging%2520role%2520of%2520Aurora%2520kinase%2520inhibitors%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Leuk.%26date%3D2007%26volume%3D1%26spage%3D325%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group">Shiotsu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umehara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozeki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoe, T.</span><span> </span><span class="NLM_article-title">KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1607</span><span class="NLM_x">–</span> <span class="NLM_lpage">1617</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1607-1617&author=Y.+Shiotsuauthor=H.+Kiyoiauthor=Y.+Ishikawaauthor=R.+Tanizakiauthor=M.+Shimizuauthor=H.+Umeharaauthor=K.+Ishiiauthor=Y.+Moriauthor=K.+Ozekiauthor=Y.+Minamiauthor=A.+Abeauthor=H.+Maedaauthor=T.+Akiyamaauthor=Y.+Kandaauthor=Y.+Satoauthor=S.+Akinagaauthor=T.+Naoe&title=KW-2449%2C+a+novel+multikinase+inhibitor%2C+suppresses+the+growth+of+leukemia+cells+with+FLT3+mutations+or+T315I-mutated+BCR%2FABL+translocation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShiotsu%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DR.%26aulast%3DShimizu%26aufirst%3DM.%26aulast%3DUmehara%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DOzeki%26aufirst%3DK.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DAbe%26aufirst%3DA.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DKanda%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DNaoe%26aufirst%3DT.%26atitle%3DKW-2449%252C%2520a%2520novel%2520multikinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520leukemia%2520cells%2520with%2520FLT3%2520mutations%2520or%2520T315I-mutated%2520BCR%252FABL%2520translocation%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1607%26epage%3D1617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group">Howard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fazal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heathcote, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tisi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinkovic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyatt, P. G.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">–</span> <span class="NLM_lpage">388</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800984v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=379-388&author=S.+Howardauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=J.+Curryauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=L.+Fazalauthor=A.+L.+Gillauthor=M.+Heathcoteauthor=S.+Mamanauthor=J.+E.+Matthewsauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=M.+Reuleauthor=D.+Tisiauthor=G.+Williamsauthor=M.+Vinkovicauthor=P.+G.+Wyatt&title=Fragment-based+discovery+of+the+pyrazol-4-yl+urea+%28AT9283%29%2C+a+multitargeted+kinase+inhibitor+with+potent+aurora+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Fjm800984v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800984v%26sid%3Dliteratum%253Aachs%26aulast%3DHoward%26aufirst%3DS.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DCurry%26aufirst%3DJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFazal%26aufirst%3DL.%26aulast%3DGill%26aufirst%3DA.%2BL.%26aulast%3DHeathcote%26aufirst%3DM.%26aulast%3DMaman%26aufirst%3DS.%26aulast%3DMatthews%26aufirst%3DJ.%2BE.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DTisi%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DVinkovic%26aufirst%3DM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520discovery%2520of%2520the%2520pyrazol-4-yl%2520urea%2520%2528AT9283%2529%252C%2520a%2520multitargeted%2520kinase%2520inhibitor%2520with%2520potent%2520aurora%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D379%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group">Bikker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooijmans, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansour, T. S.</span><span> </span><span class="NLM_article-title">Kinase domain mutations in cancer: implications for small molecule drug design strategies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1493</span><span class="NLM_x">–</span> <span class="NLM_lpage">1509</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8010542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1493-1509&author=J.+A.+Bikkerauthor=N.+Brooijmansauthor=A.+Wissnerauthor=T.+S.+Mansour&title=Kinase+domain+mutations+in+cancer%3A+implications+for+small+molecule+drug+design+strategies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies</span></div><div class="casAuthors">Bikker, Jack A.; Brooijmans, Natasja; Wissner, Allan; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1493-1509</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This review will provide a brief overview of kinase structure and function as it pertains to drug discovery, describe the location and importance of clin. mutations, and review the emerging understanding of their impact based on sequence homol., protein crystal complexes, and biochem./biophys. information.  Underlying this discussion is our appreciation that the current clin. arsenal of small mol. kinase inhibitors only contains the first weapons to be deployed in a long war against drug resistance mutations occurring in multiple kinases that target multiple cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBBjVt8P6JI7Vg90H21EOLACvtfcHk0liB2UhPIJdB0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCisr0%253D&md5=fa09d8a6e553ccd1bb1f093176ecb366</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fjm8010542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8010542%26sid%3Dliteratum%253Aachs%26aulast%3DBikker%26aufirst%3DJ.%2BA.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DKinase%2520domain%2520mutations%2520in%2520cancer%253A%2520implications%2520for%2520small%2520molecule%2520drug%2520design%2520strategies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1493%26epage%3D1509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group">Legros, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolini, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magaud, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassuto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michallet, M.</span><span> </span><span class="NLM_article-title">BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2204</span><span class="NLM_x">–</span> <span class="NLM_lpage">2206</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=2204-2206&author=L.+Legrosauthor=S.+Hayetteauthor=F.+E.+Nicoliniauthor=S.+Raynaudauthor=K.+Chabaneauthor=J.+P.+Magaudauthor=J.+P.+Cassutoauthor=M.+Michallet&title=BCR-ABL%28T315I%29+transcript+disappearance+in+an+imatinib-resistant+CML+patient+treated+with+homoharringtonine%3A+a+new+therapeutic+challenge%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLegros%26aufirst%3DL.%26aulast%3DHayette%26aufirst%3DS.%26aulast%3DNicolini%26aufirst%3DF.%2BE.%26aulast%3DRaynaud%26aufirst%3DS.%26aulast%3DChabane%26aufirst%3DK.%26aulast%3DMagaud%26aufirst%3DJ.%2BP.%26aulast%3DCassuto%26aufirst%3DJ.%2BP.%26aulast%3DMichallet%26aufirst%3DM.%26atitle%3DBCR-ABL%2528T315I%2529%2520transcript%2520disappearance%2520in%2520an%2520imatinib-resistant%2520CML%2520patient%2520treated%2520with%2520homoharringtonine%253A%2520a%2520new%2520therapeutic%2520challenge%253F%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D2204%26epage%3D2206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velentza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnchembio760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16415863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=95-102&author=F.+J.+Adrianauthor=Q.+Dingauthor=T.+Simauthor=A.+Velentzaauthor=C.+Sloanauthor=Y.+Liuauthor=G.+Zhangauthor=W.+Hurauthor=S.+Dingauthor=P.+Manleyauthor=J.+Mestanauthor=D.+Fabbroauthor=N.+S.+Gray&title=Allosteric+inhibitors+of+Bcr-abl-dependent+cell+proliferation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibitors of Bcr-abl-dependent cell proliferation</span></div><div class="casAuthors">Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Doriano; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-102</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the mol. level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity.  Encouraged by the clin. validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacol. agents that could target this kinase by a distinct mechanism.  We report the discovery of a new class of Bcr-abl inhibitors using an unbiased differential cytotoxicity screen of a combinatorial kinase-directed heterocycle library.  Compds. in this class (exemplified by GNF-2) show exclusive antiproliferative activity toward Bcr-abl-transformed cells, with potencies similar to imatinib, while showing no inhibition of the kinase activity of full-length or catalytic domain of c-abl.  We propose that this new class of compds. inhibits Bcr-abl kinase activity through an allosteric non-ATP competitive mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqjXG0lHqHurVg90H21EOLACvtfcHk0lgLDIgx_6M8Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvF2rsA%253D%253D&md5=c8617fecb6092d71ae163e7cda1e8f94</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fnchembio760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio760%26sid%3Dliteratum%253Aachs%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DSloan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DAllosteric%2520inhibitors%2520of%2520Bcr-abl-dependent%2520cell%2520proliferation%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D95%26epage%3D102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group">Gumireddy, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosenza, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robell, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1992</span><span class="NLM_x">–</span> <span class="NLM_lpage">1997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=1992-1997&author=K.+Gumireddyauthor=S.+J.+Bakerauthor=S.+C.+Cosenzaauthor=P.+Johnauthor=A.+D.+Kangauthor=K.+A.+Robellauthor=M.+V.+Reddyauthor=E.+P.+Reddy&title=A+non-ATP-competitive+inhibitor+of+BCR-ABL+overrides+imatinib+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGumireddy%26aufirst%3DK.%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DCosenza%26aufirst%3DS.%2BC.%26aulast%3DJohn%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DA.%2BD.%26aulast%3DRobell%26aufirst%3DK.%2BA.%26aulast%3DReddy%26aufirst%3DM.%2BV.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DA%2520non-ATP-competitive%2520inhibitor%2520of%2520BCR-ABL%2520overrides%2520imatinib%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2005%26volume%3D102%26spage%3D1992%26epage%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span> </span><span class="NLM_article-title">Experimental non-ATP-competitive therapies for chronic myelogenous leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">932</span><span class="NLM_x">–</span> <span class="NLM_lpage">940</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=932-940&author=A.+Quintas-Cardama&title=Experimental+non-ATP-competitive+therapies+for+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26atitle%3DExperimental%2520non-ATP-competitive%2520therapies%2520for%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DLeukemia%26date%3D2008%26volume%3D22%26spage%3D932%26epage%3D940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group">Sanz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo-Coco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowenberg, B.</span><span> </span><span class="NLM_article-title">FLT3 inhibition as a targeted therapy for acute myeloid leukemia</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">594</span><span class="NLM_x">–</span> <span class="NLM_lpage">600</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FCCO.0b013e32833118fd" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19684517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=594-600&author=M.+Sanzauthor=A.+Burnettauthor=F.+Lo-Cocoauthor=B.+Lowenberg&title=FLT3+inhibition+as+a+targeted+therapy+for+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibition as a targeted therapy for acute myeloid leukemia</span></div><div class="casAuthors">Sanz, Miguel; Burnett, Alan; Lo-Coco, Francesco; Loewenberg, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">594-600</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The management of acute myeloid leukemia (AML) presents significant challenges, and there remains a need for new therapies with greater efficacy and better tolerability than existing treatments.  An improved understanding of the genetic and mol. changes underlying AML can help both to guide treatment strategies and to predict clin. outcomes, thereby enabling more precise decision-making regarding the optimal treatment strategy for individual patients.  Recent findings: The tyrosine kinase receptor FLT3 plays an important role in the survival and proliferation of blasts, and approx. 25% of patients with AML have mutations in the FLT3 gene.  This protein is therefore an obvious therapeutic target in AML.  Amongst recently developed tyrosine kinase inhibitors of FLT3, lestaurtinib and midostaurin are two orally bioavailable agents that have shown encouraging activity, both preclinically and in relapsed AML, and are now in phase III clin. trials.  These agents are also being tested in combination with conventional chemotherapy.  Summary: Oral FLT3 inhibitors offer a hope of improved treatment outcomes for patients with relapsed and newly diagnosed AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD1m-wC-8Zk7Vg90H21EOLACvtfcHk0lgLDIgx_6M8Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjurvL&md5=223ec76f11ca4fdc147267be5a7fbc25</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e32833118fd&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e32833118fd%26sid%3Dliteratum%253Aachs%26aulast%3DSanz%26aufirst%3DM.%26aulast%3DBurnett%26aufirst%3DA.%26aulast%3DLo-Coco%26aufirst%3DF.%26aulast%3DLowenberg%26aufirst%3DB.%26atitle%3DFLT3%2520inhibition%2520as%2520a%2520targeted%2520therapy%2520for%2520acute%2520myeloid%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2009%26volume%3D21%26spage%3D594%26epage%3D600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group">Scheijen, B.; Griffin, J. D.</span><span> </span><span class="NLM_article-title">Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target in Leukemia</span>. In  <span class="citation_source-book">Protein Tyrosine Kinases: From Inhibitors to Useful Drugs</span>; <span class="NLM_contrib-group">Fabbro, D.; McCormick, F.</span>, Eds.; <span class="NLM_publisher-name">Humana Press, Inc.</span>: <span class="NLM_publisher-loc">Totowa, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">93</span>− <span class="NLM_lpage">114</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=93-114&author=B.+Scheijen&author=J.+D.+Griffinauthor=D.+Fabbro&author=F.+McCormick&title=Protein+Tyrosine+Kinases%3A+From+Inhibitors+to+Useful+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DScheijen%26aufirst%3DB.%26atitle%3DActivated%2520FLT3%2520Receptor%2520Tyrosine%2520Kinase%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Leukemia%26btitle%3DProtein%2520Tyrosine%2520Kinases%253A%2520From%2520Inhibitors%2520to%2520Useful%2520Drugs%26aulast%3DFabbro%26aufirst%3DD.%26pub%3DHumana%2520Press%252C%2520Inc%26date%3D2006%26spage%3D93%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group">Stone, R. M.</span><span> </span><span class="NLM_article-title">Induction and postremission therapy: new agents</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">496</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=496-498&author=R.+M.+Stone&title=Induction+and+postremission+therapy%3A+new+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26atitle%3DInduction%2520and%2520postremission%2520therapy%253A%2520new%2520agents%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D496%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group">Adolfsson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buza-Vidas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hultquist, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liuba, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryder, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borge, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoren, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sitnicka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sigvardsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, S. E.</span><span> </span><span class="NLM_article-title">Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">121</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">–</span> <span class="NLM_lpage">306</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2005&pages=295-306&author=J.+Adolfssonauthor=R.+Manssonauthor=N.+Buza-Vidasauthor=A.+Hultquistauthor=K.+Liubaauthor=C.+T.+Jensenauthor=D.+Bryderauthor=L.+Yangauthor=O.+J.+Borgeauthor=L.+A.+Thorenauthor=K.+Andersonauthor=E.+Sitnickaauthor=Y.+Sasakiauthor=M.+Sigvardssonauthor=S.+E.+Jacobsen&title=Identification+of+Flt3%2B+lympho-myeloid+stem+cells+lacking+erythro-megakaryocytic+potential+a+revised+road+map+for+adult+blood+lineage+commitment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdolfsson%26aufirst%3DJ.%26aulast%3DMansson%26aufirst%3DR.%26aulast%3DBuza-Vidas%26aufirst%3DN.%26aulast%3DHultquist%26aufirst%3DA.%26aulast%3DLiuba%26aufirst%3DK.%26aulast%3DJensen%26aufirst%3DC.%2BT.%26aulast%3DBryder%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBorge%26aufirst%3DO.%2BJ.%26aulast%3DThoren%26aufirst%3DL.%2BA.%26aulast%3DAnderson%26aufirst%3DK.%26aulast%3DSitnicka%26aufirst%3DE.%26aulast%3DSasaki%26aufirst%3DY.%26aulast%3DSigvardsson%26aufirst%3DM.%26aulast%3DJacobsen%26aufirst%3DS.%2BE.%26atitle%3DIdentification%2520of%2520Flt3%252B%2520lympho-myeloid%2520stem%2520cells%2520lacking%2520erythro-megakaryocytic%2520potential%2520a%2520revised%2520road%2520map%2520for%2520adult%2520blood%2520lineage%2520commitment%26jtitle%3DCell%26date%3D2005%26volume%3D121%26spage%3D295%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group">Levis, M.; Brown, P.; Small, D.</span><span> </span><span class="NLM_article-title">FLT3: A Receptor Tyrosine Kinase Target in Adult and Pediatric AML</span>. In  <span class="citation_source-book">Innovative Leukemia and Lymphoma Therapy</span>; <span class="NLM_contrib-group">Kaspers, G. J. L.; Coiffier, B.; Heinrich, M. C.; Estey, E.</span>, Eds.; <span class="NLM_publisher-name">Informa Healthcare USA, Inc.</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">379</span>− <span class="NLM_lpage">410</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=379-410&author=M.+Levis&author=P.+Brown&author=D.+Smallauthor=G.+J.+L.+Kaspers&author=B.+Coiffier&author=M.+C.+Heinrich&author=E.+Estey&title=Innovative+Leukemia+and+Lymphoma+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26atitle%3DFLT3%253A%2520A%2520Receptor%2520Tyrosine%2520Kinase%2520Target%2520in%2520Adult%2520and%2520Pediatric%2520AML%26btitle%3DInnovative%2520Leukemia%2520and%2520Lymphoma%2520Therapy%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26pub%3DInforma%2520Healthcare%2520USA%252C%2520Inc%26date%3D2008%26spage%3D379%26epage%3D410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">54</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1182%2Fblood-2004-03-0891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15345597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=54-60&author=R.+M.+Stoneauthor=D.+J.+DeAngeloauthor=V.+Klimekauthor=I.+Galinskyauthor=E.+Esteyauthor=S.+D.+Nimerauthor=W.+Grandinauthor=D.+Lebwohlauthor=Y.+Wangauthor=P.+Cohenauthor=E.+A.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Patients+with+acute+myeloid+leukemia+and+an+activating+mutation+in+FLT3+respond+to+a+small-molecule+FLT3+tyrosine+kinase+inhibitor%2C+PKC412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412</span></div><div class="casAuthors">Stone, Richard M.; DeAngelo, Daniel J.; Klimek, Virginia; Galinsky, Ilene; Estey, Eli; Nimer, Stephen D.; Grandin, Wilson; Lebwohl, David; Wang, Yanfeng; Cohen, Pamela; Fox, Edward A.; Neuberg, Donna; Clark, Jennifer; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-60</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy.  We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth.  The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiol.  The peripheral blast count decreased by 50% in 14 patients (70%).  Seven patients (35%) experienced a greater than 2-log redn. in peripheral blast count for at least 4 wk (median response duration, 13 wk; range, 9-47 wk); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%).  FLT3 autophosphorylation was inhibited in most of the responding patients, indicating in vivo target inhibition at the dose schedule used in this study.  PKC412 is an oral tyrosine kinase inhibitor with clin. activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu297bLj2zDLVg90H21EOLACvtfcHk0lgU0rlgEKMp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXis1GksA%253D%253D&md5=8683325acf03f9cb523b7b8564c531b8</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1182%2Fblood-2004-03-0891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2004-03-0891%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%2BA.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPatients%2520with%2520acute%2520myeloid%2520leukemia%2520and%2520an%2520activating%2520mutation%2520in%2520FLT3%2520respond%2520to%2520a%2520small-molecule%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%252C%2520PKC412%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D54%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FS1535-6108%2802%2900069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12124173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=433-443&author=E.+Weisbergauthor=C.+Boultonauthor=L.+M.+Kellyauthor=P.+Manleyauthor=D.+Fabbroauthor=T.+Meyerauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Inhibition+of+mutant+FLT3+receptors+in+leukemia+cells+by+the+small+molecule+tyrosine+kinase+inhibitor+PKC412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</span></div><div class="casAuthors">Weisberg, Ellen; Boulton, Christina; Kelly, Louise M.; Manley, Paul; Fabbro, Doriano; Meyer, Thomas; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">433-443</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Constitutively activating FLT3 receptor mutations have been found in 35% of patients with acute myeloblastic leukemia (AML).  Here we report the identification of a small mol. FLT3 tyrosine kinase inhibitor PKC412, which selectively induced G1 arrest and apoptosis of Ba/F3 cell lines expressing mutant FLT3 (IC50 < 10 nM) by directly inhibiting the tyrosine kinase.  Ba/F3-FLT3 cell lines made resistant to PKC412 demonstrated overexpression of mutant FLT3, confirming that FLT3 is the target of this drug.  Finally, progressive leukemia was prevented in PKC412-treated Balb/c mice transplanted with marrow transduced with a FLT3-ITD-expressing retrovirus.  PKC412 is a potent inhibitor of mutant FLT3 and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq5mVxGyiCu7Vg90H21EOLACvtfcHk0lglS9S1bgnXEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVKjsb4%253D&md5=612331d927bd2ca41319b77aaea6cfd1</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900069-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DBoulton%26aufirst%3DC.%26aulast%3DKelly%26aufirst%3DL.%2BM.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DInhibition%2520of%2520mutant%2520FLT3%2520receptors%2520in%2520leukemia%2520cells%2520by%2520the%2520small%2520molecule%2520tyrosine%2520kinase%2520inhibitor%2520PKC412%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D1%26spage%3D433%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">App, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">2588</span><span class="NLM_x">–</span> <span class="NLM_lpage">2603</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980123i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=2588-2603&author=L.+Sunauthor=N.+Tranauthor=F.+Tangauthor=H.+Appauthor=P.+Hirthauthor=G.+McMahonauthor=C.+Tang&title=Synthesis+and+biological+evaluations+of+3-substituted+indolin-2-ones%3A+a+novel+class+of+tyrosine+kinase+inhibitors+that+exhibit+selectivity+toward+particular+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases</span></div><div class="casAuthors">Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2588-2603</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs).  These compds. have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells.  By modifying the 3-substituted indolin-2-ones, we have identified compds. which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells.  Structure-activity anal. for these compds. and their relative potency and selectivity to inhibit particular RTKs has detd. that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-(substituted benzylidenyl)indolin-2-ones contg. bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compd. contg. an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs.  Recent published crystallog. data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compds. may bind in the ATP binding pocket of RTKs.  The structure-activity anal. supports the use of subsets of these compds. as specific chem. leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoPixq8Am5rVg90H21EOLACvtfcHk0lglS9S1bgnXEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkt12jtrw%253D&md5=536302b717170a630008dac14832204c</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm980123i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980123i%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DTran%26aufirst%3DN.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DApp%26aufirst%3DH.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DMcMahon%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluations%2520of%25203-substituted%2520indolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520tyrosine%2520kinase%2520inhibitors%2520that%2520exhibit%2520selectivity%2520toward%2520particular%2520receptor%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D2588%26epage%3D2603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4- dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-+dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-+dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase</span></div><div class="casAuthors">Sun, Li; Liang, Chris; Shirazian, Sheri; Zhou, Yong; Miller, Todd; Cui, Jean; Fukuda, Juri Y.; Chu, Ji-Yu; Nematalla, Asaad; Wang, Xueyan; Chen, Hui; Sistla, Anand; Luu, Tony C.; Tang, Flora; Wei, James; Tang, Cho</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1116-1119</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To improve the antitumor properties and optimize the pharmaceutical properties including soly. and protein binding of indolin-2-ones, a series of different basic and weakly basic pyrrolylmethylidene indolinones I [R1 = H, F, Cl, Br; R2 = Et2NCH2CH2, pyridin-4-ylmethyl, 2-(1,2,3-triazol-1-yl)ethyl, etc.] were designed and synthesized.  Indolinone I [R1 = F, R2 = Et2NCH2CH2 (II)] showed the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rβ tyrosine kinase at biochem. and cellular levels, soly., protein binding, and bioavailability.  II is currently in phase I clin. trials for the treatment of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptdQJ1VSPq8bVg90H21EOLACvtfcHk0lglS9S1bgnXEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSlsbg%253D&md5=f6570cfa1ae4e31703c741d90fe65382</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-%2520dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-%2520dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannah, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopeck, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span> </span><span class="NLM_article-title">Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia</span> <span class="citation_source-journal">Leuk. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">689</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.leukres.2003.11.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15158089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Smsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2004&pages=679-689&author=A.+M.+O%E2%80%99Farrellauthor=H.+A.+Yuenauthor=B.+Smolichauthor=A.+L.+Hannahauthor=S.+G.+Louieauthor=W.+Hongauthor=A.+T.+Stopeckauthor=L.+R.+Silvermanauthor=J.+E.+Lancetauthor=J.+E.+Karpauthor=M.+Albitarauthor=J.+M.+Cherringtonauthor=F.+J.+Giles&title=Effects+of+SU5416%2C+a+small+molecule+tyrosine+kinase+receptor+inhibitor%2C+on+FLT3+expression+and+phosphorylation+in+patients+with+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia</span></div><div class="casAuthors">O'Farrell, Anne-Marie; Yuen, Helene A.; Smolich, Beverly; Hannah, Alison L.; Louie, Sharianne G.; Hong, Weiru; Stopeck, Alison T.; Silverman, Lewis R.; Lancet, Jeffrey E.; Karp, Judith E.; Albitar, Maher; Cherrington, Julie M.; Giles, Francis J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">679-689</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) is assocd. with dysregulated hematopoietic cell proliferation and increased bone marrow angiogenesis, each regulated by signaling through receptor tyrosine kinases (RTKs).  SU5416 is a small mol. inhibitor of VEGF receptors, c-kit and FLT3 and therefore provides a novel opportunity to target both angiogenesis and proliferation in AML.  SU5416 was assessed in a phase II hematol. malignancy trial in the US, where partial responses were obsd. in two of 33 patients.  Since AML provides a unique platform to evaluate mechanism of action of small mol. inhibitors, investigation of the effect of SU5416 on FLT3 expression and phosphorylation in blood and bone marrow was an addnl. focus of this trial.  Phosphorylated FLT3 was detected by immunopptn./Western anal. in peripheral blood samples from 17 of 22 patients, and seven exhibited strong inhibition of phosphorylation immediately following a 1 h SU5416 infusion, demonstrating that SU5416 can modulate RTK phosphorylation in humans.  Although no clear correlation with clin. response was obsd., anal. of patient plasma drug levels suggested that a threshold SU5416 concn. of 15 μM was assocd. with FLT3 inhibition.  This observation was supported by data from an ex vivo model where AML cells were spiked into human blood, established to mimic the clin. setting and enable more rigorous anal. of effect of SU5416.  In addn., FLT3 protein levels were downregulated in patient bone marrow samples, analyzed by an RIA assay.  To identify putative predictors of response, patient plasma was analyzed for levels of secreted ligands of SU5416 targets; SCF and FLT3 ligand.  Baseline levels of SCF in patients with stable or progressive disease were significantly higher than those in normal donors, whereas FLT3 ligand levels in patients who exhibited progressive disease were significantly lower than those in normal donors.  The translational and clin. analyses described in this report provide some insights into the mechanism and duration of action of SU5416.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbKgOa_gMmDLVg90H21EOLACvtfcHk0liixgQaMGTofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Smsb8%253D&md5=343e7e6afadc2dffc09c6304e44b98b0</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2003.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2003.11.004%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DSmolich%26aufirst%3DB.%26aulast%3DHannah%26aufirst%3DA.%2BL.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DStopeck%26aufirst%3DA.%2BT.%26aulast%3DSilverman%26aufirst%3DL.%2BR.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26atitle%3DEffects%2520of%2520SU5416%252C%2520a%2520small%2520molecule%2520tyrosine%2520kinase%2520receptor%2520inhibitor%252C%2520on%2520FLT3%2520expression%2520and%2520phosphorylation%2520in%2520patients%2520with%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeuk.%2520Res.%26date%3D2004%26volume%3D28%26spage%3D679%26epage%3D689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwittay, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottmann, O. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massimini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scigalla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossfeld, D. K.</span><span> </span><span class="NLM_article-title">A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">986</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2005&pages=986-993&author=W.+Fiedlerauthor=H.+Serveauthor=H.+Dohnerauthor=M.+Schwittayauthor=O.+G.+Ottmannauthor=A.+M.+O%E2%80%99Farrellauthor=C.+L.+Belloauthor=R.+Allredauthor=W.+C.+Manningauthor=J.+M.+Cherringtonauthor=S.+G.+Louieauthor=W.+Hongauthor=N.+M.+Bregaauthor=G.+Massiminiauthor=P.+Scigallaauthor=W.+E.+Berdelauthor=D.+K.+Hossfeld&title=A+phase+1+study+of+SU11248+in+the+treatment+of+patients+with+refractory+or+resistant+acute+myeloid+leukemia+%28AML%29+or+not+amenable+to+conventional+therapy+for+the+disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DDohner%26aufirst%3DH.%26aulast%3DSchwittay%26aufirst%3DM.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DAllred%26aufirst%3DR.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DBrega%26aufirst%3DN.%2BM.%26aulast%3DMassimini%26aufirst%3DG.%26aulast%3DScigalla%26aufirst%3DP.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DHossfeld%26aufirst%3DD.%2BK.%26atitle%3DA%2520phase%25201%2520study%2520of%2520SU11248%2520in%2520the%2520treatment%2520of%2520patients%2520with%2520refractory%2520or%2520resistant%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520or%2520not%2520amenable%2520to%2520conventional%2520therapy%2520for%2520the%2520disease%26jtitle%3DBlood%26date%3D2005%26volume%3D105%26spage%3D986%26epage%3D993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yatsula, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burd, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocks, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abriola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasavada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span> </span><span class="NLM_article-title">Antitumor activity of sorafenib in FLT3-driven leukemic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=439-445&author=D.+Auclairauthor=D.+Millerauthor=V.+Yatsulaauthor=W.+Pickettauthor=C.+Carterauthor=Y.+Changauthor=X.+Zhangauthor=D.+Wilkieauthor=A.+Burdauthor=H.+Shiauthor=S.+Rocksauthor=R.+Gedrichauthor=L.+Abriolaauthor=H.+Vasavadaauthor=M.+Lynchauthor=J.+Dumasauthor=P.+A.+Trailauthor=S.+M.+Wilhelm&title=Antitumor+activity+of+sorafenib+in+FLT3-driven+leukemic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DYatsula%26aufirst%3DV.%26aulast%3DPickett%26aufirst%3DW.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DBurd%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DRocks%26aufirst%3DS.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DAbriola%26aufirst%3DL.%26aulast%3DVasavada%26aufirst%3DH.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26atitle%3DAntitumor%2520activity%2520of%2520sorafenib%2520in%2520FLT3-driven%2520leukemic%2520cells%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D439%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">198</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1093%2Fjnci%2Fdjm328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18230792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2008&pages=184-198&author=W.+Zhangauthor=M.+Konoplevaauthor=Y.+X.+Shiauthor=T.+McQueenauthor=D.+Harrisauthor=X.+Lingauthor=Z.+Estrovauthor=A.+Quintas-Cardamaauthor=D.+Smallauthor=J.+Cortesauthor=M.+Andreeff&title=Mutant+FLT3%3A+a+direct+target+of+sorafenib+in+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</span></div><div class="casAuthors">Zhang, Weiguo; Konopleva, Marina; Shi, Yue-xi; McQueen, Teresa; Harris, David; Ling, Xiaoyang; Estrov, Zeev; Quintas-Cardama, Alfonso; Small, Donald; Cortes, Jorge; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">184-198</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Internal tandem duplication (ITD) mutations in the juxtamembrane domain-coding sequence of the Fms-like tyrosine kinase 3 (FLT3) gene have been identified in 30% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  The kinase inhibitor sorafenib induces growth arrest and apoptosis at much lower concns. in AML cell lines that harbor FLT3-ITD mutations than in AML cell lines with wild-type FLT3.  The antileukemic activity of sorafenib was investigated in isogenic murine Ba/F3 AML cell lines that expressed mutant (ITD, D835G, and D835Y) or wild-type human FLT3, in primary human AML cells, and in a mouse leukemia xenograft model.  Effects of sorafenib on apoptosis and signaling in AML cell lines were investigated by flow cytometry and immunoblot anal., resp., and the in vivo effects were detd. by monitoring the survival of leukemia xenograft-bearing mice treated with sorafenib (groups of 15 mice).  In a phase 1 clin. trial, 16 patients with refractory or relapsed AML were treated with sorafenib on different dose schedules.  We detd. their FLT3 mutation status by a polymerase chain reaction assay and analyzed clin. responses by std. criteria.  All statistical tests were two-sided.  Sorafenib was 1000- to 3000-fold more effective in inducing growth arrest and apoptosis in Ba/F3 cells with FLT3-ITD or D835G mutations than in Ba/F3 cells with FLT3-D835Y mutant or wild-type FLT3 and inhibited the phosphorylation of tyrosine residues in ITD mutant but not wild-type FLT3 protein.  In a mouse model, sorafenib decreased the leukemia burden and prolonged survival (median survival in the sorafenib-treated group vs the vehicle-treated group = 36.5 vs 16 days, difference = 20.5 days, 95% confidence interval = 20.3 to 21.3 days; P = .0018).  Sorafenib reduced the percentage of leukemia blasts in the peripheral blood and the bone marrow of AML patients with FLT3-ITD (median percentages before and after sorafenib: 81% vs. 7.5% [P = .016] and 75.5% vs. 34% [P = .05], resp.) but not in patients without this mutation.  Sorafenib may have therapeutic efficacy in AML patients whose cells harbor FLT3-ITD mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNBWJSPfrsN7Vg90H21EOLACvtfcHk0liixgQaMGTofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivFygsrY%253D&md5=d747b1107866a0299c972c1bcd58c770</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjm328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjm328%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BX.%26aulast%3DMcQueen%26aufirst%3DT.%26aulast%3DHarris%26aufirst%3DD.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DMutant%2520FLT3%253A%2520a%2520direct%2520target%2520of%2520sorafenib%2520in%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2008%26volume%3D100%26spage%3D184%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group">Renhowe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pecchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shafer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machajewski, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonios-McCrea, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frazier, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feucht, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menezes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vora, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jansen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernette-Hammond, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Design, structure activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">278</span><span class="NLM_x">–</span> <span class="NLM_lpage">292</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=278-292&author=P.+A.+Renhoweauthor=S.+Pecchiauthor=C.+M.+Shaferauthor=T.+D.+Machajewskiauthor=E.+M.+Jazanauthor=C.+Taylorauthor=W.+Antonios-McCreaauthor=C.+M.+McBrideauthor=K.+Frazierauthor=M.+Wiesmannauthor=G.+R.+Lapointeauthor=P.+H.+Feuchtauthor=R.+L.+Warneauthor=C.+C.+Heiseauthor=D.+Menezesauthor=K.+Aardalenauthor=H.+Yeauthor=M.+Heauthor=V.+Leauthor=J.+Voraauthor=J.+M.+Jansenauthor=M.+E.+Wernette-Hammondauthor=A.+L.+Harris&title=Design%2C+structure+activity+relationships+and+in+vivo+characterization+of+4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%3A+a+novel+class+of+receptor+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DShafer%26aufirst%3DC.%2BM.%26aulast%3DMachajewski%26aufirst%3DT.%2BD.%26aulast%3DJazan%26aufirst%3DE.%2BM.%26aulast%3DTaylor%26aufirst%3DC.%26aulast%3DAntonios-McCrea%26aufirst%3DW.%26aulast%3DMcBride%26aufirst%3DC.%2BM.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DLapointe%26aufirst%3DG.%2BR.%26aulast%3DFeucht%26aufirst%3DP.%2BH.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26aulast%3DHeise%26aufirst%3DC.%2BC.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DV.%26aulast%3DVora%26aufirst%3DJ.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DWernette-Hammond%26aufirst%3DM.%2BE.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DDesign%252C%2520structure%2520activity%2520relationships%2520and%2520in%2520vivo%2520characterization%2520of%25204-amino-3-benzimidazol-2-ylhydroquinolin-2-ones%253A%2520a%2520novel%2520class%2520of%2520receptor%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D52%26spage%3D278%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group">Clark, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curley, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lokker, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">2867</span><span class="NLM_x">–</span> <span class="NLM_lpage">2872</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2867-2872&author=J.+J.+Clarkauthor=J.+Coolsauthor=D.+P.+Curleyauthor=J.+C.+Yuauthor=N.+A.+Lokkerauthor=N.+A.+Gieseauthor=D.+G.+Gilliland&title=Variable+sensitivity+of+FLT3+activation+loop+mutations+to+the+small+molecule+tyrosine+kinase+inhibitor+MLN518"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DJ.%2BJ.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DCurley%26aufirst%3DD.%2BP.%26aulast%3DYu%26aufirst%3DJ.%2BC.%26aulast%3DLokker%26aufirst%3DN.%2BA.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DVariable%2520sensitivity%2520of%2520FLT3%2520activation%2520loop%2520mutations%2520to%2520the%2520small%2520molecule%2520tyrosine%2520kinase%2520inhibitor%2520MLN518%26jtitle%3DBlood%26date%3D2004%26volume%3D104%26spage%3D2867%26epage%3D2872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5182</span><span class="NLM_x">–</span> <span class="NLM_lpage">5185</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5182-5185&author=H.+K.+Patelauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=J.+Jamesauthor=D.+K.+Treiberauthor=D.+J.+Lockhartauthor=P.+P.+Zarrinkarauthor=S.+S.+Bhagwat&title=Arylcarboxyamino-substituted+diaryl+ureas+as+potent+and+selective+FLT3+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DArylcarboxyamino-substituted%2520diaryl%2520ureas%2520as%2520potent%2520and%2520selective%2520FLT3%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5182%26epage%3D5185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(5-<i>tert</i>-butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7808</span><span class="NLM_x">–</span> <span class="NLM_lpage">7816</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-butyl-isoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+dihydrochloride+%28AC220%29%2C+a+uniquely+potent%2C+selective%2C+and+efficacious+FMS-like+tyrosine+kinase-3+%28FLT3%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-butyl-isoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520dihydrochloride%2520%2528AC220%2529%252C%2520a%2520uniquely%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghirdaladze, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVetten, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zodelava, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarringkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padre, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corringham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trikha, M.</span><span> </span><span class="NLM_article-title">AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-in-human (FIH) ohase 1 AML study</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">636</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=636&author=J.+Cortesauthor=J.+Foranauthor=D.+Ghirdaladzeauthor=M.+P.+DeVettenauthor=M.+Zodelavaauthor=P.+Holmanauthor=M.+J.+Levisauthor=H.+M.+Kantarjianauthor=G.+Borthakurauthor=J.+Jamesauthor=P.+P.+Zarringkarauthor=R.+N.+Gunawardaneauthor=R.+C.+Armstrongauthor=N.+M.+Padreauthor=W.+Wierengaauthor=R.+Corringhamauthor=M.+Trikha&title=AC220%2C+a+potent%2C+selective%2C+second+generation+FLT3+receptor+tyrosine+kinase+%28RTK%29+inhibitor%2C+in+a+first-in-human+%28FIH%29+ohase+1+AML+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DForan%26aufirst%3DJ.%26aulast%3DGhirdaladze%26aufirst%3DD.%26aulast%3DDeVetten%26aufirst%3DM.%2BP.%26aulast%3DZodelava%26aufirst%3DM.%26aulast%3DHolman%26aufirst%3DP.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarringkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DPadre%26aufirst%3DN.%2BM.%26aulast%3DWierenga%26aufirst%3DW.%26aulast%3DCorringham%26aufirst%3DR.%26aulast%3DTrikha%26aufirst%3DM.%26atitle%3DAC220%252C%2520a%2520potent%252C%2520selective%252C%2520second%2520generation%2520FLT3%2520receptor%2520tyrosine%2520kinase%2520%2528RTK%2529%2520inhibitor%252C%2520in%2520a%2520first-in-human%2520%2528FIH%2529%2520ohase%25201%2520AML%2520study%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2009%26volume%3D114%26spage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foran, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devetten, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padre, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, W.</span><span> </span><span class="NLM_article-title">Human pharmacokinetics of AC220, a potent and selective class III receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">ASH Annu. Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">1597</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=1597&author=J.+Cortesauthor=J.+M.+Foranauthor=M.+P.+Devettenauthor=F.+J.+Gilesauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=M.+H.+Silvermanauthor=K.+A.+Kellyauthor=N.+M.+Padreauthor=S.+Bhagwatauthor=W.+Wierenga&title=Human+pharmacokinetics+of+AC220%2C+a+potent+and+selective+class+III+receptor+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DDevetten%26aufirst%3DM.%2BP.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSilverman%26aufirst%3DM.%2BH.%26aulast%3DKelly%26aufirst%3DK.%2BA.%26aulast%3DPadre%26aufirst%3DN.%2BM.%26aulast%3DBhagwat%26aufirst%3DS.%26aulast%3DWierenga%26aufirst%3DW.%26atitle%3DHuman%2520pharmacokinetics%2520of%2520AC220%252C%2520a%2520potent%2520and%2520selective%2520class%2520III%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DASH%2520Annu.%2520Meet.%2520Abstr.%26date%3D2007%26volume%3D110%26spage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group">Schenone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brullo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botta, M.</span><span> </span><span class="NLM_article-title">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">3113</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F092986708786848613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19075657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=3113-3132&author=S.+Schenoneauthor=C.+Brulloauthor=M.+Botta&title=Small+molecules+ATP-competitive+inhibitors+of+FLT3%3A+a+chemical+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules ATP-competitive inhibitors of FLT3: a chemical overview</span></div><div class="casAuthors">Schenone, S.; Brullo, C.; Botta, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3113-3132</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  FLT3 is a tyrosine kinase (TK), member of the class III TK receptor family, normally expressed in hematopoietic, immune and neural systems, also playing an important role in the pathogenesis of acute leukemias, particularly acute myeloid leukemia (AML), where it is present in constitutively activated mutated forms, correlated with poor prognosis, in a notable percentage of patients.  For these reasons FLT3 soon appeared as a promising target for the therapeutic intervention for this severe and aggressive malignancy; the recent detn. of the crystal structure of the autoinhibited form of FLT3 gave new trend for the design and the synthesis of potent inhibitors.  Small mols. tyrosine kinase inhibitors represent one of the largest drug family currently targeted by pharmaceutical companies for the treatment of cancer.  Exciting examples of such mols. have reached advanced clin. trials and have been recently approved by FDA for the treatment of different solid or hematol. tumors.  Usually TK inhibitors share common features, namely two hydrophobic/arom. regions bearing one or more hydrogen bonding substituents.  These two regions can be connected by different spacers and almost all the mols. contain a component resembling the ATP purine structure.  This review will deal with FLT3 synthetic inhibitors, reporting not only the most important mols. that are in clin. trials, but also the new compds. that have appeared in literature in the last few years.  Our attention will be focused on chem. structures, mechanisms of action and structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMaEJysVaMAbVg90H21EOLACvtfcHk0lh5SKpZHeQ8tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptV2gsA%253D%253D&md5=f0d577bdb45e35fb063b98f35d9329d1</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.2174%2F092986708786848613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708786848613%26sid%3Dliteratum%253Aachs%26aulast%3DSchenone%26aufirst%3DS.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DBotta%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520ATP-competitive%2520inhibitors%2520of%2520FLT3%253A%2520a%2520chemical%2520overview%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D3113%26epage%3D3132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roesel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span> </span><span class="NLM_article-title">Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4451</span><span class="NLM_x">–</span> <span class="NLM_lpage">4454</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm060368s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4451-4454&author=P.+Furetauthor=G.+Boldauthor=T.+Meyerauthor=J.+Roeselauthor=V.+Guagnano&title=Aromatic+interactions+with+phenylalanine+691+and+cysteine+828%3A+a+concept+for+FMS-like+tyrosine+kinase-3+inhibition.+Application+to+the+discovery+of+a+new+class+of+potential+antileukemia+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Fjm060368s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060368s%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DRoesel%26aufirst%3DJ.%26aulast%3DGuagnano%26aufirst%3DV.%26atitle%3DAromatic%2520interactions%2520with%2520phenylalanine%2520691%2520and%2520cysteine%2520828%253A%2520a%2520concept%2520for%2520FMS-like%2520tyrosine%2520kinase-3%2520inhibition.%2520Application%2520to%2520the%2520discovery%2520of%2520a%2520new%2520class%2520of%2520potential%2520antileukemia%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4451%26epage%3D4454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0lh5SKpZHeQ8tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group">Padro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retzlaff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Tidow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesters, R. M.</span><span> </span><span class="NLM_article-title">Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1302-1310&author=T.+Padroauthor=R.+Biekerauthor=S.+Ruizauthor=M.+Steinsauthor=S.+Retzlaffauthor=H.+Burgerauthor=T.+Buchnerauthor=T.+Kesslerauthor=F.+Herreraauthor=J.+Kienastauthor=C.+Muller-Tidowauthor=H.+Serveauthor=W.+E.+Berdelauthor=R.+M.+Mesters&title=Overexpression+of+vascular+endothelial+growth+factor+%28VEGF%29+and+its+cellular+receptor+KDR+%28VEGFR-2%29+in+the+bone+marrow+of+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPadro%26aufirst%3DT.%26aulast%3DBieker%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DRetzlaff%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DBuchner%26aufirst%3DT.%26aulast%3DKessler%26aufirst%3DT.%26aulast%3DHerrera%26aufirst%3DF.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMesters%26aufirst%3DR.%2BM.%26atitle%3DOverexpression%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520and%2520its%2520cellular%2520receptor%2520KDR%2520%2528VEGFR-2%2529%2520in%2520the%2520bone%2520marrow%2520of%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26spage%3D1302%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group">Weidenaar, A. C.; de Jonge, H. J. M.; ter Elst, J.; de Bont, E. S. J. M.</span><span> </span><span class="NLM_article-title">Angiogenesis in Hematological Malignancies</span>. In  <span class="citation_source-book">Innovative Leukemia and Lymphoma Therapy</span>; <span class="NLM_contrib-group">Kaspers, G. J. L.; Coiffier, B.; Heinrich, M. C.; Estey, E.</span>, Eds.; <span class="NLM_publisher-name">Informa Healthcare USA, Inc.</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">283</span>− <span class="NLM_lpage">310</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=283-310&author=A.+C.+Weidenaar&author=H.+J.+M.+de+Jonge&author=J.+ter+Elst&author=E.+S.+J.+M.+de+Bontauthor=G.+J.+L.+Kaspers&author=B.+Coiffier&author=M.+C.+Heinrich&author=E.+Estey&title=Innovative+Leukemia+and+Lymphoma+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWeidenaar%26aufirst%3DA.%2BC.%26atitle%3DAngiogenesis%2520in%2520Hematological%2520Malignancies%26btitle%3DInnovative%2520Leukemia%2520and%2520Lymphoma%2520Therapy%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%2BL.%26pub%3DInforma%2520Healthcare%2520USA%252C%2520Inc%26date%3D2008%26spage%3D283%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group">Konopleva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Targeting the leukemia microenvironment</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">685</span><span class="NLM_x">–</span> <span class="NLM_lpage">701</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F138945007780830827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17584025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnvFagurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=685-701&author=M.+Konoplevaauthor=M.+Andreeff&title=Targeting+the+leukemia+microenvironment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the leukemia microenvironment</span></div><div class="casAuthors">Konopleva, Marina; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-701</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Normal hematopoiesis is maintained by dynamic interactions between hematopoietic cells and the bone marrow microenvironment.  In hematol. malignancies, there are reciprocal interactions between leukemic cells and cells of the bone marrow microenvironment such as stroma, osteoblasts and endothelium.  In this review, we will discuss the influence of the microenvironment on the evolution of the leukemic phenotype.  We propose that specific niches within the bone marrow microenvironment may provide a sanctuary for subpopulations of leukemic cells to evade chemotherapy-induced death and allow acquisition of a drug-resistant phenotype.  We will also discuss recent studies that suggest novel therapeutic interventions targeting the microenvironment/leukemia interaction.  Focus on this stroma-leukemia crosstalk may result in the development of strategies that alleviate the acquisition of a chemoresistant phenotype and enhance the efficacy of therapies in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIexfQEUYTtbVg90H21EOLACvtfcHk0lizpotCKYfIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnvFagurg%253D&md5=b8eb2e77c4b83f628b0d2857d7993cab</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.2174%2F138945007780830827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945007780830827%26sid%3Dliteratum%253Aachs%26aulast%3DKonopleva%26aufirst%3DM.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520leukemia%2520microenvironment%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2007%26volume%3D8%26spage%3D685%26epage%3D701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group">Limvorasak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posadas, E. M.</span><span> </span><span class="NLM_article-title">Pazopanib: therapeutic developments</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">3091</span><span class="NLM_x">–</span> <span class="NLM_lpage">3102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1517%2F14656560903436493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19954277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=3091-3102&author=S.+Limvorasakauthor=E.+M.+Posadas&title=Pazopanib%3A+therapeutic+developments"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Pazopanib: therapeutic developments</span></div><div class="casAuthors">Limvorasak, Suwicha; Posadas, Edwin M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3091-3102</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clin. development.  Like other orally available VEGFR inhibitors, pazopanib is clin. efficacious and well tolerated.  The recently reported Phase III clin. trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval.  Given the growing no. of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYSKDLcCNZq7Vg90H21EOLACvtfcHk0lizpotCKYfIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSqt7nO&md5=c05b4fdd434c65a702ec8d49d0d37236</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1517%2F14656560903436493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656560903436493%26sid%3Dliteratum%253Aachs%26aulast%3DLimvorasak%26aufirst%3DS.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26atitle%3DPazopanib%253A%2520therapeutic%2520developments%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2009%26volume%3D10%26spage%3D3091%26epage%3D3102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group">Laplante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">mTOR signaling at a glance</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">3589</span><span class="NLM_x">–</span> <span class="NLM_lpage">3594</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1242%2Fjcs.051011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19812304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3589-3594&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+at+a+glance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling at a glance</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3589-3594</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The authors highlight and summarize the current understanding of how mTOR nucleates distinct multiprotein complexes, how intra- and extracellular signals are processed by the mTOR complexes, and how such signals affect cell metab., growth, proliferation, and survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5es3QIlHS6bVg90H21EOLACvtfcHk0lizpotCKYfIZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKitrvP&md5=7be03ca7a8a3f52e0e974c784a0b9e73</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1242%2Fjcs.051011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.051011%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520at%2520a%2520glance%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3589%26epage%3D3594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group">Abdel-Karim, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span> </span><span class="NLM_article-title">Mammalian target of rapamycin as a target in hematological malignancies</span> <span class="citation_source-journal">Curr. Probl. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.currproblcancer.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18655914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1cvnvV2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2008&pages=161-177&author=I.+A.+Abdel-Karimauthor=F.+J.+Giles&title=Mammalian+target+of+rapamycin+as+a+target+in+hematological+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian target of rapamycin as a target in hematological malignancies</span></div><div class="casAuthors">Abdel-Karim Isam A; Giles Francis J</div><div class="citationInfo"><span class="NLM_cas:title">Current problems in cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">161-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHqulnkyE5ObjnyZkbE8yXfW6udTcc2ebuGAyJIMcRu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvnvV2qsg%253D%253D&md5=684db1ce616abf1a8964e571018cb7bf</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.currproblcancer.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.currproblcancer.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DAbdel-Karim%26aufirst%3DI.%2BA.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520as%2520a%2520target%2520in%2520hematological%2520malignancies%26jtitle%3DCurr.%2520Probl.%2520Cancer%26date%3D2008%26volume%3D32%26spage%3D161%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group">Yuan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span> </span><span class="NLM_article-title">Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">45</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1186%2F1756-8722-2-45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjlt1Cjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=45&author=R.+Yuanauthor=A.+Kayauthor=W.+J.+Bergauthor=D.+Lebwohl&title=Targeting+tumorigenesis%3A+development+and+use+of+mTOR+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy</span></div><div class="casAuthors">Yuan Ruirong; Kay Andrea; Berg William J; Lebwohl David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase positioned at a central point in a variety of cellular signaling cascades.  The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer has identified mTOR as a major link in tumorigenesis.  Consequently, inhibitors of mTOR, including temsirolimus, everolimus, and ridaforolimus (formerly deforolimus) have been developed and assessed for their safety and efficacy in patients with cancer.  Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of advanced renal cell carcinoma (RCC).  Everolimus is an oral agent that has recently obtained US FDA and EMEA approval for the treatment of advanced RCC after failure of treatment with sunitinib or sorafenib.  Ridaforolimus is not yet approved for any indication.  The use of mTOR inhibitors, either alone or in combination with other anticancer agents, has the potential to provide anticancer activity in numerous tumor types.  Cancer types in which these agents are under evaluation include neuroendocrine tumors, breast cancer, leukemia, lymphoma, hepatocellular carcinoma, gastric cancer, pancreatic cancer, sarcoma, endometrial cancer, and non-small-cell lung cancer.  The results of ongoing clinical trials with mTOR inhibitors, as single agents and in combination regimens, will better define their activity in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzXyuv_r_zDskU0YCbOU3EfW6udTcc2ebuGAyJIMcRu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjlt1Cjtw%253D%253D&md5=1d6d43cedd3187c881f7d29f21feb88b</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-2-45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-2-45%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DBerg%26aufirst%3DW.%2BJ.%26aulast%3DLebwohl%26aufirst%3DD.%26atitle%3DTargeting%2520tumorigenesis%253A%2520development%2520and%2520use%2520of%2520mTOR%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2009%26volume%3D2%26spage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group">Tsang, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X. F.</span><span> </span><span class="NLM_article-title">Targeting mammalian target of rapamycin (mTOR) for health and diseases</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=112-124&author=C.+K.+Tsangauthor=H.+Qiauthor=L.+F.+Liuauthor=X.+F.+Zheng&title=Targeting+mammalian+target+of+rapamycin+%28mTOR%29+for+health+and+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTsang%26aufirst%3DC.%2BK.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26aulast%3DZheng%26aufirst%3DX.%2BF.%26atitle%3DTargeting%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520for%2520health%2520and%2520diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D112%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group">Abraham, R. T.</span><span> </span><span class="NLM_article-title">Identification of TOR signaling complexes: more TORC for the cell growth engine</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2002&pages=9-12&author=R.+T.+Abraham&title=Identification+of+TOR+signaling+complexes%3A+more+TORC+for+the+cell+growth+engine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26atitle%3DIdentification%2520of%2520TOR%2520signaling%2520complexes%253A%2520more%2520TORC%2520for%2520the%2520cell%2520growth%2520engine%26jtitle%3DCell%26date%3D2002%26volume%3D111%26spage%3D9%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group">Corradetti, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, K. L.</span><span> </span><span class="NLM_article-title">Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">6347</span><span class="NLM_x">–</span> <span class="NLM_lpage">6360</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6347-6360&author=M.+N.+Corradettiauthor=K.+L.+Guan&title=Upstream+of+the+mammalian+target+of+rapamycin%3A+do+all+roads+pass+through+mTOR%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorradetti%26aufirst%3DM.%2BN.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DUpstream%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%253A%2520do%2520all%2520roads%2520pass%2520through%2520mTOR%253F%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6347%26epage%3D6360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group">Witzig, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghobrial, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inwards, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luyun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morton, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakhil, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5347</span><span class="NLM_x">–</span> <span class="NLM_lpage">5356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2005.13.466" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15983389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5347-5356&author=T.+E.+Witzigauthor=S.+M.+Geyerauthor=I.+Ghobrialauthor=D.+J.+Inwardsauthor=R.+Fonsecaauthor=P.+Kurtinauthor=S.+M.+Ansellauthor=R.+Luyunauthor=P.+J.+Flynnauthor=R.+F.+Mortonauthor=S.+R.+Dakhilauthor=H.+Grossauthor=S.+H.+Kaufmann&title=Phase+II+trial+of+single-agent+temsirolimus+%28CCI-779%29+for+relapsed+mantle+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma</span></div><div class="casAuthors">Witzig, Thomas E.; Geyer, Susan M.; Ghobrial, Irene; Inwards, David J.; Fonseca, Rafael; Kurtin, Paul; Ansell, Stephen M.; Luyun, Ronnie; Flynn, Patrick J.; Morton, Roscoe F.; Dakhil, Shaker R.; Gross, Howard; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5347-5356</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Mantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 mRNA.  This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.  Patients with relapsed or refractory MCL were eligible to receive temsirolimus 250 mg i.v. every week as a single agent.  Patients with a tumor response after six cycles were eligible to continue drug for a total of 12 cycles or two cycles after complete remission, and were then obsd. without maintenance.  Thirty-five patients were enrolled and were assessable for toxicity; one patient had MCL by histol. but was cyclin D1 neg. and was ineligible for efficacy.  The median age was 70 years (range, 38 to 89 years), 91% were stage 4, and 69% had two or more extranodal sites.  Patients had received a median of three prior therapies (range, one to 11), and 54% were refractory to the last treatment.  The overall response rate was 38% (13 of 34 patients; 90% Cl, 24% to 54%) with one complete response (3%) and 12 partial responses (35%).  The median time-to-progression in all patients was 6.5 mo (95% Cl, 2.9 to 8.3 mo), and the duration of response for the 13 responders was 6.9 mo (95% Cl, 5.2 to 12.4 mo).  Hematol. toxicities were the most common, with 71% (25% of 35 patients) having grade 3 and 11% (four of 35 patients) having grade 4 toxicities obsd.  Thrombocytopenia was the most frequent cause of dose redns. but was of short duration, typically resolving within 1 wk.  Single-agent temsirolimus has substantial antitumor activity in relapsed MCL.  This study demonstrates that agents that selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit.  Further studies of this agent in MCL and other lymphoid malignancies are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLDxT9yqiLVrVg90H21EOLACvtfcHk0li5G5auDtteSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtLk%253D&md5=98d5b88a5f8468e922fb8bb8ff0e4cd0</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.13.466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.13.466%26sid%3Dliteratum%253Aachs%26aulast%3DWitzig%26aufirst%3DT.%2BE.%26aulast%3DGeyer%26aufirst%3DS.%2BM.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DInwards%26aufirst%3DD.%2BJ.%26aulast%3DFonseca%26aufirst%3DR.%26aulast%3DKurtin%26aufirst%3DP.%26aulast%3DAnsell%26aufirst%3DS.%2BM.%26aulast%3DLuyun%26aufirst%3DR.%26aulast%3DFlynn%26aufirst%3DP.%2BJ.%26aulast%3DMorton%26aufirst%3DR.%2BF.%26aulast%3DDakhil%26aufirst%3DS.%2BR.%26aulast%3DGross%26aufirst%3DH.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DPhase%2520II%2520trial%2520of%2520single-agent%2520temsirolimus%2520%2528CCI-779%2529%2520for%2520relapsed%2520mantle%2520cell%2520lymphoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5347%26epage%3D5356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group">Peponi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drakos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventaki, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassidakis, G. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medeiros, L. J.</span><span> </span><span class="NLM_article-title">Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">169</span><span class="NLM_x">, </span> <span class="NLM_fpage">2171</span><span class="NLM_x">–</span> <span class="NLM_lpage">2180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2353%2Fajpath.2006.051078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17148679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvV2nsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2006&pages=2171-2180&author=E.+Peponiauthor=E.+Drakosauthor=G.+Reyesauthor=V.+Leventakiauthor=G.+Z.+Rassidakisauthor=L.+J.+Medeiros&title=Activation+of+mammalian+target+of+rapamycin+signaling+promotes+cell+cycle+progression+and+protects+cells+from+apoptosis+in+mantle+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma</span></div><div class="casAuthors">Peponi, Evangelia; Drakos, Elias; Reyes, Guadalupe; Leventaki, Vasiliki; Rassidakis, George Z.; Medeiros, L. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2171-2180</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Mantle cell lymphoma (MCL) is characterized by the t(11;14) and cyclin D1 overexpression.  However, addnl. mol. events are most likely required for oncogenesis, possibly through cell cycle and apoptosis deregulation.  We hypothesized that mammalian target of rapamycin (mTOR) is activated in MCL and contributes to tumor proliferation and survival.  In MCL cell lines, pharmacol. inhibition of the phosphoinositide 3-kinase/AKT pathway was assocd. with decreased phosphorylation (activation) of mTOR and its downstream targets phosphorylated (p)-4E-BP1, p-p70S6 kinase, and p-ribosomal protein S6, resulting in apoptosis and cell cycle arrest.  These changes were assocd. with down-regulation of cyclin D1 and the anti-apoptotic proteins cFLIP, BCL-XL, and MCL-1.  Furthermore, silencing of mTOR expression using mTOR-specific short interfering RNA decreased phosphorylation of mTOR signaling proteins and induced cell cycle arrest and apoptosis.  Silencing of eukaryotic initiation factor (eIF4E), a downstream effector of mTOR, recapitulated these results.  We also assessed mTOR signaling in MCL tumors using immunohistochem. methods and a tissue microarray: 10 of 30 (33%) expressed Ser473p-AKT, 13 of 21 (62%) Ser2448p-mTOR, 22 of 22 (100%) p-p70S6K, and 5 of 20 (25%) p-ribosomal protein S6.  Total eIF4E binding protein 1 and eukaryotic initiation factor 4E were expressed in 13 of 14 (93%) and 16 of 29 (55%) MCL tumors, resp.  These findings suggest that the mTOR signaling pathway is activated and may contribute to cell cycle progression and tumor cell survival in MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpz8nXkoZHe97Vg90H21EOLACvtfcHk0lh-10aM9CZDpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvV2nsw%253D%253D&md5=97b2c4a9fa1003de6aaec34d2704db55</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2006.051078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2006.051078%26sid%3Dliteratum%253Aachs%26aulast%3DPeponi%26aufirst%3DE.%26aulast%3DDrakos%26aufirst%3DE.%26aulast%3DReyes%26aufirst%3DG.%26aulast%3DLeventaki%26aufirst%3DV.%26aulast%3DRassidakis%26aufirst%3DG.%2BZ.%26aulast%3DMedeiros%26aufirst%3DL.%2BJ.%26atitle%3DActivation%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520signaling%2520promotes%2520cell%2520cycle%2520progression%2520and%2520protects%2520cells%2520from%2520apoptosis%2520in%2520mantle%2520cell%2520lymphoma%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2006%26volume%3D169%26spage%3D2171%26epage%3D2180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bookstein, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenstein, A.</span><span> </span><span class="NLM_article-title">Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">5027</span><span class="NLM_x">–</span> <span class="NLM_lpage">5034</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5027-5034&author=Y.+Shiauthor=J.+Geraauthor=L.+Huauthor=J.+H.+Hsuauthor=R.+Booksteinauthor=W.+Liauthor=A.+Lichtenstein&title=Enhanced+sensitivity+of+multiple+myeloma+cells+containing+PTEN+mutations+to+CCI-779"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGera%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHsu%26aufirst%3DJ.%2BH.%26aulast%3DBookstein%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLichtenstein%26aufirst%3DA.%26atitle%3DEnhanced%2520sensitivity%2520of%2520multiple%2520myeloma%2520cells%2520containing%2520PTEN%2520mutations%2520to%2520CCI-779%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5027%26epage%3D5034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group">Zeng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarbassov dos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samudio, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munsell, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellen Jackson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konopleva, M.</span><span> </span><span class="NLM_article-title">Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">3509</span><span class="NLM_x">–</span> <span class="NLM_lpage">3512</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=3509-3512&author=Z.+Zengauthor=D.+Sarbassov+dosauthor=I.+J.+Samudioauthor=K.+W.+Yeeauthor=M.+F.+Munsellauthor=C.+Ellen+Jacksonauthor=F.+J.+Gilesauthor=D.+M.+Sabatiniauthor=M.+Andreeffauthor=M.+Konopleva&title=Rapamycin+derivatives+reduce+mTORC2+signaling+and+inhibit+AKT+activation+in+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DSarbassov%2Bdos%26aufirst%3DD.%26aulast%3DSamudio%26aufirst%3DI.%2BJ.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DMunsell%26aufirst%3DM.%2BF.%26aulast%3DEllen%2BJackson%26aufirst%3DC.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DAndreeff%26aufirst%3DM.%26aulast%3DKonopleva%26aufirst%3DM.%26atitle%3DRapamycin%2520derivatives%2520reduce%2520mTORC2%2520signaling%2520and%2520inhibit%2520AKT%2520activation%2520in%2520AML%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D3509%26epage%3D3512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group">Feldman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roboz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curcio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albitar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laliberte, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bedrosian, C. L.</span><span> </span><span class="NLM_article-title">A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6631</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2005.09.133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16170170" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=6631&author=E.+Feldmanauthor=F.+Gilesauthor=G.+Robozauthor=K.+Yeeauthor=T.+Curcioauthor=V.+M.+Riveraauthor=M.+Albitarauthor=R.+Laliberteauthor=C.+L.+Bedrosian&title=A+phase+2+clinical+trial+of+AP23573%2C+an+mTOR+inhibitor%2C+in+patients+with+relapsed+or+refractory+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.133%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DE.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DRoboz%26aufirst%3DG.%26aulast%3DYee%26aufirst%3DK.%26aulast%3DCurcio%26aufirst%3DT.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DAlbitar%26aufirst%3DM.%26aulast%3DLaliberte%26aufirst%3DR.%26aulast%3DBedrosian%26aufirst%3DC.%2BL.%26atitle%3DA%2520phase%25202%2520clinical%2520trial%2520of%2520AP23573%252C%2520an%2520mTOR%2520inhibitor%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520hematologic%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D6631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group">Goss, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanceron, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, S. J.</span><span> </span><span class="NLM_article-title">Generating rapamycin analogues by directed biosynthesis: starter acid substrate specificity of mono-substituted cyclohexane carboxylic acids</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">4071</span><span class="NLM_x">–</span> <span class="NLM_lpage">4073</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=4071-4073&author=R.+J.+Gossauthor=S.+E.+Lanceronauthor=N.+J.+Wiseauthor=S.+J.+Moss&title=Generating+rapamycin+analogues+by+directed+biosynthesis%3A+starter+acid+substrate+specificity+of+mono-substituted+cyclohexane+carboxylic+acids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DR.%2BJ.%26aulast%3DLanceron%26aufirst%3DS.%2BE.%26aulast%3DWise%26aufirst%3DN.%2BJ.%26aulast%3DMoss%26aufirst%3DS.%2BJ.%26atitle%3DGenerating%2520rapamycin%2520analogues%2520by%2520directed%2520biosynthesis%253A%2520starter%2520acid%2520substrate%2520specificity%2520of%2520mono-substituted%2520cyclohexane%2520carboxylic%2520acids%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2006%26volume%3D4%26spage%3D4071%26epage%3D4073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group">Graziani, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritacco, F. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Summers, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabriskie, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernan, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, G. T.</span><span> </span><span class="NLM_article-title">Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol034591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=2385-2388&author=E.+I.+Grazianiauthor=F.+V.+Ritaccoauthor=M.+Y.+Summersauthor=T.+M.+Zabriskieauthor=K.+Yuauthor=V.+S.+Bernanauthor=M.+Greensteinauthor=G.+T.+Carter&title=Novel+sulfur-containing+rapamycin+analogs+prepared+by+precursor-directed+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1021%2Fol034591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol034591k%26sid%3Dliteratum%253Aachs%26aulast%3DGraziani%26aufirst%3DE.%2BI.%26aulast%3DRitacco%26aufirst%3DF.%2BV.%26aulast%3DSummers%26aufirst%3DM.%2BY.%26aulast%3DZabriskie%26aufirst%3DT.%2BM.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DBernan%26aufirst%3DV.%2BS.%26aulast%3DGreenstein%26aufirst%3DM.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DNovel%2520sulfur-containing%2520rapamycin%2520analogs%2520prepared%2520by%2520precursor-directed%2520biosynthesis%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D2385%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group">Gregory, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petkovic, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lill, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaisser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leadlay, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheridan, R. M.</span><span> </span><span class="NLM_article-title">Mutasynthesis of rapamycin analogues through the manipulation of a gene governing starter unit biosynthesis</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4757</span><span class="NLM_x">–</span> <span class="NLM_lpage">4760</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2005&pages=4757-4760&author=M.+A.+Gregoryauthor=H.+Petkovicauthor=R.+E.+Lillauthor=S.+J.+Mossauthor=B.+Wilkinsonauthor=S.+Gaisserauthor=P.+F.+Leadlayauthor=R.+M.+Sheridan&title=Mutasynthesis+of+rapamycin+analogues+through+the+manipulation+of+a+gene+governing+starter+unit+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGregory%26aufirst%3DM.%2BA.%26aulast%3DPetkovic%26aufirst%3DH.%26aulast%3DLill%26aufirst%3DR.%2BE.%26aulast%3DMoss%26aufirst%3DS.%2BJ.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DGaisser%26aufirst%3DS.%26aulast%3DLeadlay%26aufirst%3DP.%2BF.%26aulast%3DSheridan%26aufirst%3DR.%2BM.%26atitle%3DMutasynthesis%2520of%2520rapamycin%2520analogues%2520through%2520the%2520manipulation%2520of%2520a%2520gene%2520governing%2520starter%2520unit%2520biosynthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2005%26volume%3D44%26spage%3D4757%26epage%3D4760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group">Khaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohm, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staunton, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leadlay, P. F.</span><span> </span><span class="NLM_article-title">Mutational biosynthesis of novel rapamycins by a strain of <i>Streptomyces hygroscopicus</i> NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase</span> <span class="citation_source-journal">J. Bacteriol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">814</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9473033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1cXhtVGls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=1998&pages=809-814&author=L.+E.+Khawauthor=G.+A.+Bohmauthor=S.+Metcalfeauthor=J.+Stauntonauthor=P.+F.+Leadlay&title=Mutational+biosynthesis+of+novel+rapamycins+by+a+strain+of+Streptomyces+hygroscopicus+NRRL+5491+disrupted+in+rapL%2C+encoding+a+putative+lysine+cyclodeaminase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase</span></div><div class="casAuthors">Khaw, Lake Ee; Bohm, Gunter A.; Metcalfe, Su; Staunton, James; Leadlay, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bacteriology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">809-814</span>CODEN:
                <span class="NLM_cas:coden">JOBAAY</span>;
        ISSN:<span class="NLM_cas:issn">0021-9193</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Gene rapL lies within the region of the Streptomyces hygroscopicus chromosome which contains the biosynthetic gene cluster for the immunosuppressant rapamycin.  Introduction of a frameshift mutation into rapL by ΦC31 phage-mediated gene replacement gave rise to a mutant which did not produce significant amts. of rapamycin.  Growth of this rapL mutant on media contg. added L-pipecolate restored wild-type levels of rapamycin prodn., consistent with a proposal that rapL encodes a specific L-lysine cyclodeaminase important for the prodn. of the L-pipecolate precursor.  In the presence of added proline derivs., rapL mutants synthesized novel rapamycin analogs, indicating a relaxed substrate specificity for the enzyme catalyzing pipecolate incorporation into the macrocycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXMq_O_SW6i7Vg90H21EOLACvtfcHk0lhcAPQtMyyY2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtVGls7k%253D&md5=d7ed92c4fbc5ba34d1411f7af95a5b5d</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhaw%26aufirst%3DL.%2BE.%26aulast%3DBohm%26aufirst%3DG.%2BA.%26aulast%3DMetcalfe%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DLeadlay%26aufirst%3DP.%2BF.%26atitle%3DMutational%2520biosynthesis%2520of%2520novel%2520rapamycins%2520by%2520a%2520strain%2520of%2520Streptomyces%2520hygroscopicus%2520NRRL%25205491%2520disrupted%2520in%2520rapL%252C%2520encoding%2520a%2520putative%2520lysine%2520cyclodeaminase%26jtitle%3DJ.%2520Bacteriol.%26date%3D1998%26volume%3D180%26spage%3D809%26epage%3D814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group">Verheijen, J.; Yu, K.; Zask, A.; John, E. M.</span><span> </span><span class="NLM_article-title">mTOR Inhibitors in Oncology</span>. In  <span class="citation_source-book">Annual Reports in Medicinal Chemistry</span>; <span class="NLM_publisher-name">Academic Press</span>: San Diego, CA,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">43</span>, Chapter 12, pp  <span class="NLM_fpage">189</span>− <span class="NLM_lpage">202</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=189-202&author=J.+Verheijen&author=K.+Yu&author=A.+Zask&author=E.+M.+John&title=Annual+Reports+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVerheijen%26aufirst%3DJ.%26atitle%3DmTOR%2520Inhibitors%2520in%2520Oncology%26btitle%3DAnnual%2520Reports%2520in%2520Medicinal%2520Chemistry%26pub%3DAcademic%2520Press%26date%3D2008%26volume%3D43%26spage%3D189%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group">Garlich, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dey, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kundra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durden, D. L.</span><span> </span><span class="NLM_article-title">A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=206-215&author=J.+R.+Garlichauthor=P.+Deauthor=N.+Deyauthor=J.+D.+Suauthor=X.+Pengauthor=A.+Millerauthor=R.+Muraliauthor=Y.+Luauthor=G.+B.+Millsauthor=V.+Kundraauthor=H.+K.+Shuauthor=Q.+Pengauthor=D.+L.+Durden&title=A+vascular+targeted+pan+phosphoinositide+3-kinase+inhibitor+prodrug%2C+SF1126%2C+with+antitumor+and+antiangiogenic+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarlich%26aufirst%3DJ.%2BR.%26aulast%3DDe%26aufirst%3DP.%26aulast%3DDey%26aufirst%3DN.%26aulast%3DSu%26aufirst%3DJ.%2BD.%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DKundra%26aufirst%3DV.%26aulast%3DShu%26aufirst%3DH.%2BK.%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DDurden%26aufirst%3DD.%2BL.%26atitle%3DA%2520vascular%2520targeted%2520pan%2520phosphoinositide%25203-kinase%2520inhibitor%2520prodrug%252C%2520SF1126%252C%2520with%2520antitumor%2520and%2520antiangiogenic%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D206%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group">Maira, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stauffer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brueggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brachmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chene, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pover, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoemaker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simonen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1851</span><span class="NLM_x">–</span> <span class="NLM_lpage">1863</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-08-0017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18606717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1851-1863&author=S.+M.+Mairaauthor=F.+Staufferauthor=J.+Brueggenauthor=P.+Furetauthor=C.+Schnellauthor=C.+Fritschauthor=S.+Brachmannauthor=P.+Cheneauthor=A.+De+Poverauthor=K.+Schoemakerauthor=D.+Fabbroauthor=D.+Gabrielauthor=M.+Simonenauthor=L.+Murphyauthor=P.+Finanauthor=W.+Sellersauthor=C.+Garcia-Echeverria&title=Identification+and+characterization+of+NVP-BEZ235%2C+a+new+orally+available+dual+phosphatidylinositol+3-kinase%2Fmammalian+target+of+rapamycin+inhibitor+with+potent+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity</span></div><div class="casAuthors">Maira, Sauveur-Michel; Stauffer, Frederic; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; Brachmann, Saskia; Chene, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; Murphy, Leon; Finan, Peter; Sellers, William; Garcia-Echeverria, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1851-1863</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention.  NVP-BEZ235 is an imidazo[4,5-c]quinoline deriv. that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.  In cellular settings using human tumor cell lines, this mol. is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest.  The cellular activity of NVP-BEZ235 translates well in in vivo models of human cancer.  Thus, the compd. was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.  Ex vivo pharmacokinetic/pharmacodynamic analyses of tumor tissues showed a time-dependent correlation between compd. concn. and PI3K/Akt pathway inhibition.  Collectively, the preclin. data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties.  NVP-BEZ235 is currently in phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyO784qv52vrVg90H21EOLACvtfcHk0ljlEGtMY-nRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb4%253D&md5=5b1979e134dd12065198d86dbc11ce15</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-08-0017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-08-0017%26sid%3Dliteratum%253Aachs%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DBrueggen%26aufirst%3DJ.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBrachmann%26aufirst%3DS.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DSchoemaker%26aufirst%3DK.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DGabriel%26aufirst%3DD.%26aulast%3DSimonen%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DFinan%26aufirst%3DP.%26aulast%3DSellers%26aufirst%3DW.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520NVP-BEZ235%252C%2520a%2520new%2520orally%2520available%2520dual%2520phosphatidylinositol%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitor%2520with%2520potent%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1851%26epage%3D1863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group">Tomillero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moral, M. A.</span><span> </span><span class="NLM_article-title">Gateways to clinical trials</span> <span class="citation_source-journal">Methods Find. Exp. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18985183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1cjhvV2kug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=543-588&author=A.+Tomilleroauthor=M.+A.+Moral&title=Gateways+to+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Gateways to clinical trials</span></div><div class="casAuthors">Tomillero A; Moral M A</div><div class="citationInfo"><span class="NLM_cas:title">Methods and findings in experimental and clinical pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">543-88</span>
        ISSN:<span class="NLM_cas:issn">0379-0355</span>.
    </div><div class="casAbstract">Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses.  The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com.This issue focuses on the following selection of drugs: ABT-263, AC-2307, Aclidinium bromide, Adefovir dipivoxil, ADH-1, Agatolimod sodium, Alefacept, Aliskiren fumarate, Aminolevulinic acid methyl ester, Anakinra, Apaziquone, Aprepitant, Aripiprazole, ASM-8, Atiprimod hydrochloride, AVE-0277, AVE-1642, AVE-8062, Axitinib, Azacitidine, AZD-0530; Bazedoxifene acetate, Bevacizumab, Bexarotene, BI-2536, Biphasic insulin aspart, BMS-387032, BMS-663513, Bortezomib, BQ-123, Brivanib alaninate, BSI-201; Caspofungin acetate, CDX-110, Cetuximab, Ciclesonide, CR-011, Cypher; Daptomycin, Darbepoetin alfa, Dasatinib, Decitabine, Deferasirox, Denosumab, Dexlansoprazole, Dexmethylphenidate hydrochloride, DNA-Hsp65 vaccine, Dovitinib, Drotrecogin alfa (activated), DTaP-HBV-IPV/Hibvaccine, DTaP-IPV-HB-PRP-T, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Elacytarabine, Emtricitabine, Endothelin, Entecavir, Eplivanserin fumarate, Escitalopram oxalate, Everolimus, Ezetimibe, Ezetimibe/simvastatin; Farletuzumab, Fesoterodine fumarate, Fibrin sealant (human), Fulvestrant; Gefitinib, Gemtuzumab ozogamicin, Glufosfamide, GSK-1562902A; Hib-TT; Imatinib mesylate, IMC-11F8, Imidazoacridinone, IMP-321, INCB-18424, Indiplon, Indisulam, INNO-406, Irinotecan hydrochloride/Floxuridine, ITF-2357, Ixabepilone; KRN-951; Lasofoxifene tartrate; Lenalidomide, LGD-4665, Lonafarnib, Lubiprostone, Lumiliximab; MDX-1100, Melan-A/MART-1/gp100/IFN-alfa, Methyl-CDDO, Metreleptin, MLN-2704, Mycophenolic acid sodium salt; Na-ASP-2, Naproxcinod, Nilotinib hydrochloride monohydrate, NPI-2358; Oblimersen sodium, Odanacatib; Paclitaxel nanoparticles, PAN-811, Panobinostat, PBI-1402, PC-515, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Perillyl alcohol, Perphenazine 4-aminobutyrate, PeviPRO/breast cancer, PF-03814735, PHA-739358, Pimecrolimus, Plitidepsin, Posaconazole, Prasterone, Prasugrel, Pregabalin, Prucalopride, PRX-08066; rAAV2-TNFR:Fc, Ranelic acid distrontium salt, Ranibizumab, rCD154-CLL, Retapamulin, RTS,S/SBAS2, rV-PSA-TRICOM/rF-PSA-TRICOM; SG-2000, Sinecatechins, Sirolimus-eluting stent, Sorafenib, SP-1640, Strontium malonate, Succinobucol, Sunitinib malate; Taxus, Teduglutide, Telavancin hydrochloride, Telbivudine, Telmisartan/hydrochlorothiazide, Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ustekinumab; V-5 Immunitor, Voriconazole, Vorinostat; Xience V, XL-184, XL-647, XL-765; Y-39983, Zibotentan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkoCAaeXJeddts4TFFB11gfW6udTcc2eZZ5FKXxGitIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cjhvV2kug%253D%253D&md5=66e9a6225768b0c9891162278400e8d7</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTomillero%26aufirst%3DA.%26aulast%3DMoral%26aufirst%3DM.%2BA.%26atitle%3DGateways%2520to%2520clinical%2520trials%26jtitle%3DMethods%2520Find.%2520Exp.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D30%26spage%3D543%26epage%3D588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group">McCloskey, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMullin, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, A. E.</span><span> </span><span class="NLM_article-title">The therapeutic potential of the proteasome in leukaemia</span> <span class="citation_source-journal">Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fhon.848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18324639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1ygs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=73-81&author=S.+M.+McCloskeyauthor=M.+F.+McMullinauthor=B.+Walkerauthor=A.+E.+Irvine&title=The+therapeutic+potential+of+the+proteasome+in+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic potential of the proteasome in leukemia</span></div><div class="casAuthors">McCloskey, Scott Marshall; McMullin, Mary Frances; Walker, Brian; Irvine, Alexandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Hematological Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-81</span>CODEN:
                <span class="NLM_cas:coden">HAONDL</span>;
        ISSN:<span class="NLM_cas:issn">0278-0232</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized.  Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms.  The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients.  Malignant cells are more sensitive to proteasome inhibition than normal hematopoietic cells.  Proteasome inhibition enhances many conventional therapies and its role in leukemia is promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS02KkqqnMqrVg90H21EOLACvtfcHk0ljlEGtMY-nRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1ygs74%253D&md5=ac7a2b5fe7c0b91cfc7043ec8c20e08e</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fhon.848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhon.848%26sid%3Dliteratum%253Aachs%26aulast%3DMcCloskey%26aufirst%3DS.%2BM.%26aulast%3DMcMullin%26aufirst%3DM.%2BF.%26aulast%3DWalker%26aufirst%3DB.%26aulast%3DIrvine%26aufirst%3DA.%2BE.%26atitle%3DThe%2520therapeutic%2520potential%2520of%2520the%2520proteasome%2520in%2520leukaemia%26jtitle%3DHematol.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D73%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group">Richardson, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hideshima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsiades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, K.</span><span> </span><span class="NLM_article-title">Proteasome inhibition in hematologic malignancies</span> <span class="citation_source-journal">Ann. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">304</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F07853890410030877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15224657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=304-314&author=P.+G.+Richardsonauthor=T.+Hideshimaauthor=C.+Mitsiadesauthor=K.+Anderson&title=Proteasome+inhibition+in+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition in hematologic malignancies</span></div><div class="casAuthors">Richardson, Paul; Hideshima, Teru; Mitsiades, Constantine; Anderson, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Medicine (Basingstoke, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">ANMDEU</span>;
        ISSN:<span class="NLM_cas:issn">0785-3890</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Hematol. malignancies, including multiple myeloma (MM), will account for more than 100,000 new cases of cancer and over 57,000 deaths in the United States in 2003.  Treatment of MM is a serious challenge, because despite a variety of available therapies, median survival is short.  A new therapeutic area focuses on inhibiting the activity of the proteasome, a 26S protease complex involved in cell cycle regulation, cell adhesion, inflammation, and protein turnover.  The novel proteasome inhibitor, bortezomib (Velcade), was recently approved for use in patients with refractory and relapsed MM and to date is the only proteasome inhibitor to have entered clin. trials.  Bortezomib has demonstrated activity with manageable toxicity in a variety of hematol. malignancies in addn. to MM, including leukemia and non-Hodgkin's lymphoma.  This article reviews clin. information on bortezomib in hematol. malignancies both as monotherapy and in combination with dexamethasone.  Preliminary reports of bortezomib in combination with Doxil (pegylated liposomal doxorubicin), melphalan, and thalidomide are discussed, and current trials are described.  Available data suggest that bortezomib will be useful in the treatment of a variety of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoASaZlt6m5CLVg90H21EOLACvtfcHk0ljlEGtMY-nRNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKmtbg%253D&md5=40c9d98b19cf9c829278388481c3b46a</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1080%2F07853890410030877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07853890410030877%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMitsiades%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DK.%26atitle%3DProteasome%2520inhibition%2520in%2520hematologic%2520malignancies%26jtitle%3DAnn.%2520Med.%26date%3D2004%26volume%3D36%26spage%3D304%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group">Vink, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. J.</span><span> </span><span class="NLM_article-title">Proteasome inhibition as novel treatment strategy in leukaemia</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1111%2Fj.1365-2141.2006.06170.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16787504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XosFCju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2006&pages=253-262&author=J.+Vinkauthor=J.+Cloosauthor=G.+J.+Kaspers&title=Proteasome+inhibition+as+novel+treatment+strategy+in+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition as novel treatment strategy in leukemia</span></div><div class="casAuthors">Vink, J.; Cloos, J.; Kaspers, G. J. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Following its success in multiple myeloma (MM), proteasome inhibition has become a topic of interest as novel treatment strategy of cancer.  By simultaneously affecting multiple pathways in the cancer cell, such as deregulation of the programmed degrdn. of many cellular proteins, proteasome inhibition causes rapid apoptosis of these cells.  Both in rapidly proliferating leukemic cell lines and in primary leukemic cells isolated from patients, proteasome inhibition results in antileukemic activity.  The normal counterparts of these cells are much more resistant to proteasome inhibitors (PI), thereby resulting in a favorable therapeutic index.  Importantly, while leukemic stem cells are sensitive to proteasome inhibition, normal hematopoietic stem cells are still viable after drug exposure.  Nowadays, many PIs are being identified; bortezomib is the most well known since obtaining Food and Drug Administration approval for clin. use in MM.  This review summarizes the biol. and clin. aspects of proteasome inhibition and discusses the potential role of these inhibitors in the treatment of leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobY9NbVguu5rVg90H21EOLACvtfcHk0lhPM2Taqri-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosFCju7g%253D&md5=91044b824ce9ce6fba2d6874dcd2437c</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2006.06170.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2006.06170.x%26sid%3Dliteratum%253Aachs%26aulast%3DVink%26aufirst%3DJ.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26atitle%3DProteasome%2520inhibition%2520as%2520novel%2520treatment%2520strategy%2520in%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2006%26volume%3D134%26spage%3D253%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruickshank, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grenier, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klunder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plamondon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, R. L.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">333</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FS0960-894X%2898%2900029-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=9871680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADyaK1cXhsFKjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=333-338&author=J.+Adamsauthor=M.+Behnkeauthor=S.+Chenauthor=A.+A.+Cruickshankauthor=L.+R.+Dickauthor=L.+Grenierauthor=J.+M.+Klunderauthor=Y.+T.+Maauthor=L.+Plamondonauthor=R.+L.+Stein&title=Potent+and+selective+inhibitors+of+the+proteasome%3A+dipeptidyl+boronic+acids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids</span></div><div class="casAuthors">Adams, Julian; Behnke, Mark; Chen, Shaowu; Cruickshank, Amy A.; Dick, Lawrence R.; Grenier, Louis; Klunder, Jancie M.; Ma, Yu-Ting; Plamondon, Louis; Stein, Ross L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-338</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Potent and selective dipeptidyl boronic acid proteasome inhibitors are described.  As compared to peptidyl aldehyde compds., boronic acids in this series display dramatically enhanced potency.  Compds. (I; R = Ph, 1-naphthyl), in particular I (R = Ph), are promising new therapeutics for treatment of cancer and inflammatory diseases.  I (R = Ph) and I (R = 1-naphthyl) in vitro inhibited 20S proteasome with Ki of 0.62 and 0.18, resp., whereas I (R = Ph) showed Ki of 2,300, 630, 320, and 13,000 against common serine proteases such as human leukocyte elastase, human cathepsin G, human chymotrypsin, and thrombin, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeLVVXMKjfPbVg90H21EOLACvtfcHk0lhPM2Taqri-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhsFKjsr8%253D&md5=e9287f4977f5ab655fedd1fd702aa456</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2898%2900029-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252898%252900029-8%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DBehnke%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCruickshank%26aufirst%3DA.%2BA.%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DGrenier%26aufirst%3DL.%26aulast%3DKlunder%26aufirst%3DJ.%2BM.%26aulast%3DMa%26aufirst%3DY.%2BT.%26aulast%3DPlamondon%26aufirst%3DL.%26aulast%3DStein%26aufirst%3DR.%2BL.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520proteasome%253A%2520dipeptidyl%2520boronic%2520acids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1998%26volume%3D8%26spage%3D333%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iqbal, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernardini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernareggi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassara, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arasmo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferretti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Munari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliva, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzoni, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allievi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strepponi, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1068</span><span class="NLM_x">–</span> <span class="NLM_lpage">1072</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7010589" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1068-1072&author=B.+D.+Dorseyauthor=M.+Iqbalauthor=S.+Chatterjeeauthor=E.+Mentaauthor=R.+Bernardiniauthor=A.+Bernareggiauthor=P.+G.+Cassaraauthor=G.+D%E2%80%99Arasmoauthor=E.+Ferrettiauthor=S.+De+Munariauthor=A.+Olivaauthor=G.+Pezzoniauthor=C.+Allieviauthor=I.+Strepponiauthor=B.+Ruggeriauthor=M.+A.+Atorauthor=M.+Williamsauthor=J.+P.+Mallamo&title=Discovery+of+a+potent%2C+selective%2C+and+orally+active+proteasome+inhibitor+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer</span></div><div class="casAuthors">Dorsey, Bruce D.; Iqbal, Mohamed; Chatterjee, Sankar; Menta, Ernesto; Bernardini, Raffaella; Bernareggi, Alberto; Cassara, Paolo G.; D'Arasmo, Germano; Ferretti, Edmondo; De Munari, Sergio; Oliva, Ambrogio; Pezzoni, Gabriella; Allievi, Cecilia; Strepponi, Ivan; Ruggeri, Bruce; Ator, Mark A.; Williams, Michael; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1068-1072</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome pathway plays a central role in regulation of the prodn. and destruction of cellular proteins.  These pathways mediate proliferation and cell survival, particularly in malignant cells.  The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy.  Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclin. development, [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid 20 (CEP-18770), is disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojkNeu3d81vbVg90H21EOLACvtfcHk0lhPM2Taqri-xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKls78%253D&md5=cfc22ee09c2a4f4d9c695010187c4693</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1021%2Fjm7010589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010589%26sid%3Dliteratum%253Aachs%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DIqbal%26aufirst%3DM.%26aulast%3DChatterjee%26aufirst%3DS.%26aulast%3DMenta%26aufirst%3DE.%26aulast%3DBernardini%26aufirst%3DR.%26aulast%3DBernareggi%26aufirst%3DA.%26aulast%3DCassara%26aufirst%3DP.%2BG.%26aulast%3DD%25E2%2580%2599Arasmo%26aufirst%3DG.%26aulast%3DFerretti%26aufirst%3DE.%26aulast%3DDe%2BMunari%26aufirst%3DS.%26aulast%3DOliva%26aufirst%3DA.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DAllievi%26aufirst%3DC.%26aulast%3DStrepponi%26aufirst%3DI.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520active%2520proteasome%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1068%26epage%3D1072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group">Macherla, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manam, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deyanat-Yazdi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenical, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuteboom, S. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potts, B. C. M.</span><span> </span><span class="NLM_article-title">Structure activity relationship studies of Salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">3684</span><span class="NLM_x">–</span> <span class="NLM_lpage">3687</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm048995%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=3684-3687&author=V.+R.+Macherlaauthor=S.+S.+Mitchellauthor=R.+R.+Manamauthor=K.+A.+Reedauthor=T.-H.+Chaoauthor=B.+Nicholsonauthor=G.+Deyanat-Yazdiauthor=B.+Maiauthor=P.+R.+Jensenauthor=W.+F.+Fenicalauthor=S.+T.+C.+Neuteboomauthor=K.+S.+Lamauthor=M.+A.+Palladinoauthor=B.+C.+M.+Potts&title=Structure+activity+relationship+studies+of+Salinosporamide+A+%28NPI-0052%29%2C+a+novel+marine+derived+proteasome+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Fjm048995%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm048995%252B%26sid%3Dliteratum%253Aachs%26aulast%3DMacherla%26aufirst%3DV.%2BR.%26aulast%3DMitchell%26aufirst%3DS.%2BS.%26aulast%3DManam%26aufirst%3DR.%2BR.%26aulast%3DReed%26aufirst%3DK.%2BA.%26aulast%3DChao%26aufirst%3DT.-H.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DDeyanat-Yazdi%26aufirst%3DG.%26aulast%3DMai%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DP.%2BR.%26aulast%3DFenical%26aufirst%3DW.%2BF.%26aulast%3DNeuteboom%26aufirst%3DS.%2BT.%2BC.%26aulast%3DLam%26aufirst%3DK.%2BS.%26aulast%3DPalladino%26aufirst%3DM.%2BA.%26aulast%3DPotts%26aufirst%3DB.%2BC.%2BM.%26atitle%3DStructure%2520activity%2520relationship%2520studies%2520of%2520Salinosporamide%2520A%2520%2528NPI-0052%2529%252C%2520a%2520novel%2520marine%2520derived%2520proteasome%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D3684%26epage%3D3687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchholz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smyth, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallone, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molineaux, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span> </span><span class="NLM_article-title">Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6383</span><span class="NLM_x">–</span> <span class="NLM_lpage">6391</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F0008-5472.CAN-06-4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17616698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=6383-6391&author=S.+D.+Demoauthor=C.+J.+Kirkauthor=M.+A.+Aujayauthor=T.+J.+Buchholzauthor=M.+Dajeeauthor=M.+N.+Hoauthor=J.+Jiangauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=F.+Parlatiauthor=K.+D.+Shenkauthor=M.+S.+Smythauthor=C.+M.+Sunauthor=M.+K.+Valloneauthor=T.+M.+Wooauthor=C.+J.+Molineauxauthor=M.+K.+Bennett&title=Antitumor+activity+of+PR-171%2C+a+novel+irreversible+inhibitor+of+the+proteasome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome</span></div><div class="casAuthors">Demo, Susan D.; Kirk, Christopher J.; Aujay, Monette A.; Buchholz, Tonia J.; Dajee, Maya; Ho, Mark N.; Jiang, Jing; Laidig, Guy J.; Lewis, Evan R.; Parlati, Francesco; Shenk, Kevin D.; Smyth, Mark S.; Sun, Congcong M.; Vallone, Marcy K.; Woo, Tina M.; Molineaux, Christopher J.; Bennett, Mark K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6383-6391</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Clin. studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and non-Hodgkin's lymphoma.  However, significant toxicities have restricted the intensity of bortezomib dosing.  Here we describe the antitumor activity of PR-171, a novel epoxyketone-based irreversible proteasome inhibitor that is currently in clin. development.  In comparison to bortezomib, PR-171 exhibits equal potency but greater selectivity for the chymotrypsin-like activity of the proteasome.  In cell culture, PR-171 is more cytotoxic than bortezomib following brief treatments that mimic the in vivo pharmacokinetics of both mols.  Hematol. tumor cells exhibit the greatest sensitivity to brief exposure, whereas solid tumor cells and nontransformed cell types are less sensitive to such treatments.  Cellular consequences of PR-171 treatment include the accumulation of proteasome substrates and induction of cell cycle arrest and/or apoptosis.  Administration of PR-171 to animals results in the dose-dependent inhibition of the chymotrypsin-like proteasome activity in all tissues examd. with the exception of the brain.  PR-171 is well tolerated when administered for either 2 or 5 consecutive days at doses resulting in >80% proteasome inhibition in blood and most tissues.  In human tumor xenograft models, PR-171 mediates an antitumor response that is both dose and schedule dependent.  The antitumor efficacy of PR-171 delivered on 2 consecutive days is stronger than that of bortezomib administered on its clin. dosing schedule.  These studies show the tolerability, efficacy, and dosing flexibility of PR-171 and provide validation for the clin. testing of PR-171 in the treatment of hematol. malignancies using dose-intensive schedules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquzP-VJ4DNRbVg90H21EOLACvtfcHk0lhr7X7D4LKPbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsVyqtLY%253D&md5=301bcab3e60cbfd518b2f88fb479fa79</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4086%26sid%3Dliteratum%253Aachs%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBuchholz%26aufirst%3DT.%2BJ.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DSmyth%26aufirst%3DM.%2BS.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DVallone%26aufirst%3DM.%2BK.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DMolineaux%26aufirst%3DC.%2BJ.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26atitle%3DAntitumor%2520activity%2520of%2520PR-171%252C%2520a%2520novel%2520irreversible%2520inhibitor%2520of%2520the%2520proteasome%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D6383%26epage%3D6391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group">Adams, J.</span><span> </span><span class="NLM_article-title">The proteasome: a suitable antineoplastic target</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">360</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc1361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15122206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=349-360&author=J.+Adams&title=The+proteasome%3A+a+suitable+antineoplastic+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome: a suitable antineoplastic target</span></div><div class="casAuthors">Adams, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-360</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The proteasome is an abundant multi-enzyme complex that provides the main pathway for degrdn. of intracellular proteins in eukaryotic cells.  As such, it controls the levels of proteins that are important for cell-cycle progression and apoptosis in normal and malignant cells; for example, cyclins, caspases, BCL2, and nuclear factor of κB.  A proteasome inhibitor - bortezomib - was developed that has shown efficacy as an anticancer agent in the clinic.  How can targeting such a universal, broadly active cellular component provide the selectivity and specificity that are required for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdI0j9dL6efrVg90H21EOLACvtfcHk0lgmQRE1gJPJwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSlu7k%253D&md5=eeb2566e017e4aa1223b7bc8adb3b419</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1038%2Fnrc1361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1361%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DThe%2520proteasome%253A%2520a%2520suitable%2520antineoplastic%2520target%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D349%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Q.</span><span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and structure−activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of α-amino acid boronates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4192</span><span class="NLM_x">–</span> <span class="NLM_lpage">4199</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9005093" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4192-4199&author=Y.+Zhuauthor=X.+Zhaoauthor=X.+Zhuauthor=G.+Wuauthor=Y.+Liauthor=Y.+Maauthor=Y.+Yuanauthor=J.+Yangauthor=Y.+Huauthor=L.+Aiauthor=Q.+Gao&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+structure%E2%88%92activity+relationship+%28SAR%29+discussion+of+dipeptidyl+boronate+proteasome+inhibitors%2C+part+I%3A+comprehensive+understanding+of+the+SAR+of+%CE%B1-amino+acid+boronates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Fjm9005093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9005093%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DAi%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DQ.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520structure%25E2%2588%2592activity%2520relationship%2520%2528SAR%2529%2520discussion%2520of%2520dipeptidyl%2520boronate%2520proteasome%2520inhibitors%252C%2520part%2520I%253A%2520comprehensive%2520understanding%2520of%2520the%2520SAR%2520of%2520%25CE%25B1-amino%2520acid%2520boronates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4192%26epage%3D4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group">Adams, J.</span><span> </span><span class="NLM_article-title">Development of the proteasome inhibitor PS-341</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=9-16&author=J.+Adams&title=Development+of+the+proteasome+inhibitor+PS-341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520the%2520proteasome%2520inhibitor%2520PS-341%26jtitle%3DOncologist%26date%3D2002%26volume%3D7%26spage%3D9%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacobucci, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, E.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">303</span><span class="NLM_x">–</span> <span class="NLM_lpage">310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18496498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1czjt1elsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=303-310&author=G.+Martinelliauthor=I.+Iacobucciauthor=S.+Paoliniauthor=E.+Ottaviani&title=Farnesyltransferase+inhibition+in+hematologic+malignancies%3A+the+clinical+experience+with+tipifarnib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib</span></div><div class="casAuthors">Martinelli Giovanni; Iacobucci Ilaria; Paolini Stefania; Ottaviani Emanuela</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-10</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">Increased understanding of the cellular mechanisms associated with various malignancies has allowed researchers to develop agents that selectively target the cellular proteins and pathways implicated in the pathogenesis of malignancy.  Tipifarnib is a specific and potent farnesyltransferase inhibitor that demonstrates in vivo and in vitro activity against a variety of human cancers.  Although tipifarnib was initially thought to target the Ras protein, recent evidence suggests that the presence of ras mutations is not necessary for the antitumor effects of tipifarnib, and that tipifarnib may exert its effects downstream of Ras.  The oral administration and favorable toxicity profile of tipifarnib, combined with its activity in a variety of intracellular pathways that have been implicated in the pathogenesis of hematologic malignancies, make it an especially attractive agent for use in patients with acute myeloid leukemia (AML), myelodysplastic syndromes, chronic myelogenous leukemia (CML), and multiple myeloma.  Because hematologic malignancies are likely driven by multiple genetic aberrations, the most effective treatment strategy will likely combine multiple agents with complementary mechanisms of action.  Thus, additional studies of combination regimens that incorporate tipifarnib with other antineoplastic agents are crucial.  Early results from studies combining tipifarnib with imatinib or etoposide in CML and AML have been promising and warrant further evaluation in larger clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeRshcOAsdIvtos8R3JUhXfW6udTcc2eZ67i2GLo_KXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czjt1elsw%253D%253D&md5=c4450d3586652e9a2e94a5cad462d54d</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DIacobucci%26aufirst%3DI.%26aulast%3DPaolini%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DE.%26atitle%3DFarnesyltransferase%2520inhibition%2520in%2520hematologic%2520malignancies%253A%2520the%2520clinical%2520experience%2520with%2520tipifarnib%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2008%26volume%3D6%26spage%3D303%26epage%3D310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group">Kupperman, E.; Berger, A.; Yu, L.; Tsu, C.; Frank, B.; Liu, J.; Blank, J.; Larry, D.; Paul, F.; Yueying, C.; Bannerman, B.; Fitzgerald, M.; Zhang, J.; Yu, J.; Hales, P.; Manfredi, M.; Bolen, J.; Rolfe, M.</span><span> </span><span class="NLM_article-title">Preclinical Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer</span>. In  <span class="citation_source-book">Proceedings of the Annual Meeting of the American Association of Cancer Research</span>; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>Supplement, Abstract 5636.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=E.+Kupperman&author=A.+Berger&author=L.+Yu&author=C.+Tsu&author=B.+Frank&author=J.+Liu&author=J.+Blank&author=D.+Larry&author=F.+Paul&author=C.+Yueying&author=B.+Bannerman&author=M.+Fitzgerald&author=J.+Zhang&author=J.+Yu&author=P.+Hales&author=M.+Manfredi&author=J.+Bolen&author=M.+Rolfe&title=Proceedings+of+the+Annual+Meeting+of+the+American+Association+of+Cancer+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKupperman%26aufirst%3DE.%26atitle%3DPreclinical%2520Evaluation%2520of%2520the%2520Orally%2520Active%2520Proteasome%2520Inhibitor%2520MLN9708%2520in%2520Preclinical%2520Models%2520of%2520Human%2520Cancer%26btitle%3DProceedings%2520of%2520the%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520of%2520Cancer%2520Research%26pub%3DAACR%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group">Zhou, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dajee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demo, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laidig, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muchamuel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parlati, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ring, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenk, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shwonek, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sylvain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span> </span><span class="NLM_article-title">Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3028</span><span class="NLM_x">–</span> <span class="NLM_lpage">3038</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801329v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=3028-3038&author=H.-J.+Zhouauthor=M.+A.+Aujayauthor=M.+K.+Bennettauthor=M.+Dajeeauthor=S.+D.+Demoauthor=Y.+Fangauthor=M.+N.+Hoauthor=J.+Jiangauthor=C.+J.+Kirkauthor=G.+J.+Laidigauthor=E.+R.+Lewisauthor=Y.+Luauthor=T.+Muchamuelauthor=F.+Parlatiauthor=E.+Ringauthor=K.+D.+Shenkauthor=J.+Shieldsauthor=P.+J.+Shwonekauthor=T.+Stantonauthor=C.+M.+Sunauthor=C.+Sylvainauthor=T.+M.+Wooauthor=J.+Yang&title=Design+and+synthesis+of+an+orally+bioavailable+and+selective+peptide+epoxyketone+proteasome+inhibitor+%28PR-047%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)</span></div><div class="casAuthors">Zhou, Han-Jie; Aujay, Monette A.; Bennett, Mark K.; Dajee, Maya; Demo, Susan D.; Fang, Ying; Ho, Mark N.; Jiang, Jing; Kirk, Christopher J.; Laidig, Guy J.; Lewis, Evan R.; Lu, Yan; Muchamuel, Tony; Parlati, Francesco; Ring, Eileen; Shenk, Kevin D.; Shields, Jamie; Shwonek, Peter J.; Stanton, Timothy; Sun, Congcong M.; Sylvain, Catherine; Woo, Tina M.; Yang, Jinfu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3028-3038</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epoxypeptides such as I are prepd. as carfilzomib analogs and proteasome inhibitors for use as antitumor agents; the inhibition of human 20S proteasomes and of the growth of multidrug-resistant and nonresistant cancer cells by selected compds. and their stabilities in simulated gastric and intestinal fluids and in liver microsomes are detd.  I selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (β5) and immunoproteasome (LMP7) and demonstrated an abs. bioavailability of up to 39% in rodents and dogs.  I is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response equiv. to i.v. administered carfilzomib in multiple human tumor xenograft and mouse syngeneic models.  I is prepd. in eight steps (longest linear sequence) from Cbz-L-phenylalanine, Boc-O-methyl-L-serine, 2-methyl-5-thiazolecarboxylic acid, and isopropenylmagnesium bromide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouNBIBwb8w47Vg90H21EOLACvtfcHk0ljB0i38cODw5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFemtLw%253D&md5=688c8d0942539bab2e50617d083bf89a</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm801329v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801329v%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.-J.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBennett%26aufirst%3DM.%2BK.%26aulast%3DDajee%26aufirst%3DM.%26aulast%3DDemo%26aufirst%3DS.%2BD.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DHo%26aufirst%3DM.%2BN.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DLaidig%26aufirst%3DG.%2BJ.%26aulast%3DLewis%26aufirst%3DE.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMuchamuel%26aufirst%3DT.%26aulast%3DParlati%26aufirst%3DF.%26aulast%3DRing%26aufirst%3DE.%26aulast%3DShenk%26aufirst%3DK.%2BD.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DShwonek%26aufirst%3DP.%2BJ.%26aulast%3DStanton%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DC.%2BM.%26aulast%3DSylvain%26aufirst%3DC.%26aulast%3DWoo%26aufirst%3DT.%2BM.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520an%2520orally%2520bioavailable%2520and%2520selective%2520peptide%2520epoxyketone%2520proteasome%2520inhibitor%2520%2528PR-047%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D3028%26epage%3D3038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group">Peese, K.</span><span> </span><span class="NLM_article-title">Orally bioavailable proteasome inhibitors: preclinical development of PR-047</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">906</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=905-906&author=K.+Peese&title=Orally+bioavailable+proteasome+inhibitors%3A+preclinical+development+of+PR-047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeese%26aufirst%3DK.%26atitle%3DOrally%2520bioavailable%2520proteasome%2520inhibitors%253A%2520preclinical%2520development%2520of%2520PR-047%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D905%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, C. M.</span><span> </span><span class="NLM_article-title">Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2600</span><span class="NLM_x">–</span> <span class="NLM_lpage">2605</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm070421s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2600-2605&author=K.+B.+Kimauthor=C.+M.+Crews&title=Chemical+genetics%3A+exploring+the+role+of+the+proteasome+in+cell+biology+using+natural+products+and+other+small+molecule+proteasome+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1021%2Fjm070421s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070421s%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DChemical%2520genetics%253A%2520exploring%2520the%2520role%2520of%2520the%2520proteasome%2520in%2520cell%2520biology%2520using%2520natural%2520products%2520and%2520other%2520small%2520molecule%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2600%26epage%3D2605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krupnik, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConkey, D.</span><span> </span><span class="NLM_article-title">The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1836</span><span class="NLM_x">–</span> <span class="NLM_lpage">1843</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-06-0066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16891470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1836-1843&author=S.+Ruizauthor=Y.+Krupnikauthor=M.+Keatingauthor=J.+Chandraauthor=M.+Palladinoauthor=D.+McConkey&title=The+proteasome+inhibitor+NPI-0052+is+a+more+effective+inducer+of+apoptosis+than+bortezomib+in+lymphocytes+from+patients+with+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia</span></div><div class="casAuthors">Ruiz, Stacey; Krupnik, Yelena; Keating, Michael; Chandra, Joya; Palladino, Michael; McConkey, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1836-1843</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Proteasome inhibitors are potent inducers of apoptosis in isolated lymphocytes from patients with chronic lymphocytic leukemia (CLL).  However, the reversible proteasome inhibitor bortezomib (PS-341; Velcade) did not display substantial antitumor activity in CLL patients.  Here, we compared the effects of bortezomib and a new irreversible proteasome inhibitor (NPI-0052) on 20S chymotryptic proteasome activity and apoptosis in isolated CLL cells in vitro.  Although their steady-state (3 h) IC50s as proteasome inhibitors were similar, NPI-0052 exerted its effects more rapidly than bortezomib, and drug washout expts. showed that short exposures to NPI-0052 resulted in sustained (≥24 h) 20S proteasome inhibition, whereas 20S activity recovered in cells exposed to even 10-fold higher concns. of bortezomib.  Thus, brief (15 min) pulses of NPI-0052 were sufficient to induce substantial apoptosis in CLL cells, whereas longer exposure times (≥8 h) were required for commitment to apoptosis in cells exposed to equiv. concns. of bortezomib.  Commitment to apoptosis seemed to be related to caspase-4 activation, in that cells exposed to bortezomib or NPI-0052 could be saved from death by addn. of a selective caspase-4 inhibitor up to 8 h after drug exposure.  Our results show that NPI-0052 is a more effective proapoptotic agent than bortezomib in isolated CLL cells and suggest that the chem. properties of NPI-0052 might also make it an effective therapeutic agent in CLL patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsejYcANSNgrVg90H21EOLACvtfcHk0lha0ZMiTME4ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksbk%253D&md5=c4522479c523151d6c6d44c197c67fd7</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0066%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DKrupnik%26aufirst%3DY.%26aulast%3DKeating%26aufirst%3DM.%26aulast%3DChandra%26aufirst%3DJ.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DMcConkey%26aufirst%3DD.%26atitle%3DThe%2520proteasome%2520inhibitor%2520NPI-0052%2520is%2520a%2520more%2520effective%2520inducer%2520of%2520apoptosis%2520than%2520bortezomib%2520in%2520lymphocytes%2520from%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1836%26epage%3D1843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group">Miller, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palladino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandra, J.</span><span> </span><span class="NLM_article-title">Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">4289</span><span class="NLM_x">–</span> <span class="NLM_lpage">4299</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4289-4299&author=C.+P.+Millerauthor=S.+Rudraauthor=M.+J.+Keatingauthor=W.+G.+Wierdaauthor=M.+Palladinoauthor=J.+Chandra&title=Caspase-8+dependent+histone+acetylation+by+a+novel+proteasome+inhibitor%2C+NPI-0052%3A+a+mechanism+for+synergy+in+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DC.%2BP.%26aulast%3DRudra%26aufirst%3DS.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DPalladino%26aufirst%3DM.%26aulast%3DChandra%26aufirst%3DJ.%26atitle%3DCaspase-8%2520dependent%2520histone%2520acetylation%2520by%2520a%2520novel%2520proteasome%2520inhibitor%252C%2520NPI-0052%253A%2520a%2520mechanism%2520for%2520synergy%2520in%2520leukemia%2520cells%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4289%26epage%3D4299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group">Dick, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, P. E.</span><span> </span><span class="NLM_article-title">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.drudis.2010.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=20116451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=243-249&author=L.+R.+Dickauthor=P.+E.+Fleming&title=Building+on+bortezomib%3A+second-generation+proteasome+inhibitors+as+anti-cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy</span></div><div class="casAuthors">Dick, Lawrence R.; Fleming, Paul E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5/6</span>),
    <span class="NLM_cas:pages">243-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Inhibition of the proteasome (a highly abundant enzymic complex responsible for intracellular protein turnover) is an effective anti-cancer therapeutic approach, as demonstrated by the first-in-class agent bortezomib.  Various new proteasome inhibitors are now in development, including peptide boronic acid analogs MLN9708 and CEP-18770, peptide epoxyketones carfilzomib and PR-047, and NPI-0052, a β-lactone compd.  All are potent inhibitors of proteasome activity in vitro but show differences in enzyme binding kinetics, which might affect their pharmacol. and result in different efficacy and safety profiles.  Here, we review the second-generation proteasome inhibitors and assess the potential pharmacol. impact of their different chem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuklkNi02WRbVg90H21EOLACvtfcHk0lha0ZMiTME4ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFyns7s%253D&md5=6a6ceeb81601f467ea56debc9f607738</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DDick%26aufirst%3DL.%2BR.%26aulast%3DFleming%26aufirst%3DP.%2BE.%26atitle%3DBuilding%2520on%2520bortezomib%253A%2520second-generation%2520proteasome%2520inhibitors%2520as%2520anti-cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D243%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Clinical activity of tipifarnib in hematologic malignancies</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=381-392&author=E.+Jabbourauthor=H.+Kantarjianauthor=J.+Cortes&title=Clinical+activity+of+tipifarnib+in+hematologic+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DClinical%2520activity%2520of%2520tipifarnib%2520in%2520hematologic%2520malignancies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D381%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span> </span><span class="NLM_article-title">Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene</span> <span class="citation_source-journal">J. Exp. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">181</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=1995&pages=307-313&author=C.+L.+Sawyersauthor=J.+McLaughlinauthor=O.+N.+Witte&title=Genetic+requirement+for+Ras+in+the+transformation+of+fibroblasts+and+hematopoietic+cells+by+the+Bcr-Abl+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DMcLaughlin%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DGenetic%2520requirement%2520for%2520Ras%2520in%2520the%2520transformation%2520of%2520fibroblasts%2520and%2520hematopoietic%2520cells%2520by%2520the%2520Bcr-Abl%2520oncogene%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1995%26volume%3D181%26spage%3D307%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action</span> <span class="citation_source-journal">Leuk. Lymphoma</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2187</span><span class="NLM_x">–</span> <span class="NLM_lpage">2195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1080%2F10428190412331272677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15512806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFGgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=2187-2195&author=E.+Jabbourauthor=H.+Kantarjianauthor=J.+Cortes&title=Clinical+activity+of+farnesyl+transferase+inhibitors+in+hematologic+malignancies%3A+possible+mechanisms+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Activity of Farnesyl Transferase Inhibitors in Hematologic Malignancies: Possible Mechanisms of Action</span></div><div class="casAuthors">Jabbour, Elias; Kantarjian, Hagop; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2187-2195</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Farnesyl transferase inhibitors (FTIs) are a novel class of anti-cancer agents that competitively inhibit farnesyl protein transferase (FTase).  Initially developed to inhibit the prenylation necessary for Ras activation, their mechanism of action seems to be more complex, involving other proteins unrelated to Ras.  FTIs have been developed and tested across a wide range of human cancers.  At least 3 agents within this family have been investigated in hematol. malignancies.  These are tipifarnib (R115777, Zarnestra), lonafarnib (SCH66336, SarasarTM), both of which are orally administered, and BMS-214662, which is given i.v.  Preliminary results from clin. trials demonstrate enzyme target inhibition, a favorable toxicity profile and promising efficacy.  Ongoing studies will better det. their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6YPfzcgcuRrVg90H21EOLACvtfcHk0lhCncCI1Ybg6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFGgt7s%253D&md5=a88cf71dee56244c04321f42671221d5</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1080%2F10428190412331272677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428190412331272677%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DClinical%2520activity%2520of%2520farnesyl%2520transferase%2520inhibitors%2520in%2520hematologic%2520malignancies%253A%2520possible%2520mechanisms%2520of%2520action%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2004%26volume%3D45%26spage%3D2187%26epage%3D2195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soignet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deutsch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazina, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pezzuli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spriggs, D.</span><span> </span><span class="NLM_article-title">A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3894</span><span class="NLM_x">–</span> <span class="NLM_lpage">3903</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=11751480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD38XltV2qtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3894-3903&author=C.+D.+Brittenauthor=E.+K.+Rowinskyauthor=S.+Soignetauthor=A.+Patnaikauthor=S.+L.+Yaoauthor=P.+Deutschauthor=Y.+Leeauthor=R.+B.+Lobellauthor=K.+E.+Mazinaauthor=H.+McCreeryauthor=S.+Pezzuliauthor=D.+Spriggs&title=A+phase+I+and+pharmacological+study+of+the+farnesyl+protein+transferase+inhibitor+L-778%2C123+in+patients+with+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies</span></div><div class="casAuthors">Britten, Carolyn D.; Rowinsky, Eric K.; Soignet, Steven; Patnaik, Amita; Yao, Siu-Long; Deutsch, Paul; Lee, Yih; Lobell, Robert B.; Mazina, Kathryn E.; McCreery, Heather; Pezzuli, Sandy; Spriggs, David</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3894-3903</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This Phase I study was performed to assess the feasibility of administering L-778,123, a peptidomimetic farnesyl protein transferase (FPTase) inhibitor, as a continuous i.v. infusion for 7 days every 3 wk and to det. the recommended dose for subsequent disease-directed trials.  This study also sought to characterize the pharmacol. behavior of L-778,123 and to det. whether the desired biol. effect, inhibition of protein farnesylation, could be detected and assessed during treatment.  Patients with advanced solid malignancies were treated with L-778,123 as a continuous i.v. infusion for 7 days every 3 wk at doses ranging from 35 to 1120 mg/m2/day.  On the basis of preclin. studies, toxicity assessments included cardiac telemetry, electrocardiograms, and electroretinograms in addn. to more routine safety monitoring lab. tests.  Plasma sampling was performed to characterize the pharmacokinetics of L-778,123, and peripheral blood mononuclear cells (PBMCs) were sampled to detect and monitor the inhibitory effects of L-778,123 on the prenylation of HDJ2, a chaperone protein that undergoes farnesylation.  Twenty-five patients received 51 complete courses of L-778,123.  An unacceptably high incidence of dose-limiting toxicities, consisting of grade 4 thrombocytopenia, significant prolongation of the QTc interval, and profound fatigue, was obsd. at the 1120 mg/m2/day dose level.  At the next lower L-778,123 dose level, 560 mg/m2/day, seven new patients had no unacceptable toxicity.  Instead, myelosuppression was mild to moderate and QTc prolongation was negligible.  Pharmacokinetics were linear, and L-778,123 plasma concns. at steady-state (mean, 8.09 ± 3.11 μM at 560 mg/m2/day) exceeded IC50 values (range, 0.07-5.35 μM) required for growth inhibition and cytotoxicity in preclin. studies.  The systemic clearance of L-778,123 averaged 106.4 ± 45.6 mL/min/m2, and the terminal half-life of elimination was 2.8 ± 1.0 h.  L-778,123 inhibited HDJ2 prenylation for the duration of the drug infusion in a dose-dependent manner, but seemed to plateau above 560 mg/m2/day.  At the 560 mg/m2/day dose level, the mean percentage of HDJ2 protein in its unprenylated form increased from 1.41% ± 1.71% (pretreatment) to 28.76% ± 6.10% (day 4) and 30.86 ± 4.96 (day 8) and declined to 2.28% ± 2.11% one week after drug discontinuation (day 16).  L-778,123 administered as a continuous 7-day i.v. infusion for 7 days every 21 days is well tolerated at doses of 560 mg/m2/day and results in biol. relevant concns. and consistent inhibition of HDJ2 prenylation in PBMCs.  Although the relationship between drug-related inhibition of HDJ2 prenylation in PBMCs and both prenylation of relevant proteins and growth inhibition in tumor cells is unknown, serial analyses of HDJ2 prenylation provide a pharmacodynamic marker of protein prenylation that may be useful in optimizing the development of drugs targeting FPTase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvNQ9MDGkiAbVg90H21EOLACvtfcHk0lhCncCI1Ybg6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltV2qtA%253D%253D&md5=e598b14bc9b6b808e66a9caa42beb683</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26aulast%3DSoignet%26aufirst%3DS.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DS.%2BL.%26aulast%3DDeutsch%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DMazina%26aufirst%3DK.%2BE.%26aulast%3DMcCreery%26aufirst%3DH.%26aulast%3DPezzuli%26aufirst%3DS.%26aulast%3DSpriggs%26aufirst%3DD.%26atitle%3DA%2520phase%2520I%2520and%2520pharmacological%2520study%2520of%2520the%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520L-778%252C123%2520in%2520patients%2520with%2520solid%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3894%26epage%3D3903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhide, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penhallow, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricca, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusarchyk, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-7-cyano-2,3,4, 5-tetrahydro-1-(1<i>H</i>-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1<i>H</i>-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3587</span><span class="NLM_x">–</span> <span class="NLM_lpage">3595</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000248z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3587-3595&author=J.+T.+Huntauthor=C.+Z.+Dingauthor=R.+Batorskyauthor=M.+Bednarzauthor=R.+Bhideauthor=Y.+Choauthor=S.+Chongauthor=S.+Chaoauthor=J.+Gullo-Brownauthor=P.+Guoauthor=S.+H.+Kimauthor=F.+Y.+Leeauthor=K.+Leftherisauthor=A.+Millerauthor=T.+Mittauthor=M.+Patelauthor=B.+A.+Penhallowauthor=C.+Riccaauthor=W.+C.+Roseauthor=R.+Schmidtauthor=W.+A.+Slusarchykauthor=G.+Viteauthor=V.+Manne&title=Discovery+of+%28R%29-7-cyano-2%2C3%2C4%2C+5-tetrahydro-1-%281H-imidazol-4-ylmethyl%29-3-+%28phenylmethyl%29-4-%282-thienylsulfonyl%29-1H-1%2C4-benzodiazepine+%28BMS-214662%29%2C+a+farnesyltransferase+inhibitor+with+potent+preclinical+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1021%2Fjm000248z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000248z%26sid%3Dliteratum%253Aachs%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DDing%26aufirst%3DC.%2BZ.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%26aulast%3DBhide%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DChong%26aufirst%3DS.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMitt%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPenhallow%26aufirst%3DB.%2BA.%26aulast%3DRicca%26aufirst%3DC.%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DSlusarchyk%26aufirst%3DW.%2BA.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DManne%26aufirst%3DV.%26atitle%3DDiscovery%2520of%2520%2528R%2529-7-cyano-2%252C3%252C4%252C%25205-tetrahydro-1-%25281H-imidazol-4-ylmethyl%2529-3-%2520%2528phenylmethyl%2529-4-%25282-thienylsulfonyl%2529-1H-1%252C4-benzodiazepine%2520%2528BMS-214662%2529%252C%2520a%2520farnesyltransferase%2520inhibitor%2520with%2520potent%2520preclinical%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3587%26epage%3D3595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group">Venet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span> </span><span class="NLM_article-title">Farnesyl protein transferase inhibitor ZARNESTRA R115777—history of a discovery</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1095</span><span class="NLM_x">–</span> <span class="NLM_lpage">1102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F1568026033452050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12769710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=1095-1102&author=M.+Venetauthor=D.+Endauthor=P.+Angibaud&title=Farnesyl+protein+transferase+inhibitor+ZARNESTRA+R115777%E2%80%94history+of+a+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery</span></div><div class="casAuthors">Venet, Marc; End, David; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1095-1102</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  R115777 (R)-6-amino[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl) methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice.  Taking its roots into Janssen's ketoconazole and retinoic acid catabolism programs, our interest into Ras prenylation process led us stepwise to identify the key structural features of R115777.  Methodol., structure activity relationships, and pharmacol. will be presented.  R115777 is currently in phase III clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtyeCXKOTqLVg90H21EOLACvtfcHk0lh8jvgTVKYolw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLo%253D&md5=c96fe763cddde79d030cec6a51c04fc7</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.2174%2F1568026033452050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026033452050%26sid%3Dliteratum%253Aachs%26aulast%3DVenet%26aufirst%3DM.%26aulast%3DEnd%26aufirst%3DD.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DFarnesyl%2520protein%2520transferase%2520inhibitor%2520ZARNESTRA%2520R115777%25E2%2580%2594history%2520of%2520a%2520discovery%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26spage%3D1095%26epage%3D1102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group">Zujewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horak, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woestenborghs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">End, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrovsky, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopp, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noone, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakim, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gress, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussenblatt, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan, K. H.</span><span> </span><span class="NLM_article-title">Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">927</span><span class="NLM_x">–</span> <span class="NLM_lpage">941</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=10673536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1aku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=927-941&author=J.+Zujewskiauthor=I.+D.+Horakauthor=C.+J.+Bolauthor=R.+Woestenborghsauthor=C.+Bowdenauthor=D.+W.+Endauthor=V.+K.+Piotrovskyauthor=J.+Chiaoauthor=R.+T.+Bellyauthor=A.+Toddauthor=W.+C.+Koppauthor=D.+R.+Kohlerauthor=C.+Chowauthor=M.+Nooneauthor=F.+T.+Hakimauthor=G.+Larkinauthor=R.+E.+Gressauthor=R.+B.+Nussenblattauthor=A.+B.+Kremerauthor=K.+H.+Cowan&title=Phase+I+and+pharmacokinetic+study+of+farnesyl+protein+transferase+inhibitor+R115777+in+advanced+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer</span></div><div class="casAuthors">Zujewski, J.; Horak, I. D.; Bol, C. J.; Woestenborghs, R.; Bowden, C.; End, D. W.; Piotrovsky, V. K.; Chiao, J.; Belly, R. T.; Todd, A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F. T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.; Cowan, K. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">927-941</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To det. the max.-tolerated dose, toxicities, and pharmacokinetic profile of the farnesyl protein transferase inhibitor R115777 when administered orally bid for 5 days every 2 wk.  Patients and Methods: Twenty-seven patients with a median age of 58 yr received 85 cycles of R115777 using an intrapatient and interpatient dose escalation schema.  Drug was administered orally at escalating doses as a soln. (25 to 850 mg bid) or as pellet capsules (500 to 1300 mg bid).  Pharmacokinetics were assessed after the first dose and the last dose administered during cycle 1.  Results: Dose-limiting toxicity of grade 3 neuropathy was obsd. in one patient and grade 2 fatigue (decrease in two performance status levels) was seen in four of six patients treated with 1,300 mg bid.  The most frequent clin. grade 2 or 3 adverse events in any cycle included nausea, vomiting, headache, fatigue, anemia, and hypotension.  Myelosuppression was mild and infrequent.  Peak plasma concns. of R115777 were achieved within 0.5 to 4 h after oral drug administration.  The elimination of R115777 from plasma was biphasic, with sequential half-lives of about 5 h and 16 h.  There was little drug accumulation after bid dosing, and steady-state concns. were achieved within 2 to 3 days.  The pharmacokinetics were dose proportional in the 25 to 325 mg/dose range for the oral soln.  Urinary excretion of unchanged R115777 was less than 0.1% of the oral dose.  One patient with metastatic colon cancer treated at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, and radiog. stable disease for 5 mo.  Conclusion: R115777 is bioavailable after oral administration and has an acceptable toxicity profile.  Based upon pharmacokinetic data, the recommended dose for phase II trials is 500 mg orally bid (total daily dose, 1,000 mg) for 5 consecutive days followed by 9 days of rest.  Studies of continuous dosing and studies of R115777 in combination with chemotherapy are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj_0aFhrLXFLVg90H21EOLACvtfcHk0lh8jvgTVKYolw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1aku7s%253D&md5=8cb117c4efd19580a0c99468e5d4d2e1</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZujewski%26aufirst%3DJ.%26aulast%3DHorak%26aufirst%3DI.%2BD.%26aulast%3DBol%26aufirst%3DC.%2BJ.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DBowden%26aufirst%3DC.%26aulast%3DEnd%26aufirst%3DD.%2BW.%26aulast%3DPiotrovsky%26aufirst%3DV.%2BK.%26aulast%3DChiao%26aufirst%3DJ.%26aulast%3DBelly%26aufirst%3DR.%2BT.%26aulast%3DTodd%26aufirst%3DA.%26aulast%3DKopp%26aufirst%3DW.%2BC.%26aulast%3DKohler%26aufirst%3DD.%2BR.%26aulast%3DChow%26aufirst%3DC.%26aulast%3DNoone%26aufirst%3DM.%26aulast%3DHakim%26aufirst%3DF.%2BT.%26aulast%3DLarkin%26aufirst%3DG.%26aulast%3DGress%26aufirst%3DR.%2BE.%26aulast%3DNussenblatt%26aufirst%3DR.%2BB.%26aulast%3DKremer%26aufirst%3DA.%2BB.%26aulast%3DCowan%26aufirst%3DK.%2BH.%26atitle%3DPhase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520R115777%2520in%2520advanced%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2000%26volume%3D18%26spage%3D927%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span> </span><span class="NLM_article-title">In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">849</span><span class="NLM_x">–</span> <span class="NLM_lpage">855</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=849-855&author=R.+A.+Mesaauthor=A.+Tefferiauthor=L.+A.+Grayauthor=T.+Reederauthor=G.+Schroederauthor=S.+H.+Kaufmann&title=In+vitro+antiproliferative+activity+of+the+farnesyltransferase+inhibitor+R115777+in+hematopoietic+progenitors+from+patients+with+myelofibrosis+with+myeloid+metaplasia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DL.%2BA.%26aulast%3DReeder%26aufirst%3DT.%26aulast%3DSchroeder%26aufirst%3DG.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DIn%2520vitro%2520antiproliferative%2520activity%2520of%2520the%2520farnesyltransferase%2520inhibitor%2520R115777%2520in%2520hematopoietic%2520progenitors%2520from%2520patients%2520with%2520myelofibrosis%2520with%2520myeloid%2520metaplasia%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D849%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group">Yanamandra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colaco, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parquet, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buzzeo, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulware, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaupre, D. M.</span><span> </span><span class="NLM_article-title">Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1078-0432.CCR-05-1792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16428505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=591-599&author=N.+Yanamandraauthor=N.+M.+Colacoauthor=N.+A.+Parquetauthor=R.+W.+Buzzeoauthor=D.+Boulwareauthor=G.+Wrightauthor=L.+E.+Perezauthor=W.+S.+Daltonauthor=D.+M.+Beaupre&title=Tipifarnib+and+bortezomib+are+synergistic+and+overcome+cell+adhesion-mediated+drug+resistance+in+multiple+myeloma+and+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Tipifarnib and Bortezomib are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia</span></div><div class="casAuthors">Yanamandra, Niranjan; Colaco, Nandita M.; Parquet, Nancy A.; Buzzeo, Robert W.; Boulware, David; Wright, Gabriela; Perez, Lia E.; Dalton, William S.; Beaupre, Darrin M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">591-599</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">It has been established in preclin. models of multiple myeloma and acute myeloid leukemia (AML) that the bone marrow microenvironment provides protection from chemotherapy- and death receptor-mediated apoptosis.  This form of resistance, termed de novo drug resistance, occurs independent of chronic exposure to cancer-related therapies and likely promotes the development of multidrug resistance.  Consequently, it is of major interest to identify compds. or drug combinations that can overcome environment-mediated resistance.  In this study, we investigated the activity of tipifarnib (Zarnestra, formerly R115777) combined with bortezomib (Velcade, formerly PS-341) in microenvironment models of multiple myeloma and AML.  The combination proved to be synergistic in multiple myeloma and AML cell lines treated in suspension culture.  Even in tumor cells relatively resistant to tipifarnib, combined activity was maintained.  Tipifarnib and bortezomib were also effective when multiple myeloma and AML cells were adhered to fibronectin, providing evidence that the combination overcomes cell adhesion-mediated drug resistance (CAM-DR).  Of importance, activation of the endoplasmic reticulum stress response was enhanced and correlated with apoptosis and reversal of CAM-DR.  Multiple myeloma and AML cells cocultured with bone marrow stromal cells also remained sensitive, although stromal-adhered tumor cells were partially protected (relative to cells in suspension or fibronectin adhered).  Evaluation of the combination using a transwell app. revealed that stromal cells produce a protective sol. factor.  Investigations are under way to identify the cytokines and/or growth factors involved.  In summary, our study provides the preclin. rationale for trials testing the tipifarnib and bortezomib combination in patients with multiple myeloma and AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa3pLLNQpARLVg90H21EOLACvtfcHk0ljeW7fsTsQP9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlKgsw%253D%253D&md5=69fb7360fcc8b0ca5f5fed7844383b99</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1792%26sid%3Dliteratum%253Aachs%26aulast%3DYanamandra%26aufirst%3DN.%26aulast%3DColaco%26aufirst%3DN.%2BM.%26aulast%3DParquet%26aufirst%3DN.%2BA.%26aulast%3DBuzzeo%26aufirst%3DR.%2BW.%26aulast%3DBoulware%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DPerez%26aufirst%3DL.%2BE.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26atitle%3DTipifarnib%2520and%2520bortezomib%2520are%2520synergistic%2520and%2520overcome%2520cell%2520adhesion-mediated%2520drug%2520resistance%2520in%2520multiple%2520myeloma%2520and%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D591%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group">Njoroge, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remiszewski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallams, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonso, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vibulbhan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deskus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarez, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Rosario, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossman, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganguly, A. K.</span><span> </span><span class="NLM_article-title">(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11(<i>R</i>)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">4890</span><span class="NLM_x">–</span> <span class="NLM_lpage">4902</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm980462b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4890-4902&author=F.+G.+Njorogeauthor=A.+G.+Taverasauthor=J.+Kellyauthor=S.+Remiszewskiauthor=A.+K.+Mallamsauthor=R.+Wolinauthor=A.+Afonsoauthor=A.+B.+Cooperauthor=D.+F.+Raneauthor=Y.+T.+Liuauthor=J.+Wongauthor=B.+Vibulbhanauthor=P.+Pintoauthor=J.+Deskusauthor=C.+S.+Alvarezauthor=J.+del+Rosarioauthor=M.+Connollyauthor=J.+Wangauthor=J.+Desaiauthor=R.+R.+Rossmanauthor=W.+R.+Bishopauthor=R.+Pattonauthor=L.+Wangauthor=P.+Kirschmeierauthor=A.+K.+Ganguly&title=%28%2B%29-4-%5B2-%5B4-%288-Chloro-3%2C10-dibromo-6%2C11-dihydro-5H-benzo%5B5%2C6%5Dcyclohepta%5B1%2C2-b%5Dpyridin-11%28R%29-yl%29-1-piperidinyl%5D-2-oxo-ethyl%5D-1-piperidinecarboxamide+%28SCH-66336%29%3A+a+very+potent+farnesyl+protein+transferase+inhibitor+as+a+novel+antitumor+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm980462b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980462b%26sid%3Dliteratum%253Aachs%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DRemiszewski%26aufirst%3DS.%26aulast%3DMallams%26aufirst%3DA.%2BK.%26aulast%3DWolin%26aufirst%3DR.%26aulast%3DAfonso%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DA.%2BB.%26aulast%3DRane%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DDeskus%26aufirst%3DJ.%26aulast%3DAlvarez%26aufirst%3DC.%2BS.%26aulast%3Ddel%2BRosario%26aufirst%3DJ.%26aulast%3DConnolly%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DR.%2BR.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DPatton%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DGanguly%26aufirst%3DA.%2BK.%26atitle%3D%2528%252B%2529-4-%255B2-%255B4-%25288-Chloro-3%252C10-dibromo-6%252C11-dihydro-5H-benzo%255B5%252C6%255Dcyclohepta%255B1%252C2-b%255Dpyridin-11%2528R%2529-yl%2529-1-piperidinyl%255D-2-oxo-ethyl%255D-1-piperidinecarboxamide%2520%2528SCH-66336%2529%253A%2520a%2520very%2520potent%2520farnesyl%2520protein%2520transferase%2520inhibitor%2520as%2520a%2520novel%2520antitumor%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4890%26epage%3D4902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doll, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lalwani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girijavallabhan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsor, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollinger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomeir, A.</span><span> </span><span class="NLM_article-title">Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11(<i>R</i>)-yl)-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3854</span><span class="NLM_x">–</span> <span class="NLM_lpage">3864</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm010463v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3854-3864&author=A.+G.+Taverasauthor=C.+Akiauthor=J.+Chaoauthor=R.+J.+Dollauthor=T.+Lalwaniauthor=V.+Girijavallabhanauthor=C.+L.+Stricklandauthor=W.+T.+Windsorauthor=P.+Weberauthor=F.+Hollingerauthor=M.+Snowauthor=R.+Pattonauthor=P.+Kirschmeierauthor=L.+Jamesauthor=M.+Liuauthor=A.+Nomeir&title=Exploring+the+role+of+bromine+at+C%2810%29+of+%28%2B%29-4-%5B2-%5B4-%288-chloro-3%2C10-dibromo-+6%2C11-dihydro-5H-benzo%5B5%2C6%5Dcyclohepta%5B1%2C2-b%5Dpyridin-11%28R%29-yl%29-1-piperidinyl%5D-2-oxoethyl%5D-1-piperidinecarboxamide+%28Sch-66336%29%3A+the+discovery+of+indolocycloheptapyridine+inhibitors+of+farnesyl+protein+transferase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1021%2Fjm010463v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010463v%26sid%3Dliteratum%253Aachs%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DAki%26aufirst%3DC.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DLalwani%26aufirst%3DT.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DStrickland%26aufirst%3DC.%2BL.%26aulast%3DWindsor%26aufirst%3DW.%2BT.%26aulast%3DWeber%26aufirst%3DP.%26aulast%3DHollinger%26aufirst%3DF.%26aulast%3DSnow%26aufirst%3DM.%26aulast%3DPatton%26aufirst%3DR.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNomeir%26aufirst%3DA.%26atitle%3DExploring%2520the%2520role%2520of%2520bromine%2520at%2520C%252810%2529%2520of%2520%2528%252B%2529-4-%255B2-%255B4-%25288-chloro-3%252C10-dibromo-%25206%252C11-dihydro-5H-benzo%255B5%252C6%255Dcyclohepta%255B1%252C2-b%255Dpyridin-11%2528R%2529-yl%2529-1-piperidinyl%255D-2-oxoethyl%255D-1-piperidinecarboxamide%2520%2528Sch-66336%2529%253A%2520the%2520discovery%2520of%2520indolocycloheptapyridine%2520inhibitors%2520of%2520farnesyl%2520protein%2520transferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3854%26epage%3D3864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirschmeier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span> </span><span class="NLM_article-title">Sch-66336 (Sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1103</span><span class="NLM_x">–</span> <span class="NLM_lpage">1114</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2174%2F1568026033452104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=12769711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=1103-1114&author=A.+G.+Taverasauthor=P.+Kirschmeierauthor=C.+M.+Baum&title=Sch-66336+%28Sarasar%29+and+other+benzocycloheptapyridyl+farnesyl+protein+transferase+inhibitors%3A+discovery%2C+biology+and+clinical+observations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Sch-66336 (Sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: Discovery, biology and clinical observations</span></div><div class="casAuthors">Taveras, Arthur G.; Kirschmeier, Paul; Baum, Charles M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1103-1114</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clin. trials.  Sch-66336 (Sarasar), a benzocycloheptapyridyl Farnesyl Transferase Inhibitor (FTI), has been effective in cellular proliferation assays and in in vivo oncol. models both as a single agent and in combination with other anti-cancer agents.  Clin., early evidence is being generated that suggests efficacy in humans, particularly in patients with leukemia.  Herein, we review the biol. of FPT, the discovery of Sch-66336 and other benzocycloheptapyridyl FTIs, and the clin. evaluation of Sch-66336 for the treatment of leukemia and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHkVTUw3LvDLVg90H21EOLACvtfcHk0ljeW7fsTsQP9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjslGlsLs%253D&md5=5fd2662afbbe26c76ed68098c5739081</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.2174%2F1568026033452104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026033452104%26sid%3Dliteratum%253Aachs%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26atitle%3DSch-66336%2520%2528Sarasar%2529%2520and%2520other%2520benzocycloheptapyridyl%2520farnesyl%2520protein%2520transferase%2520inhibitors%253A%2520discovery%252C%2520biology%2520and%2520clinical%2520observations%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2003%26volume%3D3%26spage%3D1103%26epage%3D1114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group">Rose, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monticello, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span> </span><span class="NLM_article-title">Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">7507</span><span class="NLM_x">–</span> <span class="NLM_lpage">7517</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7507-7517&author=W.+C.+Roseauthor=F.+Y.+Leeauthor=C.+R.+Fairchildauthor=M.+Lynchauthor=T.+Monticelloauthor=R.+A.+Kramerauthor=V.+Manne&title=Preclinical+antitumor+activity+of+BMS-214662%2C+a+highly+apoptotic+and+novel+farnesyltransferase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DFairchild%26aufirst%3DC.%2BR.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DMonticello%26aufirst%3DT.%26aulast%3DKramer%26aufirst%3DR.%2BA.%26aulast%3DManne%26aufirst%3DV.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520BMS-214662%252C%2520a%2520highly%2520apoptotic%2520and%2520novel%2520farnesyltransferase%2520inhibitor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7507%26epage%3D7517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurzrock, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrajoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2805</span><span class="NLM_x">–</span> <span class="NLM_lpage">2812</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2005.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=15728224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktleqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=2805-2812&author=J.+Cortesauthor=S.+Faderlauthor=E.+Esteyauthor=R.+Kurzrockauthor=D.+Thomasauthor=M.+Beranauthor=G.+Garcia-Maneroauthor=A.+Ferrajoliauthor=F.+Gilesauthor=C.+Kollerauthor=S.+O%E2%80%99Brienauthor=J.+Wrightauthor=S.+A.+Baiauthor=H.+Kantarjian&title=Phase+I+study+of+BMS-214662%2C+a+farnesyl+transferase+inhibitor+in+patients+with+acute+leukemias+and+high-risk+myelodysplastic+syndromes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes</span></div><div class="casAuthors">Cortes, Jorge; Faderl, Stefan; Estey, Elihu; Kurzrock, Razelle; Thomas, Deborah; Beran, Miloslav; Garcia-Manero, Guillermo; Ferrajoli, Alessandra; Giles, Francis; Koller, Charles; O'Brien, Susan; Wright, John; Bai, Stephen A.; Kantarjian, Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2805-2812</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The aim of this study was to investigate the dose-limiting toxicity (DLT) and max.-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS).  Patients with relapsed or refractory acute leukemias or MDS, or previously untreated but poor candidates for chemotherapy, were included in this phase I study with a 3+3 dose escalation design.  BMS-214662 was administered as a 1-h bolus once weekly at doses of 42 to 157 mg/m2.  Once the MTD was identified, the schedule was changed to a 24-h continuous infusion once weekly (starting dose, 300 mg/m2).  Thirty patients were treated at a dose of 42 (n = 1), 56 (n = 3), 84 (n = 3), 118 (n = 13), 157 (n = 6) or 300 mg/m2 (n = 4).  DLT occurred in 3 patients at 157 mg/m2, including nausea, vomiting, diarrhea, hypokalemia and cardiovascular problems.  No DLT occurred with 24-h continuous infusion.  MTD with a 1-h infusion was 118 mg/m2, with no MTD identified with the 24-h infusion.  Plasma concns. of BMS-214662 correlated with the dose.  Inhibition of FTase activity of approx. 60% occurred after the infusion with recovery to near baseline after 24 h.  Five patients had evidence of antileukemia activity, including two with complete remission with incomplete platelet recovery, one with hematol. improvement, and two with morphol. leukemia-free state.  BMS-214662 is well tolerated at doses of up to 118 mg/m2 as a 1-h infusion.  The toxicity profile and efficacy may be improved with prolonged exposure.  Further investigation of this agent in leukemia is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokuHmnmuGYe7Vg90H21EOLACvtfcHk0ljet9chRQZYNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktleqtrc%253D&md5=459b44185b0d32b2d4859b33367b90aa</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKurzrock%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DD.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DFerrajoli%26aufirst%3DA.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKoller%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DS.%2BA.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DPhase%2520I%2520study%2520of%2520BMS-214662%252C%2520a%2520farnesyl%2520transferase%2520inhibitor%2520in%2520patients%2520with%2520acute%2520leukemias%2520and%2520high-risk%2520myelodysplastic%2520syndromes%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D2805%26epage%3D2812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group">Gomez-Benito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naval, J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1991</span><span class="NLM_x">–</span> <span class="NLM_lpage">1998</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=1991-1998&author=M.+Gomez-Benitoauthor=I.+Marzoauthor=A.+Anelauthor=J.+Naval&title=Farnesyltransferase+inhibitor+BMS-214662+induces+apoptosis+in+myeloma+cells+through+PUMA+up-regulation%2C+Bax+and+Bak+activation%2C+and+Mcl-1+elimination"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Benito%26aufirst%3DM.%26aulast%3DMarzo%26aufirst%3DI.%26aulast%3DAnel%26aufirst%3DA.%26aulast%3DNaval%26aufirst%3DJ.%26atitle%3DFarnesyltransferase%2520inhibitor%2520BMS-214662%2520induces%2520apoptosis%2520in%2520myeloma%2520cells%2520through%2520PUMA%2520up-regulation%252C%2520Bax%2520and%2520Bak%2520activation%252C%2520and%2520Mcl-1%2520elimination%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D1991%26epage%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group">Marzo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez-Galan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giraldo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Royuela, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Benito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larrad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasierra, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio-Felix, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naval, J.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1604</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=1599-1604&author=I.+Marzoauthor=P.+Perez-Galanauthor=P.+Giraldoauthor=N.+Lopez-Royuelaauthor=M.+Gomez-Benitoauthor=L.+Larradauthor=P.+Lasierraauthor=D.+Rubio-Felixauthor=A.+Anelauthor=J.+Naval&title=Farnesyltransferase+inhibitor+BMS-214662+induces+apoptosis+in+B-cell+chronic+lymphocytic+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarzo%26aufirst%3DI.%26aulast%3DPerez-Galan%26aufirst%3DP.%26aulast%3DGiraldo%26aufirst%3DP.%26aulast%3DLopez-Royuela%26aufirst%3DN.%26aulast%3DGomez-Benito%26aufirst%3DM.%26aulast%3DLarrad%26aufirst%3DL.%26aulast%3DLasierra%26aufirst%3DP.%26aulast%3DRubio-Felix%26aufirst%3DD.%26aulast%3DAnel%26aufirst%3DA.%26aulast%3DNaval%26aufirst%3DJ.%26atitle%3DFarnesyltransferase%2520inhibitor%2520BMS-214662%2520induces%2520apoptosis%2520in%2520B-cell%2520chronic%2520lymphocytic%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2004%26volume%3D18%26spage%3D1599%26epage%3D1604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group">Copland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allan, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holyoake, T. L.</span><span> </span><span class="NLM_article-title">BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2843</span><span class="NLM_x">–</span> <span class="NLM_lpage">2853</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2843-2853&author=M.+Coplandauthor=F.+Pellicanoauthor=L.+Richmondauthor=E.+K.+Allanauthor=A.+Hamiltonauthor=F.+Y.+Leeauthor=R.+Weinmannauthor=T.+L.+Holyoake&title=BMS-214662+potently+induces+apoptosis+of+chronic+myeloid+leukemia+stem+and+progenitor+cells+and+synergizes+with+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCopland%26aufirst%3DM.%26aulast%3DPellicano%26aufirst%3DF.%26aulast%3DRichmond%26aufirst%3DL.%26aulast%3DAllan%26aufirst%3DE.%2BK.%26aulast%3DHamilton%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWeinmann%26aufirst%3DR.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26atitle%3DBMS-214662%2520potently%2520induces%2520apoptosis%2520of%2520chronic%2520myeloid%2520leukemia%2520stem%2520and%2520progenitor%2520cells%2520and%2520synergizes%2520with%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2843%26epage%3D2853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group">Pellicano, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mountford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holyoake, T. L.</span><span> </span><span class="NLM_article-title">BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38− cells, through activation of protein kinase Cbeta</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">4186</span><span class="NLM_x">–</span> <span class="NLM_lpage">4196</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=4186-4196&author=F.+Pellicanoauthor=M.+Coplandauthor=H.+G.+Jorgensenauthor=J.+Mountfordauthor=B.+Leberauthor=T.+L.+Holyoake&title=BMS-214662+induces+mitochondrial+apoptosis+in+chronic+myeloid+leukemia+%28CML%29+stem%2Fprogenitor+cells%2C+including+CD34%2B38%E2%88%92+cells%2C+through+activation+of+protein+kinase+Cbeta"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPellicano%26aufirst%3DF.%26aulast%3DCopland%26aufirst%3DM.%26aulast%3DJorgensen%26aufirst%3DH.%2BG.%26aulast%3DMountford%26aufirst%3DJ.%26aulast%3DLeber%26aufirst%3DB.%26aulast%3DHolyoake%26aufirst%3DT.%2BL.%26atitle%3DBMS-214662%2520induces%2520mitochondrial%2520apoptosis%2520in%2520chronic%2520myeloid%2520leukemia%2520%2528CML%2529%2520stem%252Fprogenitor%2520cells%252C%2520including%2520CD34%252B38%25E2%2588%2592%2520cells%252C%2520through%2520activation%2520of%2520protein%2520kinase%2520Cbeta%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D4186%26epage%3D4196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group">Beaupre, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cepero, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obeng, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boise, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lichtenheld, M. G.</span><span> </span><span class="NLM_article-title">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=14985458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=179-186&author=D.+M.+Beaupreauthor=E.+Ceperoauthor=E.+A.+Obengauthor=L.+H.+Boiseauthor=M.+G.+Lichtenheld&title=R115777+induces+Ras-independent+apoptosis+of+myeloma+cells+via+multiple+intrinsic+pathways"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways</span></div><div class="casAuthors">Beaupre, Darrin M.; Cepero, Enrique; Obeng, Esther A.; Boise, Lawrence H.; Lichtenheld, Mathias G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Ras activation is frequently obsd. in multiple myeloma either by mutation or through interleukin-6 receptor signaling.  Recently, drugs designed to inhibit Ras have shown promise in preclin. myeloma models and in clin. trials.  In this report, we characterize the pathways by which the clin. tested farnesyl transferase inhibitor (FTI) R115777 induces apoptosis in multiple myeloma cells.  Contrary to the proposed mechanistic action of FTIs, we found that R115777 induces cell death despite Ras prenylation implying participation of Ras-independent mechanism(s).  Apoptosis proceeded via an intrinsic cascade and was assocd. with an increase in the expression and activity of Bax.  Bax activation correlated with a loss of mitochondrial membrane integrity and activation of the endoplasmic reticulum (ER) stress response.  These pathways activate caspase-9 and consistent with this, cell death was prevented by caspase-9 blockade.  Interestingly, cells over-expressing Bcl-XL remained partially sensitive to R115777 despite suppression of mitochondrial membrane dysfunction and ER-related stress.  Taken together, these results indicate that R115777 induces apoptosis in a Ras-independent fashion via multiple intrinsic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosdUKBKAfDIbVg90H21EOLACvtfcHk0liBq0L54eG29w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFCitr8%253D&md5=0f36fe2c3351caf511152fcecf89fd9f</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DCepero%26aufirst%3DE.%26aulast%3DObeng%26aufirst%3DE.%2BA.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26aulast%3DLichtenheld%26aufirst%3DM.%2BG.%26atitle%3DR115777%2520induces%2520Ras-independent%2520apoptosis%2520of%2520myeloma%2520cells%2520via%2520multiple%2520intrinsic%2520pathways%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D179%26epage%3D186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belly, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span> </span><span class="NLM_article-title">Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=56&author=M.+Raponiauthor=R.+T.+Bellyauthor=J.+E.+Karpauthor=J.+E.+Lancetauthor=D.+Atkinsauthor=Y.+Wang&title=Microarray+analysis+reveals+genetic+pathways+modulated+by+tipifarnib+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DBelly%26aufirst%3DR.%2BT.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DAtkins%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DMicroarray%2520analysis%2520reveals%2520genetic%2520pathways%2520modulated%2520by%2520tipifarnib%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBMC%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group">Braun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenaux, P.</span><span> </span><span class="NLM_article-title">Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">141</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1111%2Fj.1365-2141.2008.07099.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18410457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVaqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2008&pages=576-586&author=T.+Braunauthor=P.+Fenaux&title=Farnesyltransferase+inhibitors+and+their+potential+role+in+therapy+for+myelodysplastic+syndromes+and+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia</span></div><div class="casAuthors">Braun, Thorsten; Fenaux, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">576-586</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Novel strategies are required for treatment of acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) patients who are not eligible for intensive chemotherapy and/or allogenic stem cell transplantation.  As activating RAS mutations are frequent in these diseases, one novel approach, consisting of interfering with isoprenylation of RAS proteins by farnesyltransferase inhibitors (FTIs), has been proposed.  Clin. phase II studies with the oral FTIs tipifarnib and lonafarnib in previously untreated AML, MDS and chronic myelomonocytic leukemia yielded rather encouraging results while results in relapsed and/or refractory AML were disappointing.  Results of a phase III trial in untreated AML in the elderly with tipifarnib were also disappointing.  Clin. responses were not related to RAS mutations, suggesting addnl. actions of FTIs on other mol. targets.  The combination of existing FTIs with other treatments, such as chemotherapy (in AML) and hypomethylating agents (in MDS and AML), is under investigation.  Ongoing studies will also det. if gene profiling anal. may help to identify patients that will respond to FTIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobd4NZVItqWLVg90H21EOLACvtfcHk0lhjWBlTyHg75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVaqs7o%253D&md5=7e36330cac4bb7ae30322a67003ce56b</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2008.07099.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2008.07099.x%26sid%3Dliteratum%253Aachs%26aulast%3DBraun%26aufirst%3DT.%26aulast%3DFenaux%26aufirst%3DP.%26atitle%3DFarnesyltransferase%2520inhibitors%2520and%2520their%2520potential%2520role%2520in%2520therapy%2520for%2520myelodysplastic%2520syndromes%2520and%2520acute%2520myeloid%2520leukaemia%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2008%26volume%3D141%26spage%3D576%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group">Raz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span> </span><span class="NLM_article-title">Farnesyl transferase inhibitor resistance probed by target mutagenesis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2102</span><span class="NLM_x">–</span> <span class="NLM_lpage">2109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2102-2109&author=T.+Razauthor=V.+Nardiauthor=M.+Azamauthor=J.+Cortesauthor=G.+Q.+Daley&title=Farnesyl+transferase+inhibitor+resistance+probed+by+target+mutagenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRaz%26aufirst%3DT.%26aulast%3DNardi%26aufirst%3DV.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26atitle%3DFarnesyl%2520transferase%2520inhibitor%2520resistance%2520probed%2520by%2520target%2520mutagenesis%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2102%26epage%3D2109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group">Senderowicz, A. M.</span><span> </span><span class="NLM_article-title">Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=1-9&author=A.+M.+Senderowicz&title=Development+of+cyclin-dependent+kinase+modulators+as+novel+therapeutic+approaches+for+hematological+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26atitle%3DDevelopment%2520of%2520cyclin-dependent%2520kinase%2520modulators%2520as%2520novel%2520therapeutic%2520approaches%2520for%2520hematological%2520malignancies%26jtitle%3DLeukemia%26date%3D2001%26volume%3D15%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooker-McEldowney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broering, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozanski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colevas, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span> </span><span class="NLM_article-title">Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">404</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=399-404&author=J.+C.+Byrdauthor=T.+S.+Linauthor=J.+T.+Daltonauthor=D.+Wuauthor=M.+A.+Phelpsauthor=B.+Fischerauthor=M.+Moranauthor=K.+A.+Blumauthor=B.+Rovinauthor=M.+Brooker-McEldowneyauthor=S.+Broeringauthor=L.+J.+Schaafauthor=A.+J.+Johnsonauthor=D.+M.+Lucasauthor=N.+A.+Heeremaauthor=G.+Lozanskiauthor=D.+C.+Youngauthor=J.+R.+Suarezauthor=A.+D.+Colevasauthor=M.+R.+Grever&title=Flavopiridol+administered+using+a+pharmacologically+derived+schedule+is+associated+with+marked+clinical+efficacy+in+refractory%2C+genetically+high-risk+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMoran%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DRovin%26aufirst%3DB.%26aulast%3DBrooker-McEldowney%26aufirst%3DM.%26aulast%3DBroering%26aufirst%3DS.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DLozanski%26aufirst%3DG.%26aulast%3DYoung%26aufirst%3DD.%2BC.%26aulast%3DSuarez%26aufirst%3DJ.%2BR.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26atitle%3DFlavopiridol%2520administered%2520using%2520a%2520pharmacologically%2520derived%2520schedule%2520is%2520associated%2520with%2520marked%2520clinical%2520efficacy%2520in%2520refractory%252C%2520genetically%2520high-risk%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D399%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-06-0614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17363487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=926-934&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=P.+Mahajanauthor=V.+Waghauthor=S.+Shenoyauthor=D.+Bhatiaauthor=S.+Chileauthor=M.+Sivakumarauthor=A.+Maierauthor=H.+H.+Fiebigauthor=S.+Sharma&title=P276-00%2C+a+novel+cyclin-dependent+inhibitor+induces+G1-G2+arrest%2C+shows+antitumor+activity+on+cisplatin-resistant+cells+and+significant+in+vivo+efficacy+in+tumor+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Mahajan, Pravin; Wagh, Vilas; Shenoy, Satyendra; Bhatia, Dimple; Chile, Shailaja; Sivakumar, Meenakshi; Maier, Armin; Fiebig, Heinz-Herbert; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent.  In this study, we have selected a panel of human tumor cell lines and xenografts to allow detn. of selectivity and efficacy of P276-00.  When tested against a panel of 16 cisplatin-sensitive and cisplatin-resistant cell lines, the antiproliferative potential of P276-00 was found to be ∼30-fold higher than cisplatin.  Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was ∼26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers.  Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells.  Asynchronous population of human prostate carcinoma (PC-3) and human promyelocytic leukemia (HL-60) cells when exposed to P276-00 showed arrest of slow-growing PC-3 cells in G2-M with no significant apoptosis obsd. up to 72 h.  Unlike PC-3, significant apoptosis was seen in fast-growing HL-60 cells at 6 h.  However, synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells showed arrest of cells in G1.  H-460 cells undergo apoptosis, which increases with longer exposure to the compd. and also after exposure to P276-00 for 48 h followed by recovery.  In contrast, the normal cells (WI-38) remain arrested in G1 with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells.  After promising in vitro results, P276-00 was checked for in vivo efficacy in murine tumor and human xenograft models.  Growth inhibition of murine colon cancer (CA-51) was significant when P276-00 was administered i.p. at 50 mg/kg daily for 20 treatments.  However, in murine lung carcinoma model (Lewis lung), an increased dose of 60 mg/kg (30 mg/kg twice daily) administered every alternate day i.p. for seven treatments showed significant inhibition in the growth.  Further studies were undertaken to establish the efficacy profile of P276-00 in human tumor xenograft models.  In the two xenograft models studied, P276-00 showed potent in vivo antitumor potential.  Compd. P276-00 at a dose of 35 mg/kg administered daily via the i.p. route for 10 days showed significant (P < 0.05) inhibition in the growth of human colon carcinoma HCT-116 xenograft.  Furthermore, P276-00 at a dose of 50 mg/kg once daily and 30 mg/kg twice daily administered via i.p. route for 20 treatments significantly (P < 0.05) inhibited growth of human non-small cell lung carcinoma H-460 xenograft.  Thus, the in vitro cellular potency, together with in vivo antitumor activity, confirms the potential of P276-00, a cyclin-dependent kinase inhibitor as an anticancer mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogJ_J7_PmrDrVg90H21EOLACvtfcHk0lhjWBlTyHg75Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D&md5=04e65ada85eb38521909544a4e16a739</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0614%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DWagh%26aufirst%3DV.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DD.%26aulast%3DChile%26aufirst%3DS.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DA.%26aulast%3DFiebig%26aufirst%3DH.%2BH.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DP276-00%252C%2520a%2520novel%2520cyclin-dependent%2520inhibitor%2520induces%2520G1-G2%2520arrest%252C%2520shows%2520antitumor%2520activity%2520on%2520cisplatin-resistant%2520cells%2520and%2520significant%2520in%2520vivo%2520efficacy%2520in%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D926%26epage%3D934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group">Christian, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span> </span><span class="NLM_article-title">Flavopiridol in the treatment of chronic lymphocytic leukemia</span> <span class="citation_source-journal">Curr. Opin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FCCO.0b013e3282efb9da" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17906454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=573-578&author=B.+A.+Christianauthor=M.+R.+Greverauthor=J.+C.+Byrdauthor=T.+S.+Lin&title=Flavopiridol+in+the+treatment+of+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol in the treatment of chronic lymphocytic leukemia</span></div><div class="casAuthors">Christian, Beth A.; Grever, Michael R.; Byrd, John C.; Lin, Thomas S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">573-578</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The synthetic flavone flavopiridol induces apoptosis of chronic lymphocytic leukemia cells in vitro; however, initial studies administering flavopiridol by a 24- to 72-h continuous i.v. infusion demonstrated no clin. activity.  This review focuses on a novel dosing regimen that has achieved significant clin. activity in relapsed, poor-risk chronic lymphocytic leukemia.  Recent findings: Binding to human plasma proteins reduces free flavopiridol concn. and makes continuous i.v. infusion dosing ineffective.  Pharmacokinetic modeling indicated that administering flavopiridol by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion would achieve serum concns. necessary to induce in-vivo apoptosis.  Our institution conducted a phase I study in relapsed chronic lymphocytic leukemia.  Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia.  Careful monitoring and aggressive intervention for hyperkalemia, including hemodialysis if necessary, allowed flavopiridol to be given safely.  Nineteen of 42 patients responded (45%), including five of 12 patients (42%) with del(17p13) and 13 of 18 patients (72%) with del(11q22).  Summary: Flavopiridol, when administered by a 30-min i.v. bolus followed by a 4-h continuous i.v. infusion, is active in high-risk, refractory chronic lymphocytic leukemia.  Careful monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for safe drug administration.  Further studies to optimize the dose and schedule of administration, and to study this drug in other hematol. malignancies, are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6YGpEb0iAxLVg90H21EOLACvtfcHk0ljHCyxuNUyWAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnu7zL&md5=9682028742de790c116d8e99a9aa60c5</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e3282efb9da&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e3282efb9da%26sid%3Dliteratum%253Aachs%26aulast%3DChristian%26aufirst%3DB.%2BA.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DT.%2BS.%26atitle%3DFlavopiridol%2520in%2520the%2520treatment%2520of%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2007%26volume%3D19%26spage%3D573%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group">Lin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connolly, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetter, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emanuel, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruninger, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuentes-Pesquera, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugg, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolliffe, L. K.</span><span> </span><span class="NLM_article-title">1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">4208</span><span class="NLM_x">–</span> <span class="NLM_lpage">4211</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050267e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4208-4211&author=R.+Linauthor=P.+J.+Connollyauthor=S.+Huangauthor=S.+K.+Wetterauthor=Y.+Luauthor=W.+V.+Murrayauthor=S.+L.+Emanuelauthor=R.+H.+Gruningerauthor=A.+R.+Fuentes-Pesqueraauthor=C.+A.+Ruggauthor=S.+A.+Middletonauthor=L.+K.+Jolliffe&title=1-Acyl-1H-%5B1%2C2%2C4%5Dtriazole-3%2C5-diamine+analogues+as+novel+and+potent+anticancer+cyclin-dependent+kinase+inhibitors%3A+synthesis+and+evaluation+of+biological+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fjm050267e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050267e%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DR.%26aulast%3DConnolly%26aufirst%3DP.%2BJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DWetter%26aufirst%3DS.%2BK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMurray%26aufirst%3DW.%2BV.%26aulast%3DEmanuel%26aufirst%3DS.%2BL.%26aulast%3DGruninger%26aufirst%3DR.%2BH.%26aulast%3DFuentes-Pesquera%26aufirst%3DA.%2BR.%26aulast%3DRugg%26aufirst%3DC.%2BA.%26aulast%3DMiddleton%26aufirst%3DS.%2BA.%26aulast%3DJolliffe%26aufirst%3DL.%2BK.%26atitle%3D1-Acyl-1H-%255B1%252C2%252C4%255Dtriazole-3%252C5-diamine%2520analogues%2520as%2520novel%2520and%2520potent%2520anticancer%2520cyclin-dependent%2520kinase%2520inhibitors%253A%2520synthesis%2520and%2520evaluation%2520of%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4208%26epage%3D4211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group">Phelps, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozewski, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farley, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moran, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooker-McEldowney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarjoura, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaaf, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span> </span><span class="NLM_article-title">Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">2637</span><span class="NLM_x">–</span> <span class="NLM_lpage">2645</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=2637-2645&author=M.+A.+Phelpsauthor=T.+S.+Linauthor=A.+J.+Johnsonauthor=E.+Hurhauthor=D.+M.+Rozewskiauthor=K.+L.+Farleyauthor=D.+Wuauthor=K.+A.+Blumauthor=B.+Fischerauthor=S.+M.+Mitchellauthor=M.+E.+Moranauthor=M.+Brooker-McEldowneyauthor=N.+A.+Heeremaauthor=D.+Jarjouraauthor=L.+J.+Schaafauthor=J.+C.+Byrdauthor=M.+R.+Greverauthor=J.+T.+Dalton&title=Clinical+response+and+pharmacokinetics+from+a+phase+1+study+of+an+active+dosing+schedule+of+flavopiridol+in+relapsed+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPhelps%26aufirst%3DM.%2BA.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DHurh%26aufirst%3DE.%26aulast%3DRozewski%26aufirst%3DD.%2BM.%26aulast%3DFarley%26aufirst%3DK.%2BL.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DFischer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BM.%26aulast%3DMoran%26aufirst%3DM.%2BE.%26aulast%3DBrooker-McEldowney%26aufirst%3DM.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJarjoura%26aufirst%3DD.%26aulast%3DSchaaf%26aufirst%3DL.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DClinical%2520response%2520and%2520pharmacokinetics%2520from%2520a%2520phase%25201%2520study%2520of%2520an%2520active%2520dosing%2520schedule%2520of%2520flavopiridol%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D2637%26epage%3D2645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattenburg, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colevas, A. D.</span><span> </span><span class="NLM_article-title">Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">4467</span><span class="NLM_x">–</span> <span class="NLM_lpage">4473</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1078-0432.CCR-07-0381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17671131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlGqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4467-4473&author=J.+E.+Karpauthor=B.+D.+Smithauthor=M.+J.+Levisauthor=S.+D.+Goreauthor=J.+Greerauthor=C.+Hattenburgauthor=J.+Brielauthor=R.+J.+Jonesauthor=J.+J.+Wrightauthor=A.+D.+Colevas&title=Sequential+flavopiridol%2C+cytosine+arabinoside%2C+and+mitoxantrone%3A+a+phase+II+trial+in+adults+with+poor-risk+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia</span></div><div class="casAuthors">Karp, Judith E.; Smith, B. Douglas; Levis, Mark J.; Gore, Steven D.; Greer, Jacqueline; Hattenburg, Catherine; Briel, Janet; Jones, Richard J.; Wright, John J.; Colevas, A. Dimitri</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15, Pt. 1</span>),
    <span class="NLM_cas:pages">4467-4473</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Flavopiridol is a cyclin-dependent kinase inhibitor that is cytotoxic to leukemic blasts.  In a phase I study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%.  We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML.  Exptl. Design: Flavopiridol (50 mg/m2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 gm/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone on day 9.  RESULTS: Flavopiridol caused a ≥50% decrease in peripheral blood blasts in 44% by median day 2 and ≥80% decrease in 26% by day 3.  Self-limited tumor lysis occurred in 53%.  Three (5%) died during therapy (2 multiorgan failure and 1 fungal pneumonia).  Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary AML, 18 of 24 (75%) first relapse after short CR (median CR, 9 mo, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory AML.  Disease-free survival for all CR patients is 40% at 2 years, with newly diagnosed patients having a 2-yr disease-free survival of 50%.  CONCLUSIONS: Flavopiridol has anti-AML activity directly and in combination with ara-C and mitoxantrone.  This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcTLT6Fcz5sbVg90H21EOLACvtfcHk0ljHCyxuNUyWAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlGqtLs%253D&md5=50904a84f2442f965c30b8e054699661</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0381%26sid%3Dliteratum%253Aachs%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DGore%26aufirst%3DS.%2BD.%26aulast%3DGreer%26aufirst%3DJ.%26aulast%3DHattenburg%26aufirst%3DC.%26aulast%3DBriel%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26atitle%3DSequential%2520flavopiridol%252C%2520cytosine%2520arabinoside%252C%2520and%2520mitoxantrone%253A%2520a%2520phase%2520II%2520trial%2520in%2520adults%2520with%2520poor-risk%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4467%26epage%3D4473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span> </span><span class="NLM_article-title">Alvocidib: Orphan Drug Status</span>. Presented at the Committee for Orphan Medicinal Products 84th Plenary Meeting, U.S. Food and Drug Administration,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Alvocidib%3A+Orphan+Drug+Status.+Presented+at+the+Committee+for+Orphan+Medicinal+Products+84th+Plenary+Meeting%2C+U.S.+Food+and+Drug+Administration%2C+2007."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DAlvocidib%253A%2520Orphan%2520Drug%2520Status%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group">Joshi, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mascarenhas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamble, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-06-0613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17363486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=918-925&author=K.+S.+Joshiauthor=M.+J.+Rathosauthor=R.+D.+Joshiauthor=M.+Sivakumarauthor=M.+Mascarenhasauthor=S.+Kambleauthor=B.+Lalauthor=S.+Sharma&title=In+vitro+antitumor+properties+of+a+novel+cyclin-dependent+kinase+inhibitor%2C+P276-00"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Joshi, Rajendra D.; Sivakumar, Meenakshi; Mascarenhas, Malcolm; Kamble, Shrikant; Lal, Bansi; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (Cdk) and their assocd. pathways represent some of the most attractive targets for the development of anticancer therapeutics.  Based on antitumor activity in animal models, a variety of Cdk inhibitors are undergoing clin. evaluation either as a single agent or in combination with other approved drugs.  In our anticancer drug discovery program, a novel series of flavones were synthesized for evaluation against the activity of Cdk4-D1.  This enzyme catalyzes the phosphorylation of retinoblastoma protein, thus inhibiting its function.  We have identified a series of potent Cdk4-D1 inhibitors with IC50 below 250 nmol/L.  In this report, we have described the properties of one of the best compd., P276-00 of the flavone's series.  P276-00 shows 40-fold selectivity toward Cdk4-D1, compared with Cdk2-E.  The specificity toward 14 other related and unrelated kinases was also detd.  P276-00 was found to be more selective with IC50s <100 nmol/L for Cdk4-D1, Cdk1-B, and Cdk9-T1, as compared with other Cdks, and less selective for non-Cdk kinases.  It showed potent antiproliferative effects against various human cancer cell lines, with an IC50 ranging from 300 to 800 nmol/L and was further compared for its antiproliferative activity against cancer and normal fibroblast cell lines.  P276-00 was found to be highly selective for cancer cells as compared with normal fibroblast cells.  To delineate its mechanism of action, the effect of P276-00 on cell cycle proteins was studied in human breast cancer cell line (MCF-7) and human non-small cell lung carcinoma (H-460).  A significant down-regulation of cyclin D1 and Cdk4 and a decrease in Cdk4-specific pRb Ser780 phosphorylation was obsd.  P276-00 produced potent inhibition of Cdk4-D1 activity that was found to be competitive with ATP and not with retinoblastoma protein.  The compd. also induced apoptosis in human promyelocytic leukemia (HL-60) cells, as evidenced by the induction of caspase-3 and DNA ladder studies.  These data suggest that P276-00 has the potential to be developed as an anti-Cdk chemotherapeutic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0IzehRnQJk7Vg90H21EOLACvtfcHk0liPfOBNm2Baeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntbc%253D&md5=7cc9256a1cd7a960e5e5497ad409a18b</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0613%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%2BS.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DJoshi%26aufirst%3DR.%2BD.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMascarenhas%26aufirst%3DM.%26aulast%3DKamble%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DIn%2520vitro%2520antitumor%2520properties%2520of%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520P276-00%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D918%26epage%3D925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group">Havlicek, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanus, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vesely, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leclerc, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strnad, M.</span><span> </span><span class="NLM_article-title">Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">408</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm960666x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=408-412&author=L.+Havlicekauthor=J.+Hanusauthor=J.+Veselyauthor=S.+Leclercauthor=L.+Meijerauthor=G.+Shawauthor=M.+Strnad&title=Cytokinin-derived+cyclin-dependent+kinase+inhibitors%3A+synthesis+and+cdc2+inhibitory+activity+of+olomoucine+and+related+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Fjm960666x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960666x%26sid%3Dliteratum%253Aachs%26aulast%3DHavlicek%26aufirst%3DL.%26aulast%3DHanus%26aufirst%3DJ.%26aulast%3DVesely%26aufirst%3DJ.%26aulast%3DLeclerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DG.%26aulast%3DStrnad%26aufirst%3DM.%26atitle%3DCytokinin-derived%2520cyclin-dependent%2520kinase%2520inhibitors%253A%2520synthesis%2520and%2520cdc2%2520inhibitory%2520activity%2520of%2520olomoucine%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D408%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">417</span><span class="NLM_x">–</span> <span class="NLM_lpage">425</span></span><div class="citationLinks">[<a href="/doi/10.1021/ar0201198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2003&pages=417-425&author=L.+Meijerauthor=E.+Raymond&title=Roscovitine+and+other+purines+as+kinase+inhibitors.+From+starfish+oocytes+to+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Far0201198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far0201198%26sid%3Dliteratum%253Aachs%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DRoscovitine%2520and%2520other%2520purines%2520as%2520kinase%2520inhibitors.%2520From%2520starfish%2520oocytes%2520to%2520clinical%2520trials%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2003%26volume%3D36%26spage%3D417%26epage%3D425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group">Legraverend, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tunnah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ducrot, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grierson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leost, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1282</span><span class="NLM_x">–</span> <span class="NLM_lpage">1292</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9911130" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1282-1292&author=M.+Legraverendauthor=P.+Tunnahauthor=M.+Nobleauthor=P.+Ducrotauthor=O.+Ludwigauthor=D.+S.+Griersonauthor=M.+Leostauthor=L.+Meijerauthor=J.+Endicott&title=Cyclin-dependent+kinase+inhibition+by+new+C-2+alkynylated+purine+derivatives+and+molecular+structure+of+a+CDK2-inhibitor+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1021%2Fjm9911130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9911130%26sid%3Dliteratum%253Aachs%26aulast%3DLegraverend%26aufirst%3DM.%26aulast%3DTunnah%26aufirst%3DP.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DDucrot%26aufirst%3DP.%26aulast%3DLudwig%26aufirst%3DO.%26aulast%3DGrierson%26aufirst%3DD.%2BS.%26aulast%3DLeost%26aufirst%3DM.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DEndicott%26aufirst%3DJ.%26atitle%3DCyclin-dependent%2520kinase%2520inhibition%2520by%2520new%2520C-2%2520alkynylated%2520purine%2520derivatives%2520and%2520molecular%2520structure%2520of%2520a%2520CDK2-inhibitor%2520complex%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1282%26epage%3D1292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group">Arris, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvert, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewsbury, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrie, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span> </span><span class="NLM_article-title">Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">2797</span><span class="NLM_x">–</span> <span class="NLM_lpage">2804</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990628o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=2797-2804&author=C.+E.+Arrisauthor=F.+T.+Boyleauthor=A.+H.+Calvertauthor=N.+J.+Curtinauthor=J.+A.+Endicottauthor=E.+F.+Garmanauthor=A.+E.+Gibsonauthor=B.+T.+Goldingauthor=S.+Grantauthor=R.+J.+Griffinauthor=P.+Jewsburyauthor=L.+N.+Johnsonauthor=A.+M.+Lawrieauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=E.+A.+Sausvilleauthor=R.+Schultzauthor=W.+Yu&title=Identification+of+novel+purine+and+pyrimidine+cyclin-dependent+kinase+inhibitors+with+distinct+molecular+interactions+and+tumor+cell+growth+inhibition+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Fjm990628o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990628o%26sid%3Dliteratum%253Aachs%26aulast%3DArris%26aufirst%3DC.%2BE.%26aulast%3DBoyle%26aufirst%3DF.%2BT.%26aulast%3DCalvert%26aufirst%3DA.%2BH.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGarman%26aufirst%3DE.%2BF.%26aulast%3DGibson%26aufirst%3DA.%2BE.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DJewsbury%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26aulast%3DLawrie%26aufirst%3DA.%2BM.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSchultz%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DW.%26atitle%3DIdentification%2520of%2520novel%2520purine%2520and%2520pyrimidine%2520cyclin-dependent%2520kinase%2520inhibitors%2520with%2520distinct%2520molecular%2520interactions%2520and%2520tumor%2520cell%2520growth%2520inhibition%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D2797%26epage%3D2804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group">Popowycz, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettayeb, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferandin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamigeon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirado, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mateo-Lozano, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Notario, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, B.</span><span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (<i>R</i>)-roscovitine analogue</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm801340z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=655-663&author=F.+Popowyczauthor=G.+Fournetauthor=C.+Schneiderauthor=K.+Bettayebauthor=Y.+Ferandinauthor=C.+Lamigeonauthor=O.+M.+Tiradoauthor=S.+Mateo-Lozanoauthor=V.+Notarioauthor=P.+Colasauthor=P.+Bernardauthor=L.+Meijerauthor=B.+Joseph&title=Pyrazolo%5B1%2C5-a%5D-1%2C3%2C5-triazine+as+a+purine+bioisostere%3A+access+to+potent+cyclin-dependent+kinase+inhibitor+%28R%29-roscovitine+analogue"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Fjm801340z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801340z%26sid%3Dliteratum%253Aachs%26aulast%3DPopowycz%26aufirst%3DF.%26aulast%3DFournet%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DC.%26aulast%3DBettayeb%26aufirst%3DK.%26aulast%3DFerandin%26aufirst%3DY.%26aulast%3DLamigeon%26aufirst%3DC.%26aulast%3DTirado%26aufirst%3DO.%2BM.%26aulast%3DMateo-Lozano%26aufirst%3DS.%26aulast%3DNotario%26aufirst%3DV.%26aulast%3DColas%26aufirst%3DP.%26aulast%3DBernard%26aufirst%3DP.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DJoseph%26aufirst%3DB.%26atitle%3DPyrazolo%255B1%252C5-a%255D-1%252C3%252C5-triazine%2520as%2520a%2520purine%2520bioisostere%253A%2520access%2520to%2520potent%2520cyclin-dependent%2520kinase%2520inhibitor%2520%2528R%2529-roscovitine%2520analogue%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D655%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quin, J.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toogood, P. L.</span><span> </span><span class="NLM_article-title">Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2371</span><span class="NLM_x">–</span> <span class="NLM_lpage">2387</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049355%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2371-2387&author=S.+N.+VanderWelauthor=P.+J.+Harveyauthor=D.+J.+McNamaraauthor=J.+T.+Repineauthor=P.+R.+Kellerauthor=J.+Quinauthor=R.+J.+Boothauthor=W.+L.+Elliottauthor=E.+M.+Dobrusinauthor=D.+W.+Fryauthor=P.+L.+Toogood&title=Pyrido%5B2%2C3-d%5Dpyrimidin-7-ones+as+specific+inhibitors+of+cyclin-dependent+kinase+4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1021%2Fjm049355%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049355%252B%26sid%3Dliteratum%253Aachs%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DQuin%26aufirst%3DJ.%26aulast%3DBooth%26aufirst%3DR.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DPyrido%255B2%252C3-d%255Dpyrimidin-7-ones%2520as%2520specific%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25204%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2371%26epage%3D2387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Gahmen, U.</span><span> </span><span class="NLM_article-title">Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3826</span><span class="NLM_x">–</span> <span class="NLM_lpage">3831</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0600388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3826-3831&author=H.+Luauthor=U.+Schulze-Gahmen&title=Toward+understanding+the+structural+basis+of+cyclin-dependent+kinase+6+specific+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition</span></div><div class="casAuthors">Lu, Heshu; Schulze-Gahmen, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3826-3831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are key players in cell cycle control, and genetic alterations of CDKs and their regulators have been linked to a variety of cancers.  Hence, CDKs are obvious targets for therapeutic intervention in various proliferative diseases, including cancer.  To date, drug design efforts have mostly focused on CDK2 because methods for crystn. of its inhibitor complexes have been well established.  CDK4 and CDK6, however, may be at least as important as enzymes for cell cycle regulation and could provide alternative treatment options.  We describe here two complex structures of human CDK6 with a very specific kinase inhibitor, PD0332991, which is based on a pyrido[2,3-d]pyrimidin-7-one scaffold, and with the less specific aminopurvalanol inhibitor.  Anal. of the structures suggests that relatively small conformational differences between CDK2 and CDK6 in the hinge region are contributing to the inhibitor specificity by inducing changes in the inhibitor orientation that lead to sterical clashes in CDK2 but not CDK6.  These complex structures provide valuable insights for the future development of CDK-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt5qOCDA_blLVg90H21EOLACvtfcHk0ljGQD6ocYg4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D&md5=218bcdfeac3e7371e3ae16ab0a5799db</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fjm0600388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600388%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520cyclin-dependent%2520kinase%25206%2520specific%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3826%26epage%3D3831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group">Dickson, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, G. K.</span><span> </span><span class="NLM_article-title">Development of cell-cycle inhibitors for cancer therapy</span> <span class="citation_source-journal">Curr. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19370178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1M3otVaqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=36-43&author=M.+A.+Dicksonauthor=G.+K.+Schwartz&title=Development+of+cell-cycle+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Development of cell-cycle inhibitors for cancer therapy</span></div><div class="casAuthors">Dickson M A; Schwartz G K</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology (Toronto, Ont.)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">36-43</span>
        ISSN:<span class="NLM_cas:issn">1198-0052</span>.
    </div><div class="casAbstract">The cell cycle governs the transition from quiescence through cell growth to proliferation.  The key parts of the cell cycle machinery are the cyclin-dependent kinases (CDKS) and the regulatory proteins called cyclins.  The CDKS are rational targets for cancer therapy because their expression in cancer cells is often aberrant and their inhibition can induce cell death.  Inhibitors of CDKS can also block transcription.Several drugs targeting the cell cycle have entered clinical trials.  These agents include flavopiridol, indisulam, AZD5438, SNS-032, bryostatin-1, seliciclib, PD 0332991, and SCH 727965.  Phase i studies have demonstrated that these drugs can generally be administered safely.  Phase ii studies have shown little single-agent activity in solid tumors, but combination studies with cytotoxic chemotherapy have been more promising.  In hematologic malignancies, reports have shown encouraging single-agent and combination activity.  Pharmacodynamic studies show that the dose and schedule of these drugs are crucial to permit maximum therapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgaRuY_68sqszK395ZObgVfW6udTcc2eYU93NbwDoprbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3otVaqsg%253D%253D&md5=450695393901bd4eee8c4183717b1e42</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDickson%26aufirst%3DM.%2BA.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DDevelopment%2520of%2520cell-cycle%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Oncol.%26date%3D2009%26volume%3D16%26spage%3D36%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group">Misra, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bednarz, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulheron, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roongta, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranadive, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavletich, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimball, S. D.</span><span> </span><span class="NLM_article-title"><i>N</i>-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. <i>N</i>-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1719</span><span class="NLM_x">–</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0305568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1719-1728&author=R.+N.+Misraauthor=H.+Y.+Xiaoauthor=K.+S.+Kimauthor=S.+Luauthor=W.+C.+Hanauthor=S.+A.+Barbosaauthor=J.+T.+Huntauthor=D.+B.+Rawlinsauthor=W.+Shanauthor=S.+Z.+Ahmedauthor=L.+Qianauthor=B.+C.+Chenauthor=R.+Zhaoauthor=M.+S.+Bednarzauthor=K.+A.+Kellarauthor=J.+G.+Mulheronauthor=R.+Batorskyauthor=U.+Roongtaauthor=A.+Kamathauthor=P.+Maratheauthor=S.+A.+Ranadiveauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=N.+P.+Pavletichauthor=F.+Y.+Leeauthor=K.+R.+Websterauthor=S.+D.+Kimball&title=N-%28Cycloalkylamino%29acyl-2-aminothiazole+inhibitors+of+cyclin-dependent+kinase+2.+N-%5B5-%5B%5B%5B5-%281%2C1-Dimethylethyl%29-2-oxazolyl%5Dmethyl%5Dthio%5D-2-thiazolyl%5D-4-+piperidinecarboxamide+%28BMS-387032%29%2C+a+highly+efficacious+and+selective+antitumor+agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1021%2Fjm0305568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0305568%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DR.%2BN.%26aulast%3DXiao%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DW.%2BC.%26aulast%3DBarbosa%26aufirst%3DS.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DAhmed%26aufirst%3DS.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%2BC.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DKellar%26aufirst%3DK.%2BA.%26aulast%3DMulheron%26aufirst%3DJ.%2BG.%26aulast%3DBatorsky%26aufirst%3DR.%26aulast%3DRoongta%26aufirst%3DU.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DRanadive%26aufirst%3DS.%2BA.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DKimball%26aufirst%3DS.%2BD.%26atitle%3DN-%2528Cycloalkylamino%2529acyl-2-aminothiazole%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25202.%2520N-%255B5-%255B%255B%255B5-%25281%252C1-Dimethylethyl%2529-2-oxazolyl%255Dmethyl%255Dthio%255D-2-thiazolyl%255D-4-%2520piperidinecarboxamide%2520%2528BMS-387032%2529%252C%2520a%2520highly%2520efficacious%2520and%2520selective%2520antitumor%2520agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1719%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group">Chen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierda, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chubb, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawtin, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plunkett, W.</span><span> </span><span class="NLM_article-title">Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">4637</span><span class="NLM_x">–</span> <span class="NLM_lpage">4645</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4637-4645&author=R.+Chenauthor=W.+G.+Wierdaauthor=S.+Chubbauthor=R.+E.+Hawtinauthor=J.+A.+Foxauthor=M.+J.+Keatingauthor=V.+Gandhiauthor=W.+Plunkett&title=Mechanism+of+action+of+SNS-032%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+in+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DChubb%26aufirst%3DS.%26aulast%3DHawtin%26aufirst%3DR.%2BE.%26aulast%3DFox%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BJ.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DPlunkett%26aufirst%3DW.%26atitle%3DMechanism%2520of%2520action%2520of%2520SNS-032%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4637%26epage%3D4645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group">Choong, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafimova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arkin, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoch, U.</span><span> </span><span class="NLM_article-title">A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5763</span><span class="NLM_x">–</span> <span class="NLM_lpage">5765</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2Fj.bmcl.2008.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18842409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht12rs77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5763-5765&author=I.+C.+Choongauthor=I.+Serafimovaauthor=J.+Fanauthor=D.+Stockettauthor=E.+Chanauthor=S.+Cheetiauthor=Y.+Luauthor=B.+Fahrauthor=P.+Phamauthor=M.+R.+Arkinauthor=D.+H.+Walkerauthor=U.+Hoch&title=A+diaminocyclohexyl+analog+of+SNS-032+with+improved+permeability+and+bioavailability+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties</span></div><div class="casAuthors">Choong, Ingrid C.; Serafimova, Iana; Fan, Junfa; Stockett, David; Chan, Erica; Cheeti, Sravanthi; Lu, Yafan; Fahr, Bruce; Pham, Phuongly; Arkin, Michelle R.; Walker, Duncan H.; Hoch, Ute</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5763-5765</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The identification of a selective CDK2, 7, and 9 inhibitor (compd. 4) with improved permeability is described.  Compd. 4 exhibits comparable CDK selectivity profile to SNS-032, but shows improved permeability and higher bioavailability in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEqkByuQcxcbVg90H21EOLACvtfcHk0lgkr5rp6K7RIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht12rs77M&md5=d956b4c2e3b15b3d52ddd76f2cef997e</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DChoong%26aufirst%3DI.%2BC.%26aulast%3DSerafimova%26aufirst%3DI.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DStockett%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DFahr%26aufirst%3DB.%26aulast%3DPham%26aufirst%3DP.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DHoch%26aufirst%3DU.%26atitle%3DA%2520diaminocyclohexyl%2520analog%2520of%2520SNS-032%2520with%2520improved%2520permeability%2520and%2520bioavailability%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5763%26epage%3D5765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fahr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockett, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheeti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serafimova, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pham, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoch, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choong, I. C.</span><span> </span><span class="NLM_article-title">Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">6236</span><span class="NLM_x">–</span> <span class="NLM_lpage">6239</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=6236-6239&author=J.+Fanauthor=B.+Fahrauthor=D.+Stockettauthor=E.+Chanauthor=S.+Cheetiauthor=I.+Serafimovaauthor=Y.+Luauthor=P.+Phamauthor=D.+H.+Walkerauthor=U.+Hochauthor=I.+C.+Choong&title=Modifications+of+the+isonipecotic+acid+fragment+of+SNS-032%3A+analogs+with+improved+permeability+and+lower+efflux+ratio"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DFahr%26aufirst%3DB.%26aulast%3DStockett%26aufirst%3DD.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DCheeti%26aufirst%3DS.%26aulast%3DSerafimova%26aufirst%3DI.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPham%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DD.%2BH.%26aulast%3DHoch%26aufirst%3DU.%26aulast%3DChoong%26aufirst%3DI.%2BC.%26atitle%3DModifications%2520of%2520the%2520isonipecotic%2520acid%2520fragment%2520of%2520SNS-032%253A%2520analogs%2520with%2520improved%2520permeability%2520and%2520lower%2520efflux%2520ratio%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D6236%26epage%3D6239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saxty, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seavers, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squires, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trewartha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1<i>H</i>-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltellauthor=E.+J.+Lewisauthor=R.+L.+McMenaminauthor=E.+F.+Navarroauthor=M.+A.+O%E2%80%99Brienauthor=M.+O%E2%80%99Reillyauthor=M.+Reuleauthor=G.+Saxtyauthor=L.+C.+Seaversauthor=D.+M.+Smithauthor=M.+S.+Squiresauthor=G.+Trewarthaauthor=M.+T.+Walkerauthor=A.+J.+Woolford&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DLewis%26aufirst%3DE.%2BJ.%26aulast%3DMcMenamin%26aufirst%3DR.%2BL.%26aulast%3DNavarro%26aufirst%3DE.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DSeavers%26aufirst%3DL.%2BC.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DSquires%26aufirst%3DM.%2BS.%26aulast%3DTrewartha%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DM.%2BT.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group">Lapenna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Cell cycle kinases as therapeutic targets for cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">547</span><span class="NLM_x">–</span> <span class="NLM_lpage">566</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrd2907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19568282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=547-566&author=S.+Lapennaauthor=A.+Giordano&title=Cell+cycle+kinases+as+therapeutic+targets+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle kinases as therapeutic targets for cancer</span></div><div class="casAuthors">Lapenna, Silvia; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">547-566</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Several families of protein kinases orchestrate the complex events that drive the cell cycle, and their activity is frequently deregulated in hyperproliferative cancer cells.  Although several mols. that inhibit cell cycle kinases have been developed and clin. screened as potential anticancer agents, none of these has been approved for com. use and an effective strategy to specifically control malignant cell proliferation has yet to be established.  However, recent genetic and biochem. studies have provided information about the requirement for certain cell cycle kinases by specific tumors and specialized tissue types.  Here, we discuss the potential and limitations of established cell cycle kinases as targets in anticancer drug discovery as well as novel strategies for the design of new agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH7YptkwzjgrVg90H21EOLACvtfcHk0ljouDAZK0Bsbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvFans78%253D&md5=7acb71b7aaf0ab644227103f7c14b892</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnrd2907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2907%26sid%3Dliteratum%253Aachs%26aulast%3DLapenna%26aufirst%3DS.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCell%2520cycle%2520kinases%2520as%2520therapeutic%2520targets%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D547%26epage%3D566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group">Chu, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkovitz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Packman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goelzer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moliterni, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graves, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotouhi, N.</span><span> </span><span class="NLM_article-title">Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6549</span><span class="NLM_x">–</span> <span class="NLM_lpage">6560</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0606138" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6549-6560&author=X.+J.+Chuauthor=W.+DePintoauthor=D.+Bartkovitzauthor=S.+S.+Soauthor=B.+T.+Vuauthor=K.+Packmanauthor=C.+Lukacsauthor=Q.+Dingauthor=N.+Jiangauthor=K.+Wangauthor=P.+Goelzerauthor=X.+Yinauthor=M.+A.+Smithauthor=B.+X.+Higginsauthor=Y.+Chenauthor=Q.+Xiangauthor=J.+Moliterniauthor=G.+Kaplanauthor=B.+Gravesauthor=A.+Loveyauthor=N.+Fotouhi&title=Discovery+of+%5B4-amino-2-%281-methanesulfonylpiperidin-4-ylamino%29pyrimidin-5-yl%5D%282%2C3-difluoro-6-methoxyphenyl%29methanone+%28R547%29%2C+a+potent+and+selective+cyclin-dependent+kinase+inhibitor+with+significant+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1021%2Fjm0606138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0606138%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DX.%2BJ.%26aulast%3DDePinto%26aufirst%3DW.%26aulast%3DBartkovitz%26aufirst%3DD.%26aulast%3DSo%26aufirst%3DS.%2BS.%26aulast%3DVu%26aufirst%3DB.%2BT.%26aulast%3DPackman%26aufirst%3DK.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGoelzer%26aufirst%3DP.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DHiggins%26aufirst%3DB.%2BX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DXiang%26aufirst%3DQ.%26aulast%3DMoliterni%26aufirst%3DJ.%26aulast%3DKaplan%26aufirst%3DG.%26aulast%3DGraves%26aufirst%3DB.%26aulast%3DLovey%26aufirst%3DA.%26aulast%3DFotouhi%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%255B4-amino-2-%25281-methanesulfonylpiperidin-4-ylamino%2529pyrimidin-5-yl%255D%25282%252C3-difluoro-6-methoxyphenyl%2529methanone%2520%2528R547%2529%252C%2520a%2520potent%2520and%2520selective%2520cyclin-dependent%2520kinase%2520inhibitor%2520with%2520significant%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6549%26epage%3D6560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amboldi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cervi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colotta, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’ Alessio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzeri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quartieri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vianello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5163</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9006559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5152-5163&author=M.+G.+Brascaauthor=N.+Amboldiauthor=D.+Ballinariauthor=A.+Cameronauthor=E.+Casaleauthor=G.+Cerviauthor=M.+Colomboauthor=F.+Colottaauthor=V.+Crociauthor=R.+D%E2%80%99+Alessioauthor=F.+Fiorentiniauthor=A.+Isacchiauthor=C.+Mercurioauthor=W.+Morettiauthor=A.+Panzeriauthor=W.+Pastoriauthor=P.+Pevarelloauthor=F.+Quartieriauthor=F.+Rolettoauthor=G.+Traquandiauthor=P.+Vianelloauthor=A.+Vulpettiauthor=M.+Ciomei&title=Identification+of+N%2C1%2C4%2C4-tetramethyl-8-%7B%5B4-%284-methylpiperazin-1-yl%29phenyl%5Damino%7D-4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline-3-carboxamide+%28PHA-848125%29%2C+a+potent%2C+orally+available+cyclin+dependent+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1021%2Fjm9006559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9006559%26sid%3Dliteratum%253Aachs%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmboldi%26aufirst%3DN.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCervi%26aufirst%3DG.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DColotta%26aufirst%3DF.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599%2BAlessio%26aufirst%3DR.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMercurio%26aufirst%3DC.%26aulast%3DMoretti%26aufirst%3DW.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DVianello%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520N%252C1%252C4%252C4-tetramethyl-8-%257B%255B4-%25284-methylpiperazin-1-yl%2529phenyl%255Damino%257D-4%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline-3-carboxamide%2520%2528PHA-848125%2529%252C%2520a%2520potent%252C%2520orally%2520available%2520cyclin%2520dependent%2520kinase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5152%26epage%3D5163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amici, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traquandi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piutti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sansonna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulici, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martina, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritzen, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nugent, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciomei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roletto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastori, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsiglio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clare, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiorentini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varasi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vulpetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warpehoski, M. A.</span><span> </span><span class="NLM_article-title">3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3367</span><span class="NLM_x">–</span> <span class="NLM_lpage">3380</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm031145u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=3367-3380&author=P.+Pevarelloauthor=M.+G.+Brascaauthor=R.+Amiciauthor=P.+Orsiniauthor=G.+Traquandiauthor=L.+Cortiauthor=C.+Piuttiauthor=P.+Sansonnaauthor=M.+Villaauthor=B.+S.+Pierceauthor=M.+Puliciauthor=P.+Giordanoauthor=K.+Martinaauthor=E.+L.+Fritzenauthor=R.+A.+Nugentauthor=E.+Casaleauthor=A.+Cameronauthor=M.+Ciomeiauthor=F.+Rolettoauthor=A.+Isacchiauthor=G.+Fogliattoauthor=E.+Pesentiauthor=W.+Pastoriauthor=A.+Marsiglioauthor=K.+L.+Leachauthor=P.+M.+Clareauthor=F.+Fiorentiniauthor=M.+Varasiauthor=A.+Vulpettiauthor=M.+A.+Warpehoski&title=3-Aminopyrazole+inhibitors+of+CDK2%2Fcyclin+A+as+antitumor+agents.+1.+Lead+finding"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1021%2Fjm031145u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031145u%26sid%3Dliteratum%253Aachs%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DAmici%26aufirst%3DR.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DTraquandi%26aufirst%3DG.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DPiutti%26aufirst%3DC.%26aulast%3DSansonna%26aufirst%3DP.%26aulast%3DVilla%26aufirst%3DM.%26aulast%3DPierce%26aufirst%3DB.%2BS.%26aulast%3DPulici%26aufirst%3DM.%26aulast%3DGiordano%26aufirst%3DP.%26aulast%3DMartina%26aufirst%3DK.%26aulast%3DFritzen%26aufirst%3DE.%2BL.%26aulast%3DNugent%26aufirst%3DR.%2BA.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DCameron%26aufirst%3DA.%26aulast%3DCiomei%26aufirst%3DM.%26aulast%3DRoletto%26aufirst%3DF.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPastori%26aufirst%3DW.%26aulast%3DMarsiglio%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%2BL.%26aulast%3DClare%26aufirst%3DP.%2BM.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DVarasi%26aufirst%3DM.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DWarpehoski%26aufirst%3DM.%2BA.%26atitle%3D3-Aminopyrazole%2520inhibitors%2520of%2520CDK2%252Fcyclin%2520A%2520as%2520antitumor%2520agents.%25201.%2520Lead%2520finding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D3367%26epage%3D3380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group">Vassilev, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tovar, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knezevic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span> </span><span class="NLM_article-title">Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">10660</span><span class="NLM_x">–</span> <span class="NLM_lpage">10665</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=10660-10665&author=L.+T.+Vassilevauthor=C.+Tovarauthor=S.+Chenauthor=D.+Knezevicauthor=X.+Zhaoauthor=H.+Sunauthor=D.+C.+Heimbrookauthor=L.+Chen&title=Selective+small-molecule+inhibitor+reveals+critical+mitotic+functions+of+human+CDK1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26aulast%3DTovar%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKnezevic%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DSelective%2520small-molecule%2520inhibitor%2520reveals%2520critical%2520mitotic%2520functions%2520of%2520human%2520CDK1%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2006%26volume%3D103%26spage%3D10660%26epage%3D10665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref242"><div class="reference"><strong class="refLabel"><a href="#ref242" class="rightTabRefNumLink">242</a></strong><div class="NLM_citation" id="rightTab-cit242"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref242/cit242&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit242R"><div class="casContent"><span class="casTitleNuber">242</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lgayBRhjn49Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit242&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref243"><div class="reference"><strong class="refLabel"><a href="#ref243" class="rightTabRefNumLink">243</a></strong><div class="NLM_citation" id="rightTab-cit243"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pevarello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, J. R.</span><span> </span><span class="NLM_article-title">CDK inhibitors in cancer therapy: what is next?</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=16-21&author=M.+Malumbresauthor=P.+Pevarelloauthor=M.+Barbacidauthor=J.+R.+Bischoff&title=CDK+inhibitors+in+cancer+therapy%3A+what+is+next%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit243&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DPevarello%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26aulast%3DBischoff%26aufirst%3DJ.%2BR.%26atitle%3DCDK%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520what%2520is%2520next%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D16%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref244"><div class="reference"><strong class="refLabel"><a href="#ref244" class="rightTabRefNumLink">244</a></strong><div class="NLM_citation" id="rightTab-cit244"><span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. C.</span><span> </span><span class="NLM_article-title">Heat shock protein 90: inhibitors in clinical trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref244/cit244&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+de+Waterauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=D.+Perretauthor=W.+C.+Lee&title=Heat+shock+protein+90%3A+inhibitors+in+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit244R"><div class="casContent"><span class="casTitleNuber">244</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0lgayBRhjn49Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit244&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%2BC.%26atitle%3DHeat%2520shock%2520protein%252090%253A%2520inhibitors%2520in%2520clinical%2520trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref245"><div class="reference"><strong class="refLabel"><a href="#ref245" class="rightTabRefNumLink">245</a></strong><div class="NLM_citation" id="rightTab-cit245"><span><span class="NLM_contrib-group">Pollard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimore, M.</span><span> </span><span class="NLM_article-title">Discovery and development of Aurora kinase inhibitors as anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">2629</span><span class="NLM_x">–</span> <span class="NLM_lpage">2651</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012129" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref245/cit245&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2629-2651&author=J.+R.+Pollardauthor=M.+Mortimore&title=Discovery+and+development+of+Aurora+kinase+inhibitors+as+anticancer+agents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit245R"><div class="casContent"><span class="casTitleNuber">245</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Pollard, John R.; Mortimore, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2629-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article summarizes the roles that each of the Aurora kinases plays in mitosis and cancer biol. and discusses how different Aurora inhibition selectivity profiles impact the cellular and in vivo behavior of the drug candidates.  In addn., the wealth of structural biol. information for the Aurora kinases is reviewed.  This will be used to provide a rationale for the cross-reactivity profiles of some the Aurora kinase drug candidates and will review current theories for how selectivity within the Aurora kinase family has been achieved.  Finally the discovery and development of the clin. candidates targeting Aurora kinases will be summarized together with a brief discussion of notable structure-activity relationships (SAR).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojisjXqX2odrVg90H21EOLACvtfcHk0ljf750I3YgDwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Gmtbc%253D&md5=bb59ec8929dd81ae89e606cfb84f18df</span></div><a href="/servlet/linkout?suffix=cit245&amp;dbid=16384&amp;doi=10.1021%2Fjm8012129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012129%26sid%3Dliteratum%253Aachs%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26aulast%3DMortimore%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520development%2520of%2520Aurora%2520kinase%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2629%26epage%3D2651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref246"><div class="reference"><strong class="refLabel"><a href="#ref246" class="rightTabRefNumLink">246</a></strong><div class="NLM_citation" id="rightTab-cit246"><span><span class="NLM_contrib-group">Deangelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attar, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fearen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallob, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freedman, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aster, J.</span><span> </span><span class="NLM_article-title">A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">6585</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=6585&author=D.+J.+Deangeloauthor=R.+M.+Stoneauthor=L.+B.+Silvermanauthor=W.+Stockauthor=E.+C.+Attarauthor=I.+Fearenauthor=A.+Dallobauthor=C.+Matthewsauthor=J.+Stoneauthor=S.+J.+Freedmanauthor=J.+Aster&title=A+phase+I+clinical+trial+of+the+notch+inhibitor+MK-0752+in+patients+with+T-cell+acute+lymphoblastic+leukemia%2Flymphoma+%28T-ALL%29+and+other+leukemias"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit246&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeangelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DSilverman%26aufirst%3DL.%2BB.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DAttar%26aufirst%3DE.%2BC.%26aulast%3DFearen%26aufirst%3DI.%26aulast%3DDallob%26aufirst%3DA.%26aulast%3DMatthews%26aufirst%3DC.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DFreedman%26aufirst%3DS.%2BJ.%26aulast%3DAster%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%2520clinical%2520trial%2520of%2520the%2520notch%2520inhibitor%2520MK-0752%2520in%2520patients%2520with%2520T-cell%2520acute%2520lymphoblastic%2520leukemia%252Flymphoma%2520%2528T-ALL%2529%2520and%2520other%2520leukemias%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D6585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref247"><div class="reference"><strong class="refLabel"><a href="#ref247" class="rightTabRefNumLink">247</a></strong><div class="NLM_citation" id="rightTab-cit247"><span><span class="NLM_contrib-group">Tamm, I.</span><span> </span><span class="NLM_article-title">AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer</span> <span class="citation_source-journal">Curr. Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">646</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=638-646&author=I.+Tamm&title=AEG-35156%2C+an+antisense+oligonucleotide+against+X-linked+inhibitor+of+apoptosis+for+the+potential+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit247&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamm%26aufirst%3DI.%26atitle%3DAEG-35156%252C%2520an%2520antisense%2520oligonucleotide%2520against%2520X-linked%2520inhibitor%2520of%2520apoptosis%2520for%2520the%2520potential%2520treatment%2520of%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D9%26spage%3D638%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref248"><div class="reference"><strong class="refLabel"><a href="#ref248" class="rightTabRefNumLink">248</a></strong><div class="NLM_citation" id="rightTab-cit248"><span><span class="NLM_contrib-group">Schimmer, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallman, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hedley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandwein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaCasse, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacob, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolivet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreeff, M.</span><span> </span><span class="NLM_article-title">Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4741</span><span class="NLM_x">–</span> <span class="NLM_lpage">4746</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2009.21.8172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19652057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref248/cit248&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4741-4746&author=A.+D.+Schimmerauthor=E.+H.+Esteyauthor=G.+Borthakurauthor=B.+Z.+Carterauthor=G.+J.+Schillerauthor=M.+S.+Tallmanauthor=J.+K.+Altmanauthor=J.+E.+Karpauthor=J.+Kassisauthor=D.+W.+Hedleyauthor=J.+Brandweinauthor=W.+Xuauthor=D.+H.+Makauthor=E.+LaCasseauthor=C.+Jacobauthor=S.+J.+Morrisauthor=J.+Jolivetauthor=M.+Andreeff&title=Phase+I%2FII+trial+of+AEG35156+X-linked+inhibitor+of+apoptosis+protein+antisense+oligonucleotide+combined+with+idarubicin+and+cytarabine+in+patients+with+relapsed+or+primary+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit248R"><div class="casContent"><span class="casTitleNuber">248</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia</span></div><div class="casAuthors">Schimmer, Aaron D.; Estey, Elihu H.; Borthakur, Gautam; Carter, Bing Z.; Schiller, Gary J.; Tallman, Martin S.; Altman, Jessica K.; Karp, Judith E.; Kassis, Jeannine; Hedley, David W.; Brandwein, Joseph; Xu, Wei; Mak, Duncan H.; La Casse, Eric; Jacob, Christine; Morris, Stephen J.; Jolivet, Jacques; Andreeff, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">4741-4746</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: X-linked inhibitor of apoptosis protein (XIAP) is an inhibitor of caspases 3 and 9 which are overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance.  We report on a phase I/II trial of the XIAP antisense oligonucleotide AEG35156 in combination with reinduction chemotherapy.  Patients and Methods: Twenty-four patients with rapidly relapsed or refractory AML were treated with escalating doses of AEG35156 (12 to 250 mg/m2) as an i.v. soln. over 2 h and 32 patients were treated with the highest planned dose of 350 mg/m2 in combination with idarubicin and high-dose cytarabine reinduction chemotherapy.  Correlative studies were conducted to det. the effects of AEG35156 on levels of XIAP mRNA.  Results: Knockdown of XIAP mRNA during treatment increased with the dose of the antisense.  All patients who received 350 mg/m2 of AEG35156 had higher than 30% target knockdown with a median maximal knockdown of 90% (range, 48% to 100%).  The overall response rate was higher among the patients receiving the highest dose of AEG35156.  In this group, 15 (47%) of 32 patients achieved complete response (CR)/CR with incomplete platelet count recovery (CRp) compared with only one (4%) of 24 receiving 12 to 250 mg/m2 AEG35156.  Among the patients receiving 350 mg/m2 of AEG35156 in combination with chemotherapy, 10 (91%) of 11 who were refractory to a single induction chemotherapy regimen achieved CR/CRp after reinduction with AEG35156 and chemotherapy.  AEG35156 was well:tolerated save for two cases of peripheral neuropathy in patients receiving multiple doses of AEG35156.  Conclusion: At the highest dose tested, AEG35156 knocks down its target and appears very effective when combined with chemotherapy in patients with AML refractory to a single induction regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPRjZ4-Ji1c7Vg90H21EOLACvtfcHk0ljf750I3YgDwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGgtbbN&md5=5accdec3d8e3e12e23f327f4a24b0ad4</span></div><a href="/servlet/linkout?suffix=cit248&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.21.8172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.21.8172%26sid%3Dliteratum%253Aachs%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26aulast%3DEstey%26aufirst%3DE.%2BH.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCarter%26aufirst%3DB.%2BZ.%26aulast%3DSchiller%26aufirst%3DG.%2BJ.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26aulast%3DAltman%26aufirst%3DJ.%2BK.%26aulast%3DKarp%26aufirst%3DJ.%2BE.%26aulast%3DKassis%26aufirst%3DJ.%26aulast%3DHedley%26aufirst%3DD.%2BW.%26aulast%3DBrandwein%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DMak%26aufirst%3DD.%2BH.%26aulast%3DLaCasse%26aufirst%3DE.%26aulast%3DJacob%26aufirst%3DC.%26aulast%3DMorris%26aufirst%3DS.%2BJ.%26aulast%3DJolivet%26aufirst%3DJ.%26aulast%3DAndreeff%26aufirst%3DM.%26atitle%3DPhase%2520I%252FII%2520trial%2520of%2520AEG35156%2520X-linked%2520inhibitor%2520of%2520apoptosis%2520protein%2520antisense%2520oligonucleotide%2520combined%2520with%2520idarubicin%2520and%2520cytarabine%2520in%2520patients%2520with%2520relapsed%2520or%2520primary%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4741%26epage%3D4746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref249"><div class="reference"><strong class="refLabel"><a href="#ref249" class="rightTabRefNumLink">249</a></strong><div class="NLM_citation" id="rightTab-cit249"><span><span class="NLM_contrib-group">Lai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H.-X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CU-0201, a potent, small molecule, multi-targeted inhibitor of HDAC, Abl and Src, effectively inhibits proliferation of both hematological and solid-tumor derived cancer cell lines</span> <span class="citation_source-journal">AACR Meet. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">2008</span><span class="NLM_x">, </span> <span class="NLM_fpage">5717</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2008&publication_year=2008&pages=5717&author=C.+Laiauthor=X.+Taoauthor=S.+Liuauthor=Y.+Liuauthor=L.+Zhangauthor=R.+Baoauthor=X.+Caiauthor=H.-X.+Zhaiauthor=C.+Qian&title=CU-0201%2C+a+potent%2C+small+molecule%2C+multi-targeted+inhibitor+of+HDAC%2C+Abl+and+Src%2C+effectively+inhibits+proliferation+of+both+hematological+and+solid-tumor+derived+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit249&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DZhai%26aufirst%3DH.-X.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCU-0201%252C%2520a%2520potent%252C%2520small%2520molecule%252C%2520multi-targeted%2520inhibitor%2520of%2520HDAC%252C%2520Abl%2520and%2520Src%252C%2520effectively%2520inhibits%2520proliferation%2520of%2520both%2520hematological%2520and%2520solid-tumor%2520derived%2520cancer%2520cell%2520lines%26jtitle%3DAACR%2520Meet.%2520Abstr.%26date%3D2008%26volume%3D2008%26spage%3D5717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref250"><div class="reference"><strong class="refLabel"><a href="#ref250" class="rightTabRefNumLink">250</a></strong><div class="NLM_citation" id="rightTab-cit250"><span><span class="NLM_contrib-group">Kang, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plescia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beebe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scroggins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altieri, D. C.</span><span> </span><span class="NLM_article-title">Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">454</span><span class="NLM_x">–</span> <span class="NLM_lpage">464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1172%2FJCI37613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19229106" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref250/cit250&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivF2kt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=454-464&author=B.+H.+Kangauthor=J.+Plesciaauthor=H.+Y.+Songauthor=M.+Meliauthor=G.+Colomboauthor=K.+Beebeauthor=B.+Scrogginsauthor=L.+Neckersauthor=D.+C.+Altieri&title=Combinatorial+drug+design+targeting+multiple+cancer+signaling+networks+controlled+by+mitochondrial+Hsp90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit250R"><div class="casContent"><span class="casTitleNuber">250</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90</span></div><div class="casAuthors">Kang, Byoung Heon; Plescia, Janet; Song, Ho Young; Meli, Massimiliano; Colombo, Giorgio; Beebe, Kristin; Scroggins, Bradley; Neckers, Len; Altieri, Dario C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">454-464</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Although therapeutically targeting a single signaling pathway that drives tumor development and/or progression has been effective for a no. of cancers, in many cases this approach has not been successful.  Targeting networks of signaling pathways, instead of isolated pathways, may overcome this problem, which is probably due to the extreme heterogeneity of human tumors.  However, the possibility that such networks may be spatially arranged in specialized subcellular compartments is not often considered in pathway-oriented drug discovery and may influence the design of new agents.  Hsp90 is a chaperone protein that controls the folding of proteins in multiple signaling networks that drive tumor development and progression.  Here, we report the synthesis and properties of Gamitrinibs, a class of small mols. designed to selectively target Hsp90 in human tumor mitochondria.  Gamitrinibs were shown to accumulate in the mitochondria of human tumor cell lines and to inhibit Hsp90 activity by acting as ATPase antagonists.  Unlike Hsp90 antagonists not targeted to mitochondria, Gamitrinibs exhibited a "mitochondriotoxic" mechanism of action, causing rapid tumor cell death and inhibiting the growth of xenografted human tumor cell lines in mice.  Importantly, Gamitrinibs were not toxic to normal cells or tissues and did not affect Hsp90 homeostasis in cellular compartments other than mitochondria.  Therefore, combinatorial drug design, whereby inhibitors of signaling networks are targeted to specific subcellular compartments, may generate effective anticancer drugs with novel mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwkmCaJwfFbrVg90H21EOLACvtfcHk0lgsR_aloPtP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivF2kt78%253D&md5=fe90af9059cb26c6f906c7cea2a17432</span></div><a href="/servlet/linkout?suffix=cit250&amp;dbid=16384&amp;doi=10.1172%2FJCI37613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI37613%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DB.%2BH.%26aulast%3DPlescia%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DH.%2BY.%26aulast%3DMeli%26aufirst%3DM.%26aulast%3DColombo%26aufirst%3DG.%26aulast%3DBeebe%26aufirst%3DK.%26aulast%3DScroggins%26aufirst%3DB.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DAltieri%26aufirst%3DD.%2BC.%26atitle%3DCombinatorial%2520drug%2520design%2520targeting%2520multiple%2520cancer%2520signaling%2520networks%2520controlled%2520by%2520mitochondrial%2520Hsp90%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2009%26volume%3D119%26spage%3D454%26epage%3D464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref251"><div class="reference"><strong class="refLabel"><a href="#ref251" class="rightTabRefNumLink">251</a></strong><div class="NLM_citation" id="rightTab-cit251"><span><span class="NLM_contrib-group">Kamb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span> </span><span class="NLM_article-title">Why is cancer drug discovery so difficult?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">120</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=115-120&author=A.+Kambauthor=S.+Weeauthor=C.+Lengauer&title=Why+is+cancer+drug+discovery+so+difficult%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit251&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWee%26aufirst%3DS.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DWhy%2520is%2520cancer%2520drug%2520discovery%2520so%2520difficult%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D115%26epage%3D120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref252"><div class="reference"><strong class="refLabel"><a href="#ref252" class="rightTabRefNumLink">252</a></strong><div class="NLM_citation" id="rightTab-cit252"><span><span class="NLM_contrib-group">Bonnet, D.</span><span> </span><span class="NLM_article-title">Normal and leukaemic stem cells</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">479</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1111%2Fj.1365-2141.2005.05596.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16098060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref252/cit252&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVentb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2005&pages=469-479&author=D.+Bonnet&title=Normal+and+leukaemic+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit252R"><div class="casContent"><span class="casTitleNuber">252</span><div class="casTitle"><span class="NLM_cas:atitle">Normal and leukaemic stem cells</span></div><div class="casAuthors">Bonnet, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-479</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  The blood-related cancer leukemias were the first diseases where human cancer stem cells, or leukemic stem cells (LSC), were isolated.  The hematopoietic system is one of the best tissues for investigating cancer stem cells, because the developmental hierarchy of normal blood formation is well defined.  Leukemias can now be viewed as aberrant hematopoietic processes initiated by rare LSC that have maintained or reacquired the capacity for indefinite proliferation through accumulated mutations and/or epigenetic changes.  Yet, despite their crit. importance, much remains to be learned about the developmental origin of LSC and the mechanisms responsible for their emergence in the course of the disease.  This report will review our current knowledge on normal and LSC development and examine the impact of these discoveries may have clin. and in our understanding of the leukemogenic process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeycxtJ9l9x7Vg90H21EOLACvtfcHk0lgsR_aloPtP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVentb%252FO&md5=15be1b20cc64ae92c080b2e923e15df5</span></div><a href="/servlet/linkout?suffix=cit252&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2141.2005.05596.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2141.2005.05596.x%26sid%3Dliteratum%253Aachs%26aulast%3DBonnet%26aufirst%3DD.%26atitle%3DNormal%2520and%2520leukaemic%2520stem%2520cells%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2005%26volume%3D130%26spage%3D469%26epage%3D479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref253"><div class="reference"><strong class="refLabel"><a href="#ref253" class="rightTabRefNumLink">253</a></strong><div class="NLM_citation" id="rightTab-cit253"><span><span class="NLM_contrib-group">Passegue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ailles, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, I. L.</span><span> </span><span class="NLM_article-title">Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">11842</span><span class="NLM_x">–</span> <span class="NLM_lpage">11849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=11842-11849&issue=Suppl.+1&author=E.+Passegueauthor=C.+H.+Jamiesonauthor=L.+E.+Aillesauthor=I.+L.+Weissman&title=Normal+and+leukemic+hematopoiesis%3A+are+leukemias+a+stem+cell+disorder+or+a+reacquisition+of+stem+cell+characteristics%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit253&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPassegue%26aufirst%3DE.%26aulast%3DJamieson%26aufirst%3DC.%2BH.%26aulast%3DAilles%26aufirst%3DL.%2BE.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26atitle%3DNormal%2520and%2520leukemic%2520hematopoiesis%253A%2520are%2520leukemias%2520a%2520stem%2520cell%2520disorder%2520or%2520a%2520reacquisition%2520of%2520stem%2520cell%2520characteristics%253F%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2003%26volume%3D100%26issue%3DSuppl.%25201%26spage%3D11842%26epage%3D11849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref254"><div class="reference"><strong class="refLabel"><a href="#ref254" class="rightTabRefNumLink">254</a></strong><div class="NLM_citation" id="rightTab-cit254"><span><span class="NLM_contrib-group">Zou, G. M.</span><span> </span><span class="NLM_article-title">Cancer stem cells in leukemia, recent advances</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">213</span><span class="NLM_x">, </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1002%2Fjcp.21140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17541982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref254/cit254&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2007&pages=440-444&author=G.+M.+Zou&title=Cancer+stem+cells+in+leukemia%2C+recent+advances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit254R"><div class="casContent"><span class="casTitleNuber">254</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer stem cells in leukemia, recent advances</span></div><div class="casAuthors">Zou, Gang-Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">440-444</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  The history of stem cell research was started in the early 1900s in Europe where the researcher realized that various types of blood cells came from a particular "stem cells.".  However, it was not until 1963 that the first quant. description of the self-renewal activities of transplanted mouse bone marrow cells were documented by Canadian scientist Ernest A McCulloch and James E Till in Toronto.  The concept of cancer stem cells was used over 50 years ago; whereas the strong evidence for the existence of a Cancer Stem Cells was obtained recently.  Consequently, there is increasing attention in recent year about cancer stem cells.  The findings from recent studies support the concept that stem cells are integral to the development of several forms of human cancer.  Changes in stem cell behavior can contribute to tumor formation.  Leukemia is a cancer of blood-forming tissue, including the bone marrow and lymphatic system.  Leukemic stem cells represent the cancer stem cells in the leukemia.  In this review, we summarize the recent advance in the study of leukemic stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1E0vG_tSOLVg90H21EOLACvtfcHk0lgsR_aloPtP5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKnu7vL&md5=53b983f72e13d6bef49ca2d300101d3e</span></div><a href="/servlet/linkout?suffix=cit254&amp;dbid=16384&amp;doi=10.1002%2Fjcp.21140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.21140%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DG.%2BM.%26atitle%3DCancer%2520stem%2520cells%2520in%2520leukemia%252C%2520recent%2520advances%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2007%26volume%3D213%26spage%3D440%26epage%3D444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref255"><div class="reference"><strong class="refLabel"><a href="#ref255" class="rightTabRefNumLink">255</a></strong><div class="NLM_citation" id="rightTab-cit255"><span><span class="NLM_contrib-group">Kavalerchik, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, C. H.</span><span> </span><span class="NLM_article-title">Chronic myeloid leukemia stem cells</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2911</span><span class="NLM_x">–</span> <span class="NLM_lpage">2915</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1200%2FJCO.2008.17.5745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18539972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref255/cit255&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A280%3ADC%252BD1czntFOhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=2911-2915&author=E.+Kavalerchikauthor=D.+Goffauthor=C.+H.+Jamieson&title=Chronic+myeloid+leukemia+stem+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit255R"><div class="casContent"><span class="casTitleNuber">255</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myeloid leukemia stem cells</span></div><div class="casAuthors">Kavalerchik Edward; Goff Daniel; Jamieson Catriona H M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2911-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although rare, chronic myeloid leukemia (CML) represents an important paradigm for understanding the molecular events leading to malignant transformation of primitive hematopoietic progenitors.  CML was the first cancer to be associated with a defined genetic abnormality, BCR-ABL, that is necessary and sufficient for initiating chronic phase disease as well as the first cancer to be treated with molecular targeted therapy.  Malignant progenitors or leukemia stem cells (LSCs) evolve as a result of both epigenetic and genetic events that alter hematopoietic progenitor differentiation, proliferation, survival, and self-renewal.  LSCs are rare and divide less frequently, and thus, represent a reservoir for relapse and resistance to a molecularly targeted single agent.  On subverting developmental processes normally responsible for maintaining robust life-long hematopoiesis, the LSCs are able to evade the majority of current cancer treatments that target rapidly dividing cells.  Enthusiasm for the enormous success of tyrosine kinase inhibitors at controlling the chronic phase disease is tempered somewhat by the persistence of the LSC pool in the majority of the patients.  Combined therapies targeting aberrant properties of LSC may obviate therapeutic resistance and relapse in advanced phase and therapeutically recalcitrant CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEj901OUiIPENoizSOkG_FfW6udTcc2eZOo-nfpwpfRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czntFOhtg%253D%253D&md5=b331eb46b7f19258a52a32d40e1d0ec6</span></div><a href="/servlet/linkout?suffix=cit255&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.5745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.5745%26sid%3Dliteratum%253Aachs%26aulast%3DKavalerchik%26aufirst%3DE.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DJamieson%26aufirst%3DC.%2BH.%26atitle%3DChronic%2520myeloid%2520leukemia%2520stem%2520cells%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D2911%26epage%3D2915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref256"><div class="reference"><strong class="refLabel"><a href="#ref256" class="rightTabRefNumLink">256</a></strong><div class="NLM_citation" id="rightTab-cit256"><span><span class="NLM_contrib-group">Lane, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scadden, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">The leukemic stem cell niche: current concepts and therapeutic opportunities</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1150</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=1150-1157&author=S.+W.+Laneauthor=D.+T.+Scaddenauthor=D.+G.+Gilliland&title=The+leukemic+stem+cell+niche%3A+current+concepts+and+therapeutic+opportunities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit256&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLane%26aufirst%3DS.%2BW.%26aulast%3DScadden%26aufirst%3DD.%2BT.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DThe%2520leukemic%2520stem%2520cell%2520niche%253A%2520current%2520concepts%2520and%2520therapeutic%2520opportunities%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D1150%26epage%3D1157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref257"><div class="reference"><strong class="refLabel"><a href="#ref257" class="rightTabRefNumLink">257</a></strong><div class="NLM_citation" id="rightTab-cit257"><span><span class="NLM_contrib-group">Hill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span> </span><span class="NLM_article-title">PTEN, stem cells, and cancer stem cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">11755</span><span class="NLM_x">–</span> <span class="NLM_lpage">11759</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=11755-11759&author=R.+Hillauthor=H.+Wu&title=PTEN%2C+stem+cells%2C+and+cancer+stem+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit257&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DPTEN%252C%2520stem%2520cells%252C%2520and%2520cancer%2520stem%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D11755%26epage%3D11759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref258"><div class="reference"><strong class="refLabel"><a href="#ref258" class="rightTabRefNumLink">258</a></strong><div class="NLM_citation" id="rightTab-cit258"><span><span class="NLM_contrib-group">Guo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosessian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iruela-Arispe, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span> </span><span class="NLM_article-title">Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">453</span><span class="NLM_x">, </span> <span class="NLM_fpage">529</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2008&pages=529-533&author=W.+Guoauthor=J.+L.+Laskyauthor=C.+J.+Changauthor=S.+Mosessianauthor=X.+Lewisauthor=Y.+Xiaoauthor=J.+E.+Yehauthor=J.+Y.+Chenauthor=M.+L.+Iruela-Arispeauthor=M.+Varella-Garciaauthor=H.+Wu&title=Multi-genetic+events+collaboratively+contribute+to+Pten-null+leukaemia+stem-cell+formation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit258&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DLasky%26aufirst%3DJ.%2BL.%26aulast%3DChang%26aufirst%3DC.%2BJ.%26aulast%3DMosessian%26aufirst%3DS.%26aulast%3DLewis%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYeh%26aufirst%3DJ.%2BE.%26aulast%3DChen%26aufirst%3DJ.%2BY.%26aulast%3DIruela-Arispe%26aufirst%3DM.%2BL.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26atitle%3DMulti-genetic%2520events%2520collaboratively%2520contribute%2520to%2520Pten-null%2520leukaemia%2520stem-cell%2520formation%26jtitle%3DNature%26date%3D2008%26volume%3D453%26spage%3D529%26epage%3D533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref259"><div class="reference"><strong class="refLabel"><a href="#ref259" class="rightTabRefNumLink">259</a></strong><div class="NLM_citation" id="rightTab-cit259"><span><span class="NLM_contrib-group">Essers, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Offner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco-Bose, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waibler, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalinke, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchosal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp, A.</span><span> </span><span class="NLM_article-title">IFNalpha activates dormant haematopoietic stem cells in vivo</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">458</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">908</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2009&pages=904-908&author=M.+A.+Essersauthor=S.+Offnerauthor=W.+E.+Blanco-Boseauthor=Z.+Waiblerauthor=U.+Kalinkeauthor=M.+A.+Duchosalauthor=A.+Trumpp&title=IFNalpha+activates+dormant+haematopoietic+stem+cells+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit259&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEssers%26aufirst%3DM.%2BA.%26aulast%3DOffner%26aufirst%3DS.%26aulast%3DBlanco-Bose%26aufirst%3DW.%2BE.%26aulast%3DWaibler%26aufirst%3DZ.%26aulast%3DKalinke%26aufirst%3DU.%26aulast%3DDuchosal%26aufirst%3DM.%2BA.%26aulast%3DTrumpp%26aufirst%3DA.%26atitle%3DIFNalpha%2520activates%2520dormant%2520haematopoietic%2520stem%2520cells%2520in%2520vivo%26jtitle%3DNature%26date%3D2009%26volume%3D458%26spage%3D904%26epage%3D908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref260"><div class="reference"><strong class="refLabel"><a href="#ref260" class="rightTabRefNumLink">260</a></strong><div class="NLM_citation" id="rightTab-cit260"><span><span class="NLM_contrib-group">Sipkins, D. A.</span><span> </span><span class="NLM_article-title">Rendering the leukemia cell susceptible to attack</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1307</span><span class="NLM_x">–</span> <span class="NLM_lpage">1309</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1056%2FNEJMcibr0904291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19776414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref260/cit260&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wjur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1307-1309&author=D.+A.+Sipkins&title=Rendering+the+leukemia+cell+susceptible+to+attack"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit260R"><div class="casContent"><span class="casTitleNuber">260</span><div class="casTitle"><span class="NLM_cas:atitle">Rendering the leukemia cell susceptible to attack</span></div><div class="casAuthors">Sipkins, Dorothy A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1307-1309</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyHjj_mV-1IbVg90H21EOLACvtfcHk0lgfq4F1JM6j4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wjur%252FF&md5=fc08183619b47c1a579b49aa354c3220</span></div><a href="/servlet/linkout?suffix=cit260&amp;dbid=16384&amp;doi=10.1056%2FNEJMcibr0904291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcibr0904291%26sid%3Dliteratum%253Aachs%26aulast%3DSipkins%26aufirst%3DD.%2BA.%26atitle%3DRendering%2520the%2520leukemia%2520cell%2520susceptible%2520to%2520attack%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1307%26epage%3D1309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref261"><div class="reference"><strong class="refLabel"><a href="#ref261" class="rightTabRefNumLink">261</a></strong><div class="NLM_citation" id="rightTab-cit261"><span><span class="NLM_contrib-group">Forsberg, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Passegue, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prohaska, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagers, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissman, I. L.</span><span> </span><span class="NLM_article-title">Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">e8785</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=e8785&author=E.+C.+Forsbergauthor=E.+Passegueauthor=S.+S.+Prohaskaauthor=A.+J.+Wagersauthor=M.+Koevaauthor=J.+M.+Stuartauthor=I.+L.+Weissman&title=Molecular+signatures+of+quiescent%2C+mobilized+and+leukemia-initiating+hematopoietic+stem+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit261&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForsberg%26aufirst%3DE.%2BC.%26aulast%3DPassegue%26aufirst%3DE.%26aulast%3DProhaska%26aufirst%3DS.%2BS.%26aulast%3DWagers%26aufirst%3DA.%2BJ.%26aulast%3DKoeva%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DJ.%2BM.%26aulast%3DWeissman%26aufirst%3DI.%2BL.%26atitle%3DMolecular%2520signatures%2520of%2520quiescent%252C%2520mobilized%2520and%2520leukemia-initiating%2520hematopoietic%2520stem%2520cells%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26spage%3De8785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref262"><div class="reference"><strong class="refLabel"><a href="#ref262" class="rightTabRefNumLink">262</a></strong><div class="NLM_citation" id="rightTab-cit262"><span><span class="NLM_contrib-group">Buzzai, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licht, J. D.</span><span> </span><span class="NLM_article-title">New molecular concepts and targets in acute myeloid leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">82</span><span class="NLM_x">–</span> <span class="NLM_lpage">87</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2FMOH.0b013e3282f3ded0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=18300752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref262/cit262&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjslWisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=82-87&author=M.+Buzzaiauthor=J.+D.+Licht&title=New+molecular+concepts+and+targets+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit262R"><div class="casContent"><span class="casTitleNuber">262</span><div class="casTitle"><span class="NLM_cas:atitle">New molecular concepts and targets in acute myeloid leukemia</span></div><div class="casAuthors">Buzzai, Monica; Licht, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">82-87</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Most patients with acute myeloid leukemia treated with chemotherapy relapse.  It is increasingly recognized that the cause of chemoresistance and relapse resides within the leukemia stem cell population.  Successful eradication of leukemia stem cells would require a comprehensive profile of both the acquired mol. lesions and intrinsic features of leukemia stem cells.  This review describes recent work identifying mol. markers that may lead to development of novel therapeutics, ultimately aiming to eradicate leukemia stem cells in acute myeloid leukemia.  Recent findings: In recent years, novel specific cell surface antigens have allowed identification of leukemia stem cells and permitted their distinction from normal hematopoietic stem cells.  Novel concepts of leukemia stem cells and niche interaction have elucidated the mechanisms that control leukemia stem cell survival and chemoresistance.  Recent detection of genetic aberrations affecting regulators of HOX gene expression and chromatin modifying enzymes, such as CDX2 and hDOT1L, resp., elucidates new key players in stem cell self-renewal and leukemic transformation.  Summary: The discovery of novel markers and survival pathways for leukemia stem cells has increased our potential to specifically target and eliminate the leukemic stem cell compartment, which is likely to improve clin. outcomes in acute myeloid leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkaiagIzCJkbVg90H21EOLACvtfcHk0lg74Pfze1oA1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjslWisLo%253D&md5=53848253a2201d2d77b2ed567b986d00</span></div><a href="/servlet/linkout?suffix=cit262&amp;dbid=16384&amp;doi=10.1097%2FMOH.0b013e3282f3ded0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMOH.0b013e3282f3ded0%26sid%3Dliteratum%253Aachs%26aulast%3DBuzzai%26aufirst%3DM.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26atitle%3DNew%2520molecular%2520concepts%2520and%2520targets%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2008%26volume%3D15%26spage%3D82%26epage%3D87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref263"><div class="reference"><strong class="refLabel"><a href="#ref263" class="rightTabRefNumLink">263</a></strong><div class="NLM_citation" id="rightTab-cit263"><span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span> </span><span class="NLM_article-title">Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">807</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.2165%2F00003088-200746100-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=17854232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref263/cit263&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1yktr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=807-824&author=I.+S.+Vizirianakis&title=Clinical+translation+of+genotyping+and+haplotyping+data%3A+implementation+of+in+vivo+pharmacology+experience+leading+drug+prescription+to+pharmacotyping"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit263R"><div class="casContent"><span class="casTitleNuber">263</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping</span></div><div class="casAuthors">Vizirianakis, Ioannis S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">807-824</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Wolters Kluwer Health</span>)
        </div><div class="casAbstract">A review.  The completion of the Human Genome Project has raised expectations for the translation of genomic knowledge into clin. forms that would lead to improved diagnosis of diseases and identification of new drug targets.  Such an opportunity is quite challenging within science and society, although there is still uncertainty regarding its outcomes in new drug development and healthcare.  Undoubtedly, however, the recent approval by the US FDA of the first two pharmacogenomic tests for genotyping drug-metabolizing enzymes is expected to empower and eventually lead to general applicability of various genetic diagnostic tools to improve pharmacotherapy outcomes in the post-genomic era.  To this end, the application of genomic knowledge and technologies in everyday clin. practice leads personalized medicine concepts towards the achievement of individualized drug selection and dosage profiling (i.e. pharmacotyping) for ensuring max. drug effectiveness and safety.  Within this framework, pharmacogenomic information can implement the existing clin. pharmacol. experience in clin. diagnosis and drug delivery.  The latter can be further advanced through the development of workflow information-based operating systems in healthcare to support the utilization, assessment and outcome of engaged clin. and genomic information.  Such a direction may help to suitably revise and adjust clin. regulatory guidelines as well as clin. pharmacol. guidelines.  This will further facilitate better designing of clin. trials for new drug development as well as pharmacovigilance registries and evaluation of these data.  To critically describe the existing environment, this article comprehensively discusses scientific efforts aimed at making clin. translation of genotyping and haplotyping data more efficient and productive in forms that are readily applicable in everyday healthcare.  In addn., specific and systematic pharmacogenomic and clin. attempts related to the development of new molecularly targeted drugs, as well as improvement of the efficacy and safety of commonly prescribed drugs, are presented.  To this end, the clin. pharmacogenomic experience gained thus far in the use of tyrosine kinase inhibitors in oncol., as well as the process of empowerment through the use of genomic knowledge of the cardiac safety of drugs modulating the function of the human ether-a-go-go-related gene (HERG) potassium channel, represent examples of how the implementation of clin. experience with genomic information guides the development of new drugs and the improvement of pharmacotherapy outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOsrPLCpNNyLVg90H21EOLACvtfcHk0lg74Pfze1oA1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1yktr%252FN&md5=c30091c9bd805d5fd8ad183d7958419f</span></div><a href="/servlet/linkout?suffix=cit263&amp;dbid=16384&amp;doi=10.2165%2F00003088-200746100-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200746100-00001%26sid%3Dliteratum%253Aachs%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26atitle%3DClinical%2520translation%2520of%2520genotyping%2520and%2520haplotyping%2520data%253A%2520implementation%2520of%2520in%2520vivo%2520pharmacology%2520experience%2520leading%2520drug%2520prescription%2520to%2520pharmacotyping%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2007%26volume%3D46%26spage%3D807%26epage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref264"><div class="reference"><strong class="refLabel"><a href="#ref264" class="rightTabRefNumLink">264</a></strong><div class="NLM_citation" id="rightTab-cit264"><span><span class="NLM_contrib-group">Evans, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Relling, M. V.</span><span> </span><span class="NLM_article-title">Pharmacogenomics: translating functional genomics into rational therapeutics</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">286</span><span class="NLM_x">, </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">491</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=487-491&author=W.+E.+Evansauthor=M.+V.+Relling&title=Pharmacogenomics%3A+translating+functional+genomics+into+rational+therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit264&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DW.%2BE.%26aulast%3DRelling%26aufirst%3DM.%2BV.%26atitle%3DPharmacogenomics%253A%2520translating%2520functional%2520genomics%2520into%2520rational%2520therapeutics%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D487%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref265"><div class="reference"><strong class="refLabel"><a href="#ref265" class="rightTabRefNumLink">265</a></strong><div class="NLM_citation" id="rightTab-cit265"><span><span class="NLM_contrib-group">Weinshilboum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span> </span><span class="NLM_article-title">Pharmacogenomics: bench to bedside</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">739</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=739-748&author=R.+Weinshilboumauthor=L.+Wang&title=Pharmacogenomics%3A+bench+to+bedside"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit265&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeinshilboum%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26atitle%3DPharmacogenomics%253A%2520bench%2520to%2520bedside%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D739%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref266"><div class="reference"><strong class="refLabel"><a href="#ref266" class="rightTabRefNumLink">266</a></strong><div class="NLM_citation" id="rightTab-cit266"><span><span class="NLM_contrib-group">Bullinger, L.; Dohner, H.; Pollack, J. R.</span><span> </span><span class="NLM_article-title">Genomics in Leukemias</span>. In  <span class="citation_source-book">Genomics and Personalized Medicine</span>; <span class="NLM_contrib-group">Willard, H. F.; Ginsbeing, G. S.</span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Burlington, MA</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">844</span>− <span class="NLM_lpage">855</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref266/cit266&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1016%2FB978-0-12-369420-1.00070-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=844-855&author=L.+Bullinger&author=H.+Dohner&author=J.+R.+Pollackauthor=H.+F.+Willard&author=G.+S.+Ginsbeing&title=Genomics+and+Personalized+Medicine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit266&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-369420-1.00070-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-369420-1.00070-6%26sid%3Dliteratum%253Aachs%26aulast%3DBullinger%26aufirst%3DL.%26atitle%3DGenomics%2520in%2520Leukemias%26btitle%3DGenomics%2520and%2520Personalized%2520Medicine%26aulast%3DWillard%26aufirst%3DH.%2BF.%26pub%3DElsevier%26date%3D2009%26spage%3D844%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref267"><div class="reference"><strong class="refLabel"><a href="#ref267" class="rightTabRefNumLink">267</a></strong><div class="NLM_citation" id="rightTab-cit267"><span><span class="NLM_contrib-group">Tamayo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slonim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesirov, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitareewan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dmitrovsky, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lander, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golub, T. R.</span><span> </span><span class="NLM_article-title">Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">2907</span><span class="NLM_x">–</span> <span class="NLM_lpage">2912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=2907-2912&author=P.+Tamayoauthor=D.+Slonimauthor=J.+Mesirovauthor=Q.+Zhuauthor=S.+Kitareewanauthor=E.+Dmitrovskyauthor=E.+S.+Landerauthor=T.+R.+Golub&title=Interpreting+patterns+of+gene+expression+with+self-organizing+maps%3A+methods+and+application+to+hematopoietic+differentiation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit267&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamayo%26aufirst%3DP.%26aulast%3DSlonim%26aufirst%3DD.%26aulast%3DMesirov%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DKitareewan%26aufirst%3DS.%26aulast%3DDmitrovsky%26aufirst%3DE.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26atitle%3DInterpreting%2520patterns%2520of%2520gene%2520expression%2520with%2520self-organizing%2520maps%253A%2520methods%2520and%2520application%2520to%2520hematopoietic%2520differentiation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D2907%26epage%3D2912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref268"><div class="reference"><strong class="refLabel"><a href="#ref268" class="rightTabRefNumLink">268</a></strong><div class="NLM_citation" id="rightTab-cit268"><span><span class="NLM_contrib-group">Karas-Kuzelicki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mlinaric-Rascan, I.</span><span> </span><span class="NLM_article-title">Individualization of thiopurine therapy: thiopurine <i>S</i>-methyltransferase and beyond</span> <span class="citation_source-journal">Pharmacogenomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1309</span><span class="NLM_x">–</span> <span class="NLM_lpage">1322</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1309-1322&author=N.+Karas-Kuzelickiauthor=I.+Mlinaric-Rascan&title=Individualization+of+thiopurine+therapy%3A+thiopurine+S-methyltransferase+and+beyond"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit268&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaras-Kuzelicki%26aufirst%3DN.%26aulast%3DMlinaric-Rascan%26aufirst%3DI.%26atitle%3DIndividualization%2520of%2520thiopurine%2520therapy%253A%2520thiopurine%2520S-methyltransferase%2520and%2520beyond%26jtitle%3DPharmacogenomics%26date%3D2009%26volume%3D10%26spage%3D1309%26epage%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref269"><div class="reference"><strong class="refLabel"><a href="#ref269" class="rightTabRefNumLink">269</a></strong><div class="NLM_citation" id="rightTab-cit269"><span><span class="NLM_contrib-group">Cheok, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pottier, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kager, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, W. E.</span><span> </span><span class="NLM_article-title">Pharmacogenetics in acute lymphoblastic leukemia</span> <span class="citation_source-journal">Semin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1053%2Fj.seminhematol.2008.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19100367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref269/cit269&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2009&pages=39-51&author=M.+H.+Cheokauthor=N.+Pottierauthor=L.+Kagerauthor=W.+E.+Evans&title=Pharmacogenetics+in+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit269R"><div class="casContent"><span class="casTitleNuber">269</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmocogenetics in acute lymphoblastic leukemia</span></div><div class="casAuthors">Cheok, Meyling H.; Pottier, Nicolas; Kager, Leo; Evans, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Hematology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">SEHEA3</span>;
        ISSN:<span class="NLM_cas:issn">0037-1963</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.  This exemplary progress is largely due to the optimization of existing treatment modalities rather than the discovery of new antileukemic agents.  However, despite these high cure rates, the annual no. of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers.  The aim of pharmacogenetics is to develop strategies to personalize treatment and tailor therapy to individual patients, with the goal of optimizing efficacy and safety through better understanding of human genome variability and its influence on drug response.  In this review, we summarize recent pharmacogenomic studies related to the treatment of pediatric ALL.  These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp77ZaumGqwLrVg90H21EOLACvtfcHk0ljy5rcddH5aVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVWitL0%253D&md5=f29bfc618f12bb73cf934034160faae1</span></div><a href="/servlet/linkout?suffix=cit269&amp;dbid=16384&amp;doi=10.1053%2Fj.seminhematol.2008.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminhematol.2008.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DCheok%26aufirst%3DM.%2BH.%26aulast%3DPottier%26aufirst%3DN.%26aulast%3DKager%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26atitle%3DPharmacogenetics%2520in%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DSemin.%2520Hematol.%26date%3D2009%26volume%3D46%26spage%3D39%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref270"><div class="reference"><strong class="refLabel"><a href="#ref270" class="rightTabRefNumLink">270</a></strong><div class="NLM_citation" id="rightTab-cit270"><span><span class="NLM_contrib-group">Kager, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, W. E.</span><span> </span><span class="NLM_article-title">Pharmacogenomics of acute lymphoblastic leukemia</span> <span class="citation_source-journal">Curr. Opin. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1097%2F01.moh.0000231424.46148.f9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=16755223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref270/cit270&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFGrsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=260-265&author=L.+Kagerauthor=W.+E.+Evans&title=Pharmacogenomics+of+acute+lymphoblastic+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit270R"><div class="casContent"><span class="casTitleNuber">270</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacogenomics of acute lymphoblastic leukemia</span></div><div class="casAuthors">Kager, Leo; Evans, William E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Hematology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-265</span>CODEN:
                <span class="NLM_cas:coden">COHEF4</span>;
        ISSN:<span class="NLM_cas:issn">1065-6251</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: The cure rate in children with acute lymphoblastic leukemia now exceeds almost 80% in most treatment protocols in industrialized countries.  This has mainly been achieved empirically through carefully controlled, randomized clin. trials.  Due to relative nonspecific action and narrow therapeutic indexes of antileukemic medications, however, current therapy can be assocd. with significant short and long-term adverse effects, and around 20% of patients will not be cured despite intensified treatment.  Pharmacogenomics, which studies the role of inheritance in individual variation in drug disposition and response, could be a useful tool to further improve outcome in this heterogeneous disease by individualization of therapy based on information gained from the genetic 'make-up' of normal host cells and lymphoblastic leukemia cells.  Recent findings: The focus of this review is on recent progress in the field by discussing the results of selected studies in which information from functional genomics, high-throughput mol. analyses, and pharmacodynamics has been integrated to establish pharmacogenomic models.  These models may be used to both maximize efficacy and minimize toxicity of existing antileukemic medications, or to identify novel therapeutic targets in lymphoblasts that are resistant to conventional antileukemic drugs.  Summary: The findings from recent pharmacogenomic studies can be integrated into decision-making in future clin. trials.  Thus there is great promise for advancing event-free survival in childhood leukemia in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_znYJ0KGY6bVg90H21EOLACvtfcHk0ljy5rcddH5aVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFGrsbc%253D&md5=8d5b5640dc778b4bc16dc47157e9f96c</span></div><a href="/servlet/linkout?suffix=cit270&amp;dbid=16384&amp;doi=10.1097%2F01.moh.0000231424.46148.f9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.moh.0000231424.46148.f9%26sid%3Dliteratum%253Aachs%26aulast%3DKager%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DW.%2BE.%26atitle%3DPharmacogenomics%2520of%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DCurr.%2520Opin.%2520Hematol.%26date%3D2006%26volume%3D13%26spage%3D260%26epage%3D265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref271"><div class="reference"><strong class="refLabel"><a href="#ref271" class="rightTabRefNumLink">271</a></strong><div class="NLM_citation" id="rightTab-cit271"><span><span class="NLM_contrib-group">Karas-Kuzelicki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jazbec, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mlinaric-Rascan, I.</span><span> </span><span class="NLM_article-title">Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=971-974&author=N.+Karas-Kuzelickiauthor=J.+Jazbecauthor=M.+Milekauthor=I.+Mlinaric-Rascan&title=Heterozygosity+at+the+TPMT+gene+locus%2C+augmented+by+mutated+MTHFR+gene%2C+predisposes+to+6-MP+related+toxicities+in+childhood+ALL+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit271&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaras-Kuzelicki%26aufirst%3DN.%26aulast%3DJazbec%26aufirst%3DJ.%26aulast%3DMilek%26aufirst%3DM.%26aulast%3DMlinaric-Rascan%26aufirst%3DI.%26atitle%3DHeterozygosity%2520at%2520the%2520TPMT%2520gene%2520locus%252C%2520augmented%2520by%2520mutated%2520MTHFR%2520gene%252C%2520predisposes%2520to%25206-MP%2520related%2520toxicities%2520in%2520childhood%2520ALL%2520patients%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref272"><div class="reference"><strong class="refLabel"><a href="#ref272" class="rightTabRefNumLink">272</a></strong><div class="NLM_citation" id="rightTab-cit272"><span><span class="NLM_contrib-group">Lindpaintner, K.</span><span> </span><span class="NLM_article-title">The impact of pharmacogenetics and pharmacogenomics on drug discovery</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">469</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=463-469&author=K.+Lindpaintner&title=The+impact+of+pharmacogenetics+and+pharmacogenomics+on+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit272&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindpaintner%26aufirst%3DK.%26atitle%3DThe%2520impact%2520of%2520pharmacogenetics%2520and%2520pharmacogenomics%2520on%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D463%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref273"><div class="reference"><strong class="refLabel"><a href="#ref273" class="rightTabRefNumLink">273</a></strong><div class="NLM_citation" id="rightTab-cit273"><span><span class="NLM_contrib-group">Suzuki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrest, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Nimwegen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balwierz, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassmann, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravasi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Hoon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carninci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaru, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanamori-Katayama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubosaki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akalin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asahara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajic, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckhouse, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjorkegren, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brombacher, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bulger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalk, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloonan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dostie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engstrom, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essack, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faulkner, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fredman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gojobori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gough, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimmond, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gustafsson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatakeyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinzel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hide, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornquist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huminiecki, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishihara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwayanagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawaji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koga, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krogh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenhard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lennartsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lizio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macpherson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maqungo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matigian, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto-Sato, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakabayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakachi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nygaard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okazaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda-Yabukami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlando, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otomo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachkov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrovsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plessy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quackenbush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radovanovic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandelin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmeier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schonbach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semple, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sera, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirahige, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Laurent, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweet, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taft, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teasdale, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tegner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teichmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahlestedt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterhouse, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winther, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yanagawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zavolan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hume, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawashima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawazu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitazume, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kojima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murata, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ninomiya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiyori, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sano, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tagami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashizaki, Y.</span><span> </span><span class="NLM_article-title">The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">553</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1038%2Fng.375" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19377474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref273/cit273&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks12ktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2009&pages=553-562&author=H.+Suzukiauthor=A.+R.+Forrestauthor=E.+van+Nimwegenauthor=C.+O.+Daubauthor=P.+J.+Balwierzauthor=K.+M.+Irvineauthor=T.+Lassmannauthor=T.+Ravasiauthor=Y.+Hasegawaauthor=M.+J.+de+Hoonauthor=S.+Katayamaauthor=K.+Schroderauthor=P.+Carninciauthor=Y.+Tomaruauthor=M.+Kanamori-Katayamaauthor=A.+Kubosakiauthor=A.+Akalinauthor=Y.+Andoauthor=E.+Arnerauthor=M.+Asadaauthor=H.+Asaharaauthor=T.+Baileyauthor=V.+B.+Bajicauthor=D.+Bauerauthor=A.+G.+Beckhouseauthor=N.+Bertinauthor=J.+Bjorkegrenauthor=F.+Brombacherauthor=E.+Bulgerauthor=A.+M.+Chalkauthor=J.+Chibaauthor=N.+Cloonanauthor=A.+Daweauthor=J.+Dostieauthor=P.+G.+Engstromauthor=M.+Essackauthor=G.+J.+Faulknerauthor=J.+L.+Finkauthor=D.+Fredmanauthor=K.+Fujimoriauthor=M.+Furunoauthor=T.+Gojoboriauthor=J.+Goughauthor=S.+M.+Grimmondauthor=M.+Gustafssonauthor=M.+Hashimotoauthor=T.+Hashimotoauthor=M.+Hatakeyamaauthor=S.+Heinzelauthor=W.+Hideauthor=O.+Hofmannauthor=M.+Hornquistauthor=L.+Huminieckiauthor=K.+Ikeoauthor=N.+Imamotoauthor=S.+Inoueauthor=Y.+Inoueauthor=R.+Ishiharaauthor=T.+Iwayanagiauthor=A.+Jacobsenauthor=M.+Kaurauthor=H.+Kawajiauthor=M.+C.+Kerrauthor=R.+Kimuraauthor=S.+Kimuraauthor=Y.+Kimuraauthor=H.+Kitanoauthor=H.+Kogaauthor=T.+Kojimaauthor=S.+Kondoauthor=T.+Konnoauthor=A.+Kroghauthor=A.+Krugerauthor=A.+Kumarauthor=B.+Lenhardauthor=A.+Lennartssonauthor=M.+Lindowauthor=M.+Lizioauthor=C.+Macphersonauthor=N.+Maedaauthor=C.+A.+Maherauthor=M.+Maqungoauthor=J.+Marauthor=N.+A.+Matigianauthor=H.+Matsudaauthor=J.+S.+Mattickauthor=S.+Meierauthor=S.+Miyamotoauthor=E.+Miyamoto-Satoauthor=K.+Nakabayashiauthor=Y.+Nakachiauthor=M.+Nakanoauthor=S.+Nygaardauthor=T.+Okayamaauthor=Y.+Okazakiauthor=H.+Okuda-Yabukamiauthor=V.+Orlandoauthor=J.+Otomoauthor=M.+Pachkovauthor=N.+Petrovskyauthor=C.+Plessyauthor=J.+Quackenbushauthor=A.+Radovanovicauthor=M.+Rehliauthor=R.+Saitoauthor=A.+Sandelinauthor=S.+Schmeierauthor=C.+Schonbachauthor=A.+S.+Schwartzauthor=C.+A.+Sempleauthor=M.+Seraauthor=J.+Severinauthor=K.+Shirahigeauthor=C.+Simonsauthor=G.+St+Laurentauthor=M.+Suzukiauthor=T.+Suzukiauthor=M.+J.+Sweetauthor=R.+J.+Taftauthor=S.+Takedaauthor=Y.+Takenakaauthor=K.+Tanauthor=M.+S.+Taylorauthor=R.+D.+Teasdaleauthor=J.+Tegnerauthor=S.+Teichmannauthor=E.+Valenauthor=C.+Wahlestedtauthor=K.+Wakiauthor=A.+Waterhouseauthor=C.+A.+Wellsauthor=O.+Wintherauthor=L.+Wuauthor=K.+Yamaguchiauthor=H.+Yanagawaauthor=J.+Yasudaauthor=M.+Zavolanauthor=D.+A.+Humeauthor=T.+Arakawaauthor=S.+Fukudaauthor=K.+Imamuraauthor=C.+Kaiauthor=A.+Kaihoauthor=T.+Kawashimaauthor=C.+Kawazuauthor=Y.+Kitazumeauthor=M.+Kojimaauthor=H.+Miuraauthor=K.+Murakamiauthor=M.+Murataauthor=N.+Ninomiyaauthor=H.+Nishiyoriauthor=S.+Nomaauthor=C.+Ogawaauthor=T.+Sanoauthor=C.+Simonauthor=M.+Tagamiauthor=Y.+Takahashiauthor=J.+Kawaiauthor=Y.+Hayashizaki&title=The+transcriptional+network+that+controls+growth+arrest+and+differentiation+in+a+human+myeloid+leukemia+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit273R"><div class="casContent"><span class="casTitleNuber">273</span><div class="casTitle"><span class="NLM_cas:atitle">The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line</span></div><div class="casAuthors">Suzuki, Harukazu; Forrest, Alistair R. R.; van Nimwegen, Erik; Daub, Carsten O.; Balwierz, Piotr J.; Irvine, Katharine M.; Lassmann, Timo; Ravasi, Timothy; Hasegawa, Yuki; de Hoon, Michiel J. L.; Katayama, Shintaro; Schroder, Kate; Carninci, Piero; Tomaru, Yasuhiro; Kanamori-Katayama, Mutsumi; Kubosaki, Atsutaka; Akalin, Altuna; Ando, Yoshinari; Arner, Erik; Asada, Maki; Asahara, Hiroshi; Bailey, Timothy; Bajic, Vladimir B.; Bauer, Denis; Beckhouse, Anthony G.; Bertin, Nicolas; Bjoerkegren, Johan; Brombacher, Frank; Bulger, Erika; Chalk, Alistair M.; Chiba, Joe; Cloonan, Nicole; Dawe, Adam; Dostie, Josee; Engstroem, Paer G.; Essack, Magbubah; Faulkner, Geoffrey J.; Fink, J. Lynn; Fredman, David; Fujimori, Ko; Furuno, Masaaki; Gojobori, Takashi; Gough, Julian; Grimmond, Sean M.; Gustafsson, Mika; Hashimoto, Megumi; Hashimoto, Takehiro; Hatakeyama, Mariko; Heinzel, Susanne; Hide, Winston; Hofmann, Oliver; Hoernquist, Michael; Huminiecki, Lukasz; Ikeo, Kazuho; Imamoto, Naoko; Inoue, Satoshi; Inoue, Yusuke; Ishihara, Ryoko; Iwayanagi, Takao; Jacobsen, Anders; Kaur, Mandeep; Kawaji, Hideya; Kerr, Markus C.; Kimura, Ryuichiro; Kimura, Syuhei; Kimura, Yasumasa; Kitano, Hiroaki; Koga, Hisashi; Kojima, Toshio; Kondo, Shinji; Konno, Takeshi; Krogh, Anders; Kruger, Adele; Kumar, Ajit; Lenhard, Boris; Lennartsson, Andreas; Lindow, Morten; Lizio, Marina; MacPherson, Cameron; Maeda, Norihiro; Maher, Christopher A.; Maqungo, Monique; Mar, Jessica; Matigian, Nicholas A.; Matsuda, Hideo; Mattick, John S.; Meier, Stuart; Miyamoto, Sei; Miyamoto-Sato, Etsuko; Nakabayashi, Kazuhiko; Nakachi, Yutaka; Nakano, Mika; Nygaard, Sanne; Okayama, Toshitsugu; Okazaki, Yasushi; Okuda-Yabukami, Haruka; Orlando, Valerio; Otomo, Jun; Pachkov, Mikhail; Petrovsky, Nikolai; Plessy, Charles; Quackenbush, John; Radovanovic, Aleksandar; Rehli, Michael; Saito, Rintaro; Sandelin, Albin; Schmeier, Sebastian; Schoenbach, Christian; Schwartz, Ariel S.; Semple, Colin A.; Sera, Miho; Severin, Jessica; Shirahige, Katsuhiko; Simons, Cas; St. Laurent, George; Suzuki, Masanori; Suzuki, Takahiro; Sweet, Matthew J.; Taft, Ryan J.; Takeda, Shizu; Takenaka, Yoichi; Tan, Kai; Taylor, Martin S.; Teasdale, Rohan D.; Tegner, Jesper; Teichmann, Sarah; Valen, Eivind; Wahlestedt, Claes; Waki, Kazunori; Waterhouse, Andrew; Wells, Christine A.; Winther, Ole; Wu, Linda; Yamaguchi, Kazumi; Yanagawa, Hiroshi; Yasuda, Jun; Zavolan, Mihaela; Hume, David A.; Arakawa, Takahiro; Fukuda, Shiro; Imamura, Kengo; Kai, Chikatoshi; Kaiho, Ai; Kawashima, Tsugumi; Kawazu, Chika; Kitazume, Yayoi; Kojima, Miki; Miura, Hisashi; Murakami, Kayoko; Murata, Mitsuyoshi; Ninomiya, Noriko; Nishiyori, Hiromi; Noma, Shohei; Ogawa, Chihiro; Sano, Takuma; Simon, Christophe; Tagami, Michihira; Takahashi, Yukari; Kawai, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Using deep sequencing (deepCAGE), the FANTOM4 study measured the genome-wide dynamics of transcription-start-site usage in the human monocytic cell line THP-1 throughout a time course of growth arrest and differentiation.  Modeling the expression dynamics in terms of predicted cis-regulatory sites, we identified the key transcription regulators, their time-dependent activities and target genes.  Systematic siRNA knockdown of 52 transcription factors confirmed the roles of individual factors in the regulatory network.  These results indicate that cellular states are constrained by complex networks involving both pos. and neg. regulatory interactions among substantial nos. of transcription factors and that no single transcription factor is both necessary and sufficient to drive the differentiation process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoHvH8iKtmmLVg90H21EOLACvtfcHk0lgPLQGTSQmjSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks12ktrc%253D&md5=34bcab613d6036655b35ce8d82047534</span></div><a href="/servlet/linkout?suffix=cit273&amp;dbid=16384&amp;doi=10.1038%2Fng.375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.375%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DForrest%26aufirst%3DA.%2BR.%26aulast%3Dvan%2BNimwegen%26aufirst%3DE.%26aulast%3DDaub%26aufirst%3DC.%2BO.%26aulast%3DBalwierz%26aufirst%3DP.%2BJ.%26aulast%3DIrvine%26aufirst%3DK.%2BM.%26aulast%3DLassmann%26aufirst%3DT.%26aulast%3DRavasi%26aufirst%3DT.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3Dde%2BHoon%26aufirst%3DM.%2BJ.%26aulast%3DKatayama%26aufirst%3DS.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCarninci%26aufirst%3DP.%26aulast%3DTomaru%26aufirst%3DY.%26aulast%3DKanamori-Katayama%26aufirst%3DM.%26aulast%3DKubosaki%26aufirst%3DA.%26aulast%3DAkalin%26aufirst%3DA.%26aulast%3DAndo%26aufirst%3DY.%26aulast%3DArner%26aufirst%3DE.%26aulast%3DAsada%26aufirst%3DM.%26aulast%3DAsahara%26aufirst%3DH.%26aulast%3DBailey%26aufirst%3DT.%26aulast%3DBajic%26aufirst%3DV.%2BB.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DBeckhouse%26aufirst%3DA.%2BG.%26aulast%3DBertin%26aufirst%3DN.%26aulast%3DBjorkegren%26aufirst%3DJ.%26aulast%3DBrombacher%26aufirst%3DF.%26aulast%3DBulger%26aufirst%3DE.%26aulast%3DChalk%26aufirst%3DA.%2BM.%26aulast%3DChiba%26aufirst%3DJ.%26aulast%3DCloonan%26aufirst%3DN.%26aulast%3DDawe%26aufirst%3DA.%26aulast%3DDostie%26aufirst%3DJ.%26aulast%3DEngstrom%26aufirst%3DP.%2BG.%26aulast%3DEssack%26aufirst%3DM.%26aulast%3DFaulkner%26aufirst%3DG.%2BJ.%26aulast%3DFink%26aufirst%3DJ.%2BL.%26aulast%3DFredman%26aufirst%3DD.%26aulast%3DFujimori%26aufirst%3DK.%26aulast%3DFuruno%26aufirst%3DM.%26aulast%3DGojobori%26aufirst%3DT.%26aulast%3DGough%26aufirst%3DJ.%26aulast%3DGrimmond%26aufirst%3DS.%2BM.%26aulast%3DGustafsson%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DT.%26aulast%3DHatakeyama%26aufirst%3DM.%26aulast%3DHeinzel%26aufirst%3DS.%26aulast%3DHide%26aufirst%3DW.%26aulast%3DHofmann%26aufirst%3DO.%26aulast%3DHornquist%26aufirst%3DM.%26aulast%3DHuminiecki%26aufirst%3DL.%26aulast%3DIkeo%26aufirst%3DK.%26aulast%3DImamoto%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DIshihara%26aufirst%3DR.%26aulast%3DIwayanagi%26aufirst%3DT.%26aulast%3DJacobsen%26aufirst%3DA.%26aulast%3DKaur%26aufirst%3DM.%26aulast%3DKawaji%26aufirst%3DH.%26aulast%3DKerr%26aufirst%3DM.%2BC.%26aulast%3DKimura%26aufirst%3DR.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DY.%26aulast%3DKitano%26aufirst%3DH.%26aulast%3DKoga%26aufirst%3DH.%26aulast%3DKojima%26aufirst%3DT.%26aulast%3DKondo%26aufirst%3DS.%26aulast%3DKonno%26aufirst%3DT.%26aulast%3DKrogh%26aufirst%3DA.%26aulast%3DKruger%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DLenhard%26aufirst%3DB.%26aulast%3DLennartsson%26aufirst%3DA.%26aulast%3DLindow%26aufirst%3DM.%26aulast%3DLizio%26aufirst%3DM.%26aulast%3DMacpherson%26aufirst%3DC.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DMaher%26aufirst%3DC.%2BA.%26aulast%3DMaqungo%26aufirst%3DM.%26aulast%3DMar%26aufirst%3DJ.%26aulast%3DMatigian%26aufirst%3DN.%2BA.%26aulast%3DMatsuda%26aufirst%3DH.%26aulast%3DMattick%26aufirst%3DJ.%2BS.%26aulast%3DMeier%26aufirst%3DS.%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DMiyamoto-Sato%26aufirst%3DE.%26aulast%3DNakabayashi%26aufirst%3DK.%26aulast%3DNakachi%26aufirst%3DY.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DNygaard%26aufirst%3DS.%26aulast%3DOkayama%26aufirst%3DT.%26aulast%3DOkazaki%26aufirst%3DY.%26aulast%3DOkuda-Yabukami%26aufirst%3DH.%26aulast%3DOrlando%26aufirst%3DV.%26aulast%3DOtomo%26aufirst%3DJ.%26aulast%3DPachkov%26aufirst%3DM.%26aulast%3DPetrovsky%26aufirst%3DN.%26aulast%3DPlessy%26aufirst%3DC.%26aulast%3DQuackenbush%26aufirst%3DJ.%26aulast%3DRadovanovic%26aufirst%3DA.%26aulast%3DRehli%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DSandelin%26aufirst%3DA.%26aulast%3DSchmeier%26aufirst%3DS.%26aulast%3DSchonbach%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%2BS.%26aulast%3DSemple%26aufirst%3DC.%2BA.%26aulast%3DSera%26aufirst%3DM.%26aulast%3DSeverin%26aufirst%3DJ.%26aulast%3DShirahige%26aufirst%3DK.%26aulast%3DSimons%26aufirst%3DC.%26aulast%3DSt%2BLaurent%26aufirst%3DG.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DTaft%26aufirst%3DR.%2BJ.%26aulast%3DTakeda%26aufirst%3DS.%26aulast%3DTakenaka%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DM.%2BS.%26aulast%3DTeasdale%26aufirst%3DR.%2BD.%26aulast%3DTegner%26aufirst%3DJ.%26aulast%3DTeichmann%26aufirst%3DS.%26aulast%3DValen%26aufirst%3DE.%26aulast%3DWahlestedt%26aufirst%3DC.%26aulast%3DWaki%26aufirst%3DK.%26aulast%3DWaterhouse%26aufirst%3DA.%26aulast%3DWells%26aufirst%3DC.%2BA.%26aulast%3DWinther%26aufirst%3DO.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYanagawa%26aufirst%3DH.%26aulast%3DYasuda%26aufirst%3DJ.%26aulast%3DZavolan%26aufirst%3DM.%26aulast%3DHume%26aufirst%3DD.%2BA.%26aulast%3DArakawa%26aufirst%3DT.%26aulast%3DFukuda%26aufirst%3DS.%26aulast%3DImamura%26aufirst%3DK.%26aulast%3DKai%26aufirst%3DC.%26aulast%3DKaiho%26aufirst%3DA.%26aulast%3DKawashima%26aufirst%3DT.%26aulast%3DKawazu%26aufirst%3DC.%26aulast%3DKitazume%26aufirst%3DY.%26aulast%3DKojima%26aufirst%3DM.%26aulast%3DMiura%26aufirst%3DH.%26aulast%3DMurakami%26aufirst%3DK.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DNinomiya%26aufirst%3DN.%26aulast%3DNishiyori%26aufirst%3DH.%26aulast%3DNoma%26aufirst%3DS.%26aulast%3DOgawa%26aufirst%3DC.%26aulast%3DSano%26aufirst%3DT.%26aulast%3DSimon%26aufirst%3DC.%26aulast%3DTagami%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DKawai%26aufirst%3DJ.%26aulast%3DHayashizaki%26aufirst%3DY.%26atitle%3DThe%2520transcriptional%2520network%2520that%2520controls%2520growth%2520arrest%2520and%2520differentiation%2520in%2520a%2520human%2520myeloid%2520leukemia%2520cell%2520line%26jtitle%3DNat.%2520Genet.%26date%3D2009%26volume%3D41%26spage%3D553%26epage%3D562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref274"><div class="reference"><strong class="refLabel"><a href="#ref274" class="rightTabRefNumLink">274</a></strong><div class="NLM_citation" id="rightTab-cit274"><span><span class="NLM_contrib-group">Flotho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandrock, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plass, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niemeyer, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbert, M.</span><span> </span><span class="NLM_article-title">The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1019</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1019-1028&author=C.+Flothoauthor=R.+Clausauthor=C.+Batzauthor=M.+Schneiderauthor=I.+Sandrockauthor=S.+Ihdeauthor=C.+Plassauthor=C.+M.+Niemeyerauthor=M.+Lubbert&title=The+DNA+methyltransferase+inhibitors+azacitidine%2C+decitabine+and+zebularine+exert+differential+effects+on+cancer+gene+expression+in+acute+myeloid+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit274&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFlotho%26aufirst%3DC.%26aulast%3DClaus%26aufirst%3DR.%26aulast%3DBatz%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSandrock%26aufirst%3DI.%26aulast%3DIhde%26aufirst%3DS.%26aulast%3DPlass%26aufirst%3DC.%26aulast%3DNiemeyer%26aufirst%3DC.%2BM.%26aulast%3DLubbert%26aufirst%3DM.%26atitle%3DThe%2520DNA%2520methyltransferase%2520inhibitors%2520azacitidine%252C%2520decitabine%2520and%2520zebularine%2520exert%2520differential%2520effects%2520on%2520cancer%2520gene%2520expression%2520in%2520acute%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D1019%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref275"><div class="reference"><strong class="refLabel"><a href="#ref275" class="rightTabRefNumLink">275</a></strong><div class="NLM_citation" id="rightTab-cit275"><span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span> </span><span class="NLM_article-title">Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)-RNAs hybridized to 3′-end flanking sequences of beta(major) globin gene</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1743</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1743&publication_year=2005&pages=101-114&author=I.+S.+Vizirianakisauthor=A.+S.+Tsiftsoglou&title=Blockade+of+murine+erythroleukemia+cell+differentiation+by+hypomethylating+agents+causes+accumulation+of+discrete+small+poly%28A%29-RNAs+hybridized+to+3%E2%80%B2-end+flanking+sequences+of+beta%28major%29+globin+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit275&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26atitle%3DBlockade%2520of%2520murine%2520erythroleukemia%2520cell%2520differentiation%2520by%2520hypomethylating%2520agents%2520causes%2520accumulation%2520of%2520discrete%2520small%2520poly%2528A%2529-RNAs%2520hybridized%2520to%25203%25E2%2580%25B2-end%2520flanking%2520sequences%2520of%2520beta%2528major%2529%2520globin%2520gene%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1743%26spage%3D101%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref276"><div class="reference"><strong class="refLabel"><a href="#ref276" class="rightTabRefNumLink">276</a></strong><div class="NLM_citation" id="rightTab-cit276"><span><span class="NLM_contrib-group">Miranda, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortez, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoo, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquez, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P. A.</span><span> </span><span class="NLM_article-title">DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1579</span><span class="NLM_x">–</span> <span class="NLM_lpage">1588</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=16&amp;doi=10.1021%2Fjm100189a&amp;key=10.1158%2F1535-7163.MCT-09-0013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=8&amp;doi=10.1021%2Fjm100189a&amp;key=19509260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref276/cit276&amp;dbid=32&amp;doi=10.1021%2Fjm100189a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVKgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=1579-1588&author=T.+B.+Mirandaauthor=C.+C.+Cortezauthor=C.+B.+Yooauthor=G.+Liangauthor=M.+Abeauthor=T.+K.+Kellyauthor=V.+E.+Marquezauthor=P.+A.+Jones&title=DZNep+is+a+global+histone+methylation+inhibitor+that+reactivates+developmental+genes+not+silenced+by+DNA+methylation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit276R"><div class="casContent"><span class="casTitleNuber">276</span><div class="casTitle"><span class="NLM_cas:atitle">DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation</span></div><div class="casAuthors">Miranda, Tina Branscombe; Cortez, Connie C.; Yoo, Christine B.; Liang, Gangning; Abe, Masanobu; Kelly, Theresa K.; Marquez, Victor E.; Jones, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1579-1588</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">DNA methylation, histone modifications, and nucleosomal occupancy collaborate to cause silencing of tumor-related genes in cancer.  The development of drugs that target these processes is therefore important for cancer therapy.  Inhibitors of DNA methylation and histone deacetylation have been approved by the Food and Drug Administration for treatment of hematol. malignancies.  However, drugs that target other mechanisms still need to be developed.  Recently, 3-deazaneplanocin A (DZNep) was reported to selectively inhibit trimethylation of lysine 27 on histone H3 (H3K27me3) and lysine 20 on histone H4 (H4K20me3) as well as reactivate silenced genes in cancer cells.  This finding opens the door to the pharmacol. inhibition of histone methylation.  We therefore wanted to further study the mechanism of action of DZNep in cancer cells.  Western blot anal. shows that DZNep globally inhibits histone methylation and is not selective.  Two other drugs, sinefungin and adenosine dialdehyde, have similar effects as DZNep on H3K27me3.  Intriguingly, chromatin immunopptn. of various histone modifications and microarray anal. show that DZNep acts through a different pathway than 5-aza-2'-deoxycytidine (5-aza-CdR), a DNA methyltransferase inhibitor.  These observations give us interesting insight into how chromatin structure affects gene expression.  We also detd. the kinetics of gene activation to understand if the induced changes were somatically heritable.  We found that upon removal of DZNep, gene expression is reduced to its original state.  This suggests that there is a homeostatic mechanism that returns the histone modifications to their "ground state" after DZNep treatment.  Our data show the strong need for further development of histone methylation inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGploR0o6_2Q67Vg90H21EOLACvtfcHk0lgEAI9mxLGn2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVKgtr8%253D&md5=3de46039cddbeb72ae9b5b11764422c0</span></div><a href="/servlet/linkout?suffix=cit276&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0013%26sid%3Dliteratum%253Aachs%26aulast%3DMiranda%26aufirst%3DT.%2BB.%26aulast%3DCortez%26aufirst%3DC.%2BC.%26aulast%3DYoo%26aufirst%3DC.%2BB.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DT.%2BK.%26aulast%3DMarquez%26aufirst%3DV.%2BE.%26aulast%3DJones%26aufirst%3DP.%2BA.%26atitle%3DDZNep%2520is%2520a%2520global%2520histone%2520methylation%2520inhibitor%2520that%2520reactivates%2520developmental%2520genes%2520not%2520silenced%2520by%2520DNA%2520methylation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D1579%26epage%3D1588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref277"><div class="reference"><strong class="refLabel"><a href="#ref277" class="rightTabRefNumLink">277</a></strong><div class="NLM_citation" id="rightTab-cit277"><span><span class="NLM_contrib-group">Sioud, M.</span><span> </span><span class="NLM_article-title">Therapeutic siRNAs</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=22-28&author=M.+Sioud&title=Therapeutic+siRNAs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit277&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSioud%26aufirst%3DM.%26atitle%3DTherapeutic%2520siRNAs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2004%26volume%3D25%26spage%3D22%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm100189a&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-19%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm100189a%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm100189a" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6679868b1d51d93a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
